Welcome to ATS 2018

Welcome to San Diego, CA for the 2018 American Thoracic Society International Conference. The conference, which is expected to draw more than 14,000 investigators, educators, and clinicians, is truly the destination for pediatric and adult pulmonary, critical care, and sleep medicine professionals at every level of their careers.

The conference is all about learning, networking and connections. Because it engages attendees across many disciplines and continents, the ATS International Conference draws a large, diverse group of participants, a dedicated and collegial community that inspires each of us to make a difference in patients’ lives, now and in the future. By virtue of its size — ATS 2018 features approximately 6,700 original research projects and case reports, 500 sessions, and 800 speakers — participants can attend sessions and special events from early morning to the evening. At ATS 2018 there will be something for everyone.

Don’t miss the following important events:

- **Opening Ceremony** featuring a keynote presentation by Darrell G. Kirch, MD, president and chief executive officer of the Association of American Medical Colleges.
- **Tenth Annual ATS Foundation Research Program Benefit** on Saturday honoring James Donohue, MD, with the Foundation’s Breathing for Life Award.
- **Keynote Series** highlight state of the art lectures on selected topics in an unopposed format to showcase timely and diverse topics which relate to pulmonary, critical care and sleep medicine.
- **Women’s Forum**, which will feature A. Sonia Buist, MD, Professor Emerita of Medicine, Division of Pulmonary and Critical Care Medicine, School of Medicine, Oregon Health & Science University, as the keynote speaker.
- **Respiratory Health Awards**, which includes the Trudeau Medal, Distinguished Achievement Awards, and Amberson Lecture, given by Scott T. Weiss, MD, MS, Channing Division of Network Medicine, Brigham and Women’s Hospital and Harvard Medical School
- **ATS Plenary Session** will feature a presentation on the Respiratory Effects of Natural Disasters
- **Assembly Membership Meetings**, which are open to all attendees.

These events create a sense of community among the International Conference attendees, which is precisely what our founders had hoped when they established the world’s first respiratory society.

Finally, we wish to acknowledge the hard work and outstanding efforts of the members of the International Conference Committee, Education Committee, Assembly Program Committees, and ATS staff. The success of our conference depends on the dedication, creativity, and support of these individuals.

We welcome you to the International Conference and hope you take advantage of all San Diego has to offer.

**INTERNATIONAL CONFERENCE COMMITTEE**

Jess Mandel, MD, Chair 2017-2019  
Eric White, MD, MS, Chair 2019-2021  
Alison K. Bauer, PhD  
Brian W. Carlin, MD  
Harold R. Collard, MD  
Vinicio De Jesus Perez, MD  
Sharon D. Dell, MD  
Michelle Eakin, PhD  
Laura C. Feemster, MD, MSc  
Andrew P. Fontenot, MD  
Michelle N. Gong, MD, MS  
Jill L. Guttmannson, PhD  
Tillie-Louise Hackett, PhD  
Leila Kheirandish-Gozal, MD, MSC  
Tim Lahm, MD  
Patty Lee, MD  
Tricia D. LeVan, PhD  
William Man, MD, PhD  
Benjamin D. Medoff, MD  
Sangeeta Mehta, MD  
Mark L. Metersky, MD  
Paul E. Moore, MD  
Patrick Nana-Sinkam, MD  
Frank C. Scirubba, MD  
Chun Seow, PhD  
Christopher G. Slatore, MD  
Esra Tasali, MD  
Judith Tate, PhD, RN  
Rachel Thomson, MBBS, PhD, FRACP  
Lisa R. Young, MD
PRESIDENTS

AMERICAN SANATORIUM ASSOCIATION

V.Y. Bowditch, MD, 1905-19
Lawrason Brown, MD, 1919-23
J.W. Pettit, MD, 1924-25
F.M. Pottenger, MD, 1925-26
David R. Lyman, MD, 1926-27
Robinson Bosworth, MD, 1927-28
Henry Boswell, MD, 1928-29
W. L. Rathbun, MD, 1929-30
Ralph C. Matson, MD, 1930-31
Henry D. Chadwick, MD, 1931-32
Harry L. Barnes, MD, 1932-33
Fred H. Heise, MD, 1933-34
Leroy S. Peters, MD, 1934-35
E.S. McSweeny, MD, 1935-36
William H. Ordway, MD, 1936-37
Munford Smith, MD, 1937-38
Ezra R. Bridge, MD, 1938-39
J. Burns Amberson, MD, 1939-40
Lewis L. Moorman, MD, 1940-41
Harold G. Trimble, MD, 1941-42
Henry C. Sweeney, MD, 1942-43
John B. Barnwell, MD, 1943-44
Julius L. Wilson, MD, 1944-45
Ezra R. Bridge, MD, 1945-46

Henry Boswell, MD, 1928-29
W. L. Rathbun, MD, 1929-30
Ralph C. Matson, MD, 1930-31
Henry D. Chadwick, MD, 1931-32
Harry L. Barnes, MD, 1932-33
Fred H. Heise, MD, 1933-34
Leroy S. Peters, MD, 1934-35
E.S. McSweeny, MD, 1935-36
William H. Ordway, MD, 1936-37
Munford Smith, MD, 1937-38
Ezra R. Bridge, MD, 1938-39
Bruce H. Douglas, MD, 1939

AMERICAN TRUDEAU SOCIETY

William B. Tucker, MD, 1960-61
Robert H. Ebert, MD, 1961-62
H. William Harris, MD, 1962-63
William R. Barclay, MD, 1963-64
William S. Schwartz, MD, 1964-65
Winthrop N. Davey, MD, 1965-66
John S. Chapman, MD, 1966-67
Robert L. Yeager, MD, 1967-68
Joseph B. Stocklen, MD, 1968-69
James F. Hammarsten, MD, 1969-70
Eugene D. Robin, MD, 1970-71
James Kieran, MD, 1971-72
Alan K. Pierce, MD, 1972-73
Jay A. Nadel, MD, 1973-74
Gareth M. Green, MD, 1974-75
Attilio D. Renzetti, Jr., MD, 1975-76
Hans Weill, MD, 1976-77
Richard L. Riley, MD, 1977-78
Donald F. Tierney, MD, 1978-79
Marvin A. Sackner, MD, 1979-80

William B. Tucker, MD, 1960-61
Robert H. Ebert, MD, 1961-62
H. William Harris, MD, 1962-63
William R. Barclay, MD, 1963-64
William S. Schwartz, MD, 1964-65
Winthrop N. Davey, MD, 1965-66
John S. Chapman, MD, 1966-67
Robert L. Yeager, MD, 1967-68
Joseph B. Stocklen, MD, 1968-69
James F. Hammarsten, MD, 1969-70
Eugene D. Robin, MD, 1970-71
James Kieran, MD, 1971-72
Alan K. Pierce, MD, 1972-73
Jay A. Nadel, MD, 1973-74
Gareth M. Green, MD, 1974-75
Attilio D. Renzetti, Jr., MD, 1975-76
Hans Weill, MD, 1976-77
Richard L. Riley, MD, 1977-78
Donald F. Tierney, MD, 1978-79
Marvin A. Sackner, MD, 1979-80

AMERICAN THORACIC SOCIETY

Stephen C. Crane, PhD, MPH
American Thoracic Society
New York, NY
Executive Director, 2007-2018

OFFICERS

Marc Moss, MD
University of Colorado School of Medicine
Aurora, CO
President

Polly Parsons, MD
University of Vermont
Burlington, VT
President-elect

David Gozal, MD, MBA
University of Chicago
Chicago, IL
Past-President

James Beck, MD
University of Colorado
Denver, CO
Vice President

Juan C. Celedon, MD, DrPH
Children’s Hospital of Pittsburgh, UPMC
Pittsburgh, PA
Secretary-Treasurer

Karen Collishaw, CAE
American Thoracic Society
New York, NY
Executive Director, 2018-

Stephen C. Crane, PhD, MPH
American Thoracic Society
New York, NY
Executive Director, 2007-2018

PRESIDENTS

William B. Tucker, MD, 1960-61
Robert H. Ebert, MD, 1961-62
H. William Harris, MD, 1962-63
William R. Barclay, MD, 1963-64
William S. Schwartz, MD, 1964-65
Winthrop N. Davey, MD, 1965-66
John S. Chapman, MD, 1966-67
Robert L. Yeager, MD, 1967-68
Joseph B. Stocklen, MD, 1968-69
James F. Hammarsten, MD, 1969-70
Eugene D. Robin, MD, 1970-71
James Kieran, MD, 1971-72
Alan K. Pierce, MD, 1972-73
Jay A. Nadel, MD, 1973-74
Gareth M. Green, MD, 1974-75
Attilio D. Renzetti, Jr., MD, 1975-76
Hans Weill, MD, 1976-77
Richard L. Riley, MD, 1977-78
Donald F. Tierney, MD, 1978-79
Marvin A. Sackner, MD, 1979-80

Anne L. Davis, MD, 1980-81
John F. Murray, MD, 1981-82
Robert B. Mellins, MD, 1982-83
Roland H. Ingram, Jr., MD, 1983-84
Clarence A. Guenter, MD, 1984-85
Kenneth M. Moser, MD, 1985-86
Gordon L. Snider, MD, 1986-87
Gerard M. Turino, MD, 1987-88
Joseph H. Bates, MD, 1988-89
Kenneth L. Brigham, MD, 1989-90
A. Sonia Buist, MD, 1990-91
Herbert Y. Reynolds, MD, 1991-92
James D. Crapo, MD, 1992-93
J.T. Sylvester, MD, 1993-94
Atul M. Malhotra, MD, 1994-95
Gary W. Hunninghake, MD 1995-96
Leonard D. Hudson, MD, 1996-97
Philip C. Hopewell, MD, 1997-98
Talmadge E. King, Jr., MD, 1998-99
Edward R. Block, MD, 1999-2000

William J. Martin, II, MD, 2000-01
Adam Wanner, MD, 2001-02
Thomas R. Martin, MD, 2002-03
Homer A. Boushey, Jr., MD, 2003-04
Sharon I.S. Rounds, MD, 2004-05
Peter D. Wagner, MD, 2005-06
John E. Heffner, MD, 2006-07
David H. Ingbar, MD, 2007-08
Jo Rae Wright, PhD, 2008-09
J. Randall Curtis, MD, MPH, 2009-10
Dean E. Schraufnagel, MD, 2010-11
Nicholas S. Hill, MD, 2011-12
Monica Kraft, MD, 2012-13
Patricia A. Allen, MD, 2013-14
Joseph H. Bates, MD, 2014-15
Gary W. Hunninghake, MD 1995-96
Leonard D. Hudson, MD, 1996-97
Philip C. Hopewell, MD, 1997-98
Talmadge E. King, Jr., MD, 1999-2000

ATS OFFICERS

ATS 2018 • San Diego, CA

ATS OFFICERS

ATS 2018 • San Diego, CA
ATS 2018 INTERNATIONAL CONFERENCE
MAY 18-23, SAN DIEGO

This session portion of the ATS International Conference Final Program is published by the ATS as a service to attendees. This publication contains the programs and speakers for the postgraduate courses, scientific and educational sessions presented at the conference.

While every effort is made to ensure accuracy, ATS makes no warranties, expressed or implied, related to the information. Information contained herein is subject to change without notice.

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.

1  Friday Postgraduate Courses
13  Saturday Postgraduate Courses
26  Sunday Conference Sessions
129  Monday Conference Sessions
230  Tuesday Conference Sessions
325  Wednesday Conference Sessions
In accordance with the ACCME Standards for Commercial Support, and those of the ATS Policy on Management of Conflict of Interest in Official ATS Documents, Projects and Conferences, ATS Policy Governing Relationships Between the Tobacco Industry, ATS Members, and Non-Members Who Participate in ATS Activities, and ATS Policy on Professionalism and Ethical Conduct chairs, moderators, presenters and official planners of the International Conference are required to disclose to ATS any potential conflicts of interest (COI) held by them or their spouse/life partner relevant to their presentation(s) or conference role, including all professional or other financial involvement with tobacco or e-cigarette entities, all relevant financial relationships with commercial interests, and all other relationships that could be perceived as influencing their participation. Conference presenters are also asked to disclose if there will be any discussion in the presentation of “off-label” (unapproved) use of substances/products not approved in the United States for the use under discussion (as per the U.S. Food and Drug Administration Guidance for Industry: Industry-Supported Scientific and Educational Activities).

For the 2018 International Conference, this disclosure information for all individuals in control of content was requested and received by ATS in advance of the presentation. To access the disclosures made by the faculty of the 2018 International Conference, please go to http://conference.thoracic.org/speakers

The following members of the Education Committee have disclosed no financial relationships with commercial interests:

Walter D. Conwell, MD
Alison S. Clay, MD
William G. Carlos, MD
Mark K. Abe, MD
Jess Mandel, MD
Debra M. Boyer, MD, Chair
Michelle N. Gong, MD, MS
Sangeeta Mehta, MD
Samantha A. Davis, MD
William Man, MD, PhD
Patty Lee, MD
Paul E. Moore, MD

The following members of the Education Committee have disclosed the following financial relationships with commercial interests:

Eric S. White, MD, MS, Chair Appointee
Jill L. Guttormson, PhD, MD, RN
Tricia D. LeVan, PhD
Bishoy Zakarya, MD
Amjad Horani, MD
William Carlos, MD
Leopoldo N. Segal, MD
Paul E. Moore, MD

The following members of the International Conference Committee have disclosed no financial relationships with commercial interests:

Laura C. Feemster, MSc, MD
Jess Mandel, MD, Chair
Michelle Eakin, PhD
Geralyn Paterno, MD
Tricia D. LeVan, PhD
Mark D. Siegel, MD
Lisa R. Young, MD

The following members of the International Conference Committee have disclosed the following financial relationships with commercial interests:

Eric S. White, MD, Vice Chair
Michelle Eakin, PhD
Jill L. Guttormson, PhD, MD, RN
Leopoldo N. Segal, MD
Ora Schwartz, MD

The following members of the Education Committee have disclosed the following financial relationships with commercial interests:

Debra M. Boyer, MD, Chair
Tim Lahm, MD
Bayer HealthCare Pharmaceuticals, Inc.

The following members of the International Conference Committee have disclosed the following financial relationships with commercial interests:

Mark K. Abe, MD
William Carlos, MD
Sharon D.M. Dell, MD
Frank C. Sciurba, MD

The following members of the Education Committee have disclosed no financial relationships with commercial interests:

Jill L. Guttormson, PhD, MD, RN
Tricia D. LeVan, PhD
Bishoy Zakarya, MD

The following members of the Education Committee have disclosed the following financial relationships with commercial interests:

Time S. Wang, MD, Vice Chair: Theravance Biopharma Inc. (Advisory Committee)

The following members of the International Conference Committee have disclosed no financial relationships with commercial interests:

Jess Mandel, MD
Eric S. White, MD, MS, Chair Appointee
Allison K. Bauer, PhD
Vinicio De Jesus-Perez, MD
Michelle Eakin, PhD
Laura C. Feemster, MSc, MD

The following members of the Education Committee have disclosed the following financial relationships with commercial interests:

Brian W. Carlin, MD: AstraZeneca and Nonin

Harold R. Collard, MD: AstraZeneca AB

Viswam S. Nair, MSCR, MD
Susan Pasnack, MD
Hetal J. Patel, MD
Jessica E. Pittman, MD, MPH
Jordan S. Rettig, MD

Sharon D.M. Dell, MD: Novartis Pharmaceuticals Corporation and Vertex Pharmaceuticals Incorporated (Consultant)

Tim Lahm, MD: Bayer Healthcare Pharmaceuticals Inc. (Research Support)

Mark L. Mettersky, MD: Aredigm (Research Support, Consultant)

ATS 2018 • San Diego, CA
PG1A CRITICAL CARE ULTRASOUND AND ECHOCARDIOGRAPHY I

This is part 1 of a two-part course which includes PG1B on Saturday, May 19. Those registering for PG1A will be registered for PG1A and PG1B.

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $900  In-Training Member: $675
Non-Member: $1,200  In-Training Non-Member: $775

Registrants must bring a laptop to the course to view the course material.

Assembly on Critical Care
8:00 a.m. - 4:00 p.m.  SAN DIEGO CONVENTION CENTER Room 9 (Upper Level)

Target Audience
Providers of critical care or emergency medicine

Objectives
At the conclusion of this session, the participant will be able to:
• apply ultrasound at bedside to assess critically ill patients;
• diagnose alternate etiologies of shock in the critically ill patient;
• apply ultrasound to guide common ICU procedures.

This is a two day postgraduate course that consists of didactic lectures and hands-on stations. The focus is primarily bedside transthoracic echocardiography, with some diagnostic ultrasound. The topics include basic and intermediate critical care echocardiography (including hemodynamic measures), assessment of fluid status, procedural guidance for vascular access and thoracentesis, venography. The hands-on stations will include both healthy models and simulators that can demonstrate abnormal pathology.

Chairing:  M.J. Lanspa, MD, MSCR, Salt Lake City, UT
             X. Monnet, MD, PhD, Le Kremlin-Bicetre, France

8:00 Welcome and Introduction to Critical Care Ultrasound: Training and Competency
M.J. Lanspa, MD, MSCR, Salt Lake City, UT

8:15 Basic Physics, Artifacts, Knobology
Z. Shaman, MD, Cleveland, OH

8:45 Transthoracic Windows and Views
S. Nikravan-Weber, MD, Stanford, CA

9:15 Basic Evaluation of LV Systolic Function, Measurement of Cardiac Output
S. Price, MBBS, London, United Kingdom

9:45 Basic Evaluation of RV Size and Function, Pulmonary Embolus
D. Pradhan, MD, New York, NY

10:15 Break

10:30 Practical Skills Session: Hands-On Station I
Apical Window
L. Rapoport, MD, Santa Clara, CA
V.A. Dinh, MD, Loma Linda, CA
E. Teo, MD, Atlanta, GA
P.K. Mohabir, MD, Stanford, CA
S. Price, MBBS, London, United Kingdom

Parasternal Window
X. Monnet, MD, PhD, Le Kremlin-Bicetre, France
T. Brakke, MD, Omaha, NE
Z. Shaman, MD, Cleveland, OH
A. Leibowitz, MD, Boston, MA
L. Grecu, MD, Stony Brook, NY

Subcostal Window
G. Allen, MD, Burlington, VT
J. Kasal, MD, St. Louis, MO
D. Pradhan, MD, New York, NY
S. Nikravan-Weber, MD, Stanford, CA
S. Cha, MD, Baltimore, MD

12:00 Lunch and Clinical Cases I
L. Grecu, MD, Stony Brook, NY

12:45 Chest Ultrasound
P.K. Mohabir, MD, Stanford, CA

1:15 Basic Valvulopathy
T. Brakke, MD, Omaha, NE

1:45 Basic Assessment of Diastolic Function
A. Leibowitz, MD, Boston, MA

2:15 Break

2:30 Practical Skills Session: Hands-On Station II
Lung Ultrasound (Model and Mannequin)
L. Rapoport, MD, Santa Clara, CA
Z. Shaman, MD, Cleveland, OH
D. Pradhan, MD, New York, NY
P.K. Mohabir, MD, Stanford, CA
G. Allen, MD, Burlington, VT
Diastolic Measurements
T. Brakke, MD, Omaha, NE
S. Price, MBBS, London, United Kingdom
X. Monnet, MD, PhD, Le Kremlin-Bicetre, France
A. Leibowitz, MD, Boston, MA
S. Nikravan-Weber, MD, Stanford, CA

Cardiac Output
L. Grecu, MD, Stony Brook, NY
V.A. Dinh, MD, Loma Linda, CA
J. Kasal, MD, St. Louis, MO
E. Teo, MD, Atlanta, GA
S. Cha, MD, Baltimore, MD

This session and the International Conference are supported by in-kind grants from Cook Medical, FUJIFILM Sonosite, Inc, Teleflex Medical, Inc.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

PG2 EXPANDING HORIZONS IN SUPPORT FOR RESPIRATORY FAILURE: ECMO AND BEYOND

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.
Member: $475
In-Training: $300
Non-Member: $550
In-Training Non-Member: $400
Registrants must bring a laptop to the course to view the course material.

Assemblies on Critical Care; Clinical Problems; Nursing; Pediatrics; Pulmonary Circulation
8:00 a.m. - 4:00 p.m.
SAN DIEGO CONVENTION CENTER
Room 4 (Upper Level)

Target Audience
Those who have interest in developing an ECMO program or simply learning about ECMO, will benefit from this session. Clinical staff such as physicians, nurses, NPs and PAs, perfusionists, respiratory therapists, and PTs/OTs, who treat ECMO patients

Objectives
At the conclusion of this session, the participant will be able to:

• apply best practices to patient selection and integrate ECMO into existing treatment pathways for severe respiratory failure. Appropriate patient selection for ECMO is key to provide safe and quality care to critically ill patients;
• gain understanding of the physiology of ECMO support and learn contemporary management of patients receiving ECMO, (ventilator, anticoagulation, transfusions, etc.), all critical components to successful and safe use of ECMO;
• recognize and manage common ECMO-related events and emergency scenarios. The learner will be better able to troubleshoot these events. This will improve the safety and quality of care provided to patients supported with ECMO.

Extracorporeal membrane oxygenation (ECMO) allows for gas exchange and hemodynamic support in patients failing conventional mechanical ventilation and is an evolving way of treating patients with severe respiratory failure. This session will incorporate multidisciplinary didactic and simulation sessions to educate the learner on optimal use of ECMO and tackle the challenges and questions raised surrounding its use, including patient selection, use of the ventilator during ECMO, treating unique patient populations (such as pregnant patients or those awaiting lung transplantation), physical rehabilitation during ECMO, troubleshooting common problems, and others.

Chairing:
H.J. Dalton, MD, Falls Church, VA
C. Agerstrand, MD, New York, NY

8:00 Introduction
H.J. Dalton, MD, Falls Church, VA

8:05 Roadmap to ECMO: Respiratory Failure Management and Patient Selection
E. Fan, MD, PhD, Toronto, Canada

8:35 Outcomes in Patients Treated with ECMO: What We Know and What We Don’t
C.L. Hodgson, PhD, Victoria, Australia

9:05 ECMO in Special Populations
C. Agerstrand, MD, New York, NY

9:35 Ventilator Management of the VV ECMO Patient
A. Combes, MD, PhD, Paris, France

10:05 Break

10:25 New Modalities for Support: ECCO2R and Others
A. Pesenti, MD, Milan, Italy

10:55 ECMO for Lung Transplantation: How to Select Patients and Optimize Management, Pre and Post
D. Hayes, MD, MS, Med, Columbus, OH

11:25 Can You Really Ambulate Patients and How?
D. Brodie, MD, New York, NY

11:55 LUNCH

12:40 Simulation Station 1
D. Hayes, MD, MS, Med, Columbus, OH
T. Preston, CCP, Columbus, OH

1:10 Simulation Station 2
M. Desai, MD, Falls Church, VA
T. Friedrich, RN, MSN, Rochester, MN

1:40 Simulation Station 3
H.E. Callisen, PA, Phoenix, AZ
G.J. Schears, MD, Rochester, MN

2:10 Break

2:30 Simulation Station 4
C. Alwardt, CCP, PhD, Rochester, MN
D. Brodie, MD, New York, NY

3:00 Simulation Station 5
C. Agerstrand, MD, New York, NY
M. Robinson, RN, Arcadia, OK

3:30 Simulation Station 6 ECPR in the ED
Z. Shinar, MD, San Diego, CA

This session and the International Conference are supported by an in-kind grant from FUJIFILM Sonosite, Inc.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

ATS 2018 • San Diego, CA

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
PG3  ADVANCED PAP THERAPY: TREATMENT OF SLEEP DISORDERED BREATHING BEYOND OSA

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $475  In-Training Member: $300
Non-Member: $550  In-Training Non-Member: $400

Registrants must bring a laptop to the course to view the course material.

Assemblies on Sleep and Respiratory Neurobiology; Clinical Problems; Pulmonary Rehabilitation; Medical Education Section

8:00 a.m. - 4:00 p.m.  SAN DIEGO CONVENTION CENTER
Room 10 (Upper Level)

Target Audience
Physicians in sleep medicine, pulmonary, cardiology, pediatrics and possibly critical care; physicians in training (sleep and pulmonary fellows); advanced practice nurses, physician assistants, respiratory therapists, sleep technologists

Objectives
At the conclusion of this session, the participant will be able to:

• Identify the indications for and limitations of various PAP devices in the management of obstructive and central sleep apnea syndromes and sleep-related hypoventilation;

• develop new strategies to manage the care of central sleep apnea, in heart failure or chronic opioid patients, as well as new tools for managing sleep disordered breathing with hypoventilation in chronic lung disease and neuromuscular disease;

• determine proper initial settings, adjust settings in an office based environment, trouble shoot common problems and interpret adherence data from various PAP devices used to treat a wide spectrum of OSA and CSA syndromes.

This hands-on course consists of a morning interactive didactic session, case-based break-out sessions and a final afternoon session with opportunities to experiment with different advanced PAP devices. The focus is the management of sleep disordered breathing incorporating recent findings and addressing current gaps in guidelines. The lectures will review pathophysiology and epidemiology, but primarily explore the different treatment approaches and PAP modalities, including OSA with auto-PAP, central sleep apnea and sleep-related hypoventilation sub-types. Participants will next break into small groups of 10 for case studies (selecting 3 cases out of 6 to discuss) with faculty leader. Finally they will have four hands-on experiences with different advanced modality PAP devices.

Chairing:
M.E. Billings, MD, MSc, Seattle, WA
G.W. Pien, MD, MS, Baltimore, MD

8:00  Welcome/Introduction  M.E. Billings, MD, MSc, Seattle, WA
8:05  Auto-Titration Devices for OSA: Beyond the Basics  G.W. Pien, MD, MS, Baltimore, MD
8:30  Management of Central Sleep Apnea Syndromes  M.T. Naughton, MD, Prahran, Australia

9:15  Management of Sleep-Related Hypoventilation  L.F. Wolfe, MD, Chicago, IL
10:00  Break
10:15  Breakout Session 1  J.O. Benditt, MD, Seattle, WA
10:30  Breakout Session 2  S.P. Patil, MD, PhD, Baltimore, MD
10:45  Breakout Session 3  N. Freedman, MD, Grayslake, IL
11:00  Breakout Session 4  R.J. Schwab, MD, Philadelphia, PA
11:15  Breakout Session 5  I. Gurubhagavatula, MD, MPH, Philadelphia, PA
11:30  Breakout Session 6  E.C. Parsons, MD, MSc, Seattle, WA
11:45  LUNCH
12:35  Station 1: Auto-Titrating Devices  B. Fields, MD, Atlanta, GA
1:20  Station 2: Adaptive Servo-Ventilation  R.J. Schwab, MD, Philadelphia, PA
2:05  Break
2:20  Station 3: Average Volume Assured Pressure Support  V.K. Kapur, MD, MPH, Seattle, WA
3:05  Station 4: Non-Invasive Positive Pressure Ventilation  B.N. Palen, MD, Seattle, WA
3:50  Wrap-up  M.E. Billings, MD, MSc, Seattle, WA

This session and the International Conference are supported by in-kind grants from Fisher Paykel, Philips Respironics, ResMed. All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

PG4  ASTHMA STATE OF THE ART 2018

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350  In-Training Member: $200
Non-Member: $425  In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Assembly on Allergy, Immunology and Inflammation

8:00 a.m. - 4:00 p.m.  SAN DIEGO CONVENTION CENTER
Room 6 F (Upper Level)

Target Audience
Pulmonary and allergy physicians, physicians in training, and advanced
practice providers who are focused on care of patients with asthma. Clinical, translational, and basic science researchers involved in studies of asthma pathogenesis and therapy.

**Objectives**
At the conclusion of this session, the participant will be able to:

- improve knowledge on the origins of asthma and its pathophysiology;
- diagnose different asthma phenotypes;
- gain new strategies to manage difficult asthma cases.

This session will provide a comprehensive review of the latest knowledge on asthma pathogenesis, clinical science and therapy. Discussion of newly developed therapies for asthma will be emphasized. The program will have three interactive sections: a journal club on recent papers, clinical controversies, and an expert panel discussion of difficult clinical cases.

**Chairing:** B.D. Medoff, MD, Boston, MA

P. Akuthota, MD, La Jolla, CA

M. Kraft, MD, Tucson, AZ

**8:00** **Introduction**
M. Kraft, MD, Tucson, AZ

**8:05** **Early Life Events and the Origins of Asthma**
F.D. Martinez, MD, Tucson, AZ

**8:35** **Asthma Endotypes: A New Approach to Characterizing Disease**
S.E. Wenzel, MD, Pittsburgh, PA

**9:05** **The Immunologic Basis of Asthma**
P. Vijayanand, MBBS, PhD, La Jolla, CA

**9:35** **The Role of Lung Structural Cells in Asthma**
J.L. Ingram, PhD, Durham, NC

**10:05** **Break**

**10:20** **Research Highlights from the Recent Literature**
P. Akuthota, MD, La Jolla, CA

R.A. Rahimi, MD, PhD, Boston, MA

J.L. Cho, MD, Boston, MA

**10:50** **Severe Asthma and Non-Eosinophilic Asthma**
M. Kraft, MD, Tucson, AZ

**11:20** **Asthma Exacerbations: Mechanisms and Treatment**
L.C. Denlinger, MD, PhD, Madison, WI

**11:50** **LUNCH**

**12:45** **Obesity and Asthma**
N. Lugogo, MD, Durham, NC

**1:15** **Clinical Controversies in Asthma - ACOS**
B.D. Medoff, MD, Boston, MA

M. Van Den Berge, MD, Groningen, Netherlands

S. Christenson, MD, San Francisco, CA

**2:00** **Emerging Biologic Therapies in Asthma**
G.M. Gauvreau, PhD, Hamilton, Canada

**2:30** **Break**

**2:45** **Bronchial Thermoplasty for Asthma**
S. Khatri, MD, MS, Cleveland, OH

**3:15** **Case Studies**
M. Kraft, MD, Tucson, AZ

This session and the International Conference are supported by educational grants from GlaxoSmithKline, Sanofi Genzyme and Regeneron Pharmaceuticals.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.
8:10  QI Planning: Where Do I Start? Identifying the Problem that Requires a Solution
V. Liu, MD, MS, Oakland, CA

8:30  QI Planning: Understanding the Problem: Process Mapping and Fishbone Diagrams
D.W. Ford, MD, Charleston, SC

9:00  Breakout Session 1: Process Mapping and Fishbone Diagrams

10:00  Break

10:10  QI Implementation: Plan, Do, Study, Act (PDSA) Cycles
C.T.L. Hough, MD, MSc, Seattle, WA

10:30  QI Implementation: Show Me the Data, Implementation and Patient-Centered Outcomes
A. Amaral, MD, Toronto, Canada

10:50  Breakout Session 2: PDSA Cycles and Defining Metrics

11:50  LUNCH

12:50  QI Implementation: Implementation Strategies 101
J. Stevens, MD, MS, Boston, MA

1:10  QI Implementation: Leading and Managing Implementation
D.J. Murphy, PhD, MD, Atlanta, GA

1:30  QI Implementation: Change Management and Sustaining Improvements
N. Adhikari, MD, MS, Toronto, Canada

1:50  Breakout Session 3: Lessons Learned from Multi-Stakeholder Engagement

2:50  Break

3:00  Meet the Experts: Opportunity to Query Content Experts with Specific Questions Relevant to Topic/Institution

3:30  Debrief and Wrap-Up

---

**CLINICAL POSTGRADUATE COURSE**

**PG6 SARCOIDOSIS UPDATE**

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

- **Member:** $350
- **In-Training Member:** $200
- **Non-Member:** $425
- **In-Training Non-Member:** $300

Registrants must bring a laptop to the course to view the course material.

Assemblies on Clinical Problems; Allergy, Immunology and Inflammation
8:00 a.m. - 4:00 p.m.  SAN DIEGO CONVENTION CENTER

- **Room 3 (Upper Level)**

Target Audience
Physicians, trainees, nurses, respiratory therapists, and licensed independent practitioners (e.g. PA, NP) who diagnose or treat sarcoidosis patients

Objectives
At the conclusion of this session, the participant will be able to:

- Appropriately assess systemic sarcoidosis manifestations, including use of testing to diagnose organ involvement and assessment of the likelihood that a patient-related symptom is due to sarcoidosis;
- More appropriately use activity markers and clinical features to determine when to treat patients, and to provide better prognostic information that will inform the aggressiveness of follow-up testing and therapy;
- Implement diagnostic and treatment strategies for neurologic and cardiac sarcoidosis.

This course is designed to provide foundational knowledge about the diagnosis and management of sarcoidosis, and also to update more experienced practitioners about evolving trends in a comprehensive approach to sarcoidosis. There will be a substantial focus on extrapulmonary manifestations of sarcoidosis.

**Chairing:**
D.A. Culver, DO, Cleveland, OH
J.C. Grutters, MD, Nieuwegein, Netherlands

8:00  Diagnosing Sarcoidosis
R.P. Baughman, MD, Cincinnati, OH

8:30  Radiologic Manifestations of Sarcoidosis and Its Mimickers
S.L.F. Walsh, MD, PhD, London, United Kingdom

8:55  Assessment and Treatment of Pulmonary Sarcoidosis
W.E. James, MD, Charleston, SC

9:20  Rheumatologist’s Approach to Immunosuppression
C.B. Ligon, MD, MHS, Philadelphia, PA

9:50  Break

10:10  Activity Markers and Assessing Prognosis
J.C. Grutters, MD, Nieuwegein, Netherlands

10:35  Complicated Pulmonary Sarcoidosis
S.D. Nathan, MD, Falls Church, VA

11:05  PRO: Routine, Repeated and Intense Comprehensive Screening
A.U. Wells, MD, London, United Kingdom

11:20  CON: Routine, Repeated and Intense Comprehensive Screening
D.A. Culver, DO, Cleveland, OH

11:35  Improving Quality of Life in Sarcoidosis
M. Wijenbeek, MD, PhD, Rotterdam, Netherlands

12:00  LUNCH

12:50  Neurosarcoidosis: Diagnosis and Treatment
J. Tavee, MD, Chicago, IL

1:20  Minisymposium: Recognition and Diagnosis of Cardiac Sarcoidosis
E. Joyce, MD, PhD, Cleveland, OH

1:40  Minisymposium: Imaging Tests in Cardiac Sarcoidosis
R. Blankstein, MD, Boston, MA

2:00  Minisymposium: Should All Cardiac Sarcoidosis Be Treated, and How?
N.Y. Hamzeh, MD, Denver, CO

2:20  Break

---

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
This session and the International Conference are supported by an educational grant from Mallinckrodt Pharmaceuticals. All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

**PG7 PLEURAL DISEASE 2018: EVIDENCE BASED BEST PRACTICE IN INVESTIGATIONS AND MANAGEMENT**

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

- **Member:** $350  
  - **In-Training Member:** $200
- **Non-Member:** $425  
  - **In-Training Non-Member:** $300

Registrants must bring a laptop to the course to view the course material.

**Assemblies on Clinical Problems; Pulmonary Infections and Tuberculosis; Thoracic Oncology**

- **8:00 a.m. - 4:00 p.m.**  
  - **SAN DIEGO CONVENTION CENTER**  
  - **Room 6 D (Upper Level)**

**Target Audience**
Specialists and trainees in pulmonary and critical care medicine, infectious disease physicians, intensivists, general practitioners, research scientists and related health care professionals including surgeons and nurses

**Objectives**
At the conclusion of this session, the participant will be able to:

- describe the investigation of patients with pleural disease, including pleural fluid analysis, radiology and the role of invasive diagnostic strategies;
- understand and describe current evidence and best practice in assessment and management of infectious pleural disease, including tuberculosis and bacterial etiologies;
- describe diagnosis and management of malignant pleural disease, including pleural fluid management strategies.

This session will describe the modern, evidence based approach to the broad range of Pleural Disease, from recognized world experts. The session will provide a strong base from which clinicians can go on to provide excellent, rational and evidence based patient focused care in pleural disease.

**Chairing:**  
- N. Rahman, BM BCH, MSc, Oxford, United Kingdom  
- Y.C.G. Lee, MBChB, PhD, Perth, Australia

- **8:00 Introduction**  
  - N. Rahman, BM BCH, MSc, Oxford, United Kingdom
Develop a better understanding of heart lung interactions in mechanical ventilation.

This course is focused on the bedside management of mechanical ventilation and will stress a physiologic approach to managing the ventilator and interpreting the effects of interventions. We will cover appropriate oxygenation goals, uses and physiologic effects of PEEP, heart-lung interaction as it relates to mechanical ventilation, the physiology of prone ventilation in severe ARDS, management of the flow-limited patient including status asthmaticus and severe obstructive disease, and patient-ventilator synchrony. We will explore controversies in the physiologic literature concerning these techniques and critically examine common clinical rationales for their use. The session will conclude with small group case discussions in which participants will apply the principles covered in the didactic sessions.

Chairing:
C.C. Hardin, MD, PhD, Boston, MA
K. Hibbert, MD, Boston, MA

8:00 Introduction to the Physiology of Mechanical Ventilation
C.C. Hardin, MD, PhD, Boston, MA

8:40 Oxygenation, V/Q and Gas Exchange in Mechanical Ventilation
S.R. Hopkins, MD, PhD, La Jolla, CA

9:20 Heart-Lung Interaction in Mechanical Ventilation
S.A. Magder, MD, Montreal, Canada

10:20 Break

10:40 Physiologic Effects of PEEP
S. Sharma, MD, Aurora, CO

11:20 Patient-Ventilator Synchrony and Ventilator Waveforms
B.T. Thompson, MD, Boston, MA

12:00 LUNCH

12:40 Physiology of Ventilation in Severe Asthma
D.R. Hess, PhD, Boston, MA

1:20 Physiology of Prone Ventilation
I.S. Douglas, MD, Denver, CO

2:00 Break

2:20 Case Discussions
K. Hibbert, MD, Boston, MA

Target Audience
Clinicians, trainees and allied health personnel

Objectives
At the conclusion of this session, the participant will be able to:

- diagnose lung disease due to or exacerbated by environmental and occupational exposures, leading to broader differential diagnoses, larger toolbox for managing this type of lung disease, and improved patient outcomes;
- gain new findings about emerging exposures such as e-cigarettes that cause lung disease, and have new strategies to manage the care of common exposures such as indoor allergen and mold exposure;
- gain new strategies to assess for lung diseases due to environmental and occupational exposures, including using a multi-disciplinary approach with the input of radiologists, pathologists, and occupational health practitioners.

The contribution of environmental and occupational exposures to the burden of many common lung diseases is under appreciated. Failure to recognize these contributions can lead to misdiagnosis or suboptimal treatment. Many clinicians are often unsure of how to respond to patient questions regarding whether exposures caused their lung disease. This highly interactive session will provide a multi-disciplinary approach to the diagnosis and treatment of environmental and occupational lung diseases, teach clinicians about environmental contributors to common lung diseases, and update the audience on emerging exposure related lung diseases.

Chairing:
P.S. Lai, MPH, MD, Boston, MA
Y.T. Huang, MHS, MD, Durham, NC

8:00 Opening Remarks
P.S. Lai, MPH, MD, Boston, MA

8:05 Where Do I Begin? A Clinician's Approach
D.C. Christiani, MD, MPH, MS, Boston, MA

8:40 Test or Remediate? A Diagnostic Approach
Y.T. Huang, MHS, MD, Durham, NC

9:15 How Will Imaging Help? A Radiologist's Approach
S. Hobbs, MD, Lexington, KY

9:50 When Should I Biopsy? A Pathologist's Approach
F.H.Y. Green, MD, Calgary, Canada

10:25 Break

10:35 Asthma + COPD: When Is It Work Related?
S.M. Tarlo, MBBS, Toronto, Canada

11:10 Hypersensitivity Pneumonitis - Diagnosis, Treatment, and Prognosis
F. Morell, MD, PhD, Barcelona, Spain

11:45 LUNCH

12:15 Is It Sarcoidosis?
L.A. Maier, MSPH, MD, Denver, CO

12:50 Fibrotic Interstitial Lung Disease
M. Gulati, MD, MPH, New Haven, CT

1:25 Lung Cancer and Mesothelioma
H.M. Kipen, MD, MPH, Piscataway, NJ

2:00 Break
PG10 DIFFICULT CLINICAL PROBLEMS IN PULMONARY AND CRITICAL CARE INFECTIONS

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350
In-Training Member: $200
Non-Member: $425
In-Training Non-Member: $300
Registrants must bring a laptop to the course to view the course material.

Assemblies on Pulmonary Infections and Tuberculosis; Clinical Problems; Critical Care
8:00 a.m. - 4:00 p.m. SAN DIEGO CONVENTION CENTER
Room 7 B (Upper Level)

Target Audience
Clinicians managing patients with pulmonary and critical care acquired infections

Objectives
At the conclusion of this session, the participant will be able to:

• gain a much greater understanding of the range of pulmonary infections that can occur in immunocompetent and immunocompromised hosts;
• better appreciate the evidence supporting different treatment strategies in pulmonary infections;
• have a much better knowledge of new diagnostic tests, treatments and outcome measures that can be applied in their local setting.

This course will provide clinicians with a broad overview and an update of the current challenging issues in the management of pulmonary and critical care infections, including typical bacterial pneumonia, mycobacterial, fungal, and viral infections as well as general approaches to infections in the immunocompromised host.

Chairing:
C.A. Hage, MD, Indianapolis, IN
K.A. Crothers, MD, Seattle, WA
G.W. Waterer, MBBS, MBA, PhD, Perth, Australia

8:00 What Are the Big Changes in the New VAP/HAP Treatment Guidelines?
M.L. Metersky, MD, Farmington, CT

8:25 What Is New in the Management of CAP in 2018
G.W. Waterer, MBBS, MBA, PhD, Perth, Australia

8:50 Antimicrobial Stewardship: Implications and Practical Guide for the Pulmonary Critical Care Providers
R.G. Wunderink, MD, Chicago, IL

9:15 Panel Discussion

9:30 Break

9:45 Practical Guide for the Management of Bronchiectasis, Current Update
J.D. Chalmers, MD, PhD, Dundee, United Kingdom

10:00 Updates on the Management of NTM Lung Infections
R. Thomson, MBBS, PhD, Greenslopes, Australia

10:35 Tuberculosis: What Is New in the Diagnosis and New Treatment Options
C.L. Daley, MD, Denver, CO

11:00 Panel Discussion

11:15 LUNCH

12:15 Empyema and Other Pleural Infections- Diagnosis and Management in 2018
Y.C.G. Lee, MBChB, Perth, Australia

12:40 Emerging Viral Respiratory Tract Infections of Global Significance
D.S. Hui, MD, MBBS, Shatin, Hong Kong

1:05 Vaccines for Respiratory Infection - Who Should Get What and When?
M. Griffin, MD, MPH, Nashville, TN

1:30 Panel Discussion

1:45 Break

2:00 Pneumonia in Patients Treated with Anti-TNF Therapy and Other Novel Biologics
K.L. Winthrop, MD, MPH, Portland, OR

2:25 Pulmonary Infections and Respiratory Microbiome Alterations in HIV/AIDS
K.A. Crothers, MD, Seattle, WA

2:50 Pneumonia in the Solid Organ Transplant Recipients
C.A. Hage, MD, Indianapolis, IN

3:15 Pneumonia in Patients with Hematologic Malignancies and HSCT Recipients
S.E. Evans, MD, Houston, TX

3:40 Panel Discussion
PG11: GENETIC PULMONARY MEDICINE

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350  In-Training Member: $200
Non-Member: $425  In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Assemblies on Pediatrics; Allergy, Immunology and Inflammation; Respiratory Cell and Molecular Biology; Genetics and Genomics Section

8:00 a.m. - 4:00 p.m. SAN DIEGO CONVENTION CENTER

Room 1 A (Upper Level)

Target Audience
All pulmonary physicians, pulmonary physician assistants, pulmonary fellows who care for patients with respiratory disease

Objectives
At the conclusion of this session, the participant will be able to:

• recognize and diagnose genetic lung diseases including short telomere syndrome, primary, ciliary dyskinesia, surfactant deficiency, LAM and BHD;
• integrate new treatment options in discussing HHT, CF, Duchenne muscular dystrophy or LAM with patients;
• apply basic principles of genetics and genotype-phenotype correlation, together with current classification of genetic variants to better interpret genetic test results.

This course will provide attendees with a comprehensive overview of the ever increasing role of genetics in the practice of pulmonary medicine. Regardless of background, attendees will come away from this course with a solid understanding of the basic principles of clinical genetics; they will understand when to suspect genetic disease in patients with lung disease and will be able to determine if testing in these patients is warranted; they will learn how to interpret genetic test results, and determine when further investigations are required. The course will conclude with an interactive case-based session.

Chairing:
B.A. Raby, MPH, MD, Boston, MA
T.B. Kinane, MBChB, MD, Boston, MA
L. Yonker, MD, Boston, MA

8:00 Introduction
B.A. Raby, MPH, MD, Boston, MA

8:10 Gene Panels, Whole Exome Sequencing and Whole Exome Sequencing - Nuts And Bolts
M.M. Wurfel, MD, PhD, Seattle, WA

9:05 Sequence Interpretation: Is My Mutation Pathogenic?
A. Hamvas, MD, Chicago, IL

9:35 The Use of Pluripotent Stem Cell to Determine if Mutations Are Pathogenic
F.J. Hawkins, ChB, MB, Boston, MA

10:05 Genetic Counseling: Why It Matters
N. Carmichael, MS, Boston, MA

10:35 Break

10:45 Pulmonary Vasculopathies: From PPH to HHT
W. Chung, MD, PhD, New York, NY

11:15 Pediatric Interstitial Lung Disease: How Rapid Genetic Screening Is Changing Clinical Practice
L.M. Nogee, MD, Baltimore, MD

11:45 Interstitial Lung Disease: Telomeres, Surfactant, and All That MUC
C.K. Garcia, MD, PhD, Dallas, TX

12:15 LUNCH

PG12: PEDIATRIC RESPIRATORY PHYSIOLOGY: TESTS OF LUNG FUNCTION AND DISEASES THEY TEST FOR

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350  In-Training Member: $200
Non-Member: $425  In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Assemblies on Pediatrics; Clinical Problems; Critical Care; Pulmonary Circulation; Respiratory Cell and Molecular Biology; Respiratory Structure and Function

8:00 a.m. - 4:00 p.m. SAN DIEGO CONVENTION CENTER

Room 1 B (Upper Level)

Target Audience
Fellows in training as well as established physicians in the practice of pediatric pulmonology, critical care or neonatal medicine who are interested in reviewing basic physiology principles as they apply to clinical care.

Objectives
At the conclusion of this session, the participant will be able to:

• Learn how physiologic measurements can be used to change interventions and enhance outcomes

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
• Apply several basic respiratory principles to the diagnosis and management of common pediatric respiratory disorders
• Identify the rationale for several measurement techniques and determine when these should be used

The course will consist of a series of paired lectures covering several topics in pediatric respiratory physiology, reviewing first a test of lung function and the physiological principles underlying the test, and then the companion talk will review how that test demonstrates pathophysiology relating to a particular pediatric respiratory disease. An interactive format, using questions from the speakers and audience touchpads to give answers will be used to enhance audience participation, and to allow the participant to understand key concepts or to identify areas requiring additional study.

Chairing: H.B. Panitch, MD, Philadelphia, PA
J.L. Allen, MD, Philadelphia, PA

8:00 Spirometry and Forced Oscillation Technique
J.L. Allen, MD, Philadelphia, PA

8:35 Childhood Determinants of Adult Lung Disease
T.W. Guilbert, MD, Cincinnati, OH

9:10 The Multiple Breath Washout Technique
P. Robinson, MD, PhD, Westmead, Australia

9:45 Break

9:55 Cystic Fibrosis: Structure and Function
S.M. Stick, MB BCh, Perth, Australia

10:30 Exhaled Gases
B.M. Gaston, MD, Cleveland, OH

11:05 Asthma and Exhaled Nitric Oxide
A.B. Chang, MBBS, PhD, Herston, Australia

11:40 LUNCH

12:20 Diffusing Capacity
G. Kurland, MD, Pittsburgh, PA

12:55 Sickle Cell Disease and the Lung
R.T. Cohen, MD, MPH, Boston, MA

1:30 Tidal Mechanics of the Respiratory System
J. Needleman, MD, Brooklyn, NY

2:05 Break

2:15 Mechanics of Breathing and Respiratory Failure
H.B. Panitch, MD, Philadelphia, PA

2:50 Tests of Respiratory Muscle Strength
T.G. Keens, MD, Los Angeles, CA

3:25 Chest Wall and Neuromuscular Disorders
G.J. Redding, MD, Seattle, WA

PG13 FORGOTTEN AND CONTROVERSIAL TOPICS IN PULMONARY HYPERTENSION

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.
Member: $350 In-Training Member: $200
Non-Member: $425 In-Training Non-Member: $300
Registrants must bring a laptop to the course to view the course material.

Assemblies on Pulmonary Circulation; Clinical Problems; Respiratory Structure and Function
8:00 a.m. - 4:00 p.m. SAN DIEGO CONVENTION CENTER
Room 8 (Upper Level)

Target Audience
General pulmonologists/cardiologists as well as physician extenders with an interest in PH and specialists in the field

Objectives
At the conclusion of this session, the participant will be able to:
• learn about the lesser known topics related to pulmonary hypertension including exercise pulmonary hypertension, PVOD/PCH, non-scleroderma connective tissue disease, sarcoidosis and renal failure;
• recognize the controversies regarding whether Sickle Cell Anemia should be classified as group 1 PAH and how should PH related to lung disease should be medically managed. We will also discuss gender and race inequality in pulmonary hypertension;
• learn about advanced RV assessment, PA compliance and RV:PA coupling, when to use parenteral prostacyclin, and use of DPG in the evaluation of mixed pre and post-capillary pulmonary hypertension.

There are multiple challenges and unanswered questions encountered by clinicians that evaluate, diagnose and treat patients with suspected or confirmed pulmonary vascular disease (mainly pulmonary hypertension). This course will provide a deep dive into the diagnosis and therapeutics of pulmonary hypertension supported by the literature and balanced with personal clinical experience. We have created this course specifically to address issues where uncertainty and/or controversy exists as well as highlight emerging areas that are just being incorporated into clinical practice. We seek to address the diagnostic and treatment dilemmas posed by these various clinical entities through literature review, sharing of expert opinion, and review of recent guidelines and their applicability to the multiple different nuanced presentations of pulmonary hypertension.

Chairing: M.G. Risbano, MD, MA, Pittsburgh, PA
G.A. Heresi, MD, Cleveland, OH
H.J. Ford, MD, Chapel Hill, NC

8:00 Exercise Pulmonary Hypertension: Are We There Yet?
M.G. Risbano, MD, MA, Pittsburgh, PA

8:30 Advanced RV Assessment, PA Compliance and RV:PA Coupling
M. Simon, MD, Pittsburgh, PA

9:00 The Other CTD-PAH: Beyond Scleroderma
S.H. Visovatti, MD, MA, Ann Arbor, MI
9:30 DPG? TPG? The Confusing World of Mixed Pre and Post-Capillary PH
I.M. Lang, MD, MA, Vienna, Austria

10:00 Break

10:20 Normal Hemodynamics with CTED?
G.A. Heresi, MD, Cleveland, OH

10:50 PVOD or PCH or PAH, You Be the Judge!
D. Montani, MD, PhD, Le Kremlin Bicetre, France

11:20 What Do We Really Do with PH in Lung Disease?
A Pro-Con Debate
J.A. Barbera, MD, Barcelona, Spain
S.D. Nathan, MD, Falls Church, VA

12:00 LUNCH

1:00 Sickle-Cell Disease Should Not Be Classified as Group 1 PAH: A Pro-Con Debate
M. Humbert, MD, PhD, Bicetre, France

1:20 Sickle-Cell Disease Should Be Classified as Group 1 PAH: A Pro-Con Debate
E.S. Klings, MD, Boston, MA

1:40 Sarcoid PH
H.J. Ford, MD, Chapel Hill, NC

2:10 Break

2:30 When to Use Parenteral Prostacyclins?
A. Hemnes, MD, Nashville, TN

3:00 Renal Failure and PH
M.M. Chakinala, MD, St. Louis, MO

3:30 The Minority Report: Gender and Race Inequality in PH
V. De Jesus Perez, MD, Palo Alto, CA

This session and the International Conference are supported by educational grants from Actelion Pharmaceuticals US, Inc., Bayer US. All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

Basic and clinical researchers interested in learning about cutting edge methods to measure mitochondrial metabolism in cells and tissues

Objectives
At the conclusion of this session, the participant will be able to:

- understand mitochondrial metabolism in cells in particularly cells relevant to lung biology and disease;
- learn about Seahorse technology as a way to assess mitochondrial respiration and function;
- understand the importance of assessing mitochondrial health and function in model systems and how to detect extracellular markers of mitochondrial dysfunction.

This session will discuss best practice methods to study mitochondrial function in cells and tissues. Mitochondrial function and glycolysis play critical roles in a variety of cellular processes, including cellular activation, proliferation, differentiation, cell death, and disease progression. Specific signatures of mitochondrial dysfunction that are associated with disease pathogenesis and/or progression are becoming increasingly important. In particular, the centrality of mitochondria in the pathological processes and clinical phenotypes associated with a range of lung diseases including chronic obstructive pulmonary disease, pulmonary fibrosis, acute lung injury, asthma and lung cancer is emerging. Understanding the molecular mechanisms regulating the mitochondrial processes of lung cells will help to better define phenotypes and clinical manifestations associated with respiratory disease and to identify potential diagnostic and therapeutic targets. In this session, attendees will discover how real-time, live cell analysis can provide a complete picture of mitochondrial phenotype and function in model systems and in human disease, with a particular focus on diseases area.

Chairing:
M.N. Gillespie, PhD, Mobile, AL
S.M. Cloonan, PhD, New York, NY
A.L. Mora, MD, Pittsburgh, PA

8:00 Introduction and General Welcome
S.M. Cloonan, PhD, New York, NY

8:15 An Introduction to Lung Biology and Disease
S. Meiners, PhD, BSc, Munich, Germany

8:45 Acute and Adaptive Responses to Mitochondrial Oxidative Stress
G.S. Shadel, PhD, BSc, New Haven, CT

9:15 Signals from Mitochondria to the Cell in Health and Disease
P.T. Schumacker, PhD, Chicago, IL

9:45 Break

10:00 Hallmarks of Pulmonary Hypertension: Mesenchymal and Inflammatory Cell Metabolic Reprogramming
A. D’Alessandro, PhD, Aurora, CO

10:30 Metabolic Profiling of Endogenous and Circulating Metabolites
J.A. Howrylak, MD, Lancaster, PA

11:00 Mitochondrial Function and Immunometabolism
A. Ray, PhD, Pittsburgh, PA

11:30 Bioenergetic Health Profiling of Circulating Peripheral Blood Monocytes and Immune Cells
V. Darley-Usmar, PhD, Birmingham, AL

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
12:00  Lunch Round Table Journal Club  
M.N. Gillespie, PhD, Mobile, AL  

1:00  Station 1. Designing a Seahorse Experiment. Assessment of Bioenergetic Function in Primary Lung Epithelial Cells  
A.J. Janocha, BS, Cleveland, OH  

1:40  Station 2. Hands-on Demonstration of Seahorse  
L. Torres, MD, New York, NY  

2:20  Break  

2:40  Station 3. Assays to Assess Mitochondrial Integrity: How to Know If Your Mitochondria Are Sick?  
A.L. Mora, MD, Pittsburgh, PA  
M. Bueno, PhD, Pittsburgh, PA  

3:20  Station 4. Measuring the Mitochondrial Danger Signal Extracellular mtDNA in Human Plasma  
K. Nakahira, MD, PhD, New York, NY  

This session and the International Conference are supported by an in-kind grant from Agilent Technologies. All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

---

PG15  PULMONARY FUNCTION AND CARDIOPULMONARY EXERCISE TESTING: CLINICAL UPDATES FOR 2018 AND CASE CONFERENCE  
Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.  
Member: $350  
In-Training Member: $200  
Non-Member: $425  
In-Training Non-Member: $300  
Registrants must bring a laptop to the course to view the course material.  

Assemblies on Respiratory Structure and Function; Clinical Problems  
8:00 a.m. - 4:00 p.m.  
SAN DIEGO CONVENTION CENTER  
Room 2 (Upper Level)  

Target Audience  
Current and future directors of PFT labs, attending physicians, respiratory therapists, trainees, fellows, and other interested health care providers  

Objectives  
At the conclusion of this session, the participant will be able to:  
• gain further understanding of the principles and practice of pulmonary function and exercise physiology diagnostic tests;  
• develop greater confidence interpreting pulmonary function and cardiopulmonary exercise test results in clinical practice;  
• identify strategies to approach the interpretation of pulmonary function and cardiopulmonary exercise test results in complex patients.  

This course will focus on updates in lung function testing from the new technical standards published this past year and will provide hands-on experience in small group settings with the interpretation and reporting of pulmonary function and cardiopulmonary exercise test results. We will combine didactic lectures with case-based instruction, and we will offer participants the opportunity to bring their own complex cases for review by an expert team of clinicians and physiologists. We will use a team approach to facilitating the small group discussions including content experts and pulmonary function laboratory medical directors from around the world.  

Chairing:  
C. Oropez, MD, MHS, Tucson, AZ  
M.C. McCormack, MHS, MD, Baltimore, MD  
D.A. Kaminsky, MD, Burlington, VT  

8:00  Introduction  
C. Oropez, MD, MHS, Tucson, AZ  

8:15  Just Breathe: Updates in Spirometry Reporting and Interpretation  
B.H. Culver, MD, Seattle, WA  

8:45  Size Matters: Lung Volume Measurement, Reporting, and Interpretation  
B. Borg, BS, Prahran, Australia  

9:15  Diffusion Minus the Confusion: Updates in DLCO Measurement, Reporting, and Interpretation  
C. Oropez, MD, MHS, Tucson, AZ  

9:45  Kids Count: Special Considerations for Pediatric Pulmonary Function Testing  
D.J. Weiner, MD, Pittsburgh, PA  

10:15  Break  

10:30  Airway Challenge Updates: What’s New in Bronchoprovocation Testing  
T.S. Hallstrand, MD, MPH, Seattle, WA  

11:15  Make the Case: Pulmonary Function Testing  
M.C. McCormack, MHS, MD, Baltimore, MD  

12:15  LUNCH  

12:45  Ready, Set, Go: Patient Evaluation and Exercise Protocols for Cardiopulmonary Exercise Testing  
C.D. Mottram, RPFT, RRT, Rochester, MN  

1:15  Data Overload in Cardiopulmonary Exercise Testing: Examining and Interpreting the Results  
C.G. Irvin, PhD, Burlington, VT  

1:45  Case Conference: PFT and CPET in Clinical Practice  
D.A. Kaminsky, MD, Burlington, VT  

2:30  Break  

2:45  Make the Case: Cardiopulmonary Exercise Testing  
M.C. McCormack, MHS, MD, Baltimore, MD  

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
PG1B CRITICAL CARE ULTRASOUND AND ECHOCARDIOGRAPHY II

This is part 2 of a two-part course which includes PG1A on Friday, May 18.

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Registrants must bring a laptop to the course to view the course material.

Assembly on Critical Care
8:00 a.m. - 4:00 p.m. SAN DIEGO CONVENTION CENTER
Room 9 (Upper Level)

Target Audience
Providers of critical care or emergency medicine

Objectives
At the conclusion of this session, the participant will be able to:
• apply ultrasound at bedside to assess critically ill patients;
• diagnose alternate etiologies of shock in the critically ill patient;
• apply ultrasound to guide common ICU procedures.

This is a two day postgraduate course that consists of didactic lectures and hands-on stations. The focus is primarily bedside transthoracic echocardiography, with some diagnostic ultrasound. The topics include basic and intermediate critical care echocardiography (including hemodynamic measures), assessment of fluid status, procedural guidance for vascular access and thoracentesis, venography. The hands-on stations will include both healthy models and simulators that can demonstrate abnormal pathology.

Chairing: M.J. Lanspa, MD, MSCR, Salt Lake City, UT
X. Monnet, MD, PhD, Le Kremlin-Bicetre, France

8:00 Vascular Ultrasound: DVT Evaluation
L. Rapoport, MD, Santa Clara, CA

8:20 Vascular Access
M.J. Lanspa, MD, MSCR, Salt Lake City, UT

8:45 Tamponade
G.B. Allen, MD, Burlington, VT

9:15 Using Ultrasound to Assess Intravascular Volume and Fluid Responsiveness
X. Monnet, MD, PhD, Le Kremlin-Bicetre, France

9:45 Ultrasound for Diuresis and Dialysis
E.L. Hirshberg, MD, Murray, UT

10:15 Break

10:30 Practical Skills Session: Hands-On Stations III

Volume Status
X. Monnet, MD, PhD, Le Kremlin-Bicetre, France
J. Kasal, MD, St. Louis, MO
E. Teo, MD, Atlanta, GA
S. Nikravan-Weber, MD, Stanford, CA
S. Cha, MD, Baltimore, MD

Tamponade Evolution
V.A. Dinh, MD, Loma Linda, CA
G. Allen, MD, Burlington, VT
A. Leibowitz, MD, Boston, MA
S. Price, MBBS, London, United Kingdom
T. Brakke, MD, Omaha, NE

Vascular Ultrasound
L. Rapoport, MD, Santa Clara, CA
Z. Shaman, MD, Cleveland, OH
L. Grecu, MD, Stony Brook, NY
P.K. Mohabir, MD, Stanford, CA
D. Pradhan, MD, New York, NY

12:00 Lunch and Clinical Cases II

12:45 Abdominal Ultrasonography
V.A. Dinh, MD, Loma Linda, CA

1:15 Goal Directed Management of Shock Using Echocardiography
J. Kasal, MD, St. Louis, MO

1:45 Incorporating Echocardiography into CPR
S. Cha, MD, Baltimore, MD

2:15 Break

2:30 Practical Skills Session: Hands-On Session IV

Echo in Shock and CPR
S. Cha, MD, Baltimore, MD
D. Pradhan, MD, New York, NY
T. Brakke, MD, Omaha, NE
S. Price, MBBS, London, United Kingdom
L. Grecu, MD, Stony Brook, NY

Abdominal Ultrasound
L. Rapoport, MD, Santa Clara, CA
Z. Shaman, MD, Cleveland, OH
V.A. Dinh, MD, Loma Linda, CA
G. Allen, MD, Burlington, VT
P.K. Mohabir, MD, Stanford, CA

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
Ask the Expert
A. Leibowitz, MD, Boston, MA
J. Kasal, MD, St. Louis, MO
X. Monnet, MD, PhD, Le Kremlin-Bicetre, France
S. Nikravan-Weber, MD, Stanford, CA
E. Teo, MD, Atlanta, GA

This session and the International Conference are supported by in-kind grants from Cook Medical, FUJIFILM Sonosite, Inc, Teleflex Medical, Inc.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

---

CLINICAL

POSTGRADUATE COURSE
CME Credits Available: 7

PG16 BRONCH DAY: A COMPREHENSIVE, HANDS-ON GUIDE TO BASIC BRONCHOSCOPY AND EBUS

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $475  In-Training Member: $300  Non-Member: $550  In-Training Non-Member: $400

Registrants must bring a laptop to the course to view the course material.

Assemblies on Clinical Problems; Critical Care; Pediatrics; Thoracic Oncology
8:00 a.m. - 4:00 p.m.  SAN DIEGO CONVENTION CENTER  Room 1 B (Upper Level)

Target Audience
Adult and pediatric pulmonologists and intensivists, thoracic surgeons, physicians-in-training, allied health professionals, and anesthesiologists interested in improving their skills in diagnostic and therapeutic flexible bronchoscopy and EBUS

Objectives
At the conclusion of this session, the participant will be able to:
- diagnose and manage adults and children with benign and malignant respiratory diseases;
- improve knowledge of basic flexible bronchoscopy and strengthen procedural skills;
- understand the indications for linear and radial endobronchial ultrasound and the skills necessary to perform these procedures.

This course is designed to provide a comprehensive introduction to diagnostic and therapeutic flexible bronchoscopy. Participants will acquire the knowledge and skills to improve their proficiency in basic bronchoscopic techniques and be introduced to more advanced diagnostic bronchoscopy, including linear and radial endobronchial ultrasound and navigational bronchoscopy. A series of didactic lectures will be followed by intensive, hands-on training, through the use of physical and virtual reality simulators which will help participants strengthen their procedural skills. This course will be of particular interest to providers seeking to refine their flexible bronchoscopy skills and review the data behind the various bronchoscopic techniques. An audience response system will be used during lectures.

Chairing: C. Channick, MD, Boston, MA  S.S. Oh, DO, Los Angeles, CA

8:00  Introduction  C. Channick, MD, Boston, MA

8:05  Optimizing Basic Bronchoscopy Skills: Bronchoalveolar Lavage, Endobronchial Brushings, and Endobronchial Biopsies  E.E. Folch, MD, MS, Boston, MA

8:30  Improving Your Technique and Yield for Transbronchial and Needle Aspiration Biopsies  S.S. Oh, DO, Los Angeles, CA

8:55  Performing Flexible Bronchoscopy in High-Risk Patients: How to Maximize Outcomes  A. Majid, MD, Boston, MA

9:20  The Role of Flexible Bronchoscopy in the Management of Hemoptysis  C.R. Lamb, MD, Burlington, MA

9:45  Break

10:00  The Fundamentals of Linear EBUS: Overview of the Basic Technique and the Data  C. Channick, MD, Boston, MA

10:25  Pediatric Flexible Bronchoscopy for the Adult and Pediatric Bronchoscopist  C. Spencer, MD, New York, NY

10:50  Management of Airway Foreign Bodies  A.C. Mehta, MBBS, Cleveland, OH

11:15  Introduction to Navigational Bronchoscopy: Review of the Evidence  S. Rafeq, MD, New York, NY

11:40  LUNCH

12:30  Practical Skills Session: Bronchoscopy with Biopsy and Needle Aspiration of Endobronchial Lesions  E.E. Folch, MD, MS, Boston, MA  C. Spencer, MD, New York, NY

1:00  Practical Skills Session: Bronchoscopic Management of Hemoptysis  A. Majid, MD, Boston, MA  J. Chung, MD, San Francisco, CA

1:30  Practical Skills Session: Management of the Difficult Airway  S.S. Oh, DO, Los Angeles, CA  A. Vicencio, MD, New York, NY

2:00  Practical Skills Session: Techniques for Foreign Body Removal Using Flexible Bronchoscopy  A.C. Mehta, MBBS, Cleveland, OH  C. Channick, MD, Boston, MA  B. Husta, MD, New York, NY

2:30  Practical Skills Session: Navigational Bronchoscopy  C.R. Lamb, MD, Burlington, MA  J. Cardenas-Garcia, MD, Hershey, PA

3:00  Practical Skills Station: Endobronchial Ultrasound Anatomy  A.K. Mahajan, MD, Vienna, VA  C. Argento, MD, Chicago, IL

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
PG17 STUDYING PHARMACOGENOMICS IN LUNG DISEASE AND CRITICAL ILLNESS

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350  In-Training: $200
Non-Member: $425  In-Training: $300
Registrants must bring a laptop to the course to view the course material.

Target Audience
Clinical and translational researchers interested in pharmacogenomic approaches to study the genetic basis for drug efficacy and adverse events with the ultimate goal of developing more effective and less toxic therapies for patients.

Objectives
At the conclusion of this session, the participant will be able to:

• gain working knowledge of pharmacogenomic study design and analysis;
• understand and gain working knowledge of some key successes and remaining challenges in application of pharmacogenomic approaches to the study of lung diseases;
• gain understanding of how pharmacogenomics might impact future care of patients with lung disease.

Pharmacogenomics analyzes how the genetic makeup of an individual affects his/her responses to drugs. It can provide new insights on pathophysiology, focus the use of specific therapies to those who will benefit, and divert use in whom risk of harm is too great. There are increasing numbers of successful applications of pharmacogenomics in lung diseases. This course will provide an overview of the key aspects in design and analyses of pharmacogenomic studies, some examples of its successful use, and outline some ongoing efforts to implement pharmacogenomic knowledge in clinical medicine.

Chairing: M.M. Wurfel, MD, PhD, Seattle, WA
           G.H. Koppelman, MD, PhD, Groningen, Netherlands
           D.A. Meyers, PhD, Tucson, AZ

8:00 Introduction
M.M. Wurfel, MD, PhD, Seattle, WA
Target Audience
Individuals who currently use or would like to utilize qualitative methods and analysis in their research, as well as individuals who read the literature and would like to better understand qualitative research.

Objectives
At the conclusion of this session, the participant will be able to:
- describe the theory and methods for qualitative research;
- develop a qualitative research project and analyze qualitative data;
- evaluate the rigor of published qualitative research studies.

Qualitative research is a broad approach utilized to gain in-depth understanding of phenomena, answering questions of how and why. This practical skills development course will combine didactics with workshops to provide a toolkit for clinicians, educators, and researchers to apply and evaluate rigorous qualitative methods. Attendees will be introduced to qualitative research and learn about each step from the research question to dissemination of results; in addition a variety of examples will be presented. Participants will be divided in small groups by topic area, research, medical education, and quality improvement with facilitators who have expertise in applying qualitative research in each area.

Chairing:
A. Volerman, MD, Chicago, IL
M. Eakin, PhD, Baltimore, MD

8:00 Introduction and Applications of Qualitative Research
M. Eakin, PhD, Baltimore, MD

8:10 Building Blocks: Qualitative Research Principles
C.G. Slatore, MD, Portland, OR

8:30 The Design Process: Methods and Sample in Qualitative Projects
A. Volerman, MD, Chicago, IL

9:00 Workshop: Developing Your Own Qualitative Research Study
A. Volerman, MD, Chicago, IL
M. Eakin, PhD, Baltimore, MD
C.G. Slatore, MD, Portland, OR
J. Foster, BSc(Hons), PhD, Sydney, Australia
M.R. Patel, PhD, MPH, Ann Arbor, MI
L. Hinkle, MD, Indianapolis, IN
J. Tate, PhD, RN, Columbus, OH
D. Sullivan, MD, MA, Portland, OR
K.A. Riekert, PhD, Baltimore, MD

9:40 Discussion
M. Eakin, PhD, Baltimore, MD

10:00 Time to Ask: The Topic Guide
M.R. Patel, PhD, MPH, Ann Arbor, MI

10:30 Workshop: Developing a Topic Guide
A. Volerman, MD, Chicago, IL
M. Eakin, PhD, Baltimore, MD
C.G. Slatore, MD, Portland, OR
M.R. Patel, PhD, MPH, Ann Arbor, MI
L. Hinkle, MD, Indianapolis, IN
J. Tate, PhD, RN, Columbus, OH
D. Sullivan, MD, MA, Portland, OR
K.A. Riekert, PhD, Baltimore, MD

11:10 Talk to Me: Skills for Qualitative Data Collection
J. Tate, PhD, RN, Columbus, OH

11:40 LUNCH

12:00 Building the Story: Analyzing Qualitative Data
L. Hinkle, MD, Indianapolis, IN

12:50 Workshop: Qualitative Data Analysis in Action
A. Volerman, MD, Chicago, IL
M. Eakin, PhD, Baltimore, MD
C.G. Slatore, MD, Portland, OR
M.R. Patel, PhD, MPH, Ann Arbor, MI
L. Hinkle, MD, Indianapolis, IN
J. Tate, PhD, RN, Columbus, OH
D. Sullivan, MD, MA, Portland, OR
K. Riekert, PhD, Baltimore, MD

1:30 Putting the Quality into Qualitative Data
J. Foster, BSc(Hons), PhD, Sydney, Australia

2:00 Discussion
A. Volerman, MD, Chicago, IL

2:10 Break

2:20 Finding the Quality: Evaluating Qualitative Research
K.A. Riekert, PhD, Baltimore, MD

2:40 Workshop: Reviewing Qualitative Research Studies
A. Volerman, MD, Chicago, IL
M. Eakin, PhD, Baltimore, MD
C.G. Slatore, MD, Portland, OR
M.R. Patel, PhD, MPH, Ann Arbor, MI
L. Hinkle, MD, Indianapolis, IN
J. Tate, PhD, RN, Columbus, OH
D. Sullivan, MD, MA, Portland, OR
K. Riekert, PhD, Baltimore, MD

3:10 Mixing Qualitative and Quantitative Research
D. Sullivan, MD, MA, Portland, OR

3:30 Bringing Qualitative Research Home
A. Volerman, MD, Chicago, IL
Target Audience
Clinicians, nurses, other allied health staff, researchers, investigators in basic and clinic science pertinent to interstitial lung disease, and sponsors for research.

Objectives
At the conclusion of this session, the participant will be able to:

• accurately diagnose patients with specific forms of ILD;
• gain improved understanding in current concepts of pathogenesis and genetic aspects of pulmonary fibrosis as well as knowledge of new therapeutic strategies to treat patients with ILD/pulmonary fibrosis;
• gain better insight into the endpoints used in IPF clinical trials assessment of treatment response and the significance of exploratory, subgroup, and post hoc analyses.

This course provides an update on evolving trends in diagnosis, clinical management, and research investigation of the heterogeneous group of interstitial lung diseases (ILDs) of unknown etiology, in the setting of connective tissue diseases and granulomatous ILD (hypersensitivity pneumonitis and sarcoidosis) with an emphasis on idiopathic pulmonary fibrosis (IPF). This includes new data for the diagnosis of IPF since the 2011 guidelines and perspectives for the diagnosis and management of hypersensitivity pneumonitis. Genetic factors, precision medicine for diagnosis and treatment as well as newer concepts in the pathogenesis of IPF and novel treatment strategies to modulate pulmonary fibrosis will be discussed. Attendees will be updated on evolving enhanced knowledge in the clinical management of patients with ILD. The importance of making an accurate diagnosis will be demonstrated by live interactions with a panel of experts from multiple disciplines confronted with 3-4 cases unknown to them.

Chairing:
G. Raghu, MD, Seattle, WA
L. Richeldi, MD, PhD, Rome, Italy
B. Collins, MD, Seattle, WA

8:00 Introduction
G. Raghu, MD, Seattle, WA

8:05 Interstitial Lung Disease: An Overview to Diagnosis with an Emphasis of Diagnosis of Idiopathic Pulmonary Fibrosis
G. Raghu, MD, Seattle, WA

8:30 Imaging in ILD: Clues to Diagnosis
M. Remy-Jardin, MD, Lille, France

8:55 Histopathology Features of ILD, Does Tissue Sampling Matter?: Role of Transbronchial, Cryo and Thoracoscopic Lung Biopsies
J.L. Myers, MD, Ann Arbor, MI

9:20 Genetics of Pulmonary Fibrosis: Time for Genetic Screening and Intervention?
M. Armanios, MD, Baltimore, MD

9:45 Pulmonary Fibrosis: Concepts in Pathogenesis from Bench to Bedside
M.R.J. Kolb, MD, PhD, Hamilton, Canada

10:10 Break

10:20 Connective Tissue Disease for the Pulmonologist Evaluating Interstitial Lung Disease: A Rheumatologist’s View
R. Silver, MD, Charleston, SC

10:45 Hypersensitivity Pneumonitis: What and Where Is the Antigen; Strategies for Diagnosis and Treatment?
M. Vasakova, MD, Thomayerova, Czech Republic

11:10 Case Discussion with Panel of Experts (Multidisciplinary Discussion)
B. Collins, MD, Seattle, WA

12:00 LUNCH

12:30 Sarcoidosis: Treatment Beyond Prednisone and Methotrexate
D.A. Culver, DO, Cleveland, OH

12:55 Circulating Biomarkers for Diagnosis and Management of ILD/Pulmonary Fibrosis/IPF: Still Research or Prime Time for Routine Clinical Care
A. Prasse, MD, Hannover, Germany

1:20 Pulmonary Hypertension Associated with Pulmonary Fibrosis
M. Humbert, MD, PhD, Bicetre, France

1:45 Smoking Related ILDs Other than IPF
R. Raj, MD, Stanford, CA

2:10 Break

2:20 Reducing Cough and Other Symptoms and Improving Quality of Life for Patients with IPF: Therapeutic Needs and Palliative Care
M. Wijsenbeek, MD, PhD, Rotterdam, Netherlands

2:45 Clinical Trial Endpoints for Assessing Treatment Response for Patient with IPF: What Is Meaningful and To Whom?
K. Anstrom, PhD, MD, Durham, NC

3:10 Precision Medicine and Pharmacogenomics for Treatment of IPF: Ready or Not for Prime Time
F.J. Martinez, MD, MS, New York, NY

3:35 Treatment of IPF: Current Landscape of Treatment and What Is in the Horizon -Ongoing/Upcoming Clinical Trials
L. Richeldi, MD, PhD, Rome, Italy

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
Target Audience
Pulmonologists, critical care physicians, thoracic surgeons, midlevel providers, respiratory therapists, residents, fellows, and students

Objectives
At the conclusion of this session, the participant will be able to:

• formulate a differential diagnosis of respiratory diseases based on diagnostic imaging findings;
• improve strategies for the evaluation of solitary pulmonary nodules and for staging lung cancer;
• state the value of a multidisciplinary approach to diagnosis and management of patients with diffuse lung disease.

This course will review major aspects of thoracic imaging with presentations targeted toward the pulmonologist and critical care physician using a case-based approach and audience participation. Subspecialized thoracic radiologists will give case-based presentations focusing on the practical aspects of chest imaging. Presentations will be image rich and focus on key imaging findings, differential diagnoses, and potential pitfalls. Topics will cover a broad range of chest disease and will be relevant to trainees, generalists, and specialists, alike. At the conclusion of the course, learners will have increased knowledge about thoracic imaging and be able to apply this knowledge to their respective practices.

Chairing: J.P. Kanne, MD, Madison, WI
C.C. Wu, MD, Houston, TX

8:00 Imaging Diseases of the Small Airways
T. Henry, MD, San Francisco, CA

8:30 Imaging Diseases of the Large Airways
S. Rossi, MD, Buenos Aires, Argentina

9:00 Critical Care
M.D. Martin, MD, Madison, WI

9:30 Break

9:45 Imaging of Pleural Diseases
C.C. Wu, MD, Houston, TX

10:15 Imaging of the Solitary Pulmonary Nodule
J.H. Chung, MD, Chicago, IL

10:45 Lung Cancer Imaging
A. Leung, MD, Stanford, CA

11:15 LUNCH

12:15 Imaging of Pulmonary Infections
L.H. Ketai, MD, Albuquerque, NM

12:45 HRCT of Diffuse Lung Diseases
D.A. Lynch, MBBCh, Denver, CO

1:15 Break

1:30 Multidisciplinary Approach to Diffuse Lung Diseases
K.K. Brown, MD, Denver, CO
S.D. Groshong, MD, PhD, Denver, CO
D.A. Lynch, MBBCh, Denver, CO

3:30 Imaging of Pulmonary Vascular Diseases
S.J. Kligerman, MD, San Diego, CA

PG21 A HANDS-ON INTRODUCTION TO STUDYING THE LUNG MICROBIOME

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350 In-Training Member: $200
Non-Member: $425 In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Assemblies on Pulmonary Infections and Tuberculosis; Allergy, Immunology and Inflammation
8:00 a.m. - 4:00 p.m. SAN DIEGO CONVENTION CENTER

Target Audience
Research scientists interested in designing, performing, and understanding the analysis of lung and airway microbiota using sequencing-based techniques

Objectives
At the conclusion of this session, the participant will be able to:

• research design and analytical approaches needed to conduct culture-independent assessment of microbial communities in respiratory specimens;
• apply bioinformatic tools to analyze sequencing data;
• illustrate the use of a combination of basic science as well as multi-dimensional computational approaches for investigating microbial function and mechanisms of disease.

This course will introduce methodologies used to characterize and understand lung and airway microbiota using culture-independent methods. During the proposed sessions, participants will learn how to design, execute, analyze and interpret a lung microbiome study. Hands-on experiences will include the use of Quantitative Insights Into Microbial Ecology (QIIME), a bioinformatic pipeline used to process raw sequencing data and R (Phyloseq and Vegan), statistical software packages used to analyze and graphically display microbiome data. 16S rRNA gene sequencing data will be provided to attendees to perform analyses.

Chairing: L.N. Segal, MD, New York, NY
R.P. Dickson, MD, Ann Arbor, MI
A. Pragman, MD, PhD, Minneapolis, MN

8:00 An Introduction to Thinking About the Microbiome
R.P. Dickson, MD, Ann Arbor, MI

8:50 Contaminomics
M.J. Cox, BSc(Hons), PhD, London, United Kingdom

9:20 The Role of Culture in a Culture-Independent Age
M.G. Surette, PhD, Hamilton, Canada

9:50 Break

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
10:05 Breakout Session: QIIME  
J. Clemente, PhD, New York, NY

11:35 LUNCH

12:35 Real-Time Metagenomics  
J. Erb-Downward, PhD, Ann Arbor, MI

12:55 Breakout Session: R Phyloseq/Vegan  
M. Badri, PhD, New York, NY

2:25 Break

2:40 Metabolomics  
S.K. Cribbs, MD, MSC, Decatur, GA

3:00 Longitudinal Microbiome Studies  
D. Bogart, MD, PhD, Edinburgh, United Kingdom

3:20 Multiomics  
M. Badri, PhD, New York, NY

3:40 Questions and Answers with Panel Discussion  
L.N. Segal, MD, New York, NY

The course will provide an overview and update on the latest in bronchiectasis and cystic fibrosis. The course will cover recent epidemiologic trends, radiology, microbiology, diagnosis and management in bronchiectasis and cystic fibrosis. Also, the course will cover the latest in research (including results from the national Bronchiectasis Research Registry, European EMBARC registry, CF registry, genetic epidemiologic research and recent clinical trials on inhaled and antibiotic therapy in bronchiectasis and CF). We will hold interactive case-based panel discussions and discuss common and difficult real-world patient scenarios.

Chairing:  
A. Basavaraj, MD, New York, NY  
S.H. Kasperbauer, MD, Denver, CO  
K.L. Winthrop, MD, MPH, Portland, OR

8:00 Introduction  
A. Basavaraj, MD, New York, NY

8:05 Epidemiology in Bronchiectasis and Cystic Fibrosis  
R. Thomson, MBBS, PhD, Greenslopes, Australia

8:35 Genetics in Bronchiectasis and Cystic Fibrosis  
K.N. Olivier, MD, MPH, Bethesda, MD

9:05 Diagnostic Evaluation in Bronchiectasis  
M.L. Metersky, MD, Farmington, CT

9:35 Antibiotic Management in the NTM Patient  
D.E. Griffith, MD, Tyler, TX

10:05 Break

10:20 New Pharmacologic Strategies in Cystic Fibrosis  
P.A. Flume, MD, Charleston, SC

10:50 Airway Clearance Techniques in Bronchiectasis and Cystic Fibrosis  
A.E. O’Donnell, MD, Washington, DC

11:20 Infection Prevention and Chronic Suppression in Bronchiectasis and Cystic Fibrosis  
S.T. Lommatzsch, MD, Denver, CO

11:50 LUNCH

12:45 Case-Based Panel Discussion: Bronchiectasis and NTM Cases in the Community  
K.M. O’Neil, MD, Wilmington, NC

This session and the International Conference are supported by educational grants from  
Insmed Incorporated, Vertex Pharmaceuticals Inc.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.
PG23  ADVANCES IN THE DIAGNOSIS AND MANAGEMENT OF PEDIATRIC SEVERE ASTHMA

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350  In-Training Member: $200
Non-Member: $425  In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Assembly on Pediatrics
8:00 a.m. - 4:00 p.m.  SAN DIEGO CONVENTION CENTER
Room 3 (Upper Level)

Target Audience
Providers caring for children with severe asthma

Objectives
At the conclusion of this session, the participant will be able to:

• perform a stepwise evaluation for pediatric patients referred for severe asthma;
• list biomarkers for asthma and describe their role in the asthma inflammatory pathways;
• choose biologic or non-traditional therapies for patients with severe asthma who have not responded to standard therapies.

This course provides state of the art information on the evaluation and management of severe asthma in children. Speakers will review best practices for evaluation including medication adherence monitoring and support. Discussions will range from the clinically relevant biologic mechanisms of asthma to addressing whether phenotyping and endotyping can improve outcomes. We will also discuss strategies for developing partnerships with other health care disciplines and community resources in order to achieve a patient-centered approach. The course includes small group review of difficult cases and discussion of unmet needs. Speakers will also demonstrate appropriate use of targeted therapies, and describe best practices for monitoring for adverse effects of therapies.

Chairing:  J. Gaffin, MD, Boston, MA
L.B. Bacharier, MD, St. Louis, MO
K.R. Ross, MD, MS, Cleveland, OH

8:00  Welcome and Introduction
J. Gaffin, MD, Boston, MA

8:05  Roadmap to the Practical Evaluation of Pediatric Severe Asthma
J. Gaffin, MD, Boston, MA

8:25  One Size Does Not Fit All: Diagnostic Tools and Frameworks for Characterizing the Pediatric Severe Asthma Patient
K.R. Ross, MD, MS, Cleveland, OH

8:50  Therapeutics: Which Biologic Is Right for My Patient?
L.B. Bacharier, MD, St. Louis, MO

9:15  Therapeutics: Non-Biologic Therapies and Future Options
S. Saglani, BSc(Hons), MD, MBChB, London, United Kingdom

9:40  Harnessing the ‘Difficult to Control’ Asthmatic: Psychological Assessments and Interventions to Improve Self-Management
P. Marik, PsyD, Milwaukee, WI

10:00  Break

10:20  Harnessing the ‘Difficult to Control’ Asthmatic: “Trust, but Verify” -Strategies for Adherence Monitoring
C.L. Yang, MD, MSc, Vancouver, Canada

10:45  Asthma Plus: Addressing Comorbidities - Sleep Apnea, Gastroesophageal Reflux, Rhinosinusitis, and Obesity
E. Forno, MD, MPH, Pittsburgh, PA

11:10  Case Based Small Group Discussions
J. Gaffin, MD, Boston, MA

12:00  LUNCH

12:50  Stay Out of the Red (Zone): Outpatient Management of Exacerbations
D.J. Jackson, MD, Madison, WI

1:15  Monitoring Side Effects: Steroids, Biologics, LABAs
M. Federico, MD, Aurora, CO

1:35  Outside the Clinic: Home Visits and Community Partnerships
S. Sommer, MSN, WHNP-BC, AE-C, Boston, MA

1:55  Outside the Clinic: Partnering with Schools and School Nurses
L.B. Gerald, PhD, MSPH, Tucson, AZ

2:15  Break

2:35  Multidisciplinary Severe Asthma Programs: What Are They and Are They Effective?
T.W. Guilbert, MD, Cincinnati, OH

2:55  Helping Patients Navigate: Young Adult Transition
W.M. Gibson-Scipio, APRN-BC, PhD, Detroit, MI

3:10  Helping Patients Navigate: Advocacy
T. Winders, MBA, Vienna, VA

3:25  Panel Discussion
K.R. Ross, MD, MS, Cleveland, OH

This session and the International Conference are supported by educational grants from GlaxoSmithKline, Sanofi Genzyme and Regeneron Pharmaceuticals.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.
Assemblies on Pediatrics; Nursing

8:00 a.m. - 4:00 p.m. SAN DIEGO CONVENTION CENTER
Room 6 D (Upper Level)

Target Audience
Pediatric pulmonologists, gastroenterologists, surgeons, fellows, nurses, speech therapists, and health care practitioners providing coordinated care to children with chronic multi-system disease

Objectives
At the conclusion of this session, the participant will be able to:

• integrate a multi-disciplinary approach to improve the diagnostic accuracy and outcome for children with aerodigestive disorders;
• apply and synthesize diagnostic results into an effective management plan for children with complex chronic pulmonary aspiration;
• gain new strategies and methods for pediatric pulmonologists to diagnose and manage complex but common airway diseases.

This course will aid pediatric pulmonologists and care coordinators in the development of multidisciplinary programs for children with complex chronic conditions affecting lung health. The integrated team approach to coordinated evaluation and management of children with complex diseases affecting airways and breathing, feeding and swallowing, and development, will be presented in a multi-disciplinary and interactive format.

Chairing: R.P. Boesch, DO, MS, Rochester, MN
M. Kazachkov, MD, New York, NY

8:00 Aerodigestive Care Update. What Have We Achieved in the Past Year?
R.P. Boesch, DO, MS, Rochester, MN

8:15 Aerodigestive Best of the Year
R.R. Deterding, MD, Aurora, CO

8:45 Imaging the Aerodigestive Patient
R.J. Fleck, MD, Cincinnati, OH

9:15 Is Chronic Cough an Aerodigestive Condition? - Pro
A.B. Chang, PhD, Brisbane, Australia

9:30 Is Chronic Cough an Aerodigestive Condition? - Con
M. Kazachkov, MD, New York, NY

9:45 Is Chronic Cough an Aerodigestive Condition? - Rebuttals
A.B. Chang, PhD, Brisbane, Australia

10:05 Break

10:15 Aspiration from the Otolaryngologist’s Perspective
K. Balakrishnan, MD, MPH, Rochester, MN

10:35 Aspiration from the Pulmonologist’s Perspective
R.P. Boesch, DO, MS, Rochester, MN

10:55 Aspiration from the Gastroenterologist’s Perspective
R. Rosen, MD, Boston, MA

11:15 Aspiration from the Speech Language Pathologist’s Perspective
M. Lefton-Greif, MA, PhD, Baltimore, MD

11:35 LUNCH

12:05 Multidisciplinary Approach to Robin Sequence
J.J. Soares, MD, Seattle, WA

12:55 Tracheomalacia Evaluation and Medical Management
J.C. Piccione, MS, DO, Philadelphia, PA

1:20 Surgical Management of Tracheomalacia
K. Balakrishnan, MD, MPH, Rochester, MN

1:45 Aerodigestive Approach to Recurrent Croup
D. Simon, MD, Atlanta, GA

2:15 Break

2:25 100 Ways to Get the Wrong Answer with a Flexible Bronchoscope
R.E. Wood, MD, PhD, Cincinnati, OH

2:55 Aerodigestive Case Presentations
R.E. Wood, MD, PhD, Cincinnati, OH

3:45 Wrap Up: Where Is Aerodigestive Care Headed in the Next Year?
M. Kazachkov, MD, New York, NY

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350 In-Training Member: $200
Non-Member: $425 In-Training Non-Member: $300
Registrants must bring a laptop to the course to view the course material.

Assemblies on Pulmonary Circulation; Clinical Problems; Critical Care

8:00 a.m. - 4:00 p.m. SAN DIEGO CONVENTION CENTER
Room 4 (Upper Level)

Target Audience
Providers of lung health, physicians, physician trainees, physician assistants, nurses and respiratory therapists with interest in pulmonary disorders, cardiovascular disease, pulmonary embolism, critical care or pulmonary hypertension field

Objectives
At the conclusion of this session, the participant will be able to:

• properly risk stratify patients with acute PE and assess their bleeding risk prior to starting anticoagulation;
• integrate and compare the medical, endovascular and surgical strategies to manage the care of acute PE;
• describe diagnosis and management of chronic thromboembolic pulmonary hypertension (CTEPH).

There have been many advances in the field of pulmonary embolism, including new guidelines on risk stratification and anticoagulation, as well as evolving areas in its treatment, management and follow up. The goal of this conference is to provide up-to-date information about advancements in the field of acute pulmonary embolism, including risk stratification, thrombolysis and novel endovascular and surgical techniques, as well as the management of PE complications such as chronic thromboembolic pulmonary hypertension.
We will present case vignettes, in which we will include the audience using “audience response system” for an interactive learning experience.

Chairing: B.N. Rivera-Lebron, MD, MS, Pittsburgh, PA
G.A. Heresi, MD, Cleveland, OH

8:00 Prevalence, Classification and Risk Stratification of Acute PE
B.N. Rivera-Lebron, MD, MS, Pittsburgh, PA

8:30 Bleeding Risk Consideration Prior to Initiation of Therapy
J.R. Bartholomew, MD, MS, Cleveland, OH

9:00 Indication for Systemic Lysis Over Anticoagulation
S.V. Konstantinides, MD, Mainz, Germany

9:30 Endovascular Techniques in the Treatment of Acute PE
A.K. Sista, MD, New York, NY

10:00 Break

10:15 Role of Surgical Embolectomy and ECMO in PE
B. Keeling, MD, Atlanta, GA

10:45 Multidisciplinary PE Response Team (PERT) Development and Implementation
R.N. Channick, MD, Boston, MA

11:15 Case Presentation with “Audience Response System” - Acute PE
S. Naydenov, MD, St. Louis, MO

11:45 LUNCH

12:15 IVC Filters: Is There a Role Anymore?
T.M. Bull, MD, Aurora, CO

1:15 Oral Anticoagulation Selection and Duration
R.P. Rosovsky, MD, Boston, MA

1:45 Post-PE Complications
V.F. Tapson, MD, West Hollywood, CA

2:15 Break

2:30 CTEPH Epidemiology and Diagnosis
G.A. Heresi, MD, Cleveland, OH

3:00 Medical, Endovascular, and Surgical Treatment of CTEPH
K.M. Kerr, MD, La Jolla, CA

3:30 Case Presentation with “Audience Response System” - CTEPH
W.R. Auger, MD, La Jolla, CA

CLAIRE • TRANSLATIONAL

POSTGRADUATE COURSE

PG26 THIS SESSION HAS BEEN CANCELED
PRACTICAL STRATEGIES TO ENHANCE PATIENT ENGAGEMENT IN HEALTH CARE

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
Breakout Session 1
P.A. Kritek, MD, Seattle, WA
B.A. Cockrill, MD, Boston, MA
H.L. Manning, MD, Lebanon, NH
R.M. Schwartzstein, MD, Boston, MA
B. Coruh, MD, Seattle, WA
J.T. Poston, MD, Chicago, IL
P.G. Carvalho, MD, Boise, ID
A.S. Clay, MD, Durham, NC
D.R. Crouch, MD, MS, La Jolla, CA

11:50 LUNCH

1:05 Chronic Obstructive Pulmonary Disease
R.M. Schwartzstein, MD, Boston, MA

1:35 Break

1:45 Neuromuscular Diseases
S.P. Kantrow, MD, New Orleans, LA

2:15 Idiopathic Pulmonary Fibrosis
H.L. Manning, MD, Lebanon, NH

Breakout Session 2
P.A. Kritek, MD, Seattle, WA
B.A. Cockrill, MD, Boston, MA
H.L. Manning, MD, Lebanon, NH
R.M. Schwartzstein, MD, Boston, MA
B. Coruh, MD, Seattle, WA
J.T. Poston, MD, Chicago, IL
P.G. Carvalho, MD, Boise, ID
A.S. Clay, MD, Durham, NC
D.R. Crouch, MD, MS, La Jolla, CA

Objectives
At the conclusion of this session, the participant will be able to:

• diagnose SDB in their patients;
• more comfortable referring for diagnostic testing and managing patients with SDB. Attendees will also become familiar with the use of NIV for patients with chronic respiratory failure;
• improve the quality of lives of patients through earlier diagnosis and management of OSA.

Sleep disordered breathing (SDB), which includes central and obstructive sleep apnea, is by far the most common respiratory disorder in the developed world. Pulmonary and critical care physicians receive little instruction or teaching about SDB, even though emerging evidence suggests that recognition and treatment can improve outcomes for their patients. Furthermore, new data suggest a role for non-invasive ventilation in the management of patients with chronic respiratory disease. This session is designed to provide: 1) an overview of Sleep Disordered Breathing epidemiology and pathogenesis; 2) evidence of the importance of “Overlap” Syndromes between SDB and chronic respiratory disorders such as COPD, asthma, pulmonary fibrosis. This will include new data suggesting a mortality benefit for the use of NIV in COPD. 3) review evidence for importance of recognizing SDB in the hospital, and emerging data that early diagnosis and treatment can improve outcomes.

Chairing: R.L. Owens, MD, La Jolla, CA
B.A. Phillips, MD, MPH, Lexington, KY
R.J. Schwab, MD, Philadelphia, PA

8:00 The Importance of Sleep Medicine in Pulmonary and Critical Care Medicine
B.A. Phillips, MD, MPH, Lexington, KY

8:15 Epidemiology and Consequences of OSA
N.M. Punjabi, MD, PhD, Baltimore, MD

8:40 Pathogenesis of Obstructive Sleep Apnea
R.L. Owens, MD, La Jolla, CA

9:05 Epidemiology and Pathogenesis of Central Sleep Apnea
M. Arzt, MD, Regensburg, Germany

9:35 Break

9:55 CPAP: How Good Is It, and How Can We Get Patients to Wear It?
J.P. Bakker, PhD, Boston, MA

10:20 Gizmos and Gadgets - Non PAP Therapy for OSA
B.A. Edwards, PhD, Melbourne, Australia

10:45 Do We Want to Know? OSA Screening and Post-Op Care
D.R. Hillman, MD, Nedlands, Australia

11:15 Sleep Medicine in the Hospital: Early Recognition and Management of OSA Improves Outcomes
S. Sharma, MD, Cherry Hill, NJ

11:45 LUNCH

12:45 Not Just Severe OSA: Obesity Hypoventilation and NIV
B. Mokhlesi, MD, MS, Chicago, IL

1:10 Alphabet Soup: Advanced Modes of PAP Therapy
J.F. Masa, MD, PhD, Caceres, Spain

1:35 NIV for Neuromuscular Disease
L.F. Wolfe, MD, Chicago, IL

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00</td>
<td>Upper and Lower Airways: Asthma and OSA</td>
<td>M. Teodorescu, MD, MS, Madison, WI</td>
</tr>
<tr>
<td>2:25</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>2:40</td>
<td>Upper and Lower Airways: COPD and OSA</td>
<td>W.T. McNicholas, MD, MBBS, Dublin, Ireland</td>
</tr>
<tr>
<td>3:10</td>
<td>Treatment of Hypercapnic COPD with NIV</td>
<td>P.C. Gay, MD, Rochester, MN</td>
</tr>
<tr>
<td>3:40</td>
<td>The Future of Sleep Medicine</td>
<td>R.J. Schwab, MD, Philadelphia, PA</td>
</tr>
</tbody>
</table>

**BEHAVIORAL • CLINICAL • TRANSLATIONAL**

**POSTGRADUATE COURSE**

CME Credits Available: 7

**PG29 STATE OF THE ART: LUNG CANCER IN 2018**

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

- **Member:** $350
- **In-Training Member:** $200
- **Non-Member:** $425
- **In-Training Non-Member:** $300

Registrants must bring a laptop to the course to view the course material.

Assemblies on Thoracic Oncology; Behavioral Science and Health Services Research; Clinical Problems

**8:00 a.m. - 4:00 p.m. SAN DIEGO CONVENTION CENTER**

Room 8 (Upper Level)

**Target Audience**

All providers caring for patients with lung nodules / lung cancer (pulmonologists, thoracic surgeons, radiation oncologists, nurse practitioners / physician assistants)

**Objectives**

At the conclusion of this session, the participant will be able to:

- apply recommended screening protocols in your local lung nodule clinic;
- apply the forthcoming 8th edition of the TNM Classification for Lung Cancer to the care of patients;
- integrate new and minimally invasive treatment options to improve the care of your patients with lung cancer.

This course will provide a comprehensive review of topics in the evaluation and management of patients with lung cancer. We will start with an outstanding international example of tobacco control, discuss guidelines and practical tips for lung cancer screening, the new staging system and use of biomarkers for lung cancer detection. The treatment of early-stage, locally-advanced and metastatic disease will be addressed, highlighting novel / minimally invasive approaches as well as the use of immunotherapy. Malignant effusions, mesothelioma and the importance of palliation will be reviewed in detail.

Interactive tumor boards will be held to highlight main teaching points.

**Chairing:**

- D.J. Feller-Kopman, MD, Baltimore, MD
- M.P. Rivera, MD, Chapel Hill, NC

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>Introduction</td>
<td>D.J. Feller-Kopman, MD, Baltimore, MD</td>
</tr>
<tr>
<td>8:05</td>
<td>How to Get to a 5% National Smoking Rate: Lessons from Down Under</td>
<td>M. Daube, MD, Perth, Australia</td>
</tr>
<tr>
<td>8:30</td>
<td>Pearls and Pitfalls in Developing a Lung Cancer Screening Program</td>
<td>N.T. Tanner, MD, MSCR, Charleston, SC</td>
</tr>
<tr>
<td>8:55</td>
<td>NLST vs USPFTF vs NCCN, Fleischner vs LungRads: I'm SO Confused</td>
<td>P.J. Mazzone, MPH, MD, Cleveland, OH</td>
</tr>
<tr>
<td>9:20</td>
<td>Interactive Tumor Board</td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10:10</td>
<td>Biomarkers in Lung Cancer: Ready for Prime Time?</td>
<td>C.R. Sears, MD, Indianapolis, IN</td>
</tr>
<tr>
<td>10:35</td>
<td>The New Staging System: Why It Matters and How Am I Going to Remember All of This</td>
<td>L.T. Tanoue, MD, New Haven, CT</td>
</tr>
<tr>
<td>11:00</td>
<td>Beyond the Eyeball Test: Pre-Operative Evaluation</td>
<td>M.B. Drummond, MHS, MD, Chapel Hill, NC</td>
</tr>
<tr>
<td>11:25</td>
<td>VATS and RATS - Minimally Invasive Surgery for Lung Cancer</td>
<td>D. Molena, MD, New York, NY</td>
</tr>
<tr>
<td>11:50</td>
<td>LUNCH</td>
<td></td>
</tr>
<tr>
<td>12:40</td>
<td>Beyond Diagnosis: Is Bronchoscopic Treatment of Lung Cancer Possible?</td>
<td>D.J. Feller-Kopman, MD, Baltimore, MD</td>
</tr>
<tr>
<td>1:05</td>
<td>Immunotherapy for Lung Cancer: The Dawn of a New Day</td>
<td>Z.G. Fridlender, MD, Jerusalem, Israel</td>
</tr>
<tr>
<td>1:30</td>
<td>Interactive Tumor Board</td>
<td>M.P. Rivera, MD, Chapel Hill, NC</td>
</tr>
<tr>
<td>2:10</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>2:20</td>
<td>Stage 3 Disease - Do We Have Consensus?</td>
<td>M. Das, MD, Palo Alto, CA</td>
</tr>
<tr>
<td>2:40</td>
<td>What About the Pleura: Malignant Effusions and Mesothelioma</td>
<td>J. Friedberg, MD, Baltimore, MD</td>
</tr>
<tr>
<td>3:05</td>
<td>Palliative Care in Lung Cancer</td>
<td>M.M. Hayes, MD, Boston, MA</td>
</tr>
<tr>
<td>3:30</td>
<td>Lung Cancer Journal Club: The Year's Top 5 Manuscripts</td>
<td>M.P. Rivera, MD, Chapel Hill, NC</td>
</tr>
</tbody>
</table>

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
4:30 p.m. - 5:30 p.m.

OPENING CEREMONY
SAN DIEGO CONVENTION CENTER
Hall H (Ground Level)

The American Thoracic Society invites you to attend the Opening Ceremony for the 2018 International Conference. The Ceremony will feature distinguished physician, educator, and medical scientist Darrell G. Kirch, MD, president and chief executive officer of the Association of American Medical Colleges. Dr. Kirch speaks and publishes on the need for transformation in the nation’s health care system, and how academic medicine can lead change across medical education, biomedical research, and patient care. Also during the Opening Ceremony will be an address by ATS President Marc Moss, MD, and the presentation of several Respiratory Health Awards:

Public Service Award: George D. Thurston, ScD, Tuxedo Park, NY
World Lung Health Award: Eric D. Bateman, MBChB, MD, Cape Town, South Africa
Jo Rae Wright Award for Outstanding Science: Yohannes T. Ghebre, PhD, Houston, TX

5:30 p.m. - 6:30 p.m.

THE NETWORKING EXCHANGE FOR EARLY CAREER PROFESSIONALS
MARRIOTT MARQUIS SAN DIEGO MARINA
Pacific Ballroom Foyer (North Tower, First Floor)

The Networking Exchange for Early Career Professionals is an annual networking event for early career professionals and first time conference attendees. This one hour event is intended to provide a relaxed atmosphere where attendees can network with peers, ATS leaders, program directors, associate program directors and division directors, as well as other prominent thought leaders. Cocktails and appetizers will be provided.

The Membership Committee, Training Committee, and the Members in Transition and Training Committee (MITT) jointly host the Networking Exchange for Early Career Professionals.

Conference badges are required for admission. Space is limited. There is no additional fee.
PCC1  PEDIATRIC CLINICAL CORE CURRICULUM

7:00 a.m. - 8:00 a.m.  SAN DIEGO CONVENTION CENTER
Room 1 A-B (Upper Level)

Target Audience
Pediatric pulmonary and critical care physicians who work in a clinical setting and are currently engaged in maintenance of certification

Objectives
At the conclusion of this session, the participant will be able to:
- remain current with medical knowledge relevant to their practice in pediatric pulmonology;
- evaluate their understanding of key skills and content areas in pediatric pulmonology as well as receive feedback on their comprehension of a result of a pre-test/post-test comparison;
- support clinicians who are engaged in maintenance of certification activities by providing updates on subjects included in recertification requirements.

The Pediatric Core Curriculum symposia promote lifelong learning and the enhancement of the clinical judgment and skills essential for practicing pediatrician. The symposia will address topics that have been identified by an ATS pediatric working group, which is comprised of members of the ATS Education Committee and the International Conference Committee, who have identified important areas within pediatric medicine (including severe asthma, ILD, BPD, pulmonary hypertension and pulmonary manifestations of pulmonary disease). Attendees will increase their medical knowledge as a result of attending this symposium, and this will be measured by a comparison of pre-test vs. post-test results on the corresponding maintenance of certification module. The ATS Pediatric Core Curriculum will focus on a 3-year content cycle of key medical content in the area of pediatric medicine.

Chairing:  A. Horani, MD, MPH, St. Louis, MO

7:00  Cystic Fibrosis: Update on Diagnosis
R.F. Brown, MD, Nashville, TN

K1  NHLBI AND THE EVOLUTION OF PULMONARY RESEARCH

8:15 a.m. - 9:00 a.m.  SAN DIEGO CONVENTION CENTER
Room 6 B (Upper Level)

Speaker: James P. Kiley, PhD, Bethesda, MD

K2  SLOW MEDICINE: THE KEY TO POST-ICU RECOVERY?

8:15 a.m. - 9:00 a.m.  SAN DIEGO CONVENTION CENTER
Room 6 C/F (Upper Level)

Speaker: Victoria Sweet, MD, San Francisco, CA

A1  CLINICAL YEAR IN REVIEW 1

9:15 a.m. - 11:15 a.m.  SAN DIEGO CONVENTION CENTER
Hall H (Ground Level)

Target Audience
Providers including physicians, nurses, respiratory therapists, nurse practitioners, physician assistants; trainees including residents and fellows; clinical researchers

Objectives
At the conclusion of this session, the participant will be able to:
• apply new clinical research knowledge to clinical practice;
• learn new findings about key conditions in pulmonary, critical care and sleep;
• gain new strategies to manage the care of common conditions in pulmonary, critical care, and sleep.

The annual Clinical Year in Review symposia provides concise summaries of the most impactful clinical research publications related to specific clinical topics. Speakers will highlight 5 of the most important and influential publications on their topic in written format and during their talks.

Chairing: D.W. Ford, MD, Charleston, SC
V.E. Ortega, MD, PhD, Winston Salem, NC
J.S. Lee, MD, Aurora, CO

9:15 ILD
K.A. Johannson, MD, MPH, Calgary, Canada

9:45 Pulmonary Rehabilitation
W. Man, MD, PhD, Harefield, United Kingdom

10:15 Lung Transplantation
M.M. Budev, DO, MPH, Cleveland, OH

10:45 Interventional Pulmonology
N. Navani, MD, MSc, London, United Kingdom

This session and the International Conference are supported by an educational grant from Boston Scientific Corporation.

This session and the International Conference are supported by an educational grant from Boston Scientific Corporation.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

A3 FELLOWS CASE CONFERENCE
Assemblies on Allergy, Immunology and Inflammation; Behavioral Science and Health Services Research; Clinical Problems; Members in Transition and Training Committee; Training Committee

9:15 a.m. - 11:15 a.m. SAN DIEGO CONVENTION CENTER
Ballroom 20 D (Upper Level)

Target Audience
Clinicians, nurses, fellows, residents, and researchers looking to broaden their clinical acumen to facilitate clinical and translational research

Objectives
At the conclusion of this session, the participant will be able to:
• recognize clinical, radiographic, and pathologic findings of rare diseases
• gain insight into clinical decision-making skills demonstrated by master clinicians, radiologists and pathologists which will improve the quality of learners’ practice and potentially improve quality of care for the learner’s patients
• develop strategies to evaluate patients with common symptoms that include uncommon/rare diseases in the differential diagnosis when appropriate

This session will consist of 6 unique cases presented and discussed by fellows with a panel of 3 clinical experts to moderate the discussion and provide commentary. An expert radiologist and expert pathologist will provide guidance on imaging and path. The cases will provide new insights into disease pathogenesis, diagnosis, and/or treatment. Selected cases will include clear clinical teaching points with review of associated pathology and radiology as appropriate. Finally, the discussion will highlight thoughtful medical decision.

Chairing: L.E. Crotty Alexander, MD, San Diego, CA

9:15 Welcome and Introduction
L.E. Crotty Alexander, MD, San Diego, CA

9:20 Could This Be Related to My Dog?
P. Chung, MD, Los Angeles, CA

9:30 Cloaked in Chyle: An Under Recognized Etiology
A. Egan, MD, Rochester, MN

9:40 Hunting for Zebras with a Local Hunter
A. Deitchman, MD, Baltimore, MD

9:50 A Mysterious Etiology Causing Dyspnea in a 71 Year Old Man
T. Kukkadapu, MD, Augusta, GA

10:00 Puzzling Pulmonary Nodules
Z. Salman, MD, Houston, TX

10:10 Don’t Blame It On the Fluid
A. Arjuna, MD, Newark, NJ

10:20 Expert Clinicians
M.I. Schwarz, MD, Aurora, CO
A.E. Dixon, MD, Burlington, VT
A.H. Limper, MD, Rochester, MN

This session will provide a forum for attendees to interact with the authors and editors about papers published in JAMA and the New England Journal of Medicine. Papers presented will be recent publications, selected by the editors, to be of significant importance to the field of pulmonary medicine. Attendees will have the opportunity to hear presentations directly from the author and address questions to both the authors and editors. The discussion is intended to provide a unique insight into these papers, the selection process, and how the research applies directly to the field of pulmonary medicine.

Chairing: G.W.K. Wong, MD, FRCP, Associate Editor, New England Journal of Medicine
G.T. O’Connor, MD, MS, Associate Editor, JAMA

Speakers And Talks To Be Announced
A4 SURVIVING CRITICAL ILLNESS: OPTIMIZING OUTCOMES IN THE POST-ICU SPACE

Assemblies on Critical Care; Clinical Problems; Nursing
9:15 a.m. - 11:15 a.m. SAN DIEGO CONVENTION CENTER
Ballroom 20 A (Upper Level)

Target Audience
Care providers in ICU and post-ICU settings, including registered nurses and advanced practice nurses

Objectives
At the conclusion of this session, the participant will be able to:

- recognize the growing post-ICU survivor population and their unique physiologic and disease processes that result in significant long-term sequelae;
- discuss best practice care processes that reflect individual and chronic disease elements as well as addressing the impact on families and their dynamics;
- develop new ICU practices that are focused on improving long-term post-ICU outcomes, including readmission risk assessment, identification of significant factors related to survival, and supporting meaningful quality of life functions.

Post-ICU populations are growing and survivors increasingly face challenges of poor outcomes. Besides a profound clinical and operational impact, there is a significant cost to the system for patients who require prolonged care. Better delineation of post-ICU subtypes has the potential to drive different therapeutic interventions across disciplines. However, evidence-based practice is currently dependent on only a handful of landmark studies, and best practices are scarce for assessing, intervening and transitioning post-ICU patients. Significant opportunities exist for research, innovation, and transition partnerships to achieve better patient outcomes.

Chairing: D.M. Needham, MD, PhD, Baltimore, MD
H. Dunn, MS, Chicago, IL

9:15 Introduction
D.M. Needham, MD, PhD, Baltimore, MD
H. Dunn, MS, Chicago, IL

9:35 A Patient’s Perspective
W. Gluba, Davenport, IA

9:40 Processes of Care for Persistent and Chronic Critical Illness
L. Rose, RN, PhD, Toronto, Canada

9:59 Care of Ventilated Patients at an LTACH
A. Jurban, MD, Hines, IL

10:19 The Fire is Still Burning: A Continuing Inflammatory Cascade Post-ICU
P.A. Efron, MD, Gainesville, FL

10:31 Lost in Translation: Are Interventions Designed to Assess and Support ICU Patients and Their Families Useful in the Post-ICU Period?
J. Tate, PhD, RN, Columbus, OH

10:51 Care Innovations in the Post-ICU Space
S.I. Hammerman, MD, Mechanicsburg, PA

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
A6 GLYCOBIOLOGY AND GLYCOMICS OF LUNG DISEASES

Assemblies on Respiratory Cell and Molecular Biology; Allergy, Immunology and Inflammation; Environmental, Occupational and Population Health; Pulmonary Infections and Tuberculosis; Respiratory Structure and Function

9:15 a.m. - 11:15 a.m.  MARRIOTT MARQUIS SAN DIEGO MARINA

Pacific Ballroom 18-19 (North Tower, First Floor)

Target Audience
Clinical, translational and basic lung researchers, lung research administrators, patient-care providers

Objectives
At the conclusion of this session, the participant will be able to:

- learn about the role of glycomolecules in diverse lung diseases;
- identify the therapeutic potential of glycomolecules;
- learn about the tools and resources available to study glycobiology in human and mouse samples.

Glycobiology, the study of complex carbohydrates in biologic systems, is an emerging field. Carbohydrates are by far the most abundant organic molecules in biology but its role in lungs remains unexplored, likely due to the complexity and need for specialized, multi-disciplinary expertise. Despite the successful completion of the Human Genome Project and widely applied, advanced technologies in genomics and proteomics, key macromolecules in life, such as glycans, have not experienced similar advancements. The importance of carbohydrates in cancer therapeutics has been recognized but advanced technologies have now allowed the identification and characterization of carbohydrate structure function in a variety of organs, including lung.

Chairing:
Z. Zhu, MD, PhD, Providence, RI
D.E. Wagner, PhD, Lund, Sweden
M. Tiemeyer, PhD, Athens, GA

9:15 Opening
Z. Zhu, MD, PhD, Providence, RI

9:17 Introduction to Glycobiology and Glycomics of Lung
M. Tiemeyer, PhD, Athens, GA

9:23 Use of Existing and Novel Humanized Mouse Models to Study How Airway Mucins Alter Eosinophil Survival via Siglec-F vs. Siglec-8
B.S. Bochner, MD, Chicago, IL

A7 LEVERAGING MOLECULAR MECHANISMS OF GRANULOMA FORMATION IN SARCOIDOSIS TO IMPROVE CARE

Assemblies on Allergy, Immunology and Inflammation; Environmental, Occupational and Population Health; Respiratory Cell and Molecular Biology

9:15 a.m. - 11:15 a.m.  SAN DIEGO CONVENTION CENTER

Ballroom 20 B-C (Upper Level)

Target Audience
Providers of lung health, particularly in the field of sarcoidosis and other granulomatous disorders, including researchers, clinicians and educators. Those needing instruction in areas of medicine outside their specialty.

Objectives
At the conclusion of this session, the participant will be able to:

- discuss models and define mechanisms that can be used to help determine genes and pathways that could be targeted for therapeutics
- define new phenotypes of disease based on genes and pathways
- define mechanisms occurring during early granuloma formation that have implications for the pathogenesis and treatment of severe sarcoidosis phenotypes.

Sarcoidosis is unlike other granulomatous disorders in that the cause of the disease remains poorly understood. This session will present recent progress in the field of sarcoidosis, including exciting data from novel disease models and new scientific research platforms that are rapidly advancing our understanding of the disease, and could lead to new biomarkers and therapeutic targets to improve the care of sarcoidosis patients.
**Chairing:**
- N.Y. Hamzeh, MD, Iowa City, IA
- K.C. Patterson, MD, Brighton, United Kingdom
- J.C. Grutters, MD, Nieuwegein, Netherlands

9:15 **A Patient’s Perspective**
T. Waters, ANP-BC, MBA, Houston, TX

9:20 **A Brief Review of Granuloma Immunology**
L. Koth, MD, San Francisco, CA

9:30 **Insights into Early Sarcoidosis Granuloma Formation in Sarcoidosis and TB using a Human in Vitro Model**
E.D. Crouser, MD, Columbus, OH

9:50 **mTORC1: A Checkpoint for Sarcoidosis Progression and Novel Mouse Model of Disease**
T. Weichhart, PhD, Vienna, Austria

10:10 **Genetic, Environmental and Microbiome Drivers of Granuloma Formation in Sarcoidosis**
L.A. Maier, MSPH, MD, Denver, CO

10:30 **The Integral Role of Transcriptomics in Disease Manifestations: New Insights from the NHLBI GRADS Study**
N. Kaminski, MD, New Haven, CT

10:50 **Pursuit of the Holy Grail of Sarcoidosis: Identifying Disease Causing Antigens**
A.P. Fontenot, MD, Aurora, CO

11:10 **General Discussion**

---

**A8 CURRENT CONTROVERSIES IN PAH DISEASE MECHANISMS: A PRO/CON DEBATE**

**Target Audience:**
Basic, translational and clinical researchers and clinicians (adult and pediatric) interested in pulmonary vascular disease and right heart failure

**Objectives:**
1. summarize the evidence why PAH has cancer-like features;
2. learn about fundamental disease mechanisms in PAH that involve other organs beyond the lung vasculature;
3. acknowledge the role of the adventitia in PAH pathogenesis and critically weigh the existence and role of capillary rarefaction in right ventricular failure in PAH.

This session will critically evaluate opposing views of how pulmonary hypertension and right heart failure develops, and identify points of agreement and disagreement with the ultimate goal to reach a consensus to identify novel treatment targets for PAH.

**Chairing:**
- E.F. Spiekerkoetter, MD, Palo Alto, CA
- W. Kuebler, MD, Berlin, Germany
- S.S. Pulmansetti, PhD, Bad Nauheim Hessen, Germany

9:15 **PRO: PAH is a Cancer-Like Disease**
E.A. Goncharova, PhD, Pittsburgh, PA

9:30 **CON: PAH is NOT a Cancer-Like Disease**
C. Guignabert, PhD, Le Kremlin Bicetre, France

9:45 **PRO: PAH is a Systemic Disease**
M. Rabinovich, MD, Stanford, CA

10:00 **CON: PAH is NOT a Systemic Disease**
L.A. Maier, MSPH, MD, Denver, CO

10:15 **PRO: Vascular Remodeling in PAH is Initiated in the Adventitia**
N.F. Voelkel, MD, El Prado, NM

10:30 **CON: Vascular Remodeling in PAH is NOT Initiated in the Adventitia**
K.R. Stenmark, MD, Aurora, CO

10:45 **PRO: Capillary Loss Drives Right Ventricular Failure in PAH**
H.J. Bogaard, MD, PhD, Amsterdam, Netherlands

11:00 **CON: Capillary Loss Does NOT Drive Right Ventricular Failure in PAH**
B.B. Graham, MD, Aurora, CO

---

**A9 ACCELERATING SCIENTIFIC ADVANCEMENT OF RARE PEDIATRIC LUNG DISEASES**

**Target Audience:**
Basic scientists, clinicians, students and postdoctoral trainees and providers of lung health. Those working in pediatric and neonatal pulmonary dysfunction with an interest in understanding the latest basic and translational approaches

**Objectives:**
1. learn about the latest advances in determining the mechanisms regulating the development and progression of Pediatric Rare Lung Disease (PRLD);
2. improve knowledge of the pre-clinical models for assessing the treatment of Pediatric Rare Lung Disease (PRLD);
3. improve understanding of the newest therapeutic approaches and their applicability in the treatment of (PRLD).
This session will evaluate recent progress made in deciphering the signaling pathways, the genetic landscapes, diagnoses and therapeutic tools for several pediatric rare lung diseases.

Chairing: A.L. Firth, PhD, Los Angeles, CA
D. Al Alam, PhD, MS, Los Angeles, CA

9:15 Neuroendocrine Cell Hyperplasia of Infancy (NEHI): What’s New and What’s NEBulous
L.R. Young, MD, Nashville, TN

9:35 Pathogenetics of Lethal Neonatal Developmental Lung Diseases
P. Stankiewicz, MD, PhD, Houston, TX

9:55 Cell/Gene Therapy for Pediatric Pulmonary Alveolar Proteinosis (PAP)
B.C. Trapnell, MD, Cincinnati, OH

10:15 The Ciliary Proteome: New Insights for PCD
L. Ostrowski, PhD, Chapel Hill, NC

10:35 Exploring ABCA3 Mutations in Pediatric Interstitial Lung Disease
M. Griese, MD, Munich, Germany

10:55 Using In Vitro Lung Models for Personalized Approaches to Treat Rare Lung Diseases
B. Gomperts, MD, Los Angeles, CA

BASIC • CLINICAL • TRANSLATIONAL
SCIENTIFIC SYMPOSIUM

A10 PATHO BIOLOGY OF AGE-RELATED LUNG DISEASE: FROM BENCH TO BEDSIDE
Assemblies on Respiratory Structure and Function; Allergy, Immunology and Inflammation; Clinical Problems; Critical Care; Environmental, Occupational and Population Health; Respiratory Cell and Molecular Biology; Sleep and Respiratory Neurobiology

9:15 a.m. - 11:15 a.m. MARRIOTT MARQUIS SAN DIEGO MARINA
Pacific Ballroom 22 (North Tower, First Floor)

Target Audience
All providers of lung health who care for geriatric patients and those with a research interest in the basic science of aging as well as in clinical investigation related to lung disease in older adults.

Objectives
At the conclusion of this session, the participant will be able to:

• learn new findings about the aging respiratory system;
• apply knowledge about the pathobiology of aging to better understand chronic lung disease;
• gain new strategies to manage the care of patients with chronic lung disease.

The aging population (65 years and older) is expected to increase rapidly over the next decade. Changes in cellular, physiologic and immunologic function are a normal part of the aging process that increases the risk for chronic lung disease. This session will highlight for the learner how the molecular biology of aging (e.g., telomere attrition, mitochondrial dysfunction, extracellular matrix deregulation, etc.) combined with immunosenescence and changes in lung structure and function can predispose elderly individuals to idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and acute respiratory distress syndrome. Increased understanding of aging pathobiology will provide insight into these diseases and their management.

Chairing: G.S. Skloot, MD, New York, NY
Y.S. Prakash, MD, PhD, Rochester, MN
P. Lee, MD, New Haven, CT

9:15 Overview of the Aging Respiratory System
Y.S. Prakash, MD, PhD, Rochester, MN

9:35 Accelerated Lung Aging and COPD
R. Gosens, PhD, Groningen, Netherlands

10:00 Idiopathic Pulmonary Fibrosis: Prototype of Aging-Related Lung Disease
V.J. Thannickal, MD, Birmingham, AL

10:25 The Impact of Aging on Acute Lung Injury and ARDS
P. Lee, MD, New Haven, CT

10:50 Anti-Aging Molecules and Therapeutic Interventions
I. Petrache, MD, Denver, CO

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
a subset of asthma accounting for approximately 5-10% of patients with asthma. However health care utilization for this subset has been estimated to be up to 40% of the total economic burden of asthma. Recently there have been significant efforts to determine the underlying basis for this disease in terms of epidemiology, physiology, immunology, and genetics that influence this phenotype. Data is emerging that severe asthma consists of several subsets termed “endotypes”. This phenotypic and now molecular classification may greatly aid in patient management with improved disease control, improved clinical outcomes and reduced medical costs. This symposium will highlight recent advances as well as highlight needed areas of research to advance treatment and prevention of this disease.

**Chairing:**

- G.P. Downey, MD, Denver, CO
- B.D. Levy, MD, Boston, MA
- K. Asano, MD, Kanagawa, Japan
- E. Bel, MD, PhD, Amsterdam, Netherlands

**9:15 Introduction and Overview of Severe Asthma**

- S.E. Wenzel, MD, Pittsburgh, PA

**9:20 ORMDL3 and Epithelial Derived Mediators for Induction of Asthmatic Response**

- C.M. Lloyd, PhD, London, United Kingdom

**9:40 Complex Crosstalk Between Epithelial Cells and Immune Cells in Asthma**

- H. Nakajima, PhD, MD, Chiba, Japan

**9:58 New Insights Into Severe Eosinophilic Inflammation: ETosis and Extracellular Traps**

- S. Ueki, MD, PhD, Akita, Japan

**10:15 Targeting IL5 in Severe Asthma: The Ligand or the Receptor?**

- P.K. Nair, MD, PhD, Hamilton, Canada

**10:35 Mitochondrial Arginine Metabolism Supported Bioenergetics in Asthma**

- S.C. Erzurum, MD, Cleveland, OH

**10:55 Early School-Based Interventions to Treat and Prevent Childhood Asthma**

- W. Shipatsanoul, MD, Boston, MA

This session and the International Conference are supported by educational grants from GlaxoSmithKline, Sanofi Genzyme and Regeneron Pharmaceuticals. All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

### A12 FROM SPANISH FLU OF 1918 TO TODAY: WHAT CAN WE LEARN FROM VIRUSES?

**Assemblies on Respiratory Cell and Molecular Biology; Critical Care; Pulmonary Infections and Tuberculosis**

**9:15 a.m. - 11:15 a.m.**

**MARRIOTT MARQUIS SAN DIEGO MARINA**

Grand Ballroom 8-9 (North Tower, Lobby Level)

**Target Audience**

Scientists and clinicians interested in the biology and treatment of viral infections

**Objectives**

At the conclusion of this session, the participant will be able to:
- enhance understanding of how viruses become pathogenic;
- become knowledgeable about the historical context of flu pandemics;
- develop global strategies to combat pandemics.

The Spanish Flu of 1918 killed more individuals than those that died in the First World War. On the 100th anniversary of this pandemic, it is timely that we present a scientific symposium of our enhanced understanding of how viruses survive and how they contribute to enhanced morbidity and mortality particularly in chronic pulmonary diseases such as asthma, pulmonary fibrosis and ARDS.

**Chairing:**

- S. Donnelly, MD, Dublin, Ireland
- B.B. Moore, PhD, Ann Arbor, MI
- C. Dela Cruz, MD, PhD, New Haven, CT
- S.M. Cloonan, PhD, New York, NY

**9:15 Spanish Flu of 1918: Lesson Learnt**

- M. Worobey, PhD, Tucson, AZ

**9:40 Viruses and Pulmonary Fibrosis**

- S. Donnelly, MD, Dublin, Ireland

**10:05 Virus, Immunity and Asthma**

- N.W. Lukacs, PhD, Ann Arbor, MI

**10:30 Viruses and Immune Memory: The Adaptation Race**

- F.E. Lee, MD, Atlanta, GA

**10:55 An Update on Ebola Virus**

- S. Schendel, PhD, San Diego, CA

### A13 ATS/ALA IMPLEMENTATION GUIDE FOR LUNG CANCER SCREENING: AN OPERATIONAL TOOLKIT

**Assemblies on Behavioral Science and Health Services Research; Clinical Problems; Nursing; Thoracic Oncology; Document Development and Implementation Committee; Tobacco Action Committee; Quality Improvement and Implementation Committee**

**9:15 a.m. - 11:15 a.m.**

**SAN DIEGO CONVENTION CENTER**

Room 16 A-B (Mezzanine Level)

**Target Audience**

Clinicians, including registered nurses and advanced practice nurses, wishing to implement or improve a lung cancer screening program, policymakers and administrators in charge of a screening program

**Objectives**

At the conclusion of this session, the participant will be able to:
- discuss the role of environmental barriers and facilitators in the implementation of lung cancer screening programs and improving screening of at-risk populations;
• apply pragmatic solutions to overcome barriers to implementing high-quality lung cancer screening;
• improve resources available to practicing clinicians to perform necessary tasks in lung cancer screening programs, including shared decision making, smoking cessation, and ensuring follow-up of nodules.

The USPSTF recommends lung cancer screening for high risk patients. However, there is a known gap between publication of high-quality evidence and subsequent adoption into practice. This is problematic for lung cancer screening given that implementation of screening programs is complex. A fraction of screen-eligible patients are screened for lung cancer. To address this gap and facilitate implementation of lung cancer screening programs, the ATS and ALA joined forces to develop an implementation toolkit for lung cancer screening. This symposium will focus on providing practical operational tools to promote implementation of and best practices in lung cancer screening programs.

Chairing:
C.C. Thomson, MD, MPH, Cambridge, MA
R.S. Wiener, MD, MPH, Boston, MA
P.J. Mazzone, MD, MPH, Cleveland, OH

Oral Presentations

9:30 ILC2s and Eosinophils Protect Against Staphylococcus Aureus Induced Sepsis/P. Krishack, T. Louviere, A.I. Sperling, P.A. Verhoef, Chicago, IL, p.A1002
9:45 Pulmonary Lymphatics Regulate Immune Cell Trafficking and Lung Injury/H. Outtz Reed, Philadelphia, PA, p.A1003
10:45 The Differential Regulation of Monocyte Derived and Tissue Resident Alveolar Macrophages by mTORC2 Promotes Lung Fibrosis/M.R. Horton, S. Collins, M.-H. Oh, Y. Chan-Li, J. Powell, Baltimore, MD, p.A1007

MINI SYMPOSIUM

A15 ICS IN COPD: THE PENDULUM KEEPS SWINGING

9:15 a.m. - 11:15 a.m. SAN DIEGO CONVENTION CENTER
Room 14 A-B (Mezzanine Level)

Chairing:
A. Roche, MD, Paris, France
N. Lugogo, MD, Ann Arbor, MI
N.A. Hanania, MD, MS, Houston, TX

Oral Presentations


MINI SYMPOSIUM

A14 LUNG IMMUNOLOGY IN HEALTH AND DISEASE

9:15 a.m. - 11:15 a.m. MARRIOTT MARQUIS SAN DIEGO MARINA
Grand Ballroom 5-6 (North Tower, Lobby Level)

Chairing:
P.A. Verhoef, PhD, MD, Chicago, IL
J.L. Cho, MD, Boston, MA
9:45  Real World Treatment Patterns of Inhaled Triple Therapy (TT) Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in United Kingdom (UK) General Practice/L. Sansbury, C. Bains, S. Landis, Collegeville, PA, p.A1011

10:00  Dual Bronchodilation Vs Triple Therapy in the Real-Life DACCORD Study/R. Buhl, C.-P.P. Cree, P. Kardos, N. Lossi, K. Kostikas, H. Worth, C. Vogelmeier, Mainz, Germany, p.A1012


MINI SYMPOSIUM

A16  AIR POLLUTION AND PEDIATRIC ASTHMA
9:15 a.m. - 11:15 a.m.  SAN DIEGO CONVENTION CENTER
Room 30 A-B (Upper Level)

Chairing:  F.D. Gilliland, MD, PhD, Los Angeles, CA
S. Bose, MD, MPH, New York, NY

Oral Presentations


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.


11:00 Can Standard Deviation of Overnight Pulse Oximetry Be Used to Screen Childhood Obstructive Sleep Apnea?/S. Warapongmanupong, A. Preutthipan, Bangkok, Thailand, p.A1031

MINI SYMPOSIUM

A18 COPD: EARLY DISEASE AND HOW TO FIND IT

9:15 a.m. - 11:15 a.m. SAN DIEGO CONVENTION CENTER

Chairing: J.C. Woods, PhD, Cincinnati, OH
E.A. Hoffman, PhD, Iowa City, IA
M. Kirby, PhD, Vancouver, Canada

Oral Presentations


11:00 Reduced FVC/TLC Ratio in Preserved Ratio Impaired Spirometry (PRISm) Is Associated with Symptoms, Increased Mortality, and Progression to COPD/S. Fortis, A.P. Comellas, V. Kim, R. Casaburi, J.E. Hokanson, J.D. Crapo, E.K. Silverman, E.S. Wan, Iowa City, IA, p.A1039

MINI SYMPOSIUM

A19 SLEEP DISORDERED BREATHING, CARDIOVASCULAR DISEASE, AND MORTALITY

9:15 a.m. - 11:15 a.m. SAN DIEGO CONVENTION CENTER

Chairing: H.K. Yaggi, MD, New Haven, CT
M. Twery, PhD, Bethesda, MD
N.M. Punjabi, MD, PhD, Baltimore, MD

Oral Presentations


RAPID: RAPID ABSTRACT POSTER DISCUSSION SESSION

A21 CLINICAL AND MECHANISTIC STUDIES OF LUNG FIBROSIS

9:15 a.m. - 11:15 a.m.  MARRIOTT MARQUIS SAN DIEGO MARINA

Pacific Ballroom 15-17 (North Tower, First Floor)

Abstract Summaries  9:15-9:45
Viewing/Discussion  9:45-11:15

Chairing:  R. Zemans, MD, Ann Arbor, MI
O. Eickelberg, MD, Denver, CO
S. Montesi, MD, Boston, MA


902 Characterizing the Role of Novel Protein, P311, in Pulmonary Repair Mechanisms/G.M. Barrón, F.F. Duan, G.M. Mutlu, A.Y. Melton, L. Schuger, Chicago, IL, p.A1049


904 Deletion of Cannabinoid Receptor 1 (CB1-R) in Myeloid Cells Prevents the Progression of Bleomycin-Induced Pulmonary Fibrosis in Mice/N.J. Coffey, J.K. Park, T. Jourdan, T. Yokoyama, W.A. Gahl, M.C.V. Malicdan, R. Cinar, G. Kunos, Rockville, MD, p.A1051

905 Sialidase Inhibitors Attenuate Pulmonary Fibrosis in a Mouse Model/T.R. Karhadkar, D. Pilling, N. Cox, R.H. Gomer, College Station, TX, p.A1052


914 Tlr5 Protects from Pulmonary Fibrosis by Promoting Epithelial Lung Inflammation and Remodeling/S.L. Wollin, C. Tomsic, K.J. Erb, Biberach, Germany, p.A1061

915 The Effect of Nintedanib in a Mouse Model of Severe Allergic Lung Inflammation and Remodeling/S.L. Wollin, C. Tomsic, K.J. Erb, Biberach, Germany, p.A1062


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
A22 NOVEL RESEARCH ON ASTHMA SELF MANAGEMENT TO REDUCE HEALTH DISPARITIES

9:15 a.m. - 11:15 a.m.  SAN DIEGO CONVENTION CENTER

Room 11 A-B (Upper Level)

Abstract Summaries  9:15-9:45

Viewing/Discussion  9:45-11:15

Chairing:  A. Volerman, MD, Chicago, IL

M. Eakin, PhD, Baltimore, MD

B.J. Sheares, MD, MS, New York, NY

Impact of a Pharmacist-Delivered Educational Intervention on Fractional Exhaled Nitric Oxide in Patients with Asthma/O


Relationship Between Sleep Quality, Asthma Control and Quality of Life in Adults with Asthma/M.K. Panigrahi, M. Padhan, P.R. Mohapatra, Bhubaneswar, India, p.A1089


Serum Levels of VEGF-C Are Elevated in Sporadic but Not Tuberous Sclerosis Associated-LAM, Correlate with the Need for Supplemental Oxygen, and Impact Lung Function Response to Sirolimus/H. Wu, N.M. Nikolaidis, L.R. Young, F.X. McCormack, Cincinnati, OH, p.A1100


Chronic Hypersensitivity Pneumonitis: A Prospective Cohort Analysis of an Under-Recognized Clinical Entity/H. Barnes, A. Watson, S. Ellis, N. Goh, G.P. Westall, A.E. Holland, I. Glaspole, Melbourne, Australia, p.A1104


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
A24  CRITICAL CARE: ARDS AND ACUTE RESPIRATORY FAILURE - CAN WE DO BETTER?

9:15 a.m. - 11:15 a.m.  SAN DIEGO CONVENTION CENTER

Room 31 A-C (Upper Level)

Abstract Summaries  9:15:9:45

Viewing/Discussion  9:45:11:15

Chairing: M.N. Gong, MS, MD, Bronx, NY
M.W. Semler, MD, MSc, Nashville, TN
A.M. Esper, MD, MS, Atlanta, GA

RAPID: RAPID ABSTRACT POSTER DISCUSSION SESSION

A24

CRITICAL CARE: ARDS AND ACUTE RESPIRATORY FAILURE - CAN WE DO BETTER?

9:15 a.m. - 11:15 a.m.

SAN DIEGO CONVENTION CENTER

Room 31 A-C (Upper Level)

Abstract Summaries  9:15:9:45

Viewing/Discussion  9:45:11:15

Chairing: M.N. Gong, MS, MD, Bronx, NY
M.W. Semler, MD, MSc, Nashville, TN
A.M. Esper, MD, MS, Atlanta, GA

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
Reductions in Driving Pressure from Positive End-Expiratory Pressure (PEEP) Titration Are Sustainable Over Short Time Intervals in ARDS Patients/S. Sahayta, D.N. Hager, R.S. Stephens, R.G. Brower, Baltimore, MD, p.A1132


Reductions in Driving Pressure from Positive End-Expiratory Pressure (PEEP) Titration Are Sustainable Over Short Time Intervals in ARDS Patients/S. Sahayta, D.N. Hager, R.S. Stephens, R.G. Brower, Baltimore, MD, p.A1132

Low Free T3 Is Associated with Worse Outcomes in Patients with Acute Respiratory Failure Requiring Invasive Mechanical Ventilation/A. Desai, G. Rothberger, P.K. Valestra, D. Khaillah, R. Calixte, L. Shapiro, Syracuse, NY, p.A1134


Abstract Summaries 9:15-9:45

Viewing/Discussion 9:45-11:15

Chairing: J.J. Saukkonen, MD, West Roxbury, MA
A. Cattamanchi, MD, San Francisco, CA
N. Shah, MD, Richmond, CA

Effect of Supplementation of Vitamin D on Tuberculosis Treatment Outcomes/A. Sowmya, T. Sahasrabudhe, C. Koneru, Pune, India, p.A1140


Pharmacokinetics of Tuberculosis Drugs in HIV Infected Patients from Irkutsk, Russian Federation/G. Lyles, S.K. Heysell, Charlottesville, VA, p.A1143

Treatment Outcomes of Pulmonary Pyrazinamide-Resistant Multidrug-Resistant Tuberculosis/S. Park, W. Ji, K.-W. Jo, T.S. Shim, Seoul, Korea, Republic of, p.A1144

High Degree of Fluoroquinolones Resistance Among Extrapulmonary Tuberculosis Patients at a Tertiary Care Center in North India/J. Chaubey, S. Pawar, S.K. Sharma, S. Sinha, P. Jorwal, New Delhi, India, p.A1145


815 Diagnostic Characteristics of Cough Aerosol Cultures of Mycobacterium Tuberculosis as Predictors of Transmission/K.P. Fennelly, C. Acuna-Villaarduña, E. Jones-Lopez, Bethesda, MD, p.A1154


### RAPID: RAPID ABSTRACT POSTER DISCUSSION SESSION

**A26 PEDIATRIC SEVERE ASTHMA AND PHENOTYPING**

9:15 a.m. - 11:15 a.m. SAN DIEGO CONVENTION CENTER

Room 6 D (Upper Level)

**Abstract Summaries**
9:15-9:45

**Viewing/Discussion**
9:45-11:15

**Chairing:** A. Bush, MD, London, United Kingdom
J. Gaffin, MD, Boston, MA
T. Simoneau, MD, Hartford, CT


203 Greater Treatment Benefit with Omalizumab in Children with Increased Asthma Severity: Exploratory Analyses from the Preventative Omalizumab or Step-up Therapy for Fall Exacerbations (PROSE) Study/S.J. Szefler, M. Kattan, B. Ortiz, B. Trzaskoma, T. Haselkorn, A. Iqbal, W.W. Busse, Aurora, CO, p.A1157

204 Use of Inhaled Tiotropium in Severe Persistent Asthma in Children/P. Gummalla, M. Shukla, Brooklyn, NY, p.A1158


209 The Relationship between the Asthma Control Test (ACT) and Spirometry in Assessment of Asthma Control/T. Simoneau, C.R. Langton, D. Foster, S.B. Roman, J.P. Hollenbach, M.M. Cloutier, Hartford, CT, p.A1159


---

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.

212 Association of Serum Carotenoids with Disease Burden in Urban Minority Obese Adolescents with Asthma/D. Rastogi, L.G. Wood, Bronx, NY, p.A1166


214 Atopic Disease in Children with Eosinophilic Esophagitis/S. Siegel, A. Budhram, R. Kane, N. Yu, A.J. Dozor, S. Krishnan, Valhalla, NY, p.A1168


### POSTER DISCUSSION SESSION

**A27** YOU GOT ANOTHER THING COMING: DIAGNOSIS AND PROGNOSTICATION IN PULMONARY HYPERTENSION

9:15 a.m. - 11:15 a.m. SAN DIEGO CONVENTION CENTER

Room 30 C-E (Upper Level)

**Poster Viewing**
9:15-10:00

**Discussion**
10:00-11:15

**Chairing:** P.J. Leary, MD, MS, Seattle, WA

I.M. Lang, MD, Vienna, Austria

M.R. Lammi, MD, MSCR, New Orleans, LA


**602** Quantification of Pulmonary Vascular Response to Nitric Oxide using Computed Tomography/F.N. Rahaghi, T. Winkler, P. Kohli, B. Fuster, R. Radhakrishnan, T. Blackwater, J. Ross, R.N. Channick, R.S. Harris, G.R. Washko, R. San Jose Estepara, Boston, MA, p.A1172

**603** Clinical and Hemodynamic Correlates of Pulmonary Arterial Stiffness in Incident, Untreated Patients with Idiopathic Pulmonary Arterial Hypertension/D. Chemla, J.C. Weatherald, E. Lau, L. Savale, A. Boucly, D. Montani, M. Humbert, O. Sitbon, P. Herve, Le Kremlin-Bicetre, France, p.A1173

**604** Pulmonary Vascular Distensibility in Pulmonary Hypertension Due to Left Heart Disease/C. Gerges, M. Gerges, I.M. Lang, Vienna, Austria, p.A1174


**610** A Retrospective Comparison of Pulmonary Arterial Hypertension (PAH) Patients with Myositis-Related Autoantibodies to Patients with Idiopathic PAH and PAH Associated with Systemic Sclerosis/S. Si, S. Weinmann, C. McEvoy, M.M. Chakinala, St. Louis, MO, p.A1180


**614** Abnormal Exercise Pulmonary Hemodynamics Predict Outcomes in Patients with Lung Disease/A. Jose, C. King, E. Welt, O.A. Shlobin, A.W. Brown, S. Ayal, N. Weir, S.D. Nathan, Washington, DC, p.A1184

**615** The Minimally Important Difference in the Six-Minute Walk Test Predicts Clinical Worsening in Pulmonary Arterial Hypertension/G.A. Heresi, Y. Rao, O.A. Minai, Cleveland, OH, p.A1185


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
A.-M. Lauzon, PhD, Montreal, Canada  
Chairing:  
Discussion 10:00-11:15  
Poster Viewing 9:15-10:00

ATS 2018 • San Diego, CA

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.


1017 Attenuation of Murine Airways Contraction Ex Vivo and In Vivo by a Gelsolin Peptide Containing the Phosphatidylinositol 4, 5-Bisphosphate Binding Domain/M. Mikami, J. Perez-Zoghi, C.W. Emala, New York, NY, p.A1228

1018 The Effect of Dietary Fatty Acids and Sphingosine-1-Phosphate on In Vitro Smooth Muscle Contractility/D. Chapman, M. Baroffio, A. Chiappori, C.G. Irvin, V. Brusasco, Ultimo, Australia, p.A1229

1019 IL-6 and Intracellular Calcium Regulation in Airway Smooth Muscle of Elderly Asthmatics/S.A. Wichert, M. Thompson, M.R. Freeman, L.J. Manlove, C.M. Pabelick, Y.S. Prakash, Rochester, MN, p.A1230


1021 Serelaxin Is a Novel Bronchodilator Which Enhances β-Adrenoceptor-Mediated Airway Relaxation in Multiple Species/J.E. Bourke, S. Royce, C. Samuel, M. Lam, Clayton, Australia, p.A1232

1022 Repeated Bronchoconstrictions Do Not Alter Respiratory Mechanics in Mice/S. Mailhot-Larouche, M. Gazzola, K. Lortie, C. Henry, Y. Bosse, Quebec, Canada, p.A1233

1023 Estrogen Receptor Beta Signaling Negatively Regulates PDGF Induced Human Airway Smooth Muscle Proliferation/N.S. Ambhore, R. Katragadda, R.S.R. Kailidhindi, M. Thompson, C.M. Pabelick, Y.S. Prakash, S. Venkatachalem, Fargo, ND, p.A1234


Chairing: A. Malhotra, MD, La Jolla, CA
P.R. Eastwood, PhD, Nedlands, Australia


302 Neural Memory of the Genioglossal Muscle During Sleep Is Stage-Dependent in Healthy Subjects/L. Taranto-Montemurro, S.A. Sands, L. Messineo, A. Azarbarzin, D.P. White, A. Wellman, Boston, MA, p.A1238

303 Linking Upper Airway Dynamics in Awake Tidal Breathing and Obstructive Sleep Apnea (OSA) Subjects with Site of Upper Airway Collapse During Sleep: Preliminary Results/C.J. Darquenne, A.R. Elliott, R.J. Theilmann, P.N. DeYoung, R.L. Owens, A. Malhotra, La Jolla, CA, p.A1239

304 Retropalatal and Retroglossal Airway Compliance and Negative Effort Dependence in Patients with Obstructive Sleep Apnea/L. Taranto-Montemurro, L. Messineo, D. White, A. Wellman, Sao Paulo, Brazil, p.A1240

305 Clinical Predictors of Respiratory System Loop Gain in Healthy Subjects and Patients with Obstructive Sleep Apnea/L. Taranto-Montemurro, A. Azarbarzin, M. Marques, N. Calianese, D.P. White, S.A. Sands, A. Wellman, Boston, MA, p.A1241


309 Dynamic Movement of Upper Airway Structures During Sleep and Apnea in Obstructive Sleep Apnea Subjects (OSA)/A.R. Elliott, R.J. Theilmann, E. Smales, P.N. DeYoung, A. Malhotra, C.J. Darquenne, La Jolla, CA, p.A1245

310 Effect of Securinine on Genioglossus Muscle Activity and Modulation of Hypoglossal Motor Neuron Excitability in Rats/W. Xu, Shanghai, China, p.A1246

311 The Pharyngeal Airway Is Most Collapsible During Mid-Expiration in Obstructive Sleep Apnea/A. Osman, J. Butler, A. Chiang, S.C. Gandevia, D.J. Eckert, Sydney, Australia, p.A1247

A31  ALLERGY AND ASTHMA CASE REPORTS
9:15 a.m. - 4:15 p.m.  SAN DIEGO CONVENTION CENTER

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: E. Brigham, MD, MHS, Baltimore, MD


P853  Pulmonary Langerhans Cell Histiocytosis in a Patient with DRESS Syndrome and Acute Respiratory Failure/J.T. Williams, D. Grunes, M. Senitko, Jackson, MS, p.A1255


P855  Extended Resolution of Severe Angiotensin Converting Enzyme Inhibitor-Induced Angioedema/N. Lapinell, S. Kamboj, C.M. Mason, New Orleans, LA, p.A1257

P856  Autopsy Study Confirms Effectiveness of Bronchial Theromoplasty/M. Allen-Proctor, S. Sanyal, J.L. Abraham, C. Curtiss, Syracuse, NY, p.A1258


Facilitator: F.K. Gibbons, MD, Boston, MA

P858  Severe Tracheal Stenosis from Neonatal Intubation Misdiagnosed as Asthma for Four Decades/A.S. Flora, R.E. Kose, Toledo, OH, p.A1260

P859  “Doc, I Can’t See!” Acute Monocular Vision Loss from Prednisone, a Rare but Important Complication/D. Golovy, D. WuDunn, M.O. Farber, Indianapolis, IN, p.A1261

P860  Disseminated Aspergillosis After IL-5 Therapy for Severe Asthma/C. Wood, Y. Im, M. Millard, Dallas, TX, p.A1262

P861  Do All the Cases of Severe Asthma Exacerbation Need Corticosteroids? A Case Study/G. Vasquez-Rios, R. Pineda-Reyes, A. Terashima, F. Mejia, Lima, Peru, p.A1263


P864  Wheezing Lymph Nodes/S. Kauli, N. Mahmoud, Madison, WI, p.A1266

**P1014** Rapid Production of Type iii Interferons After Influenza Virus Infection in Allergic Asthma Restricts Th2 Inflammation and Enhances Antiviral Resistance/H.J. Kim, Y.J. Jeon, S. An, A. Jo, Seoul, Korea, Republic of, p.A1273

**P1015** Electric Field Treatment - a Shocking Therapy in a Mouse Model of Allergic Asthma/Z. Knowland, T. Chapman, S. Eliseeva, D.A. Dean, S.N. Georas, Rochester, NY, p.A1274


**P1017** Analysis on the Correlation of Fungus Extracts Allergen and the Components of Aspergillus Fumigatus sIgE Sensitization in Respiratory Allergic Diseases Patients in Southern China/W. Luo, Z. Wu, H. Hu, B. Sun, Guangzhou, China, p.A1276


**P1022** Analysis on Correlation Between sIgE to Carbohydrate Cross-Reactive Determinants and Plant-Related Allergens sIgE/W. Luo, B. Sun, Z. Wu, Guangzhou, China, p.A1281


**P1026** Customizable Allergen Desensitization Using Biodegradable Microspheres Containing Th1 Allergen Epitopes/S. Killingbeck, A. Haczku, Davis, CA, p.A1285


**P1029** Fevripiprant, a Potent Selective Antagonist of the Prostaglandin D2 Receptor 2, Modulates the Allergic Effector Unit Via Inhibition of Eosinophil Migration Towards Mast Cells/R. Shamri, V.J. Erpenbeck, G. Dubois, D. Sandham, F. Levi-schaffer, Jerusalem, Israel, p.A1288

**P1030** Inhibitory Activity of STAT6-IP on IL-33-Mediated-IL-13 Production and Macrophage Polarization in an Innate Murine Allergy Model/V. Moarbes, H. Zhao, H. Aldossary, V. Gaudreault, J. Shan, K. Restori, E.D. Fixman, Montréal, Canada, p.A1289

**P1031** Secretory IgA Induces Cytokine Production and Inhibits Proliferation and Migration of Airway Epithelial Cells/K. Kobayashi, M. Suzukawa, S. Arakawa, H. Matsu, T. Nagase, K. Ohta, Kiyose-shi, Japan, p.A1290


---

**THEMATIC POSTER SESSION**

**A33** ASTHMA MECHANISMS

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER

Area J (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion

12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: D.C. Newcomb, PhD, Nashville, TN


**P1035** Eosinophil Binding and Activation Is Regulated Through the Coordinated Expression of miR-1 Endothelial Targets/A. Korde, F. Ahangari, S. Mehta, L.E. Cohn, A. Gonzalez, S. Takyar, New Haven, CT, p.A1293

**P1036** The Role of Elongation of Very Long Chain Fatty Acids Family Member 6 (Elov6) in Allergic Airway Inflammation/K. Yoshida, Y. Morishima, H. Sakurai, Y. Tsunoda, M. Nakajima, M. Matsuyama, T. Kawayo, M. Matsuo, I. Yukio, N. Hizawa, Tsukuba, Japan, p.A1294

---

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.

P1038 HSP90 Inhibition Reverts IL13- and IL17-Induced Goblet Cell Metaplasia in Human Airway Epithelial/A. Pezzulo, R.A. Tudas, C.G. Stewart, P.J. Taft, N.D. Gansemier, D.A. Stoltz, J. Zabner, Iowa City, IA, p.A1296


P1041 AP-1 Subunit Overexpression Drives a Non-Allergic Asthma Phenotype in Mice/L.M. Marsh, A. Gungl, V. Blaisin, A. Olschewski, G. Kwapiszewska, Graz, Austria, p.A1299


Facilitator: R.A. Rahimi, MD, PhD, Boston, MA

P1046 Dietary Fatty Acids Induce Robust Inflammatory Responses in Human Lung Cells/S. Rutting, D. Xenaki, L.G. Wood, J. Horvat, P. Hansbro, B.G. Oliver, Sydney, Australia, p.A1304


P1049 Toll-Like Receptor 2 Directly Activates Pulmonary Type2 Innate Lymphoid Cells and Modify the Asthmatic Phenotype/T. Ishii, Y. Nkura, Y. Murakami, T. Nagase, N. Yamashita, Tokyo, Japan, p.A1307


P1053 GLCCI1 Deficiency Downregulates the Glucocorticoids Activation in Asthmatic Mice/J. Feng, C. Hu, Q. Xun, X. Li, X. Hu, L. Luo, L. Qin, R. He, Changsha, China, p.A1311

P1054 Modified Si-Jun-Zi-Tang Attenuate Airway Inflammation in a Chronic Murine Model of Asthma Via Suppression of mTORC1 Pathway/H. Jin, L. Wang, J. Ye, Hangzhou, China, p.A1312


P1058 The Effects of Viral Components, Single-Stranded RNA and Double-Stranded RNA, on Allergen-Induced Airway Hyperresponsiveness and Airway Inflammation/S. Ashino, H. Kita, T. Akaba, K. Takeyama, J. Tamaoki, J. Yagi, Tokyo, Japan, p.A1316

Facilitator: I.P. Lewkowich, PhD, Cincinnati, OH


P1062 Investigation of Bronchial Epithelial Cell Repairing and Regulation of Epithelial Cytokine Expression by Glucocorticoid/K. Chibana, T. Akaba, K. Takeyama, J. Tamaoki, J. Yagi, Tokyo, Japan, p.A1320

P1064 The Influence of Alpha Lipoic Acid in Combination with L-Ascorbic Acid on the Antioxidant Enzymes Levels in the Pulmonary Tissues of Obese Asthmatic Mice/R. Pawliczak, P. Kleniewska, Lodz, Poland, p.A1322


P1067 Reproducible and Integrative Analysis of Asthma Transcriptomic Data/M. Kan, M. Shumyatcher, B.E. Himes, Philadelphia, PA, p.A1325


P1069 Phenotypic, Transcriptional and T Cell Receptor Repertoire Analysis of Human CD4 and CD8 Lung Tissue Resident Memory T Cells/N. Schottelier, J. Huffman, C.L. Hrusch, A.I. Sperling, C. Ober, Chicago, IL, p.A1327


Facilitator: A. Haczkó, MD, PhD, Davis, CA


Facilitator: A. Haczkó, MD, PhD, Davis, CA


P1076 Transcriptomic Analysis of Early Airway Epithelial Inflammatory Responses/R. Langley, S.S. Hussain, N. Bauml, M. Nair, M.A. Salathe, H.S. Chand, Mobile, AL, p.A1334


THEMATIC POSTER SESSION

A34 ASTHMA CLINICAL STUDIES I

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER

Area H (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion

12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: T.F. Carr, MD, Tucson, AZ


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.

P870 Phenotyping Older Adults with Asthma Via Clinical Cluster Analysis/R.J. Folz, J. Myers, A. Jorayeva, R.J. Folz, Cleveland, OH, p.A1345


P872 Low Dose Mepolizumab in Eosinophilic Granulomatosis with Polyangiitis/D.J. Jackson, L. Green, M. Fernandes, M. Bolton, C. Roxas, G. D’Ancona, S. Agarwal, B.D. Kent, London, United Kingdom, p.A1347

P873 Frequency of Obesity and Adiposity in Asthma and Its Relationship to Measures of Asthma Control in a Nigerian Tertiary Hospital/O.T. Ojo, Lagos, Nigeria, p.A1348


P876 Bioactive Lipids in Sputum of Older Adults with Asthma as Potential Markers of Disease Phenotypes/A. Blumenthal-Perry, A. Karim, D. Schalatzer, X. Li, A. Jorayeva, B.J. Polivka, R.J. Folz, Cleveland, OH, p.A1351

P877 Predicting Positive Bronchial Challenge Test in Older Adults with Asthma/B.J. Polivka, R. Cavallazzi, A. Jorayeva, J. Myers, B.L. Beatty, R.J. Folz, Louisville, KY, p.A1352


P879 Discovery and Development of AZD1402/PRS-060 a Potent and Selective Blocker of the IL-4 Receptor Alpha/G. Matschiner, A. Allersdorfer, B. Rattenstetter, H. Gille, A. Hohlbaum, J. Taylor, D. Keeling, M.F. Fitzgerald, Freising, Germany, p.A1354

P880 Contribution of Asthma Control Test (ACT) Total Score ≥ 20 or Improvement from Baseline ≥ 3 to the Composite Primary Effectiveness Endpoint in the Salford Lung Study in Asthma (SLS Asthma)/S. Collier, N. Barnes, N. Diar Bakerley, J.P. New, L. Frith, L.A. Jacques, J. Fletcher, H. Svedsater, J. Vestbo, A.A. Woodcock, Uxbridge, United Kingdom, p.A1355

Facilitator: L.E. Crotty Alexander, MD, San Diego, CA

P881 Improvements in Exacerbation Rate and Lung Function with Weight-Based Intravenous Reslizumab Dosing in Patients with Baseline High Body Weight/K.R. Murphy, M. McDonald, M.C. Garin, Boys Town, NE, p.A1356


P884 Obese Severe Asthmatics with Coronary Artery Disease (CAD) Have Worse Asthma Outcomes Compared to Those Without CAD/A.A. Zeki, L. Lagos, M. Wilson, Davis, CA, p.A1359

P885 Visits to Emergency Department and Urgent Care Facility by Inner-City Chicago Veterans with Asthma-COPD Overlap Who Are Treated with Montelukast for 2 Years/I. Rubin, B. Whitten, M. Heneghan, J. Ng, Chicago, IL, p.A1360

P886 Higher Baseline Eosinophil Levels Are Associated with Greater Improvement in Quality of Life with Reslizumab Treatment/J.F. Maspero, M. McDonald, M.C. Garin, Buenos Aires, Argentina, p.A1361

P887 Decreases in Blood Eosinophil Levels Correlate with Lung Function Improvement with Reslizumab Treatment/E. Bleecker, M. McDonald, M.C. Garin, Tucson, AZ, p.A1362


P889 Efficacy of Vitamin D Supplementation in Asthma Control in Asthmatic Patients with Vitamin D Deficiency/R. Andújar, L. Salinero, F. Illán, A.M. Hernández, Murcia, Spain, p.A1364


P904 Effect of Endoscopic Sinus Surgery for Chronic Rhinosinusitis

P903 Cognitive Functions in Nigerian Patients with Clinically Stable

P901 Up to Four Years of Longitudinal Follow-Up for Patients with

P900 Reslizumab High-Responder and Super-Responder Asthma

P899 Durability of Clinical Response Following Long-Term

P898 Impact of Previous Asthma Symptoms and Exacerbations on

P897 Transgender Status Is Associated with Higher Risk of Lifetime

P896 Adverse Events Associated with Oral Corticosteroids in

P895 Comparison of the Clinical Features Between Th2-High and

P894 The Role of FeNO in Cough Management: A Randomised

P893 Risk Factors and Biomarkers of Severe Asthma in Brazil: A

P892 First-in-Man Evaluation of the Pharmacokinetics of AZD7594

P891 Cross-Sectional Analysis of Adults with Previously Untreated

P890 Distinct Distribution of Intrathoracic and Visceral Fat in

P889 PrEP-001, a Novel Immunomodulator for Prevention of Viral

P888 The Efficacy of the Leukotriene Receptor Antagonist

P887 Severe Exacerbations and Inhaled Corticosteroid Load with

P886 Predictive Factors of Accelerated Lung Function Decline in

P885 Adult Asthma/

P884 Eosinophilic Asthma: The COLUMBA Study/

P883 Mild to Moderate Severe Eosinophilic Asthma: The COLUMBA Study/

P882 Treatment with Mepolizumab in Patients with Severe

P881 Severe Exacerbations and Inhaled Corticosteroid Load with

P880 Cross-Sectional Analysis of Adults with Previously Untreated

P879 Adverse Events Associated with Oral Corticosteroids in


P877 PrEP-001, a Novel Immunomodulator for Prevention of Viral

P876 Impact of Previous Asthma Symptoms and Exacerbations on

P875 Durability of Clinical Response Following Long-Term

P874 Transgender Status Is Associated with Higher Risk of Lifetime

P873 Pranlukast in Asthma Patients Complicated with Allergic

P872 The Efficacy of the Leukotriene Receptor Antagonist

P871 The Role of FeNO in Cough Management: A Randomised


Serum IgE Levels as Predictor for Treatment Outcomes in Chinese Patients with Moderate or Severe Allergic Asthma Treated with Omalizumab/J. Li, J. Kang, C.Z. Wang, J. Yang, Z. Lin, S. Wang, M. Humphries, I. Kottakis, R. Fogel, N. Zhong, Guangzhou, China, p.A1389


Use of Omalizumab in Mexican Patients with a Diagnosis of Moderate to Severe Non-Atopic Asthma: An Observational Study/J. Herrera, Puebla, Mexico, p.A1391

Severe Exacerbations and Inhaled Corticosteroid Load with As-Needed Budesonide/Formoterol vs Maintenance Budesonide in Mild Asthma/E. Bateman, H.K. Reddel, P.M. O’Byrne, P.J. Barnes, N. Zhong, C. Keen, C. Jorup, R. Lamarca, A. Siwek-Poslusza, M. FitzGerald, Cape Town, South Africa, p.A7654

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.


P920  Effect of Mepolizumab (100 mg Subcutaneous) on Exacerbation Rate in Patients with Severe Eosinophilic Asthma by Omalizumab Eligibility (US Criteria), and Immunoglobulin E and Eosinophilic Subgroups/M.C. Liu, M. Humbert, D.J. Bratton, S.W. Yancey, E.S. Bradford, S. Hozawa, F.C. Albers, Baltimore, MD, p.A7657


P922  Treatment of Steroid-Dependent Asthmatics with Mepolizumab/R.A. Strauss, Fairview Park, OH, p.A1393


P924  Effect of Low-Dose Macrolide Therapy in Asthmatic Patients with Chronic Neutrophilic Rhinosinusitis/K. Takeyama, T. Akaba, K. Arimura, Y. Shimizu, O. Yagi, E. Tagaya, M. Kondo, J. Hara, Tokyo, Japan, p.A1395

P925  A Real World, Single Center Experience of Treatment of Severe Eosinophilic Asthma with IL-5 Antagonists; Mepolizumab and Reslizumab/R. Mylvaganam, L. Rogers, New York, NY, p.A1396


P930  The Role of Forced Oscillation Technique to Diagnose Patients with Cough Variant Asthma/F. Koike, Y. Endo, Y. Nakamura, M. Akaza, T. Sasanoue, Y. Miya, A. Inase, Y. Sumi, Tokyo, Japan, p.A1401

P931  Inhaled Corticosteroid (ICS) and Long Acting Beta-Adrenoceptor Agonist (LABA) Therapy Adherence Reporting and Monitoring in Clinical Trials of Severe Adult Asthma Drug Treatments: A Systematic Review/M. Mokoka, F. Aslam, A. Arslan, T. Thakur, N. Tambe, R. Dhingra, E.S. Schulman, Philadelphia, PA, p.A1402

P932  forced oscillation technique to diagnose patients with cough variant asthma/F. Koike, Y. Endo, Y. Nakamura, M. Akaza, T. Sasanoue, Y. Miya, A. Inase, Y. Sumi, Tokyo, Japan, p.A1401


P935  The Role of Forced Oscillation Technique to Diagnose Patients with Cough Variant Asthma/F. Koike, Y. Endo, Y. Nakamura, M. Akaza, T. Sasanoue, Y. Miya, A. Inase, Y. Sumi, Tokyo, Japan, p.A1401


P937  Inhaled Corticosteroid (ICS) and Long Acting Beta-Adrenoceptor Agonist (LABA) Therapy Adherence Reporting and Monitoring in Clinical Trials of Severe Adult Asthma Drug Treatments: A Systematic Review/M. Mokoka, F. Aslam, A. Arslan, T. Thakur, N. Tambe, R. Dhingra, E.S. Schulman, Philadelphia, PA, p.A1402

P938  Exhaled Nitric Oxide (FeNO) Measurement in the Auxiliary Diagnosis of Late-Onset Asthma/M. Mokoka, F. Aslam, A. Arslan, T. Thakur, N. Tambe, R. Dhingra, E.S. Schulman, Philadelphia, PA, p.A1402

P939  Inhaled Corticosteroid (ICS) and Long Acting Beta-Adrenoceptor Agonist (LABA) Therapy Adherence Reporting and Monitoring in Clinical Trials of Severe Adult Asthma Drug Treatments: A Systematic Review/M. Mokoka, F. Aslam, A. Arslan, T. Thakur, N. Tambe, R. Dhingra, E.S. Schulman, Philadelphia, PA, p.A1402

P940  Exhaled Nitric Oxide (FeNO) Measurement in the Auxiliary Diagnosis of Late-Onset Asthma/M. Mokoka, F. Aslam, A. Arslan, T. Thakur, N. Tambe, R. Dhingra, E.S. Schulman, Philadelphia, PA, p.A1402

P941  Inhaled Corticosteroid (ICS) and Long Acting Beta-Adrenoceptor Agonist (LABA) Therapy Adherence Reporting and Monitoring in Clinical Trials of Severe Adult Asthma Drug Treatments: A Systematic Review/M. Mokoka, F. Aslam, A. Arslan, T. Thakur, N. Tambe, R. Dhingra, E.S. Schulman, Philadelphia, PA, p.A1402

P942  Exhaled Nitric Oxide (FeNO) Measurement in the Auxiliary Diagnosis of Late-Onset Asthma/M. Mokoka, F. Aslam, A. Arslan, T. Thakur, N. Tambe, R. Dhingra, E.S. Schulman, Philadelphia, PA, p.A1402


P966 The Adherens Junction Protein, αCatenin, Contributes to Airway Hyperreactivity Independently of Inflammation Via the Vagus/C.J. Gottardi, S.E. Chiarella, A. Flozak, E.E. Rabin, Chicago, IL, p.A1436

P967 Seasonal Variability of Lung Function and Asthma Quality of Life Questionnaire Scores in Adults with Severe Asthma/D. Choy, X. Yang, T. Staton, J.K. Olsson, C. Holweg, J.R. Arron, J.G. Matthews, R. Bauer, South San Francisco, CA, p.A1437

P968 Heterogeneous Parenchymal Deficits in House Dust Mite - Allergic Rats Exposed to Chronic Intermittent Hypoxia/O. Bryotman, J. Brinkman, D. Pegelow, M. Teodorescu, Madison, WI, p.A1438


P970 Determinants of Lung Function Improvement with Omalizumab in Allergic Asthma/N.A. Hanania, R. Djukancovic, L.G. Heaney, M. Yang, B.L. Trzaskoma, N.M. Griffin, B.E. Chipps, Houston, TX, p.A1440


---

**THEMATIC POSTER SESSION**

**A36 HOT TOPICS IN CRITICAL CARE MEDICINE**

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER

Area D (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion 12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: N.R. Nadig, MD, Charleston, SC


P256 What happens at the PCP Follow-Up?: Assessing Key Management Changes Following a Prolonged Hospitalization for Sepsis/M. Thau, H.C. Prescott, Ann Arbor, MI, p.A1442


P262 Variation in Vascular Outcomes Related to Peripherally Inserted Central Catheters (PICCs) in Critically-Ill Patients: A Retrospective Cohort Study/S. Govindan, A. Snyder, R.C. Hyzy, S. Flanders, V. Chopra, Ann Arbor, MI, p.A1448


P264 Daily Vs. Weekly Ventilator Circuit Change in Long Term Acute Care Unit, Outcome and Cost Analysis: A Single Center Retrospective Study/S. Sharma, Corbin, KY, p.A1450


Facilitator: K.S. Mathews, MD, MPH, New York, NY


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
A37 QUALITY IMPROVEMENT RESEARCH IN PULMONARY AND CRITICAL CARE MEDICINE

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER
Area D (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.
Discussion: 11:15-12:00: authors will be present for discussion
12:00-1:00: authors will be present for discussion with assigned facilitators


P275 Acute Respiratory Distress Syndrome in Hospitalized Patients with Community-Acquired Pneumonia/E. Barbeta, M.F. Monreal, A.T. Torres, C. Cilloniz, A. Ceccato, Barcelona, Spain, p.A1461


Facilitator: H.C. Prescott, MD, MSci, Ann Arbor, MI


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
P298  Assessment of the Knowledge of Tuberculosis Among Health Workers in Private Health Facilities in Benin City, Edo State: A Pilot Survey/N. Mokogwu, M.I. Okhawere, Benin City, Nigeria, p.A1481


Facilitator:  B.E. Jones, MD, MSc, Salt Lake City, UT

P300  Effect of a Quality Improvement Initiative in Reducing Duplicate Respiratory Viral Panel Testing in Patients Undergoing Bronchoalveolar Lavage at a University Hospital Center/A. George Jacob, T.J. Gross, Iowa City, IA, p.A1483

P301  Clinical Institute Withdrawal Assessment (CIWA) Protocol: Misunderstandings, Misuse, and Misadventures/C. Thompson, M.J. Leveno, Dallas, TX, p.A1484

P302  Retrospective Analysis of Computed Tomography Angiography-Chest (CTA) for Pulmonary Embolism/D. Akella, Q. Baig, O. Zaman, Q. Khan, V. Taware, S. Bindroo, J. Hippen, Secane, PA, p.A1485

P303  Inappropriate Utilization of Portable Chest Radiography in Diagnosis and Treatment of Cardiopulmonary Disease/A.Z. Rasheed, L. Latypov, M. Shahzadi, V.P. Vasudevan, L.N. Gerolemou, F. Arjomand, Brooklyn, NY, p.A1486


P305  Overcoming Barriers to Adolescent Access to Influenza Vaccination/B. Sufian, I.Y. Passamano, Houston, TX, p.A1488


THEMATIC POSTER SESSION

A38  UNDERSTANDING CARE DELIVERY AND OUTCOMES IN OBSTRUCTIVE SLEEP APNEA

9:15 a.m. - 4:15 p.m.  SAN DIEGO CONVENTION CENTER

Area C (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator:  M.E. Billings, MD, MSc, Seattle, WA


P173  Use of Stimulants and Continuous Positive Airway Pressure in Patients with Obstructive Sleep Apnea from a Large Claims Dataset/M. Ohayon, J. Profant, S. Gibson, C. Milesi, Palo Alto, CA, p.A1494


P176  Use of Flow-Volume Curve Associated with Body Measurement as Real-World Evidence Severity Estimation in Adult Obstructive Sleep Apnea/K.-Y. Chen, Yi-Lan County, Taiwan, p.A1497


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
A39 SARCOIDOSIS AND RARE LUNG DISEASE
SCIENTIFIC ABSTRACTS

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER
Area L (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: M.L. Ribeiro Neto, MD, Cleveland, OH

P1328 Outcomes of Directed PAH Therapy in Sarcoidosis/K. Albujqo,

P1329 Obesity Is Associated with Better Hemodynamic
Measurements in Patients with Sarcoidosis Associated
Pulmonary Hypertension/E.D. Abston, S. Hon, L. Baipayee, P.
Goverd, J.S. Berman, H.W. Farber, Boston, MA, p.A1510

P1330 Clinical Outcome Status and Organ Involvement in Minnesota
Sarcoidosis Cohort/H.S. Te, A.E. Levin, K.J. Viken, R. Tomic,
D.M. Perlman, M. Bhargava, Minneapolis, MN, p.A1511

P1331 Biomarker Relationships to Fatigue in Patients with Chronic
Sarcoidosis/L. O’Hare, P. Acosta Lara, J. Barney, Birmingham,
AL, p.A1512

P1332 Sarcoid Reaction to Malignancies/J. Serra, R. de Jesus, J.R.
Bandeira, F.M. da Costa, M. de Oliveira, B.G. Baldi, G. Prado, A.M.
Kawasaki, R.A. Kairalla, Sao Paulo, Brazil, p.A1513

P1333 The Evaluation of Neutrophil Gelatinase-Associated Lipocalin in
Patients with Pulmonary Sarcoidosis/S. Kato, N. Inui, H. Yasui, H.
Hozumi, M. Karayama, Y. Suzuki, K. Furushashi, N. Enomoto, T.
Fujisawa, Y. Nakamura, T. Suda, Hamamatsu, Japan, p.A1514

P1334 Pulmonary Function, Depression and Systemic Inflammation
in Post-Sarcoidosis Fatigue Syndrome/W. Pietrowski, A.
Kumor-Kisielewska, W. Górska, Lodz, Poland, p.A1515

Facilitator: N. Gupta, MD, Cincinnati, OH

P1335 18 FDG PET CT and Sarcoidosis/M. Carneiro, C.H. Costa, R.L.
Alves, F.M. Anselmo, B.R.A. Silva, E.J.C. Bessa, L. Bruno, Rio de
Janeiro, Brazil, p.A1516

P1336 Repository Corticotrophin Injection (RCI) for Sarcoidosis:
Results of a Delphi Study/F.F. Rahaghi, N. Sweiss, L.A.
Saketkoo, M.B. Scholand, J. Barney, A. Gerke, E.E. Lower, M.
Mirsaeidi, L. O’Hare, M.J. Rumbak, L. Samavati, R.P. Baughman,
Weston, FL, p.A1517

P1337 Clinical Characteristics of Patients in a Case Control Study of
Sarcoidosis in Brazil/J. Guimaraes, M.C. Lopes, R. Rufino, C.H.
Costa, F.M. Anselmo, B.R.A. Silva, E.J.C. Bessa, L.P. Bruno, Rio de
Janeiro, Brazil, p.A1518

P1338 Impact of Organ Involvement on Quality of Life in Sarcoidosis:
Results from the Registry for Advanced Sarcoidosis (ReAS)/T.
Tully, S.S. Birring, M.A. Judson, E.E. Lower, R.P. Baughman,
London, United Kingdom, p.A1519

P1339 Clinical Characteristics of Pulmonary Sarcoidosis Requiring
Systemic Corticosteroids/H. Kimura, S. Konno, T. Yamaguchi, N.
Shijubo, T. Hattori, Y. Yamada, K. Shimizu, M. Suzuki, M.
Nishimura, Sapporo, Japan, p.A1520

P1340 The FDG-PET Features of IgG4-Related Disease with Bilateral
Hilar Lymphadenopathy: A Comparison with Sarcoidosis/M.
Komatsu, H. Yamamoto, Y. Ozawa, A. Ushiki, K. Oguchi, S.
Kawakami, M. Yasuo, A. Fujita, M. Hanaoka, Matsumoto, Japan,
p.A1521

P1341 Potential Limitations of Activity Tracking Devices in
Monitoring Effects of Treatment for Sarcoidosis/R.P.
Baughman, R. Reeves, J. Zeigler, M.A. Judson, D.A. Culver, E.S.
Chen, N. Schweiss, N.Y. Hamzeh, D. Valeyre, J.C. Grutters, G.
Spitzer, Cincinnati, OH, p.A1522

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
A40  **ILD: CASE REPORTS I**

**9:15 a.m. - 4:15 p.m.**  
SAN DIEGO CONVENTION CENTER  
Area K (Hall A-B2, Ground Level)

**Viewing:** Posters will be on display for entire session.

**Discussion:** 11:15-12:00: authors will be present for individual discussion  
12:00-1:00: authors will be present for discussion with assigned facilitators

**Facilitator:** L.L. Silhan, MD, Baltimore, MD

---


**P1133** A Rare Case of Bronchiocentric Interstitial Fibrosis/S. Sitaula, C. Curtiss, E. Scalzetti, A. Desai, Syracuse, NY, p.A1539

**P1134** Interstitial Pneumonitis with Autoimmune Features/M. Shahzadi, A. Mogla, A.Z. Rasheed, V.P. Vasudevan, Brooklyn, NY, p.A1540

**P1135** Surfactant Protein C Deficiency and Rheumatoid Arthritis Interstitial Lung Disease in Pregnancy - A Fatal Combination/L. Barnes, P.J. Passarelli, R. Hsiao, R.E. Sell, San Diego, CA, p.A1541

**P1136** Pleuroparenchymal Fibroelastosis Following Autologous Bone Marrow Transplant/K. Lam, Stanford, CA, p.A1542


**P1138** Occam’s Razor: An Extremely Rare Presentation of a Very Rare Pulmonary Manifestation of Lupus/K. Hersi, A.-I. SeyedAmirHosseinse, A. Girdhar, Y. Sangwan, Salisbury, MD, p.A1544


**P1140** An Unusual Presentation of Pulmonary Sarcoidosis/H. Hinds, Y. Liu, N. Popnikolov, E.J. Yoo, Philadelphia, PA, p.A1546

**P1141** Hypereosinophilic Syndrome with Eosinophilic Myocarditis/J. Lam, D. Patel, R. Condos, M. Mahmoudi, New York, NY, p.A1547

**P1142** Asymmetric Migrating Diffuse Alveolar Hemorrhage/H. Itikhar, C. Zhang, G. Grasso-Knight, B.D. Dalal, Royal Oak, MI, p.A1548

**P1143** Hypersensitivity Pneumonitis and Sarcoidosis/S. Matson, M. Ragland, J.C. Lavelle, C. Cool, L.A. Maier, Aurora, CO, p.A1549

**P1144** Pleuroparenchymal Fibroelastosis a Case Report/M.A. Ramirez Candelas, O. Barreto, I. Buendia, K. Jassen Avellaneda, M. Gaxiola, Tlalpan, Mexico, p.A1550
P1145  A Common Disease Presenting Uncommonly as Stroke/M. Szczepanski, B.D. Dalal, Royal Oak, MI, p.A1551

P1146  Idiopathic Pulmonary Fibrosis in a Rail Yard Worker/S. Gandhi, J.L. Abraham, L. Muszynski, S. Sanyal, R.A. Cohen, Chicago, IL, p.A1552

P1147  Sarcoïdosis After Lymphoma - A Late Presentation/S. Patel, T. Russi, Brooklyn, NY, p.A1553


P1149  Gastric Sarcoidosis as a Possible Cause of Non-Specific Abdominal Symptoms/E. Oteng, V. Kodadhala, F.T. Ogundipe, A. Kibreab, V. Poddar, Washington, DC, p.A1555


P1152  A Case of Giant Cell Arteritis Related Interstitial Lung Disease/E. Welt, R.L. Gross, Washington, DC, p.A1558


P1155  Tunneling Through Fibrosing Mediastinitis/N. Raya, A. Gamino, Chicago, IL, p.A1562


P1158  Organizing Pneumonia as the Presenting Symptom of Anti-MDA5 Amyopathic Dermatomyositis/A. Patel, K. Warrior, M.A. Yoder, Chicago, IL, p.A1565


P1161  Rothia Mucligiosa Pneumonitis Complicating Interstitial Lung Disease/H.D. Bachert, K. Thavarajah, Detroit, MI, p.A1568

P1162  MDA-5 Positive Dermatomyositis Complicated by Pneumomediastinum/S. Farrell, N. Huprikar, P. Hiles, Fort Sam Houston, TX, p.A1569

P1163  The Intersection of Autoimmune Disease and Malignancy: A Case of Multi-Organ Paraneoplastic Vasculitis/J.M. Neborak, S.M. Montner, A.O. Adegunsoye, P. Reid, I. Ventura, M.E. Strek, Chicago, IL, p.A1570

P1164  Late Onset Pulmonary Langerhans Cell Histiocytosis (PCHL) and Concurrent Diagnosis of Lung Cancer/H. Feng, S. Narsingam, D. Seidler, Lebanon, NH, p.A1571

P1165  Strange Coincidences: A Case of Concurrent Sarcoidosis and Birt-Hogg-Dubé/J.M. Huang, R. Amer, Hamilton, Canada, p.A1572

P1166  When a Consolidated Lung Does Not Lead to a Consolidated Diagnosis: Antisynthetase Syndrome Presenting with Lymphangitic Carcinomatosis/A. Shioleno, A. Wu, New York, NY, p.A1574

P1167  Pulmonary Langerhans Cell Histiocytosis in a Heavy Marijuana Smoker/P. Khaing, R.S. Summer, Philadelphia, PA, p.A1575


P1169  Omalizumab Is Ineffective Treatment for Hypersensitivity Pneumonitis with Elevated IgE/V. Viola, J. Heath, N.G. Shah, Baltimore, MD, p.A1577

P1170  Pulmonary Langerhans Cell Histiocytosis in a Heavy Marijuana Smoker/S. Viola, J. Heath, N.G. Shah, Baltimore, MD, p.A1577


P1172  Early Onset Pulmonary Langerhans Cell Histiocytosis (PCLH) and Concurrent Diagnosis of Lung Cancer/H. Feng, S. Narsingam, D. Seidler, Lebanon, NH, p.A1577

P1173  Omalizumab Is Ineffective Treatment for Hypersensitivity Pneumonitis with Elevated IgE/V. Viola, J. Heath, N.G. Shah, Baltimore, MD, p.A1577

P1174  When a Consolidated Lung Does Not Lead to a Consolidated Diagnosis: Antisynthetase Syndrome Presenting with Organizing Pneumonia/A.Z. Alkhathlan, A. Syed, C. Donatelli, C.V. Teva, Cleveland, OH, p.A1576

P1175  A Cure or a Curse? Severe Bilateral Radiation Pneumonitis in a Patient with Scleroderma-Related Interstitial Lung Disease and Lung Adenocarcinoma/P. Khaing, R.S. Summer, Philadelphia, PA, p.A1573

P1176  Strange Coincidences: A Case of Concurrent Sarcoidosis and Birt-Hogg-Dubé/J.M. Huang, R. Amer, Hamilton, Canada, p.A1572

P1177  A Case or a Curse? Severe Bilateral Radiation Pneumonitis in a Patient with Scleroderma-Related Interstitial Lung Disease and Lung Adenocarcinoma/P. Khaing, R.S. Summer, Philadelphia, PA, p.A1573

P1178  Strange Coincidences: A Case of Concurrent Sarcoidosis and Birt-Hogg-Dubé/J.M. Huang, R. Amer, Hamilton, Canada, p.A1572

P1179  A Cure or a Curse? Severe Bilateral Radiation Pneumonitis in a Patient with Scleroderma-Related Interstitial Lung Disease and Lung Adenocarcinoma/P. Khaing, R.S. Summer, Philadelphia, PA, p.A1573
P1177  What You Don't Know Can Hurt You: A Rare Form of Pulmonary Fibrosis in the Setting of Chronic Cyclophosphamide/K. Waksmundzki-Silva, J. Mickelson, S.E. Kopec, Worcester, MA, p.A1583

P1181  Quantified CT and Pulmonary Function in Idiopathic Pulmonary Fibrosis (ILD) Patients/Z. Hu, C. Que, Beijing, China, p.A1584


P1185  Autoimmune Testing Patterns Associated with IPF Diagnostic Confidence/M.B. Scholand, J. Moore, J. Stauffer, W. Pan, S. Limb, Salt Lake City, UT, p.A1588

P1186  Demographic Factors Associated with IPF Diagnostic Confidence/M.B. Scholand, J. Moore, J. Stauffer, K. Raimundo, W. Pan, S. Limb, Salt Lake City, UT, p.A1589


P1191  Histological Analysis of Vascular Changes Associated with Pulmonary Hypertension in Combined Pulmonary Fibrosis and Emphysema: Comparison with Idiopathic Pulmonary Fibrosis or Emphysema Alone/N. Awanoo, Tokyo, Japan, p.A1594


Facilitator: M. Salisbury, MD, Ann Arbor, MI


P1196  Clinical Significance of Serum KL-6 and Surfactant Protein D in Idiopathic Interstitial Pneumonias/C. Sakai, M. Masuda, S. Ano, N. Kikuchi, Y. Ishii, Tsuchiura, Japan, p.A1599

P1197  Physiological Impairment in Patients with Interstitial Lung Disease at the Time of Referral to a Specialty Clinic/P. Jamali, M. Guay-Gagnon, H. Manganas, J. Morisset, C. Poirier, Montréal, Canada, p.A1600


P1201 Impact of Lung Function Decline on Health-Related Quality of Life in Patients with Idiopathic Pulmonary Fibrosis (IPF)/M. Kreuter, W. Stansel, S. Stowasser, N. Schoof, Heidelberg, Germany, p.A1604


P1203 Increased Mortality in Idiopathic Pulmonary Fibrosis Patients When Admitted to the Intensive Care Unit with Mechanical Ventilation/S. Chaaban, E. Cassity, A. Kelly, S. Dhar, P.E. Morris, Lexington, KY, p.A1606

P1204 Sex-Specific Predictors of Death in Idiopathic Pulmonary Fibrosis/T. Zaman, H.R. Collard, J.S. Lee, Aurora, CO, p.A1607

Facilitator: A.W. Brown, MD, Falls Church, VA


P1209 Distance Saturation Product Predicts an Elevated Pulmonary Vascular Resistance in Patients with Combined Pulmonary Fibrosis and Empyema/J. Brown, O.A. O’Corragain, N. Marchetti, G.J. Criner, Philadelphia, PA, p.A1612


P1212 Six-Minute Walk Distance and Mortality in Idiopathic Pulmonary Fibrosis in Brazil/E. Viana Manucuzo, M.R. Soares, C.A.D.C. Pereira, Belo Horizonte, Brazil, p.A1615


Facilitator: S.A. Guler, MD, Vancouver, Canada


P1224 A New Method For The Diagnosis Of Bleomycin Toxicity: Thoracic Ultrasonography/C. Dogan, S. Cómer, B.N. Caglayan, S.B. Sagmen, E.T. Parmaksiz, N. Kiral, A. Fidan, B.M. Salepci, Istanbul, Turkey, p.A7661


P1231 Synthetic Peptide dNP-15 Targeting TGF-Beta Signaling Prevents Pulmonary Fibrosis Induced by Bleomycin in Rats/Y. Ding, X. Li, L. Xiao, R. Chen, X. Liu, X. Chen, Chengdu, China, p.A1631

P1232 A Study of Tolerability and Therapeutic Effect of Antifibrotic Agents for Elderly Patients with Idiopathic Pulmonary Fibrosis/T. Sawata, Ootaku, Japan, p.A1632


P1234 Association of Angiotensin Modulators with the Course of Idiopathic Pulmonary Fibrosis/M. Kreuter, L. Frankenstein, D.J. Lederer, M. Molina-Molina, I. Noth, C. Valenzuela, D. Weycker, K.-U. Kirchgaessler, V. Cottin, Heidelberg, Germany, p.A1634

P1235 Indication for and Impact of Switching from Pirfenidone to Nintedanib in Idiopathic Pulmonary Fibrosis/C. Hogben, V. Kouranos, M. Kokosi, E.A. Renzoni, F. Chua, A.U. Wells, T.M. Maher, P.L. Molyneaux, P.M. George, London, United Kingdom, p.A1635


P1239 Mycophenolate and Rituximab in Patients with Interstitial Lung Disease Associated with Connective Tissue Disorder in the Setting of Positive Myositis Antibodies: A Retrospective Analysis/R. Burnside, I.C. Mira-Avendano, Jacksonville, FL, p.A1639


P1247 Baseline Characteristics from a Pre-Specified Interim Analysis of a Phase IIb, Randomized, Double-Blind, Placebo-Controlled Trial of Sildenafil Added to Pirfenidone in Patients with Advanced Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension/J. Behr, S.D. Nathan, S. Harari, W. Wuyts, K.-U. Kirchgässler, M. Bengus, F. Gilberg, A.U. Wells, Munich, Germany, p.A1647


P1253 The Effectiveness, Safety and Tolerability of Pirfenidone Therapy Among Turkish Patients with Idiopathic Pulmonary Fibrosis/I. Hanta, A. Cilli, C. Sevinc, H. Dirol, S. Kuleci, Adana, Turkey, p.A1653


Facilitator: A. Brown, MD, BSN, Atlanta, GA


P1262 The Role of Infection in Acute Exacerbation of Idiopathic Pulmonary Fibrosis/D. Weng, L. Huiping, Shanghai, China, p.A1662

P1263 Pharmacological Treatment for Acute Exacerbation of Fibrosing Interstitial Pneumonia: A Retrospective Study of 95 Patients/S. Sakamoto, Tokyo, Japan, p.A1663

P1264 Acute Exacerbation of Idiopathic Pulmonary Fibrosis Over a 9-Year Period in a Community Teaching Hospital in Japan/M. Yamazoe, H. Tonomura, Kobe, Japan, p.A1664


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.

Facilitator: J.S.V. Sheth, MD, Ann Arbor, MI


P1283 Circulating Fibrocytes as Biomarkers of Disease Activity Among Patients with Connective Tissue Disease-Associated Interstitial Lung Disease and Interstitial Pneumonitis with Autoimmune Features/J. Odackal, Y. Yu, M.D. Burdick, B. Mehrad, Charlottesvile, VA, p.A1680


P1286 Prospective Study of Patients Evaluated at an Interstitial Lung Disease Clinic in Singapore Over 5 Years/Y.H. Tan, S.Y. Low, Singapore, Singapore, p.A1683


P1290 Non-Tuberculous Mycobacteria in Interstitial Lung Disease: To Treat or Not to Treat?/H.T. Oakland, V.S. Taskar, J.A. Lasky, R.C. Klingsberg, New Orleans, LA, p.A1687


Facilitator: B. Graney, MD, Aurora, CO

P1295 High Prevalence of Possible Usual Interstitial Pneumonia Pattern in Chronic Hypersensitivity Pneumonitis at a Brazilian Reference Center/A.F. Amaral, J.V.K. Schubsky, F.E. Arimura, M.V.Y. Sawamura, B.G. Baldi, C.R.R. Carvalho, Sao Paulo, Brazil, p.A1692


P1298 A Rare Combination of Lymphangioleiomyomatosis with Hypersensitivity Pneumonia/R.B. Filho, M. Rodrigues de Oliveira, A.F. Amaral, E. Nascimento, F.E. Arimura, B.G. Baldi, R.A. Kairalla, C.R.R. Carvalho, Sao Paulo, Brazil, p.A1695


P1301 Low Vitamin K Status in Idiopathic Pulmonary Fibrosis/B. de Brouwer, E.S. White, R. Janssen, Nijmegen, Netherlands, p.A1698


P1304 To Determine Which Pulmonary Function Parameters Should Be Considered for Grading Severity of Restrictive Lung Disease/R.J. Cho, K. Wyzros, E.O. Corazalla, H. Kim, MInneapolis, MN, p.A1701


THEMATIC POSTER SESSION

A44 COPD: PHENOTYPES AND COMORBIDITIES

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER

Facilitator: A.P. Comellas, MD, Iowa City, IA


Facilitator: V. Kim, MD, Philadelphia, PA


Discussion:


THEMATIC POSTER SESSION

A45 TOPICS IN INTERVENTIONAL PULMONARY

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER

Area L (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion 12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: K.L. Kovitz, MD, MBA, Elk Grove Village, IL


P1367  Diagnostic Utility of Bronchoalveolar Lavage Among Post-Hematopoietic Stem Cell Transplant Patients with Abnormal HRCT Chest Imaging/A. Vose, A.G. Jacob, F. Rafullah, T.J. Gross, Iowa City, IA, p.A1731
Facilitator:  R. Semaan, MD, Pittsburgh, PA


P1371  Endo Bronchial Ultrasound Guided Trans-Vascular Needle Aspiration (TVNA), Our Experience with Twenty-One Patients/A. Sheikh, K.J. Diab, Indianapolis, IN, p.A1735

P1372  Lung Fissure Interruption on Computer Tomography Imaging as a Diagnostic Tool for Interlobar Fusion/T. Vandemoortele, D. St-Pierre, G. Rakovich, Montreal, Canada, p.A1736


P1376  Description of the Operative Characteristics of Flexible Fiberoptic Bronchoscopy in the Diagnosis of Pulmonary Pathologies in Adult Patients at University Hospital Fundacion Santa Fe de Bogota Between 2012 to 2014/M.P. Caicedo, D. Londoño, J.H. Roa, L.P. Prada, M.A. Castillo, Bogota, Colombia, p.A1740


P1378  Examination of Anesthetic Dose and Risk Factors When Performing a Bronchial Thermoplasty Under Local Anesthesia/Y. Tsujimoto, S. Ishii, M. Ikura, H. Sugiyama, Tokyo, Japan, p.A1742


P1383  Yield in Electromagnetic Navigational Bronchoscopy (ENB) for Peripheral Pulmonary Nodules/M. Ahmad, J.F. Santacruz, E. Graviss, D. Nguyen, Houston, TX, p.A1747


P1385  The Effect of the Environment on Outdoor Six-Minute Walk Test Performance in Individuals with Alpha-1 Antitrypsin Deficiency and Chronic Obstructive Pulmonary Disease/J. Chung, A. Ataya, J. Nolte, V.A. Segui, M.L. Brantly, L. Benninger, Gainesville, FL, p.A1751


P1387  Results from a Large-Scale Screening Program for Alpha-1 Antitrypsin Deficiency: A History of Bronchiectasis Is Associated with the ZZ Genotype/M. Brantly, C. Charleston, R. Oshins, S. Kavanagh, A.M. Davis, Gainesville, FL, p.A1750

P1388  The Information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.

Facilitator: R.A. Stockley, MD, DSc, Birmingham, United Kingdom

P1395 Characterization of a Liquid Presentation of the Alpha-1-Proteinase Inhibitor Prolastin®/M. Cruz, J. Lang, K. Merritt, K. Wee, T. Willis, Research Triangle Park, NC, p.A1757

P1396 Alpha 1 Antitrypsin Therapy: A Satisfaction Survey of Individuals Self-Administering/R.A. Sandhaus, B.S. Boyd, Littleton, CO, p.A1758


A47 NEUROMUSCULAR DISEASE AND RESPIRATION

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER

Area L (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators: J. Porszasz, MD, PhD, Torrance, CA
K.A. Kevill, MD, Stony Brook, NY


P1403 Objective Effort of Breathing Scores in Critically Ill Children/J. Hotz, S. Shein, R.G. Khemani, Los Angeles, CA, p.A1762

P1404 The Natural History of Patients with Congenital Muscular Dystrophy at Children's National Health System: A Tertiary Medical Center Experience/H. Fanous, G.R. Nino, G. Perez, Washington, DC, p.A1763


P1410 Airway Clearance Device Prescriptions for Patients with Amyotrophic Lateral Sclerosis (ALS) Vary Widely but Correlate with Lung Function, Overall Functional Status, and Bulbar Phenotype/E. Malsin, J.M. Coleman, L.F. Wolfe, Chicago, IL, p.A1769


A48 DYSPNEA: CASE REPORTS I

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER

Area L (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators: S. Sahetya, MD, Baltimore, MD
B.T. Tran, MD, MSc, Chicago, IL


P1418 Rare Case of Idiopathic Plastic Bronchitis in Adult/M.M. Rachid, P. Sharma, A. Kumar, M. Sunbuli, E. Mekhail, Oak Lawn, IL, p.A1774

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
P1419  Re-Expansion Pulmonary Edema Complicating Thoracentesis/ J.J. Dorsch, A. Sachdeva, Baltimore, MD, p.A1775


P1421  To Drain or Not to Drain/D.J. deCosta, D.W. Hsia, Torrance, CA, p.A1777

P1422  Sudden Onset Shortness of Breath and Chest Pain in a Pregnant Woman: A Rare Case of Pulmonary Embolism/M. Hunter, T. Barreiro, Youngstown, OH, p.A1778


P1425  Pulmonary Extramedullary Hematopoiesis in a Patient with Polycythemia Vera/W.J. Chang, K. Friedman, R.J. Schilz, Cleveland, OH, p.A1781

P1426  Practically Living with One Lung: A Rare Adult Presentation of Congenital Pulmonary Airway Malformation/M.B. Abdelfattah, S. Hadique, Morgantown, WV, p.A1782

P1427  Closure of Atrial Septal Defect Causing Worsening Hypoxemia/D. Robinson, A.J. Hayek, F. Perez-Guerra, Temple, TX, p.A1783


P1431  Low Oxygen Affinity Hemoglobinopathy: A Rare Sixth Cause of Hypoxemia/K.R. Davidson, A. Gupta, T. Huie, Aurora, CO, p.A1787

P1432  Unusual Cause of Dyspnea/M. Al-Charaikh, A. Chebbo, P.F. Quiroga, Phoenix, AZ, p.A1788

P1433  Acute Epiglottitis Due to Group B Streptococcus in an Adult/V. Kaul, F.K. Suhail, M.E. Warshawsky, Elmhurst, NY, p.A1789


P1435  A Case of Spontaneous Hemothorax in a Man with Neurofibromatosis Type 1/R. Sidhom, F.A. Youssef, M.A. Tanios, Orange, CA, p.A1791

P1436  Patient with Dyspnea and No Heart Sounds: Where Did the Heart Go?/P. Iyer, M.P. Muthiah, Memphis, TN, p.A1792


Facilitator: J. Leung, MD, Vancouver, Canada

P1440  Unexplained Dyspnea in a Patient with Rheumatoid Arthritis/L. Holt, Miami, FL, p.A1796


P1443  Kommerell’s Diverticulum Causing Dysphagia Lusoria and Tracheal Compression/A. Gupta, K. Davidson, Aurora, CO, p.A1799


**THEMATIC POSTER SESSION**

A49  CRITICAL CARE: LOOKING FOR CLUES - BIOMARKERS IN ARDS, SEPSIS, AND ACUTE CRITICAL ILLNESS

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER

Area D (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion

12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators: J.P. Reilly, MD, MSCE, Philadelphia, PA

C.M. Shaver, MD, PhD, Nashville, TN


Increased Bronchoalveolar Lavage Fluid Peroxiredoxin 6 Levels in Acute Respiratory Distress Syndrome/D. Yang, C. Wang, J. Liu, C. Chen, Y. Song, Shanghai, China, p.A1805


The Predictive Effect of Multiple Biomarkers in Sepsis Patient in Intensive Care Unit/L. Jiang, Dalian, China, p.A1811


Hypermobility Inhibitor-1 as Predictors of Outcome in Acute Respiratory Distress Syndrome/W. Wang, J. Liu, C. Chen, Y. Song, Shanghai, China, p.A1820


P338 Acute Lung Injury Induces Differential Effects on Respiratory Facilitator:
E. Wilcox, MD, MPH, Toronto, Canada


Facilitator: E. Wilcox, MD, MPH, Toronto, Canada


P333 Pilot Study to Evaluate the Effects of Sound Modulation on Sympathetic Arousals in Critically Ill Patients/A. George Jacob, B.K. Gehlbach, Iowa City, IA, p.A1824


P349 Cardiac Overexpression of Melusine Protects from Lipopolysaccharide-Induced Sepsis Cardiomyopathy/P. Arina, A. Costamagna, L. Brazzi, V.M. Ranieri, V. Fanelli, M. Brancaccio, Torino, Italy, p.A1839


P351 Cell Therapy Using Genetically Modified Mesenchymal Stem Cell in a Murine Model of Sepsis/J. Bringue, Sabadell, Spain, p.A1841


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>P354</td>
<td>Recombinant Thrombomodulin Attenuates Sepsis-Induced Pulmonary Injury Via Protection of Endothelial Glycocalyx Structure</td>
</tr>
<tr>
<td>Facilitators:</td>
<td>J.C. Gardner, PhD, Cincinnati, OH J.A. Bastarache, MD, Nashville, TN</td>
</tr>
<tr>
<td>P355</td>
<td>Ventilatory Pattern Variability Decreases and Brainstem Interleukin-18 (IL-18) Increases During Sepsis</td>
</tr>
<tr>
<td>P356</td>
<td>Trans-Pulmonary Thermodilution Technique for Assessment of Fluid Response in Septic Porcine Model During Low Tidal Volume Ventilation</td>
</tr>
<tr>
<td>P357</td>
<td>Hyaluronan Shedding and Clearance During Experimental Sepsis and Acute Lung Injury</td>
</tr>
<tr>
<td>P358</td>
<td>Depletion of Components of the Hepatic Malate-Aspartate Shuttle May Limit Energy Utilization in Pseudomonas Aeruginosa Septic Shock in Dogs</td>
</tr>
<tr>
<td>Facilitators:</td>
<td>S. Cheng, Winnipeg, Canada, p.A1848</td>
</tr>
<tr>
<td>P359</td>
<td>B. Anthracis Edema Toxin Inhibition of Phenylephrine Stimulated Aortic Ring Contraction Is Mediated Via Both Protein Kinase A (PKA) and Exchange Protein Directly Activated by cAMP (Epac) Pathways</td>
</tr>
<tr>
<td>Facilitators:</td>
<td>Y. Li, X. Cui, Y. Fitz, P.Q. Eichacker, Bethesda, MD, p.A1849</td>
</tr>
<tr>
<td>P360</td>
<td>Anthrax Lethal Toxin but Not Edema Toxin Increases Pulmonary Vascular Permeability in an Isolated Perfused Rat Lung Model</td>
</tr>
<tr>
<td>P361</td>
<td>Loss of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Drives Lung Endothelial Barrier Failure in Pneumonia-Induced Acute Respiratory Distress Syndrome (ARDS)</td>
</tr>
<tr>
<td>P362</td>
<td>Comparison of Nebulized Plasminogen Activators for Management of Inhalational Smoke Induced Acute Lung Injury (ISALI) in Sheep: Impact on Physiological Profile</td>
</tr>
<tr>
<td>Facilitators:</td>
<td>S. Bihari, D. DeBellis, D.-L. Dixon, M.D. Lawrence, A.D. Bersten, Bedford Park, Australia, p.A1861</td>
</tr>
<tr>
<td>P363</td>
<td>Cell Therapies for the Treatment of Acute Lung Injury in an Experimental Model</td>
</tr>
<tr>
<td>Facilitators:</td>
<td>M. Camprubi-Rimbals, R. Guillamat-Prats, N. Tantinyà, J. Bringue, M. Gómez, L. Blanch, A. Artigas, Sabadell, Spain, p.A1852</td>
</tr>
<tr>
<td>P364</td>
<td>Mesenchymal Stromal/Stem Cells Enhance Macrophage Phagocytosis and Clearance in Preclinical Sepsis Models Via Enhanced Macrophage Hemoxygenase-1 Expression</td>
</tr>
<tr>
<td>P365</td>
<td>Endothelial Group V Phospholipase A2 (gPLA2) Mediates Acute Lung Injury Caused by Methicillin-Resistant Staphylococcus Aureus (MRSA) in Mice</td>
</tr>
<tr>
<td>P366</td>
<td>Optical Assessment of Pulmonary Vascular Leak Using a Model of Ex Vivo Lung Perfusion</td>
</tr>
<tr>
<td>P367</td>
<td>Blood Carboxyhemoglobin Elimination Curve, Half-Life Time and Arteriovenous Differences in Acute Phase of Smoke Inhalation Injury in Ovine Model</td>
</tr>
<tr>
<td>P368</td>
<td>Ex Vivo Repletion of Phosphatidylglycerol and Restoration of Surfactant Function in ARDS/C</td>
</tr>
<tr>
<td>P369</td>
<td>Increased Staining for Renin/Prorenin in the Lungs in a Rat Model of Fat Embolism Is Enhanced by Captopril and Losartan Which Ameliorate the Pulmonary Damage</td>
</tr>
<tr>
<td>P370</td>
<td>Quantitative Tracking of Mesenchymal Stem Cells Using Fluorescent Nanodiamond in the Murine Model of Bleomycin-Induced Acute Lung Injury</td>
</tr>
<tr>
<td>P371</td>
<td>Time Course for Development and Resolution of Fluid Induced Lung Injury in an Animal Model Following 0.9% Saline Bolus Administration</td>
</tr>
<tr>
<td>Facilitators:</td>
<td>S. Bihari, D. DeBellis, D.-L. Dixon, M.D. Lawrence, A.D. Bersten, Bedford Park, Australia, p.A1861</td>
</tr>
<tr>
<td>P372</td>
<td>Imaging Pulmonary Metabolism and Inflammation During Mechanical Ventilation Using Hyperpolarized Carbon-13/M</td>
</tr>
<tr>
<td>P373</td>
<td>Regional Distribution of Metabolic Activity During Progression of Acute Lung Injury: A Hyperpolarized Carbon-13 Study</td>
</tr>
<tr>
<td>P374</td>
<td>Effects of Ursolic Acid on Acute Lung Injury Induced Diaphragm Dysfunction Effects of Ursolic Acid on Acute Lung Injury Induced Diaphragm Dysfunction</td>
</tr>
<tr>
<td>P375</td>
<td>Variable Phase Relationship Between PaO2 Variation and Mechanical Ventilation Settings in Experimental Lung Injury</td>
</tr>
<tr>
<td>P376</td>
<td>Reanalyzing 23 Preclinical Studies for Fibrinolytic Therapy of Acute Lung Injury</td>
</tr>
<tr>
<td>Facilitators:</td>
<td>C. Liu, Z. Su, Y. Ma, M. Zhang, X. Li, R. Zhao, M. Matthay, H. Ji, Xinxiang, China, p.A1866</td>
</tr>
</tbody>
</table>
A52 CRITICAL CARE: BEYOND THE LUNGS - NON-PULMONARY CRITICAL CARE

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER
Area D (Hall A-B2, Ground Level)

Facilitators: B. Rochwerda, MD, MSCE, Hamilton, Canada
A.M. Ahasic, MD, MPH, Norwalk, CT

P378 Neurologic Presentations in an Ethiopian Medical Intensive Care Unit: Clinical Trajectories and Implications for Triage and Management

P379 Institutional Incidence of tPA-Induced Angioedema in Ischemic Cerebral Vascular Accidents

P380 Implications of Delayed Result of Herpes Simplex Virus Real-Time Polymerase Chain Reaction (PCR) Testing in Suspected Meningoencephalitis Cases and Possible Solution

P381 The Physiological Determinants of Cerebral Oxygenation During the First 24 Hours of Critical Illness

P382 Red Blood Cell Transfusion and Clinical Outcomes in Critically Ill Patients with Acute Brain Injury: A Single-Center Observational Cohort Study

P383 The Effect of Socioeconomic Variables on Massive Transfusion Outcomes on Non-Trauma Patients

P384 Intensive Care Unit ICU Readmission in Patients with Cancer

P385 The Prognosis of Patients Admitted to the Intensive Care Unit with Hepatitis C Infection as a Comorbidity

P386 Outcomes of Septic Patients Requiring New Onset Renal Replacement Therapy - A Single Center Retrospective Analysis

P387 Outcomes of Critically Ill Elderly Patients in Alcohol Withdrawal

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
Facilitator: C.A. Redlich, MD, MPH, New Haven, CT


Facilitator: S. Guerra, MD, PhD, Tucson, AZ

P1095 Lifetime History of Suicide Attempts and Current Asthma Among Puerto Rican Adults/E. Forno, Y.Y. Han, G.J. Canino, J.C. Celedon, Pittsburgh, PA, p.A1897


P1102 A Global Perspective on Socioeconomic Factors Influencing Asthma-Related Mortality/P. Mondal, A. Sinharoy, Hershey, PA, p.A1904


Facilitator: C.D. Ramsey, MD, Winnipeg, Canada


P1106 Lower Airway Immune Response to Di-Butyl Phthalate (DBP) and Allergen Co-Exposure/D. Maestre-Batlle, R.D. Huff, D. Wooding, A.K. Bolling, C. Carlsten, Vancouver, Canada, p.A1908


P1109 Tropical Pulmonary Eosinophilia - Lessons Learned from 180 Patients at Tertiary Care Teaching Hospital/A. Khan, A. Nath, Z. Hashim, V. Agarwal, V. Agarwal, Lucknow, India, p.A1911
THEMATIC POSTER SESSION

A55 ENVIRONMENTAL AND OCCUPATIONAL GENETICS, GENOMICS, AND EPIGENETICS
9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER
Area A (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.
Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

THEMATIC POSTER SESSION

A56 NON-TUBERCULOUS MYCOBACTERIA: CASE REPORTS
9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER
Area C (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.
Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
Facilitator: J. Philley, MD, Tyler, TX


Facilitator: W.-J. Koh, MD, Seoul, Republic of Korea


P222 A Case of Mycobacterium Simiae in an Immunocompetent Post-Menopausal Woman with Persistent Cough/E.A. Libre, V.S. Katikineni, Falls Church, VA, p.A1962

P223 Pulmonary Manifestations of Crohn’s Disease/A. Parra, Medellin, Colombia, p.A1963


Facilitator: M. Holt, MBBS, BSc, Brisbane, Australia


P226 Mounier-Kuhn Syndrome Complicated by Mycobacterium Abscessus Infection in an Active Duty Soldier/M. Koroscil, J.C. Reis, JBSA-Fort Sam Houston, TX, p.A1966


Facilitator: A. Basavaraj, MD, New York, NY


P245 Development of a Primary Care Screening Tool for Bronchiectasis/E. Fardon, Dundee, United Kingdom, p.A1970


Facilitator: A.E. O'Donnell, MD, Washington, DC


P251 Audit of Bronchiectasis Patients Attending a Respiratory Clinic/M. Docherty, K. McGee, E. Livingston, Glasgow, United Kingdom, p.A1976


THEMATIC POSTER SESSION

A57 BRONCHIECTASIS
9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER
Area C (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

THEMATIC POSTER SESSION

A58 NON-TUBERCULOUS MYCOBACTERIA: OFF THE BEATEN TRACK
9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER
Area C (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.


P553 Association of Anthropometric Measures and Obstructive Sleep Apnea in Children/R. Bhattacharjee, S. Christensen, G. Dever, La Jolla, CA, p.A2002


P568  Modified Interpretation of Fractional Exhaled Nitric Oxide in Preschoolers/J. Bao, Shanghai, China, p.A2015


Facilitator:  M. Arteta, MD, Ann Arbor, MI


P574  Status Asthmaticus Requiring ECMO Associated with Rhinovirus Infection/L. Greenawald, A. Strang, A. Chidekel, C. Froehlich, Wilmington, DE, p.A2021


P576  Diagnostic Accuracy of Impulse Oscillometry in Preschool Children with Asthma/E. Dueñas, D.C. Duarte, C. Aguirre, L.F. Giraldo-Cadavid, Bogota, Colombia, p.A2023


P579  Perception of Exercise-Induced Bronchoconstriction by Children and Their Parents/N. Lammers, M.H.T. van Hoesel, J.M.M. Diessen, J. Van Der Palen, B. Thio, Enschede, Netherlands, p.A2026


Facilitator:  K.M. Kloepfer, MD, MS, Indianapolis, IN


Facilitator:  L.M. Sarzynski, MD, Columbus, OH


P590  Does Obesity Increase Respiratory Tract Infections (RTI) and Respiratory Sequelae in Patients with Asthma/M. Tang, R.J. Henderson, J.T. Holbrook, J. Lang, Durham, NC, p.A2037


P592  Indicators of Asthma Control and Patterns of Care among Children with Asthma Residing in Poor Urban Areas/B. Ortiz, A. Kavati, P. Sullivan, V. Ghushchyan, P. Navaratnam, H. Friedman, B. Lanier, East Hanover, NJ, p.A2039


P594  Characterization of Severe Asthma in Children Aged 6 to 15 Years in a Middle-income Developing Country/E. Dueñas, C.A. Torres-Duque, E. Correa, M. Suarez, C. Vásquez, J. Jurado, O. Barón, A. Pachón, Bogota, Colombia, p.A2041

A61  CARE OF TECHNOLOGY-DEPENDENT CHILDREN

9:15 a.m. - 4:15 p.m.  SAN DIEGO CONVENTION CENTER

Area F (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators: A.I. Cristea, MD, Indianapolis, IN
G.F. Perez, MD, Washington, DC

P596  Treatment of Asthma Exacerbation in Chilean Children: a Multicenter Observational Study/A.M. Herrera, G. Cavada, Santiago, Chile, p.A2043


P600  Esophageal Pressure: A Reliable Monitoring to Estimate Transpulmonary Pressure in Children?/G. Emeriaud, G. Mortamet, S. Essourri, N. Poirier, P. Jouvet, Montreal, Canada, p.A2046


P604  Utility of Surveillance Cultures in Pediatric Tracheostomy Patients for Guiding Treatment in the Setting of Acute Illness/A. Gupta, T. Simoneau, C.M. Schramm, Hartford, CT, p.A2050


A62  SICKLE CELL DISEASE

9:15 a.m. - 4:15 p.m.  SAN DIEGO CONVENTION CENTER

Area F (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators: E. Machogu, MBChB, MS, Indianapolis, IN
F.O. Ogunlesi, MD, Washington, DC


P610  Use of Beta Agonists in Prevention of Acute Chest Syndrome in Pediatric Patients with Sickle Cell Disease and Asthma/J. Green, P.A. Ross, C.J. Newth, R.G. Khemani, Los Angeles, CA, p.A2062


P613  Pulmonary Dysfunction Among Adolescents and Adults with Sickle Cell Anemia in Nigeria/O.B. Ozoh, O.O. Kalejaeye, Y.O. Adelabu, D.A. Nmadu, O.E. Eromosele, M.O. Kehinde, Lagos, Nigeria, p.A2059


P616  Airway Inflammatory Patterns in Sickle Cell Disease/A. De, S. Agrawal, K. Morrone, D. Manwani, D. Rastogi, Bronx, NY, p.A2061

P618  Evaluating Children with Sickle Cell Disease and Asthma with Spirometry and Impulse Oscillimetry/P. Mondal, A. Yirinec, C. Moses, A.E.F. Dimmock, R. Bascom, Hershey, PA, p.A2063


A63  RIDE THE LIGHTNING: BASIC AND TRANSLATIONAL STUDIES IN PULMONARY HYPERTENSION

9:15 a.m. - 4:15 p.m.  SAN DIEGO CONVENTION CENTER

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator:  J.W. Barnes, PhD, MSc, Birmingham, AL


P79  Understanding Mechanisms Regulating Endothelin-1 Induced Pulmonary Artery Smooth Muscle Contractility Using Real-Time Measured Impedance/J. Wilson, R.R. Warburton, P. Polgar, N.S. Hill, Boston, MA, p.A2067


P81  Transfer of BMPR2 Protein to Human Pulmonary Artery Endothelial Cells Using Designed Microvesicles/J. Jang, R.L. Benza, M. Passineau, Pittsburgh, PA, p.A2069

P82  Mitochondrial Proteins Regulate Experimental Pulmonary Hypertension/I. S. Bazan, J.D. Marshall, S.-J. Kim, P. Shan, P. Lee, New Haven, CT, p.A2070

P83  PTEN Depletion in Pulmonary Arteries Does Not Augment Chronic Hypoxia-Induced Pulmonary Arterial Hypertension/G.B. Wayapa, K.A. Smith, V.J. Dudley, P.T. Schumacker, Chicago, IL, p.A2071

P84  Translationally Controlled Tumour Protein Inhibits Apoptosis and Promotes Proliferation and Migration of Rat Lung Microvascular Endothelial Cells/M. Ho, D.J. Stewart, Ottawa, Canada, p.A2072

P85  VEGFR-2 Expression Is Augmented in Mouse Cardiac Endothelial Cells Exposed to Shear Stress/G. Peloquin, L. Johnston, M. Damarla, R.L. Damico, P.M. Hassoun, T.M. Kolb, Baltimore, MD, p.A2073


P87  Circulating Cluster of Differentiation CD3 Cells Derived Extracellular Vesicles Are Increased in Chronic Pulmonary Vascular Diseases/U. Deo, Giessen, Germany, p.A2075


P89  Purinergic-Dependent Contraction of Small Intrapulmonary Veins in a Pulmonary Arterial Hypertension Rat Model/M.G. Henriquez, O. Arellano, M. Fonseca, E. Sanhueza, Santiago, Chile, p.A2077

P90  17-Beta Estradiol Regulates AIF, MIF and PARP-1 Expression in Overproliferation of Pulmonary Arterial Smooth Muscle Cell/T. Chen, P. Yuan, J. Liu, Shanghai, China, p.A2078


Facilitators:  J. Leopold, MD, Boston, MA
                H. Karmouty-Quintana, PhD, Houston, TX

P93  Estrogen Improves the Proliferation of PASMCs Through Notch Signaling Pathway/W.H. Wu, J.-M. Liu, Shanghai, China, p.A2081


P95  Macrophages Increase the Bone Morphogenetic Protein Antagonist Gremlin-1 in Response to Hypoxia/L. Mthinzi, U. Knaus, P. McLoughlin, Dublin, Ireland, p.A2083

P96  Nodes of Redundancy in Inflammatory Mediators of Pulmonary Hypertension/G. Grunig, N. Durmus, Tuxedo, NY, p.A2084

P97  Hypoxia-Inducible Factor-1 Regulation Via the Beta-Adrenergic Receptor/O.R. Stephens, S.C. Erzurum, Cleveland, OH, p.A2085


P99  P2x1 Antagonism Blocks Pulmonary Arterial Smooth Muscle Cell Contraction/P. Robichaud, S.H. Visovatti, Ann Arbor, MI, p.A2087

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
P100  Splenectomy Deteriorate Chronic Hypoxia-Pulmonary Vascular Remodeling/Y. Zhao, Y. Yao, M.-L. Chan, H.Z. Yun, L. Wu, M. de Perrot, J.T. Granton, Toronto, Canada, p.A2088

P101  Adventitial Fibroblast Phenotype Is Dependent on Matrix and Interstitial Fluid Flow: Implications for Pulmonary Hypertension/M. Yeager, K.L. Colvin, Aurora, CO, p.A2089

P102  Fibroblast Generated Extracellular Vesicles Induces Pro-Inflammatory and Metabolic Reprogramming in Bone Marrow Derived Macrophages/S. Kumar, S. Riddle, M. Li, H. Zhang, A. Flockton, B.A. McKeon, M.G. Frid, K.R. Stenmark, Aurora, CO, p.A2090

P103  Splenectomy Blocks the Development of Pulmonary Hypertension in the Monocrotaline Rat Model/Y. Yao, Y. Zhao, M.-L. Chan, M. de Perrot, J.T. Granton, Toronto, Canada, p.A2091


P105  Effects of Carbohydrate Metabolism on Development of Pulmonary Hypertension/L.R. Villegas, J. Yates, J.H. Chun, H. Austin, B. Ramos, A. Hanson, D. Pokhrel, C. King, M.T. Le, Aurora, CO, p.A2093


P107  Role of Connexins in Hypoxic-Induced Proliferation and Migration in Rat Pulmonary Artery Fibroblast and Smooth Muscle Cells/A. McNair, P. Martin, D.J. Welsh, Y. Dempsie, Glasgow, United Kingdom, p.A2095


P109  BKCa Channel Activation Normalizes Elevated Vasoconstriction in Pulmonary Arteries from Rats with Pulmonary Hypertension/R. Clements, T. Mancini, A. Vang, N.R. Kue, G. Choudhary, Providence, RI, p.A2097

P110  Up-Regulation of Calcium Homeostasis Modulator-1 in Pulmonary Artery Smooth Muscle Cells with Idiopathic Pulmonary Arterial Hypertension/M. Rodriguez, J.X.J. Yuan, Tucson, AZ, p.A2098

P111  The Role of Mitophagy in Development of Pulmonary Hypertension/A. Saraji, N. Sommer, K. Schäfer, A. Sydovsky, M. Hecker, W. Seeger, A.H. Ghofrani, R.T. Schermuly, N. Weissmann, O. Pak, Giessen, Germany, p.A2099


P114  Aromatase Expression of Liver in Portopulmonary Hypertension/S. Sahay, R. Barrios, M. Deavers, Y. Ren, A.E. Frost, Houston, TX, p.A2102


P117  Overexpression of NEF Protein Leads to More Severe Pulmonary Complex Vascular Lesions Associated with the Human Immunodeficiency Virus/J.L. Sandoval Gutierrez, R. Rivera, E. Sevilla Reyes, J. Rodriguez Silverio, F.J. Flores, Merriota, Mexico City, Mexico, p.A2105

P118  Na⁺-H⁺Exchanger 1 Determines Atherosclerotic Lesion Acidification Andpromotes Atherogenesis/C. Liu, G. Sukhova, L. Peter, G.-P. Shi, Boston, MA, p.A2106


P120  Bone Morphogenic Protein 2 Is an Important Regulator of Angiogenesis in Clonally Enriched Lung Endothelial Cells/A. Bhagwani, S. Hultman, D. Farkas, R.L. Heise, M.C. Yoder, M. Clauss, R.J. Freishtat, L. Farkas, Richmond, VA, p.A2108

P121  Enhanced Therapeutic Efficacy of Vasodilator Therapy in Combination with a Novel Human Anti-OPG Antibody in Experimental Pulmonary Arterial Hypertension/A. Lawrie, L. West, N. Arnold, H. Casbolt, J.A. Pickworth, J. Carvalho, J. Iremonger, L. Renshall, A. Braithwaite, M. McCourt, V. Germaschewski, Sheffield, United Kingdom, p.A2109


P123  SU5416 Plus Hypoxia but Not Selective VEGFR2 Inhibition with Cabozantinib Plus Hypoxia Induces Pulmonary Hypertension in Rats: Potential Role of BMPR2 Signaling/R. Sitapara, C. Sugarragcha, L. Zisman, Rensselaer, NY, p.A2174
THEMATIC POSTER SESSION

A64  LET’S GO TRIPPIN’: DIAGNOSTICS AND RISK ASSESSMENT IN PULMONARY HYPERTENSION
9:15 a.m. - 4:15 p.m.  SAN DIEGO CONVENTION CENTER
Area B (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.
Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator:  J.S. Sager, MD, MSc, Santa Barbara, CA


P126  The Motion Study to Assess the Effect of Riociguat on Patient-Reported Outcomes in PAH: Correlations Between the Living with Pulmonary Hypertension Questionnaire and Secondary Endpoints/F. Rahaghi, S. Meldred-Groves, D.M. Platt, A. LaRose, F. Kleinjung, G.M. O’Brien, Weston, FL, p.A2110


P128  Wall Shear Stress Is Associated with Severity of Idiopathic Pulmonary Arterial Hypertension/L. Wang, J. Shi, J. Liu, Shanghai, China, p.A2112


P132  Myositis-Related Autoantibodies and Pulmonary Arterial Hypertension (PAH): Another Sub-Type of PAH Associated with Autoimmune Conditions/S. Si, S. Weinmann, C. McEvoy, M.M. Chakinala, St. Louis, MO, p.A2116

Facilitator:  M.M. Chakinala, MD, St. Louis, MO


P138  Relationship of Interferon Beta Use in Multiple Sclerosis and Development of Pulmonary Arterial Hypertension/Z. Saflor, Houston, TX, p.A2122


P140  A Modified Risk Assessment Score for Pulmonary Arterial Hypertension/W. Xiong, M. Xu, L. Wang, J. Guo, J. Liu, Shanghai, China, p.A2124


P142  Hypoxaemia Cause or Consequence of Pulmonary Hypertension/S. Walsh, H. Clare, C. Minnock, S.G. Gaine, B.N. McCullagh, Dublin, Ireland, p.A2126


P144  Variation in Pulmonary Capillary Wedge Pressure Tracings; Are Pressures Lower than We Think?/S. Johnson, E. Pomerantsev, A. Witkin, J.M. Rodriguez-Lopez, R. Channick, Boston, MA, p.A2128


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
P147 Hemodynamic Response to Provocative Maneuvers During Right Heart Catheterization/A. Arunachalam, A. Bhattacharyya, F. Qadir, R. Khan, T. Naal, B.J. Abuhalimeh, A.R. Tonelli, N.F. Chaisson, Cleveland, OH, p.A2131

P148 Pulmonary Artery Aneurysm: A 10 Year Community Hospital Experience/S. Chaudhary, A. Wahab, A. Ayaz, S. Dukkipati, W. Alshweiat, R. Kakarala, Flint, MI, p.A2132

Facilitator: N. Al-Naamani, MD, MS, Philadelphia, PA


P152 Gender Differences in Risk Factors Associated with Pulmonary Artery Systolic Pressure in the Jackson Heart Study/S. Lakshmanan, M.D. Jankowich, W.-C. Wu, C. Black shear, S. Abbasi, G. Choudhury, Providence, RI, p.A2136

P153 Improving Appropriate Treatment of PAH: Success of Online CME/J. Spyropoulos, S. Hughes, Purchase, NY, p.A2137


P156 Improving Adherence to Pulmonary Hypertension Screening in Patients with Systemic Sclerosis: Overcoming the Provider-Level Barriers/G. Wigger, C. Lebeck-Lee, S. Cogorno, J.M. Elwing, M.A. Zafar, Cincinnati, OH, p.A2140


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.


---

**A66** PULMONARY REHABILITATION: CLINICAL STUDIES IN COPD

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER

Area E (Hall A-B2, Ground Level)

**Viewing:** Posters will be on display for entire session.

**Discussion:** 11:15-12:00: authors will be present for individual discussion

12:00-1:00: authors will be present for discussion with assigned facilitators

**Facilitator:** R.S. Novitch, MD, White Plains, NY


**P489** The Impact of Pulmonary Rehabilitation on People with Mild Chronic Obstructive Pulmonary Disease: A Randomised Controlled Trial/A. Lahham, C.F. McDonald, N.S. Cox, S. Rawlings, A. Nichols, R. Moore, A. Liacos, A.E. Holland, Melbourne, Australia, p.A2154

**P490** Inhalation Technique of Patients with Obstructive Diseases and History of Exacerbations/D. Zujovic, V. Zugic, Belgrade, Serbia, p.A2155


**P493** Effects of Age on Pulmonary Rehabilitation Outcomes in Patients with COPD - a Retrospective Analysis/ T. Schneebberger, R. Gloeckl, I. Jarosch, K. Kenn, A.R. Koczulla, Schoenau am Koenigssee, Germany, p.A2158

**Facilitator:** E.N. Schachter, MD, New York, NY


**P495** Short and Long Term Effects of Exacerbations on Functional Status in Patients with COPD - A Systematic Review/C. Burtin, M. Barusso, J. De Brandt, M.A. Spruit, Diepenbeek, Belgium, p.A2160

**P496** Management of COPD Via a Clinical Guidance System: 16th Year of a Continuous Improvement Model/B.L. Tiep, M. Barnett, R.R. Carter, R. Murray, Monrovia, CA, p.A2161


**P498** Community Based Pulmonary Rehabilitation Improves Individuals and Forms Part of an Overall Strategy to Keep COPD Patients Well/M.C. Apps, K.-A. Keeling, C. Goodrich, H. Olympio-Anang, I. Young, A. Kopacz, Billericay, Essex, United Kingdom, p.A2163


**Facilitator:** T.C. Harvey-Dunstan, MSc, Leicester, United Kingdom

**P501** Cultural Diversity in Pulmonary Rehabilitation: How Diverse Is It Really?/F. Blackstock, K. Harris, B. McCarren, C. Tang, Penrith, Australia, p.A2166


**P503** Do Physiotherapy and Rehabilitation Students Want to Be a Cardiopulmonary Physiotherapist?/E. Safran, H.N. Gürses, Z. Hosbay, H. Aksu, O. Bingöl, Istanbul, Turkey, p.A2168

**P504** Long-Term Use of Guaifenesin in a Patient with COPD, Chronic Bronchitis and Multiple Recurring Infections/T. Hooker, Brandon, FL, p.A2169


**P506** Pranayama Improves Inflammatory Profile in COPD/A. Talwar, A. Trivedi, N. Akhtar, R. Guleria, G. Bade, D. Ghosh, New Delhi, India, p.A2171

*The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.*
P515 Bariatric Surgery Reduces Aerobic Exercise Capacity/
C. M. Nolan, MSc, Harefield, United Kingdom

P508 Skeletal Muscle Wasting as Predictor of Future Cystic Fibrosis


P514 Ghrelin, Leptin, Adiponectin and HIF-a1 Expression in Hypoxia and Its Effect for Weight Loss in Obesity/N.C. Netzer, L.K. Rausch, S. Pramsohler, Bad Aibling, Germany, p.A2178


P517 Changes in Functional Quality and Quality of Life in Patients with Restrictive Lung Disease in a Pulmonary Rehabilitation Programme/N. Torres del Castillo, J. Betancourt Peña, J.C. Avila Valencia, P. Toussaint, Cali, Colombia, p.A2181


P520 Effects of Respiratory Rate and Dynamic Hyperinflation on Respiratory System Resistance in Patients with Bronchiectasis/R. Moroll, D.O. Santos, L. Perossi, M. Holtz, J.A. Baddini-Martinez, A. Gastaldi, Ribeirao Preto, Brazil, p.A2184

P521 Attain Health - Integrating Telehealth and Integrative Health Coaching in Cystic Fibrosis Care/C. Landon, K.Q. Porco, Ventura, CA, p.A2185


P525 Pulmonary Function Measurements in Patients with Major Burn Injury and Smoke Inhalation/S. Joo, Seoul, Republic of Korea, p.A2189


P528 An Unusual Case of Mycobacterial Wound Infection/P. Sharma, B. Smith, M. Yassin, Pittsburgh, PA, p.A2192

P626 Transforming Growth Factor Beta 1 (TGF-β1) Induced Profound Methylation Changes in Fibroblasts, and Revealed an Unexpected Role of Homer1 in Idiopathic Pulmonary Fibrosis/M. Negrreros, J.S. Hagood, C. Espinoza, Y.I. Balderas-Martinez, M. Selman, A. Pardo, Mexico City, Mexico, p.A2196


P629 The Ubiquitin-Proteasome System Regulates Mitochondria Quality Control in Alveolar Epithelial Type II Cells After Bleomycin/H. Shaghaghi, D. Schriner, X. Hong, D. Sales, V. Desai, A. Bhushan, M. Ramirez, F. Romero, Philadelphia, PA, p.A2199


Facilitator: B.B. Moore, PhD, Ann Arbor, MI

Role for Defensins in Epithelial Injury and Fibrosis/R. Vittal, E. Cipolla, Ann Arbor, MI, p.A2201


P635 The Role of HuR in Myofibroblast Differentiation: Implication for Pulmonary Fibrosis/F. F. Al-Habeeb, P.K. Nair, I. Azuelos, C. Baghole, Montreal, Canada, p.A2205


P638 mTORC1 Controls Cellular Senescence in Alveolar Epithelial Type II Cells/R.S. Summer, H. Shaghaghi, D. Schriner, X. Hong, D. Sales, V. Desai, A. Bhushan, M. Ramirez, F. Romero, Philadelphia, PA, p.A2208

Facilitator: P. Chen, MD, Los Angeles, CA


P641 Nuclear Heparan Sulfate Upregulates Pro-Fibrotic Gene Expression And is Abundant in Pulmonary Fibroblasts from IPF Patients/W.B. LaRiviere, S.-W. Park, M.-S. Haeger, S. Liao, A.R. Lara, E.P. Schmidt, Y. Yang, Aurora, CO, p.A2211


| P645 | A Causative Role for Inflammatory Peroxidase Enzymes in Bleomycin-Induced Pulmonary Fibrosis/C. DiFelice, I. Zinonos, M.O. DeNichilo, A. Evdokiou, V. Panagopoulos, Adelaida, Australia, p.A2215 |
| Facilitator: | S.K. Madala, PhD, Cincinnati, OH |
| P647 | Reduced Expression of BCL9 and Disruption of the Beta-Catenin-BCL9 Complex May Affect the Regenerative Capacity of Alveolar Epithelial Cells/K. Rydell-Tormanen, G. Westergren-Thorsson, Lund, Sweden, p.A2217 |
| P648 | Aberrant Resistance of IPF Fibroblasts to Ionizing Radiation Induced Apoptosis Via FoxM1 Alteration/R. Nho, J. Im, J. Lawrence, Minneapolis, MN, p.A2218 |
| P650 | Anti-Fibrotic Effects of Azithromycin in Human Lung Fibroblasts from Idiopathic Pulmonary Fibrosis Patients Compared to Control Fibroblasts/M. Funke, K. Krempaska, R. Schliep, L. Knudsen, T.K. Geiser, Bern, Switzerland, p.A2220 |
| P654 | Altered Six1 and BMPR2 in Pulmonary Fibrosis/C. Wilson, S. Collum, A.M. Hernandez, T. Mertens, L. Headley, K. Rajagopal, S.S. Jyothula, H. Karmouty-Quintana, Houston, TX, p.A2224 |
| Facilitator: | D. Kass, MD, Pittsburgh, PA |
| P656 | Understanding the Cellular Dysfunction Caused by Pathogenic Surfactant Protein C Mutant I73T/J. Dickens, M.O. Ellis, S.J. Marciniak, Cambridge, United Kingdom, p.A2226 |
| P659 | A Proteomic Analysis of Extracellular Matrix from Idiopathic Pulmonary Fibrosis Patient-Derived Fibroblasts in Response to Transforming Growth Factor B1/L. Knüppel, J. Merl-Pham, E. Hennen, R. Hatz, J. Behr, O. Eickelberg, S.M. Hauck, C.A. Staab-Weijnitz, Munich, Germany, p.A2229 |
| P660 | M10, a 10 Amino Acid Peptide, Regulates the Extracellular Matrix Expression Via a Dual Mechanism in Scleroderma Associated Lung Fibrosis/T. Akter, I. Atanelishvili, R.M. Silver, G.S. Bogatkevich, Charleston, SC, p.A2230 |
| P661 | Nuclear Factor of Activated T Cells 2 Contributes to Pulmonary Fibrosis in a Bleomycin Induced Lung Injury Model/IP. Cao, K. Misumi, N.M. Walker, R. Braeuer, V.N. Lama, Ann Arbor, MI, p.A2231 |
| P665 | Human Anti- Wnt1-Inducible Signaling Protein 1 Antibodies Attenuate Experimental Lung Fibrosis Ex Vivo/M. Lehmman, S. Klee, G. Kaufmann, M. Koenigshoff, München, Germany, p.A2235 |
| P668 | Activation of p130/E2F4 Promotes Differentiation of Bone Marrow-Derived Mesenchymal Stem Cells into Type II Alveolar Epithelial Cells/X. Zhang, F. Guo, J. Chen, M. Xue, A. Liu, H. Qiu, Nanjing, China, p.A7678 |
A69 NOVEL SIGNALING CASCADES IN LUNG INJURY, INFLAMMATION, AND REPAIR

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER
Area G (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.
Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: A. Schwingshackl, MD, PhD, Los Angeles, CA


P672 Variation of SiglecF Expression in Sessile Alveolar Macrophages/L. Li, G.A. Gusarova, N. Islam, J. Bhattacharya, New York, NY, p.A2239

P673 Disruption of the Genes for NAD(P)H Quinone Reductase (NQO1) or NQO2 Leads to Greater Susceptibility than Wild Type Mice to Hyperoxic Lung Injury In Vivo: Protection by ß-Naphthoflavone (BNF) Administration/B. Moorthy, X. Zhang, P. Shan, P.J. Lee, New Haven, CT, p.A2240

P674 Stanniocalcin-1 Promotes Angiogenesis During the Resolution of Hyperoxia Induced Acute Lung Injury Through TLR4/Y. Li, P. Shan, L. Sheng, J. Zhao, Y. Zhao, Pittsburgh, PA, p.A2241


Facilitator: X. Sun, PhD, San Diego, CA


P680 Toll-Like Receptor 8 (TLR8) Protein Degradation Limits Inflammatory Signaling/J. Evanovitch, T. Lear, R.K. Mallampalli, B. Chen, Pittsburgh, PA, p.A2247

P681 LPS Reduces SCF-Fbxo9 to Elevate PRMT4 Protein Levels in Lymphocytes in an Acute Lung Injury Model/C. Zou, Y. Lai, X. Li, J. Li, Pittsburgh, PA, p.A2248

Facilitator: K. Suresh, MD, Baltimore, MD


P684 FBXO17 Uregulates Akt Activity and Increases Survival of Lung Epithelial Cells/T.L. Suber, I. Nikolli, J. Zhao, R.K. Mallampalli, Y. Zhao, Pittsburgh, PA, p.A2251

P685 GAT107, a Novel Alpha7 Acetylcholine Nicotinic Receptor ago-PAM, Attenuates Hyperoxia-Compromised Macrophage Phagocytic Function/A. Gauthier, R. Sitapara, G. Thakur, L. Mantell, Jamaica, NY, p.A2252

P686 Adipose Derived Mesenchymal Stem Cell Therapy Is Comparable or Superior to Bone-Marrow Derived on Hypoxia-Induced Lung Injury in Primary Rat Alveolar Epithelial Cells/N. Shologu, D. O’Toole, M. Scully, J.G. Laffey, Galway, Ireland, p.A2253

P687 Molecular Regulation of the Stability of SIGIRR in Ubiquitin-Proteasome System/L. Li, J. Wei, S. Li, J. Zhao, Y. Zhao, Pittsburgh, PA, p.A2254

P688 Na+/H+ Exchanger 8 Regulates Alveolar Active Sodium Transport in Heart Failure/Z.S. Azzam, S. Kinaneh, R.M. Ismael-Badarneh, E. Khoury, Y. Kinaneh, J. Zou, Y. Bai, Y. Fang, Y. M. Ren, Y. Dong, Chengdu, China, p.A2255


P690 Cell Division Autoantigen 1 Plays a Profibrotic Role by Modulating TGF-ß/Smad Signaling Pathway in MRC-5 Model of Lung Fibrosis Secondary to ALI/M. Dong, Chengdu, China, p.A2257


P692 Mitochondrial Dysfunction in Sepsis-Related Acute Respiratory Distress Syndrome/S. Han, M. Chi, G.S. Budinger, N.S. Chandel, Chicago, IL, p.A2259

Facilitator: N.V. Kolliputi, PhD, Tampa, FL

P693 Reanalyzing Acute Respiratory Distress Syndrome Associated Genetic Variants in Current Case-Control Studies/J. Wu, Q. Ren, Y. Bai, Y. Ma, H.-L. Ji, Xinxiang, China, p.A2260
P716  Low-Temperature Exposure Suppresses the Production of B Cell Activating Factor Via TLR3 in BEAS-2B Cells/Y. Yoshino, K. Misu, K. Seo, I. Koga, T. Kitazawa, Y. Ota, Tokyo, Japan, p.A2280


THEME POSTER SESSION

A71  THE EPICGENOME, GENOME AND NON-CODING RNAs IN LUNG DISEASE

9:15 a.m. - 4:15 p.m.  SAN DIEGO CONVENTION CENTER

Area G (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator:  S. Christenson, MD, San Francisco, CA


P735  The Genetics of Smoking in Individuals with Chronic Obstructive Pulmonary Disease/M. Obeidat, G. Zhou, X. Li, N.N. Hansel, N. Rafaels, R. Mathias, I. Ruczinski, T.H. Beatty, K. Barnes, P.D. Pare, D.D. Sin, Vancouver, Canada, p.A2296


P737  In-Vivo Deletion of FENDRR, A Large Non-Coding RNA, Induces Spontaneous Fibrotic Changes in Knockout Mouse Lungs/N. Xylourgidis, K. Sakamoto, N. Aurenlen, N. Kaminski, New Haven, CT, p.A2298


Facilitator: I.O. Rosas, MD, Boston, MA

P739  Comparison of mRNA and miRNA Expression in Endobronchial Epithelial Lining Fluid and Bronchoalveolar Lavage of Patients with Idiopathic Pulmonary Fibrosis/N. Kahn, A. Smolinska, M. Schneider, M. Meister, R. Eberhardt, A. Boots, T. Muley, F.J. Herth, M. Kreuter, Heidelberg, Germany, p.A2300


P746  Lung Macrophage Function in Cystic Fibrosis - Regional Differences Correlating with Severity of Lung Damage/D. Seidler, A. Nymon, J. Czum, D. Dorman, J. Dessaint, A. Ashare, Lebanon, NH, p.A2311

A72  WHAT’S NEW IN CYSTIC FIBROSIS, BPD AND OTHER CONGENITAL PEDIATRIC LUNG DISEASES

9:15 a.m. - 4:15 p.m.  SAN DIEGO CONVENTION CENTER

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: A. Hilgendorff, MD, Munich, Germany


P748  Oxygen Effect on Breathing Pattern in Multiple Breath Nitrogen Washout Persists into Preschool Years but Is of Smaller Magnitude than Found in Infants/P. Robinson, A. Lindblad, A. Wong, E. Coward, P. Cooper, D.A. Fitzgerald, C. Pandit, H. Selvadurai, P.M. Gustafsson, Westmead Sydney, Australia, p.A2305


P753  CFTR Independent Purinergic Receptor Activated Bicarbonate Secretion in Human Native Small Airways/A. K.M. Shamsuddin, P.M. Quinton, La Jolla, CA, p.A2310

P754  Lung Macrophage Function in Cystic Fibrosis - Regional Differences Correlating with Severity of Lung Damage/D. Seidler, A. Nymon, J. Czum, D. Dorman, J. Dessaint, A. Ashare, Lebanon, NH, p.A2311

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
P778 Establishing the Mouse Pulmonary Fibrosis Model Induced by Bleomycin Via the Microsprayer. Z. Zeng, Y. Yin, T. Yang, Y. Ou, M. Zhang, T. Wang, D. Qin, W. Wang, L. Dai, N. Zeng, Chengdu, China, p.A2333


P782 Evaluation of Idiopathic Pulmonary Fibrosis by 18F-FDG PET-CT Scan: Importance of the Correction for the Density in the Interpretation of the Results/A. Castiaux, G. Van Samaey, S. Goldman, B. Bondue, Brussels, Belgium, p.A2337

Facilitator: S. Dua, MD, New York, NY

P783 A Rare Missense Variant in TERT Is Associated with Idiopathic Pulmonary Fibrosis in a Chinese Han Family/X. Zhan, C. Zheng, Z. Tong, W. Li, Beijing, China, p.A2338


P791 The Safety of Transbronchial Lung Cryobiopsy in Patients with Poor Pulmonary Function/C. Massacesi, S. Colella, F. Fioretti, V. D’Emilio, G. Panella, R. Pela, Ascoli Piceno, Italy, p.A2346

Facilitator: M.L. Dowell, MD, Chicago, IL


P800 Correlations Between Lung Parenchymal Changes on Computed Tomographic Imaging and Both Disease Progression and Response to Sirolimus Therapy in Lymphangioleiomyomatosis/V. Gopalakrishnan, J. Yao, N.A. Avila, A.M. Taveira-DaSilva, M. Stylianou, J. Moss, Chicago, IL, p.A2355


Facilitator: H. Parameswaran, PhD, Boston, MA


P803 The thymicrometic Sobetirome (GC-1) Inhibits Bleomycin Induced Pulmonary Fibrosis in Mice/G. Yu, G. Ibarra, G. Deluilis, T. Scanlan, N. Kaminski, New Haven, CT, p.A2358
P804 Assessment of Lung Function and Structure Using a Multibreath Hyperpolarized (HP) 129Xe Imaging Technique in a Two-Hit Radiation Induced Lung Injury (RILI) Model/

P805 Immunoglobulin A as a Predictor of Disease Severity and Outcomes in Idiopathic Pulmonary Fibrosis Transplant Patients/

P806 Assessing Pulmonary Fibrosis Progression in a Model of Surfactant Protein C Mutation with Ultra-Short Echo-Time Magnetic Resonance Imaging/Z.I. Cleveland, S. Sitaraiman, I. Stecker, M.S. Freeman, E.P. Martin, J. Guo, T.E. Weaver, Cincinnati, OH, p.A2361

P807 NOX4 Antisense Oligonucleotides Are Effective at Preventing Bleomycin-Induced Pulmonary Fibrosis in Mice/C. Zhao, J.R. Crosby, D. Bai, M. Zhang, A. Bell, B. Monia, S. Guo, Carlsbad, CA, p.A2362


P811 Effect of Variation in Ambient Temperature of Circulating Air on Rate of Cooling of Heat Stroke Model/

P812 Assessment of Increased Expiratory Flows as the Earliest Pulmonary Function Test Abnormalities in Patients with Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases/S.M. Alyami, O. Morgan Mendoza, Kingston, Canada, p.A7689

P813 Gastroesophageal Impedance and pH Testing in Pulmonary Fibrosis (IPF) Patients Treated with Pamrevlumab (FG-3019)/J. Gagermeier, R. Mahmood, V. Ananthanarayanan, A. Molefe, M. Venu, Maywood, IL, p.A7690

Facilitator: C. Seow, PhD, Vancouver, Canada


P815 Molecular Basis of Hypoxia-Induced Excessive Erythrocytosis of High Altitude/P. Azad, G.G. Haddad, La Jolla, CA, p.A2366


Facilitator: H. Katsura, MD, Chiba, Japan


P821 Improvements in Functional Exercise Performance at Six Months Following Bariatric Surgery, A Prospective Cohort Study/A. Gorek Dilektasli, E. Dilektasli, F. Coskun, M. Karadag, Bursa, Turkey, p.A2372

### P826 Ultrasound Assessment of Pulmonary Edema Using B-Line

P827 Epigenetic Modifications in Cardiopulmonary Developmental Adaptations to Chronic Hypoxia?/S. Krishnan, F. Fang, A. Beuchlein, B. Stearnman, M. Ivan, K. Nephew, T. Lahm, R.S. Tepper, Indianapolis, IN, p.A2378


### P829 Effect of Hemoglobin on Exercise Capacity and Cardiopulmonary Exercise Test Parameters/A. Sharma, T. Kaiser, D. Datta, Farmington, CT, p.A2380

### P830 Sonographic Assessment of Pulmonary Edema Using B-Line Scores During Incremental Ascent to Altitude/R. Lim, I. Ma, C. Nysten, T. Brutseart, T. Day, Calgary, Canada, p.A2381

### A75 COPD: TARGETS, MODELS, AND CLINICAL STUDIES

**9:15 a.m. - 4:15 p.m.**

**Area E (Hall A-B2, Ground Level)**

**Viewing:** Posters will be on display for entire session.

**Discussion:** 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

**Facilitator:** N. Tanabe, MD, PhD, Kyoto, Japan

**P453 Lung Function and BMI Predictive Models to Assess CT Emphysema Extent in COPD/M. Occhipinti, M. Paolletti, F. Bigazzi, J. Sieren, M. Palazzi, G. Camiciottoli, M. Pistolesi, Firenze, Italy, p.A2382**

**P454 Climate-controlled Hospital Patient Rooms Reduce Indoor Heat Stress in Patients with Chronic Obstructive Pulmonary Diseases and Prevent an Increased Cardiorespiratory Coupling/C. Witt, J. Krämer, U. Liebers, M. Drozdek, J. Kurths, N. Wessel, Berlin, Germany, p.A2383**

**P455 In Vivo Imaging Using Micro-CT Demonstrates Airway Remodeling in Ferrets with Cigarette Smoke-Induced COPD and Chronic Bronchitis/D. Stanford, J. LaFontaine, S. Byzek, S. Bodduluri, S.P. Bhatt, S.V. Raju, S.M. Rowe, Birmingham, AL, p.A2384**

**P456 Effects Of Recombinant Alpha1-Antitrypsin IgG1 Fc-fusion Protein (AAT-Fc) In Experimental Emphysema/K. Takeda, S. Kim, I. Petracek, E.W. Gelfand, Denver, CO, p.A2385**


**P461 Tiotropium/Olodaterol Improves Symptoms of Chronic Obstructive Pulmonary Disease Compared with Tiotropium: Results from the DYNAGITO Trial/A. Anzueto, P.M. Calverley, K. Carter, K. Tetzlaff, A. de la Hoz, C. Jenkins, K.F. Rabe, J.A. Wedzicha, San Antonio, TX, p.A2390**


**P464 Fibroblast Growth Factor 10 (FGF10) Haploinsufficiency Is Associated with Smaller Airways Lumen: Implications for Chronic Obstructive Pulmonary Disease (COPD) Susceptibility/H. Traboulsi, B.M. Smith, C. Baglole, Montreal, Canada, p.A2393**

**P465 Acute Response to Umeclidinium 62.5 Mcg and Vilanterol 25 Mcg in Chronic Obstructive Lung Disease/E.P. Oliveira, M.S. Tavares, J. Barbas Filho, C.S.V. Barbas, Sao Paulo, Brazil, p.A2394**


**P467 The Expression of Diacetyl/L-xylulose Reductase (DCXR) in Airway Epithelium in Chronic Obstructive Pulmonary Disease (COPD)/M. Jin, A. Tam, M. Obeidat, T.-L. Hackett, D.D. Sin, Vancouver, Canada, p.A2396**

---

**The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.**
P199 The Effect of CPAP Treatment on Excessive Daytime Sleepiness and Serum Substance P Levels in OSAS Patients/O. Aydin Guclu, A. Ursavas, F. Kasapoglu, Y. Ozarda, C. Bozyigit, G. Ocakoglu, M. Karaday, Bursa, Turkey, p.A2424


Facilitators: K. Chin, MD, Kyoto, Japan
I. Gurubhagavatula, MD, MPH, Philadelphia, PA


P205 Patient with Obstructive Sleep Apnea Are Not at an Increased Risk of Complications When Undergoing Carotid Endarterectomy/V. Kraskovsky, P. Fay, R. Metta, M. J. Mador, Buffalo, NY, p.A2430


P207 Association Between Sleep Apnea and Syntax Score/S. Ishiwata, Y. Tomita, T. Kasai, H. Daida, K. Narui, Tokyo, Japan, p.A2432


Facilitator: R.J. Schwab, MD, Philadelphia, PA


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
ATS DIVERSITY FORUM
MANCHESTER GRAND HYATT SAN DIEGO
Grand Hall B (Lobby Level)

The annual ATS Diversity Forum focuses on diversity within the fields of pulmonary, critical care, and sleep medicine and research. At this forum we will hear from Kirsten Bibbins-Domingo, PhD, MD, MAS, Inaugural Vice Dean for Population Health and Health Diversity, and Professor, Epidemiology & Biostatistics, at the University of California, San Francisco School of Medicine, who will address career and diversity issues followed by a question and answer period.

The Minority Trainee Development Scholarships (MTDS), which recognize trainees who are members of underrepresented minority groups, will also be presented at this forum to 40 individuals. MTDS recipients are selected for the quality of the science in their submitted abstract, among other criteria.

All conference attendees, including past MTDS recipients, are invited to attend this forum which provides an opportunity for discussion and networking among attendees. Attendees will find inspiration and valuable career insights.

The Diversity Forum is organized and presented by the ATS Membership Committee and will be hosted by its chair Janet Lee, MD. The Minority Trainee Development Scholarships are supported by the American Thoracic Society. Join us to hear from our speaker and to recognize the Scholarship recipients!

Conference badges are required for admission.
Space is limited and admittance is on a first-come, first-served basis. There is no additional fee. A plated lunch will be served.
WS1  DIAGNOSING PRIMARY CILIARY DYSKINESIA IN ADULTS AND CHILDREN

Registration Fee: $75 (includes box lunch)
Attendance is limited. Pre-registration is required.
Assemblies on Pediatrics; Clinical Problems
11:45 a.m. - 1:15 p.m. SAN DIEGO CONVENTION CENTER
Room 9 (Upper Level)

Target Audience
Providers of lung health to neonates, children and adults; scientists interested in translational advances in motile ciliopathies

Objectives
At the conclusion of this session, the participant will be able to:

• recognize which symptoms warrant a diagnostic work up for primary ciliary dyskinesia in neonates, children and adults;

• diagnose primary ciliary dyskinesia using currently available clinical tests;

• more appropriately refer patients with suspected primary ciliary dyskinesia to specialized diagnostic and management centers.

This session will provide the learner with an evidence based approach to diagnosing primary ciliary dyskinesia (PCD). The reference standard diagnostic test for PCD for the past 50 plus years has been ciliary ultrastructural abnormalities detected with a transmission electron microscope. We now know that this reference standard is flawed with significant false positive and false negative results. This workshop will educate attendees about a recently completed ATS guidelines project on the diagnosis of PCD, which evaluates evidence from the explosion of genetic and molecular scientific discovery on ciliopathies that has taken place in the past decade. Topics covered will include the utility of genetics, videomicroscopy, and nasal nitric oxide testing for the diagnosis of PCD.

Chairing:
A.J. Shapiro, MD, Montreal, Canada
S.D. Dell, MD, Toronto, Canada

11:45  Case Presentations
D. Polineni, MPH, MD, Kansas City, KS

11:55  Overview of PCD Pathophysiology and Utility of Clinical Symptoms for Diagnosis
S.D. Dell, MD, Toronto, Canada

12:15  High Speed Video Microscopy and Nasal Nitric Oxide for Diagnosing PCD
A.J. Shapiro, MD, Montreal, Canada

12:35  Utility of Genetic Testing in Diagnosing PCD
D. Polineni, MPH, MD, Kansas City, KS

12:50  Summary of Recommendations for the Diagnosis of PCD
A.J. Shapiro, MD, Montreal, Canada

1:00  Question and Answer Period
S.D. Dell, MD, Toronto, Canada

WS2  BRONCHOSCOPIC CRYOBIOPSY IN INTERSTITIAL LUNG DISEASE: EVIDENCE AND TECHNIQUE

Registration Fee: $75 (includes box lunch)
Attendance is limited. Pre-registration is required.
Assemblies on Clinical Problems; Allergy, Immunology and Inflammation; Thoracic Oncology
11:45 a.m. - 1:15 p.m. SAN DIEGO CONVENTION CENTER
Room 10 (Upper Level)

Target Audience
Broad audience appeal to providers including: general pulmonary physicians, advance bronchoscopists, interventional pulmonologists, thoracic surgeons, and trainees

Objectives
At the conclusion of this session, the participant will be able to:

• learn evidence of transbronchial cryobiopsy use in diffused parenchymal lung disease;

• diagnose interstitial lung disease with transbronchial cryobiopsies;

• apply different approaches in performing a standardized transbronchial cryobiopsy.

Transbronchial cryobiopsy (TBCB) is a technique where a cryotherapy probe is advanced to the lung parenchyma via the working channel of a standard bronchoscope following which cold temperatures (0° C) are generated at the tip of the probe leading to lung tissue adhesion. The probe and bronchoscope are then removed from the patient retrieving significantly larger pieces of lung tissue than those obtained via traditional transbronchial forceps biopsy (TBBX). TBCB compared to TBBX in patients with diffuse lung disease showed significantly larger biopsy pieces, more alveolar tissue, and less parenchymal damage/crush artifact. TBCB has recently become more popular for numerous diagnostic indications, with several recent studies suggesting the validity of TBCB for the diagnosis of diffuse parenchymal lung disease. However, the risk of procedural complications such as pneumothorax and moderate to severe bleeding needs to be considered when planning for this procedure.

Chairing:
G.Z. Cheng, MD, PhD, Durham, NC
M.M. Wahidi, MBA, MD, Durham, NC

11:45  Evidence of Cryobiopsy in Interstitial Lung Disease
L.B. Yarmus, DO, Baltimore, MD

12:05  Technique in Transbronchial Cryobiopsy: American Perspective
M.M. Wahidi, MBA, MD, Durham, NC

12:25  Technique in Transbronchial Cryobiopsy: European Perspective
F.J. Herth, MD, Heidelberg, Germany

12:45  Interactive Session: Learning from the Experts
G.Z. Cheng, MD, PhD, Durham, NC
L.B. Yarmus, DO, Baltimore, MD
M.M. Wahidi, MBA, MD, Durham, NC
F.J. Herth, MD, Heidelberg, Germany
CC1 SLEEP MEDICINE CLINICAL CORE CURRICULUM I
11:45 a.m. - 1:15 p.m. SAN DIEGO CONVENTION CENTER
Hall H (Ground Level)

Target Audience
Practicing internists, subspecialists, registered nurses and advanced practice nurses in pulmonary, critical care, and sleep medicine who work in a clinical setting and are currently engaged in maintenance of certification.

Objectives
At the conclusion of this session, the participant will be able to:
• remain current with medical knowledge relevant to their practice in pulmonary, critical care, and sleep medicine;
• evaluate their understanding of key skills and content areas in pulmonary, critical care and sleep medicine, as well as receive feedback on their comprehension of a result of a pre-test/post-test comparison;
• support clinicians who are engaged in maintenance of certification activities by providing updates on subjects included in recertification requirements.

The ATS Clinical Core Curriculum Symposia focus on a 3-year content cycle of key medical content in the areas of Pulmonary, Critical Care, and Sleep Medicine. The topics are also aligned with corresponding MOC Medical Knowledge modules. This symposium is intended to assist clinicians with staying current with the growth of information relevant to their medical practice, as well as provide an opportunity to evaluate individual knowledge and skills while earning MOC Medical Knowledge points.

Chairing: S.M. Jamil, MD, La Jolla, CA
T.S. Wang, MD, Los Angeles, CA
W.D. Conwell, MD, Aurora, CA

11:45 Etiology and Assessment of Hypersomnia
J. Cooksey, MD, Chicago, IL

12:15 Narcolepsy: Pathophysiology and Treatment
M. Cao, DO, Redwood City, CA

12:45 Non-Narcoleptic Hypersomnias: Pathophysiology and Treatment
L.A. Panossian, MD, Martinez, CA

CENTERS FOR DISEASE CONTROL AND PREVENTION

L1 UPDATE FROM CDC’S TB TRIALS CONSORTIUM AND TB EPI STUDIES CONSORTIUM
12:15 p.m. - 1:15 p.m. SAN DIEGO CONVENTION CENTER
Room 14 A-B (Mezzanine Level)

Target Audience
Clinicians and other health professionals involved in clinical and public health aspects of TB prevention, clinical care and control.

Objectives
At the conclusion of this session, the participant will be able to:
• better utilize the new diagnostics for LTBI and improve the management of LTBI testing in children;
• describe the PK and tolerability of high dose levofloxacin in the treatment of MDR TB;
• describe new findings about use of high dose rifamycins.

CDC’s two TB research consortia are engaged in clinical trials and epidemiologic studies relevant to the clinical and public health management, and prevention of, tuberculosis. This session provides updates from both groups.

Chairing: P. Nahid, MD, MPH, San Francisco, CA
J.E. Stout, MD, Durham, NC

12:15 Latent Class Analysis Assessing Test Characteristics of QFT, TSPOT, TST
J.E. Stout, MD, Durham, NC

12:30 Predictive Value of Latent TB Testing in Children, IGRAs vs. TST
A. Ahmed, MD, Charlotte, NC

12:45 Pharmacokinetics and Tolerability of High Dose Levofloxacin in MDR-TB
C.R. Horsburgh, MD, Boston, MA

1:00 High Dose Rifamycins for TB: Update on TBTC Study 31/ACTG A5349, and Related Work
P. Nahid, MD, MPH, San Francisco, CA

NATIONAL AERONAUTICS AND SPACE ADMINISTRATION

L2 USING NASA’S SATELLITE REMOTE SENSORS FOR THE STUDY OF THE ENVIRONMENT AND RESPIRATORY RELATED DISEASES
12:15 p.m. - 1:15 p.m. SAN DIEGO CONVENTION CENTER
Room 3 (Upper Level)

Target Audience
This session provides pulmonary health researchers environmental data to understand the geographic, environmental, and meteorological differences in pulmonary diseases. The clinicians and researcher will hear from an public health researchers.

Objectives
At the conclusion of this session, the participant will be able to:
• Inform clinicians and researchers about ongoing NASA projects related to lung and cardiac diseases.
• Provide a synopsis of a project using observations of earth’s environment and public health applications that are of interest to pulmonary clinicians and researchers.
• Provide an overview of the NASA Health and Air Quality Program relating to public health applications that are of interest to pulmonary clinicians and researchers.

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
Satellite earth observations present a unique vantage point of the earth’s environment from space which offers a wealth of health applications for researchers. The session shows results of the remote sensing observations of earth and health applications. This session will detail on-going projects within NASA and specifically related to incorporating satellite remote sensing for studying PM2.5 and other Air Quality issues and their relationship to diseases such as asthma, and other environmentally-induced lung and cardiac diseases. There will also be an introduction the Health and NASA Air Quality Team of Researchers that work to assist health researchers in the study of causes of environmental diseases.

Chairing: S. Estes, M.S., Huntsville, AL  
J. Haynes, MS, Washington, DC

12:15 NASA’s Public Health and Studying Respiratory Diseases  
J. Haynes, MS, Washington, DC

12:27 Linking Satellite Data with Respiratory Health: The NASA Health and Air Quality Applied Sciences Team (HAQAST)  
T. Holloway, PhD, Madison, WI

12:39 High Resolution Particulate Matter Data for Improved Satellite-Based Assessments of Community Health  
P.L. Kinney, ScD, Boston, MA

12:51 Association of Wildfire Smoke with Pharmaceutical, Inpatient, and Outpatient claims for Cardiopulmonary Disease: Oregon 2012  
S. Magzamen, PhD, Fort Collins, CO

1:03 Retrospective Daily Fine Particulate Matter Time-Series Generation at Fine-Scale Using Near-Real Time Satellite and Dispersion Modeling Techniques  
F. Freedman, PhD, San Jose, CA

12:15 Epithelial Cytokines and Airway Inflammation  
S.F. Ziegler, PhD, Seattle, WA

12:29 Airway Epithelial Reprogramming in Asthma  
D.J. Erle, MD, San Francisco, CA

12:43 Chromosome 17q21 Genes and Airway Remodeling in Asthma  
D.H. Broide, MBChB, La Jolla, CA

12:57 Surfactant Protein A: An Innate Immune Modulator in Asthma?  
M. Kraft, MD, Tucson, AZ

L4 THIS SESSION HAS BEEN CANCELED  
CHALLENGES AND OPPORTUNITIES OF CARING FOR MINERS

L5 CAREGIVING AND SELF-MANAGEMENT: A SCIENTIFIC UPDATE FROM ATS AND NINR

Target Audience  
Early carer professionals; those with research interests in caregiving and self-management research funding; health professionals who care for patients and their families with pulmonary and sleep disorders as well as those with needs requiring critical care.

Objectives  
At the conclusion of this session, the participant will be able to:

• learn new strategies involving interventions to reduce burden on caregivers;
• improve medical/nursing adherence for young children with cystic fibrosis and their families/caregivers;
• learn all about the current and future caregiving research focus within NINR and Funding Opportunity Announcements (FOAs).

Clinicians and funding agencies recognize that the effects of acute and/or chronic illness extend beyond the patient and family members/caregivers are profoundly affected. Caring for such patients by necessity involves caregivers. The session will focus on caregiving and the needs of patients and their caregivers. Innovative approaches and new tools are needed to understand and improve health outcomes of patients with sleep disorders, chronic lung conditions and those whose family members are critically ill. Additionally, this session will address the future of caregiver research from an NINR perspective. NINR’s targeted interests and future research focus will be addressed.

Chairing: E.G. Collins, PhD, Chicago, IL  
J. Tate, PhD, RN, Columbus, OH  
K. Huss, PhD, Bethesda, MD

12:15 Technology Applications for Family Caregivers  
S. Czaja, PhD, Miami, FL
12:15 Product Development for Pulmonary Hypertension
R.A. Johns, MD, MD, Baltimore, MD

12:30 A Novel Therapeutic Candidate for Idiopathic Pulmonary Fibrosis
N. Kaminski, MD, New Haven, CT

12:45 A Targeted Approach to Asthma Management G.L. Chupp, MD, New Haven, CT

1:00 Panel Discussion/Questions

The translation of scientific evidence into therapeutic products to treat respiratory diseases and sleep is an exciting yet challenging process. Investigators funded through the Centers for Advanced Diagnostic and Experimental Therapeutics (CADET II) program supported by NHLBI will share their experience in translating their own scientific discoveries into therapeutic products for lung diseases. They will describe the biologic basis for their selected therapeutic targets and their approach to identifying candidate drugs to modify the target, as well as the process of selecting a therapeutic candidate to advance.

Chairing: J.P. Kiley, MS, PhD, Bethesda, MD

12:15 PETAL Overview/Update
R.G. Brower, MD, Baltimore, MD

12:25 Update on the Neuromuscular Blockade in Severe ARDS (ROSE) Trial
D.T. Huang, MD, MPH, Pittsburgh, PA

12:37 Update on the Vitamin D (VIOLET) Trial
A. Ginde, MD, MPH, Aurora, CO

12:49 Update on the Clovers Trial
I.S. Douglas, FRCP, MD, Denver, CO

1:05 Questions and Answers

SPIROMICS is an NHLBI-sponsored study that supports the prospective collection and analysis of phenotypic, biomarker, genetic, genomic, and clinical data from subjects with COPD for the purpose of identifying subpopulations and intermediate outcome measures. Participants in this session will learn about the progress of the SPIROMICS study, specifically the study design, and progress in general enrollment, genomics, biomarkers, and radiology.

Chairing: L. Postow, PhD, Bethesda, MD
P. Woodruff, MD, MPH, San Francisco, CA

12:15 The SPIROMICS II Study
P. Woodruff, MD, MPH, San Francisco, CA

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
L9 INITIAL FINDINGS FROM THE NHLBI PVDOMICS PROGRAM: DEEP PHENOTYPING OF PATIENTS WITH PULMONARY HYPERTENSION

12:15 p.m. - 1:15 p.m. SAN DIEGO CONVENTION CENTER
Room 29 A-D (Upper Level)

Target Audience
Health providers, trainees, and researchers

Objectives
At the conclusion of this session, the participant will be able to:

• learn about metabolomic characterization in PH;
• learn new exercise (CPET, RHC) findings in PH;
• learn and understand new imaging (Echo, MRI) findings in PH.

Pulmonary hypertension (PH) currently has no cure, thus PH research remains a high priority for NHLBI. In 2014, NHLBI launched a major multi-center clinical study of PH named: Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics (PVDOMICS). This program includes one Data Coordinating Center (DCC) and six U.S. clinical centers that are conducting an observational study in patients with all types of PH. The overall goal of the PVDOMICS network is to perform comprehensive phenotyping across WHO groups as well as intermediate phenotypes in order to reconstruct the traditional classification and define new meaningful subclassifications. Currently, since the start of enrollment in 2017, there have been over 235 participants with a goal of 1500 by March 2019. This session will describe initial results from the study in approximately the first 700 subjects.

Chairing: L. Xiao, MD, PhD, Bethesda, MD
S. C. Erzurum, MD, Cleveland, OH
G. Beck, PhD, Cleveland, OH

12:15 Overall Summary of PVDOMICS Participants
E. Horn, MD, New York, NY

12:30 PVDOMICS Exercise (CPET, RHC) Finding
F. P. Rischard, MD, Tucson, AZ

12:45 PVDOMICS Imaging (Echo, MRI) Findings
R. P. Frantz, MD, Rochester, MN

1:00 PVDOMICS Metabolomic Characterization
J. Leopold, MD, Boston, MA

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
ME1 ASSESSING YOUR LEARNERS: AVOIDING PITFALLS AND MAKING IT MEANINGFUL

Registration Fee: $70 (includes box lunch)
Attendance is limited. Pre-registration is required.
12:15 p.m. - 1:15 p.m. SAN DIEGO CONVENTION CENTER
Room 2 (Upper Level)

Target Audience
This session is targeted at anyone who develops or uses assessment tools for evaluation. The content of the session is relevant to all types of assessment tools including MCQs, checklists, global rating scales, questionnaires and surveys.

Objectives
At the conclusion of this session, the participant will be able to:

• describe validity evidence for assessment tools
• evaluate the worth/completeness of validity evidence for an assessment tool
• develop assessment tools with reasonable validity evidence

We will critically appraise the validity of a variety of existing assessment tools. Participants will review problems commonly encountered during assessment tool development and strategies to minimize these challenges. The session will be interactive and participants are encouraged to bring assessment tools they are currently developing or using, so that they can receive feedback on how to improve these tools. Participants will leave with relevant, practical skills.

Speakers:
R. Adamson, MBBS, Seattle, WA
D. Nelson, MD, Rochester, MN
K. De Boer, MD, Ottawa, Canada
J. McSparron, MD, Ann Arbor, MI

ME1 ASSESSING YOUR LEARNERS: AVOIDING PITFALLS AND MAKING IT MEANINGFUL

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
A81  PEDIATRIC YEAR IN REVIEW

Assembly on Pediatrics

2:15 p.m. - 4:15 p.m.  SAN DIEGO CONVENTION CENTER

Room 6 B (Upper Level)

Target Audience
Pediatricians; pediatric assembly members; attendees interested in pediatric care

Objectives
At the conclusion of this session, the participant will be able to:

• improve the treatment of children with severe asthma;
• learn new findings about the respiratory microbiome, with application to pediatric pulmonary medicine;
• apply scientific advances to the management of children with neuromuscular diseases.

Pediatric Year in Review focuses on 4 topics in Pediatrics where there have been significant advances over the past year. Topics are chosen which have broad interest to the Assembly. The discussants will use recent publications to provide an update and perspective on scientific developments that have clinical relevance in Pediatrics.

Chairs: P.E. Moore, MD, Nashville, TN
S.D. Dell, MD, Toronto, Canada

2:15  Update on Management of Severe Asthma in Children
C.L. Yang, MD, MSc, Vancouver, Canada

2:45  Enhancing Innate Immune Function to Counter Multidrug-Resistant Superbugs in Pneumonia and Cystic Fibrosis
V. Nizet, MD, La Jolla, CA

3:15  What to Expect When You’re Expectorating: Update on the Pediatric Respiratory Microbiome
L.R. Hoffman, MD, PhD, Seattle, WA

3:45  Update on Treatment of Neuromuscular Diseases in Children
R. Amin, MD, Toronto, Canada

This session and the International Conference are supported by educational grants from GlaxoSmithKline, Sanofi Genzyme and Regeneron Pharmaceuticals, Vertex Pharmaceuticals Inc.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

A82  REACHING FOR THE GOLD: ADDRESSING GAPS IN THE CURRENT GOLD GUIDELINES

Assembly on Clinical Problems

2:15 p.m. - 4:15 p.m.  SAN DIEGO CONVENTION CENTER

Ballroom 20 B-C (Upper Level)

Target Audience
Physicians; nurses; advanced practice practitioners (APRNs and PAs); and allied health (respiratory care) providers who are involved in the management of patients with chronic obstructive lung disease.

Objectives
At the conclusion of this session, the participant will be able to:

• integrate updates to the current GOLD guidelines into the management of their COPD patients;
• recognize research gaps in the management of COPD patients;
• learn new findings about topic areas not adequately addressed in the current GOLD guidelines and begin integrating this evidence into the management of COPD patients.

This session will provide a brief introduction summarizing major changes in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) current guidelines and will then focus on areas of COPD management that are either not addressed or not adequately addressed by the current guidelines. The session will conclude with a panel discussion focused on the future direction of the GOLD guidelines as it relates to the topics discussed.

Chairs: B.R. Celli, MD, Boston, MA
J.A. Wedzicha, MD, PhD, London, United Kingdom
S.P. Bhatt, MD, Birmingham, AL

2:15  GOLD Guidelines 2018: Where are We Going and Where Have We Been?
A. Agusti, MD, Barcelona, Spain

2:25  The Forgotten Phenotypes: Symptomatic Smokers and Chronic Bronchitis
V. Kim, MD, Philadelphia, PA
2:40 Exercise Testing and Physical Activity Assessment: Who, When and Why?  
R. Casaburi, MD, PhD, Torrance, CA

2:55 Beyond the Lung: Addressing Comorbidity Screening and Treatment  
J.M. Bon, MD, MS, Pittsburgh, PA

3:10 Not Just Smoking Cessation: Addressing Non-Tobacco Smoke COPD Risk Factors  
N.N. Hansel, MD, MPH, Baltimore, MD

3:25 Treatment in stable COPD: Navigating the LABA/LAMA/ICS Road Map  
J.A. Wedzicha, MD, PhD, London, United Kingdom

3:40 Treatment in Stable and Unstable COPD: Non-Invasive Ventilation  
N. Hart, MD, London, United Kingdom

3:55 Panel Discussion  
B.R. Celli, MD, Boston, MA

This session and the International Conference are supported by educational grants from AstraZeneca LP, GlaxoSmithKline, Sunovion Pharmaceuticals Inc. All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

A83 GREAT CASES: CLINICAL, RADIOLOGIC, AND PATHOLOGIC CORRELATIONS BY MASTER PHYSICIANS

Council of Chapter Representatives

2:15 p.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER  
Ballroom 20 D (Upper Level)

Target Audience
Clinicians in the fields of pulmonary and critical care medicine, pediatric pulmonology, sleep medicine, thoracic surgery, and infectious disease

Objectives
At the conclusion of this session, the participant will be able to:

• integrate the clinical presentation, radiologic and pathologic findings for 7 challenging cases;
• understand the clinical reasoning used to determine differential diagnosis by Master clinicians using a multidisciplinary approach;
• describe the associated pathology and radiology of the cases.

Learners will have the opportunity to observe master clinicians approach challenging clinical problems by working through 7 unknown cases selected from the abstract pool. Collaboration with a master radiologist reviewing the films and a master pathologist reviewing pathology slides will demonstrate the multidisciplinary approach to difficult cases. The audience will participate through interactive questions that are tallied electronically. Additional discussion by presenters and master panelists will enhance the educational experience.

Chairing: A.C. Wang, MD, La Jolla, CA  
S.P. Kantrow, MD, New Orleans, LA

2:15 A Persistent Narrowing  
L. Riley, MD, Gainesville, FL

2:25 Homeless in LA  
S.C. Guo, MD, Los Angeles, CA

2:35 Looking Past the Heartache  
K.I. Aronson, MD, New York, NY

2:45 Casting a Wide Diagnostic Net in Pediatric Respiratory Failure  
J. Levin, MD, Boston, MA

2:55 Things That Go Bump in the Airway  
J. Ng, MD, Boston, MA

3:05 A Mosaic Mystery  
B.L. Icard, DO, Roanoke, VA

3:15 The Lungs as “The Punisher”  
M. Scoulos-Hanson, DO, Pittsburgh, PA

3:25 Radiologic Findings  
A.G. Wilcox, Los Angeles, CA

3:37 Pathologic Findings  
J.L. Myers, MD, Ann Arbor, MI

3:50 Master Clinicians  
S.I. Rounds, MD, Providence, RI  
M.I. Schwarz, MD, Aurora, CO  
P.C. Stillwell, MD, Aurora, CO

A84 THE NEW ENGLAND JOURNAL OF MEDICINE AND JAMA. DISCUSSION ON THE EDGE: REPORTS OF RECENTLY PUBLISHED CRITICAL CARE RESEARCH

2:15 p.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER  
Room 29 A-D (Upper Level)

This session will provide a forum for attendees to interact with the authors and editors about papers published in JAMA and the New England Journal of Medicine. Papers presented will be recent publications, selected by the editors, to be of significant importance to the field of critical care medicine. Attendees will have the opportunity to hear presentations directly from the author and address questions to both the authors and editors. The discussion is intended to provide a unique insight into these papers, the selection process, and how the research applies directly to the field of critical care medicine.

Chairing: H. Bauchner, MD, Editor in Chief, JAMA, The JAMA Network  
P.A. Kritek, MD, EDM, Associate Editor, NEJM Journal Watch

Speakers And Talks To Be Announced

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
A85 MITOCHONDRIAL DYSFUNCTION AND REPROGRAMMING IN LUNG AGING AND DISEASE

Assemblies on Allergy, Immunology and Inflammation; Respiratory Cell and Molecular Biology; Respiratory Structure Function

2:15 p.m. - 4:15 p.m. MARRIOTT MARQUIS SAN DIEGO MARINA
Pacific Ballroom 21 (North Tower, First Floor)

Target Audience
Basic scientists, physiologists, allergists, pulmonologists, translational researchers, fellows and residents, and graduate trainees interested in lung pathophysiology

Objectives
At the conclusion of this session, the participant will be able to:

• understand how aging can contribute to mitochondrial dysfunction in disease pathogenesis;
• describe potential options for mitochondrial reprogramming as a therapeutic approach;
• aware of how new findings are being positioned to promote research direction and therapeutic strategies that focus on mitochondria.

Chronic lung diseases are diseases of the elderly and mechanisms that link aging with the pathogenesis of lung disease have recently been discovered. In particular, over the last decade, accumulating evidence has suggested a causative link between mitochondrial dysfunction and major phenotypes associated with aging, such as inflammation, tissue remodeling, and aberrant wound repair. Thus mitochondrial dysfunction has become a focus for our understanding of lung aging and disease mechanisms and the potential of reprogramming mitochondria function for the development of new therapies is emerging. This integrated symposium highlights emerging understanding of the breadth and integrated pathobiological responses of mitochondria during aging and disease, how these may contribute to lung tissue destruction, and potential for this knowledge to inform development of mitochondria-reprogramming therapies.

Chairing: S.M. Cloonan, PhD, New York, NY
A.L. Mora, MD, Pittsburgh, PA

2:15 Aging, Mitochondria and Cellular Senescence: Implications for Chronic Lung Disease
J. Campisi, PhD, Novato, CA

2:39 Targeting Mitochondrial Dysfunction in Pulmonary Fibrosis to Drive Development of Novel Therapeutics
N. Kaminski, MD, New Haven, CT

3:03 Mitochondria and Telomere Dysfunction During Lung Aging and Disease
J. Passos, PhD, Newcastle upon Tyne, United Kingdom

3:27 Propagation of Deleterious Mitochondrial Genomes is a Consequence of Prolonged Stress Response Signaling
C. Haynes, PhD, Worcester, MA

3:51 Mitochondrial Adaptation and Homeostasis in Tumorigenesis
E.P. Henske, MD, Boston, MA
### TRANSLATIONAL SCIENTIFIC SYMPOSIUM

**A87 MECHANISMS OF PERSISTENT ORGAN DYSFUNCTION AFTER CRITICAL ILLNESS**

Assemblies on Critical Care; Allergy, Immunology and Inflammation; Clinical Problems; Respiratory Cell and Molecular Biology; Respiratory Structure and Function

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:15 p.m. - 4:15 p.m.</td>
<td><strong>SAN DIEGO CONVENTION CENTER</strong> Ballroom 20 A (Upper Level)</td>
</tr>
</tbody>
</table>

**Target Audience**

Fellows, physician-scientists, translational scientists. Those interested in the clinical epidemiology of and health services delivery to patients with persistent critical illness and post-intensive care syndrome.

**Objectives**

At the conclusion of this session, the participant will be able to:

- understand fundamental mechanisms of persistent organ dysfunction in survivors of critical illness
- contextualizing the development and emergence of new pharmacological and non-pharmacological interventions to limit, treat and prevent persistent organ dysfunction in survivors of critical illness
- understand how the basic science in the field of persistent organ injury can be translated to the bedside, how it impacts our management now and implications for the future

Patients who survive the acute phase of sepsis frequently acquire new organ dysfunction and enter a state or persistent critical illness, or fail to recover from their acute injuries and experience post-intensive care syndrome. Current attempts to mitigate these effects have focused on reducing harms done in the ICU and maximizing rehabilitation. Can specific pathways be leveraged to ameliorate the morbidity and mortality experienced by critical illness survivors? This session will describe the emerging understanding of the mechanisms that set the stage for persistent organ dysfunction in survivors of acute critical illness.

**Chairing:**

- C.C. Dos Santos, MD, Toronto, Canada
- B. Singer, MD, PhD, Ann Arbor, MI
- S.J. Denstaedt, MD, Ann Arbor, MI

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:15</td>
<td><strong>Of Mitochondria and Muscle in Mice and Men</strong> D.C. Files, MDWinston-Salem, NC</td>
</tr>
<tr>
<td>2:35</td>
<td><strong>After the Fire of Sepsis, Smoldering Neuroinflammation</strong> B. Singer, MD, PhD, Ann Arbor, MI</td>
</tr>
<tr>
<td>2:55</td>
<td><strong>Acceleration of Cardiovascular Disease After Sepsis</strong> A. Murat Kaynar, MD, MPH, Pittsburgh, PA</td>
</tr>
<tr>
<td>3:15</td>
<td><strong>Sepsis: Earthquake in the Genomic Landscape?</strong> E. Davenport, DPhil, Cambridge, MA</td>
</tr>
<tr>
<td>3:35</td>
<td><strong>Immune Reprogramming and Cardiovascular Disease</strong> S. Bekkering, PhD, Nijmegen, Netherlands</td>
</tr>
<tr>
<td>3:55</td>
<td><strong>Innocence and Experience: Training of Innate Immunity</strong> J. Cheng, PhD, Hsinchu City, Taiwan</td>
</tr>
</tbody>
</table>

## BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL SCIENTIFIC SYMPOSIUM

**A88 CPAP AND WEIGHT GAIN: MECHANISMS AND BEYOND**

Assembly on Sleep and Respiratory Neurobiology

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:15 p.m. - 4:15 p.m.</td>
<td><strong>SAN DIEGO CONVENTION CENTER</strong> Room 7 A-B (Upper Level)</td>
</tr>
</tbody>
</table>

**Target Audience**

Pulmonologists, respiratory therapists, clinical and basic researchers, primary care practitioners, and other health professionals who are interested in treating patients with sleep apnea and obesity

**Objectives**

At the conclusion of this session, the participant will be able to:

- recognize the role of CPAP in weight gain and understand its clinical significance;
- understand the mechanisms whereby CPAP use may lead to weight gain with respect to components of energy balance (i.e. dietary intake, physical activity, energy expenditure);
- learn about novel mobile health interventions used to improve efforts at weight loss that can be incorporated into management of patients with OSA.

Based on recent analyses of randomized trials suggesting that continuous positive airway pressure (CPAP) treatment of obstructive sleep apnea (OSA) is associated with weight gain, this multidisciplinary symposium brings together experts from obesity, behavioral, pulmonary and sleep medicine fields to address essential questions: What could be the underlying mechanisms for weight gain after CPAP, including its impact on energy expenditure, food intake, and physical activity? What is the clinical significance of the weight gain after CPAP? How does CPAP affect body composition? What are novel, technology-based weight loss interventions to mitigate weight gain in OSA management?

**Chairing:**

- E. Tasali, MD, Chicago, IL
- M.T. Naughton, MD, Prahran, Australia
- C.P. O’Donnell, PhD, Pittsburgh, PA
- N. Ayas, MPH, MD, Vancouver, Canada

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:15</td>
<td><strong>CPAP and Weight Gain: Up to Date Evidence From Randomized Clinical Trials</strong> L.F. Drager, MD, Sao Paulo, Brazil</td>
</tr>
<tr>
<td>2:35</td>
<td><strong>CPAP and Weight Gain: What do We Know About the Mechanisms?</strong> S. Pamidi, MD, Montreal, Canada</td>
</tr>
<tr>
<td>3:00</td>
<td><strong>Is the Weight Gain After CPAP Clinically Meaningful?</strong> D. Schoeller, PhD, Madison, WI</td>
</tr>
</tbody>
</table>

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
EMERGING CONCEPTS IN CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION

Assemblies on Pulmonary Circulation; Clinical Problems
2:15 p.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER
Room 15 A-B (Mezzanine Level)

Target Audience
Translational and clinical researchers interested in chronic thromboembolic disease. Clinicians and trainees who care for patients after acute pulmonary embolism, and patients with pulmonary hypertension

Objectives
At the conclusion of this session, the participant will be able to:
• describe the epidemiology of CTEPH and appropriate screening strategies for acute PE survivors;
• understand how the pathology of CTEPH affects the rationale for management strategies;
• describe the different surgical, interventional and medical treatment options and appropriate patient selection.

This session will focus on novel and emerging concepts in chronic thromboembolic pulmonary hypertension (CTEPH). The evolution of acute pulmonary embolism (PE) to chronic disease and the epidemiology of CTEPH are poorly defined. Similarly, little is known about the pathologic and pathogenetic underpinnings of this disease. Time-tested diagnostic and therapeutic strategies are being challenged by advances in imaging, interventional procedures and medical therapy. This session will address these knowledge gaps by providing novel evidence describing the incidence of CTEPH after acute PE and the importance of collateral circulation in the pathology of CTEPH. Advances in surgical techniques will be reviewed, as well as the emergence of balloon pulmonary angioplasty as a treatment option.

Chairing: G.A. Heresi, MD, MS, Cleveland, OH
W.R. Auger, MD, La Jolla, CA

2:15 From Acute PE to CTEPH: Epidemiology and Detection - Can We Do Better?
F.E.A. Klok, MD, PhD, Leiden, Netherlands

2:35 CTEPH Pathogenesis and Pathology: A New Understanding
P. Dorfmuller, PhD, MD, Le Plessis Robinson, France

2:55 Diagnosis and Surgical Treatment: Time Tested Strategies and Recent Advances
W.R. Auger, MD, La Jolla, CA

3:15 Chronic Thromboembolic Disease Without Pulmonary Hypertension: A New Frontier?
G.A. Heresi, MD, MS, Cleveland, OH

3:35 Balloon Pulmonary Angioplasty: The “Not So New” Kid on the Block
D.S. Poch, MD, La Jolla, CA

3:55 Medical Therapy and Future Perspectives in CTEPH
N.H. Kim, MD, La Jolla, CA

CRACKING THE VACCINE CODE IN TB: INNATE IMMUNITY

Assemblies on Pulmonary Infections and Tuberculosis; Allergy, Immunology and Inflammation
2:15 p.m. - 4:15 p.m. MARRIOTT MARQUIS SAN DIEGO MARINA
Grand Ballroom 8-9 (North Tower, Lobby Level)

Target Audience
Clinicians; fellows; basic scientists; epidemiologists

Objectives
At the conclusion of this session, the participant will be able to:
• identify distinctive “failure” aspects of the current vaccine in TB (T cell mediated immunity)
• identify distinctive “novel” aspects of the future vaccine in TB (Innate Immunity, Epigenetic reprogramming of Stem Cells)

Historically, vaccines have been designed to generate antigen-specific memory B and T cell responses that act rapidly upon antigen reencounter. Although control of TB requires T cells to prevent disease progression, multiple clinical trials, including the latest MVA85A using T cell targeted vaccine approaches have failed to provide protection against Mycobacterium tuberculosis (Mtbt) infection. In addition, hyper-conserved Mtbt genes involved in the production of immunodominant T cell epitopes have recently been described indicating that Mtbt may paradoxically benefit from recognition by T cells. These results suggest that the concept of vaccines aimed at generating robust memory T cell responses for protection against TB needs to be profoundly revisited.

Chairing: M. Divangahi, PhD, Montreal, Canada
J.M. Keane, MD, Dublin, Ireland
D.M. Lewinsohn, MD, PhD, Portland, OR

2:15 Conventional T Cells in Vaccines Against TB
J.D. Ernst, MD, New York, NY

2:35 Interferon-Gamma and Vaccines Against TB
S. Behar, MD, PhD, Worcester, MA

2:55 Unconventional T Cells in TB Vaccine Development
D.M. Lewinsohn, MD, PhD, Portland, OR

3:15 The Impact of Diabetes on Immunity Against TB
H. Kornfeld, MD, Worcester, MA
A91 REDUCING DISPARITIES IN ENVIRONMENTAL LUNG DISEASE: EMERGING METHODS IN EXPOSURE MITIGATION

Assemblies on Environmental, Occupational and Population Health; Pediatrics
2:15 p.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER
Room 30 A-B (Upper Level)

Target Audience
Individuals involved in care of patients with environmentally-mediated lung disease (i.e. asthma, COPD, occupational lung disease); basic, clinical, and translational researchers focused on environmental/occupational exposures and respiratory health

Objectives
At the conclusion of this session, the participant will be able to:

• identify populations disproportionately affected by respiratory morbidity and mortality attributable to disparities in environmental exposure to air pollution;
• describe emerging methods for personal exposure mitigation, including the evidence supporting these methods and remaining knowledge gaps;
• apply appropriate techniques to mitigate environmental exposures in unique patient populations.

Populations disproportionately affected by environmental pollution demonstrate a higher prevalence of lung disease and associated health effects. While the social and economic factors underlying these disparities are complex, personal exposure modification provides a means to target susceptible populations and achieve meaningful reductions in pollutant exposure. This session will provide insight into emerging methods of exposure mitigation that may be used to reduce disparities in environmentally-mediated lung disease.

Chairing: J.C. Celedon, DrPH, MD, Pittsburgh, PA
E. Brigham, MD, MHS, Baltimore, MD
F.D. Gilliland, MD, PhD, Los Angeles, CA
B.J. Sheares, MD, MS, New York, NY

2:15 Disparities in Environmental Exposures and Lung Health
J.R. Balmes, MD, San Francisco, CA

2:40 Home Air Purifier Implementation
S. Bose, MD, MPH, Baltimore, MD

3:00 Reducing Exposures Through Patient Advocacy: Legal Partnerships
D. Harris, MD, New Haven, CT

3:20 A Patient’s Perspective
M. Brisuela, Chicago, IL

3:30 Interventions to Reduce Occupational Exposure Disparities
D. Heederik, PhD, Utrecht, Netherlands

3:50 Clean Cook Stove Interventions
C.C. Hooper Miele, MD, Baltimore, MD

4:10 Questions and Answers

A92 FROM PRINCIPLES TO PRACTICE: EXPLORING MECHANISTIC KNOWLEDGE TO ADVANCE CLINICAL CARE

2:15 p.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER
Room 33 A-C (Upper Level)

Target Audience
Clinicians, basic and translational researchers and trainees interested in successes delivered from basic research in COPD, cystic fibrosis and lung transplantation access and morbidity. The session will show how primary discovery research can address daunting clinical challenges in these pulmonary disease arenas.

Objectives
At the conclusion of this session, the participant will be able to:

• improve understanding of lung and systemic type 2 inflammation and eosinophilia in COPD;
• learn new strategies to manage the care of cystic fibrosis;
• understand the roles of Extracorporeal Membrane Oxygenation and Ex Vivo Lung Perfusion to optimize outcomes for selected lung transplant candidates.

Basic research conducted by several laboratories has led to major advances in the management of COPD, Cystic Fibrosis and other airway disorders. Since lung transplantation is effective for severe COPD and CF, technologies to expand availability of donor lungs can be transformative for patients. This session will present the basic findings which underscore the use of mepolizumab for eosinophilic COPD, CFTR potentiators for cystic fibrosis and ex vivo lung perfusion and ECMO to rescue nonideal donor lungs for transplantation and avail tolerance for long wait list times. The clinical utility of these findings, complementing basic narratives, will show how primary discovery propels clinical advances for airway disorders.

Chairing: E.R. Neptune, MD, Baltimore, MD
J.L. Koff, MD, New Haven, CT
J.M. Pilewski, MD, Pittsburgh, PA

2:15 Paradigmatic Breakthroughs for COPD, CF and Lung Transplantation
E.R. Neptune, MD, Baltimore, MD

2:20 Defining Eosinophilic and Type 2 Inflammation in COPD
S. Christenson, MD, San Francisco, CA

2:35 Therapeutic Interventions for COPD with Eosinophilic Inflammation
J.M. Wells, MD, Birmingham, AL

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
2:50 Questions and Answers

2:58 Improving the Quality of Life in Patients with CF Through CFTR Modulation
J.L. Taylor-Cousar, MD, Denver, CO

3:13 Multi-Drug CFTR Modulator Therapy Targeting the F508del CFTR Mutation
S.M. Rowe, MD, Birmingham, AL

3:28 Questions and Answers

3:36 Advances in Extracorporeal Membrane Oxygenation (ECMO) as a Bridge to Transplantation
J.M. Reynolds, MD, Durham, NC

3:51 Emergence of Ex Vivo Lung Perfusion (EVLP) to Assess and Optimize Donor Lungs
J. D’Cunha, MD, PhD, Pittsburgh, PA

4:06 Questions and Answers

This session and the International Conference are supported by educational grants from AstraZeneca LP, GlaxoSmithKline, Sunovion Pharmaceuticals Inc., Vertex Pharmaceuticals Inc. All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.


3:45 Spontaneous Mutation in Pituitary Tumor Transforming Gene-1 Contributes to Increased Susceptibility to Severe Pulmonary Arterial Hypertension Induced by SU5416 in Rats/K. R. Chaudhary, Y. Deng, A. Yang, K. Rowe, E. Cuppen, D. J. Stewart, Ottawa, Canada, p.A2448

4:00 Bone Morphogenetic Protein Receptor 2 Expression Is Reduced in Blood Across Pulmonary Arterial Hypertension Subtypes but Does Not Reflect Disease Severity/A. Sweat, R. E. Wells, N. Purington, H. Hedlin, D. Sudheendra, A. Hsi, R. T. Zamanian, E. F. Spiekerkoetter, Stanford, CA, p.A2449


MINI SYMPOSIUM

A97 RE-DEFINING ALI PATHOGENESIS

2:15 p.m. - 4:15 p.m. MARRIOTT MARQUIS SAN DIEGO MARINA Pacific Ballroom 22 (North Tower, First Floor)

Chairing: C.M. Shaver, MD, PhD, Nashville, TN
N. Meyer, MD, MS, Philadelphia, PA
C.J. Britto-Leon, MD, New Haven, CT

Featured Speaker

2:15 ARDS: How to Reduce Heterogeneity to Facilitate Patient Selection for Clinical Trials/M.A. Matthay, MD, San Francisco, CA

Oral Presentations


2:45 Role of Microtubule-Associated Signaling in Staphylococcus Aureus-Induced Lung Injury/P. Karki, Y. Tian, Y. Ke, N. Sarich, A. Birukova, Baltimore, MD, p.A2466


4:00 Cigarette Smoke Exposure Induces Loss of Lung WWOX Expression Which Is Associated with Increased Vascular Leak During ARDS/S. Singla, Z. Shakhir, M.T. Gomes, N.M. Jones, V. Natarajan, R.F. Machado, Chicago, IL, p.A2471

MINI SYMPOSIUM

A98 CLINICAL STRATEGIES TO IMPROVE LUNG CANCER EARLY DETECTION: WHO IS AT RISK HERE?

2:15 p.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER Room 6 C/F (Upper Level)

Chairing: M.B. Schabath, PhD, Tampa, FL
N.T. Tanner, MD, MSCR, Charleston, SC
J. Iaccarino, MD, MSc, Boston, MA

Oral Presentations

2:15 Determination of the Eligibility Criteria for Cancer Care Ontario’s Lung Cancer Screening Pilot for People at High Risk/M. Tammemagi, B. Miller, M. Yurcan, T. Patel, H. Schmidt, G. Darling, St. Catharines, Canada, p.A2472


2:45 Stratification of Screening Participants in the National Lung Screening Trial According to COPD Status and Outcomes in the NLST-ACRIN Sub-Study (N=10,054)/R.J. Hopkins, F. Duan, C. Chiles, G.D. Gamble, D. Aberle, R.P. Young, Auckland, New Zealand, p.A2474

3:00 Genetic Risk Score from 12 SNP Panel Predicts Lung Cancer Lethality in the National Lung Screening Trial (NLST) - A Validation Study in the NLST-ACRIN (N=10,054)/R.P. Young, R.J. Hopkins, F. Duan, C. Chiles, D. Aberle, G.D. Gamble, Auckland, New Zealand, p.A2475


3:30 Providence VA Lung Cancer Screening Program: Performance: Comparison of Local False Positive and Invasive Procedure Rates to Published Trial Data/E.J. Gartman, M.D. Jankowich, J. Baptiste, L. Nici, Providence, RI, p.A2477


Featured Speaker

4:00 Screening for Lung Cancer: A good Beginning but Still a Long Way to Go/J.R. Jett, MD, Denver, CO
### RAPID: RAPID ABSTRACT POSTER DISCUSSION SESSION

**A101 MECHANISMS AND CLINICAL FEATURES OF SEVERE ASTHMA**

| 2:15 p.m. - 4:15 p.m. | SAN DIEGO CONVENTION CENTER  
| Room 11 A-B (Upper Level) |

| Abstract Summaries | 2:15-2:45 |
| Viewing/Discussion | 2:45-4:15 |

**Chairing:** M. Kraft, MD, Tucson, AZ  
F. Holguin, MD, MPH, Aurora, CO  
L.E. Crotty Alexander, MD, San Diego, CA

| 406 | Regulation of the Cyclic AMP Signaling Axis in Monocytic Cells by Inflammatory Polarizing Cytokines: Implications for Severe Asthma/N.M. Weathington, H. Wong, B. Modena, S.E. Wenzel, Pittsburgh, PA, p.A2484 |
| 407 | MBD2 Promotes Th17 Differentiation in Severe Asthma Via Modulating SOCS3 Expression/W. Sun, X. Xiang, Changsha, China, p.A2485 |
| 408 | Validation of the Six-Gene Sputum Signature for Inflammatory Phenotyping Severe Asthma/M. Christensen, K.J. Baines, P.G. Gibson, V. Backer, A. Sverrild, A.V. Bülow, C. Porsbjerg, Copenhagen, Denmark, p.A2486 |
| 409 | Distinct Profile of Inflammatory and Remodeling Biomarkers in Sputum of Severe Asthmatic Patients with or Without Persistent Airway Obstruction/S. Cianchetti, S. Brighindi, E. Bacci, C. Cardini, F.L. Dente, M. Latorre, I. Puxeddu, P. Paggiaro, Pisa, Italy, p.A2487 |


**414** Microbial Profiles of Severe Asthma Exacerbations Requiring Admission to Intensive Care/A. Ershadi, J.L. Gomez, Derby, CT, p.A2492

**415** The Identify Project: Do We Know the Most Prevalent Allergens in Severe Asthma/?J. Schreiber, C. Mailander, Magdeburg, Germany, p.A2493


**RAPID:rapid abstract poster discussion session**

**A102 DETERMINANTS OF OUTCOMES AND HIGH-VALUE CARE IN COPD**

2:15 p.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER Room 28 C-E (Upper Level)

Abstract Summaries 2:15-2:45

Viewing/Discussion 2:45-4:15

Chairing: V.G. Press, MD, MPH, Chicago, IL

V. Prieto-Centurion, MD, Chicago, IL

L.C. Feemster, MSc, MD, Seattle, WA


Impact of Antibiotic Utilization in Acute Exacerbations of Chronic Obstructive Pulmonary Disease in Hospitalized Patients with Normal Procalcitonin Levels/K. Ma, H. Bean, D. Bremer, M. Moffa, C. Watson, T. Walsh, Pittsburgh, PA, p.A2503


Barriers for Delivering Care to COPD Patients: A Physician Survey/A. Bocharnikov, Y.-C.T. Huang, Durham, NC, p.A2513
Validation of a Scalable Efficient Interoperable Linkage Process for Patient-Level EMR Data to Patient-Reported Registration Data Within the COPD Foundation Powered Research Network: Building on Common PCORNet Data Networks Toward a Comprehensive /R.A. Mularski, B. Clark, C. Pasquale, S.E. Gillespie, P. Crawford, E. Malanga, V. Malanga, B.P. Yawn, M.A. McBurnie, K.J. Davis, Portland, OR, p.A2514


Cost-Effectiveness of Home Oxygen Therapy-Home Mechanical Ventilation (HOT-HMV) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) with Chronic Hypercapnic Respiratory Failure Following an Acute Exacerbation of COPD in the United Kingdom (U/P.B. Murphy, B. Brueggenjuergen, T. Reinhold, L. Fusfeld, Q. Gu, T. Goss, N. Hart, London, United Kingdom, p.A2517

Cost-Effectiveness of Home Oxygen Therapy-Home Mechanical Ventilation (HOT-HMV) for Treatment of Chronic Obstructive Pulmonary Disease (COPD) with Chronic Hypercapnic Respiratory Failure Following an Acute Exacerbation of COPD in the United States (US)/G.J. Criner, Q. Gu, P.B. Murphy, L. Fusfeld, B. Brueggenjuergen, T. Goss, N. Hart, Philadelphia, PA, p.A2518

Do Pulmonary Function Tests Provided Through Non-VA Coordinated Care Provide Timely and More Efficient Patient Care?/O. Abdul-Kafi, M.J. Joo, T. Pham, Chicago, IL, p.A2519


Long-Term Outcome of Metallic Stenting for Airway Involvement in Relapsing Polychondritis/X. Wu, Shanghai, China, p.A2523

Identifying Imaging Markers for Disease Progression in Longitudinal CTs of Patients with Idiopathic Pulmonary Fibrosis/H. Prosch, J. Pan, J. Hofmanninger, N. Sverzellati, V. Poletti, F. Paryer, M. Holzer, G. Langs, Vienna, Austria, p.A2524


Predicting Mortality in Idiopathic Pulmonary Fibrosis (IPF) Patients Treated with Nintedanib/I. Tang, S. Menjoge, S. Stowasser, J. Korell, Ridgefield, CT, p.A2530


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.


The Relationship Between the Prognosis of Sarcoidosis and Th17/Treg Imbalance/D. Weng, M. Zhao, L. Huiping, Shanghai, China, p.A2542


The Relationship Between the Prognosis of Sarcoidosis and Th17/Treg Imbalance/D. Weng, M. Zhao, L. Huiping, Shanghai, China, p.A2542


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.


A707 CLINICAL AND TRANSLATIONAL INVESTIGATIONS INTO ACUTE RESPIRATORY INFECTIONS 2:15 p.m. - 4:15 p.m. MARRIOTT MARQUIS SAN DIEGO MARINA Pacific Ballroom 24-26 (North Tower, First Floor) Poster Viewing 2:15-3:00 Discussion 3:00-4:15 Chairing: C. Feldman, MD, PhD, DSc, Johannesburg, South Africa R.G. Wunderink, MD, Chicago, IL C. Dela Cruz, MD, PhD, New Haven, CT

Multi-Drug Therapy for Pulmonary Mycobacterium Avium Complex Disease Using the Japanese Adverse Drug


A Latent Class Analysis of Prolonged Mechanical Ventilation Patients at a Long-Term Acute Care Hospital: Subtype Differences in Outcomes/H. Dunn, F. Laghi, L. Quinn, S. Corbridge, K. Elderirawi, M. Kapella, A. Steffen, E.G. Collins, Chicago, IL, p.A2650


Family Member Perspectives and Coping Strategies to Manage Anxiety, Depression, and Acute Stress in the Medical Intensive Care Unit: A Qualitative Study/N. Held, M. Meater, B.J. Clark, M. Moss, P.D. Sottie, Aurora, CO, p.A2653


RAPID: RAPID ABSTRACT POSTER DISCUSSION SESSION

A109 NOVEL EXPERIMENTAL MODELS AND APPROACHES IN LUNG BIOLOGY

2:15 p.m. - 4:15 p.m. MARRIOTT MARQUIS SAN DIEGO MARINA

Abstract Summaries

2:15-2:45

Viewing/Discussion

2:45-4:15

Chairing: A. Haczkus, MD, PhD, Davis, CA
F.E. Lee, MD, Atlanta, GA
B.D. Southern, MD, Cleveland, OH
A110 NOVEL MECHANISMS AND TARGETS IN LUNG CANCER PROGRESSION

2:15 p.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER
Room 5 A-B (Upper Level)

Abstract Summaries 2:15-2:45
Viewing/Discussion 2:45-4:15

Chairing:
Z.G. Fridlender, MD, Jerusalem, Israel
C. Bai, MD, PhD, Shanghai, China
A.M. Houghton, MD, Seattle, WA

101 DNA Repair Protein Xeroderma Pigmentation Group C (XPC) Protects Against Carcinogen-Induced Lung Cancer Development Through Oxidative DNA Damage Repair and Preserved DNA Damage Response/C.R. Sears, H. Zhou, G.E. Sandusky, Indianapolis, IN, p.A2679


103 Serum Exosomes from Epidermal Growth Factor Receptor (EGFR) Mutated Adenocarcinoma Patients Induce Epithelial to Mesenchymal Transition (EMT)/P. Nadarajan, S.G. Chong, M. O’Callaghan, R. Kane, G. Cooke, M.P. Keane, Dublin, Ireland, p.A2681


105 In Vivo Function of an EGFR Ligand in Lung Cancer Y. Maeda, K. Tomoshige, M. Guo, I. Fink-Baldauf, Cincinnati, OH, p.A2683


107 γδT17 Cells in Malignant Pleural Effusion/X.-B. Pei, H.-Z. Shi, Beijing, China, p.A2685


109 Interferon Regulatory Factor 9 Mediated Regulation of Lung Cancer Progression and Metastasis/D. Brunn, F. Grimminger, W. Seeger, R. Savai, Bad Nauheim, Germany, p.A2687

110 NLRP3 Inflammasome Activation Involves in LPS and Coal Tar Pitch Extract-Induced Malignant Transformation of Human Bronchial Epithelial Cells/F. Feng, S. Duan, N. Wang, L. Huang, H. Shao, Zhengzhou, China, p.A2688

111 Treatment of Malignant Mesothelioma Using Novel Potent Radiosensitizer Suloquinovosylacylpropandiol/E. Inamasu, Nagasaki, Japan, p.A2689


115 Myokines as Anti-Proliferative Agents in Lung Adenocarcinoma: An In Vitro Study into Exercise and Lung Cancer/M. Zhang, M. Della Cruz, S. Chowdhury, H. Roy, Boston, MA, p.A2693


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
4:30 p.m. - 5:45 p.m.

RESPIRATORY HEALTH AWARDS PRESENTATION OF
THE AMBERSON LECTURE, TRUDEAU MEDAL AND DISTINGUISHED ACHIEVEMENT AWARDS

SAN DIEGO CONVENTION CENTER
Hall H (Ground Level)

Amberson Lecture
The Amberson Lecturer is an individual with a career of major lifetime contributions to clinical or basic pulmonary research and/or clinical practice. The Lecture is given in honor of James Burns Amberson, an international authority on chest disease and tuberculosis.
Lecturer: Scott T. Weiss MD, MS, Boston, MA
Lecture Title: Network Methods to Prevent Asthma

Trudeau Medal
The Trudeau Medalist is an individual with lifelong major contributions to prevention, diagnosis and treatment of lung disease through leadership in research, education, or clinical care. This award was established in 1926 and is given in honor of Edward Livingston Trudeau, a founder and the first president of the American Lung Association.
Awardee: Jeffrey A. Whitsett, MD, Cincinnati, OH

Distinguished Achievement Award
The Distinguished Achievement Award is given to individuals who have made outstanding contributions to fighting respiratory disease through research, education, patient care, or advocacy.
Awardees: Qutayba Hamid, MBChB, PhD, Quebec, Canada
Monica Kraft, MD, Tuscon, AZ

ASSEMBLY MEMBERSHIP MEETINGS

The fourteen Assemblies are the primary groups of the American Thoracic Society. Each Assembly holds an annual Membership Meeting at the International Conference. All Assembly members and other interested individuals are invited to attend. The Assembly Membership Meetings will be held on Monday, May 21st, 4:30 p.m. -7:00 p.m., with the exception of the Assemblies on Behavioral Science and Health Services Research and Pediatrics (see below.)

The Assembly Membership Meetings provide an update on the Assembly’s activities via the Assembly’s Leadership and provide Assembly members the chance to have input on future directions, information on how to get involved and networking opportunities. Voting results for the Assembly’s future leaders will also be announced.

5:00 p.m. - 7:00 p.m.

PEDIATRICS
MANCHESTER GRAND HYATT SAN DIEGO
Harbor Ballroom A-C (Second Level, Harbor Tower)

Chairing: Stephanie D. Davis, MD, Indianapolis, IN

6:00 p.m. - 8:00 p.m.

BEHAVIORAL SCIENCE AND HEALTH SERVICES RESEARCH
MANCHESTER GRAND HYATT SAN DIEGO
Seaport Ballroom F (Second Level, Seaport Tower)

Chairing: Christopher H. Goss, MD, MSc, Seattle, WA
6:00 p.m. - 8:00 p.m.
SECTION ON GENETICS AND GENOMICS MEMBERSHIP MEETING
MANCHESTER GRAND HYATT SAN DIEGO
Seaport Ballroom C (Second Level, Seaport Tower)

The Section meetings are open to all ATS members and other interested individuals. Items to be discussed include the Sections’ current projects and future directions.

Chairing: Blanca E. Himes, PhD, Philadelphia, PA
Michael H. Cho, MPH, MD, Cambridge, MA

7:00 p.m.-10:00 p.m.
ASSEMBLY ON PEDIATRICS DINNER
MANCHESTER GRAND HYATT SAN DIEGO
Seaport Ballroom A-B (Second Level, Seaport Tower)

The Pediatric Assembly will hold a dinner immediately following the Assembly Membership Meeting. Assembly members and non-members, students and fellows are invited to join us for an evening of networking, great company, and camaraderie. This is a wonderful opportunity to introduce young members and trainees to Assembly leaders, to connect with old friends and to set up new interactions and collaborations.

Pre-registration and an additional fee are required. Seating is limited.

$86.00 Fellow
$106.00 Member
$116.00 Non-Member

7:00 p.m. – 9:00 p.m.
STRATEGIES FOR TB CONTROL: POSTER SESSION
Sponsored by:
U.S. CENTERS FOR DISEASE CONTROL AND PREVENTION
STOP TB USA
MARRIOTT MARQUIS SAN DIEGO MARINA
Grand Ballroom 11-13 (North Tower, Lobby Level)

This public health poster forum will focus on innovative techniques, which are helping to meet the challenges of TB control, prevention, and elimination in the United States.

Target Audience:
National, state and local TB program staff, public health professionals (nurses, physicians, epidemiologists), pulmonary specialists, infectious disease specialists, TB and HIV clinicians, epidemiologists, TB consultants, laboratory scientists, and microbiologists.

Chairing: N. Shah, MD, Richmond, CA
S. Bamrah Morris, MD, MBA, Atlanta, GA
The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.

**PCC2  PEDIATRIC CLINICAL CORE CURRICULUM**

**7:00 a.m. - 8:00 a.m.**  
**SAN DIEGO CONVENTION CENTER**  
Room 1 A-B (Upper Level)

**Target Audience**
Pediatric pulmonary and critical care physicians who work in a clinical setting and are currently engaged in maintenance of certification

**Objectives**
At the conclusion of this session, the participant will be able to:

- remain current with medical knowledge relevant to their practice in pediatric pulmonology;
- evaluate their understanding of key skills and content areas in pediatric pulmonology as well as receive feedback on their comprehension of a result of a pre-test/post-test comparison;
- support clinicians who are engaged in maintenance of certification activities by providing updates on subjects included in recertification requirements.

The Pediatric Core Curriculum symposia promote lifelong learning and the enhancement of the clinical judgment and skills essential for practicing pediatrician. The symposia will address topics that have been identified by an ATS pediatric working group, which is comprised of members of the ATS Education Committee and the International Conference Committee, who have identified important areas within pediatric medicine (including severe asthma, ILD, BPD, pulmonary hypertension and pulmonary manifestations of pulmonary disease). Attendees will increase their medical knowledge as a result of attending this symposium, and this will be measured by a comparison of pre-test vs. post-test results on the corresponding maintenance of certification module. The ATS Pediatric Core Curriculum will focus on a 3-year content cycle of key medical content in the area of pediatric medicine.

**Chairing:** P.E. Moore, MD, Nashville, TN

**7:00 Neuromuscular Disorders in Children**  
O.H. Mayer, MD, Philadelphia, PA

**7:30 Update on Management of Children with SMA and DMD**  
R. Shell, MD, Columbus, OH

---

**SUNRISE SEMINARS**

| Registration Fee: $50.00 (includes continental breakfast.)  
Attendance is limited. Pre-registration is required.  
7:00 a.m. - 8:00 a.m. MARRIOTT MARQUIS SAN DIEGO MARINA |

| SS101 SEVERE ASTHMA FOR THE CLINICIAN  
M. Gauthier, MD, Pittsburgh, PA  
Grand Ballroom 1 (North Tower, Lobby Level) |

| SS102 DESIGNING BEHAVIOR CHANGE INTERVENTIONS ONE BARRIER AT A TIME  
I. Riley, MD, MPH, Durham, NC  
V. Prieto-Centurion, MD, Chicago, IL  
Grand Ballroom 2 (North Tower, Lobby Level) |

| SS103 COPD AND BRONCHIECTASIS OVERLAP SYNDROME  
M. Prickett, MD, Chicago, IL  
Grand Ballroom 3 (North Tower, Lobby Level) |

| SS104 LUNG TRANSPLANT FOR CONNECTIVE TISSUE ASSOCIATED ILD  
R. Jablonski, MD, Chicago, IL  
Grand Ballroom 4 (North Tower, Lobby Level) |

| SS105 NAVIGATING THE DIAGNOSIS AND MANAGEMENT OF MYOSITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE  
D. Assayag, MD, CM, Montreal, Canada  
Presidio 1 (North Tower, Lobby Level) |

| SS106 PULMONARY MANIFESTATIONS OF VASCULITIS  
L. Fussner, MD, Columbus, OH  
Presidio 2 (North Tower, Lobby Level) |

| SS107 DIAGNOSIS AND MANAGEMENT OF NEUROLOGIC AND CARDIAC SARCIOIDOSIS: A GUIDE FOR PULMONOLOGISTS  
M.L. Ribeiro Neto, MD, Cleveland, OH  
Temecula 1-2 (North Tower, First Floor) |

| SS108 NEUROMUSCULAR RESPIRATORY FAILURE: IMPROVING QUALITY OF LIFE AND SURVIVAL WITH NIPPV  
K. Provost, DO, PhD, Buffalo, NY  
Temecula 3-4 (North Tower, First Floor) |

| SS109 CHRONIC HYPERSENSITIVITY PNEUMONITIS: DIAGNOSTIC AND TREATMENT DILEMMAS  
D.M. Perlman, MD, Minneapolis, MN  
Leucadia (South Tower, First Floor) |

| SS110 DEFINING AND ADDRESSING SOCIAL DETERMINANTS OF HEALTH: IMPLICATIONS FOR PULMONARY DISEASE  
T. Parekh, DO, Birmingham, AL  
Point Loma (South Tower, First Floor) |

| SS111 A PRACTICAL TOOLKIT FOR IMPROVING PATIENT AND FAMILY ENGAGEMENT IN THE ICU  
S. Beesley, MD, Murray, UT  
Solana (South Tower, First Floor) |

| SS112 BRONCHOALVEOLAR LAVAGE IN THE IMMUNOCOMPROMISED HOST: MOVING BEYOND TRADITIONAL DIAGNOSTIC METHODS FOR FUNGAL INFECTION  
O. Epelbaum, MD, Valhalla, NY  
Balboa (South Tower, Third Floor) |
The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.

Regardless of anticipated career path, graduating clinical fellows, post-doctoral fellows, and early career faculty members are frequently presented with options of remaining at their “home” institution versus seeking new opportunities through a change in location. However, trainees and early career faculty may not be equipped to weigh advantages and disadvantages of these competing options. Moreover, it can be difficult to obtain objective guidance on these decisions, as mentors, current and potential future employers may be inherently conflicted. This session will identify and discuss the opportunities, risks and potential benefits of different options, and address strategies to navigate the decision making process.

Chairing: J.C. Horowitz, MD, Ann Arbor, MI
N.S. Sharma, MD, Birmingham, AL

Speakers: R. Paine, MD, Salt Lake City, UT
J. Richards, MD, MA, Boston, MA
Y. Huang, MD, Ann Arbor, MI

The Keynote Series provides state of the art lectures on selected topics in an unopposed format showcasing timely and diverse topics which relate to pulmonary, critical care and sleep medicine.

Two sessions are presented each morning during the conference. Below are the topics for the Monday, May 21st

K3 NATURE AND NURTURE OF TISSUE RESIDENT MACROPHAGES IN HEALTH AND DISEASE
8:15 a.m. - 9:00 a.m. SAN DIEGO CONVENTION CENTER
Room 6 B (Upper Level)

Speaker: Christopher K. Glass, MD, PhD, La Jolla, CA

K4 REDUCING BURNOUT AND PROMOTING ENGAGEMENT: INDIVIDUAL AND ORGANIZATIONAL APPROACHES TO PHYSICIAN WELL-BEING
8:15 a.m. - 9:00 a.m. SAN DIEGO CONVENTION CENTER
Room 6 C/F (Upper Level)

Speaker: Tait D. Shanafelt, MD, Stanford, CA
B1 CLINICAL YEAR IN REVIEW 2
9:15 a.m. - 11:15 a.m.
SAN DIEGO CONVENTION CENTER
Hall H (Ground Level)

Target Audience
Providers including physicians, nurses, respiratory therapists, nurse practitioners, physician assistants; trainees including residents and fellows; clinical researchers

Objectives
At the conclusion of this session, the participant will be able to:
• apply new clinical research knowledge to clinical practice;
• learn new findings about key conditions in pulmonary, critical care and sleep;
• gain new strategies to manage the care of common conditions in pulmonary, critical care, and sleep.

The annual Clinical Year in Review symposia provides concise summaries of the most impactful clinical research publications related to specific clinical topics. Speakers will highlight 5 of the most important and influential publications on their topic in written format and during their talks.

Chairing:
D.W. Ford, MD, Charleston, SC
V.E. Ortega, MD, PhD, Winston Salem, NC
J.S. Lee, MD, Aurora, CO

9:15 COPD
M. Drummond, MHS, MD, Chapel Hill, NC

9:45 Asthma
L.C. Denlinger, MD, PhD, Madison, WI

10:15 Lung Cancer
R.S. Wiener, MD, MPH, Boston, MA

10:45 Management in Pleural Disease
V.C. Broaddus, MD, San Francisco, CA

This session and the International Conference are supported by educational grants from AstraZeneca LP, GlaxoSmithKline, Sanofi Genzyme and Regeneron Pharmaceuticals, Sunovion Pharmaceuticals Inc.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

B2 INTERSTITIAL LUNG DISEASE (ILD), IDIOPATHIC INTERSTITIAL PNEUMONIA (IIP) AND HYPERSENSITIVITY PNEUMONITIS (HP): CONTROVERSIES IN MANAGEMENT. A PRO/CON DEBATE

Assemblies on Clinical Problems; Allergy, Immunology and Inflammation; Behavioral Science and Health Services Research; Environmental, Occupational and Population Health; Nursing

9:15 a.m. - 11:15 a.m.
SAN DIEGO CONVENTION CENTER
Ballroom 20 B-C (Upper Level)

Target Audience
Clinicians, registered nurses, advance practice nurses, other allied health staff, researchers, investigators in basic and clinic science pertinent to interstitial lung disease, and sponsors for research

Objectives
At the conclusion of this session, the participant will be able to:
• describe genetic screening for patients with IIP and IPF and discuss implications of this with patients;
• discuss the potential role of cryobiopsy in diagnosis of IIP and HP and how this can be used in clinical practice;
• compare and contrast predictive models and the potential role of such models in diagnosis of IIP and HP.

This session will consist of 4 Pro/Con debates on challenging aspects of diagnosing and treating Idiopathic Interstitial Pneumonia (IIP) and Hypersensitivity Pneumonitis (HP). The first debate will center on whether circulating serum biomarkers are useful in guiding diagnosis and management for patients with IIP. The second will focus on the role of cryobiopsy versus surgical and transbronchial lung biopsies in diagnosis of IIP and HP. The third debate will address the role of predictive models in diagnosis of IIP and HP. The fourth will be centered on whether genetic screening should routinely be performed among patients with IIP.

Chairing:
G. Raghu, MD, Seattle, WA
B. Collins, MD, Seattle, WA

9:15 Introduction and Opening Remarks
G. Raghu, MD, Seattle, WA

9:19 Case Presentation
B. Collins, MD, Seattle, WA

9:23 Serum Biomarkers are Useful in the Guiding Diagnosis and Treatment of Idiopathic Interstitial Pneumonia and Hypersensitivity Pneumonitis
B. Crestani, MD, Paris, France

9:33 Serum Biomarkers are Not Useful in the Guiding Diagnosis and Treatment of Idiopathic Interstitial Pneumonia and Hypersensitivity Pneumonitis
N. Kaminski, MD, New Haven, CT

9:43 Rebuttal: Comments and Discussion
B. Collins, MD, Seattle, WA

9:47 Case Presentation
G. Raghu, MD, Seattle, WA

9:51 Cryobiopsy is the Procedure of Choice for Obtaining Lung Tissue for Diagnosis of ILD/IIP/HP
V. Poletti, MD, PhD, Forli, Italy

10:01 Cryobiopsy is Not the Procedure of Choice for Obtaining Lung Tissue for Diagnosis of ILD/IIP/HP
A.C. Mehta, MBBS, Cleveland, OH

10:11 Rebuttal: Comments and Discussion
G. Raghu, MD, Seattle, WA

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
10:15 Case Presentation
B. Collins, MD, Seattle, WA

10:19 Predictive Models Are Useful in Diagnosis of HP and IIP
K.A. Johannson, MD, MPH, Calgary, Canada

10:29 Predictive Models Are Not Useful in Diagnosis of HP and IIP
C.J. Ryerson, MD, Vancouver, Canada

10:39 Rebuttal: Comments and Discussion
B. Collins, MD, Seattle, WA

10:43 Case Presentation
G. Raghu, MD, Seattle, WA

10:48 Genetic Screening Should be Routinely Done for Patients with Interstitial Pneumonia of Unknown Etiology
D.A. Schwartz, MD, Aurora, CO

10:58 Genetic Screening Should Not be Routinely Done for Patients with Interstitial Pneumonia of Unknown Etiology
M. Armanios, MD, Baltimore, MD

11:08 Rebuttal: Comments and Discussion
G. Raghu, MD, Seattle, WA

11:12 Closing Remarks
G. Raghu, MD, Seattle, WA

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
Chairing: M.M. Churpek, MD, MPH, PhD, Chicago, IL
V. Liu, MD, MS, Oakland, CA
H.C. Prescott, MD, MSci, Ann Arbor, MI

9:15 Targeting Earlier Identification: From qSOFA to Big Data
M.M. Churpek, MD, MPH, PhD, Chicago, IL

9:32 Aiming for Early Antibiotics: Should we Move the Needle to the Pre-Hospital Setting?
C.W. Seymour, MD, MSc, Pittsburgh, PA

9:49 Should We be Clearing Lactate for All our Patients?
V. Liu, MD, MS, Oakland, CA

10:06 Fever Control as a Therapeutic Target in Sepsis: Is it Cool to Be Hot or Hot to Be Cold?
P. Young, MBChB, Wellington, New Zealand

10:23 Intravenous Vitamin C: An Evolving Role in Sepsis and Acute Lung Injury
A.A. Fowler, MD, Richmond, VA

10:40 Restoring the Microbiome to Improve Recovery
H.C. Prescott, MD, MSci, Ann Arbor, MI

10:57 How I Treat Patients with Sepsis in 2018
L.E. Evans, MD, MSc, New York, NY

B5 MITOCHONDRIA AND NUCLEAR-DERIVED DANGER-ASSOCIATED MOLECULAR PATTERNS (DAMPS) IN PULMONARY DISEASES

Assemblies on Respiratory Cell and Molecular Biology; Allergy, Immunology and Inflammation

9:15 a.m. - 11:15 a.m. MARRIOTT MARQUIS SAN DIEGO MARINA
Pacific Ballroom 21 (North Tower, First Floor)

Target Audience
Basic and translational scientists working on lung diseases; lung health researchers, students, fellows, residents on both clinical and basic research scientists

Objectives
At the conclusion of this session, the participant will be able to:

- learn about the scope of DAMPs and what the mitochondrial and nuclear-derived DAMPs are, and their potential roles in pulmonary health;
- understand the cellular and molecular mechanisms underlying how DAMPs affect immune responses in pulmonary diseases;

Emerging evidence sheds light on the role of danger or damage associated molecular patterns (DAMPs), the host-derived endogenous signals, in many inflammatory lung diseases. Both mitochondrial and nuclear components, such as mitochondrial DNA and high-mobility group box 1 (HMGB1), when released into the extracellular milieu, can induce both innate and adaptive immune responses. These DAMPs can alter the resistance of host defense in both plants and animals to pathogens, causing cellular injury and lung diseases. The goal of this symposium is to highlight the recent advances in mitochondria and nuclear-derived DAMPs, particularly in their cell signaling, redox status, and the therapeutic potential of targeting these DAMPs in pulmonary diseases (acute lung injury, pulmonary infections, and COPD).

Chairing: T. Dolinay, MD, PhD, Philadelphia, PA
I. Rahman, PhD, Rochester, NY
P. Lee, MD, New Haven, CT
S. Graziioli, MD, Geneva, Switzerland

9:15 A Patient’s Perspective
K. Erickson, Thousand Oaks, CA

9:20 Pathogen Recognition Receptors in the Generation of Protective Innate Immune Responses of the Lung
T.J. Standiford, MD, Ann Arbor, MI

9:39 Mitochondrial DAMPs and Regulation of Abnormal Inflammation in COPD
I.H. Heijink, PhD, Groningen, Netherlands

9:58 Mitochondrial Danger Signals in Acute and Chronic Lung Disease
A.M. Choi, MD, New York, NY

10:17 HMGB1 in Innate Immunity Against Pulmonary Infections in CF and VAP
L. Mantell, MD, PhD, East Meadow, NY

10:36 Mitochondrial DNA in Asthma and Chronic Bronchitis
Y. Tesfai, PhD, Albuquerque, NM

10:55 Mitochondrial DAMPS in Aging and Lung Fibrosis
A.L. Mora, MD, Pittsburgh, PA
Exercise training forms the key component of pulmonary rehabilitation (PR). Speakers will draw on current advances in basic science to debate outstanding issues in PR, and how they relate to cardiopulmonary diseases. While PR is the most effective therapy for COPD and other cardiopulmonary diseases, the basic mechanisms underlying this benefit are not well known. Debates will center on the mechanisms of skeletal muscle dysfunction and whether PR addresses these deficiencies. Pro and con positions in each of 4 topics will be presented over 12 minutes, with 1 minute for rebuttal and 5 minutes discussion with the audience.

Chairing: R. Casaburi, MD, PhD, Torrance, CA
M. Steiner, MBBS, MD, Leicester, United Kingdom

9:15 Introduction
R. Casaburi, MD, PhD, Torrance, CA

9:17 Increasing Physical Fitness Should Be the Primary Goal of Pulmonary Rehabilitation
H.B. Rossiter, PhD, Torrance, CA

9:31 Increasing Physical Activity Should Be the Primary Goal of Pulmonary Rehabilitation
T. Troosters, PT, PhD, Leuven, Belgium

9:45 Muscle Fiber Atrophy in COPD Starts with Loss of Integrity in the Neuromuscular Junction
R. Hepple, PhD, Gainsville, FL

10:00 Muscle Fiber Atrophy in COPD Starts with Inflammatory-Mediated Ubiquitin Proteasome Activation
E. Barreiro, MD, PhD, Barcelona, Spain

10:15 Ventilatory Limitation is the Major Etiology of Exercise Intolerance in COPD
D.E. O’Donnell, MD, Kingston, Canada

10:30 Skeletal Muscle Oxygen Delivery and Utilization Limitations are the Major Etiologies of Exercise Intolerance in COPD
R. Casaburi, MD, PhD, Torrance, CA

10:45 Exercise Training Reverses Muscle Dysfunction in COPD
P.D. Wagner, MD, La Jolla, CA

11:00 Exercise Training Does Not Reverse Muscle Dysfunction in COPD
F. Malais, MD, Quebec, Canada

B7 GENETICS, EPIGENETICS, AND GENOMICS OF CHILDHOOD LUNG DISEASES

Assemblies on Pediatrics; Allergy, Immunology and Inflammation; Pulmonary Circulation; Respiratory Cell and Molecular Biology; Genetics and Genomics Section

9:15 a.m. - 11:15 a.m. SAN DIEGO CONVENTION CENTER Room 1 A-B (Upper Level)

Target Audience
Pediatricians, primary care providers, and pulmonary specialists taking care of children with chronic lung disorders. Scientists whose main research focus is on the mechanisms and pathophysiology of pediatric lung disease.

Objectives
At the conclusion of this session, the participant will be able to:

- learn new findings on the genetic and genomic basis of important pediatric lung diseases such as asthma, cystic fibrosis, pulmonary hypertension, and bronchopulmonary dysplasia.
- discuss the impact that these findings have in the prognosis and management of patients with these diseases.
- explore future directions for research aimed at understanding the genetic underpinning of these and other pediatric lung diseases.

Our understanding of the genetic basis of pediatric lung disease has advanced exponentially over the past several years. Beyond single-point mutations, research on the determinants of pediatric lung disease has incrementally focused on epigenetic regulation, gene-by-environment interactions, transcriptomic profiling, and other complex mechanisms. In this session, we will discuss the latest developments in the genetics and genomics of childhood asthma, cystic fibrosis, pulmonary hypertension, and bronchopulmonary dysplasia. We will also discuss the clinical implications of these recent findings.

Chairing: E. Forno, MD, MPH, Pittsburgh, PA
E.D. Austin, MD, Nashville, TN

9:15 Introduction
E. Forno, MD, MPH, Pittsburgh, PA

9:20 Recent Advances in the Genetics and Epigenetics of Childhood Asthma
E. Forno, MD, MPH, Pittsburgh, PA

9:40 Questions and Answers
E. Forno, MD, MPH, Pittsburgh, PA

9:43 The Role of the Transcriptome in Asthma and Glucocorticoid Response
B.E. Himes, PhD, Philadelphia, PA

10:03 Questions and Answers
B.E. Himes, PhD, Philadelphia, PA

10:06 CFTR Regulation, Disease Modifiers, and Their Interactions
L. Strug, PhD, Toronto, Canada

10:26 Questions and Answers
L. Strug, PhD, Toronto, Canada

10:29 Genomic Regulation in Pulmonary Hypertension
E.D. Austin, MD, Nashville, TN

10:49 Questions and Answers
E.D. Austin, MD, Nashville, TN

10:52 Genetics and Epigenetics of Bronchopulmonary Dysplasia
N. Ambalavanan, MD, Birmingham, AL

11:12 Questions and Answers
N. Ambalavanan, MD, Birmingham, AL

This session and the International Conference are supported by an educational grant from Vertex Pharmaceuticals Inc.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.
**B8 NONTUBERCULOUS MYCOBACTERIA INFECTION: CURRENT KNOWLEDGE AND RECENT ADVANCES**

Assembly on Pulmonary Infections and Tuberculosis
9:15 a.m. - 11:15 a.m. MARRIOTT MARQUIS SAN DIEGO MARINA
Grand Ballroom 8-9 (North Tower, Lobby Level)

**Target Audience**
Nurses, respiratory therapists, pulmonologists, post graduate trainees, inclusive/advanced practitioners.

**Objectives**
At the conclusion of this session, the participant will be able to:
• identify sources of NTM in the environment and trends in NTM epidemiology
• gain new or better strategies to diagnose NTM infections
• gain appropriate strategies to treat NTM infections

Nontuberculous mycobacteria (NTM) are present in the environment, and cause pulmonary disease that is increasingly common. Diagnosis and treatment of nontuberculous mycobacteria (NTM) remains substantially complex. The 2007 treatment guidelines for NTM (including Mycobacterium avium complex), based primarily on expert opinion, have been updated and will be published prior to the ATS 2018 meeting. The session will review our current knowledge of NTM epidemiology, diagnosis, and treatment and present the latest global research updates.

**Chairing:**
K.L. Winthrop, MD, MPH, Portland, OR
S.H. Kasprzak, MD, Denver, CO
K.N. Olivier, MD, MPH, Bethesda, MD

9:15 **A Patient’s Perspective**
M. O’Bryan, Palm Desert, CA

9:20 **NTM Epidemiology**
E. Henkle, PhD, MPH, Portland, OR

9:35 **Environmental NTM**
R. Thomson, MBBS, PhD, Greenslopes, Australia

9:55 **Molecular Epidemiology**
J. van Ingen, PhD, Nijmegen, Netherlands

10:15 **Immunology/Pathogenesis**
K.N. Olivier, MD, MPH, Bethesda, MD

10:35 **Diagnosis of NTM**
K. Moriimoto, MD, Tokyo, Japan

10:55 **Updates in Pulmonary NTM Disease Treatment: At the Start of a Pipeline?**
C.L. Daley, MD, Denver, CO

**B9 TH17 CELLS: FRIEND, FOE OR BOTH IN CHRONIC LUNG DISEASES**

Assemblies on Allergy, Immunology and Inflammation; Environmental, Occupational and Population Health; Respiratory Cell and Molecular Biology
9:15 a.m. - 11:15 a.m. MARRIOTT MARQUIS SAN DIEGO MARINA
Grand Ballroom 5-6 (North Tower, Lobby Level)

**Target Audience**
All basic, translational and clinical investigators, junior faculty and fellows with an interest in innate and adaptive immune cell development and function during the progression of chronic lung diseases and resultant therapeutic interventions.

**Objectives**
At the conclusion of this session, the participant will be able to:
• acquire an understanding of how innate or adaptive immune dysfunction contributes to pathophysiology in chronic lung disease.
• understand Th17 plasticity and evolution in chronic lung inflammation.
• identify novel mechanisms that facilitate Th17 pathogenesis

This session will delineate the contribution of Th17 cells in chronic lung disease with a focus on its contribution to pathophysiology or clinical resolution.

**Chairing:**
W.P. Drake, MD, Nashville, TN
A.P. Fontenot, MD, Aurora, CO
P.A. Verhoef, PhD, MD, Chicago, IL

9:15 **Metabolic Dependencies of T Cells in Inflammation**
J. Rathmell, PhD, Nashville, TN

9:35 **IL-17A Drives Infectious and Noninfectious Pulmonary Fibrosis**
T. Wynn, PhD, Bethesda, MD

9:55 **Significance of Th17 Pathway Signaling in IPF Clinical Outcome**
J.D. Herazo-Maya, MD, New Haven, CT

10:15 **Recalibrating Severe Asthma: Th1 and Th17 Cells**
A. Ray, PhD, Pittsburgh, PA

10:35 **Hormonal Control of Th17-Mediated Inflammation in Asthma**
D.C. Newcomb, PhD, Nashville, TN

10:55 **IL-17 and Lung Epithelial Signaling in Host Defense**
J.K. Kolls, MD, New Orleans, LA

This session and the International Conference are supported by educational grants from GlaxoSmithKline, Sanofi Genzyme and Regeneron Pharmaceuticals. All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.
**B10  LUNG CANCER SCREENING: WHO’S IN AND WHO’S OUT? A PRO/CON DEBATE**

Assemblies on Thoracic Oncology; Behavioral Science and Health Services Research

9:15 a.m. - 11:15 a.m.  
SAN DIEGO CONVENTION CENTER  
Room 32 A-B (Upper Level)

**Target Audience**
Providers of lung health, practitioners who manage lung cancer screening, policy makers, behavioral and clinical scientists, translational scientists with an interest in lung cancer

**Objectives**
At the conclusion of this session, the participant will be able to:
- understand the risks and benefits of lung cancer screening for patients with severe COPD and incorporate this knowledge into clinical decision-making.
- understand and be able to apply various methods for determining patient eligibility for lung cancer screening
- learn the potential role for biomarkers in determining patient eligibility for lung cancer screening and how this may be integrated into clinical practice.

The NSLT showed a 20% reduction in lung cancer mortality with yearly LDCT screening of high-risk patients. Current USPSTF guidelines recommend yearly screening in patients aged 55-80 with a greater than 30 pack-year smoking history who currently smoke or have quit within 15 years. Using a pro-con debate approach, this session will address key questions about patient selection for LDCT screening such as: what is the role for screening in patients with severe COPD, should patient selection for screening be based on guideline criteria or individual risk factors, and should biomarkers be used in determining which patients should undergo screening.

**Chairing:**  
J. Iaccarino, MD, Boston, MA  
M.P. Rivera, MD, Chapel Hill, NC  
L.T. Tanoue, MD, New Haven, CT  
C.R. Sears, MD, Indianapolis, IN

**9:15**  
**Patients with Moderate to Severe COPD Should Undergo LDCT Screening for Lung Cancer**  
J.J. Zulueta, MD, Navarra, Spain

**9:35**  
**Patients with Moderate to Severe COPD Should Not Undergo LDCT Screening for Lung Cancer**  
J. Iaccarino, MD, Boston, MA

**9:55**  
**LDCT Screening Patient Selection Should Be Based on USPSTF Guideline Criteria**  
C.G. Slatore, MD, Portland, OR

**10:15**  
**LDCT Screening Patient Selection Should Be Based on Personalized Lung Cancer Risk Prediction Models**  
M.C. Tamemagi, PhD, Toronto, Canada

**10:35**  
**Biomarkers Should Be Utilized in Determining Patient Selection for Lung Cancer Screening**  
R.P. Young, MBChB, MD, PhD, Auckland, New Zealand

**10:55**  
**Biomarkers Should Not Be Utilized in Determining Patient Selection in Lung Cancer Screening**  
C.R. Sears, MD, Indianapolis, IN
### Clinical Scientific Symposium

**B12 GLOBAL CARE FOR SLEEP DISORDERS: TOWARDS UNIVERSAL ACCESS**

Assemblies on Behavioral Science and Health Services Research; Clinical Problems; Nursing; Pediatrics; Sleep and Respiratory Neurobiology; International Health Committee

**9:15 a.m. - 11:15 a.m.**  
SAN DIEGO CONVENTION CENTER  
Room 7 A-B (Upper Level)

**Target Audience**
Physicians, health services and outcomes researchers, registered nurses, advanced practice nurses, quality and comparative effectiveness researchers, pediatric and adult residents and trainees

**Objectives**
At the conclusion of this session, the participant will be able to:

- discuss the global burden of sleep problems, sleep apnea and the current gap in health services;
- compare the innovative models of care that rely on technology to improve access, efficiency and quality of care;
- apply lessons from diverse health systems around the world to develop, test and implement novel models of care that aim to provide quality accessible care for all.

To discuss diverse models of care for Sleep Apnea (SA) and other sleep disorders across different geographical /socioeconomic regions, throughout the world, and how we can extend the reach of sleep health service provision to under-resourced areas. Innovative models of care from diverse countries and health systems will be discussed with a focus on quality and cost-effectiveness tools employed in each unique setting.

**Chairing:**
- M. Teodorescu, MD, MS, Madison, WI
- A.S. Buist, MD, Portland, OR
- C. Chai-Coetzer, MBBS, PhD, Adelaide, Australia
- B. Prasad, MD, Chicago, IL

**9:15**  
**Introduction: Burden of Sleep Disorders Around the World**  
A. Malhotra, MD, La Jolla, CA

**9:33**  
**Primary Care Physician and Specialist Nurse Led Models of Care for OSA: Data from Down Under**  
C. Chai-Coetzer, MBBS, PhD, Adelaide, Australia

### Behavioral ATS President’s Symposium

**B13 METACOGNITION IN MEDICINE: UNDERSTANDING HOW THE MIND WORKS TO IMPROVE TEACHING, LEARNING, AND PATIENT CARE**

**9:15 a.m. - 11:15 a.m.**  
SAN DIEGO CONVENTION CENTER  
Room 3 (Upper Level)

**Target Audience**
Physicians and nurses, respiratory therapists and pharmacists who provide patient or medical education and clinical care would benefit from this session. Medical trainees, including students, residents, and fellows would also value this session.

**Objectives**
At the conclusion of this session, the participant will be able to:

- describe core cognitive process in critical thinking and clinical decision making;
- discuss how to apply core concepts in thinking and decision making to effective, efficient, and evidence-based teaching strategies in a variety of clinical classroom settings;
- describe the patient's perspective in teaching and learning, and identify effective strategies for teaching patients and families with the goal of optimizing patient understanding and clinical outcomes.
Education is a core skill of an effective health care provider. From teaching patients and families about clinical issues, to training the next generation of physicians and other health care providers, effective and efficient educational skills are critical for all health care providers. This Symposium will review the foundational processes of how humans think and how to leverage those concepts for effective teaching in a variety of settings. Educating patients will be specifically emphasized, including considerations for teaching adherence and active participation in one’s own medical care, with the goal of improving patient outcomes.

Chairing:
R. Adamson, MBBS, Seattle, WA
G.W. Garrison, MD, Burlington, VT
J.B. Richards, MD, MA, Boston, MA

9:15 Introduction
J.B. Richards, MD, MA, Boston, MA

9:20 Diagnostic Reasoning in Medicine: How Doctors Think
G. Norman, MD, Hamilton, Canada

9:40 How to Make it Stick: Secrets From the Science of Learning
W.G.G. Carlos, MD, MSCR, Indianapolis, IN

9:55 Thinking Critically About Critical Thinking: Teaching Better Thinking
R.M. Schwartzstein, MD, Boston, MA

10:15 Interprofessional Education: Learning Together to Improve Outcomes
P.A. Kritek, MD, Seattle, WA

10:35 Educating Patients and Families to Improve Outcomes
F. Blackstock, PhD, Penrith, Australia

10:55 The Patient Perspective: What You Taught vs. What I Learned
A.S. Clay, MD, Durham, NC

11:10 Summary
R. Adamson, MBBS, Seattle, WA
G.W. Garrison, MD, Burlington, VT

LATE BREAKING MINI SYMPOSIUM

B14 LATE BREAKING CLINICAL TRIALS AND FIRST REPORTS IN ASTHMA AND COPD SAN DIEGO CONVENTION CENTER

9:15 a.m. - 11:15 a.m.

SAN DIEGO CONVENTION CENTER
Room 33 A-C (Upper Level)

Chairing: D.D. Sin, MD, Vancouver, Canada
P.J. Dubin, MD, Memphis, TN
N. Lugogo, MD, Ann Arbor, MI

Oral Presentations


MINI SYMPOSIUM

B15 IMMUNE PATHWAYS IN LUNG INJURY AND REPAIR

9:15 a.m. - 11:15 a.m.

MARRIOTT MARQUIS SAN DIEGO MARINA
Pacific Ballroom 22 (North Tower, First Floor)

Chairing: M.M. Wurfel, MD, PhD, Seattle, WA
A. Rogers, MPH, MD, Stanford, CA

Oral Presentations


10:30 IL-22 Reduces Influenza Pneumonia by Promoting Thymic Integrity and T Regulatory Cell Maturation/N. McLaughlin, Metairie, LA, p.A2705


10:00 Reaching Under Served and Resourced Rural Children and Youth with Asthma Through School Based Programs/L.C. Cicutt, M. McCullough, K. Crews, Denver, CO, p.A2711


MINI SYMPOSIUM

B17 CRITICAL CARE: BURDEN OF SURVIVAL - OUTCOMES AFTER CRITICAL ILLNESS IN ADULTS AND CHILDREN

9:15 a.m. - 11:15 a.m. SAN DIEGO CONVENTION CENTER

Chairing: A.A. Hope, MD, Bronx, NY
I.M. Cheifetz, MD, Durham, NC
S. Beesley, MD, Salt Lake City, UT

Oral Presentations


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
10:30  The AMPAC Physical Therapy Assessment at Hospital Discharge Predicts Death and Recovery in Older Survivors of Acute Respiratory Failure/S. Norris, W.C. Gonzalez, J.S. Pfeffer, M.R. Baldwin, New York, NY, p.A2721


MINI SYMPOSIUM

B18  PATIENT AND FAMILY ENGAGEMENT IN RESPIRATORY AND CRITICAL CARE

9:15 a.m. - 11:15 a.m.  SAN DIEGO CONVENTION CENTER
Room 30 A-B (Upper Level)

Chairing: J. Yorke, BN, PhD, Manchester, United Kingdom
J.B. Seaman, PhD, RN, Pittsburgh, PA

Oral Presentations


9:30  Individualized Sleep Promotion for Hospitalized Patients: Identification and Mitigating Factors that Disturb Sleep/L. Ye, R.L. Owens, P. Dykes, Boston, MA, p.A2725

9:45  Developing a Brief Tailored Shared Decision-Making Intervention for African American Adults with Asthma: Results of a Qualitative Study to Identify Desired Intervention Features/M.R. George, A. Chung, J.-M. Brusszee, New York, NY, p.A2726

10:00  Intense Interventions for Treating Tobacco Use and Dependence/P.A. Folan, C. Fardellone, A. Spatarella, R. Abramova, N. Kohn, Great Neck, NY, p.A2727


11:00  The AMPAC Physical Therapy Assessment at Hospital Discharge Predicts Death and Recovery in Older Survivors of Acute Respiratory Failure/S. Norris, W.C. Gonzalez, J.S. Pfeffer, M.R. Baldwin, New York, NY, p.A2721


MINI SYMPOSIUM

B19  SURF’S UP: RIDING THE WAVE OF CLINICAL RESEARCH IN PULMONARY HYPERTENSION

9:15 a.m. - 11:15 a.m.  MARRIOTT MARQUIS SAN DIEGO MARINA
Pacific Ballroom 18-19 (North Tower, First Floor)

Chairing: M. Humbert, MD, PhD, Bicetre, France
E.S. Klings, MD, Boston, MA
R.F. Machado, MD, Indianapolis, IN

Oral Presentations

9:15  Low-Grade Albuminuria in Linked to Inflammation and Is Associated with Poor Outcome in Pulmonary Arterial Hypertension/N. Nickel, E.D. Austin, V. De Jesus Perez, R.T. Zamanian, J.D. West, M. de Caestecker, H. Yang, Stanford, CA, p.A2731

9:30  Novel Causative Genes for Heritable Pulmonary Arterial Hypertension/S. Graf, M. Haimel, M. Bleda, C. Hadinnapola, N.W. Morrell, Cambridge, United Kingdom, p.A2732


10:30  Right Ventricular Dysfunction in Pulmonary Hypertension Due to Chronic Lung Disease: Male Gender Is Associated with RV-PA Uncoupling/L. Rose, K.W. Prins, S.L. Archer, M. Pritzker, E.K. Weir, T. Thenappan, Minneapolis, MN, p.A2736

10:45  Cardiac Sympathetic Dysfunction in Pulmonary Arterial Hypertension: Lesson from Left Sided Heart Failure/V. Mercurio, T. Pellegrino, P. Parrella, V. Piscopo, G. Campi, G. Bosso, C.G. Tocchetti, M. Petretta, P.M. Hassoun, A. Cuocolo, D. Bonaduce, Baltimore, MD, p.A2737


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
B20  ASTHMA: NEW FINDINGS IN AIRWAY SMOOTH MUSCLE PATHOPHYSIOLOGY AND POTENTIAL THERAPY

9:15 a.m. - 11:15 a.m.  SAN DIEGO CONVENTION CENTER
Room 15 A-B (Mezzanine Level)

Chairing: Y. Bosse, PhD, Québec, Canada
J.E. Bourke, PhD, Clayton, Australia
J.H. Bates, PhD, DSc, Burlington, VT

Oral Presentations


9:45  Protein Kinase C, L-Type Voltage-Gated Calcium Channels and Non-Muscle Myosin II Are Involved in Force Adaptation/M. Gazzola, A. Lee-Gosselin, L. Auger, K. Lortie, Y. Bosse, Quebec, Canada, p.A2741


11:00  Improvements in Functional Image Impedance Modelling of Asthmatic Lungs Using K-Means Clustering/C. Church, H. Young, G. Parraga, G.N. Maksym, Halifax, Canada, p.A2746

612 **Assessment of Respiratory Outcomes in Exacerbating COPD Patients from Italy: The MISTRAL Study**/P. Schino, C. Franco, B. Canino, P. Maestrelli, P. Candoli, M. Bartezaghi, P. Morini, P.A. Porporiglia, Acqua viva delle Fonti, Italy, p.A2758

613 **Features of the Common Cold that Would Lead to an Exacerbation of Chronic Obstructive Pulmonary Disease**/H. Xu, L. Finney, J. Wedzicha, G. Donaldson, London, United Kingdom, p.A2759

614 **A Study of Infective Etiology in Patients with Acute Exacerbation of COPD**/A. Mangla, A.D. Shah, S. Francis, K. Shah, Vadodara, India, p.A2760


617 **Outcomes Following Hypercarbic Versus Non-Hypercarbic Respiratory Failure During Acute Exacerbation of COPD**/A. Chen, P.F. Simonelli, B.M. Walsh, Danville, PA, p.A2763

618 **Compliance with Appropriate Treatment on Discharge in Patients with COPD Exacerbation: A Retrospective Quality Improvement Project**/A. Karki, C.A. Thurm, J. Morante, A. Karki, N. Sawaged, A. Khan, Gainesville, FL, p.A2764


620 **Efficacy of a Home Discharge Care Bundle After Acute Exacerbation of Chronic Obstructive Pulmonary Disease**/S. Cousse, M. Salaun, L. Thiberville, A. Cuvelier, M. Patout, Rouen, France, p.A2766


623 **Optimization of COPD Management Among Inpatients with Acute Exacerbations of COPD**/C. Wirth, E.D. Penz, D.D. Marciniuk, Saskatoon, Canada, p.A2769


625 **Gender Differences in Veterans Admitted to the Hospital for COPD Exacerbation**/B. Bade, E. DeRycke, M. Skanderson, K.A. Crothers, L. Bastian, K.M. Akgun, New Haven, CT, p.A2771

**RAPID: RAPID ABSTRACT POSTER DISCUSSION SESSION**

**B22 **CRITICAL CARE: MICROBIOME, GENETICS, AND OTHER BIOMARKERS IN ACUTE CRITICAL ILLNESS**

9:15 a.m. - 11:15 a.m. **SAN DIEGO CONVENTION CENTER**

Room 31 A-C (Upper Level)

**Abstract Summaries**

9:15-9:45

**Viewing/Discussion**

9:45-11:15

**Chairing:** C.C. Dos Santos, MD, Toronto, Canada

C.S. Calfee, MD, San Francisco, CA

B. Singer, MD, PhD, Ann Arbor, MI


**703 Extrapulmonary Expression of Surfactant Protein D and Modulation of the Gut Microbiome**/A. Arciniegas, J.A. Englert, R.M. Baron, Boston, MA, p.A2774

**704 The Gut Microbiota Promotes Intravascular Immunity Against Bacterial Dissemination During Sepsis**/B. McDonald, C. Jenne, Calgary, Canada, p.A2775


**707 Heparan Sulfate Fragments Released During Sepsis Initiate Persistent Neurocognitive Dysfunction Through Sequestration of Hippocampal Brain-Derived Neurotrophic Factor**/J.A. Huppensteel, J.E. Orfila, J.A. Ford, G. Su, F. Zhang, X. Liu, X. Han, J. Liu, R.J. Linhardt, P. Herson, E.P. Schmidt, Aurora, CO, p.A2778

**708 Neuroinflammation in Survivors of Murine Pneumosepsis**/B. Singer, S.J. Denstaedt, A. Zhao, M. Newstead, T.J. Standiford, Ann Arbor, MI, p.A2779


Prognostic Implication of Sequential C-Reactive Protein Measurement in Critically Ill Patients with Pneumonia/C.-M. Chen, S.-F. Huang, C.-Y. Kuo, Y.-C. Tsai, J.-R. Tsai, M.-J. Tsai, W.-A. Chang, C.-C. Sheu, Kaohsiung, Taiwan, p.A2786

Low-Level Enteral Dextrose Infusion Induces Increases in the Proprotein Convertase Subtilisin/Kexin Type 9 Low-Level Enteral Dextrose Infusion Induces Increases in the Proprotein Convertase Subtilisin/Kexin Type 9 Low-Level Enteral Dextrose Infusion Induces Increases in the Proprotein Convertase Subtilisin/Kexin Type 9 Low-Level Enteral Dextrose Infusion Induces Increases in the Proprotein Convertase Subtilisin/Kexin Type 9


Neutrophil-to-Lymphocyte Ratio as a Prognostic Marker in Acute Respiratory Distress Syndrome Patients: A Retrospective Study/Y. Wang, D. Zhang, Y. Song, Shanghai, China, p.A2795


108 The Air They Breathe; Where Children Are Exposed To Air Pollution/A. Whitehouse, J.M. Grigg, London, United Kingdom, p.A2803


110 Reducing Exposure Of Asthmatic Children To Black Carbon Particle Matter Air Pollution/L.C. Koh, S. Cunningham, J. Grigg, London, United Kingdom, p.A2805

111 Residential Proximity to Traffic is Associated with Lifetime Rhinitis and Seasonal Allergy Symptoms among Urban Mexican American Children/K. Eldeirawi, C. Kunzweiler, V. Persky, Chicago, IL, p.A2806


116 Allergy Tests in Patients with Severe Asthma/H. Cao, B. Ortiz, E. Stanek, Q. Huang, L. Wang, D. Wertz, A. Kavati, East Hanover, NJ, p.A2811


B25 CHRONIC SUPPURATIVE LUNG DISEASE IN CHILDREN

9:15 a.m. - 11:15 a.m. SAN DIEGO CONVENTION CENTER
Room 6 D (Upper Level)

Abstract Summaries 9:15-9:45
Viewing/Discussion 9:45-11:15

Chairing:
M. Rosenfeld, MD, Seattle, WA
A.J. Shapiro, MD, Montreal, Canada
M.G. O’Connor, MD, Nashville, TN


B26 PEDIATRIC VIRAL AIRWAYS DISEASE: MECHANISMS AND CLINICAL IMPACT

9:15 a.m. - 11:15 a.m. SAN DIEGO CONVENTION CENTER
Room 6 E (Upper Level)

Abstract Summaries
9:15-9:45

Viewing/Discussion
9:45-11:15

Chairing: M.B. Hershenson, MD, Ann Arbor, MI
C. Rosas-Salazar, MD, MPH, Brentwood, TN
T.J. Moraes, MD, Toronto, Canada

301 Non-Canonical Regulation of Beta2 Adrenergic Receptor in Response to RSV Infection in Human Primary Airway Smooth Muscle Cells

302 Respiratory Syncytial Virus Infections Placental Cells and Villus Explants In Vitro

303 Glucocorticoid Receptor Dysfunction in Response to Respiratory Syncytial Virus Infection in Human Primary Airway Smooth Muscle Cells
T.J. Harford, V. Bokun, F. Rezaee, G. Piedimonte, Cleveland, OH, p.A2856

304 Hyaluronan Dependent Leukocyte Adhesion Is Enhanced by Viral Infection, but Not by Aeroallergen Exposure in Human Lung Fibroblasts
S.R. Reeves, I. Kang, K.A. Barrow, M.P. White, T.N. Wight, J.S. Debley, Seattle, WA, p.A2857

305 Predictors of Treatment Failure Among Infants with Acute Lower Respiratory Infection Due to Respiratory Syncytial Virus in Botswana

306 Endocytosis of Tight Junction Proteins Following RSV Infection Leads to Airway Epithelial Barrier Dysfunction
D. Linfield, A.I. Ivanov, G. Piedimonte, F. Rezaee, Cleveland, OH, p.A2859

307 Alveolar-Like Macrophages Can Limit Respiratory Syncytial Virus Infection in Mice
T.J. Moraes, S. Cen, M.L. Litvack, M. Post, Toronto, Canada, p.A2860

308 Redefining Bronchiolitis: Respiratory Phenotyping of Viral Lower Respiratory Tract Infections Identifies Subsets with Distinct Acute Severity and Recurrence of Respiratory Illnesses During Early Life

309 Adaptive Immune Response in RSV and RV Infants Hospitalized for Bronchiolitis

310 Bronchiolitis Diagnosis Relies on Patient’s Age
311 Increased Use of Non-Invasive Positive Pressure Associated with Decreased Use of Other Invasive Devices in Children with Bronchiolitis/S.Soshnick, C.L. Carroll, A.S. Cowl, Hartford, CT, p.A2864


Chairing: V. De Jesus Perez, MD, Palo Alto, CA

J.P. Fessel, MD, PhD, Nashville, TN

N.W. Morrell, MD, Cambridge, United Kingdom

801 NKKX2.5 Is Associated to Endothelial-to-Mesenchymal Transition in Pulmonary Arterial Hypertension/ J. Santos Cade, I. Papaioannou, C. Denton, D. Abraham, M. Ponticos, London, United Kingdom, p.A2873


805 Unfolded Protein Response and Mitochondria Crosstalk Drives PINK1 Downregulation and Mitochondrial Dysfunction in Pulmonary Endothelial Cells/L. Tu, M. Bueno, L. Voltz, A.L. Mora, Pittsburgh, PA, p.A2877


807 Pericyte Fate Mapping in Mice with Hypoxia-Induced PAH/K. Yuan, E. Shamshkhou, M. Orcholski, K. Red-Horse, V. De Jesus Perez, Palo Alto, CA, p.A2879


811 Inhibition of Purine Nucleoside Phosphorylase Retards the Progression of Angioproliferative Pulmonary Hypertension in Female Rats/S.P. Tofovic, J. Hu, J. Milosevic, E.K. Jackson, Pittsburgh, PA, p.A2883

812 178-Estradiol And Its Receptor ERα Protect Against Right Ventricular Vascular Loss In Experimental Pulmonary Hypertension/A.L. Frump, M. Albrecht, B. Yakubov, T. Laehn, Indianapolis, IN, p.A2884
Rapid: Rapid Abstract Poster Discussion Session

B28  CELL AND MATRIX MICROENVIRONMENTS MODULATE LUNG DISEASE
9:15 a.m. - 11:15 a.m.  MARRIOTT MARQUIS SAN DIEGO MARINA
Pacific Ballroom 15-17 (North Tower, First Floor)

Abstract Summaries 9:15-9:45
Viewing/Discussion 9:45-11:15

Chairing: F.E. Lee, MD, Atlanta, GA
C.E. Barkauskas, MD, Durham, NC
D.J. Tschumperlin, PhD, Rochester, MN


2. Eps-15 Homology Domains: Role In The Pathogenesis Of Pulmonary Arterial Hypertension/S.A. Predescu, S. Qin, C. Bardita, D.N. Predescu, Chicago, IL, p.A2886


11. Group V phospholipase A2 (gVPLA2) mediates responses to mexitilline-resistant Staph aureus (MRSA) in lung endothelium/Y.M. Htwe, L. Meliton, T. Kawasaki, S.M. Dudek, Chicago, IL, p.A2895

12. Niches of Wnt/Beta-Catenin Signaling in Distal Adult Human and Mouse Lung During Homeostasis and Injury/A. Lam, A. Misharin, A. Flocak, C. Chung, G.S. Budinger, C.J. Gottardi, Chicago, IL, p.A2896


14. The Role of Retinoid and Hedgehog Signaling in the Derivation of Lung Specific Mesenchymal Progenitors from iPSC Cells/H.A. Marquez, W. Shi, D.N. Kotton, Boston, MA, p.A2898

15. Rare Pulmonary Connective Tissue Type Mast Cells Regulate Endothelial Cell Angiogenesis/Y. Ren, Y. Lyu, J.A. Mereness, J. Pang, G.S. Pryhuber, T.J. Mariani, Rochester, NY, p.A2899


916 Importance of the Large Conductance Potassium Ion Channel Subunit KCNM8 in the Differentiation of Fibroblasts to Myofibroblasts/A. Scruiggs, S.K. Huang, Ann Arbor, MI, p.A2911


918 4E-BP1/EIF4E Cap Dependent Translational Signaling and Regulation in Lung Mesenchymal Cells/V.N. Lama, N.M. Walker, Ann Arbor, MI, p.A2913


922 The Pathological Effects of Decellularized Fibrotic Extracellular Matrix from IPF Patients/R. Nho, J. Im, Minneapolis, MN, p.A2917


924 Alveolar Macrophages Contribute to the Type 2 Alveolar Epithelial Stem Cell Niche/J.B. Smith, R.M. Tighe, C. Barkauskas, Durham, NC, p.A2919


Chairing: A.J. Ammit, PhD, Ultimo, Australia
J.J. Fredberg, PhD, Boston, MA
C. Pascoe, PhD, Winnipeg, Canada


1003 Comparison of Decellularization Between Normal and Silicotic Lungs on Function and Extracellular Matrix Components/F.F. Cruz, V. Martins, V. Capelozzi, P.L. Silva, P.R.M. Rocco, Rio de Janeiro, Brazil, p.A2923


1012 Real-Time Imaging of Mechanical Stress-Induced ATP Release in Rat Lungs: from In Vitro to Ex Vivo/O.J. Tan, F. Boudreault, E. Brochiero, R. Grygorczyk, Montreal, Canada, p.A2932
1013 Integrin Alpha2Beta1 Transmits Tension in Smooth Muscle Via Interaction with Collagen and Laminin/S. Liu, D. Sheppard, A.B. Sundaram, San Francisco, CA, p.A2933


1018 Elastin Degradation Mediated by Proteinase 3 Is a Novel Biomarker of COPD/J.M.B. Sand, N.S. Gudmann, T. Manon-Jensen, C. Diefenbach, M.A. Karsdal, D.J. Leeming, Herlev, Denmark, p.A2938


P872 Both Chronic Hyperglycemia and Chronic Hyperinsulinemia

P874 Surfactant Protein-A Nanobody-Conjugated Liposomes

P873 A Phagocyte-Targeted Toll-Like Receptor Nano-Inhibitor

P871 Circulating Monocyte Responses Are Associated with

P870 Cholesterolic Acid Is a Biomarker and Anti-Inflammatory Facilitator:

R.S. Knipe, MD, Boston, MA

ATS 2018 • San Diego, CA

THEMATIC POSTER SESSION

B32 CLINICAL STUDIES IN AUTOIMMUNE LUNG DISEASE

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER

Area G (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion

12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: J.S. Lee, MD, Aurora, CO


P624 An Uncommon Presentation of Cavitary Lesions in Granulomatosis with Polyangiitis/M. Koster, K. Patel, A. Desai, Syracuse, NY, p.A2992

P625 Recognizing the Pattern: Anti- MDA 5 Associated Clinically Amyopathic Dermatomyositis (CADM) with Rapidly Progressive Interstitial Lung Disease (RP-ILD) Presenting as Multi-Focal Pneumonia/A. Abu Homoud, S. Kooragayalu, N. Bhandari, Chicago, IL, p.A2993

P626 “I’m Bleeding from My Eyes” - Acute Onset Dacryoadenitis, Later Diagnosed with Granulomatosis with Polyangiitis/K. Kongpakpaisarn, K.N. Cao, Tampa, FL, p.A2994

P627 Diffuse Cobblestone Appearance of the Tracheobronchial Tree: A Rare Presentation of Granulomatosis with Polyangiitis/A. Karim, S. Velani, J. Khalib, B.P. Young, Cleveland, OH, p.A2995

P628 IgG4 Related Lung Disease Found in a Patient with a Pancreatic Mass/C. Schuring, A. Yankovich, A. Sodhi, Memphis, TN, p.A2996

P629 Dysphonia and Dyspnea in Idiopathic Hypereosinophilic Syndrome Treated with Mepolizumab/D. Kay, A. Ataya, D.R. Urine, Gainesville, FL, p.A2997

Facilitator: J.J. Swigris, DO, MS, Denver, CO


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
P631  Cultural and Medical Complexity: Pulmonary-Renal Vasculitis with Severe Anemia/A. Zanoto, K.R. Ham, Minneapolis, MN, p.A2999

P632  Reveling the Mystery of a Previously Diagnosed Inflammatory Pseudotumor of the Lungs/D. Khateeb, D. Young, Philadelphia, PA, p.A3000


P636  A Rare Case of Polangitis Overlap Syndrome: Granulomatosis with Polyangiitis and Eosinophilic Granulomatosis with Polyangiitis/M. Quan, S.K. Frankel, M. Maleki, L. Tan, Colton, CA, p.A3004

Facilitator: J.C. Horowitz, MD, Ann Arbor, MI

P637  Bloody Lungs and Broken Kidneys Bandied in One Blight/C. Vahdatpour, O. Amoran, Philadelphia, PA, p.A3005

P638  A Case of Allergic Granulomatosis Induced by Leukotriene Receptor Antagonists/E. Albaddawi, A. Ammar, R. Khan, W. Nasser, Orlando, FL, p.A3006


Facilitator: S.K. Danoff, MD, PhD, Baltimore, MD


P648  Small Airway Disease a Potential Feature of Scleroderma Lung Disease/L. Pourzand, G.H. Kim, F. Abtin, D.P. Tashkin, J. Goldin, Los Angeles, CA, p.A3016

Facilitator: V. Cottin, PhD, MD, Lyon, France


THEMATIC POSTER SESSION

B33  COPD: MAINTENANCE THERAPY

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER

Area L (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion

12:00-1:00: authors will be present for discussion with assigned facilitators

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.


P1327  Assessment of Internal Medicine Residents’ Knowledge of Common Inhaler Identification and Operation/D. Chin, J. Kelly, M. Kiazand, A. Perez, Pittsburgh, PA, p.A3023


P1329  Seebri™ Neohaler® (Glycopyrrolate) Versus Placebo in Patients with Moderate to Severe COPD: Findings from a Health-Related Quality of Life (HRQoL) Study from the GEM1 Study/G. Feldman, C. Dembek, K. Rajagopalan, Spartanburg, SC, p.A3025

P1330  Seebri™ Neohaler® (Glycopyrrolate) Versus Placebo in Patients with Moderate to Severe COPD: Findings from a Health-Related Quality of Life (HRQoL) Study from the GEM2 Study/E.M. Kerwin, C. Dembek, K. Rajagopalan, Medford, OR, p.A3026

P1331  Revefenacin, a Long-Acting Muscarinic Antagonist (LAMA), Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo- and Positive-Controlled Thorough QT Study/M. Borin, C. Barnes, B. Dargo, S. Pendyala, D. Bourdet, South San Francisco, CA, p.A3027


P1337  Absorption, Distribution, Metabolism, and Excretion of Revefenacin, a Long-Acting Muscarinic Antagonist (LAMA), in Healthy Male Subjects/D. Bourdet, S. Yeola, P.-J. Colson, S. Pendyala, C.N. Barnes, M. Borin, South San Francisco, CA, p.A3033


Facilitator: R.C. Balkissoon, MD, Denver, CO

P1339  Safety of Tiotropium/Olodaterol in Chronic Obstructive Pulmonary Disease: Pooled Analysis of Three Large, 52-Week, Randomized Clinical Trials/G.T. Ferguson, R. Buhl, A. de la Hoz, U. Bothner, F. Voss, A. Anzueto, P.M. Calverley, Farmington Hills, MI, p.A3035

P1340  Incidence of Chronic Obstructive Pulmonary Disease Symptom-Defined Exacerbations: Exploratory Analysis from a Long-Term Open-Label Active-Controlled Safety Trial of Nebulized Glycopyrrolate/eFlow® CS/E.M. Kerwin, V. Ganapathy, L. Murray, K. Rajagopalan, Medford, OR, p.A3036


P1342  Use of Pulmonary Function Testing to Predict Successful Inhaler Device Technique/B.A. Kelly, A.L. Martitosov, Detroit, MI, p.A3038

P1343  Safety Profile of Roflumilast in a Real Life Experience/A. Cilli, H. Dirol, H. Bal, Antalya, Turkey, p.A3039


Facilitator: J.F. Donohue, MD, Chapel Hill NC

P1346  Long-Term Consequences of Clinically Important Deterioration in Patients with Chronic Obstructive Pulmonary Disease Treated with Twice-Daily Inhaled Corticosteroid/Long-Acting ß2-Agonist Therapy: Results from the TORCH Study/I. Naya, M.T. Driessen, V. Paly, N. Gunsoy, N. Risebrough, A. Briggs, A.S. Ismaila, Brentford, United Kingdom, p.A3042


B34 AUTOIMMUNE LUNG DISEASE CASE REPORTS

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER
Area G (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: R. Beckford, MD, Nashville, TN

P659 Failure of Removal of Inhaled Corticosteroids in Patients with Chronic Obstructive Pulmonary Disease in a Clinical Setting/ F. Pyarali, A.S. Calzadilla, K. Medepalli, M.A. Campos, Miami, FL, p.A3044

P660 Searching for a Cause: Apical Cavitory Lesion in an Immunocompetent Young Adult/W. Mazalewski, K.N. Cao, Tampa, FL, p.A3050

P661 A Rare Case of Mitral Valve Libman-Sachs Endocarditis Caused by Antiphospholipid Antibody Syndrome Leading to Diffuse Alveolar Hemorrhage/R. Hyde, M.C. Runnstrom, A. Anderson, G. Graves, H.M. Alnuaimat, A. Ataya, Gainesville, FL, p.A3051


P665 A Catastrophic Presentation of Antisynthetase Syndrome with Rapidly Progressing Interstitial Lung Disease and Its Antibodies/A. Arthur, A. Alaverdian, East Meadow, NY, p.A3055


Facilitator: K. Milger, MD, Munich, Germany

P668 DAH: A Rare Presentation of Anca-Associated Vasculitis/O. Sheriff, Philadelphia, PA, p.A3058

P669 A Co-Occurrence of Good Pastures Disease and Graves Disease/G. Stevens, N. Khan, D.G. Washburn, Loma Linda, CA, p.A3059


P671 Bronchiolitis Obliterans from Paraneoplastic Pemphigus Associated with Unicentric Castleman Disease/J. Koenitzer, K. Tsui, R.R. Rachem, P.R. Aguilar, St. Louis, MO, p.A3061

P672 Pulmonary Nodular Lymphoid Hyperplasia Associated with Multiple Sclerosis/D. Kay, D.R. Urbine, Gainesville, FL, p.A3062

P673 Unusual Presentation of IgG4 Related Disease/K. Patel, B.E. DiSilvio, O.A. Bajwa, Pittsburgh, PA, p.A3063


P675 Diffuse Alveolar Hemorrhage in ANCA-Negative Pauci-Immune Crescentic Glomerulonephritis: A Rare Case Report/Y. Eslaamizaad, K. Schaphorst, P. Almalouf, Mobile, AL, p.A3065


P677 Why Won’t this Pneumonia Go Away/L.A. Benninger, R.G. Valentin, I. Faruqi, Gainesville, FL, p.A3067

P679  Pulmonary Arteritis Mimicking Recurrent Pulmonary Embolism in a Patient with Bechet’s Disease/T. Plush, Philadelphia, PA, p.A3069


P681  A Case of Sarcoidosis with Symptomatic Pleural Effusion/A. Ammar, J. Coleman, R. Garcia-Pacheco, Orlando, FL, p.A3071

Facilitator:  R. Hallowell, MD, Boston, MA


P683  Granulomatosis with Polyangiitis in a Patient with Non Specific Systemic Signs/R. Samannan, Z. Smith, J. Kedissi, Oklahoma City, OK, p.A3074


P686  The Other “Baby Lung”: Shrinking Lung Syndrome in the Absence of Confirmed Connective Tissue Disease/C. Brehm, J.M. Bishop, K. Richardson, D. LoVerde, Winston-Salem, NC, p.A3076

P687  A Bad Case of Rheumatoid Arthritis: From Cavitative Nodule to Bronchopleural Fistula/N. Solanki, H.D. Montenegro, Cleveland, OH, p.A3077


P690  Pyoderma Gangrenosum as the Initial Presentation of Granulomatosis with Polyangiitis/S. Mayo, B.K. Patibandla, B. Moulton, Portland, OR, p.A3086

P691  Multiorgan Autoimmune Paraneoplastic Syndrome: Constrictive Bronchiolitis Associated with Paraneoplastic Pemphigus in Follicular Lymphoma/M.P. Caicedo, D. Cañon, C.S. Leib, Cali, Colombia, p.A3089

P692  Pyoderma Gangrenosum as the Initial Presentation of a Patient with Bechet’s Disease/K. Lam, Stanford, CA, p.A3074

P693  Pulmonary Arteritis Mimicking Recurrent Pulmonary Embolism in a Patient with Bechet's Disease/K. Lam, Stanford, CA, p.A3074

P694  Increased Peribronchiolar and Perivascular Cysteine Protease Activity Is Associated with Bronchiolitis Obliterans Syndrome/ C. Morrone, N.F. Smirnova, N. Kneidinger, M. Mann, H.B. Schiller, O. Eickelberg, A.O. Yildirim, Munich, Germany, p.A3095

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
P1354 Untargeted Metabolomics Analysis Identifies Novel Biomarkers for Pulmonary Function in Multi-Ethnic Populations/B. Yu, C. Flexeder, A. Wyss, K.E. North, E. Boerwinkle, H. Schulz, S. London, Houston, TX, p.A3121


P1358 The Role of Measuring Fractional Exhaled Nitric Oxide in Chronic Obstructive Pulmonary Disease Patients with Frequent Exacerbations/M. Howsare, A. Bhatt, R. Cavallazzi, H.L. Rivas-Perez, Louisville, KY, p.A3126


P1361 Persistent Eosinophilia Is Associated with Increased Chronic Obstructive Pulmonary Disease Exacerbations/W. Cheung, G. Hamad, M.G. Crooks, A.H. Morice, Cottingham, United Kingdom, p.A3129

P1362 Low Concentrations of 25-Hydroxyvitamin D and Long-Term Prognosis of COPD: A Prospective Cohort Study/Y. Colak, G. Faer, S. Afzal, B.G. Norstedgaard, Herlev, Denmark, p.A3130


Facilitator: I.D. Pavord, MD, Oxford, United Kingdom


P1367 Prospective Evaluation of Algorithms Based on Blood Biomarkers as Guides for COPD Assessment and Risk Stratification/B. Hansen, G.B. Diette, C. Hanson, A. Fawzy, A. Koch, N. Putcha, N.N. Hansel, Baltimore, MD, p.A3139


Facilitator: J.M. Bon, MD, MS, Pittsburgh, PA


P1371 Association of Omega-3 and Omega-6 Fatty Acid Intake with Plasma Acetyl-Proline-Glycine-Proline (AcPGP) and COPD Characteristics and Outcomes of COPD Patients with Blood Eosinophils ≥50 Cells/µL Who Continue to Exacerbate Whilst Treated with Multiple Inhaler Triple Therapy/H. Müllerová, D. Galkin, F.C. Albers, S.H. Landis, W.H. Meeraus, Uxbridge, United Kingdom, p.A3137

P1372 Identifying Populations with Severe COPD and Eosinophil Counts ≥150 Cells/µL/H. Müllerová, E. Simard, G. Mu, B. Hahn, Uxbridge, United Kingdom, p.A3140

P1373 Association of Serum Uric Acid Levels and Outcomes of Patients with Chronic Obstructive Pulmonary Disease/J.R.T. Galamay, T.S. De Guia, F.G. Ayuyao, M.E. Limpin, Quezon City, Philippines, p.A3141
P738 Removal of Endobronchial Endodontics Equipments with the Self Expanding Metallic Stent (SEMS) and Tracheal

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER

Area G (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion

12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: M. Weir, MBChB, Philadelphia, PA


P738 Removal of Endobronchial Endodontics Equipments with the Help of Flexible Videobronchoscope; Single Centre Experience Catering to Rural and Tribal Population of Central India/D. Muthreja, R. Swarnakar, A. Sontakke, Nagpur, India, p.A3143

P739 Recurrent Bilateral Chylothorax in a Patient with Malignant Mesothelioma/S. Brahmandam, G. Hayes, Dayton, OH, p.A3144


P741 Indwelling Pleural Catheter Track Metastasis/A.H. Alraiyes, M. Elinfai, W.S. Jaber, North Chicago, IL, p.A3146


P743 A Recurrent Extramedullary Hematopoietic-Related Pleural Effusion Managed with an Indwelling Pleural Catheter/D. Herman, J.N. Allen, Columbus, OH, p.A3148


Facilitator: R. Semaan, MD, Pittsburgh, PA


P747 Hemorrhage in a Patient Undergoing Bronchial Thermooplasty/M. Patel, J. Thomas, Rancho Mirage, CA, p.A3152

P748 Multi-Modality Management of a Lone Mediastinal Scleroses Presenting as an Extremely Rare Case of Chylothorax/K. Hersi, A. Girdhar, S. Afshar-Imani, Y. Sangwan, Delmar, MD, p.A3153


P752 Make the Definitive Diagnosis: The Importance of Pleural Biopsy in Diagnosing Nonmalignant Pleural Effusions in Cancer Patients/K. Bakhsh, A. Borah, E. Abramian, Philadelphia, PA, p.A3157

Facilitator: B.G. Harvey, MD, New York, NY


P755 Mucus Ball Formation and Pneumomediastinum, an Unusual Complication of Trans-Tracheal Oxygen Catheter (TTO) Placement/A. Shari, R. Zein, A.D. Duder, M. Zalt, Detroit, MI, p.A3160

P756 Critical Care Endobronchial Ultrasound Bronchoscopy (EUS-B) on 100% FiO2/P.H. Patel, A. Krvavac, V. Kanchustambaham, S. Patolia, St. Louis, MO, p.A3161

P757 Bronchial Dieulafoy’s Disease and Mediastinal Arteriovenous Malformation/A.Z.X. Foo, A. Hsu, Clayton, Australia, p.A3162

P758 Early Stent Removal Using Topical Mitomycin C in Patients with Bronchial Stenosis/C. Kim, Y. Ko, H.-S. Nam, G.M. Seong, Jeju-si, Korea, Republic of, p.A3163


Facilitator: G.Z. Cheng, MD, PhD, Durham, NC


P762 Veno-Venous Extracorporeal Membrane Oxygenation for Severe Tracheal Stenosis Related Acute Respiratory Failure: Preventing a Fatal Outcome/M. Moopanar, R. Madansein, Durban, South Africa, p.A3167

P763 Using EBUS to Sample Pulmonary Artery Tumors/M. Mallegos, K. Haas, Chicago, IL, p.A3168

P764 Early Stent Removal Using Topical Mitomycin C in Patients with Bronchial Stenosis/C. Kim, Y. Ko, H.-S. Nam, G.M. Seong, Jeju-si, Korea, Republic of, p.A3163


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
P766 Winning a Battle, Losing the War: A Case of Bronchoscopic Treatment of Endoluminal Squamous Cell Carcinoma/A. Badwan, Augusta, ME, p.A3171


P768 Extranodal Natural Killer/T Cell Lymphoma, Nasal Type: A Rare Pulmonary Presentation/J. Phillips, S. Thakore, N.A. Ninan, A. Chichra, New Orleans, LA, p.A3173

Facilitator: J. Akulian, MD, MPH, Chapel Hill, NC


P770 Mediastinal Abscess Following Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration: A Rare but Serious Complication/W.S. Naji, P. Hegde, Fresno, CA, p.A3175

P771 Bypassing the Stent Trial in Tracheobronchomalacia/S. Niedermeyer, J.B. Smith, G.Z. Cheng, Durham, NC, p.A3176

P772 Chest Wall Abscess Ruptures into Post-Radiation Bulla Creating Multiple Bronchopleural Fistulas/M. Hagner, A.A. Zander, S. Benzaquen, Cincinnati, OH, p.A3177


Facilitator: W.A. Bulman, MD, New York, NY

P777 Long Term Efficacy of Radio Frequency Ablation for Superficial Lesions of the Tracheobronchial Tree/C. Steppert, Bayreuth, Germany, p.A3182


P779 A Rare Case of Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia Diagnosed with Transbronchial Lung Cryobiopsy/Z.G. Swank, A.A. Aragaki Nakahodo, D. Zander, S. Benzaquen, Cincinnati, OH, p.A3184

P780 Palliation of an Unusual Fixed Airway Obstruction/J. Harvey, G.E. Abraham, Jackson, MS, p.A3185

P781 A Case of Posterior Mediastinal Hematoma After a Traumatic Fall/A. Subramanian, B. Giri, R.J. Long, Temple, TX, p.A3186

P782 BAPE, a Rare Cause of Exudate Effusion/E. Sherman, A. Nepal, O. Chaudhary, G. Trikha, Syracuse, NY, p.A3187

P783 Urinothorax: A Rare Complication of Percutaneous Nephrostolithotomy/M.J. Miles, B. Styssy, J.N. Gonzales, Augusta, GA, p.A3188

P784 A 64 Year Old Woman with a Painful Anterior Chest Wall Mass/T.J. Sjulin, D.D. Nettlow, R.J. Walter, Fort Sam Houston, TX, p.A3189

THEMATIC POSTER SESSION

B38 ISSUES IN UNDERSTANDING AND MANAGING COUGH

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER

Area G (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators: S.P. Duffy, MD, Philadelphia, PA
A.A. Petrov, MD, Pittsburgh, PA


P790 The Multidimensional Cough Index (MCI): a New Tool to Evaluate Patients with Cough/J. Baddini-Martinez, T. Chinarelli, V. Cardamoni, I. A. Bricoreli, A. Araújo, Ribeirão Preto, Brazil, p.A3192

P791 Bronchial Provocation Test with Inhaled Mannitol to Identify Cough Sensitivity in Patients with Cough/J. D. Brannan, C. Lake, K. H. Wong, H. O. Koska, New Lambton, Australia, p.A3193


P793 Using Bronchial Biopsies and Cultures to Improve the Diagnostic Yield of Bronchoscopy for Chronic Unexplained Cough/M. Heching, B. Pertsov, D. Rosengarten, A. Unterman, M. R. Kramer, Petach Tikva, Israel, p.A3195

P794 The Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Propolis and N-Acetylcysteine Compared to Placebo in Adults in Acute Condition with Sputum Production/D. Zujovic, V. Zugic, Belgrade, Serbia, p.A3196

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
B39 PLEURAL DISEASE: CASE REPORTS I
9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER
Area G (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.
Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators
Facilitator: N. Patel, MD, New York, NY


P801 An Exudative Pleural Effusion in Congestive Heart Failure: Time to Broaden the Differential/ B. Seth, S. Belok, F. Schembri, Boston, MA, p.A3200


P803 Pneumothorax as a Complication of Septic Pulmonary Emboli with Tricuspid Valve Endocarditis/D. Chen, Louisville, KY, p.A3202

P804 An Exudative Urinothorax with Low Creatinine and Low pH/N. Maniar, H. Karnib, B.A. Jali, H.L. Rivas-Perez, Louisville, KY, p.A3203


Facilitator: B. Quon, MD, MBA, Vancouver, Canada

P806 Rare Cause of Recurrent Unilateral Pleural Effusion/A. Ganesh, S. Behera, Wheeling, WV, p.A3205

P807 Chylothorax: The NTM Way!/M.A. Saeed, V.B. Wookey, J.D. Dickinson, Omaha, NE, p.A3206

P808 A Rare Case of Disseminated Pulmonary Streplococcus Constellatus Infection in an Immunocompetent Host with No Risk Factors/A. Fried, A. Rahma, M. Ali, J. Baskaran, R. Vivekanandan, Omaha, NE, p.A3207

P809 A Rare Case of Thoracic Endometriosis Presenting with Hemoptoemthorax/X. Yang, D. Steiger, L. Miyakawa, J. Filopei, New York, NY, p.A3208

P810 Birt Hogg Dube Syndrome - A Rare Cause of Recurrent Pneumothorax/V. Jaganathan, S. Subramanian, K. Bharath, S. Chellamuthu, Coimbatore, India, p.A3209

P811 Catamenial Hemothorax a Rare Cause of Recurrent Pleural Effusion/Y. Debeilla, V. Arunthari, M.M. Johnson, C. Vytlacil, B. Colaco, Jacksonville, FL, p.A3210


Facilitator: W. Shapiro, MD, Philadelphia, PA

P815 But It Is Not Empyema/V. Sharma, H. Li, M.T. Watanabe-Tejada, J. Bailitz, Chicago, IL, p.A3214


Facilitator: C. Riley, MD, Pittsburgh, PA

P820 Recurrent Pneumothorax in a Woman of Reproductive Age/D.J.O. Rillera, R.-J.R. Guarin, E.V. Tamayo, P.M.P. Rozul, N. Bambalan, Las Piñas City, Philippines, p.A3219

P821 Case of Post-Pericardiotomy (Dressler’s) Syndrome After a Thymectomy for Myasthenia Gravis/A. Syed, S. Velani, A. Karim, B.P. Young, Cleveland, OH, p.A3220


P824 Massive Hemoptysis as a Complication of Bedside Thoracentesis/R. Masrourjeh, B. Alencherry, Cleveland, OH, p.A3223


P826 Fungus Among Us: A Rare Case of Infected Chylothorax/N. Fitzpatrick, Hershey, PA, p.A3225

Facilitator: J.K. O'Brien, MD, Denver, CO

P828  Primary Effusion Lymphoma Masquerading as a Complicated Pleural Infection/B.D. Salguero, A. Shujaat, New York, NY, p.A3227


P832  Delayed Presentation of Occult Secondary Pneumothorax After Rear-End Collision Without Injury/C. Chan, P. Nystrom, Dayton, OH, p.A3231

P833  Rare Diagnosis of Myelomatous Pleural Effusions in Kappa-Light Chain Multiple Myeloma/K.I. Aronson, S.A. Ely, A. Sanders, New York, NY, p.A3232

Facilitator: K.V. Shenoy, MD, Philadelphia, PA

P834  Recurrent Pleural Effusion 39 Years After Radiation Therapy/V. Thapak, J. Wining er, Raleigh, NC, p.A3233

P835  Rare Presentation of a Rare Disease/A. Fadda, J.W.S. Mand, Phoenix, AZ, p.A3234


P837  A Rare Case of Tension Hydro pneumothorax from Disseminated Endometriosis/R. Cipriano, J. Chowdhury, Philadelphia, PA, p.A3236


Facilitator: I. Barbash, MD, Pittsburgh, PA


P841  Misleading Transudative Pleural Effusion in Heart Failure Patient/V. Thapak, J. Wining er, Raleigh, NC, p.A3240


P843  Recurrent Pleural Effusion: A Rare Manifestation of Sarcoidosis/D. Zhang, H.J. Patel, Dallas, TX, p.A3242

P844  Pancreato pleural Fistula: An Obscure Cause of Right-Sided Pleural Effusion/R.A.D. Wilson, H.R. Sequeira, R. Scatena, Norwalk, CT, p.A3243


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
P1385 Pre-COPD - A Clinical Entity/P. Sharma, N. Khan, Pittsburgh, PA, p.A3255


P1387 An Effective Diagnostic Model of ACO in China/A. Zhou, P. Chen, Y. Chen, Changsha, China, p.A3257

P1388 The Association Between Epworth Sleepiness Score (ESS) and STOP-BANG Questionnaire in COPD Patients/A. Alraje, Y. Aldabayyan, B. Adebaio, K. Akinlabi, S. Mansell, S. Mandal, M. Lipman, J. Hurst, London, United Kingdom, p.A3258

Facilitator: M.G. Foreman, MD, MS, Atlanta, GA

P1389 Inadequate Cardiovascular Risk Factor Control in COPD Patients/H.M. Lee, Irvine, CA, p.A3259


P1393 Patients with Chronic Obstructive Pulmonary Disease Have Increased Risk of Developing Traumatic Brain Injury/T.-H. Huang, Tainain, Taiwan, p.A3263


Facilitator: D.A. Mahler, MD, Hanover, NH


P1399 Effects of Roflumilast on Re-hospitalization and Mortality in Patients Hospitalized with a COPD Exacerbation/N. Marchetti, M.R. Jacobs, H. Zhao, G.J. Criner, Philadelphia, PA, p.A7732

P1400 New Opportunities for Monitoring Patients with Bronchiectasis/G. Ignatova, V. Antonov, Chelyabinsk, Russian Federation, p.A7733

**THEMATIC POSTER SESSION**

**B41 CRITICAL CARE: LOST IN THE FLOOD - FLUIDS, MONITORING, AND MANAGEMENT OF SHOCK**

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER

Area E (Hall A-B2, Ground Level)

**Viewing:** Posters will be on display for entire session.

**Discussion:** 11:15-12:00: authors will be present for discussion. 12:00-1:00: authors will be present for discussion with assigned facilitators

**Facilitators:** T.W. Rice, MD, MSc, Nashville, TN
J.-T.T. Chen, MD, Bronx, NY


**P433 Association Between Intravenous Fluid Administration and Biomarker Trajectory During Prehospital Care/E. Brant, J. Kennedy, C. Callaway, C. Martin-Gill, D. Yealy, D.C. Angus, C.W. Seymour, Pittsburgh, PA, p.A3270

**P434 Readily Available Clinical Metrics Have Moderate Discriminatory Ability for Hemodynamic Worsening in Patients with Persistent Septic Shock/F. Farooq, F.M. Celestin, M. Mullapudi, S. Khalil, L.L. Price, P. LaCamera, Boston, MA, p.A3271

**P435 Ultrasound and Clinical Hemodynamic Assessment of the Critically Ill Patient/V. Sharma, R. Gueret, J. Bailitz, A. Tulaimat, Chicago, IL, p.A3272

P437 Noninvasive Cardiac Output Monitoring in Critically Ill Adults: A Comparison of Bioreactance (NICOM™) with Transthoracic Echocardiography/M. Abdulmahdi, V. Amaral, A. Skaanland, P. Garcia, Baltimore, MD, p.A3274


P439 Comparing Cardiac Indices Using Non-Invasive Finger-Cuff and Arterial Pulse Contour Analysis in the Medical ICU/B.A. Jalili, J. Guardiola, R. Cavallazzi, Louisville, KY, p.A3276


P442 CRITICAL CARE: THE FEVER - INFECTIONS IN THE ICU

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER

Area E (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators: G.B. Allen, MD, Burlington, VT
F.E. Arancibia, MD, Santiago, Chile

P443 High Fever: Etiology, Demographics, and Outcomes/A. Pearce, R.E. Sell, San Diego, CA, p.A3279


P445 Procalcitonin for Predicting Recurrence in Culture-Negative Ventilator Associated Pneumonia/Y. T.H. Hoang, Ho Chi Minh City, Viet Nam, p.A3281


P448 Multifocal Reversed Halo Sign Indicates Pulmonary Involvement of Klebsiella Pneumonia Blood Stream Infection/X. Zhan, Z. Tong, X. Zhai, Beijing, China, p.A3284


P450 Invasive Aspergillosis Fumigatus in Immunocompetent Host Complicating Influenza B Infection/A. Mittal, R.G. Sangani, M. Poling, Morgantown, WV, p.A3286


Facilitator: J.C. Deng, MS, MD, Ann Arbor, MI


P453 Antimicrobial Use in Intensive Care Units Across Ontario, Canada: A Population-Based Study/E. Lee, M. Steinberg, C.M. Bell, M.E. Detsky, A.M. Morris, Toronto, Canada, p.A3289


P455 The Treatment of Pneumonia at a VA MICU/W. Rodriguez, J. Torres-Luna, J. Ramos-Rossy, San Juan, PR, p.A3291


P457 Clinical Experience with Telavancin for the Treatment of Monomicrobial Staphylococcus Aureus Lower Respiratory Tract Infections in Patients: Preliminary Results from the Telavancin Observational Use Registry (TOUR™)/J.C. Deng, MS, MD, Ann Arbor, MI, p.A3293

P458 Pneumonia Severity Index Correlates with High RAPID Category Pleural Effusion in the Critically Ill with Pneumonia/H. Li, M.T. Watanabe, J. Rodriguez, S. Sahni, V. Sharma, Chicago, IL, p.A3294

### THEMATIC POSTER SESSION

**B43**  
**CRITICAL CARE: I STILL HAVEN’T FOUND WHAT I'M LOOKING FOR - IDENTIFYING AND MANAGING SEPSIS**

**9:15 a.m. - 4:15 p.m.**  
**SAN DIEGO CONVENTION CENTER**  
**Area E (Hall A-B2, Ground Level)**

**Viewing:** Posters will be on display for entire session.

**Discussion:** 11:15-12:00: authors will be present for individual discussion  
12:00-1:00: authors will be present for discussion with assigned facilitators

**Facilitators:**  
T.S. Valley, MD, MSc, Ann Arbor, MI  
G.L. Anesi, MD, MSCE, MBE, Philadelphia, PA

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>P463</td>
<td>Relationships Among SIRS, qSOFA, and Sepsis-2 or Sepsis-3 Organ Dysfunction in Emergency Department Patients with Suspected Infection</td>
<td>S. Parashar, K. Lembke, S.P. Taylor, Charlotte, NC, p.A3298</td>
<td>9:15 a.m. - 4:15 p.m.</td>
</tr>
<tr>
<td>P465</td>
<td>Updated Validation of a Method to Identify Immunocompromised Patients with Severe Sepsis Utilizing ICD 10 Codes</td>
<td>N. Raya, J.A. Greenberg, S.F. Hohmann, M.Z. David, Chicago, IL, p.A3300</td>
<td>9:15 a.m. - 4:15 p.m.</td>
</tr>
<tr>
<td>P466</td>
<td>1 Year After SEPSIS 3.0: Evaluating the Physicians’ Awareness and Knowledge of the New Definition</td>
<td>G. Kamel, S. Patolia, Z. Jamkhana, St. Louis, MO, p.A3301</td>
<td>9:15 a.m. - 4:15 p.m.</td>
</tr>
<tr>
<td>P468</td>
<td>Superiority of Apache IV Versus SOFA &amp; qSOFA in Predicting Mortality in Patients with Sepsis Admitted to the ICU</td>
<td>R. Patterson, A. Shakespeare, S.B. Tanner, K. Zolfaghari, J. Ettinger, E. Jimenez, H.D. White, A. Arroliga, S.A. Ghamande, Temple, TX, p.A3303</td>
<td>9:15 a.m. - 4:15 p.m.</td>
</tr>
</tbody>
</table>

**Facilitators:**  
C. Polito, MD, Atlanta, GA  
D.L. Hotchkin, MD, MSce, Portland, OR

**P471**  
**Severe Sepsis: Compliance with Protocol Based Fluid Resuscitation**  

**P472**  
**Severe Sepsis: Failure of Protocol-Based Fluid Therapy to Improve Mortality**  

**P473**  
**The Effect of Thiamine on Oxygen Consumption in the Critically Ill: A Randomized Controlled Trial**  
K.M. Berg, A. Grosssteiner, L. Andersen, M.W. Donnino, Boston, MA, p.A3308

**P474**  
**The Effect of Beta Agonist on Lactate Kinetics in Patients with Suspected Sepsis**  

**P475**  
**Sepsis: Age and Initial Lactate Level Affect Survival but Not Gender**  
R. Spector, S.A. Blau, West Islip, NY, p.A3310

**P476**  
**Platelet Parameters and Patient Outcomes in Bacteremic and Non-Bacteremic Sepsis**  
A. Bhatt, T. Mikorombindo, R. Cavallazzi, K. Eklund, Louisvile, KY, p.A3311

**P477**  
**A Risk-Factor Derived, Equation-Based Approach as a Predictor for Severe Sepsis/Septic Shock and Associated Clinical Outcomes**  
C. Willner, P.D. Bozyk, Royal Oak, MI, p.A3312

**P478**  
**△PCO2/△O2 Content as a Predictor of Morbidity and Mortality in Critically Ill Patients**  
B. Sakoul, H.A. Jaliwala, R.J. Bernardo, J.I. Keddissi, Oklahoma City, OK, p.A3313

**P479**  
**Time Is Toxin: Mitochondrial Dysfunction in Sepsis: A Systematic Review**  

**P480**  
**Bolus Administration of 20% Albumin Combines Hemodynamic Efficacy with Less Adverse Physiological Effects than Crystalloids or 4% Albumin**  
S.P. Taylor, Charlotte, NC, p.A3309

**P481**  
**Albumin 5% Compared to Ringer’s Lactate Reduces Lung and Kidney Damage in Experimental Acute Respiratory Distress Syndrome**  

**P482**  
**Monocyte Distribution Width, A Novel Indicator, Detects Sepsis in High Risk Patients Presenting to the Emergency Department**  

---

*The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.*
**THEMATIC POSTER SESSION**

**B44**  
**CRITICAL CARE: MY ACHY BREAKY**  
**HEART-CARDIAC ARREST, CARDIAC SURGERY,**  
**AND COMPLICATIONS OF THE HEART IN CRITICAL**  
**ILLNESS**

9:15 a.m. - 4:15 p.m.  
**SAN DIEGO CONVENTION CENTER**  
Area E (Hall A-B2, Ground Level)

**Viewing:** Posters will be on display for entire session.

**Discussion:** 11:15-12:00: authors will be present for individual discussion  
12:00-1:00: authors will be present for discussion with assigned facilitators

**Facilitators:**  
E.A. Vail, MD, MSc, New York, NY  
E. Fan, MD, PhD, Toronto, Canada

**P484**  

**P485**  
Heart Rate Variability: Can It Be Used as a Vital Sign in Critically III Monitored Patients?/G.L. Jones, M.V. Kamath, V. Patel, Hamilton, Canada, p.A3318

**P486**  
Commode Codes: Toilet Related Cardiac Arrest and Telemetry Monitoring/S. Tyagi, J.R. Beitler, R.E. Sell, San Diego, CA, p.A3319

**P487**  
Vasopressin During Resuscitation for In-Hospital Cardiac Arrest/L. Barnes, M.F. Odish, J. Abella, R.E. Sell, J.R. Beitler, San Diego, CA, p.A3320

**P488**  

**P489**  
Better Outcomes in Rural Emergency Rooms for Out-of-Hospital Cardiac Arrest/K. Kailasam, P.P. Patel, G.S. Thind, S. Sivsammye, Kalamazoo, MI, p.A3322

**P490**  

**P491**  

**P492**  
Evaluation of Therapeutic Hypothermia After Cardiac Arrest Due to Shockable and Non-Shockable Rhythm/Y.R. Ahmad, A. Elantably, S. Shah, E. Stevenson, Salem, MA, p.A3325

**P493**  
A Comparison of Cardiac Arrest Patients with and Without Anoxic Brain Injury at a Large University Hospital/C. Yan, K. Bush, R.J. White, M. Trayhan, M. Zand, C. Quill, Rochester, NY, p.A3326

**P494**  
THEMATIC POSTER SESSION

B45  CRITICAL CARE CASE REPORTS: ACID-BASE, ELECTROLYTES, ENDOCRINE, METABOLIC, AND RENAL ABNORMALITIES

9:15 a.m. - 4:15 p.m.  SAN DIEGO CONVENTION CENTER
Area K (Hall A-B2, Ground Level)

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Viewing: Posters will be on display for entire session.

Facilitators: P.B. Desai, MD, Philadelphia, PA
J. Ninan, MD, La Crosse, WI


P1132 Euglycemic Diabetic Ketoacidosis in a Patient on a SGLT-2 Inhibitor Presenting with Acute Pancreatitis/K. Badwal, T. Tariq, Kalamazoo, MI, p.A3340


P1134 Thyroid Storm Following Strangulation/R. Arciniegas Flores, M. Mirsaedi, Miami, FL, p.A3342


P1136 Intravenous Immune Globulin (IVIG) Administration to Successfully Treat Life-Threatening Ovarian Hyperstimulation Syndrome: A First Report/O. Rahman, H.M.S. Qursahi, R. Rani, A. Munir, K. Van Ryzin, M. Bruner, Indianapolis, IN, p.A3344

P1137 Nivolumab: Unusual Cause of Severe Type B Lactic Acidosis/B. Alkinj, K. Gopalratnam, J.S. Kwon, C. Winterbottom, Bridgeport, CT, p.A3345

P1138 Management of Extreme Hyperammonemia in a Patient with Cirrhosis and Renal Tubular Acidosis/K. Philip, V. Secasanu, J.W. Christman, Columbus, OH, p.A3346

P1139 Reversible Quadriplegia; Establishing the Diagnosis of Hypokalemie Periodic Paralysis/A. Mohamed, F. Kukkon, K. Manzoor, Pawtucket, RI, p.A3347


Facilitators: A. Montgomery-Yates, MD, Lexington, KY
G. Netzer, MD, Baltimore, MD

P1141 Acute Renal Failure Due to Pneumoperitoneum/J.C. Edelson, N. Huprikar, C.V. Edelson, M. Korscil, S.D. Deas, San Antonio, TX, p.A3349


P1145 Diffuse Alveolar Hemorrhage After a Nephrectomy... What’s the Association?/M. Ghobrial, A. Chowdhury, Cleveland, OH, p.A3353

P1146 An Unusual Case of Heroind Induced Central Diabetes Insipidus/H. Iftikhar, C. Zhang, J. Hehar, G. Nair, Royal Oak, MI, p.A3354

P1147 Severe Hyperammonemia Caused by Cryptococcal Meningitis/R. Masroujeh, C.V. Teba, Cleveland, OH, p.A3355


P1149 Inferior Vena Caval Filter Migration Causing Ileo-Caval Thrombosis, Bilateral Renal Vein Thrombosis and Acute Renal Failure/T. Bekker, G. George, Philadelphia, PA, p.A3357

P1150 Hyperammonemic Encephalopathy: A Late Complication of Ureterosigmoidostomy/M.M. Munawar, V. Kodadhal, S. Timberline, C. Karodeh, A. Thomas, Washington, DC, p.A3358

Facilitator: I. Peltan, MD, MSc, Murray, UT


P1152 Accidental Hypothermia: Nobody Is Dead Until Warm and Dead/R. Masroujeh, A. Pandit, A. Syed, Cleveland, OH, p.A3360


P1155 A Shocking Case of Spontaneous Carcinoid Crisis/D.-V. Nguyen, G.P. Marelich, Sacramento, CA, p.A3363

P1156 Septic Cavernous Sinus Thrombosis Complicating Diabetic Ketoacidosis/A.C. Miller, E. Charbek, R. Farhat, St. Louis, MO, p.A3364


P1158 Myxedema Coma Presenting as a Refractory Cardiac Arrest/F.A. Solorio, Y. Abdel-Aziz, Y. Yoon, Toledo, OH, p.A3366

P1159 Pregnancy Induced Thyroid Storm with Hepatic Dysfunction/M. Chopra, J.A. O’Hear, R. Garcia, Phoenix, AZ, p.A3367


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
A Rare Cause of Central Pontine Myelinolysis

High Osmolar Gap Unfigured

Purpura Fulminans with Refractory Hyperkalemia

An Extreme Case of Life Threatening Metabolic Acidosis and Pancreatic Mass Presenting with Diabetic Ketoacidosis in a Patient with Type 2 Diabetes Mellitus

Diabetic Ketoacidosis Masquerading as ST-Elevation Myocardial Infarction During Hurricane Irma

Development of Pyogenic Liver Abscess from Hematogenous Spread from Dental Abscess, Presenting as Diabetic Ketoacidosis

Diarrhoea and Vomiting Leading to Metformin Associated Lactic Acidosis: A Case Report

The Perfect Storm - An Unusual Case of Heat Stroke in a Young Male

Alcoholic Ketoacidosis: What pH Is the New Low?

An Extreme Case of Life Threatening Metabolic Acidosis and Diabetic Ketoacidosis

Purpura Fulminans with Refractory Hyperkalemia

High Osmolar Gap Unfigured

Pancreatic Mass Presenting with Diabetic Ketoacidosis in a Patient with Type 2 Diabetes Mellitus

A Rare Cause of Central Pontine Myelinolysis

CRITICAL CARE CASE REPORTS: HEMATOLOGY, ONCOLOGY, RHEUMATOLOGY, AND IMMUNOLOGY

9:15 a.m. - 4:15 p.m.

Area K (Hall A-B2, Ground Level)

B46

Crisis/D. Padmanabhan Menon, P.E. Lowman, Jacksonville, FL, p.A3381


Bilateral Pulmonary Nodules and Intravascular Pulmonary Histiocytosis: A Rare Presentation of Hemophagocytic Lymphohistiocytosis Secondary to Epstein-Barr Virus Infection/Y. Zayed, M. Osman, B. Khei, G. Bachuwa, Flint, MI, p.A3385


Successful Treatment of Hemophagocytic Lymphohistiocytosis Secondary to Ehrlichia Infection/R. Samannan, D.R. McCaffree, Oklahoma City, OK, p.A3388

Multi-Organ Failure with Hemophagocytic Lymphohistiocytosis Due to Coexistent Ehrlichia and Epstein-Barr Virus Infections/S. Patel, P. Denoux, A. Manohar, T. Boreseker, A.L. Fernandez, Tallahassee, FL, p.A3389

Hidden in Plain Sight: An Extremely Rare Case of Primary Adrenal Lymphoma Presenting as HLH Syndrome/K. Gandhi, A. McEvoy, M. Robison, D. Tannhill, Chesterfield, MO, p.A3390


Secondary Hemophagocytic Lymphohistiocytosis in AIDS Associated EBV+ Diffuse Large B-Cell Lymphoma/N. Lin, J.A. Hippensteel, A. Neumeier, Aurora, CO, p.A3392


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
P1190 A Bad Bite: Cat Bite as a Rare Cause of Thrombocytopenic Thrombotic Purpura (TTP)/K. Yashi, J.P.S. Virk, I.G. Amzuta, Syracuse, NY, p.A3397

P1191 In Hospital Spontaneous Splenic Rupture as the Diagnostic Presentation of a Hepatosplenic T Cell Lymphoma/J. Aponte, E. Jirru, K. Hawkins, New York, NY, p.A3398


Facilitator: S.M. Pastores, MD, New York, NY

P1193 Critical Crystals- A Case of Crystal Arthropathy Leading to ICU Admission/C. Shappell, L.M. Kimmig, Chicago, IL, p.A3400


P1195 Nebulized Tranexamic Acid/M. Abdelkader, L. Tudor, York, PA, p.A3402

P1196 Fat Embolism Syndrome: A Rare Complication of Sickle Cell Disease/M. Thorp, J.W. Leatherman, Minneapolis, MN, p.A3403

P1197 Eosinophilic Syndrome Presenting as Chronic Cough Progressing to Multisystem Organ Failure Successfully Treated with Mepulizomab/T. Tseng, E. Savilo, R. Suyyagh, Phoenix, AZ, p.A3404

P1198 Cardiac Lymphoma Presenting as Pericardial Effusion/A. Arjuna, M. Mody, P. Patel, T. Anandarangam, Newark, NJ, p.A3405

P1199 Atypical Presentation of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitides in a 71 Year Old African American/B. Ahmad, N. Ganta, F.T. Ogundipe, A. Thomas, Washington, DC, p.A3406

P1200 A Rare Case of Fatal Bilateral Leg Pain and Swelling/J. Laman, M. Mortagy, G. Kousourou, Kalamazoo, MI, p.A3407

P1201 Microscopic Polyangiitis Complicated Due to Mucormycosis/S. Poursahid, R. Lopez, D. Genin, Jamaica, NY, p.A3408

P1202 A Rare Case of Fatal Bilateral Leg Pain and Swelling/J. Laman, M. Mortagy, G. Kousourou, Kalamazoo, MI, p.A3407

P1201 Microscopic Polyangiitis Complicated Due to Mucormycosis/S. Poursahid, R. Lopez, D. Genin, Jamaica, NY, p.A3408

P1202 A Rare Case of Fatal Bilateral Leg Pain and Swelling/J. Laman, M. Mortagy, G. Kousourou, Kalamazoo, MI, p.A3407

P1203 “I’m Sick” How Sick? A Rare Presentation of Autoimmune Crisis/C. Dahn, H. Gandhi, T.T. Bellamkonda, Bronx, NY, p.A3410

P1204 Catastrophic Antiphospholipid Syndrome and Heparin Induced Thrombocytopenia After Pulmonary Vein Isolation Ablation/L. Khalid, T.B.D. Ferreira, O. Sheikh, J.J. Byrnes, Miami, FL, p.A3411

P1205 Everything’s Atypical About this Atypical Hemolytic Uremic Syndrome/F. Yousufi, S.N. Mahmood, Washington, DC, p.A3412


P1207 A Rare Case of Cutaneous Metastasis from Gastrointestinal Adenocarcinoma/K. Young, S. Fountain, G. Chu, Phoenix, AZ, p.A3414


P1210 Intravascular Large B-Cell Lymphoma: A Rare Lymphoma with Bewildering Clinical Manifestations/Y. Wakwuya, S.P. Malkoski, Aurora, CO, p.A3417

P1211 Primary Aortogastric Fistula Caused by Ulcerated Gastric Carcinoma Occurring 23 Years After Surgical Treatment for Esophageal Carcinoma/M. Li, S. Chen, W. Xie, Shenzhen, China, p.A3418

Facilitator: L.P. Voigt, MD, New York, NY

P1212 A Case of Suspected Metastatic Choriocarcinoma Versus Ectopic Beta-HCG Producing Adenocarcinoma Causing Acute Hypoxic Respiratory Distress and Thyroid Storm/J. Buono, S. Worah, Brooklyn, NY, p.A3419


P1214 Paroxysmal Nocturnal Hemoglobinuria Masquerading as a Vasculitis/J. Prest, M. Hsu, J. Lamb, C. Wright, W.G.G. Carlos, Indianapolis, IN, p.A3421

P1215 Multisystem Organ Failure from Cryoglobulinemia, Precipitated by Therapeutic/ S. Mucha, C. Sammaras, Cleveland, OH, p.A3422

P1216 A Critically Ill Postpartum Woman with Thrombotic Thrombocytopenic Purpura (TTP) Vs Hemolysis, Elevated Liver Enzymes, and Low Platelets Syndrome (HELLP)/R. Johnson-Paben, N. Lin, R.W. Vandivier, Aurora, CO, p.A3423


P1219 Successfully Treated Heparin Induced Thrombocytopenia with Intravenous Immunoglobulin/J. Keshavamurthy, Augusta, GA, p.A3426

P1220 A Rare Case of Thrombotic Thrombocytopenic Purpura Presenting as Non-ST Elevation Myocardial Infarction/A. Gheith, A. Abulsoaud, K. Satish, Little Rock, AR, p.A3427

B47 CRITICAL CARE CASE REPORTS: CARDIOVASCULAR DISEASES AND ECHOCARDIOGRAPHY

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER

Area K (Hall A-B2, Ground Level)
B48 CRITICAL CARE CASE REPORTS: STRAIGHT FROM THE HEART - CARDIOVASCULAR DISEASES IN THE ICU

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER
Area K (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators:
- P.L. Silva, PhD, Rio De Janeiro, Brazil
- M. Rahamian, MD, Bronx, NY

P1272 The Way to a Man’s Heart Shouldn’t Be Through His Esophagus/E. Landa, A. Pasha, R. Singh, K. Hipp, M. Machado, Southfield, MI, p.A3478


P1274 From Meth to Methylene Blue: A Unique Case of Vasopressor Refractory Shock/M. Chopra, N. Shamsid-Deen, R. Garcia-Orr, Phoenix, AZ, p.A3480


P1278 Hemothorax After Cardiac Catheterization/A. Rai, R. Radhakrishnan, D. Cardona, Salem, MA, p.A3484

P1279 Spontaneous Coronary Artery Dissection in the Postpartum Period: A Rare Phenomenon/A. Botsch, S.M. Khoncarly, N. Niraula, Akron, OH, p.A3485

P1280 A Case of Salmonella Enterica Aortitis with Saccular Aneurysm and Retroperitoneal Abscesses/A. Anandarangam, P.S. Patel, Newark, NJ, p.A3487

P1281 A Case of Esophageal Squamous Cell Carcinoma Presenting as Dysphagia Complicated by Cardiac Tamponade Secondary to Esophagopericardial Fistula/H. Nazir, K. Edebiri, S.V. Coleman, G. Petersen, A. Heidari, Orlando, FL, p.A3486

- E.M. Viglianti, MD, MPH, Ann Arbor, MI

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER

B49 OCCUPATIONAL EXPOSURES

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER

P1317 Tricuspid Regurgitation: Interference with Resuscitation in Critical Care Units?/J.P.S. Virk, K. Yashi, A. Shawkat, Syracuse, NY, p.A3523


MONDAY • MAY 21 173

THEMATIC POSTER SESSION

B50 COPD

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER

P1401 Chronic Respiratory Diseases in out of Hospital Sudden Death Victims/M. Mirzaei, G. Joodi, B.M. Bogle, R.J. Simpson, Chapel Hill, NC, p.A3542

P1402 Airflow Limitation Confers the Same Risk of Cardiovascular Death as Diabetes in High Risk Smokers in the NLST-ACRIN Sub-Study of the National Lung Screening Trial (N=10,054)/R.J. Hopkins, F. Duan, C. Chiles, G.D. Gamble, D. Aberle, R.P. Young, Auckland, New Zealand, p.A3543


P1405 Validity of Self-Reported Health Professional Diagnosed Chronic Obstructive Pulmonary Disease (COPD) - National

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.

P1406  Validity of the Global Physical Activity Questionnaire in Older Adults with Chronic Obstructive Pulmonary Disease/S. Gore, J. Blackwood, A. Goldberg, M.H. Huang, M. Shoemaker, Charleston, MA, p.A3547


Facilitator:  S.E. Hines, MD, MSPH, Baltimore, MD


P1412  Consequences of Community-Acquired Pneumonia (CAP) in Patients with Chronic Obstructive Pulmonary Disease (COPD)/C.B. Pasquale, J. Vietri, R. Choate, E. Malanga, K.D. Ford, A. McDaniel, R. Sato, Washington, DC, p.A3553

P1413  ED Visits, Discharges and Inpatient Admissions for COPD Exacerbation - Findings from the Nationwide Emergency Department Sample (NEDS) from 2006 to 2014/A. Agrawal, S. Sahni, A. Agarwal, D. Mehta, M. Peck, R. Sikachi, New Hyde Park, NY, p.A3554


P1417  Residential Air Quality and COPD Health Events/D.G. Dearborn, R.F. Silver, F. Jacono, K. Byrne, S. Greenberg, S. Debanne, O. Farhan, J. Mozes, J. McDonald, K. Loparo, Cleveland, OH, p.A3558


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
B52  BACTERIAL INFECTION CASE REPORTS

9:15 a.m. - 4:15 p.m.  SAN DIEGO CONVENTION CENTER
Area A (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.
Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

THEMATIC POSTER SESSION

B52  BACTERIAL INFECTION CASE REPORTS

9:15 a.m. - 4:15 p.m.  SAN DIEGO CONVENTION CENTER
Area A (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.
Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
P16  P. Mirabilis Pleural Empyema Secondary to a Staghorn Calculus in the Left Kidney/S.J. Patel, S. Holland, D. Fullerton, Crewe, United Kingdom, p.A3597
Facilitator: M.S. Niederman, MD, New York, NY

P17  Salmonella Empyema: A Rare Complication Associated with Immunocompromised State Resulting in Sepsis/A. Yanamadala, J. Portocarrero, A.M. Canelas, Berwyn, IL, p.A3598


P20  Legionella and Mycoplasma Pneumonia: Co-Incidence or Co-Infection?/L.N. Saladi, B. Zaidi, O.G. Toolsie, M. Adrish, Bronx, NY, p.A3601

P21  A Rare Case of Pneumonia Caused by Alcaligenes Faecalis Bacteria/S.Z. Junejo, S. Tuli, T. Traandafrescu, Jamaica, NY, p.A3602


P24  Blame the Fistula for the Pneumonia/M. Farokhi, M. Megally, J. Jolly, T.M. McGarry, M.E. Warshawsky, Queens, NY, p.A3605

Facilitator: J.D. Chalmers, MD, PhD, Dundee, United Kingdom

P26  An Interesting Case of Dyspnea: Recurrence of Disseminated Whipple’s Disease/J.P.S. Virk, K. Yashi, A. Ghimire, Syracuse, NY, p.A3607

P27  From Toe to Head! A Case of Disseminated Nocardiosis Presenting as Foot Drop/A.M. Pasha, P.K. Sinha, M. Ehtesham, Southfield, MI, p.A3608

P28  Development of Post-Coital Pneumatocele in a Patient Who Had Previously Undergone Thoracotomy for Total Decortication Due to Empyema/A.C. Boulos, J. Gordon, J. Petty, Pueblo, CO, p.A3609

P29  A Rare Presentation of Pulmonary Nocardiosis with Ruptured Necrotizing Subcarinal Node in HIV/N. Nakwan, Haytai, Thailand, p.A3610

P30  Acinetobacter Baumannii as a Cause of Community Acquired Pneumonia/F. Alghoula, A. Nayefh, N. Addasi, J.D. Parekh, M. Krishnan, T. Kassim, M. Reddy, Omaha, NE, p.A3611


P33  Late Onset Pneumonectomy Adenocarcinoma Recurrence Presenting as Empyema Necessitans/W. Rodriguez, D. Vazquez, A. Cordero-Gomez, J. Torres-Palacios, J. Casal, San Juan, PR, p.A3614
Facilitator: R. Menendez, MD, Valencia, Spain


P35  Empyema Causing Hemidiaphragmatic Depression/S. Joshi, S. Sitaula, M. Patel, A. Ghimire, Syracuse, NY, p.A3616

P36  ‘Kennel Cough’ in a Patient Following Orthotopic Heart Transplant/M. Naddour, M. Kalani, E. Biehler, Pittsburgh, PA, p.A3617

P37  Military Pneumonia as a Novel Radiological Manifestation of Q Fever/S. Couillard, M. Bélanger, N. Bouchard, Sherbrooke, Canada, p.A3618


P41  A Rare Case of Nocardia Pneumonia Presenting as Empyema Necessitans—The First Report of a Case of Burkholderia Cepacia Infection in an Immunocompetent Male Immunocompetent Male/J. Portocarrero, A.M. Canelas, Berwyn, IL, p.A3622

THEMATICAL POSTER SESSION

B53  ENHANCING PRACTICE ENVIRONMENTS, PATIENT SAFETY, AND OUTCOMES

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER
Area B (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: C.L. French, PhD, ANP-BC, Worcester, MA

P116  Preparing Graduate Nurses for the Psychological Stress and Trauma of Working as an Acute Care Bedside Nurse: Results of a National Survey/M. Mealer, K. Cochran, M. Moss, Aurora, CO, p.A3623

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
B54  CHRONIC DISORDERS: EVALUATION AND INTERVENTION

9:15 a.m. - 4:15 p.m.  SAN DIEGO CONVENTION CENTER
Area B (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.
Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators
Facilitator:  L.A. Matura, PhD, RN, Philadelphia, PA


P118  Assessment of Knowledge and Practices for Identifying Patients with Sepsis Among RNs and CNAs on a General Medical Floor in a Tertiary Care Center: A Pilot Study/A. Thakkar, P. Poojary, K. McKenna, R. Schneider, R. Ernest Jean, New York, NY, p.A3625


P120  Sepsis Screening in a Long-Term Care Hospital: Improving Timely Identification and Effective Treatment/J. Brock, G. D’Souza, D.R. Nelson, M.S. Hassenplug, Hyden, KY, p.A3627

P121  The Mechanical Ventilator Alarm Default Setting Project/P.R. Harris, S. Strickland, R. Zink, M.N. Flack, San Rafael, CA, p.A3628

Facilitator:  M.E. Corrigan, MSN, Portland, ME

P122  Do We Face a Facebook Problem? Use of Social Media Among Nurses and Impact on Patient Safety/A. Aiyer, S.R. Surani, B. Anderson, A. Suleman, S. Soomro, Corpus Christi, TX, p.A3629

P123  Ability to Predict Other Team Members’ Behaviors in ICU Teams Is Associated with Routine Implementation of a Complex Care Bundle in a Statewide Quality Collaborative/E. Boltey, T.J. Iwashyna, R.C. Hyzy, S. Watson, C. Pope, D.K. Costa, Ann Arbor, MI, p.A3630

P124  Use of High-Fidelity Simulation for Teaching Therapeutic Pronation to Nursing Staff/E. Solbes, K. Yoneda, Sacramento, CA, p.A3631


P126  Educational Initiative to Improve the Team-Based Care of Patients with IPF/E.R. Fernandez Perez, P. Zelarney, S. Thomas, D.A. Shoop, J.L. Munson, K.D. Johnson, M.E. Slem, S. Meadows, Denver, CO, p.A3633


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.

P551 Peripheral Airway Obstruction in Children with Congenital Diaphragmatic Hernia/H.M. Emanuel, Houston, TX, p.A3658


---

B55 PEDIATRIC CLINICAL STUDIES

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER

Area F (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: K. Lu, MD, Irvine, CA


P545 Disease Spectrum and Management of Children Admitted with Acute Respiratory Infection in Viet Nam/P. Nguyen, V. Nguyen, H. Truong, D. Tran, S. Graham, B. Marais, Da Nang, Viet Nam, p.A3652


Facilitator: P.A. Phinizy, MD, New York, NY


---

THEMATIC POSTER SESSION

B56 CYSTIC FIBROSIS

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER

Area F (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: J. Rayment, MD, MSc, Vancouver, Canada


P551 Peripheral Airway Obstruction in Children with Congenital Diaphragmatic Hernia/H.M. Emanuel, Houston, TX, p.A3658


---

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.

P562 Linkage of the Cystic Fibrosis Foundation Patient Registry (CFFPR) and Pediatric Health Information System (PHIS) Database/J. Cogen, M. Hall, D. Loeffler, A. Fink, Seattle, WA, p.A3667


Facilitator: A. Deschamp, MD, MS, Omaha, NE

P564 Total Cyanide in the Sputum of Cystic Fibrosis Patients During an Acute Exacerbation/D. Guck, N. Tubbs, D. Kim, P. Haouzi, Hershey, PA, p.A3669


P567 Comparison of Handheld to Conventional Spirometry in Pediatric Cystic Fibrosis/N. Avdimiretz, D. Wilson, Toronto, Canada, p.A3672


P569 Comparison of Nutritional Status, Lung Functions Between Amish and Non Amish Children with Cystic Fibrosis/R. Padman, D. Gilham, T. Laturner, Fort Wayne, IN, p.A3674

P570 Hispanics with Cystic Fibrosis Are More Likely to Acquire Pseudomonas Infection/M. McGarry, N.P. Ly, San Francisco, CA, p.A3675


Facilitator: S.E. Kirby, MD, Columbus, OH


P573 Correlation of Molecular-Level Markers with Clinical Outcomes in Cystic Fibrosis Via the CF-ABLE Score/O.J. McElvaney, D. Horan, C. Gunaratnam, E.P. Reeves, N.G. McElvaney, Dublin, Ireland, p.A3678


P575 THAM Improves Bacterial Killing in Human Cystic Fibrosis Airway Epithelial Cell Cultures/Z. Holliday, M. Abou Alaia, A. Pezzullo, I. Thornell, N. Gansemer, J. Zabner, D.A. Stoltz, Iowa City, IA, p.A3680

P576 Ahr Promotes Pseudomonas Aeruginosa-Induced Intracellular Infection in Bronchial Epithelial Cells/P. Bortolotti, E. Faure, J. Berube, C. Baglione, S. Rousseau, Montreal, Canada, p.A3681


THEMATIC POSTER SESSION

B58 WHO’S BAD: CASE REPORTS IN PULMONARY VASCULAR MEDICINE I

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER
Area J (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: T. Thenappan, MD, Minneapolis, MN


P1010 McConnell’s Sign Without Central PE in a Rare Case of Thrombotic Pulmonary Vasculopathy/A.T. Wickramarathne, R. Subramanian, Atlanta, GA, p.A3694


P1014 Metastatic Pulmonary Tumor Emboli Mimicking Chronic Thromboembolic Pulmonary Hypertension/A. Vaidy, P.R. Forfia, C. Dass, A. Vaidya, Philadelphia, PA, p.A3698


P1016 From Ovarian Coils to Pulmonary Emboli/J. Tonkin, B. Madden, London, United Kingdom, p.A3700

P1017 Hughes-Stovin Syndrome and Chronic Thromboembolic Pulmonary Hypertension: A Case Report/J.D. Joel, D.G. Papamatheakis, M.M. Madani, N.H. Kim, La Jolla, CA, p.A3701

P1018 Pulmonary Hypertension Associated with Idiopathic Hilar Fibrosis Successfully Treated with Calcium Channel Blocker/S.A. Suliman, J.S. Smith, K. El-Kersh, Louisville, KY, p.A3702

Facilitator: C. Kholdani, MD, Stanford, CA


P1020 Metastatic Renal Cell Carcinoma Mimicking Chronic Thromboembolic Pulmonary Hypertension/G. Senyel, D.G. Papamatheakis, W.R. Auger, V.G. Prentorius, T.M. Fernandes, La Jolla, CA, p.A3704

P1021 Extracorporeal Membrane Oxygenation (ECMO) as a Bridge to Recovery (BTR) in Incidents Adult Patients with Severe Pulmonary Hypertension (PH) and Right Heart Failure: A Single Center Case Series/S. Sultan, S. Savajiyani, T.N. Hodges, R. Alalawi, R. Saggar, Phoenix, AZ, p.A3705

P1022 An Unusual Indication for Congenital Prothrombin Deficiency Associated with Thrombosis: A Report of Two Members in a Congenital Prothrombin Deficient Family/L. Wang, R. Han, J. Liu, S. Gong, Q. Zhao, Shanghai, China, p.A3706


P1024 High Output Cardiac Failure Associated with the Use of Riociguat for Pulmonary Hypertension/K.J. Cruz Morel, K. Lam, A. Sweatt, C. Kholdani, Y.K. Sung, Stanford, CA, p.A3708

P1025 Bronchopulmonary-Coronary Arterial Fistulas in Chronic Thromboembolic Pulmonary Hypertension: Series of 3 Cases/M. Pessi, E.P. Oliveira, D. Calderaro, C. Fernandes, C. Jardim, R. Souza, Sao Paulo, Brazil, p.A3709


P1027 Morphing Physiology: A Case of Occult Systemic Sclerosis Sine Scleroderma Associated Pulmonary Hypertension/N. Ruopp, H.W. Farber, Boston, MA, p.A3711

P1028 Ketogenic Diet in Group 1 Pulmonary Hypertension Patient/J. Dyer, S. Wolver, D. Grinnan, Richmond, VA, p.A3712

Facilitator: S. Pugliese, MD, Philadelphia, PA


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.


P1034 Rare Case of Metastatic Leiomyosarcoma Complicated by Pulmonary Arteriovenous Malformation/M. Patel, G. Trikha, Syracuse, NY, p.A3718


P1037 Opioid Epidemic and Pulmonary Hypertension, What Do They Have in Common?/M. Berrou, M. Chaker, P. Almalouf, Mobile, AL, p.A3721


P1039 P.E. or Not P.E: A Rare Case of Pulmonary Artery Stump A. Trammell, MD, Atlanta, GA

Facilitator:

P1040 Acute Cor Pulmonale and Cardiovascular Collapse Following Illicit Cosmetic Silicone Injections/C. Graziani, J. Hsieh, D. Smith, W. Neveu, B. Demoss, C. Grodzin, Atlanta, GA, p.A3723


P1043 My Baby Gave Me Hypoxemia/D. Aponte, M.A. Farinacci Vilaro, M.J. Cruz Caliz, K.X. Rivera, J.R. Adorno, San Juan, PR, p.A3726

P1044 An Unusual Cause of Massive Pulmonary Embolism/S. Whealon, E.B. Friedman, Wynnewood, PA, p.A3727

P1045 In-Situ Pulmonary Artery Thrombosis in a Patient with Pulmonary Arterial Hypertension Due to Sinus Venosus Atrial Septal Defect/A. Wong, A.S. Witkin, J.M. Rodriguez-Lopez, R.N. Channick, Boston, MA, p.A3728


Facilitator:

P1048 An Unusual Cause of Hypoxemia/in History Lies All the Secrets/I.A.Z. Rasheed, M. Shahzadi, L.N. Gerolemon, V.P. Vasudevan, F. Arjomand, Brooklyn, NY, p.A3731

Facilitator:


P1053 Knockout of TRPC4 Reduces Cytosolic Ca2+ Transients and Delays Store-Operated Ca2+ Entry/N. Xu, C.M. Francis, M.T. Lin, T. Stevens, Mobile, AL, p.A3736


Facilitator:

P1057 Inhibition of YAP1 Via Verteporfin Attenuates Hypoxia- or Hypoxia Sugen Mediated Pulmonary Hypertension and Pulmonary Vascular Remodeling in Rodents/J. Chen, S. Zhao, Y. Wang, N. Felesena, L. Huang, R.F. Machado, Chicago, IL, p.A3740

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.

ATS 2018 • San Diego, CA

P1059 Increased Circulating miR-596 Levels Is Associated with Poor Survival in Idiopathic Pulmonary Arterial Hypertension/P. Yuan, L. Jimin, Shanghai, China, p.A3741


P1069 Hemodynamics Changes in the Progression of Pulmonary Arterial Hypertension in Two Animal Models/D. Valdez-Jasso, D. Velez-Rendon, La Jolla, CA, p.A3752


P1072 Association of Circulating miR-144-3p and miR-574-5p with Hemodynamics in Patients with Idiopathic Pulmonary Arterial Hypertension/P. Yuan, Shanghai, China, p.A3755


P1077 Potential Role for Adipose-Derived 16α-Hydroxyestrone in the Development of Experimental Pulmonary Hypertension/K. Mair, A.D. Henry, K.Y. Harvey, M. Nilsen, M.R. MacLean, Glasgow, United Kingdom, p.A3760


THEMATIC POSTER SESSION

B60 HERE WE CLOT AGAIN: CLINICAL STUDIES IN PE AND CTEPH

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER

Area J (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators: G.A. Heresi, MD, Cleveland, OH
T.S. de Guia, MD, Quezon City, Philippines


### P1109 Postoperative Clinical Factors Associated with Long-Term Prognosis Following Pulmonary Endarterectomy in Patients with Chronic Thromboembolic Pulmonary Hypertension/D. Aoyama, S. Fukui, T. Ogo, R. Asano, N. Konagai, J. Ueda, A. Tsuji, T. Arakawa, M. Nakanishi, K. Uehara, H. Sasaki, H. Matsuda, S. Yasuda, Suita City, Osaka, Japan, p.A3791


### P1112 Clinical Features of Pulmonary Tumor Thrombosis Microangiopathy: Analysis of 149 Cases in Literature/R. Godbole, N. Kamangar, Orange, CA, p.A3794

---

### B61 EPITHELIAL CELL BIOLOGY IN RESPIRATORY DISEASE

**Area H (Hall A-B2, Ground Level)**

**9:15 a.m. - 4:15 p.m.**

**SUNDEO CONVENTION CENTER**

**Thematic Poster Session**

**B61**

<table>
<thead>
<tr>
<th><strong>Poster</strong></th>
<th><strong>Title</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>P882</strong></td>
<td>Mechanisms for Bone Marrow Multipotent Stem Cells to Restore Alveolar Fluid Clearance Via Epithelial Sodium Channels in Lung Progenitor Cells/J. Chang, Shenyang, China, p.A3795</td>
</tr>
<tr>
<td><strong>P883</strong></td>
<td>Hypercapnia Decreases Na,K-ATPase β-Subunit Cell Surface Abundance by Inducing ER Retention of the Protein in Alveolar Epithelial Cells/V. Kryvenko, W. Seeger, I. Vadasz, Giessen, Germany, p.A3796</td>
</tr>
<tr>
<td><strong>P884</strong></td>
<td>MMP28 Is upregulated in Idiopathic Pulmonary Fibrosis (IPF) Epithelium and Is a Promising Biomarker to Distinguish IPF from Non-IPF Patients/M. Maldonado, I. Buendia, V. Vicens Zygmunt, L. Planas, M. Molina Molina, M. Selman, A. Pardo, Mexico City, Mexico, p.A3797</td>
</tr>
<tr>
<td><strong>P885</strong></td>
<td>Epithelial TIK-1 Potassium Channels Protect Alveolar Barrier Function/A. Schwingshackl, B. Lopez, B. Teng, C.M. Waters, Los Angeles, CA, p.A3798</td>
</tr>
</tbody>
</table>

**Facilitator:** J.L. Hook, MD, New York, NY

**Discussion:** 11:15-12:00: posters will be available for individual discussion. 12:00-1:00: authors will be present for discussion with assigned facilitators.

**Viewing:** Posters will be on display for the entire session.

---

**The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the [online program itinerary](https://example.com).**

**ATS 2018 • San Diego, CA**

P902 Intermittent Cigarette Smoke Promotes Proliferation of Alveolar Epithelial Type 2 Cells More than the Continuous Cigarette Smoke/H. Irie, S. Chubachi, A. Tsutsumi, N. Kameyama, K. Sakurai, M. Ozaki, M. Ishii, A.E. Hegab, T. Betsuyaku, Tokyo, Japan, p.A3815

P903 FGF2 Augments EMT Gene Expression in Airway Epithelial Cells Exposed to TGFβ1/L. El-Baz, N. Shoukry, M. Salem, H. Hafez, R. Guzy, Chicago, IL, p.A3816


P907 Alterations of Exosome Cargo Induced by Oxidative Stress in Human Bronchial Epithelial Cells/N. Olave, C.V. Lal, S. Fleisher, B. Halloran, N. Ambalavanan, Birmingham, AL, p.A3820

P908 A Dynamic and Morphological Analysis of Airway Epithelial Stem Cells During the Maturation of Porcine Lung/Y. Jia, J. Yang, J. Shi, J. Xue, J. Wu, X. Liu, Yinchuan, China, p.A3821


P910 Retinoic Acid Upregulates Endothelial-Derived Angiocrine Factors to Promote Human Alveolar Epithelial Repair/J. Alçada, D. Shao, M.J. Griffths, C. Dean, M. Hind, London, United Kingdom, p.A3823


P913 LYPD2, Likely Functioning Through the CHRA7 Nicotine Receptor, Plays a Central Role in Modulating Inflammation-Related Gene Expression in the Airway Epithelium/H. Zhang, J. Salit, R.G. Crystal, New York, NY, p.A3826


P919 sgSCG Stimulators Modulate BK Channel Activity in Human Airway Epithelial Cells/M. Kim, Y. Pantoja, M. Yoshida, N. Baumlin, M.A. Salathe, Miami, FL, p.A3832

P920 The Bcl-2 Family Protein, Noxa, Inhibits NF-κB Heterodimers and FXYD5 Compete for the Regulation of the Alveolar Epithelial Barrier/J. Verheyden, PhD, La Jolla, CA


P922 Transcriptome Analysis of Type II-Gated Alveolar Epithelial Cells Reveals Convergent and Divergent Molecular Signatures in COPD and IPF Lung Explants/S. Chu, S. Poli, Y. Sakairi, A. Bandyopadhyay, K. Donlon, J. Myers, J. Ashton, G.S. Pryhuber, T.J. Mariani, Rochester, NY, p.A3834

P923 Pulmonary Fibrosis MUC5B Risk Allele rs35705950 Is Associated with Transcriptional Profiles of Senescence and Epithelial-Mesenchymal Transition in Airway Cells Cultured at Air-Liquid Interface/J.S. Kurche, J. Huber, E. Dobrinskikh, J.S. Kurche, C.M. Evans, I.V. Yang, D.A. Schwartz, Aurora, CO, p.A3836
The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
### B63 INFLAMMATION AND CELLULAR RESPONSES IN CYSTIC FIBROSIS

**9:15 a.m. - 4:15 p.m.**

**Area H (Hall A-B2, Ground Level)**

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>P949</td>
<td>Elevated Free Heme Predisposes to Bacterial Lung Infection After Acute Inhalation Injury</td>
</tr>
<tr>
<td>P950</td>
<td>The Role of the IL-22 Pathway in the Lung Following Influenza Infection</td>
</tr>
<tr>
<td>P951</td>
<td>Serine Glycine One-Carbon Metabolism Drives Effector Responses to Influenza Infection in Macrophages</td>
</tr>
<tr>
<td>P952</td>
<td>Epidermal Growth Factor Receptor (EGFR) Signaling in the Nucleus Modulates Antiviral Immunity</td>
</tr>
<tr>
<td>P953</td>
<td>High Mobility Group Box-1 as a Marker for Respiratory Syncytial Virus Infection</td>
</tr>
<tr>
<td>P954</td>
<td>Mechanisms of RSV Attachment and Infection in a Physiological Model of Human Pediatric Lung Epithelial Cells</td>
</tr>
<tr>
<td>P955</td>
<td>Role of Autophagic Markers During Clearance of Aspergillus Fumigatus from Epithelial Cells</td>
</tr>
<tr>
<td>P956</td>
<td>Development of a Dual Organism Model for Aspergillus Fumigatus Spores and Human Airway Epithelial Cells at the Single Cell-Spore Level</td>
</tr>
<tr>
<td>P957</td>
<td>Mesenchymal Stem Cell Conditioned Medium Retains Antibacterial Properties After Vibrating Mesh Nebulisation</td>
</tr>
</tbody>
</table>

### Facilitator:
Y. Song, MD, Shanghai, China

### Posters on Display

- **MONDAY • MAY 21**
- **Area H (Hall A-B2, Ground Level)**

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>P949</td>
<td>Elevated Free Heme Predisposes to Bacterial Lung Infection After Acute Inhalation Injury</td>
</tr>
<tr>
<td>P952</td>
<td>Epidermal Growth Factor Receptor (EGFR) Signaling in the Nucleus Modulates Antiviral Immunity</td>
</tr>
<tr>
<td>P953</td>
<td>High Mobility Group Box-1 as a Marker for Respiratory Syncytial Virus Infection</td>
</tr>
<tr>
<td>P954</td>
<td>Mechanisms of RSV Attachment and Infection in a Physiological Model of Human Pediatric Lung Epithelial Cells</td>
</tr>
<tr>
<td>P955</td>
<td>Role of Autophagic Markers During Clearance of Aspergillus Fumigatus from Epithelial Cells</td>
</tr>
<tr>
<td>P956</td>
<td>Development of a Dual Organism Model for Aspergillus Fumigatus Spores and Human Airway Epithelial Cells at the Single Cell-Spore Level</td>
</tr>
<tr>
<td>P957</td>
<td>Mesenchymal Stem Cell Conditioned Medium Retains Antibacterial Properties After Vibrating Mesh Nebulisation</td>
</tr>
</tbody>
</table>

### Facilities:
- **Facilitator:** Y. Song, MD, Shanghai, China

### Discussion and Viewing:
- **Discussion:** 11:15-12:00: authors will be present for individual discussion.
- **Viewing:** Posters will be on display for entire session.

### Themes:
- **THEMATIC POSTER SESSION**

### The Information Contained in This Program Is Up to Date as of April 16, 2018. For the Most Current Session Information, Please Visit the Online Program Itinerary.
P978 Applying Epix™ Technology to Enable Ex Vivo Theratyping Using ATS 2018 • San Diego, CA
9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER B64 COPD: LUNG FUNCTION, IMAGING AND PATHOPHYSIOLOGY


P976 Evaluation of Apremilast as a Novel Therapeutic Agent in Cystic Fibrosis/Y. Tang, G. Bolger, S.M. Rowe, S.V. Raju, Birmingham, AL, p.A3883

P977 Exosomes Derived from Human Circulating Endothelial Progenitor Cells Ameliorates Acute Lung Injury by Transferring mir-126/W. Xu, Shanghai, China, p.A3884


P1425 Dyspnea and Its Relation to Air Trapping in Chronic Obstructive Pulmonary Disease/M. Slootsky, M. Miller, M. Koc, R.A. Patel, A. Baydur, Los Angeles, CA, p.A3890

P1426 Diagnostic and Prognostic Obstruction Degree Based on FEV1 and MEF50 in Elderly Patients that Had Treatment at Zainal Abidin General Hospital Aceh/S. Bahry, L. Julisafrida, H. Priyanto, S. Saminan, Banda Aceh, Indonesia, p.A3891


P1429 The Relationship Among Lung Volume Subdivisions in Patients with Obstructive Airway Disease/M.-L. Chuang, I.-F. Lin, Taichung, Taiwan, p.A3894


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.

P1437 Non-Contact Measurement of Tidal Breathing Using Structured Light Plethysmography (SLP) to Support Diagnosis in Undiagnosed COPD/C. Landon, R. Wilson, S. Motamedei-Fakhri, Ventura, CA, p.A3902

P1438 Lung Elasticity Distribution as an Imaging Bio Marker for COPD Lung Physiology/A. Santhanam, K. Hasse, D. Low, Los Angeles, CA, p.A3903

Facilitator: C. J. Galban, PhD, Ann Arbor, MI

P1439 MEF75s, MEF25-75 and Serum Cystatin C Are Predictors of Chronic Obstructive Pulmonary Disease in Adults/D. Feng, H. Yang, W. Zhao, Y. Wang, X. Zou, Y. Zhou, T. Zhang, Guang Zhou, China, p.A3904

P1440 Proposal and Validation of a Minimal Clinically Important Difference (MCID) for Annual Pulmonary CT Density Decline/D. Crossley, D. Subramanian, R. A. Stockley, A. M. Turner, Birmingham, United Kingdom, p.A3905


P1445 Spirometric Screening Behind the Latest World COPD and Asthma Days in Romania/R. Nedelcu, R. Umeanu, F. Mihaitan, Bucharest, Romania, p.A3910


Facilitator: E. J. Gartman, MD, Providence, RI


P1451 The Correlation Between Lung Volume Analyzed with High-Resolution Computed Tomography and Respiratory Impedance in Patients with Emphysema/Z. Isobe, Fukuya-shi, Satama-ken, Japan, p.A3916


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
B65  ASTHMA: PATHOPHYSIOLOGY AND CLINICAL TRIALS

9:15 a.m. - 4:15 p.m.  SAN DIEGO CONVENTION CENTER

Area H (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion

12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator:  S. Bose, MD, MPH, New York, NY

P980  Methacholine Challenge Testing and Baseline FEV1/T.J. Moraes, D. Wilson, Toronto, Canada, p.A3923


P985  Low Frequency Lung Resistance is a Global Bronchoconstriction Detection Measure, but is Still Sensitive to Small Airways Disease/B. Foy, A. Bell, S.H. Siddiqui, D. Kay, Oxford, United Kingdom, p.A3928

Facilitator:  A. Lee, MD, New York, NY


P990  Improvement of Pulmonary Function Test Produced by Phosphodiesterase-5 Inhibitor ‘Sildenafil’ in Healthy and in Asthmatic Patients/S.Y. Khatib, H. Lababidi, M. Moazin, Iribid, Jordan, p.A3933


P993  Spontaneous Pneumomediastinum and Pneumoperitoneum as a Complication of Severe Asthma Exacerbation/P. Shah, A. Chauhan, A. Sharma, Farmington, CT, p.A3936

Facilitator:  J. Leung, MD, Vancouver, Canada

P994  Effects of Variable Airway Wall Nitric Oxide Concentrations on Predicted FeNO/P. Muchmore, E.B. Rappaport, S.P. Eckel, Y. Zhang, W.S. Linn, R. Habre, F.D. Gilliland, Los Angeles, CA, p.A3937

P995  Reclassification of Bronchodilator Reversibility in the U-Biopred Adult Asthma Cohort Using Z-Scores/S.J. Fowler, A.J. Simpson, Manchester, United Kingdom, p.A3938


P998  Justification of the Inhalation Parameters to Provide Patients with Dose Confirmation Feedback When They Use a Digitally Enabled Albuterol Multidose Dry Powder Inhaler (eMDPI)/H. Chrystyn, G. Safioti, D. Buck, F. Ruiter, J. Blair, Leeds, United Kingdom, p.A3941

P999  The Accuracy of an Electronic Multidose Dry Powder Inhaler (eMDPI) to Measure Inhalation Parameters When Used by Patients/H. Chrystyn, D. Saralaya, A. Shenoy, S. Toor, K. Kastango, E. Calderon, G. Safioti, Leeds, United Kingdom, p.A3942

P1000  Delay Between the Last Dose of Long-Acting Beta-Agonist and FEV1 Reversibility in Children/N. Beydon, J. Taytard, C. Aupiais, C. Alberti, Paris, France, p.A3943

Facilitator:  J.K. Burgess, PhD, Groningen, Netherlands

P1001  Evaluation of the Suitability of the Respimat® Inhaler for the Treatment of Preschool Children/W. Kamin, M.M. Metzger, A. Sharma, H. Wachtel, Hamm, Germany, p.A3944


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.


P1108 Novel Endoscopic Techniques for Patients with Severe Asthma and Airway Stenosis/J. Faul, C.M. Burke, W. Shah, L. Cormican, L. thong, Dublin, Ireland, p.A7746
B68 DIAGNOSIS AND TREATMENT OF SLEEP DISORDERED BREATHING

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER
Area C (Hall A-B2, Ground Level)

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
P272 Pembrolizumab-Induced Bronchiolitis in a Patient with Stage IV Non-Small Cell Lung Cancer/A. Blanchard, N. Bouchard, P. Larivée, Sherbrooke, Canada, p.A4008


P276 Rare Case of Adenoid Cystic Carcinoma and the Management of Post-Operative Complications/B. Li, S. Hussain, New Brunswick, NJ, p.A4012

P277 Sweet Syndrome with Pulmonary Involvement: High Index of Suspicion Important for Differentiation from Pneumonia and Timely Treatment/A. Syed, S. Velani, A. Alkhatlan, B.P. Young, Cleveland, OH, p.A4013

P284 Incidental Diagnosis of Primary Pulmonary Synovial Sarcoma (PPSS) in an Elderly Patient with Pulmonary Fibrosis Complicated by Radiation Pneumonitis/M.A. Jacob, T.R. Chandak, Pittsfield, MA, p.A4019


P286 Pulmonary Large Cell Neuro-Endocrine Cancer: A Diagnostic Difficulty and Therapeutic Dilemma/A.C. Gour, A. Shenoy, Mineola, NY, p.A4021


P288 Delayed Pulmonary Metastasis of Endometrial Stromal Sarcoma Decades After Surgical Excision Presenting as Hemoptysis: A Rare Presentation of a Rare Clinical Entity/M. Moizuddin, T. Schnell, Z. Ahmad, R. Bradley, J. Bucks, Columbia, SC, p.A4023


P291 Biphasic Pulmonary Blastoma Invading the Mediastinum and Pleura with Brain Metastasis in an Adult Female/M. Post, F. Reyes, W.I. Ezegbunam, M. Noorikolooni, J. Mahoney, Brooklyn, NY, p.A4026

P292 A Case of Non-Small Cell Lung Cancer with Accompanying Neuroendocrin Hyperplasia in Pathological Specimen/D. Dogan Mullazimoglu, A. Ciledag, F. Ciftci, S. Erol, K. Ceyhan, O.O. Kumbasar, Ankara, Turkey, p.A4027

P293 A Rare Case of a Chest Wall Atypical Epithelioid Schwannoma/K. Zakharov, O. Jaikaran, J. Guiner, A. Rapkiewicz, M. Vaynblat, Brooklyn, NY, p.A4028


P297 Chronic Hemoptysis: Manifestation of a Rare, Obscure, and Fatal Diagnosis/R. Klein, V. Patel, Royal Oak, MI, p.A4032
**P298** A Rare Case of Pneumococcal During CT Guided Lung Biopsy/C. Pisano, J. O’Connor, S. Krick, D. Russell, Birmingham, AL, p.A4033

**P299** Abscopal Effect Following CT Guided Permanant Seed Brachytherapy for Metastatic Adenoid Cystic Carcinoma to Lung/S. Doggett, S. Chino, T. Lempert, K. Sidhar, Mission Viejo, CA, p.A4034

**P300** Atypical Carcinoid Successfully Treated with Endobronchial Therapy/K. Kongpakpaisarn, S. Suchartkitwong, A.J. Schwall, W. Vithikraivit, R. Alalawi, Tampa, FL, p.A4035

**P301** Primary Synovial Sarcoma of the Pleura: A Rare Cause of a Lung Mass/F. Berenyi, A. Chowdhury, Melbourne, Australia, p.A4036

**P302** A Bronchus-Associated Lymphoid Tissue Lymphoma Presenting as an Asymptomatic Pulmonary Consolidation/C.A. Askin, M. Koroscil, J.A. Hayes, San Antonio, TX, p.A4037

**P303** Aerogenous Metastasis Imitating Miliary Tuberculosis/I. Kugasias, A. Shengelia, N. Kozlova, O. Epelbaum, R.J. Basir, Valhalla, NY, p.A4038

**B71** CASE REPORTS IN THORACIC ONCOLOGY III

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER Area D (Hall A-B2, Ground Level)

**Viewing:** Posters will be on display for entire session.

**Discussion:** 11:15-12:00: authors will be present for individual discussion 12:00-1:00: authors will be present for discussion with assigned facilitators

**Facilitators:** A. Vachani, MD, Philadelphia, PA T. Isobe, MD, PhD, Izumo Shimane, Japan

**P304** Lung Scar: A Reason to Worry?/H. Yasin, H.S. Al-Jaroushi, H.E. Mohamed, Charleston, WV, p.A4039

**P305** An Atypical Bronchopulmonary Carcinoid Tumor Manifesting as Abdominal Cramping/N.A. Kaur, M. Kantor, Y. Orive, D. Bonilla, L. Bosch, Miami, FL, p.A4040

**P306** Peripheral Eosinophilia as a Rare Presentation of Bronchoalveolar Carcinoma/B. Eperjesiova, A.M. Stone, Park Ridge, IL, p.A4041

**P307** The Unusual Case of the Cavitating Adenocarcinoma/R.D. Mantilla, A.P. Noriega Aldave, D.S. Lala, Roanoke, VA, p.A4042


**P309** ‘NET’ Again: Pulmonary Carcinoid in a Case of MEN Type 1/T. Young, J. Martires, D. Karunasiri, A. Lo, N. Kamangar, Los Angeles, CA, p.A4044

**P310** A Rare Cause of Hemoptysis: Inflammatory Myofibroblastic Tumor of the Trachea/R. Winsett, M.I. Velez, O. Bode-Omoleye, San Antonio, TX, p.A4045

**P311** Primary Lung Malignancy Presenting as Bibasilar Consolidation Mimicking Pneumonia/A. King, I. Berim, Omaha, NE, p.A4046

**P312** Diffuse Bronchioalveolar Carcinoma: A Rare Type of Pulmonary Adenocarcinoma/K.J. Lasafin, Makati City, Philippines, p.A4047

**P313** An Autopsied Case of Neurofibromatosis Type 1 (von Recklinghausen’s Disease) Associated Malignant Peripheral Nerve Sheath Tumor Carcinomatous Pleurisy with Giant Intrathoracic Meningoceles/M. Furukawa, H. Ota, K. Sugino, Y. Nakamura, Y. Nihonyanagi, N. Tochigi, S.A. Homma, Tokyo, Japan, p.A4048

**Facilitator:** C.A. Powell, MD, New York, NY

**P314** Metastatic Non-Seminomatous Germ Cell Tumor Mimicking Empyema Necissitans on Imaging/F.K. Suhail, V. Kaul, T.M. McGarry, Great River, NY, p.A4049

**P315** A Rare Presentation of Malignant Mesothelioma in a Young Adult/K. Ilyas, M. Raza, J. Subramanian, Grand Rapids, MI, p.A4050


**P318** Occipital Condyle Syndrome as the Initial Presentation of Lung Cancer/M. Doraiswamy, M. Kamau, A. Jacob, P. Angi, Long Branch, NJ, p.A4053

**P319** Wheezing and the Assumption of Asthma in a Young Atopic Patient/S. Barned, O.M. Ahmedtaha, A. Thomas, Washington, DC, p.A4054

**P320** A Rare Cause of Hemoptysis: Inflammatory Myofibroblastic Tumor of the Trachea/R. Winsett, M.I. Velez, O. Bode-Omoleye, San Antonio, TX, p.A4045


**P322** Diffuse Large B-Cell Lymphoma Presenting as Diffuse Alveolar Hemorrhage/G. Al-Helou, A. Jose, A.W. McLean, K. Dodds, J.E. Ahari, G. Gutierrez, Washington, DC, p.A4056

**P323** Lung Inflammatory Pseudotumor in an Adult Smoker/J.B. Quist, D. Enriquez, M.F. Schmidt, Brooklyn, NY, p.A4057

**P324** Synchronous BALT Lymphoma and Primary Adenocarcinoma Presenting as Pneumonia/P. Stetsyuk, M.A. Jacob, C.R. Galvez-Padilla, T.R. Chandak, Pittsfield, MA, p.A4058

**Facilitator:** M.P. Rivera, MD, Chapel Hill, NC


**P326** Symptomatic Pleural Restriction Due to Pseudo-Progression of Unknown Metastatic Breast Cancer in a Patient Treated with Pembrolizumab/G. Stroh, S. Markovic, T. Peikert, Rochester, MN, p.A4060

---

_The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary._
B72 CASE REPORTS IN THORACIC ONCOLOGY IV

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER
Area D (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators: M.P. Rivera, MD, Chapel Hill, NC
Y. Nakanishi, MD, PhD, Fukuoka, Japan


P332 Neurofibromatosis 1 Presenting with a Large Mediastinal Mass/M.F. Odish, D.J. Conrad, La Jolla, CA, p.A4065

P333 Broncho-Oesophageal Fistula the Cause of Non Resolving Pneumonia/N. Appusamy, Trichy, India, p.A4066

P334 Myelolipoma: A Rare Tumor in a Rare Location/Y. Nakanishi, MD, PhD, Fukuoka, Japan


Facilitator: D.E. Midthun, MD, Rochester, MN

P336 Rare Variant of High-Grade B-Cell Lymphoma Presenting as a Pleural-Based Mass in an Immunocompetent Patient/R. Godbole, J. Xu, G. Shestakova, F.A. Youssef, B. Saatian, Orange, CA, p.A4069

P337 Large Cell Lung Carcinoma with Rhabdoid Phenotype with a Targetable Mutation/Y. Simons, A.I. Velazquez, New York, NY, p.A4070


P339 Primary Pulmonary Diffuse Large B Cell Lymphoma Mimicking Pulmonary Infection Primary Pulmonary Diffuse B-Cell Lymphoma Mimicking Pulmonary Infection/H. Khudayar, P. Pinargote, A. Zia, I. Ribizziakhtar, Pawtucket, RI, p.A4072

P340 Primary Pulmonary Lymphoma Masquerading as Pneumonia/M. Abdelkader, V. Singh, York, PA, p.A4073

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.

A Case of Mesothelioma with Cystic Mediastinal Lymphadenopathy/K. Tallon, C.C. Tyas, Saskatoon, Canada, p.A4119

When You Hear Hooves, Do Not Ignore the Zebra: Malignancy Disguised as Recurrent Pneumonia/C. Ba Mendoza, M. Sherman, S. Fidahussein, Suwanee, GA, p.A4120


Facilitator: T. Vandemoortele, MD, Montreal, Canada


Tracheobronchial Inflammatory Myofibroblastic Tumor in a Young Adult with Subsequent Sarcoidosis/M. K. Hayat Syed, K.M. Kuniak, Minneapolis, MN, p.A4123


Diagnostic Process of a Patient with FDG PET Negative Pulmonary Metastases and Prostate Adenocarcinoma/K. M. Eu, C.V. Choong, Z. Ng, J.A. Abisheganaden, Singapore, Singapore, p.A4126

Paraganglioma of the Middle Mediastinum: Challenging Diagnosis and Curative Treatment/M. Naddour, O. Ashraf, M. Beg, A. Singh, Pittsburgh, PA, p.A4127


Facilitator: Y.B. Gesthalter, MD, Boston, MA

An Atypical Case of Cardiac Tamponade Leading to a Diagnosis of Metastatic Adenocarcinoma/J. Trabanco, Z. Burden, N. Najjar, W. Jung, Jacksonville, FL, p.A4130


Diffuse Pleural Metastases as a Manifestation of Recurrence in Adenoid Cystic Carcinoma/B. Birnbaum, M. Oron, B.A. Mina, New York, NY, p.A4133

Diplopia: A Presentation of Leptomeningeal Carcinomatosis Due to Small Cell Lung Cancer/Y.-C. Wu, J. Lio, G. Barmaimon, P.S. Patrawalla, New York, NY, p.A4134


The Sneak Attack: A Case of Superior Vena Caval Invasion by a Recurrent Thymoma/A.A. Khan, B. Pannu, N. Sher, S. Raheel, Chicago, IL, p.A4137

THEMATIC POSTER SESSION

B75 CASE REPORTS IN THORACIC ONCOLOGY VII

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER

Area D (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.
Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators: D.A. Arenberg, MD, Ann Arbor, MI
M.M. Tor, MD, Zonguldak, Turkey

A Case of Cavitary Lung Lesions: A Diagnostic Dilemma/M.R. Jordan, A. Musa, S. Chaaban, Lexington, KY, p.A4138


New Spinal Kaposi Sarcoma Lesions Despite Improvement of Endobronchial Kaposi Sarcoma After Treatment with Chemotherapy/M. Wei, N. Kamangar, Sylmar, CA, p.A4140


Atypical Chest Pain and Dyspnea as Presenting Symptoms of an Isolated Mediastinal Extradural Plasmacytoma/G. Ivashchuk, M. Sanchez Sierra Marino, R. Arauco Brown, McAllen, TX, p.A4142

Pulmonary Sarcomatoid Carcinoma: An Often Missed Diagnosis with Poor Prognosis/S.I. DeSouza, K. Gopalratnam, J. Persico, Bridgeport, CT, p.A4143


Malignant Pleural Effusion with Unknown Primary Cancer: A Single Center Experience of Three Cases with Non-Revealing Radiographic Studies/S. Awadallah, A. Mohan, Greenville, NC, p.A4145

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
ATS 2018 • San Diego, CA

ATS WOMEN’S FORUM
MANCHESTER GRAND HYATT SAN DIEGO
Grand Hall B (Lobby Level)

11:45 a.m. - 1:15 p.m.

The annual ATS Women’s Forum recognizes the achievements and supports the advancement of women in pulmonary, critical care, and sleep medicine and research. We are pleased to have A. Sonia Buist, MD, Professor Emerita of Medicine, Division of Pulmonary and Critical Care Medicine, School of Medicine, Oregon Health & Science University, as our speaker this year.

Dr. Buist is ATS past president and the founder of the ATS Methods in Epidemiologic, Clinical, and Operations Research (MECOR) program. She is a passionate advocate for advancing global public health policy through research, and truly embodies the ATS vision of “helping the world breathe.” Dr. Buist will discuss issues that are relevant to female medical professionals followed by a question and answer period.

In addition, the 2018 Elizabeth A. Rich, MD Award, which honors the memory and work of Elizabeth Rich, MD, will be presented to V. Courtney Broaddus, MD, Professor at the University of California, San Francisco, who will also address the audience. This award is given annually to a woman who has made significant achievements in the practice or science of pulmonary, critical care, or sleep medicine; demonstrated leadership in her field; and has shown dedicated mentorship of junior colleagues.

The forum provides a valuable opportunity for women to meet new colleagues and ATS leaders. Men are also welcome to attend the forum. Attendees will find value in the inspirational messages and career insights the speakers share as well as vibrant networking opportunities.

The forum is organized and presented by the ATS Membership Committee, and will be hosted by Janet Lee, MD, chair of the committee.

Conference badges are required for admission.

Space is limited and admittance is on a first-come, first-served basis. There is no additional fee. A plated lunch will be served.
WS3  HOW TO DESIGN A ROBUST CLINICAL TRIAL IN SLEEP APNEA: LOOKING BACK, LOOKING AHEAD

Registration Fee: $75 (includes box lunch)

Attendance is limited. Pre-registration is required.

Assemblies on Sleep and Respiratory Neurobiology; Behavioral Science and Health Services Research; Clinical Problems

11:45 a.m. - 1:15 p.m.  SAN DIEGO CONVENTION CENTER
   Room 9 (Upper Level)

Target Audience
Junior and senior investigators interested in designing clinical trials in sleep medicine; providers of sleep apnea treatment; those interested in behavioral science and health services research

Objectives
At the conclusion of this session, the participant will be able to:

• identify limitations of recently published negative clinical trials in sleep apnea;
• learn new strategies to design future clinical trials in sleep apnea such as novel clinical trial designs, choosing individual vs. composite endpoints vs. surrogate measures of important clinical outcomes;
• integrate new strategies (learnt from COPD, Cystic Fibrosis and Hypertension clinical trials) to improve CPAP adherence in future clinical trials in sleep apnea.

This workshop will provide participants with the tools to design the next best clinical trial in sleep apnea. The workshop will begin with a brief synopsis of the limitations of previously published trials (e.g. SAVE trial) and its major focus will be to discuss strategies for designing robust future clinical trials in sleep apnea. These strategies will include: novel clinical trial design application; choosing the right study endpoint(s); applying lessons learnt from other pulmonary disease trials (such as from COPD and Cystic Fibrosis) to improve CPAP adherence; CPAP dosing and interpretation in clinical trials.

Chairing:
N.A. Shah, MD, MPH, MSci, New York, NY
S. Pamidi, MD, Montreal, Canada
D.J. Gottlieb, MD, MPH, Boston, MA

11:45  Introduction
N.A. Shah, MD, MPH, MSci, New York, NY

11:55  Looking Ahead: Future Clinical Trial Designs in Sleep Apnea
S.S. Redline, MD, Boston, MA

12:15  Dosing and Interpretation of CPAP Adherence in Clinical Trials
D.M. Rapoport, MD, New York, NY

12:35  Strategies to Improve CPAP Adherence in Future Clinical Trials: Lessons From Other Disciplines
K.A. Riekert, PhD, Baltimore, MD

12:55  Individual and Composite Study Endpoints: Separating the Wheat from the Chaff
R.J. Goldberg, PhD, Worcester, MA

WS4  CARING FOR THE CHRONICALLY-VENTILATED CHILD: FROM HOSPITAL TO HOME

Registration Fee: $75 (includes box lunch)

Attendance is limited. Pre-registration is required.

Assembly on Pediatrics

11:45 a.m. - 1:15 p.m.  SAN DIEGO CONVENTION CENTER
   Room 10 (Upper Level)

Target Audience
Pulmonologists, intensivists, neonatologists, fellows/residents, practitioners from both large academic centers and smaller community hospitals

Objectives
At the conclusion of this session, the participant will be able to:

• summarize and implement the ATS Chronic Home Invasive Ventilation Guidelines;
• develop and/or improve a center-specific standardized discharge process and care plan for the chronically-ventilated children who receive care at their respective institutions.

Children with chronic respiratory failure may benefit from long-term mechanical ventilation via tracheostomy at home. Although caring for a chronically-ventilated child at home poses implicit risk, such care can be provided safely in this setting. In some cases, chronic respiratory failure improves over time and permits weaning ventilation and tracheostomy decannulation. Approaches to caring for technology-dependent children vary significantly among centers. Experts in pediatric pulmonology, aerodigestive evaluation, critical care, and sleep medicine will discuss important aspects of caring for this fragile patient population. An interactive roundtable discussion will follow to encourage audience participation.

Chairing:
C.D. Baker, MD, Aurora, CO
A. Cristea, MD, Indianapolis, IN

11:45  Pediatric Chronic Home Invasive Ventilation Guidelines
L.M. Sterni, MD, Baltimore, MD

11:55  A Standardized Discharge Process for Unique Chronically-Ventilated Children
C.D. Baker, MD, Aurora, CO

12:05  Trach Safe: Improving the Safety of Every Child with a Trach
J.J. Soares, MD, Seattle, WA

12:15  Variation in the Approach to Chronic Ventilation: Location Matters
J. Edwards, MD, MA, New York, NY

12:30  Weaning Chronic Ventilation and Decannulation: It’s All About the Timing
A. Cristea, MD, Indianapolis, IN

12:45  Round Table Discussion (with all speakers)
C.D. Baker, MD, Aurora, CO

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
rhinitis in predicting asthma severity. Also data from an ongoing birth cohort (URECA) will be used to demonstrate the relation between different asthma phenotypes and asthma severity.

Chairing: P.J. Gergen, MD, MPH, Rockville, MD
12:15 Are There Phenotypes of Airflow Obstruction in Asthma and Do They Contribute to Disease Severity?
R.L. Sorkness, PhD, Madison, WI
12:35 If Asthma Is a “One Airway Disease” How Does Rhinitis Affect Disease Severity?
A. Togias, MD, Bethesda, MD
12:55 What Phenotypes in Childhood Asthma Emerge in Association with Disease Severity?
L.B. Bacharier, MD, Saint Louis, MO
L15 RESEARCH FUNDING OPPORTUNITIES
12:15 p.m. - 1:15 p.m. SAN DIEGO CONVENTION CENTER
Room 15 A-B (Mezzanine Level)

Target Audience
Any ATS conference attendees who are conducting research and seeking research funding

Objectives
At the conclusion of this session, the participant will be able to:
• describe the research priorities of each funding agency represented on the panel;
• describe the research funding mechanisms of each agency represented on the panel;
• identify a funding agency that is most closely aligned with the attendee’s research interest/program of research.

This session will introduce programs and research grant opportunities offered from various funding agencies. Speakers will present current research priorities and mechanisms of research funding available from each agency.

Chairing: J. Tate, PhD, RN, Columbus, OH
J.L. Guttormson, PhD, Milwaukee, WI

12:15 ATS Foundation
R.J. Schwab, MD, Philadelphia, PA

12:25 American Lung Association
S. Rappaport, MPH, New York, NY

12:35 National Institute of Nursing Research
K. Huss, PhD, Bethesda, MD

12:45 National Heart, Lung, and Blood Institute
L.A. Reineck, MD, Bethesda, MD

12:55 Patient-Centered Outcomes Research Institute
J. Slutsky, PA, MSPH, Washington DC, DC

1:05 Panel Discussion
J. Tate, PhD, RN, Columbus, OH

L17 COLLABORATIVE PROJECTS TO ACCELERATE RESEARCH IN ORGAN FIBROSIS
12:15 p.m. - 1:15 p.m. SAN DIEGO CONVENTION CENTER
Room 33 A-C (Upper Level)

Target Audience
Researchers interested in lung or multi-organ fibrosis; Researchers developing collaborative, interdisciplinary research programs.

Objectives
At the conclusion of this session, the participant will be able to:
• Learn new findings about common mechanisms of fibrosis across organ systems including the lung
• Be able to more effectively design and organize collaborative interdisciplinary research efforts
• Increase awareness of novel therapeutic targets and biomarkers to treat and diagnose fibrosis

This session highlights work from an NHLBI-sponsored program that fosters collaborations among researchers studying fibrosis in the lung and other organ systems that aims to characterize mechanisms of aberrant fibrosis in different organ systems, develop novel therapeutic strategies to lessen organ fibrosis, and improve technologies to study fibrosis.

Chairing: M. Craig, PhD, Bethesda, United States

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
L18 HOUSEHOLD AIR POLLUTION AND HEALTH: A MULTI-COUNTRY LPG INTERVENTION TRIAL
12:15 p.m. - 1:15 p.m. SAN DIEGO CONVENTION CENTER
Room 32 A-B (Upper Level)

Target Audience
Lung health professionals and clinical and basic researchers; environmental health clinical and bsic researchers; biomarker researchers

Objectives
At the conclusion of this session, the participant will be able to:
• learn new finding about indoor air pollution and its consequences for health;
• improve the quality of life/ health status of patients using indoor air pollutants;
• understand the difficulties of pairing interventional and behavioral treatments in the low to middle income setting.

Globally, nearly 3 billion people rely on solid fuels for cooking and heating, the majority in low- and middle-income countries (LMICs). The resulting household air pollution (HAP) is the third leading risk factor in the 2010 global burden of disease, accounting for an estimated 4.3 million deaths annually, largely among women and young children. The presenters will describe to the audience a large-scale field trial with liquefied petroleum gas (LPG) cookstoves that is aiming at reducing exposure to levels that produce meaningful health improvements. The trial is randomizing 3,200 households in four LMICs (India, Guatemala, Peru, and Rwanda).

Chairing: A. Punturieri, MD, Bethesda, MD

12:15 Introduction to the HAP Trial
T. Clasen, PhD, Atlanta, Georgia

12:27 Environmental Exposures and Indoor Air Pollution in HAP
J.L. Peel, MPH, PhD, Fort Collins, CO

12:39 HAP Trial Design and Clinical Outcomes
W. Checkley, MD, PhD, Baltimore, MD

12:51 The HAP Biomarker Study
M. Clark, PhD, Fort Collins, CO

1:03 Questions and Answers

MEET THE PROFESSOR SEMINARS
CME Credits Available: 1

MP501 REFRACTORY ASTHMA: A MULTIDISCIPLINARY APPROACH
P. Akuthota, MD, La Jolla, CA
P. Vijayanand, MBBS, PhD, La Jolla, CA
Grand Ballroom 1 (North Tower, Lobby Level)

MP502 PREPARING TO TEACH ONLINE: FROM LECTURE TO ENGAGEMENT
G.L. Narsavage, PhD, MSN, RN, APRN, Morgantown, WV
Grand Ballroom 2 (North Tower, Lobby Level)
MP503 INTERPRETATION OF SEROLOGIES DURING INTERSTITIAL LUNG DISEASE INVESTIGATION
S. Chartrand, MD, Montreal, Canada
Grand Ballroom 3 (North Tower, Lobby Level)

MP504 ALPHA-1 ANTITRYPSIN DEFICIENCY: STATE OF THE ART
J.K. Stoller, MD, MS, Cleveland, OH
Grand Ballroom 4 (North Tower, Lobby Level)

MP505 METAPHORIC SIGNS IN CT CHEST IMAGING
A.C. Mehta, MBBS, Cleveland, OH
Presidio 1 (North Tower, Lobby Level)

MP506 STRATEGIES FOR ENHANCING CRITICAL THINKING AT THE BEDSIDE
R.M. Schwartzstein, MD, Boston, MA
Presidio 2 (North Tower, Lobby Level)

MP507 EXTRACORPOREAL MEMBRANE OXYGENATION: PHYSIOLOGICAL CURIOSITIES
K.M. Wille, MD, MSPH, Birmingham, AL
B. Zakhary, MD, New York, NY
N.S. Sharma, MD, Birmingham, AL
Temecula 1-2 (North Tower, First Floor)

MP508 SUBSTANCE ABUSE, INCLUDING THE OPIOID CRISIS AND ITS CONTRIBUTION TO THE GLOBAL BURDEN OF RESPIRATORY DISEASES
M. Akpinar-Elci, MD, MPH, Norfolk, VA
K.L. Bailey, MD, Omaha, NE
Temecula 3-4 (North Tower, First Floor)

MP509 MANAGEMENT OF PATIENTS WITH SEVERE COMMUNITY-ACQUIRED PNEUMONIA
C. Feldman, MD, PhD, Johannesburg, South Africa
Leucadia (South Tower, First Floor)

MP510 EXPERIENCES IN OUTPATIENT PULMONARY PALLIATIVE CARE
D.M. Donesky, PhD, ANP-BC, San Francisco, CA
S. Booth, MD, Cambridge, United Kingdom
Point Loma (South Tower, First Floor)

MP511 WHAT’S NEW IN THE PULMONARY MANAGEMENT OF NEUROMUSCULAR DISEASE
G.D. Sharma, MD, Chicago, IL
Solana (South Tower, First Floor)

MP512 CTEPH: MEDICINE, SURGERY OR ANGIOPLASTY?
N.H. Kim, MD, La Jolla, CA
D.S. Poch, MD, La Jolla, CA
M. Madani, MD, La Jolla, CA
Balboa (South Tower, Third Floor)

MP513 OBESITY HYPOVENTILATION SYNDROME: WHAT THE CLINICIAN NEEDS TO KNOW
B. Sunwoo, MBBS, San Diego, CA
O. Mesarwi, MD, La Jolla, CA
B. Mokhlesi, MD, MS, Chicago, IL
Mission Hills (South Tower, Third Floor)

MP514 SIMPLIFYING CLINICAL RELEVANCE OF BRONCH-BIOPSY TUMOR GENOMICS: WHAT PULMONOLOGISTS NEED TO KNOW
D. Upadhyay, MD, Fresno, CA
Cardiff (South Tower, Third Floor)

MP515 OFFICIAL ATS DOCUMENTS: HOW TO GET INVOLVED
K.C. Wilson, MD, Boston, MA
R.A. Dweik, MD, Cleveland, OH
Del Mar (South Tower, Third Floor)

MP516 PLEURAL INFECTION: MODERN EVIDENCE BASED MANAGEMENT
N. Rahman, BM BCH, MSc, DPhil, Oxford, United Kingdom
Miramar (South Tower, Third Floor)

MEDICAL EDUCATION SEMINAR
CME Credits Available: 1

ME2 COMPOSING AN EDUCATIONAL SYMPHONY: INTERDISCIPLINARY TEACHING IN THE ICU
Registration Fee: $70 (includes box lunch)
Attendance is limited. Pre-registration is required.
12:15 p.m. - 1:15 p.m. SAN DIEGO CONVENTION CENTER Room 2 (Upper Level)

Target Audience
All providers who participate in ICU rounds—including but not limited to: students, residents, fellows, nurses, pharmacists, and respiratory therapists.

Objectives
At the conclusion of this session, the participant will be able to:
• Develop strategies to create an educational environment that promotes interdisciplinary teaching in the ICU
• Formulate questions that create focused opportunities for teaching by interdisciplinary team members
• Manage the flow of interdisciplinary teaching in order to maintain rounds that are both inclusive and efficient

This session will focus on strategies to promote interdisciplinary teaching in the intensive care unit. We will present an overview of the literature supporting the importance of interdisciplinary teams and discuss approaches to creating an environment conducive to collaborative teaching. Through video portrayals of common teaching and learning scenarios that occur during ICU rounds, we will explore opportunities for teaching by various team members, such as nurses, respiratory therapists, and pharmacists. In addition, through interactive discussion, the group will identify specific strategies to address common challenges and avoid potential pitfalls related to interdisciplinary teaching.

Speakers:
A. Anandaiah, MD, Boston, MA
J. O’Toole, DO, Burlington, VT
K. Burkart, MD, MSc, New York, NY
TSS1  NEUROMUSCULAR RESPIRATORY FAILURE: PART 2

Registration Fee: $140 for full series (includes box lunch)
Attendance is limited. Pre-registration is required.
This is part 2 of a 3-part series. Those registering for this seminar series will be registered for all 3 parts. The program for the full series is included with the Sunday, May 20, 12:15 p.m. program.

12:15 p.m. - 1:15 p.m. MARRIOTT MARQUIS SAN DIEGO MARINA
Palomar (South Tower, Third Floor)

Update on the Management of Respiratory Failure in DMD
R. Shell, MD, Columbus, OH

Extubation Protocols for the “Unweanable”
L. Wolfe, MD, Chicago, IL
CC3  SLEEP MEDICINE CLINICAL CORE CURRICULUM II
2:15 p.m. - 4:15 p.m.  SAN DIEGO CONVENTION CENTER
Hall H (Ground Level)

Target Audience
Practicing internists, subspecialists, registered nurses and advanced practice nurses in pulmonary, critical care, and sleep medicine who work in a clinical setting and are currently engaged in maintenance of certification

Objectives
At the conclusion of this session, the participant will be able to:
• remain current with medical knowledge relevant to their practice in pulmonary, critical care, and sleep medicine;
• evaluate their understanding of key skills and content areas in pulmonary, critical care and sleep medicine, as well as receive feedback on their comprehension of a result of a pre-test/post-test comparison;
• support clinicians who are engaged in maintenance of certification activities by providing updates on subjects included in recertification requirements.

The ATS Clinical Core Curriculum Symposia focus on a 3-year content cycle of key medical content in the areas of Pulmonary, Critical Care, and Sleep Medicine. The topics are also aligned with corresponding MOC Medical Knowledge modules. This symposium is intended to assist clinicians with staying current with the growth of information relevant to their medical practice, as well as provide an opportunity to evaluate individual knowledge and skills while earning MOC Medical Knowledge points.

Chairing: S.M. Jamil, MD, La Jolla, CA
T.S. Wang, MD, Los Angeles, CA
W.D. Conwell, MD, Aurora, CO

2:15  RLS/PLMD
B.A. Philips, MD, MPH, Lexington, KY
S. Pasha, MD, Lexington, KY

2:45  REM Behavior Disorders
B. Fields, MD, Decatur, GA

3:15  Sleep in Neurologic Disorders
M. Lipford, MD, Rochester, MN

3:45  Sleep in Neuromuscular Disease
T. Russell, MD, St. Louis, MO

B81  NURSING YEAR IN REVIEW
Assembly on Nursing
2:15 p.m. - 4:15 p.m.  SAN DIEGO CONVENTION CENTER
Room 30 A-B (Upper Level)

Target Audience
Clinicians and researchers, including registered nurses and advanced practice nurses who care or study older adults who experience chronic pulmonary illness, an ICU admission, or sleep problems.

Objectives
At the conclusion of this session, the participant will be able to:
• describe current knowledge as well as gaps in knowledge in aging biology of the lung, acute and chronic pulmonary conditions, sleep disorders, and pulmonary rehabilitation in the older adult;
• identify future research directions and clinical practice initiatives targeted to older adults who experience pulmonary, critical illness or sleep disorders;
• discuss policy and advocacy implications for older adults with pulmonary disease, critical illness and sleep disorders.

This session will review the current state of knowledge of older adults in pulmonary, critical care and sleep. Topic areas will include: aging lung physiology; critical care;chronic pulmonary disorders;pulmonary rehabilitation;sleep and health policy. Each speaker will review recent studies, discuss current gaps and highlight implications to clinical practice and future research.

Chairing: J. Tate, PhD, RN, Columbus, OH
J.L. Guttormson, PhD, RN, Milwaukee, WI

2:15  Physiologic Considerations in Older Adults with Pulmonary, Critical Care, and Sleep Conditions
C.M. Risaliti, MD, Columbus, OH

2:35  Older Adults and Chronic Pulmonary Disorders
V.M. McDonald, PhD, New Lambton Heights, Australia

2:55  Critical Illness and Older Adults
J. Tate, PhD, RN, Columbus, OH

3:15  Pulmonary Rehabilitation in the Older Adult
G.S. Bauldoff, PhD, RN, Columbus, OH

3:35  Sleep Disordered Breathing in Older Adults
L. Baniak, PhD, RN, Pittsburgh, PA

3:55  Health Policy and the Older Adult
S.J. Crowder, PhD, Fishers, IN
**B82 CONTROVERSIES IN THE DIAGNOSIS AND TREATMENT OF COPD**

Assemblies on Clinical Problems; Allergy, Immunology and Inflammation; Nursing; Pulmonary Rehabilitation; Respiratory Cell and Molecular Biology; Respiratory Structure and Function

2:15 p.m. - 4:15 p.m.  SAN DIEGO CONVENTION CENTER  
Ballroom 20 B-C (Upper Level)

**Target Audience**
Clinicians, researchers, fellows in training, registered nurses, advanced practice nurses and therapists who care for patients with COPD

**Objectives**
- At the conclusion of this session, the participant will be able to:
  - discuss whether airflow obstruction is necessary to diagnose and treat COPD.
  - determine whether a personalized treatment plan for COPD is feasible.
  - evaluate whether a new concept or definition of what constitutes an exacerbation of COPD is needed.

The GOLD 2017 Report provides current evidence-based information to make recommendations regarding optimal COPD patient diagnosis and treatment for the clinician. However, there are gaps in the recommendations in some aspects of care because of contradictory evidence in the current medical literature. This session will focus on the current gaps in knowledge in the most important areas that exist in the care of the COPD patient. Hopefully this session will initiate and spur a sustained dialogue about these issues between clinicians, researchers and patients and help foster a creative multidisciplinary approach to addressing these gaps in current knowledge.

Chairing:  
G.J. Criner, MD, Philadelphia, PA  
B.R. Celli, MD, Boston, MA  
A. Agusti, MD, Barcelona, Spain

**3:25**  
**PRO:** A New Definition of COPD Exacerbation is Needed  
R. Rodriguez-Roisin, MD, PhD, Barcelona, Spain

**3:35**  
**PRO:** Pulmonary Treatment of Exacerbations is Currently Adequate  
J.A. Wedzicha, MD, PhD, London, United Kingdom

**3:45**  
**CON:** Pulmonary Treatment of Exacerbations is Currently Adequate  
G.J. Criner, MD, Philadelphia, PA

**3:55**  
**Panel Discussion: Controversies in COPD Treatment**

This session is supported by educational grants from AstraZeneca LP, GlaxoSmithKline, Sunovion Pharmaceuticals Inc.

**All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.**

---

**CLINICAL**

**B83 THE OTHER (NON-NON SMALL CELL LUNG CANCER) THORACIC MALIGNANCIES**

Assemblies on Thoracic Oncology; Clinical Problems

2:15 p.m. - 4:15 p.m.  SAN DIEGO CONVENTION CENTER  
Room 1 A-B (Upper Level)

**Target Audience**
Clinicians of various specialties (Pulmonary medicine, thoracic surgery, oncology, pathology, radiology) who are involved in the care of patients with thoracic tumors, nurses, clinical researchers, pulmonary trainees.

**Objectives**
- At the conclusion of this session, the participant will be able to:
  - understand and implicate diagnosis of different thoracic tumors
  - know and implicate local and systemic management of thoracic tumors
  - Recognize future challenges in the research of non-NSCLC thoracic tumors

In recent years there has been substantial progress in the understanding and management of non-small cell lung cancer. In this symposium we aim to illuminate all the rest of the thoracic tumors, both malignant and benign, that a care-giver in oncology, pathology, radiology) who are involved in the care of patients with thoracic tumors, nurses, clinical researchers, pulmonary trainees.

Chairing:  
Z.G. Fridlender, MD, Jerusalem, Israel  
D.H. Sterman, MD, New York, NY  
N. Beaty, New York, NY

**2:15**  
**PRO:** Introduction: Not All Thoracic Malignancies are NSCLC  
Z.G. Fridlender, MD, Jerusalem, Israel

**2:22**  
**A Patient’s Perspective**  
N. Beaty, New York, NY

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
B84 SIX CONTROVERSIES IN FLUID ADMINISTRATION IN SEPSIS

Assemblies on Critical Care; Clinical Problems
2:15 p.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER
       Ballroom 20 A (Upper Level)

Target Audience
All clinicians who practice in an intensive care unit and researchers who
conduct science related to sepsis

Objectives
At the conclusion of this session, the participant will be able to:
• Be able to recognize when and how to administer fluid to the septic patient.
• Know the different effects of different types of fluid on patients, and be able
to tailor fluid therapy for a given patient.
• Recognize the potential harms of fluid administration and know when to
consider diuresis or dialysis in septic patients.

Fluid administration is a key therapy in sepsis. Despite its long history, much
uncertainty persists about how best to administer fluid. This session will cover
six of the biggest questions on fluid administration in sepsis, including when to
administer fluid, how to administer fluid, and when to consider diuresis or
dialysis. Experts in the field will review the most recent evidence and offer
answers to these questions. This session is of value to any clinician who treats
sepsis, and any clinical or translational researcher who works in sepsis.

Chairing: N. Shapiro, MD, Boston, MA
V. Liu, MD, MS, Oakland, CA
M.J. Lanspa, MD, MSCR, Salt Lake City, UT

2:15 What Is the Correct Target for Fluid Administration?
D. Kelm, MD, Rochester, MN

2:35 How Do We Predict Response to Fluid Administration?
M.J. Lanspa, MD, MS, Salt Lake City, UT

2:55 When Should We Administer Fluid?
N. Shapiro, MD, Boston, MA
2:55  HIF-1 Alpha Metabolically Reprograms Recruited Macrophages to Promote Alveolar Repair  
W.J. Janssen, MD, Denver, CO

3:15  Mitochondrial Iron Metabolism in the Pathogenesis of COPD  
S.M. Cloonan, PhD, New York, NY

3:35  Macrophage Mitochondria as Effectors of Bacterial Killing in Health and Disease  
D. Dockrell, MD, PhD, Edinburgh, United Kingdom

3:55  Trained Innate Immunity and Metabolic Regulation of Sepsis  
J. Cheng, PhD, Hsinchu City, Taiwan

---

B86  FIRING ON ALL CYLINDERS: OPTIMIZING CRITICAL CARE DELIVERY AND IMPROVING OUTCOMES
Assemblies on Critical Care; Behavioral Science and Health Services Research; Nursing; Quality Improvement and Implementation Committee; ICU Directors Working Group

2:15 p.m. - 4:15 p.m.  SAN DIEGO CONVENTION CENTER  
Room 33 A-C (Upper Level)

Target Audience
Critical care clinicians; registered nurses and advanced practice nurses, hospital and ICU administrators; health services researchers

Objectives
At the conclusion of this session, the participant will be able to:
• identify knowledge gaps in ICU design and critical care delivery that are barriers to optimizing clinical outcomes, operational efficiency, and system costs;
• summarize the current literature and future directions for ICU staffing including off-hours bedside intensivists, advanced practitioners, and patient-intensivist ratios;
• discuss how thorough analysis of electronic health and patient flow data can help guide an appropriate and nuanced approach to ICU bed allocation and triage decisions.

This session will present established and emerging research addressing strategies for critical care delivery with the goals to optimize clinical outcomes, operational efficiency, and system costs. Specifically, the symposium will address centralized critical care governance, off-hours intensivist staffing, advanced practice providers in the ICU, assessments of the net benefit of ICU admission, the optimal intensivist patient load, and modeling ICU and step-down unit patient flow.

Chairing:  
G.L. Anesi, MD, MBE, Philadelphia, PA  
M.N. Gong, MS, MD, Bronx, NY  
J. Stevens, MD, MS, Boston, MA

2:15  Evolution of Modern Critical Care Medicine: From the Past to Future  
M.N. Gong, MD, MS, Bronx, NY

2:27  Overnight Intensivist Staffing: Myths, Facts, and Lessons Learned  
M.P. Kerlin, MD, MSCE, Philadelphia, PA

2:45  Allies in Critical Care: Integrating Advanced Practice Providers into ICU Teams  
D.K. Costa, PhD, RN, Ann Arbor, MI

3:03  In Pursuit of the Optimal Patient Load for Intensivists  
H. Wunsch, MD, MSc, Toronto, Canada

3:21  Determining ICU Net Benefit in Peri-Critical Illness  
G.L. Anesi, MD, MBE, Philadelphia, PA

3:39  Modeling ICU Patient Flow to Optimize Bed Allocation  
K.S. Mathews, MD, MPH, New York, NY

3:57  Who’s in Charge: Novel Organizational Models of Centralized Critical Care Governance  
S.M. Pastores, MD, New York, NY

---

B87  PAYING TOO HIGH A PRICE! THE LUNG HEALTH COST OF ENERGY EXTRACTION
Assemblies on Environmental, Occupational and Population Health; Clinical Problems; Nursing; Pediatrics; Environmental Health Policy Committee; Health Policy Committee; International Health Committee; Health Equality and Diversity Committee

2:15 p.m. - 4:15 p.m.  SAN DIEGO CONVENTION CENTER  
Room 7 A-B (Upper Level)

Target Audience
Providers of lung health, including registered nurses and advanced practice nurses, particularly those with clinical, epidemiological or translational research, administrative responsibilities, policy makers, and energy industry

Objectives
At the conclusion of this session, the participant will be able to:
• diagnose and manage coal mine dust lung disease and uranium miners’ pneumoconiosis, using newer descriptions of disease that vary from the classical disease descriptions;
• discuss hazards associated with petrochemical/natural gas industry;
• determine the health hazards of climate change and lung health-based need for renewable energy

The acquisition, processing and transport of energy resources have significant direct and indirect effects on human lung health in the United States and across the world. This session will educate clinicians about novel aspects related to lung disease seen in workers in the fossil fuel energy industry and look to the future of renewables.

Chairing:  
A. Sood, MD, MPH, Albuquerque, NM  
T.K. Takaro, MD, New Westminster, Canada  
M.B. Rice, MD, MPH, Boston, MA
2:15  A Day in the Life of an American Miner
W. Jarrell, CMSP, Grants, NM

2:25  The Life Cycle of Respiratory Disease in Coal Miners
R.A. Cohen, MD, Chicago, IL

2:45  Update on Respiratory Hazards of Natural Gas Extraction by Hydraulic Fracturing (Fracking)
D.N. Weissman, MD, Morgantown, WV

3:00  Petrochemical Industry and the Lung: A Clinical Translational Study on the Gulf of Mexico Oil Spill
V.B. Antony, MD, Birmingham, AL

3:20  Uranium Industry and Lung Disease: Why “Clean” Fuel Might Not Be so Clean!
N.A. Assad, MD, Albuquerque, NM

3:35  The Health Impact of Greenhouse Gas Production: A Nigerian Perspective
O.N. Nwankwo, MBBS, MSc, Calabar, Nigeria

3:55  Alternatives to Fossil Fuels: California’s Policies to Promote Clean Energy
M.D. Nichols, JD, Sacramento, CA

B88 JUST DO IT: REDUCING PEDIATRIC RESPIRATORY HEALTH DISPARITIES

Assemblies on Pediatrics; Behavioral Science and Health Services Research; Clinical Problems; Environmental, Occupational and Population Health; Nursing

2:15 p.m. - 4:15 p.m.  SAN DIEGO CONVENTION CENTER
Room 6 B (Upper Level)

Target Audience
Clinicians, behavioral scientists, researchers, fellows, pediatricians, internists, registered nurses, advanced practice nurses, asthma and other health educators

Objectives
At the conclusion of this session, the participant will be able to:

- identify populations at risk for health disparities across several pediatric pulmonary diseases
- advocate for legislative and policy changes affecting poor and at risk children.
- integrate new strategies in clinical practice and research that will have the effect of closing the disparity gap for economically disadvantaged and at risk children in the US and globally.


Chairing: B.J. Sheares, MD, MS, New York, NY
S. Lovinsky-Desir, MD, New York, NY
E. Brigham, MD, MHS, Baltimore, MD

2:15  Targeting Poverty to Reduce Respiratory Health Disparities in Children
B. Dreyer, MD, New York, NY

2:40  Pediatric Asthma Disparities: Better, Worse, or About the Same
E.G. Burchard, MD, MPH, Danville, CA

3:05  Upscaling Interventions to Reduce Disparities in Childhood Pneumonia: A Global Imperative
H.J. Zar, MD, PhD, Cape Town, South Africa

3:30  Disparities in Cystic Fibrosis Outcomes: How Can We Close the Gap?
S.A. McColley, MD, Chicago, IL

3:50  Disparities in Sleep: Is This a Silent Epidemic?
B.J. Sheares, MD, MS, New York, NY

This session and the International Conference are supported by educational grants from GlaxoSmithKline, Sanofi Genzyme and Regeneron Pharmaceuticals, Vertex Pharmaceuticals Inc.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

B89 NOT JUST THE LUNGS: PAH AS A SYSTEMIC VASCULAR DISORDER

Assemblies on Pulmonary Circulation; Respiratory Cell and Molecular Biology; Respiratory Structure and Function

2:15 p.m. - 4:15 p.m.  MARRIOTT MARQUIS SAN DIEGO MARINA
Grand Ballroom 5-6 (North Tower, Lobby Level)

Target Audience
Pulmonary and critical care physicians, cardiologists, nurse practitioners, pulmonary vascular biologists and trainees who conduct research in diseases of the pulmonary circulation

Objectives
At the conclusion of this session, the participant will be able to:

- Review the state of the art knowledge regarding vascular dysfunction in PAH and introduce novel evidence that links higher incidence of systemic vascular diseases in these patients.

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
• Discuss similarities and differences in disease mechanisms of vascular dysfunction in pulmonary vs. systemic manifestations of PAH.

• Discuss recent evidence that link PAH with higher incidence of the following diseases: CAD, stroke, renal vasculopathy, bronchial arterial vasculopathy, PVOD as well as new developments in microbiome research pertinent to PAH.

Since its initial description, pulmonary arterial hypertension (PAH) has been considered a vascular disease exclusive to the lungs. However, recent studies have uncovered evidence that patients with PAH also demonstrate abnormalities in the systemic circulation that compound the clinical impact of the lung disease. Understanding the nature of this crosstalk between pulmonary and systemic circulation promises to open exciting possibilities not only to understand the mechanisms behind vascular dysfunction but also revise our approach to patient care in PAH.

Chairing: V. De Jesus Perez, MD, Palo Alto, CA
K. Goss, MD, Madison, WI
K. Tran-Lundmark, MD, PhD, Lund, Sweden

2:15 A Patient's Perspective
M. Rushing, CRNA, Petaluma, CA

2:20 Insulin Resistance, Diabetes and Pulmonary Hypertension
A. Hemnes, MD, Nashville, TN

2:35 The Systemic Bronchial Circulation in PAH: Friend or Foe?
P. Dorfmuller, PhD, MD, Le Plessis Robinson, France

2:50 The Microbiome and Gut-Lung Axis in PAH
F. Perros, PhD, Le Kremlin Bicetre, France

3:05 PVOD: The Other Pulmonary Hypertension
D. Montani, MD, PhD, Le Kremlin Bicetre, France

3:20 PAH, the Brain and the Heart
S. Bonnet, PhD, MSc, Quebec City, Canada

3:35 Lung-Renal Vascular Dysfunction in PAH
E.D. Austin, MD, Nashville, TN

3:50 Skeletal Muscle Dysfunction in PAH
S. Provencher, MD, Quebec City, Canada

This session and the International Conference are supported by educational grants from Actelion Pharmaceuticals US, Inc., Bayer US. All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

Objectives
At the conclusion of this session, the participant will be able to:

• learn new findings about novel molecular diagnostic tests for acute pneumonia;
• diagnose patients with acute pneumonia;
• implement new strategies to treat patients with CAP or VAP.

This session will provide attendees an update on the development of diagnostic technologies for rapid identification and susceptibility of pathogens causing acute pneumonia. The speakers will 1) describe the scientific basis of the new molecular tests; 2) provide a perspective from the clinical microbiology laboratory on the advantages and challenges in implementing and integrating these new and emerging methodologies into clinical practice; and 3) assess the clinical utility of the rapidly evolving diagnostic technology. Due to the number new tests and concepts, we plan to leave adequate time for Questions and Answers.

Chairing: R. Nusrat, MD, Princeton, NJ
R. Patel, MD, Rochester, MN
S. Yende, MD, Pittsburgh, PA

2:15 Introduction
R. Nusrat, MD, Princeton, NJ

2:19 The Microbiology Laboratory in the Age of Rapid Diagnostics
R. Patel, MD, Rochester, MN

2:39 Application of Rapid Technology to Community Acquired Pneumonia
M.L. Metersky, MD, Farmington, CT

2:59 Application of Technology to Hospital and Ventilator Associated Pneumonia
M.H. Kollef, MD, St. Louis, MO

3:19 Predictive Values and Cost Considerations
R. Nusrat, MD, Princeton, NJ

3:39 What Should a Research Agenda Look Like to Define the Clinical Utility of New Diagnostic Tests?
M.S. Niederman, MD, New York, NY

B90 RAPID MOLECULAR DIAGNOSTICS FOR PNEUMONIA: IS SPEED THE ONLY THING?

Assemblies on Pulmonary Infections and Tuberculosis; Clinical Problems; Critical Care; Thoracic Oncology

2:15 p.m. - 4:15 p.m. MARRIOTT MARQUIS SAN DIEGO MARINA
Grand Ballroom 8-9 (North Tower, Lobby Level)

Target Audience
Pulmonologists, critical care physicians, hospitalists, microbiologists, oncologists, infectious disease specialists, and infection control specialists

Objectives
At the conclusion of this session, the participant will be able to:

• learn new findings about novel molecular diagnostic tests for acute pneumonia;
• diagnose patients with acute pneumonia;
• implement new strategies to treat patients with CAP or VAP.

This session will provide attendees an update on the development of diagnostic technologies for rapid identification and susceptibility of pathogens causing acute pneumonia. The speakers will 1) describe the scientific basis of the new molecular tests; 2) provide a perspective from the clinical microbiology laboratory on the advantages and challenges in implementing and integrating these new and emerging methodologies into clinical practice; and 3) assess the clinical utility of the rapidly evolving diagnostic technology. Due to the number new tests and concepts, we plan to leave adequate time for Questions and Answers.

Chairing: R. Nusrat, MD, Princeton, NJ
R. Patel, MD, Rochester, MN
S. Yende, MD, Pittsburgh, PA
This session will focus on cellular and tissue engineering approaches in the lungs. It will explore a variety of approaches including lung organoid/spheroid, microfluidic organ engineering methods like lung-on-a-chip, as well matrix based recellularized tissues. This symposium will also discuss application of such approaches for disease modeling, drug testing, biomarker discovery and regenerative medicine.

Chairing: Z. Borok, MD, Los Angeles, CA
B.R. Stripp, PhD, Los Angeles, CA

2:15 Lung Organoids: Current Uses and Future Promises
C. Barkauskas, MD, Durham, NC

2:39 Modeling Human Airway Diseases in Three Dimension: Introducing Small Airway-on-a-Chip and Breathing-Smoking Lung-on-a-Chip Microfluidic Technologies
K. Hajipouran Benam, PhD, Aurora, CO

3:03 Engineering Native Biomaterials for Pulmonary Regenerative Therapeutics
X. Ren, PhD, Pittsburgh, PA

3:27 In Vivo Tissue-Engineering of Human Airways
E. Martinod, MD, Paris, France

3:51 Regenerative Pharmacology in COPD
X. Gosens, PhD, Groningen, Netherlands

The session will also describe some of the statistical issues in papers and how these should be addressed. During the session, an example of the videos produced for AJRCCM papers will be shown. The session will focus on some of the key papers in airways disease, critical care, neonatology and interstitial lung disease that have been recently published.

Chairing: J.A. Wedzicha, MD, London, United Kingdom
L.J. Brochard, MD, Toronto, Canada

2:15 Issues in Publication Ethics for Authors
J.A. Wedzicha, MD, London, United Kingdom

2:35 Detecting Plagiarism and Image Manipulation
E. Gumpert, ., New York, NY

2:50 Statistical Pointers for AJRCCM Authors
G.C. Donaldson, PhD, BSc(Hons), London, United Kingdom

3:10 Highlights in Critical Care
L.J. Brochard, MD, Toronto, Canada

3:25 Highlights in Asthma
F.D. Martinez, MD, Tucson, AZ

3:40 Highlights in COPD and Interstitial Lung Disease
F.J. Martinez, MD, MS, New York, NY

3:55 Neonatology and Paediatric Critical Care in AJRCCM
S.H. Abman, MD, Aurora, CO

This session and the International Conference are supported by educational grants from AstraZeneca LP, GlaxoSmithKline, Sanofi Genzyme and Regeneron Pharmaceuticals, Sunovion Pharmaceuticals Inc. All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.
B94 ADDRESSING PALLIATIVE AND PSYCHOSOCIAL NEEDS AMONG PATIENTS AT END OF LIFE, THEIR FAMILIES, AND THE CHRONICALLY CRITICALLY ILL

2:15 p.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER
Room 14 A-B (Mezzanine Level)

Chairing: E.K. Kross, MD, Seattle, WA
J. Hart, MD, MS, Philadelphia, PA
A.E. Turnbull, DVM, MPH, PhD, Baltimore, MD

Oral Presentations


---

**MINI SYMPOSIUM**

**B96 GENETICS, EPIGENETICS, AND SMOKING**

2:15 p.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER

Room 15 A-B (Mezzanine Level)

**Chairing:** D.L. DeMeo, MD, Boston, MA

I.V. Yang, BS, PhD, Aurora, CO

**Oral Presentations**


---

**MINI SYMPOSIUM**

**B97 IMPORTANCE OF LONGITUDINAL COHORT STUDIES IN PEDIATRICS**

2:15 p.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER

Room 6 C/F (Upper Level)

**Chairing:** T.W. Ferkol, MD, St. Louis, MO

P. Subbarao, MD, Toronto, Canada

**Featured Speaker**

2:15 A Path to Precision: The Cystic Fibrosis Model/T.W. Ferkol, MD, St. Louis, MO

**Oral Presentations**


**RAPID: RAPID ABSTRACT POSTER DISCUSSION SESSION**

**B101 NEW DEVELOPMENTS IN PLEURAL DISEASE DIAGNOSIS AND TREATMENT**

2:15 p.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER

**Abstract Summaries**

2:15-2:45

**Viewing/Discussion** 2:45-3:15

Chairing: C. Argento, MD, Chicago, IL
J. Akulian, MD, MPH, Chapel Hill, NC
F.J.F. Herth, MD, Heidelberg, Germany


503 Thoracocentesis Under Copedigorel Is Not Associated with Excessive Bleeding Events/S. Perl, M. Bondarenko, N. Natif, I. Shpirer, B. Fox, Beer Yaakov, Israel, p.A4204

504 The Use of Untunneled Indwelling Pleural Catheters for Non-Malignant Pleural Effusions in the Outpatient/J. M. A. Lopez, A. Miotto, P. A. A. Honda, D. C. A. Dias, J. H. Rivaben, R. H. Roja, T. B. Hassegawa, M. C. Braz, M. Botter, Sao Paulo, Brazil, p.A4205


---

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
Measurement of Pleural Pressure to Symptoms Developing During Thoracentesis and Remaining of Pleural Effusion/A.H. Alraiyes, K. Teerapuncharoen, D. Khemasuwan, North Chicago, IL, p.A4209

Efficacy of Intrapleural Alteplase and DNase Therapy for Symptomatic Non-Draining Indwelling Pleural Catheters in Malignant Pleural Effusions in a Rural Community Pleural Service/A. Guhan, S. Dissanayaka, H. Rahim, N. Morgan, Ayr, United Kingdom, p.A4210

Pleural Fibrinolytics in Empyema- Could a Shorter Course Lead to Equivalent Outcomes?/C. Harris, H. Collins, J. Herre, S.J. Marciniaik, M. Knoile, Cambridge, United Kingdom, p.A4211


Evaluation of Thorascopic Double Loop Ligation of Bullae for Spontaneous Pneumothorax/R. Takahashi, Kanagawa, Japan, p.A4213


Incidence of Asymptomatic Pneumothorax in University Students/S. Takanashi, R. Uruma, Hirosaki, Japan, p.A4216


Pleural Fluid Glucose Testing Using a Finger Stick Glucometer; a Novel Bedside Test with Potential for a Prompt Diagnosis and Decision/T. Abd, H. Bhardwaj, J.I. Kedissi, H.A. Youness, Oklahoma City, OK, p.A4222


Effect of Twice-Daily Aclidinium/Formoterol versus Monotherapy or Tiotropium on 24-Hour Bronchodilation and Symptom Control in Patients with COPD: Results from AMPLIFY/E.M. Kerwin, S. Sethi, G.T. Ferguson, R. Mroz, H. Watz, R. Segarra, E. Molins, J. Jarrest, E. Garcia Gil, Medford, OR, p.A4235

Glycopyrrolate/Formoterol Fumarate Fixed-Dose Combination Delivered by Metered Dose Inhaler Improves Lung Function and Symptoms in Patients with COPD: Results from the PINNACLE-4 Study in Asia, Europe, and the USA/B. Lipworth, D.J. Collier, Y. Gon, N. Zhong, K. Nishi, R. Chen, S. Arora, A. Maes, S. Siddiqui, C. Reisner, U.J. Martin, Dunedie, Scotland, United Kingdom, p.A4236

Patient-Reported Outcomes of Long-Acting Muscarinic Antagonists (LAMA) or Long-Acting Beta2-Agonists (LABA) Monotherapy Versus LAMALABA Fixed Dose Combination (FDC) in Adult Patients with Chronic Obstructive Pulmonary Disease (COPD) in the Real-World Set/E. Wittbrodt, L. Millet, J. Tong, M. Carlyle, J. Kurlander, V. Walkers, M. DePietro, Wilmington, DE, p.A4237

Comparative Efficacy of Once-Daily LAMA/LABAs in COPD Patients with High and Low Use of Rescue Medication/I. Naya, B. Alcázar Navarrete, G.J. Feldman, A.R. Sousa, D.A. Lipson, C. Compton, Brentford, United Kingdom, p.A4238

Revefenacin, a Once-Daily, Long-Acting Muscarinic Antagonist for Nebulized Therapy of Chronic Obstructive Pulmonary Disease (COPD): Results of a 52-Week Safety and Tolerability Phase 3 Trial in Participants with Moderate to Very Severe COPD/E.M. Kerwin, J.F. Donohue, S. Sethi, B. Baumann, S. Pendyala, L. Dean, C.N. Barnes, E.J. Moran, G.D. Crater, Medford, OR, p.A4239

All-Cause Mortality in COPD Patients Treated with Aclidinium and Other Inhaled Bronchodilators/C. Rebordos, J. Castellsague, J. Aguado, S. Thomas, E. Planas, E. Garcia Gil, A. Le, S. Perez-Guthmann, Barcelona, Spain, p.A4240


Lung Deflation and Improvement of Cardiac End-Diastolic Volumes with Indacaterol/Glycopyrronium Reduce Dyspnea and Improve Health Status in Hyperinflated COPD Patients: The CLAIM Study/J.M. Hohlfeld, J. Vogel-Claussen, H. Biller, D. Berliner, K. Berschneider, H.C. Tillmann, A. Hildt, J. Bauersachs, T. Welte, Hannover, Germany, p.A4244


Measure Maximum Forced Inspiratory Flow (FImax) to Predict PIFR-Resistance Value in Ambulatory Patients with COPD/L. Tung, A.G. Duarte, W. Zhang, J. Mills, J. Martinez, G. Sharma, Galveston, TX, p.A4249

Peak Inspiratory Flow Rate Monitoring and Inhaler Selection in a COPD Population/E. Backer, Lebanon, NH, p.A4250


RAPID: RAPID ABSTRACT POSTER DISCUSSION SESSION

B103 ILD: MANAGEMENT

2:15 p.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER
Room 6 D (Upper Level)

Abstract Summaries
2:15-2:45
Viewing/Discussion
2:45-3:15

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
Chaining:  K. Flaherty, MD, Ann Arbor, MI  
M. Porteous, MD, Philadelphia, PA  
J. Behr, MD, Munich, Germany


209  The Effect of Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) for Patients with Mild-to-Moderate Autoimmune Pulmonary Alveolar Proteinosis (APAP) in China/X. Tian, X. Guo, L. Chen, X. Li, S. Meng, Y. Zhao, Y. Xiao, K. Xu, Beijing, China, p.A4260


Outcomes of Antifibrotic Treatment in Idiopathic Pulmonary Fibrosis (IPF) Patients with Circulating Autoantibodies/A. Smith, G. Ding, J. Kropski, W. Mason, L.H. Lancaster, Nashville, TN, p.A4265


Use of Steroids Prior to Hospitalization in Interstitial Lung Disease Patients Admitted with Pneumonia/C. Zhang, H. Ittkhik, M.S. Niederman, G. Nair, Royal Oak, MI, p.A4267


Physician Characteristics Associated with Treatment Initiation Patterns in Idiopathic Pulmonary Fibrosis: Results from an Online, Self-Administered Survey/P. LaCamera, S.L. Limb, T. Quaresma, M. Wijsenbeek, Heidelberg, Germany, p.A4275

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
Predicting Hospital Length of Stay After Intensive Care Unit Discharge with Machine Learning

Retrospective Cohort of a Machine-Learning Algorithm for Early Warning for Acute Respiratory Failure or Mortality as it Relates to Hospital Readmission/C. Dahn, Y. Wu, P. Mirhaji, M.N. Gong, Bronx, NY, p.A4288

Validation of an Electronic Sequential Organ Failure Assessment Score in Intensive Care Unit Patients/L.E. Huerta, M.W. Semler, Nashville, TN, p.A4289

Regenerating Evidence from Landmark Trials in ARDS Using Structural Causal Models on Electronic Health Record/M. Bikak, M. Adibuzzaman, Y. Jung, Y. Yih, E. Bareinboim, Indianapolis, IN, p.A4290


Clinician Responses to a Novel Early Alert System Targeting Deteriorating Patients/C.G. Murphy, P. Mirhaji, M.N. Gong, Bronx, NY, p.A4292


Minimal Impact of Implemented Early Warning Score and Best Practice Alert for Patient Deterioration/A. Bedoya, M. Clement, M. Phelan, R.C. Steorts, C. O’Brien, B.A. Goldstein, Durham, NC, p.A4295


Outcomes and Predictors of Delayed Versus Immediate Intensive Care Unit Transfer Following Rapid Response Team Activation for Suspected Sepsis/A. Pearce, J.R. Beitler, R.E. Sell, San Diego, CA, p.A4297


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
**B105 MYCOBACTERIAL HOST DEFENSE AND PATHOGENESIS**

**2:15 p.m. - 4:15 p.m.**

**MARRIOTT MARQUIS SAN DIEGO MARINA**

Grand Ballroom 11-13 (North Tower, Lobby Level)

**Poster Viewing**

2:15-3:00

**Discussion**

3:00-4:15

**Chairing:** J.M. Keane, MD, Dublin, Ireland

**L. Bermudez, MD, Corvallis, OR**

M. Divangahi, PhD, Montreal, Canada

**801 The Breadth and Spectrum of Antigen Recognition After BCG Vaccination and M. Tuberculosis (Mt) Infection/S. Singh, M. Bolz, A.R. Cornelius, J.D. Ernst, New York, NY, p.A4300**


**803 The Roles of Programmed Death-1, Regulatory T Cells and Myeloid Derived Suppressor Cells in Patients with Mycobacterium Avium Complex- or Mycobacterium Abscessus-Lung Disease/C.-C. Shu, Taipei, Taiwan, p.A4302**


**807 TLR1 Polymorphisms Associated with Susceptibility to Latent Tuberculosis Infection and Active Tuberculosis/M. Zhang, J.-Q. He, Chengdu, China, p.A4306**

**808 Association of TLR8 and TLR9 Polymorphism with Tuberculosis Among Chinese Han Population/M. Wang, J.Q. He, Chengdu, China, p.A4307**


**810 Mycobacterial Species Differ in Intracellular Survival, Cytokine mRNA Expression, NF-Kappa B Activation, and Macrophage Apoptosis/E.D. Chan, X. Bai, A. Musheyev, A. Bai, L. Li, J.R. Honda, Z. Feng, Denver, CO, p.A4309**

---

**MONDAY AFTERNOON**

**Poster Viewing 2:15-3:00**

805 Cigarette Smoke Impairs Macrophage Defense Against Resident CD4+ T Cells in the M. Tuberculosis-Induced BAL

802 The Roles of Programed Death-1, Regulatory T Cells and Myeloid Derived Suppressor Cells in Patients with Mycobacterium Avium Complex- or Mycobacterium Abscessus-Lung Disease/C.-C. Shu, Taipei, Taiwan, p.A4302

**Discussion 3:00-4:15**

**Chairing:** J.M. Keane, MD, Dublin, Ireland

**L. Bermudez, MD, Corvallis, OR**

M. Divangahi, PhD, Montreal, Canada

**811 NFE2L2 Polymorphisms Associated with Susceptibility to Tuberculosis in Chinese Tibetan Population/J. He, Chengdu, China, p.A4310**


**814 Association Between Mannose-Binding Lectin (MBL) Polymorphisms and Serum MBL Levels with Pulmonary Tuberculosis/X. Tong, D. Wang, H. Fan, Chengdu, China, p.A4313**


**816 Coronin-1: Possible Anti-TB Drug Target?/M. Kohli, V. Upadhyay, S. Sinha, Delhi, India, p.A4315**

**817 The Effect of Metformin Versus Sulfonylurea on the Risk of Tuberculosis Disease in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study/W. Su, S.-W. Pan, Y.-F. Yen, V.Y. Su, P.-H. Chuang, J.-Y. Feng, Taipei, Taiwan, p.A4316**


**819 Immunological Influences of Hepcidin, A Major Iron Metabolism Regulatory Peptide, in Pulmonary Tuberculosis**


**823 Rescuing Poly-Functional T Cells by Inhibiting PD-1 Promotes M. Tuberculosis Clearance and Disease Resolution/D. Mitra, D. Kamboj, Delhi, India, p.A7750**

---

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
Poster Discussion Session

B106 Pulmonary Rehabilitation: Outcomes and Extra-Pulmonary Manifestations

2:15 p.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER
Room 11 A-B (Upper Level)

Poster Viewing 2:15-3:00
Discussion 3:00-4:15

Chairing:
F. Maltais, MD, Quebec City, Canada
E. Hillegass, PT, PhD, Dahlonega, GA
R. Evans, MBChB, PhD, Leicester, United Kingdom

401 The Effects of Pulmonary Rehabilitation on Blood Neutrophil Activation and Functional Subsets in COPD/A. Jenkins, N.S. Holden, A.W. Jones, Lincoln, United Kingdom, p.A4322

402 Effects of Pulmonary Rehabilitation on Sleep Quality in Patients with Chronic Obstructive Pulmonary Disease (COPD)/M. Roberts, J.-G. Cho, J.R. Wheatley, Wentworthville, Australia, p.A4323

403 Can Upright Partitioned Exercise, Propulsion of a 3-Wheeled Scooter, Alter Leg Muscle Activity and Shift the Relationship Between Breathing and Leg HEaviness in Patients With Chronic Obstructive Pulmonary Disease (COPD)/T.E. Dolmage, J. Dubois-Webster, R.S. Goldstein, Toronto, Canada, p.A4324


406 Dynamic Hyperinflation in Patients with Severe Asthma/S. Majd, T.E. Dolmage, S. Hewitt, A. Murphy, S.J. Singh, P. Braidding, R. Green, R. Evans, Leicester, United Kingdom, p.A4327


408 Responsiveness and Minimum Important Difference of Quadriceps Maximum Voluntary Contraction in Chronic Obstructive Pulmonary Disease/S. Patel, C.M. Nolan, S.E. Jones, R. Barker, S.S. Kendra, W.D.-C. Man, Harefield, United Kingdom, p.A4329


411 Responsiveness of the Short Physical Performance Battery to Pulmonary Rehabilitation in Patients with Chronic Respiratory Disease and Frailty/S. Patel, C.M. Nolan, S.E. Jones, R.E. Barker, H.Y. Kwan, M. Maddocks, W.D.-C. Man, Harefield, United Kingdom, p.A4332

412 Physical Frailty in Idiopathic Pulmonary Fibrosis/C.M. Nolan, M. Maddocks, T.M. Maher, S. Patel, R.E. Barker, S.E. Jones, H.Y. Kwan, P.M. George, P. Cullinan, W.D.-C. Man, Harefield, United Kingdom, p.A4333


414 Rehabilitation Goals Towards the End of Life: What Matters to People with Advanced Respiratory Disease in Hospice Care?/M. Maddocks, L. Fettes, W. Gao, I.J. Higginson, S. Ashford, London, United Kingdom, p.A4335


416 The Association Between Physical Activity and Vitamin D in (ex-) Smokers (with and Without Airflow Obstruction) and Never Smoking Controls/H. Demeyer, M. Loeckx, F. Rodrigues, D. Vanderschueren, S. Pauwels, T. Troosters, W. Janssens, Leuven, Belgium, p.A4337


418 Analysis of Pulmonary Rehabilitation (PR) Treatment Patterns and Utilization in Patients with Chronic Obstructive Pulmonary Disease (COPD) in the United States (US)/M. Sikirica, L. Trantham, A.V. Joshi, D. Mohan, D. Neil, S.D. Candrilli, Collegeville, PA, p.A4339

419 Weight Loss Improves Dyspnea on Exertion in Obese Men/V. Bernhardt, D.M. Bhammar, R. Marines-Price, T.G. Babb, Commerce, TX, p.A4340
B107  MECHANISTIC ADVANCES IN PULMONARY FIBROSIS

2:15 p.m. - 4:15 p.m.  MARRIOTT MARQUIS SAN DIEGO MARINA
Pacific Ballroom 15-17 (North Tower, First Floor)

Abstract Summaries  2:45-4:15
Viewing/Discussion  2:15-2:45

Chairing:  C.T. Jourdan Le Saux, PhD, San Francisco, CA
C.M. Hogaboam, PhD, Los Angeles, CA
A. Lam, MD, Chicago, IL


Soluble Thy-1 Reverses Myofibroblast Differentiation and Progressive Pulmonary Fibrosis Via Its Integrin-Binding Domain/S.S. Wong, C. Tan, K. Ceonne, J. Min, C.R. Espinoza1, J.S. Hagood, La Jolla, CA, p.A4343

Secreted Frizzled-Related Protein 1 (SFRP1) as a Novel Regulator of the RhoA/Rock1 Pathway Is Expressed in a Distinct Subset of Fibroblasts in the Fibrotic Lung/A. Sengupta, B. Oehrle, M. Strunz, H.B. Schiller, G. Burgstaller, Munich, Germany, p.A4344

ILC2 Promotes Bleomycin-Induced Pulmonary Fibrosis Though IL-33/ST2 Signaling Pathway/Y. Zhao, T. Liu, F. Gonzalez De Los Santos, Z. Wu, S.H. Phan, Beijing, China, p.A4345

OATD-01, a Dual Chitinase Inhibitor, Significantly Ameliorates Pulmonary Fibrosis in the Bleomycin-Induced Mouse Model/B. Oehrle, M. Strunz, H.B. Schiller, O. Eickelberg, G. Burgstaller, Munich, Germany, p.A4344


Primary Cilia Are a Critical Component of the Fibroblast-AEC2 Self-Renewal Axis and Contribute to Protection from Pulmonary Fibrosis/C. Trempus, C. Barkauskas, S. Garnatziotis, Research Triangle Park, NC, p.A4355


Primary Cilia Are a Critical Component of the Fibroblast-AEC2 Self-Renewal Axis and Contribute to Protection from Pulmonary Fibrosis/C. Trempus, C. Barkauskas, S. Garnatziotis, Research Triangle Park, NC, p.A4355


S100a4 Mediates Murine Pulmonary Fibrosis Through Matrix Stiffness-Dependent Recruitment of Contractile Proteins to Central Stress Fibers/B.D. Southern, L. Grove, R.G. Scheraga, United Kingdom, p.A4359


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.

ATS 2018 • San Diego, CA


1018 Implication of NUDT1 in Pulmonary Arterial Hypertension/A. Binabou, M.-C. Lampron, S. Breuil-Bonnet, S. Provencher, S. Bonnet, Quebec, Canada, p.A4383


1020 PBI-4050, a Novel First-in-Class Antifibrotic Agent, Improves Pulmonary Hypertension and Fibrosis, as Well as Right Ventricular Hypertrophy and Fibrosis in Monocrotaline-Treated Rats/Q. T. Nguyen, J. C. Tardif, Y. Shi, E. Plante, E. Nguyen-Duong, B. Grouix, P. Laurin, L. Gagnon, J. Dupuis, Montreal, Canada, p.A4385

1021 Impact of BMI on Cardiopulmonary Exercise Test Variables in Pulmonary Arterial Hypertension/A. Sharma, L. Orr, N. K. Burki, R. J. Foley, D. Datta, Farmington, CT, p.A4386

1022 A New Score to Differentiate Idiopathic Pulmonary Arterial Hypertension from Pulmonary Hypertension Due to Heart Failure with Preserved Ejection Fraction/F. Dardi, N. Tanese, S. Caravita, A. Rinaldi, C. Dewachter, E. Gotti, T. Nguyen, E. Monti, A. Albini, M. Palazzini, A. Manes, J.-L. E. Vachiery, N. Galie, Bologna, Italy, p.A4387

1023 PBI-4050, a Novel First-in-Class Agent, Improves Hypoxia/Sugen Induced Pulmonary Arterial Hypertension in Rats/Q. T. Nguyen, J. C. Tardif, Y. Shi, E. Plante, E. Nguyen-Duong, B. Grouix, P. Laurin, L. Gagnon, J. Dupuis, Montreal, Canada, p.A4388

1024 Pulmonary Vascular Dysfunction Among Patients with Lung Disease and Normal Pulmonary and Systemic Pressures During Exercise/D. R. Ziehr, R. S. Harris, K. Bakken, C. G. White, P. P. Pappagianopoulos, G. D. Lewis, R. Malhotra, C. G. White, B. Mokhlesi, MD, MS, Chicago, IL, Chairing:

2:15 p.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER

Room 6 E (Upper Level)

Abstract Summaries 2:15-2:45

Viewing/Discussion 2:45-3:15

Chairing: B. Mokhlesi, MD, MS, Chicago, IL

P. J. Strollo, MD, Pittsburgh, PA

F. Barbe, MD, Lleida, Spain

301 Real World PAP Adherence: Results from a Big Data Approach in More than Two Million Patients/P. A. Cistulli, J. P. Armitstead, D. Liu, Y. Yan, J. L. Pepin, H. Woehrle, C. Nunez, A. Benjafi3ed, A. Malhotra, Sydney, Australia, p.A4391


304 Impact of CPAP Treatment on Depression in Patients with Coronary Artery Disease and Nonsleepy Obstructive Sleep Apnea: The RICCADSA Randomized Controlled Trial/Y. Peker, B. Balcan, E. Thunstrom, Istanbul, Turkey, p.A4394

A Supervised Community Physical Activity Program as an Effective Treatment in Moderate Obstructive Sleep Apnea: A Randomized Controlled Trial/M. Berger, J.-C. Barthelemy, D. Hupin, P. Labeix, M. Donnat, H. Id3dir, F. Costes, F. Roche, Saint-Etienne, France, p.A4395

305 A Supervised Community Physical Activity Program as an Effective Treatment in Moderate Obstructive Sleep Apnea: A Randomized Controlled Trial/M. Berger, J.-C. Barthelemy, D. Hupin, P. Labeix, M. Donnat, H. Id3dir, F. Costes, F. Roche, Saint-Etienne, France, p.A4395

306 Excessive Sleepiness Treated with Solriamfetol in a Phase 3 Study of Participants with Obstructive Sleep Apnea: Stratification by Adherence or Nonadherence to Primary Effective Treatment in Moderate Obstructive Sleep Apnea: A Randomized Controlled Trial/M. Berger, J.-C. Barthelemy, D. Hupin, P. Labeix, M. Donnat, H. Id3dir, F. Costes, F. Roche, Saint-Etienne, France, p.A4395


Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea-Results from the Adhere Registry/R. Mehra, K. Doghramji, R.J. Schwab, P.J. Strollo, K.P. Strohl, Cleveland, OH, p.A4402


Is Autotitration as Effective as In-Laboratory Titration for Determining Optimal CPAP Pressure in Children with OSA?/M.A. Carno, L. Gersz, B. Seaman, K. Chalanick, H.V. Connolly, Rochester, NY, p.A4406

Patient-Level Trajectories and Outcomes After Low-Dose CT Screening in the National Lung Screening Trial/J. Iaccarino, G.A. Silvestri, R.S. Wiener, Boston, MA, p.A4407


The Relationship Between Lung Cancer Risk According to the Brock PLCO2012 Model and Prevalence or Presence of COPD in the NLST-ACRIN Sub-Study (N=10,054)/R.P. Young, R.J. Hopkins, F. Duan, C. Chiles, D. Aberle, G.D. Gamble, Auckland, New Zealand, p.A4411


Pulmonary Nodule Biomarker Panoptic Study Results at 1 Year Supported by 2-Year Results/N.T. Tanner, A. Porter, S.C. Springmeyer, P. Kearney, G.A. Silvestri, Charleston, SC, p.A4413

Improvement in Compliance with Lung Cancer Screening Implementation in an Urban Teaching Hospital Internal Medicine Clinic, Following Institution of an Education Initiative/C. Olazagasti, A. Rothman, D. Sampat, D. Chow, D. Steiger, Boston, MA, p.A4414

Using Optical Coherence Tomography to Increase Tumor Biopsy Yield in Lung Nodules/L.P. Hariri, D.C. Adams, A.J. Miller, M.J. Suter, Boston, MA, p.A4415

Histology and Staging of Lung Cancer in Veterans Who Underwent Baseline Low-Dose CT Screening: Data from the Providence VA Medical Center/M.D. Jankowich, E.J. Gartman, J. Baptistle, L. Nici, Providence, RI, p.A4416


Outcomes of Lung Cancer Screening with Low-Dose Computed Tomography Among Individuals with Self-Reported Asbestos Exposure in the National Lung Screening Trial/C. Olazagasti, A. Rothman, D. Sampat, D. Chow, D. Steiger, Boston, MA, p.A4418


Genetic-Based Approach to Stratifying Risk of Lung Cancer Outperforms the Brock PLC02012 Model - Optimization of CT Screening Outcomes in the NLST-ACRIN Sub-Study (N=10,054)/R.P. Young, R.J. Hopkins, F. Duan, C. Chiles, D. Aberle, G.D. Gamble, Auckland, New Zealand, p.A4422


Screening High-Risk Patients with Low-Dose Chest CT (LDCT) Scans Over a Four-Year Period Provided a Relatively Safe and Effective Approach for Early Detection of Lung Cancers in a Veterans Health Administration Medical Center/T.K. Rubenstein, J. Demp, B. Giang, B. Elicker, M. Arjomandi, N. Trivedi, J.K. Brown, San Francisco, CA, p.A4424

4:30 p.m. - 7:00 p.m

ASSEMBLY MEMBERSHIP MEETINGS

The fourteen Assemblies are the primary groups of the AmericanThoracic Society. Each Assembly holds an annual Membership Meeting at the International Conference. All Assembly members and other interested individuals are invited to attend.

The Assembly Membership Meetings provide an update on the Assembly’s activities via the Assembly’s Leadership and provide Assembly members the chance to have input on future directions, information on how to get involved and networking opportunities. Voting results for the Assembly’s future leaders will also be announced.

The Assemblies on Behavioral Science and Health Services Research and Pediatrics meetings are held on Sunday, May 20th.

ALLERGY, IMMUNOLOGY AND INFLAMMATION
MANCHESTER GRAND HYATT SAN DIEGO
Harbor Ballroom G-I (Second Level, Harbor Tower)
Chairing: Bethany B. Moore, PhD, Ann Arbor, MI

BEHAVIORAL SCIENCE AND HEALTH SERVICES RESEARCH
MANCHESTER GRAND HYATT SAN DIEGO
Seaport Ballroom F (Second Level, Seaport Tower)
Chairing: Christopher H. Goss, MD, MSc, Seattle, WA This meeting will be held on Sunday, May 20th.

CLINICAL PROBLEMS
MANCHESTER GRAND HYATT SAN DIEGO
Grand Hall B (Lobby Level)
Chairing: Sanjay Sethi, MD, Buffalo, NY

CRITICAL CARE
MANCHESTER GRAND HYATT SAN DIEGO
Grand Hall A (Lobby Level)
Chairing: John P. Kress, MD, Chicago, IL

ENVIRONMENTAL OCCUPATIONAL AND POPULATION HEALTH
MANCHESTER GRAND HYATT SAN DIEGO
Coronado Ballroom D-E (Fourth Level)
Chairing: Howard M. Kipen, MD, MPH, Piscataway, NJ

PULMONARY INFECTIONS AND TUBERCULOSIS
MANCHESTER GRAND HYATT SAN DIEGO
Seaport Ballroom E (Second Level, Seaport Tower)
Chairing: Kevin P. Fennelly, MD, MPH, Bethesda, MD

NURSING
MANCHESTER GRAND HYATT SAN DIEGO
Coronado Ballroom A-B (Fourth Level)
Chairing: Eileen G. Collins, PhD, Chicago, IL

PEDIATRICS
MANCHESTER GRAND HYATT SAN DIEGO
Harbor Ballroom A-C(Second Level, Harbor Tower)
Chairing: Stephanie D. Davis, MD, Indianapolis, IN
This meeting will be held on Sunday, May 20th.

PULMONARY CIRCULATION
MANCHESTER GRAND HYATT SAN DIEGO
Grand Hall C (Lobby Level)
Chairing: Karen A. Fagan, MD, Mobile, AL

PULMONARY REHABILITATION
MANCHESTER GRAND HYATT SAN DIEGO
Seaport Ballroom A-B (Second Level, Seaport Tower)
Chairing: Richard Casaburi, MD, PhD, Torrance, CA

RESPIRATORY CELL AND MOLECULAR BIOLOGY
MANCHESTER GRAND HYATT SAN DIEGO
Harbor Ballroom A-C (Second Level, Harbor Tower)
Chairing: Irina Petrache, MD, Denver, CO

RESPIRATORY STRUCTURE AND FUNCTION
MANCHESTER GRAND HYATT SAN DIEGO
Grand Hall D (Lobby Level)
Chairing: Blanca Camoretti-Mercado, PhD, Tampa, FL

SLEEP AND RESPIRATORY NEUROBIOLOGY
MANCHESTER GRAND HYATT SAN DIEGO
Seaport Ballroom G-H (Second Level, Seaport Tower)
Chairing: Sanjay R. Patel, MD, Pittsburgh, PA

THORACIC ONCOLOGY
MANCHESTER GRAND HYATT SAN DIEGO
Seaport Ballroom D (Second Level, Seaport Tower)
Chairing: M. Patricia Rivera, MD, Chapel Hill, NC
7:00 p.m. - 10:00 p.m.

ASSEMBLY RECEPTIONS

Assembly members and non-members, students and fellows are invited to join us for an evening of networking, great company, and camaraderie. This is a wonderful opportunity to introduce young members and trainees to Assembly leaders, to connect with old friends and to set up new interactions and collaborations.

*Pre-registration and an additional fee are required. Seating is limited.*

The following Assemblies will hold a reception from 7:00 p.m. - 10:00 p.m. immediately following the Assembly Membership Meetings.

### Assembly on Allergy, Immunology and Inflammation
&
### Assembly on Respiratory Cell and Molecular Biology
MANCHESTER GRAND HYATT SAN DIEGO
Harbor Ballroom D-F (Second Level, Harbor Tower)

<table>
<thead>
<tr>
<th>Category</th>
<th>Fellows</th>
<th>Members</th>
<th>Non-Members</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joint Reception</td>
<td>$22.00</td>
<td>$42.00</td>
<td>$52.00</td>
</tr>
</tbody>
</table>

### Assembly on Sleep and Respiratory Neurobiology Reception
MANCHESTER GRAND HYATT SAN DIEGO
Seaport Ballroom F (Second Level, Seaport Tower)

<table>
<thead>
<tr>
<th>Category</th>
<th>Fellows</th>
<th>Members</th>
<th>Non-Members</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fellow</td>
<td>$25.00</td>
<td>$65.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Member</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-Member</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
SS210  PULMONARY TOXICITY DUE TO CHECKPOINT IMMUNOTHERAPY
K. Suresh, MD, Baltimore, MD
Point Loma (South Tower, First Floor)

SS211  CHALLENGING CASES IN CRITICAL CARE ULTRASOUND
D. Pradhan, MD, New York, NY
Solana (South Tower, First Floor)

SS212  INNOVATIVE APPROACHES TO IMPROVING INTER-PROFESSIONAL RESUSCITATION CARE: NOVEL TECHNOLOGIES AND EDUCATIONAL STRATEGIES
S.M. Kassutto, MD, Philadelphia, PA
Balboa (South Tower, Third Floor)

SS213  AN UPDATE IN PULMONARY ALVEOLAR PROTEINOSIS
A. Kumar, Michigan, Grand Rapids, MI
Mission Hills (South Tower, Third Floor)

SS214  THE INS AND OUTS OF PLEURAL SPACE INFECTION
O. Ibrahim, MD, Farmington, CT
Cardiff (South Tower, Third Floor)

SS215  EVALUATION AND MANAGEMENT OF SEVERE ASTHMA IN CHILDREN: A PERSONALIZED APPROACH
C. Rosas-Salazar, MD, MPH, Nashville, TN
Del Mar (South Tower, Third Floor)

SS216  LIFE AFTER LYTICS: UPDATES ON POST PULMONARY EMBOLISM CARE
S. Pugliese, MD, Philadelphia, PA
Miramar (South Tower, Third Floor)

SS217  SMALL AIRWAY TESTS: READY FOR CLINICS?
P. Robinson, MD, PhD, Westmead, Australia
Palomar (South Tower, Third Floor)

SS218  NON-INVASIVE VENTILATION IN CHILDREN
H.-L. Tan, MBBS, London, United Kingdom
La Costa (South Tower, Fourth Floor)

SS219  MANAGING THE AIRWAYS COMPLICATIONS OF THORACIC MALIGNANCIES
S. Shojaee, MD, CHDA, Richmond, VA
Catalina (South Tower, Fourth Floor)
• identify strategies and practical ideas to be able to promote their professional academic career development;

• engage in networking with colleagues using social media tools.

Social media can advance your career, but trainees are not taught how to productively use social media in this manner. This seminar provides concrete social media strategies for trainees and early career faculty to promote their work, engage trainees, and network. A faculty panel with knowledge in leveraging social media will provide concrete advice for effectively using social media for career advancement and scholarly success. Specifically, speakers will provide general overviews of tools, strategies, and best practices for academic success using social media. Subsequently, speakers and participants will participate in small group interactive discussions based on specific areas of interest.

Chairing: M.N. Ballinger, PhD, Columbus, OH

Speakers: N. Seam, Bethesda, MD
M. Koenigshoff, MD, PhD, Aurora, CO
G.S. Martin, MD, MSc, Atlanta, GA

C2 INTERSTITIAL LUNG DISEASE FROM CRADLE TO GRAVE

Assemblies on Clinical Problems; Pediatrics
9:15 a.m. - 11:15 a.m. SAN DIEGO CONVENTION CENTER Ballroom 20 B-C (Upper Level)

Target Audience
Providers caring for patients with interstitial lung disease

Objectives
At the conclusion of this session, the participant will be able to:

• improve knowledge on the state of the art comprehensive care of patients with interstitial lung disease;

• enable participants to develop new strategies to address management dilemmas in the care of patients with interstitial lung disease;

• integrate patient' needs to facilitate the discussion of palliative care.

This session will review the current knowledge on state of the art comprehensive care of interstitial lung disease from the entire life and disease spectrum. It will cover evolving areas in the management of interstitial lung disease. Case vignettes will illustrate the clinical relevance and introduce each of the topics. An audience response system will be used to engage the audience and gauge the clinical practices and management decisions of attendees before and after each presentation.

Chairing: J. Morisset, MD, Montreal, Canada
M. Wijsenbeek, MD, PhD, Rotterdam, Netherlands
H.R. Collard, MD, San Francisco, CA

9:15 Introduction
J. Morisset, MD, Montreal, Canada

9:20 Case Vignette 1
M. Wijsenbeek, MD, PhD, Rotterdam, Netherlands

9:25 CHILD: From Infancy to Puberty and Beyond
R.R. Deterding, MD, Aurora, CO

9:50 Case Vignette 2
M. Wijsenbeek, MD, PhD, Rotterdam, Netherlands

9:55 ILA: The Unexpected Detected and What Now?
G.M. Hunninghake, MD, MPH, Boston, MA

10:20 Case Vignette 3
M. Wijsenbeek, MD, PhD, Rotterdam, Netherlands
### C3 STATE OF THE ART PLEURAL DISEASE MANAGEMENT: CLINICAL TRIALS CHANGING CARE PRACTICE

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chairing</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:15 a.m. - 11:15 a.m.</td>
<td><strong>SAN DIEGO CONVENTION CENTER</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Ballroom 20 D (Upper Level)</strong></td>
<td></td>
</tr>
<tr>
<td>Target Audience</td>
<td>Clinicians and allied health professionals with clinical &amp; research responsibilities in respiratory diseases; chest physicians, pulmonologists, oncologists, nurses, surgeons, internists, GP, junior staff &amp; scientists engaged in translational research</td>
<td></td>
</tr>
<tr>
<td>Objectives</td>
<td>At the conclusion of this session, the participant will be able to:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• understand and review the latest clinical trial evidence on best management of malignant pleural effusions, especially regarding the use of indwelling pleural catheters vs pleurodesis; especially recently published trials in the field;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• review the latest clinical trial evidence on best management of pleural infection, especially intrapleural therapy with tPA DNase, and the ongoing work on their best delivery regime;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• review the latest research finding in TB pleural effusion and in pneumothorax management. How these work would influence clinical care will be discussed.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Recent years have seen many multicentered pleural disease trials completed with immediate impact on clinical care. These studies have been published in high impact journals: including trials on malignant effusions (eg TIME-1 and -2 trials - both in JAMA), mesothelioma (SMART trial - Lancet Oncology; MAPPs and Meso-VATS - Lancet), and pleural infection (eg MIST-2 - NEJM), and pneumothorax. Several large trials eg the AMPLE-1, IPC-PLUS, ASAP, PLEASE and MIST-3 are completed and will report results in 2017/early 2018. The proposed session will update the audience of the latest exciting advances from RCTs that impact care.</td>
<td></td>
</tr>
<tr>
<td>Chairing:</td>
<td>V.C. Broadus, MD, San Francisco, CA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>D.J. Feller-Kopman, MD, Baltimore, MD</td>
<td></td>
</tr>
<tr>
<td>9:15</td>
<td><strong>State of the Art Management of Malignant Pleural Effusions</strong></td>
<td>N. Maskell, MD, Bristol, United Kingdom</td>
</tr>
<tr>
<td>9:40</td>
<td><strong>State of the Art Management of Pleural Infection</strong></td>
<td>Y.C.G. Lee, MBChB, PhD, Perth, Australia</td>
</tr>
<tr>
<td>10:05</td>
<td><strong>State of the Art Translational Advances in Tuberculous Pleural Effusions</strong></td>
<td>C.F. Koegelenberg, MD, PhD, Cape Town, South Africa</td>
</tr>
</tbody>
</table>
10:45 How Do We Reconcile Conflicting Data? Fluids Are Harmful, but so Are Pressors  
N. Shapiro, MD, MPH, Boston, MA

11:03 Panel Discussion  
K. Hibbert, MD, Boston, MA

C5 MITOCHONDRIA-TARGETED THERAPEUTICS FOR PREVENTING OR TREATING LUNG DISEASES

Assemblies on Respiratory Structure and Function; Allergy, Immunology and Inflammation; Environmental, Occupational and Population Health; Respiratory Cell and Molecular Biology
9:15 a.m. - 11:15 a.m. MARRIOTT MARQUIS SAN DIEGO MARINA  
Pacific Ballroom 21 (North Tower, First Floor)

Target Audience
Basic and translational researchers in respiratory disease biology and clinical researchers interested in exploring new frontiers

Objectives
At the conclusion of this session, the participant will be able to:
• learn new findings about how mitochondrial health is a critical determinant of the ability of the lung to appropriately respond to stress and how mitochondria-targeted therapeutics are showing promise in chronic lung diseases and acute lung injury;
• apply knowledge about the use of mitochondria-targeted antioxidants to improve quality of life of patients;
• apply knowledge of mitochondrial metabolism and nutritional stress to better understand preventive strategies in lung disease.

Positioned at the hub of cellular metabolic flux, mitochondria are uniquely adapted to communicate with the nucleus to bring about cellular as well as extra-cellular responses to perceived threats. Lung epithelial cells are exposed to high levels of environmental stress and mitochondrial dysfunction critically contributes to the pathogenesis of a variety of lung diseases ranging from development of smoking related COPD to hypoxia induced pulmonary arterial hypertension (PAH). Mitochondria targeted antioxidants substantially improve abnormal cellular biology of airway smooth muscle from COPD patients. This session will review the current knowledge on the role of mitochondrial dysfunction in connecting environmental stress to lung disease, recent advances in targeting mitochondria and the therapeutic potential for such strategies.

Chairing:  
A. Agrawal, MD, PhD, New Delhi, India  
J. Bhattacharya, MD, New York, NY

9:15 Mitochondrial Redox Signals Regulate Cell Stress Responses  
P.T. Schumacker, PhD, Chicago, IL

9:35 Mitochondrial Mechanisms in Pulmonary Vascular Disease  
S.C. Erzurum, MD, Cleveland, OH

9:55 Smoke Induced Mitochondrial Dysfunction in Pathogenesis of Airway Disease  
C.M. Pabelick, MD, Rochester, MN

10:15 Accelerated Lung Aging in COPD: The Role of Mitochondrial Dysfunction and the Promise of Mitochondria-Targeted Antioxidants  
P.J. Barnes, MD, DSc, London, United Kingdom

10:35 Acute Lung Injury Is a Mitochondrial Disease  
M.N. Islam, PhD, New York, NY

10:55 Delivery of Exogenous Functional Mitochondria into Damaged Cells  
A. Krasnodembskaya, PhD, Belfast, United Kingdom

C6 COPD PROGRESSION: CULPRITS AND MODIFIERS

Assemblies on Respiratory Cell and Molecular Biology; Allergy, Immunology and Inflammation
9:15 a.m. - 11:15 a.m. MARRIOTT MARQUIS SAN DIEGO MARINA  
Pacific Ballroom 18-19 (North Tower, First Floor)

Target Audience
Basic and translational investigators and trainees who wish to understand how alterations in the immune system induced by cigarette smoke exposure perpetuate lung inflammation and damage after smoking cessation

Objectives
At the conclusion of this session, the participant will be able to:
• appreciate that in COPD lung inflammation persists long after smoking cessation;
• understand how alterations in the airway epithelium, immune system, or microbiome induced by cigarette smoke become self-perpetuating after smoking cessation.

Chronic exposure to cigarette smoke or other combustible organic matter is the strongest known risk factor for the development of chronic obstructive pulmonary disease (COPD). However, inflammation and lung damage persist in many patients with COPD despite smoking cessation. This session will highlight recent basic and translational studies that address why inflammation is disproportionally increased in COPD patients compared to smokers without COPD and why disease progression persists in some COPD patients even after smoking cessation.

Chairing:  
B.W. Richmond, MD, PhD, Nashville, TN  
I. Petrache, MD, Denver, CO  
J.L. Curtis, MD, Ann Arbor, MI

9:15 A Patient’s Perspective  
A. Merkens, Oceanside, CA

9:20 Cellular Senescence and Oxidative Stress Drive Persistent Inflammation and Disease Progression in COPD  
P.J. Barnes, MD, DSc, London, United Kingdom

9:40 Biologic Changes to the Human Small Airway Epithelium Following Smoking Cessation  
R.G. Crystal, MD, New York, NY

10:00 SlgA Deficiency Drives Chronic Airway Inflammation in COPD  
B.W. Richmond, MD, PhD, Nashville, TN

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
10:15  Microbiome: Breaking Bad in Chronic Lung Disease  
K. Yadava, PhD, Oxford, United Kingdom

10:30  Immunity and Autoimmunity in COPD: Two Faces of the Same Coin?  
F. Polverino, MD, PhD, Boston, MA

10:45  Dendritic Cells Drive NK Cytotoxicity in COPD, Even After Smoking Cessation  
C.M. Freeman, PhD, Ann Arbor, MI

11:00  When Smoke Doesn’t Clear: Nano Carbon Black Induces Th17 Cell-Mediated Emphysema  
F. Kheradmand, MD, Houston, TX

This session and the International Conference are supported by educational grants from AstraZeneca LP, GlaxoSmithKline, Sunovion Pharmaceuticals Inc. All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

---

**C7 MEDICATION AND BEYOND: TARGETED SYMPTOM MANAGEMENT FOR THE MECHANICALLY VENTILATED PATIENT**

Assemblies on Nursing; Critical Care

9:15 a.m. - 11:15 a.m.  
SAN DIEGO CONVENTION CENTER  
Room 30 A-B (Upper Level)

**Target Audience**  
Clinicians and researchers, including registered nurses and advanced practice nurses who interact with individuals receiving mechanical ventilation

**Objectives**  
At the conclusion of this session, the participant will be able to:

- assess common symptoms experienced by mechanically ventilated patients;
- integrate safe and effective targeted interventions into clinical practice to manage mechanically ventilated patients’ symptoms of anxiety, pain/discomfort, ventilator dysynchrony, and dyspnea;
- identify current knowledge gaps and directions for future research and clinical practice relevant to targeted management of mechanically ventilated patient symptoms.

This session will provide an overview of the current state of the science surrounding symptom assessment and targeted interventions for the management of distressful symptoms experienced by patients during mechanical ventilation. Speakers will first summarize the evidence on common patient reported symptoms, symptom assessment tools, and communication strategies to facilitate symptom assessment with this nonvocal patient population. Current knowledge in the use of targeted interventions including nonpharmacological management of pain/discomfort, anxiety, ventilator dysynchrony, and dyspnea will be featured. Implications for clinical practice and research will be discussed.

**Chairing:** J.L. Guttormson, PhD, Milwaukee, WI  
R.O. Hopkins, PhD, Murray, UT

---

**C8 TRANSLATIONAL IMMUNOLOGY AND LUNG DISEASE: INTEGRATING PATHOBIOLOGY TO THERAPY**

Assembly on Allergy, Immunology and Inflammation

9:15 a.m. - 11:15 a.m.  
MARRIOTT MARQUIS SAN DIEGO MARINA  
Grand Ballroom 5-6 (North Tower, Lobby Level)

**Target Audience**  
Pulmonary and allergy physicians, and physicians in training, who are focused on care of patients with immune based lung disease. Clinical, translational, and basic science researchers involved in studies of lung immunology and immunotherapy

**Objectives**  
At the conclusion of this session, the participant will be able to:

- learn new information about the immune basis of lung diseases;
- understand the scientific basis for new immunotherapies and how to best utilize these new therapies;
- gain new strategies for the management of patients with immune based lung disease.

This session will provide a review of several important immune based lung diseases by experts in the field of translational immunology. The talks will emphasize the immune basis of the disorders as well as the prospects for immunotherapy.

**Chairing:** B.D. Medoff, MD, Boston, MA  
L. Koth, MD, San Francisco, CA

---

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
C9  MAKING TUBERCULOSIS PREVENTION GREAT AGAIN

Assemblies on Pulmonary Infections and Tuberculosis; Clinical Problems
9:15 a.m. - 11:15 a.m.  MARRIOTT MARQUIS SAN DIEGO MARINA
               Grand Ballroom 8-9 (North Tower, Lobby Level)

Target Audience
Providers of lung health, public health officials, researchers interested in tuberculosis, policy makers

Objectives
At the conclusion of this session, the participant will be able to:
• apply current tests for latent tuberculosis infection (LTBI);
• treat LTBI using short-course regimens;
• learn new findings about predictive biomarkers and novel drug regimens that could facilitate further scale-up of targeted testing and treatment of LTBI.

More than 50 years ago, Comstock and colleagues demonstrated among Inuit communities in Alaska that mass testing and treatment of latent tuberculosis infection (LTBI) could achieve the levels of decline in tuberculosis (TB) incidence required for elimination. With the renewed emphasis on TB elimination globally and in the United States, there is increasing momentum for scale-up of LTBI testing and treatment. This symposium will explore the following: impact and cost-effectiveness of scale-up; how current tests and treatment regimens should be utilized; novel approaches in the pipeline to further improve testing and treatment; and gaps in implementation of LTBI testing and treatment.

Chairing:  A. Cattamanchi, MD, San Francisco, CA
P.A. Lobue, MD, Atlanta, GA
C.D. Hamilton, MD, Durham, NC

C10  NOVEL STRATEGIES TO COMPLEMENT PULMONARY REHABILITATION IN COPD

Assemblies on Pulmonary Rehabilitation; Behavioral Science and Health Services Research; Clinical Problems
9:15 a.m. - 11:15 a.m.  SAN DIEGO CONVENTION CENTER
               Room 16 A-B (Mezzanine Level)

Target Audience
Pulmonologists, nurses, respiratory therapists, physical therapists and exercise physiologists with clinical and research interests in pulmonary rehabilitation in COPD, and newer ways of delivering rehabilitation

Objectives
At the conclusion of this session, the participant will be able to:
• learn applicability of telehealth interventions for pulmonary rehabilitation and patient education;
• using alternative strategies such as yoga, tai chi and electrical stimulation to complement aerobic training;
• understand differences in enhancing physical activity is complementary but distinct from pulmonary rehabilitation, and learn strategies to increase physical activity.

Pulmonary rehabilitation is effective in improving the quality of life of patients with COPD. However, there are significant barriers to access to PR. In this session, speakers will describe novel strategies to enhance and deliver PR, including using smart technology for remote tele-rehabilitation, novel use of yoga, tai chi and neuromuscular electrical stimulation to complement traditional pulmonary rehabilitation, and also increase physical activity beyond the period of rehabilitation.
Chairing: S.P. Bhatt, MD, Birmingham, AL  
C. Garvey, FNP, MSN, MPH, San Francisco, CA  
R.S. Goldstein, MD, Toronto, Canada

9:15  Newer Devices for Rehabilitative Training  
M.A. Spruit, PT, PhD, Horn, Netherlands

9:35  Neuromuscular Electrical Stimulation: Can It Replace or Augment Conventional Pulmonary Rehabilitation?  
M. Maddocks, PhD, London, United Kingdom

9:55  Telehealth Interventions for Pulmonary Rehabilitation  
S.P. Bhatt, MD, Birmingham, AL

10:15  Strategies to Enhance the Physical Activity Benefits of Pulmonary Rehabilitation  
R. Casaburi, MD, PhD, Torrance, CA

10:35  Web-Based Self Management Programs  
S.J. Singh, PhD, Leicester, United Kingdom

10:55  Tai Chi and Yoga to Maintain Benefits of Pulmonary Rehabilitation Over the Long-Term  
M. Moy, MD, MSc, Boston, MA

C11  NEW PARADIGMS FOR RESOLVING SLEEP APNEA HETEROGENEITY: DEEP PHENOTYPING AND GENOMICS

Assembly on Sleep and Respiratory Neurobiology
9:15 a.m. - 11:15 a.m.  
SAN DIEGO CONVENTION CENTER  
Room 7 A-B (Upper Level)

Target Audience
Providers of respiratory and sleep medicine; trainees in pulmonary and sleep medicine; translational, clinical and basic researchers

Objectives
At the conclusion of this session, the participant will be able to:

• identify national/international resources for supporting large scale genomics studies of respiratory and sleep traits;
• describe methods for deriving physiological informative risk/susceptibility phenotypes from polysomnography studies, better characterizing subgroups with sleep apnea related risk and etiology;
• understand modern approaches for analysis of large scale omics data and identify molecular pathways that influence risk of sleep apnea.

This session will bring together international leaders in Precision Medicine initiatives as well as an inter-disciplinary group of researchers who have made advances in sleep apnea phenotyping and genomic studies of sleep apnea-related traits. The session aims to describe a modern paradigm for resolving heterogeneity of sleep apnea and for identifying risk factors for sleep apnea susceptibility that utilize quantitative phenotyping and genetic analyses. The goals are to challenge clinicians and researchers to consider a broader array of sleep apnea phenotypes both for clinical assessments and in research studies, including use in small and large-scale genetic studies. The session also will make the community aware of recent progress in linking novel sleep apnea phenotypes to genomic risk factors.

Chairing: S.S. Redline, MD, Boston, MA  
S.A. Sands, BSc, PhD, Cambridge, MA  
S. Chowdhuri, MD, MS, Detroit, MI

9:15  A Patient's Perspective  
S. Baker-Goodwin, EdD, East Lyme, CT

9:20  National Investments in Precision Medicine  
C.J. O’Donnell, MD, MPH, Boston, MA

9:30  Deep Phenotyping and Tailored Interventions  
B.A. Edwards, PhD, Melbourne, Australia

9:55  Clinical Sleep Apnea Phenotypes and Cardiovascular Disease  
A. Zinchuk, MD, New Haven, CT

10:15  Predicting Metabolic and Hemodynamic Responses to Sleep Apnea Treatment  
J.C. Jun, MD, Baltimore, MD

10:35  Genetic Associations for Novel Sleep Apnea Phenotypes From Large Population Studies  
B.E. Cade, PhD, Boston, MA

10:55  Lessons Learned From Pulmonary Genomics Studies  
S.A. Gharib, MD, Seattle, WA

C12  CHOOSING RIGHTLY: AT THE INTERSECTION OF PERSONALIZED MEDICINE AND DE-ADOPTION OF LOW-VALUE CARE

Assemblies on Behavioral Science and Health Services Research; Clinical Problems; Critical Care; Nursing; Pulmonary Circulation; Thoracic Oncology
9:15 a.m. - 11:15 a.m.  
SAN DIEGO CONVENTION CENTER  
Room 14 A-B (Mezzanine Level)

Target Audience
Clinicians, including registered nurses and advanced practice nurses, and scientists seeking to evaluate value in decision-making or interested in original research aimed at personalized medicine and de-adoptive practices will benefit from attending this session

Objectives
At the conclusion of this session, the participant will be able to:

• apply new strategies to evaluate value in health care;
• discuss unique areas of research across pulmonary medicine focused on the intersection between patient selection and optimizing value;
• evaluate future directions for patients and clinicians in value-based care.

Choosing Wisely® and other interventions to reduce low-value health care are vital. Yet, de-adoption of unnecessary care has proved difficult, partly due to the...
challenges of recognizing which patients are actually receiving low-value care. This session emphasizes how de-adoptive practices and personalized medicine can work together to reduce low-value care while also selecting patients likely to benefit from therapies. The session looks at quality of care across pulmonary medicine as leading experts discuss: areas where appropriate therapies are underutilized or misused; cutting-edge research aimed at preventing overuse; and future directions targeted to improve value in health care.

Chairing: T.S. Valley, MD, MSc, Ann Arbor, MI
R.S. Wiener, MD, MPH, Boston, MA
L.C. Feemster, MSc, MD, Seattle, WA

9:15 Identifying Pneumonia Patients Who Need Intensive Care (and Those Who Don’t)
T.S. Valley, MD, MSc, Ann Arbor, MI

9:35 Personalizing Lung Cancer Screening Through Risk Modeling and Shared Decision-Making
G.A. Silvestri, MD, Charleston, SC

9:55 Take a Deep Breath: Approaches to Selecting Patients with Chronic Lung Diseases for Self-Management
D.M. Donesky, PhD, ANP-BC, San Francisco, CA

10:15 Don’t Take Five: How Can We Reduce Inappropriate Use of PDE5 Inhibitors in Pulmonary Hypertension?
R.S. Wiener, MD, MPH, Boston, MA

10:35 Improving Safety Through De-Implementation of Unnecessary Inhaled Corticosteroids in COPD
L.C. Feemster, MSc, MD, Seattle, WA

10:55 What Do We Do After We’re Done Choosing Wisely®
S.D. Halpern, MD, PhD, Philadelphia, PA

C13 THE MICROBIOME IN CHRONIC AIRWAYS DISEASE

9:15 a.m. - 11:15 a.m. SAN DIEGO CONVENTION CENTER Room 32 A-B (Upper Level)

Chairing: G. Kitsios, MD, PhD, Pittsburgh, PA
L.N. Segal, MD, New York, NY
Y.J. Huang, MD, Ann Arbor, MI

Featured Speaker
9:15 The Relevance of Microbiome, Lessons from Outside the Lung/A.M. Morris, MD, MS, Pittsburgh, PA

Oral Presentations


10:00 Distinct Airway Microbiome Patterns Associated with Lung Cancer Development in a COPD Cohort/M.J. Mammen, M. Buck, Y. Sun, N. Waldron, S. Vallyaparambil, C. Wrona, C. Wrona, S. Sethi, Buffalo, NY, p.A4428


10:45 Distinct Airway Microbiome Patterns Associated with Frequent Exacerbator Phenotype in COPD/M.J. Mammen, N. Waldron, S. Vallyaparambil, C. Wrona, S. Sethi, Buffalo, NY, p.A4431

10:55 What Do We Do After We’re Done Choosing Wisely®
S.D. Halpern, MD, PhD, Philadelphia, PA

C14 NEW DEVELOPMENTS IN INTERVENTIONAL PULMONARY MEDICINE

9:15 a.m. - 11:15 a.m. SAN DIEGO CONVENTION CENTER Room 33 A-C (Upper Level)

Chairing: M.M. Wahidi, MD, MBA, Durham, NC
J.C. Cicenia, MD, Cleveland, OH

Oral Presentations


11:00 Cryobiopsy Followed by Surgical Lung Biopsy or Autopsy: A Five-Year Analysis/J.C. Hewlett, J.K. Pannu, J.A. Kropski, O.B. Rickman, O.M. Maldonado, R.J. Lentz, Nashville, TN, p.A4440

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.

11:00 Age-Related Modulation of Pulmonary Innate Immunity by Environmental Tobacco Smoke Against Influenza A/PR/8/34 in Mice/M. Rajavel, L. Wang, M. Poiidexter, T. Mar, C.B. Fulgar, J. Singh, K.E. Pinkerton, Davis, CA, p.A4456
9:45 Inflammatory Gene Expression Is Associated with Regional
Estimating Fiber Stresses from Pressure-Volume Curves for Spatial Distribution of Cell Injury During the Progression of Oral Presentations
Regional Aeration and Strain in the Heterogeneous Lung: Featured Speaker
C.E. Perlman, PhD, Hoboken, NJ
Chairing:
9:15 a.m. - 11:15 a.m. SAN DIEGO CONVENTION CENTER
C19 MECHANICAL VENTILATION: VISUALIZING PARENCHYMAL STRAIN AND ACUTE LUNG INJURY
9:15 Regional Aeration and Strain in the Heterogeneous Lung: Implications for Ventilator Management/D.W. Kaczka, MD, PhD, Iowa City, IA
Oral Presentations
9:30 Spatial Distribution of Cell Injury During the Progression of Ventilator-Induced Lung Injury/C. Mattson, K. Okamura, M. Kiselevach, B.J. Smith, Aurora, CO, p.A4471
11:00 Xenon-Enhanced CT for Measurement of Regional Gas Transport During Oscillatory Ventilation/J. Herrmann, J.M. Reinhardt, E.A. Hoffman, D.W. Kaczka, Iowa City, IA, p.A4477
C21 ALVEOLAR MACROPHAGE DIVERSITY IN LUNG INJURY AND REPAIR
9:15 a.m. - 11:15 a.m. MARRIOTT MARQUIS SAN DIEGO MARINA
Abstract Summaries
Viewing/Discussion 9:45-11:15
Grand Ballroom 11-13 (North Tower, Lobby Level)
801 Alveolar Macrophage Numbers Are Decreased During Acute S. Pneumoniae Pneumonia, and Are Repopulated by Both Lung and Bone Marrow-Derived Cells During Recovery/O.K. Giddings, W.J. Brickey, J.R. Martin, J.C. Gomez, J.C. Gomez, C.M. Doerschuk, Chapel Hill, NC, p.A4478
802 Resveratrol Suppresses Ly6C+ Subtype Macrophages in a Mouse Model with Acute Lung Injury/Z. Jiang, L. Li, L. Zhu, Shanghai, China, p.A4479
804 The Role of TLR Signalling Regulating Collagen Degradation by Macrophages in Pulmonary Fibrosis/B. Hay, B. Reader, J.W. Christman, M.N. Ballinger, Columbus, OH, p.A4481
805 Role of Macrophage Migration Inhibitory Factor (MIF) in Post-Influenza Bacterial Pneumonia/J.L. Koff, S. Roberts, Y. Sun, M. Piechýna, L. Leng, B.M. Juan Guardela, A. Mulenos, F. Ahangari, N. Kaminski, R. Bucalca, New Haven, CT, p.A4482
809 Apoptotic Cell Engagement Triggers Anti-Inflammatory Metabolic Reprogramming of Macrophages/A. McCubbrey, P.M. Henson, W.J. Janssen, Denver, CO, p.A4486

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
810 Distinctive Actions of Colony-Stimulating Factors on Proliferation and Activation of Two Main Pulmonary Macrophage Populations/C. Draijer, R. Penke, M. Peters-Golden, Ann Arbor, MI, p.A4487


813 Macrophage Regulation of Collagen and Alpha-Smooth Muscle Actin in Fibroblasts in the Setting of Pulmonary Fibrosis/S. Sethuraman, B. Reader, J.W. Christman, M.N. Ballinger, Columbus, OH, p.A4490

814 Sex Differences and STAT6-Dependent Regulation of IL-33 Induced Eosinophilic Airway Inflammation and Alternatively Activated Macrophage Differentiation/H. Zhao, V. Moarbesh, H. Aldossary, K. Restori, V. Gaudreault, J. Shan, E.D. Fixman, Montreal, Canada, p.A4491

815 The NLRP3 Inflammasome and IL-1ß Pathway Have a Pivotal Role in Granuloma Formation of Sarcoidosis/A. Prasse, P. Engelhard, L. Plappert, V. Hormung, F. Bauernfeind, B. Jager, Hannover, Germany, p.A4492


Chairing: W.G. Carlos, MD, MSCR, Indianapolis, IN
R. Adamson, MBBS, Seattle, WA
J.B. Richards, MD, MA, Boston, MA


409 The Effectiveness of Structured Echocardiography Simulation Training for Internal Medicine Residents/A. Alsaad, S. Davuluri, L. Simon, M. Maniaci, Jacksonville, FL, p.A4506

410 corECMO: e-Learning Within a Multimodality ECMO Curriculum for Critical Care Fellows/J. Badulak, P. Sanchez, A. Luks, M. Plourde, B. Coruh, Seattle, WA, p.A4507

411 Mapping Content of a Clinical Case Conference to Published Curricular Blueprints and Milestones/B. Block, L. Santhosh, L.E. Leard, San Francisco, CA, p.A4508


413 Expanding Training Opportunities in Patient Safety for Pulmonary and Critical Care Fellows Through a Multispecialty Graduate Medical Education Curriculum/A. Neumeier, A. Levy, E. Gottenborg, R. Pierce, D. Tad-y, Aurora, CO, p.A4510

224 Recent Alcohol Use Prolongs Hospital Length of Stay Following
223 Likelihood of Donor Utilization After Refusals Due to Donor
218 Mesenchymal Cells Cultured from Bronchoalveolar Lavage Are
217 Double Versus Single Listing Preference and “Intention-to-Treat”
Survival in the United States/A. Tabah, M.R. Anderson, A.
RoyChoudhury, D.J. Lederer, New York, NY, p.A4537
219 Post-Transplant Lymphoproliferative Disorder: A
Retrospective 17-Year Analysis/J.W. Whitson, L.D. Snyder, L.
Zaffiri, Durham, NC, p.A4540
220 Practice Patterns of Combined Lung Kidney Transplantation
Among Lung Transplant Candidates with Chronic Kidney
Disease/F. Woll, M. Mohanka, J. Mullins, S. Bollineni, V. Kaza, F.
Torres, B. Tanriover, A. Banga, Dallas, TX, p.A4540
221 Feasibility and Validity of a Home-Based Spirometry Program
After Hematopoietic Stem Cell Transplantation for the Early
Detection of Pulmonary Impairment/A. Sheshadri, A. Baiagani,
A.M. Alousi, L. Bashoura, K. Stolar, M.H. Arain, L. Noor, D.W.
Blanco, A. Ortiz, N.A. Goodwin, M. Chen, L. Li, K.R. Hess, R.F.
Chemaly, D.E. Ost, S.K. Peterson, R.E. Champlin, B.F. Dickey,
Houston, TX, p.A4541
222 Cytomegalovirus Infection Is Associated with Increased
Mortality in the New Era of Antiviral Prophylaxis for Lung
Transplant Recipients/G.S. Chandrarathine, H. Malhi, C.
Hernandez Garcia, J. Preiksaitis, K. Halloran, J.G. Weinkauf, A.
Kapasi, D.C. Lien, D. Kabbani, C. Cervera, A. Hirji, Edmonton,
Canada, p.A4542
223 Likelihood of Donor Utilization After Refusals Due to Donor
Quality/M. Schecter, E. Singh, C. Towe, J. Steger, R. Bryant III,
224 Recent Alcohol Use Prolongs Hospital Length of Stay Following
Lung Transplant in People with Advanced Lung Disease/E.M.
Lowery, C. Joyce, E.J. Kovacs, Maywood, IL, p.A4544

244 TUESDAY • MAY 22

C24 NEW TECHNOLOGIES FOR MANAGING COPD
9:15 a.m. - 11:15 a.m. SAN DIEGO CONVENTION CENTER
Room 30 C-E (Upper Level)

Abstract Summaries 9:15-9:45
Viewing/Discussion 9:45-11:15

Chairing: N. Marchetti, DO, Philadelphia, PA

601 Telehealth Exercise Intervention Reduces COPD Readmissions/
Schuman, J.M. Wells, M.M. Bamman, C.S. Bickel, J. Lowman, G.R.
Cutter, S.T. Windham, M.T. Dransfield, Birmingham, AL, p.A4545

Efficacy and Costs of Telehealth for the Management of COPD:
A Multicenter, Randomized Controlled Trial/J.B. Soriano, F.
García-Ríos, E. Vázquez Espinosa, J. Díaz de Atauri, L. López
Yepes, R. Galera Martínez, G. Peces Barba, M.T. Pérez
Warnisher, M. García Salomón, G. Segrelles, I. Ramos, J.
Conforto, P. Gonzalez, S. Jafri, J. Ancochea, Madrid, Spain,
p.A4546

Tele-Health with Chronic Obstructive Pulmonary Disease
(COPD)/A. Alrajeh, Y. Alldabayan, E. Pickett, S. Quaderi, M.
Lipman, J. Hurst, London, United Kingdom, p.A4547

Feasibility of Using a Novel Smartphone Application to
Improve Compliance and Engagement in Chronic Obstructive
Pulmonary Disease (COPD)/J.T.W. Krall, R. Alva, Greensboro,
NC, p.A4548

Natural Language Processing (NLP) to Identify Acute
Exacerbations of COPD in Real Time: A Pilot Program/J.M.
Wells, J.D. Osborne, J.K. Nichols, C.C. Blackburn, H. Chitkara, A.
Cimino, M.T. Dransfield, Birmingham, AL, p.A4549

Daily Measurements of Nocturnal Respiratory Rate Variability
May Predict COPD Exacerbations/J.Y. So, S.P. Duffy, H. Markus,
K. Rybicki, J. Dormer, A. Zaffaroni, H. Kilroy, A. Blase, B.N. Smith,

Ultrasound Use in Pulmonary Consultation/R. Shah, M. Korotun,

Combining Non-Contact Nocturnal Respiratory Monitoring with
Respiratory Symptom Characterization to Enhance Early
Detection of COPD Exacerbation/S.P. Duffy, J.Y. So, H. Markus,
K. Rybicki, J. Dormer, A. Zaffaroni, H. Kilroy, A. Blase, B.N. Smith,

Comparison in Clinical Outcomes Between Patients of Chronic
Respiratory Disease with and Without Nocturnal Hypcapnia
by Using Transcutaneous PCO2 Monitoring/M. Nonaka, Y.
Hyodo, K. Nemoto, Y. Miura, S. Oishi, K. Hayashihara, T.
Saito, Ibaraki, Japan, p.A4553

Can Smartphone-Based Pulse Oximeters Be Used for
Monitoring Patients with Chronic Obstructive Pulmonary
Disease/C. Brillante, A. Binder, J. Luo, V. Prieto-Centurion,
Chicago, IL, p.A4554

Automated Oxygen Titration and Weaning with FreeO2 During
Acute Exacerbation of COPD/F. Lellouche, P.-A. Bouchard, M.
Morissette, M. Simon, E. L’her, Québec, Canada, p.A4555

Optimization of Oxygen Titration and Weaning with FreeO2:
Update on Clinical Evaluation in More than 600 Subjects/F.
Lellouche, Québec, Canada, p.A4556

Oxygen Wristbands: A Visual Aid to Aid Safer Practice/S.J.
Patel, J. Proctor, S. Walker, S. Haddad, S. Lakehal, A. Jackson,
J. Marlow, S. Church, Warrington, United Kingdom, p.A4557

Trends in Long-Acting Bronchodilator Adherence During
Electronic Inhaler Monitoring/K. Alshabani, M. Smith, A. Attawy,
R. Rice, X. Wang, X. Han, U.S. Hatipoglu, Cleveland, OH, p.A4558

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.


617 Novel Monitoring Tools for Predicting Stable Discharge from the Emergency Department Observation Unit in Acute Exacerbation of COPD/R. Sengupta, M. Phillips, J. Ko, T. Loftus, R.J. Panos, M.A. Zafar, Cincinnati, OH, p.A4561


619 Internet Health Behaviors of Patients with Chronic Obstructive Pulmonary Disease and Their Perspectives on Disease Websites/D.A. Mahler, F. Cerasoli, L. Della, M. Rudzinski, Hanover, NH, p.A4563


621 The EMPROVE Trial - a Randomized, Controlled Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the Spiration® Valve System for Single Lobe Treatment of Severe Emphysema/G.J. Criner, A. Delage, K.G. Voelker, Philadelphia, PA, p.A7753

622 Evaluation of the Safety and Effectiveness of the Spiration Valve System for Single Lobe Treatment of Severe Emphysema in Patients with Alpha-1 Antitrypsin Deficiency/D.K. Hogarth, A. Delage, M.A. Zgoda, M.F. Reed, Chicago, IL, p.A7754

---

**RAPID: RAPID ABSTRACT POSTER DISCUSSION SESSION**

**C25 CRITICAL CARE: PATIENT AND FAMILY ENGAGEMENT, ETHICS, AND PALLIATIVE CARE**

*9:15 a.m. - 11:15 a.m. SAN DIEGO CONVENTION CENTER*

**Abstract Summaries**

9:15-9:45

**Viewing/Discussion**

9:45-11:15

**Chairing:** R.D. Stapleton, MD, PhD, Burlington, VT

N. Hajizadeh, MD, MPH, Manhasset, NY

D.B. White, MD, Pittsburgh, PA

**701 Climate of Care, Nursing Family Care and Family Well-Being in the Intensive Care Unit/N.S. McAndrew, Milwaukee, WI, p.A4564**

**702 Structured Interprofessional Bedside Rounds Increase Engagement in a Medical Intensive Care Unit/A. Chowdhury, C.J. Lehr, S. Gadre, H. Torbic, S. Smith, P. Rajendram, Cleveland, OH, p.A4565**


**708 Does Family-Reported Satisfaction Vary Between MICU Families with and Without Risk for Unmet Palliative Care Needs?/N. Roeder, N.M. Kashyap, R. McCorkle, M.D. Siegel, K.M. Akgun, New Haven, CT, p.A4571**


**710 Factors Associated with Physicians’ Predictions of Long-Term Mortality of Critically Ill Patients/B.L. Ferreyro, M.O. Harhay, S.D. Halpern, M.E. Detsky, Toronto, Canada, p.A4573**

**711 Pre-Hospital Disability and the Serial Evaluation of the SOFA Score to Predict Hospital Outcomes in Critically Ill Adults/R. Nair, M. Munoz, J.-T. Chen, M.N. Gong, A.A. Hope, Bronx, NY, p.A4574**


C26  PEDIATRIC ASTHMA: EPIDEMIOLOGY AND EPIGENETICS

9:15 a.m. - 11:15 a.m.  SAN DIEGO CONVENTION CENTER
Room 6 E (Upper Level)

Abstract Summaries  9:15-9:45
Viewing/Discussion  9:45-11:15

Chairing: A.A. Litonjua, MD, Rochester, NY
E. Forno, MD, MPH, Pittsburgh, PA
S. Lovinsky-Desir, MD, New York, NY

RAPID: RAPID ABSTRACT POSTER DISCUSSION SESSION


302 The Dietary Inflammatory Index and Current Wheeze Among U.S. Children and Adults/E. Forno, Y.Y. Han, N. Shivappa, M. Wirth, J. Hébert, J.C. Celedon, Pittsburgh, PA, p.A4590


309 Differential Roles of Rhinovirus (RV) A and RV-C Species in Respiratory Illnesses in Early Vs. Late Childhood/Y. Bochkov, M.D. Evans, K.A. Grindle, T.E. Pappas, R.F. Lemanske, D.J. Jackson, J.E. Gern, Madison, WI, p.A4597

310 Asthma Control in Preschool Years Predicts the Likelihood of Subsequent Disease Remission/F.M. Ducharme, L. Blais, M.D. Brownell, J. Quail, A. Forget, Y. Nie, W. Li, Y. Fan, R.W. Platt, Montreal, Canada, p.A4598

311 Effect of Obesity on Incident Childhood Asthma: Results from the National Pedsnet Clinical Data Research Network/J. Lang, M. Hossain, T. Wysocki, T. Bunnell, Durham, NC, p.A4599

312 Adherence to a Mediterranean Diet Attenuates the Adverse Effect of Indoor Particulate Matter on Asthma Symptoms in Children/J. Rice, E.P. Brigham, K. Koeht, M.C. McCormack, G.B. Diette, H. Woo, C. Hanson, S. Sharma, F. Kolahdooz, N.N. Hansel, Baltimore, MD, p.A4600

313 Number of Asthma Emergency Department Visits as a Predictor of Asthma Hospitalizations in Children/S. Giangioppo, N. Barrowman, V. Bijelic, D. Radhakrishnan, Ottawa, Canada, p.A4601
### RAPID: RAPID ABSTRACT POSTER DISCUSSION SESSION

#### C27  BALLROOM (PH) BLITZ: BASIC BIOLOGY

<table>
<thead>
<tr>
<th>Session Number</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>202123</td>
<td>Moraxella Dominates the Airway of Infants with Early Wheeze/K.M. Kloepfer, S. Ross, C. Hemmerich, J. Slaven, D. Rusch, S.D. Davis, Indianapolis, IN</td>
<td>Indianapolis, IN, p.A7756</td>
<td>9:15 - 11:15 a.m.</td>
<td>Room 28 C-E (Upper Level)</td>
</tr>
</tbody>
</table>

### Chairing:
- B.B. Graham, MD, Aurora, CO
- L.A. Shimoda, PhD, Baltimore, MD
- W.M. Oldham, MD, PhD, Boston, MA


### 504 Receptor for Advanced Glycation End Products (RAGE) Regulates Metabolic Reprogramming Induced Over-Proliferation in Pulmonary Hypertension/O. Rafikova, M.L. McBride, P.R. Langlais, R. Rafikov, Tucson, AZ | Tucson, AZ, p.A4613 | 9:15 - 11:15 a.m. | Room 28 C-E (Upper Level) |

### 505 2-Methoxyestradiol Attenuates Hypoxia-Induced Pulmonary Hypertension Via Alterations in Hypoxia Inducible Factor alpha/C.K. Docherty, M. Nilsen, L. Loughlin, M.R. MacLean, Glasgow, United Kingdom | Glasgow, United Kingdom, p.A4614 | 9:15 - 11:15 a.m. | Room 28 C-E (Upper Level) |

### 506 Circ-012559/miR-223 Potentially Targets AIF And PARP-1 Induced Cell Death in Pulmonary Hypertension/P. Yuan, Shanghai, China | Shanghai, China, p.A4615 | 9:15 - 11:15 a.m. | Room 28 C-E (Upper Level) |


### 510 Expression of the Tumor Suppressor WWQX in Pulmonary Artery Smooth Muscle Cells Is Lost During Hypoxia/M.T. Gomes, S. Singla, J. Chen, R.F. Machado, Indianapolis, IN | Indianapolis, IN, p.A4619 | 9:15 - 11:15 a.m. | Room 28 C-E (Upper Level) |

### 511 In Hypoxia-Exposed Human Pulmonary Artery Smooth Muscle Cells, Loss of PTEN-Induced Kinase 1 (PINK1) Occurs Through Posttranscriptional Mechanisms and Alters the Cellular Glycolytic Phenotype/D.E. Green, T.C. Murphy, C.M. Hart, Atlanta, GA | Atlanta, GA, p.A4620 | 9:15 - 11:15 a.m. | Room 28 C-E (Upper Level) |


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.


Hypoxia- and SU5416-Induced Downregulation of Nestin Causes Cell Cycle Arrest and Promotes Apoptosis in Bone Marrow Mesenchymal Stem Cells/D. Farkas, S. Hultman, K. Dandamudi, A.R. Bhagwani, L. Farkas, Richmond, VA, p.A4624


ML290, an Allosteric Relaxin-RXFP1 Agonist, Attenuates Hypoxia- and SU5416-Induced Downregulation of Nestin Causes Cell Cycle Arrest and Promotes Apoptosis in Bone Marrow Mesenchymal Stem Cells/D. Farkas, S. Hultman, K. Dandamudi, A.R. Bhagwani, L. Farkas, Richmond, VA, p.A4624

Hypoxia- and SU5416-Induced Downregulation of Nestin Causes Cell Cycle Arrest and Promotes Apoptosis in Bone Marrow Mesenchymal Stem Cells/D. Farkas, S. Hultman, K. Dandamudi, A.R. Bhagwani, L. Farkas, Richmond, VA, p.A4624

Therapeutic Targeting of High Mobility Group Box 1 in Pulmonary Hypertension/N.M. Goldenberg, Y. Hu, A. Volchuk, G. Wei, Y. Zhao, X. Hu, K.J. Tracey, Y. Al-Abed, M. de Perrot, B.E. Steinberg, W.M. Kuebler, Toronto, Canada, p.A4627

Apabetalone (RVX-208) Alone and in Combination with Standard of Care Improves Experimental PAH in Sugen-Hypoxia Rat Model/E. Tremblay, S. Paquet-Marceau, M.-C. Lampron, R. Jahagirdar, E. Kulikowski, S. Provencher, S. E. Tremblay, S. Paquet-Marceau, Sugen-Hypoxia Rat Model, Quebec City, Canada, p.A4628

Effect of Single Lung Transplantation on Native Lung Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension/A. Gibbs, J.D. Cooper, J. Robinson, R.M. Tuder, Portland, OR, p.A4629


Divergent Regulation of ATII Cell and Fibroblast Apoptosis Sensitivity by PAI-1 in Aged Mice/C. Jiang, G. Liu, J. Deshane, V.B. Antony, V.J. Thannickal, R.-M. Liu, Birmingham, AL, p.A4640


Rapid: Rapid Abstract Poster Discussion Session

C28 ROLE OF CELLULAR CROSS TALK IN LUNG HOMEOSTASIS AND AGING
9:15 a.m. - 11:15 a.m. MARRIOTT MARQUIS SAN DIEGO MARINA
Pacific Ballroom 15-17 (North Tower, First Floor)

Abstract Summaries
9:15-9:45
Viewing/Discussion
9:45-11:15

Chairing: L. Hecker, PhD, Tucson, AZ
M. Bueno, PhD, Pittsburgh, PA

Structural and Functional Changes of Alveolar Type II Cells with Age and Acute Lung Injury/C. Brandenberger, C.C. von Ziegern, C. Mühlfeld, Hannover, Germany, p.A4632


Macrophage Migration Inhibitory Factor Protects Against Cigarette Smoke-Induced Senescence/S.-J. Kim, I.S. Bazan, P. Shan, M. Saurer, L. Reng, B. Bucala, P. Lee, New Haven, CT, p.A4634

The Lung Microenvironment Shapes the Alveolar Macrophage Transcriptome During Aging/A. C. Mc Quattle-Pimentel, C.-I. Chen, Z. Ren, P.A. Reyfman, K.M. Ridge, H. Perlman, A. Misharin, G.S. Budinger, Chicago, IL, p.A4635

Investigating the Consequences of Selective Inhibition of AT2 Stem Cell Activity on Lung Alveolar Maintenance/M.B. McCarra, Y. Kazadaeva, T. Desai, Stanford, CA, p.A4636


The Lung Microenvironment Shapes the Alveolar Macrophage Transcriptome During Aging/A. C. Mc Quattle-Pimentel, C.-I. Chen, Z. Ren, P.A. Reyfman, K.M. Ridge, H. Perlman, A. Misharin, G.S. Budinger, Chicago, IL, p.A4635

Investigating the Consequences of Selective Inhibition of AT2 Stem Cell Activity on Lung Alveolar Maintenance/M.B. McCarra, Y. Kazadaeva, T. Desai, Stanford, CA, p.A4636


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
924  Foundational Mapping of the Neural Circuits that Control Intrinsic Lung Function
J. Verheyden, J. Xu, T. Zhang, W. Paltzer, Y. Xu, X. Sun, La Jolla, CA, p.A4655

925  Cigarette Smoke Induced Cellular Senescence Program Gene Profile Is Independent of Aging in Mouse Model of COPD/Emphysema

C29  LUNG STRUCTURE AND FUNCTION: NEW INSIGHTS FROM MEASUREMENT AND MODELING
9:15 a.m. - 11:15 a.m.  MARRIOTT MARQUIS SAN DIEGO MARINA


1008  Sacin Responds to Total Compliance Heterogeneity and Is Less Sensitive to Regionalisation than Scond/B. Foy, D. Kay, Oxford, United Kingdom, p.A4664

1009  Healthy Lung Units Which Constrict During One Methacholine Challenge Are More Likely to Do so Again in the Next/E. Geier, I. Neuhart, R.J. Theilmann, G.K. Prisk, R.C. Sa, San Diego, CA, p.A4665
C31 MECHANISTIC INSIGHTS INTO LUNG INFECTION
9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER
Area K (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.
Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: R. Zemans, MD, Ann Arbor, MI

P1131 IL-9 Deficiency Promotes Th17 Response in a Murine Model of Pneumocystis Pneumonia/T. Li, Z.-H. Tong, Beijing, China, p.A4699


P1134 Multi Drug Resistant Acinetobacter Baumannii Adapt to the Lung by Suppressing Inflammasome Activation/S. Gill, A.S. Prince, A.-C. Uhlemann, New York, NY, p.A4702


Facilitator: D.N. O’Dwyer, PhD, Ann Arbor, MI

P1138 The E3 Ubiquitin Ligase MARCH8 Delays the Interferon Gamma Receptor/J. D. Londino, L.S. Masa, R.K. Mallampalli, Pittsburg, PA, p.A4706


Facilitator: I. Vadasz, MD, Giessen, Germany


P1151 Bacterial Determinants of Methicillin-Resistant Staphylococcus Aureus in Post-Influenza Pneumonia/J.A. Grousd, K.J. McHugh, A.R. Richardson, V.S. Cooper, J.F. Alcorn, Pittsburgh, PA, p.A4719

P1152 Rhinovirus C Infection in Swine Respiratory Explant Cultures/W.Y. Chan, Q. Tian, K.P. Tao, H.Y. Tsui, T.J.T. Li, T.F. Leung, Hong Kong, Hong Kong, p.A4720

P1153 Mucosal Genetic Delivery of Anti-Respiratory Syncytial Virus (RSV) Antibody by Non-Human Primate-Based Adenoviral Vector to Provide Protection Against RSV Pulmonary Infection/R. Gomi, A. Sharma, W. Wu, S. Worgall, New York, NY, p.A4721

P1154 Quantification of Mitochondrial DNA in Cell-Free Plasma Isolated from Massively Transfused Trauma Patients/R. Langley, V. Pastukh, C.M. Francis, Y. Tan, D.J. Dinwiddie, J.D. Simmons, M.N. Gillespie, Mobile, AL, p.A4722

Facilitator: Y. Aschner, MD, Aurora, CO


P1159 Chromatin Immunoprecipitation (ChiP) Sequencing Identifies a Potential Role of SP-R210 in Regulating Cellular Metabolism and Trafficking Genes in Macrophages/E. Yao, Y. Chen, A. Salzberg, Y.I. Kawasawa, C. Song, Z.C. Chrones, Hershey, PA, p.A4727


P1161 ABM125 Anti-IL-25 Antibody Pre-Clinical Development for Viral Asthma Exacerbations Identifies IL-25 Mediated Regulation of Type-2 and Anti-Viral Immunity/N. Bartlett, J. Girkin, T. Williams, T. Vincent, C. Jackson, K. Alton, R. Shimkets, Newcastle, Australia, p.A7759


P1163 The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
### THEMATIC POSTER SESSION

#### C32  LUNG TRANSPLANTATION: CLINICAL STUDIES

<table>
<thead>
<tr>
<th>Session Time</th>
<th>Title</th>
<th>Facilitator</th>
<th>Area</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:15 a.m. - 4:15 p.m.</td>
<td>Calcineurin-Inhibition Drives IL13 and IL5 Production in Differentiating and Memory T Cells in a Ca++-Dependent Manner/U. Gehrmann, K. Bjorhall, J. Jirholt, Mölndal, Sweden, p.A4731</td>
<td>C.M. Lin, MD, Gainesville, FL</td>
<td>Area H (Hall A-B2, Ground Level)</td>
</tr>
</tbody>
</table>

**Facilitator:** C.M. Lin, MD, Gainesville, FL

**Discussion:**
- 11:15-12:00: authors will be present for individual discussion
- 12:00-1:00: authors will be present for discussion with assigned facilitators

### THEMATIC POSTER SESSION

#### C33  SEPSIS: CELLULAR STUDIES

<table>
<thead>
<tr>
<th>Session Time</th>
<th>Title</th>
<th>Facilitator</th>
<th>Area</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:15 a.m. - 4:15 p.m.</td>
<td>Stearoyl Lysophosphatidylcholine Inhibits LPS-Induced Extracellular Release of HMGB1 Through the G2A/Calcium/CalMKKbeta/AMPK Pathway/H.-B. Bae, J.-I. Choi, H. Quan, Gwangju, Korea, Republic of, p.A4744</td>
<td>I.S. Douglas, MD, Denver, CO</td>
<td>Area D (Hall A-B2, Ground Level)</td>
</tr>
</tbody>
</table>

**Facilitator:** J.F. McDyer, MD, Pittsburgh, PA

**Discussion:**
- 11:15-12:00: authors will be present for individual discussion
- 12:00-1:00: authors will be present for discussion with assigned facilitators

**Posters will be on display for entire session.**
C34  COPD POTPOURRI

Facilitator: B.D. Singer, MD, Chicago, IL


P261  Very Low Density (VLDL) and Low Density Lipoproteins (LDL) Mediate the Uptake of Pathogen Lipids and Stimulate the Production of IL-1β in THP-1 Macrophages/A.K.-K. Leung, J.A. Russell, J.H. Boyd, K.R. Walley, Vancouver, Canada, p.A4747


THEMATIC POSTER SESSION

C34  COPD POTPOURRI

Facilitator: B.W. Richmond, MD, PhD, Nashville, TN


P1326  Proteomic Profiling of Protein-Protein Interactions of Alpha-1 Antitrypsin in Plasma/A. Dabo, E. Eden, R.F. Foronjy, P. Geraghty, Brooklyn, NY, p.A4751

P1327  Selegiline Suppressed Cigarette Smoke-Induced Oxidative Stress and Inflammation Via MAO-B Inhibition in Rat Lung/J.C.W. Mak, Y. Cui, K.W. Liu, Y. Liang, M.S. Ip, Hong Kong, Hong Kong, p.A4752

P1328  Urine Biomarkers of COPD Exacerbation; A Feasibility Study/A. Yousuf, L. Watson, G. Parekh, V. Mistry, J. Finch, S. Parker, L. Beadle, S. Glover, L. George, C.E. Brightling, Leicester, United Kingdom, p.A4753


P1334  Distribution of Ac-PGP in Mice After Intratracheal Administration/X. Xu, J. Li, L. Viera, N. Yi, J.E. Blalock, A. Gaggar, Birmingham, AL, p.A4759

Facilitator: E.S. Wan, MD, MPH, Boston, MA


P1337  The Role of T-Helper Type (Th1/Th2) Cytokines in Regulatory Mechanisms of Specific Conversion and Activation of CD4+Th1 During Inflammatory Reaction in Chronic Obstructive Pulmonary Disease (COPD)/J.L. Sun, T. Liu, Y. Liu, Y. Yan, K.K. Huo, W.N. Zhang, H.H. Liu, Z.H. Shi, Xi’an, China, p.A4762

P1338  Aa-Val<sup>342</sup> and Aa-Val<sup>441</sup> in Early Alpha-1 Antitrypsin Deficiency/J. Stockley, P.R. Newby, R.A. Stockley, E. Sapey, Birmingham, United Kingdom, p.A4763

P1339  The Relationship Between Nod-Like Receptor Family Pyrin Domain Containing 3 Inflammasome and Dopamine in the Inflammation Regulation Mechanism of Acupuncture for Chronic Obstructive Pulmonary Disease/X. Liu, T. Fan, J. Fu, J. Guan, B. Mao, Chengdu, China, p.A4764

P1340  Do Raised Serum Ige and Eosinophils Have an Affect on Quality of Life and Patient Related Outcome in COPD/?/A.J. Yousuf, S. Parker, J. Finch, G. Parekh, S. Glover, L. Watson, L. Beadle, C. White, C.E. Brightling, Leicester, United Kingdom, p.A4765


P1343  Validation of Cell Analysis by Chipytometry in Induced Sputum Cells/S. Carstensen, O. Holz, M. Mueller, J.M. Hohlfeld, Hannover, Germany, p.A4768


Facilitator: J.M. Wells, MD, Birmingham, AL

P1345  Clinical Usefulness of Once-Daily Triple Therapy, Ciclesonide and Tiotropium Bromide/Olodaterol Combination Inhaler for COPD Patients/H. Masayuki, Tokyo, Japan, p.A4770

P1346  An Ascending, Repeat-Dose Safety and Tolerability Study of AZD8871 a Novel, Dual-Acting Bronchodilator in Healthy Volunteers/C. Astbury, L. Jimenez, B. Seoane, C. Villarroel, M. Albayaty, V. Balaguer, A. Lei, A. Aggarwal, Barcelona, Spain, p.A4771

P1347  Can RDW Be a Prognostic Factor in Patients with Stable and Acute Exacerbation of COPD Who Do Not Have Any Cardiovascular Disease?/U. Yilmaz, O. Batum, S. Ermin, U. Tapan, Izmir, Turkey, p.A4772


P1349  The Effect of PUR1800, a Novel Narrow Spectrum Kinase Inhibitor, on Viral Replication and Viral-Induced Inflammation in Primary Human Airway Cells/A. Curran, K. Ito, D. Hava, C. Charron, Lexington, MA, p.A4774


Facilitator: M. Harriff, PhD, Portland, OR

P1355  Effects of E-cigarette Use and Smoking on Inflammasome Expression in Human Lung Lavage Fluid/M. Tsai, C. McAndrew, M.-A. Song, J. McElroy, P. Shields, M.D. Wewers, Columbus, OH, p.A4780


P1358  Increased Neutrophil-Platelet Interactions in Alpha-1 Antitrypsin Deficient Individuals Is Corrected Post Augmentation Therapy/N. Lacey, O.J. McElvaney, P. Hawkins, T. McEnery, M.Q. Lee, M. Hoo, E.P. Reeves, N.G. McElvaney, Dublin, Ireland, p.A4783

P1359  Data-Driven Modeling of Sputum and Blood Cytokine Networks During COPD Exacerbations/K. Norman, C.M. Freeman, L. McCloskey, M.K. Han, F.J. Martinez, J.L. Curtis, K.B. Arnold, Ann Arbor, MI, p.A4784

P1360  Development of an Automated Metered Dose Inhaler to Deliver Fluticasone to Rats and Examine the Effects of Corticosteroids on Upper Airway Function and Structure/N. Morel, O. Broytmann, J. Martinez, M. Teodorescu, Madison, WI, p.A4785


P1363  Pro-Atherogenic Cytokine Profile of Patients with COPD and OSA Overlap Syndrome: A Pilot Study/A. Shah, S.F. Van Eeden, N. Ayas, R. Jen, Vancouver, Canada, p.A4788


---

C35  CLINICAL STUDIES IN IMMUNODEFICIENCY

9:15 a.m. - 4:15 p.m.  SAN DIEGO CONVENTION CENTER

Area H (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators: R.S. Peebles, MD, Nashville, TN
J.E. Gern, MD, Madison, WI

P864  Non-Familial Pulmonary Alveolar Proteinosis in a Pregnancy Complicated by Stenotrophomonas Maltophilia/G. Pereira, J. Barney, Birmingham, AL, p.A4790

P866  Aspergillus-Infected Pneumatocele in Hyper-Immunoglobulin E Syndrome/D. Rai, L. Valcavik, W. Shandera, Houston, TX, p.A4792


P868  The Function of B Cell Activating Factor Receptor in Immune Response of Pneumocystis Carinii Pneumonia/H. Rong, Beijing, China, p.A4794


C36  CLINICAL STUDIES IN SARCOIDOSIS

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER
Area H (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion 12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: W.P. Drake, MD, Nashville, TN


P875  Peripheral Autophagy and Apoptosis Elements Distinguish Sarcoidosis and Tuberculosis/C. Schott, C. Ascoli, Y. Huang, B. Turturice, D. Perkins, P.W. Finn, Chicago, IL, p.A4800


P878  $S100B$ as a Biomarker for Neurosarcoidosis/B. Moss, D.C. Patel, D.A. Culver, Cleveland, OH, p.A4803


Facilitator: E.D. Crouser, MD, Columbus, OH


P883  Transcriptome Analysis Reveals Regulation of Sarcoidosis Granuloma Biogenesis by IL-13, IL-10 and TLR2/V. Le, M.W. Julian, P. White, A.C. Papp, L.W. Locke, W. Sadee, L. Schlesinger, E.D. Crouser, Columbus, OH, p.A4808

P884  An Exome Sequencing Study Deciphers Rare Genetic Variants in Familial Sarcoidosis/A. Kishore, B.-S. Petersen, M. Nutsua, M. Schürmann, J. Muller-Quernheim, A. Franke, A. Fischer, S. Schreiber, M. Petrek, Kiel, Germany, p.A4809

P885  A Transcriptomic Analysis of Monocyte Subsets and Their Roles in Pulmonary Sarcoidosis/S. Machiraju, B. Benn, N. Bhakta, N. Arger, L. Koth, San Francisco, CA, p.A4810


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
C37 OPTIMIZING ASTHMA CARE ACROSS DIVERSE PATIENTS

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER

Facilitator: E. Oren, PhD, MS, San Diego, CA

P1 Effectiveness of an Educational Asthma Program/A.L.L. Godoy Fernandes, J.V. Araujo, M.M. Amorim, Sao Paulo, Brazil, p.A4824


P3 Evaluation of Asthma Symptom Control in Indian Population Using ACT and to Compare with GINA Criteria/A. Perni, R.P. Ilanagho, Chennai, India, p.A4826


P5 Features of Long-Term Dynamics of Health-Related Quality of Life in Patients with Asthma/J.M. Perelman, N.L. Perelman, Blagoveshensk, Russian Federation, p.A4828

P6 The Impact of Treatment Change on Economic and Quality of Life Outcomes Among Treated, Adherent, Uncontrolled Patients with Persistent Asthma/N. Lugogo, S. Gabriel, C.M. Carpinella, R. Ariely, L.K. Lee, G. Mosnaim, Ann Arbor, MI, p.A4829

P7 Knowledge on Self-Management and Levels of Asthma Control Among Adult Patients in Ho Chi Minh City, Vietnam/V.N. Nguyen, T.T.H. Huynh, N. Chavannes, Ho Chi Minh City, Viet Nam, p.A4830

P8 Searching the Best Statistical Model Predicting Asthma Exacerbation in Elderly/H.-W. Park, S.S. Kim, Seoul, Korea, Republic of, p.A4831

P9 Adherence Monitoring and Inhaler Reminders Benefit GPs and Patients in Family Practice Settings/J. Foster, H.K. Reddel, Sydney, Australia, p.A4832


P15 What Factors Affect Treatment Failure When Antibiotics Are Given for Asthma Exacerbations? A Database Analysis/M. Stolbrink, L.J. Bonnett, J.D. Blakley, Liverpool, United Kingdom, p.A4838
The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
P95 Two Behavioral Interventions for Patients with Major Depression and Severe COPD/R.S. Novitch, J.A. Sirey, G.S. Alexopoulos, White Plains, NY, p.A4886

P96 Evaluation of Depression and Anxiety and Their Influence on Outcomes in Adult Patients with Cystic Fibrosis/R. Gersten, B. Cannon, M. Bowen, E. Davies, A.W. Brown, Fairfax, VA, p.A4887


P98 Resilience Is Associated with Fewer Symptoms of Depression and Anxiety and Improved Quality of Life in Patients with Pulmonary Arterial Hypertension/M. King, C. Abbott, C. Carter, A. Hudler, M. Moss, P.D. Sottile, T.M. Bull, Denver, CO, p.A4889


Facilitator: D. Koinis-Mitchell, PhD, Providence, RI


P102 Coincidence of Insomnia and Depressive Disorders Play Significant Role on Acceptance to Continuous Positive Airway Pressure Therapy in Patients with Severe Obstructive Sleep Apnea/S. Tryfon, T. Drakou, M. Saroglou, D. Kazis, S. Papagiannopoulous, P.A. Steiropoulos, Thessaloniki, Greece, p.A4893

P103 Peculiarities of Psychological Profile in Young Male Patients with Grade 1 Arterial Hypertension, Severe Obstructive Sleep Apnea and Obesity/E. Elfimova, A. Aksenova, P. Galitsin, A. Litvin, I. Chazova, Moscow, Russian Federation, p.A4894

P104 Anxiety, Depression, and Symptom Control in Adult Patients with Asthma/U. Kulsum, K. Cervellione, T. Ulkah, P. Jain, A. Chester, C.A. Thurman, Jamaica, NY, p.A4895

P105 Social Complexity: A Strong Influence on Outcomes in Adolescents with Cystic Fibrosis/E. Crowley, C.D. Brown, Indianapolis, IN, p.A4896
P117  Pulmonary and Critical Care Fellows' Perceptions and Practices on Social Media at One Training Program and Potential Use in Medical Education/M.M. Lee, C.C. Fung, Los Angeles, CA, p.A4907


P119  Impact of On-Line Medical Education on Pulmonologists and Allergists/Clinical Immunologists Regarding the Definition, Evaluation and Treatment of Severe Asthma/T. Lambert, Wilmslow, United Kingdom, p.A4909


Facilitator:  S.M. Kassutto, MD, Philadelphia, PA


P129  Results of a Needs Assessment on Internal Medicine Intern Point-of-Care Ultrasound Attitudes and Skills/E. Goerlich, G. Liu, T. Zhang, B.T. Garibaldi, Baltimore, MD, p.A4919


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.


P147 Development of a Predictive Algorithm Based on Healthcare Behaviour to Support Earlier Diagnosis of Idiopathic Pulmonary Arterial Hypertension: Results of a Feasibility Study in the UK/R. Bergemann, J. Allsopp, H. Jenner, F.A. Daniels, E. Drage, Y. Samyshkin, D. Kiely, A. Lawrie, Brentford, United Kingdom, p.A4936


Facilitator: G.S. Sawicki, MPH, MD, Boston, MA

P152 Education and Employment After Lung Transplantation in Adolescents and Young Adults/H.J. Chou, D. Hayes, D. Tumin, Columbus, OH, p.A4941


P156 Validity and Reliability of ACE-I Tool for Chest Physiotherapy in Hospitalized Pediatric Patients with Respiratory Distress/B.L. Shutes, M.D. Moore-Clingenpeel, L.R. Evans, Columbus, OH, p.A4945

P157 Predictors of Prolonged Length of Hospital Stay for Infants with Bronchiolitis/C. Rodriguez Martinez, M. Sossa, G.R. Nino, Bogota, Colombia, p.A4946

Facilitator: C. Holtze, MD, MPH, Ann Arbor, MI


P159 Burden of H1N1 Influenza in India (2010-2017): Identifying Hotspots and Policy Directions/P. Chatterjee, B. Seth, T. Biswas, K. Bera, Kolkata, India, p.A4948


P164 Concordance Rates Between Nasopharyngeal (NP) Wash and Bronchoalveolar Lavage (BAL) Respiratory Viral Panel Testing in Adult Patients Undergoing Evaluation at a University Hospital Center/A. George Jacob, T.J. Gross, Iowa City, IA, p.A4953

P165 A Descriptive Study of Pulmonology-Related Medical Malpractice Claims/L. Myers, J. Skillings, L. Heard, J. Metlay, E. Mort, Boston, MA, p.A7764


THEMATICAL POSTER SESSION

C42 CONTEMPORARY TOPICS IN COPD

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER

Area L (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion

12:00-1:00: authors will be present for discussion with assigned facilitators

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
Facilitator: A.S. Gershon, MD, MSc, Toronto, Canada


P1368 Is Chronic Obstructive Pulmonary Disease (COPD) Independently Associated with Moderate-Severe Musculoskeletal Pain?/K.M. Akgun, K.A. Crothers, L. Bastian, J. Womack, C. Brandt, J.L. Goulet, West Haven, CT, p.A4957

P1369 Sit and Stand Test of 3 Minutes (3MSST) for Malagasy Healthy Non Smoker Subjects/I. Ratomaharo, D. Rakotonanahary, M. Randriantahary, L. Rabarijaona, R. Rakotoarivelou, M. Randria, Athis-Mons, France, p.A4958


P1371 Impact of Memory Impairments on Chronic Obstructive Pulmonary Disease (COPD) Outcomes/J. O'Toole, T. Eckmann, M. Eakin, Baltimore, MD, p.A4960

P1372 Insomnia Symptoms in COPD and Association with Health-Related Quality of Life Outcomes/S. Gupta, B.N. Palen, J. Mears, S.F. Jones, A. Arroliga, Temple, TX, p.A4969

P1373 Perception on the Exacerbation in Patients with COPD with Different Severity of Dyspnea/Y. Chen, W. Mi, M. Lu, W. Yao, Beijing, China, p.A4962

P1374 Factors Associated with Emergency Department Admission in COPD Exacerbations/W.M. Pruett, H. Smith, C. Ellis, Des Moines, IA, p.A4963

P1375 Predictors of Stable Discharge from the ED Observation Unit in COPD Exacerbation/M. Doers, S. Menriman, T. Loftus, R. Panos, M.A. Zafar, Cincinnati, OH, p.A4964

Facilitator: M.J. Joo, MD, MPH, Chicago, IL


P1379 The Impact of Pharmacists Versus Physicians on the Conversion from Intravenous (IV) to Oral (PO) Corticosteroids in Patients with Chronic Obstructive Pulmonary Disease (COPD)/A.F.A. Basilim, L. Calkins, M. Alshibani, S. Perona, Tucson, AZ, p.A4968


P1381 The Utilization of COPD Specific Order Sets and Associated Clinical Outcomes/J. Gresens, S.E. Jolley, E. Price-Haywood, J. Burton, New Orleans, LA, p.A4970

P1382 The Impact of Respiratory Viral Panel Results on the Length of Stay in Patients Admitted for Acute Exacerbation of Chronic Obstructive Pulmonary Disease/M.I. Shafi, Y. Tarabichi, Cleveland, OH, p.A4971


P1385 The Outcome of an Integrated Care Intervention at a Tertiary Hospital for Patients with Chronic Obstructive Pulmonary Disease: A Retrospective, Single Center, Cohort Study of the Connecting Care to Home Program/J. Jackson, M. Povitz, C. Schultz, London, Canada, p.A4974

Facilitator: S. Rinne, MD, PhD, Bedford, MA


P1388 Multidisciplinary Team Approach to Reduce COPD Readmissions in a Tertiary Care Center/N. Wynn, N. Johnson, T.B.D. Ferreira, Miami, FL, p.A4977


Diagnostic Instability and Diagnosis Reversal in Veterans with COPD/R. Zuquello, M. Intriglio, M.A. Campos, Miami, FL, p.A4985


Comparison of Health Care Utilization and Medical Cost of Chronic Obstructive Pulmonary Disease Stratified by Spirometry Results/Y.I. Hwang, K.-S. Jung, S.H. Jang, K.H. Yoo, S. Park, J.Y. Park, C.K. Rhee, Anyang-si, Korea, Republic of, p.A4987

Evaluation of Spirometry Results in Women Older than 18 Years in the General Hospital of Mexico “Dr. Eduardo Liceaga”/Y. Mares, M. Diaz, R. Hernandez, Mexico City, Mexico, p.A4988


Preference in Patients with COPD: A Comparison of the Single Inhaler Type ELLIPTA Versus Dual Inhaler Combinations/J. Van Der Palen, W. Moeskops-Van Beurden, W.-Y. James, C. Dawson, A. Preece, D. Midwinter, N. Barnes, R. Sharma, Enschede, Netherlands, p.A4992

Time to Achieve Correct Inhaler Use in Patients with COPD: A Comparison of the Single ELLIPTA Inhaler with Dual Inhaler Combinations/J. Van Der Palen, W. Moeskops-Van Beurden, W.-Y. James, C. Dawson, A. Preece, D. Midwinter, N. Barnes, R. Sharma, Enschede, Netherlands, p.A4993

Inhaler Errors in COPD: A Comparison of Using a Single Inhaler Type ELLIPTA Inhaler Versus Multiple Inhaler Types/J. Van Der Palen, W. Moeskops-Van Beurden, W.-Y. James, C. Dawson, A. Preece, D. Midwinter, N. Barnes, R. Sharma, Enschede, Netherlands, p.A4994

Facilitator: S. Bosnic-Anticevich, BPharm, PhD, Glebe, Australia


Impact of COPD Maintenance Inhaler Costs Upon the Need for Acute Care/F. Celestin, F. Farooq, J.L. Breeze, P. LaCamera, Boston, MA, p.A4997


Inhaler Prescription Pattern in Patients Over 90 Years of Age with Physician Diagnosed COPD in Inner City Chicago/M. Tole, I. Rubinstein, Chicago, IL, p.A5000


Predictors of Alpha-1 Antitrypsin Deficiency Among Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease in the United States/C.M. Blanchette, G. Stone, R. Patel, E. Zacherle, J.M. Noone, R. Howden, Charlotte, NC, p.A5003
P1415  Predictors of Alpha-1 Antitrypsin Deficiency Among Commercially Insured Chronic Obstructive Pulmonary Disease Patients in the United States/C.M. Blanchette, G. Stone, R. Patel, E. Zacherle, J.M. Noone, R. Howden, Charlotte, NC, p.A5004

Facilitator:  R.A. Maxfield, MD, New York, NY

P909  Safety and Effectiveness of Endobronchial Ultrasound (EBUS) Guided Intranodal Forcep Biopsies/A.K. Mahajan, D. Collins, K. Webster, H. Mani, S. Khandhar, Falls Church, VA, p.A5015


P911  Utility of Transbronchial Biopsy in Management Decisions Among Immunocompromised Patients with Pulmonary Processes/M.H. Bourne, E.S. Edell, Rochester, MN, p.A5017


P913  Role of Endobronchial Ultrasound Guided Miniforceps Biopsy in Mediastinal Lesions/M. Kondapaneni, J. Bowen, Mount Vernon, IL, p.A5019

P914  Transbronchial Lung Cryobiopsy in the Diagnosis of Interstitial Lung Disease: A Retrospective Single Center Experience/R. Cho, F.D. Zamora, H. Gibson, E. Dincer, Edina, MN, p.A5020


P916  Radiographic Characterization of Coil Associated Opacities/J. Killam, G.C. Michaud, W. Moore, New Haven, CT, p.A5022

P917  The Use of Indwelling Pleural Catheters for Hepatic Hydrothorax/C.M. Kniese, J.J. Diab, M. Ghabril, G.T. Bosslet, Indianapolis, IN, p.A5023


Facilitator:  F.C. Sciruba, MD, Pittsburgh, PA


P922  Exudative Effusions from Organ Dysfunction: Getting to the Heart of the Matter/S. Walker, A. Morley, E. Keenan, N.A. Maskell, Bristol, United Kingdom, p.A5028


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
P924  Diagnostic Value of Medical Thoracoscopy in Malignant Pleural Effusion Induced by Non-Hodgkin’s Lymphoma/ W. Wen, Beijing, China, p.A5030


C44  CLINICAL ISSUES IN COPD II

9:15 a.m. - 4:15 p.m.  SAN DIEGO CONVENTION CENTER
Area L (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: R.D. Yusen, MD, MPH, St. Louis, MO

P1417  Analysis of the Effectiveness of Vaccination with Conjugated Pneumococcal Vaccine in Chronic Patients with Obstructive Pulmonary Disease in 4 Years of Observation/ G. Ignatova, V. Antonov, Chelyabinsk, Russian Federation, p.A5032


P1423  Artificial Neural Networks to Classify the Severity for Exacerbation Acute of Chronic Obstructive Pulmonary Disease/ A.R. Bastidas, G.A. Hinapiel Diaz, B. Mantilla Cardozo, R. Cadavid, Chía, Colombia, p.A5038


P1425  Assessment of Lung Function Among Patients Previously Treated for Pulmonary Tuberculosis at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia/ A. Binegde, C.N. Schuler, Addis Ababa, Ethiopia, p.A5040

P1426  The Correlation of VE/VCO2 Slope with the Bode Index and Quality of Life in Patients with COPD/ M. Mirdamadi, B. Rahimi, M. Arbabian, Tehran, Islamic Republic of, p.A5041

Facilitator: M.E. O’Brien, MB BCh, PhD, Pittsburgh, PA


P1428  Yamagata University Hospital’s Criteria for Discriminating Patients Overlapping Asthma Among COPD Patients/ H. Machida, Yamagata, Japan, p.A5043


P1432  A Clinical Study of AECOPD in Southern China/ M. Mao, Wuxi, China, p.A5047


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.

ATS 2018 • San Diego, CA


Facilitator:  B.M. Thomashaw, MD, New York, NY


P1444  Venous Thromboembolism and COPD: Don’t Take This Laying Down/H. Koneru, S.A. Evans, A. Berger, P.F. Simonelli, R. Evans, Danville, PA, p.A5059

P1445  Safety and Efficacy of Oxygen Delivery Via High Flow Nasal Cannula (HFNC) in Patients with Structural Lung Disease and Chronic Respiratory Failure/A. Attaway, J.A. Faress, F. Jacono, Cleveland, OH, p.A5060


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.


P441 Carboxyhemoglobin and Survival Outcome in Patients with Acute Respiratory Distress Syndrome/W.J. Hsia, M. Kunسورska, B. Jafari, Orange, CA, p.A5074

P442 Assessment of Gradients Between Partial Pressure of Arterial CO2 and End Tidal CO2 in ARDS/F.S. Abdalrazik, M.O. Elghonemi, Cairo, Egypt, p.A5075


P445 The Role of Visceral Adipose Tissue and Subcutaneous Adipose Tissue Predict Clinical Outcomes for Patients with Acute Respiratory Distress Syndrome/Y. Ni, T. Wang, B. Liang, Z. Liang, Chengdu, China, p.A5078

P446 Critical Care Clinical Trial Reported Data Elements: Review of the Literature/V.W. Chow, J.C. O’Horo, R.R. Bartz, R. Kashyap, Lebanon, NH, p.A5079


P452 Dying to Travel - Characteristics and Outcomes of Patients Made Do-Not-Resuscitate Within 24 Hours of Admission from an Outside Hospital to MD Anderson Cancer Center ICUs/J. Myers, J. Melancon, K. Bratcher, J. Campbell, C. Gutierrez, L. Feng, Houston, TX, p.A5085


Facilitators: K.M. Akgun, MD, MS, New Haven, CT M.E. Wilson, MD, Rochester, MN

P455 Exploring the Provision of Primary and Specialty Palliative Care Consults/D. Wang, C. Ing, C. Blinderman, M. Hua, New York, NY, p.A5089

P456 Goals of Care Documentation and Palliative Care Consultations for Patients Who Die with Acute Respiratory Failure in the Medical ICU/C. Morse, J. Steiner, R.A. Engelberg, L. Downey, J.R. Curtis, E.K. Kross, Seattle, WA, p.A5088

P457 Late Latent Class Analysis of Specialized Palliative Care Utilization in Adult Intensive Care Units from a Single Academic Medical Center/D. Wang, C. Ing, C. Blinderman, M. Hua, New York, NY, p.A5089

P458 Exploring the Provision of Primary and Specialty Palliative Care Services in Critically Ill Older Adults by Pre-Hospitality Frailty/O. Emiliari, R. Nair, E. Chuang, M.N. Gong, A.A. Hope, Albert Einstein College of Medicine, Bronx, NY, p.A5090


P460 Continuous Renal Replacement Therapy as a Trigger for Palliative Care Consults/J. Y. Fung, J. Scherer, New York, NY, p.A5092


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
THEMATIC POSTER SESSION

**C47  CRITICAL CARE: LOCOMOTIVE BREATH - NON-CONVENTIONAL MECHANICAL VENTILATION, NIV, HIGH FLOW, AND ECMO**

**9:15 a.m. - 4:15 p.m.  SAN DIEGO CONVENTION CENTER**

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators:  B. Kraft, MD, Durham, NC
T.J. Bice, MD, MSc, Chapel Hill, NC


**P466** Under Humidified Pressure of Non-Invasive Ventilation (NIV): Measurement of Skin Integrity Markers at the NIV Mask-Skin Interface/I.S. Alqahtani, P. Worsley, D. Voegeli, Dammam, Saudi Arabia, p.A5097

**P467** Use of RAM Cannula for Respiratory Failure and Subsequent Intubation Rates in the Pediatric Intensive Care Unit/M. Maamari, G. Miyashita, M.P. Sharron, Washington, DC, p.A5098

**P468** A Review of the Use of High Flow Nasal Cannula on a Respiratory Ward in a District General Hospital/C. Ferguson, M. Boyle, M. Drain, Antrim, United Kingdom, p.A5099


**P471** Characterizations of High Flow Nasal Cannula Use in a Teaching Community Hospital in New York City/E.L. Altschul, Y. Mogilevskaya, A. Schwab, B.A. Mina, New York, NY, p.A5102


**P474** Effects of Nasal High Flow Therapy on PaCO2 in COPD Patients with Stable Hypercapnic Respiratory Failure: A Pilot Study/L. Pisani, L. Fasanò, A. Verhovez, V. Comellini, S. Nava, Bologna, Italy, p.A5105

Facilitators:  J.E. Levitt, MD, MSc, Stanford, CA
M.E. Prekker, MD, MPH, Minneapolis, MN


**P477** Use of Aerosolized Epoprostenol Is Associated with Improvements in Gas Exchange and Hemodynamics in Critically Ill Patients/H.A. Jaliiwala, J. Tsui, R.J. Bernardo, B.R. Brown, Oklahoma City, OK, p.A5108


**P482** The Entire Coagulation Process Is More Important than APTT/ACT Monitoring Alone in the Anticoagulation Management of VV-ECMO/T. Xiao, B. Sun, X. Li, Beijing, China, p.A5113


**P484** Extracorporeal Membrane Oxygenation Support Through Protek Duo Cannula: A Case Series/H.A. Memon, I. Ratnani, F. Masud, Houston, TX, p.A5115

**P485** Management of US Patients with ARDS Requiring ECMO: Results of the Severe ARDS Generating Evidence (SAGE) Study/N. Qadir, Los Angeles, CA, p.A5116


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
C50 CRITICAL CARE CASE REPORTS: THE LIVER, PANCREAS, AND INTESTINES

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER
Area G (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators: D.L. Hotchkin, MD, MSc, Portland, OR
L. Tan, DrMed, Loma Linda, CA

P623 Life Threatening Gastrointestinal Bleeding Following Intragastric Balloon Placement for Weight Loss/H. Nugent, Lubbock, TX, p.A5164


P626 Therapeutic Plasma Exchange Plus Insulin in a Case of Severe Hypertriglyceridemia-Induced Acute Pancreatitis/D. Ramadurai, J. Camacho, Aurora, CO, p.A5167


P630 Double Aortic Arch - An Unlikely Cause for an Upper GI Bleed/J. Lam, V. Mukherjee, New York, NY, p.A5171


Facilitator: M.A. Tamae Kakazu, MD, Grand Rapids, MI

P632 A Typical Procedure an Atypical Outcome: A Rare Case of Life Threatening Splenic Hemorrhage Following Colonoscopy/A. Sharma, A. Rander, F. Asfahan, D. Symer, Rochester, NY, p.A5173


Facilitator: D. Fein, MD, Bronx, NY


P654 Strongyloides Related Hyper-Infection Syndrome: Rare Disease with Catastrophic Outcome/M.A. Farooq, M. Dabbagh, J. Uduman, Detroit, MI, p.A5194


P656 How My Turtle Almost Killed Me: A Rare Case of Plesiomonas Shigelloides Causing Septic Shock/R. Kumar, A. Desai, Syracuse, NY, p.A5196

P657 An Unusual Case of Pneumococcal Bacteremia Associated with Cholecystitis and Disseminated Intravascular Coagulation in a Young Female/E. Matayeva, S. Gomez-Paz, H. Mashaal, W. Chua, East Meadow, NY, p.A5197

P658 An Unusual Case of Typhilitis in a Post-Partum Female/A.S. Jhand, A. Ahmad, K. Keeley, R. Norris, R. Vivekanandan, Omaha, NE, p.A5198

P659 Listeria Chorioamnionitis Sepsis Treated with Delayed Delivery/R. Wilson, S. Sudholt, A.A. Greenberg, Chicago, IL, p.A5199

P660 Pulmonary Actinomyces Infection, an Atypical Case/A. Ahmad, K. Keeley, R. Norris, R. Vivekanandan, Omaha, NE, p.A5200

P661 ARDS Due to Anaplasma and Borrelia Co-Infection; Can Corticosteroids Help?/A.S. Jhand, A. Ahmad, K. Keeley, R. Norris, R. Vivekanandan, Omaha, NE, p.A5196

P662 A Rare Case of Typhilitis in a Post-Partum Female/E. Matayeva, S. Gomez-Paz, H. Mashaal, W. Chua, East Meadow, NY, p.A5197

P663 Disseminated Candida Glabrata Leading to Empyema and Putititary Abscess in a Young Woman with Uncontrolled Diabetes/C. Hsieh, A. Hudler, S. Malkoski, Aurora, CO, p.A5201

P664 Prompt Diagnosis and Treatment of a Patient with Wound Botulism/A. Hudler, S. Malkoski, Aurora, CO, p.A5204


P666 Spontaneous Bacterial Empyema with Unusual Pathogen/M. Odeesh, K. Muddassir, Memphis, TN, p.A5206

P667 Histoplasmosis Fungemia Manifesting as Acute Respiratory Distress Syndrome/V. Badami, P. Farjo, J. Guilfoose, Morgantown, WV, p.A5207

P668 Leukemoid Reaction in a Patient with Lemierre’s Syndrome/M. Greer, F. Baig, A. Velasquez, Atlanta, GA, p.A5208


P670 Invasive Aspergillosis in a Seemingly Immunocompetent Host/J.L. Miely, A. Doyle, A.J. Gamino, Chicago, IL, p.A5210


P672 Angioinvasive Rhizopus Masquerading as a Pulmonary Embolism/E. Beck, M. Cirulis, M. Balatico, N. Hatton, Salt Lake City, UT, p.A5212


P675 It Was Not MRSA, but Legionella/S. Marco, S. Khan, F. Houshmand, H.J. Kim, Greenville, NC, p.A5215


P677 Eye Can’t See! An Unusual Manifestation of Nocardia/V. Badami, P. Farjo, J. Guilfoose, Morgantown, WV, p.A5207


P681 Corynebacterium Striatum Septicemia Due to Indwelling Pleural Catheter/S. Hossain, W. Khan, New Brunswick, NJ, p.A5221

P682 Killer Yeast: A Rare Case of Fatal Reactivation Cryptococcal Infection/M. Qi, G.T. Bosslet, D. Patel, Indianapolis, IN, p.A5222

P683 Rare Pathogen: An Unexpected Case of Pulmonary Myiasis/W. Bzdawka, Y. Yang, D. Maki, Madison, WI, p.A5223

P684 A Rare Case of Fulminant Community Acquired Acinetobacter Pneumonia in Northeast Pennsylvania/D. Saha, Danville, PA, p.A5224


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.


P688  Group A Streptococcal Pneumonia: A Case Report/A. Amin, S. Kwatra, S. Sheth, Youngstown, OH, p.A5228


Facilitator:  E. Festic, MD, Jacksonville, FL

P691  Disseminated Varicella in an Immunocompetent Host/A. Bhushan, B.K. Patibandla, B. Moulton, Portland, OR, p.A5231


P693  Severe Case of Tetanus Infection in an Unvaccinated Patient/U. Ibe, N. Jiwa, S. Rehman, A. Gega, Waterbury, CT, p.A5233


P696  Deadly Bite: Fulminant Sepsis Due to Capnocytophaga Canimorsus in an Elderly Man/P. Echeverria, L. Osei, J. Saa, M. Jacob, E. Yeager, Belleville, IL, p.A5236


P698  Splenic Infarction, a Rare Complication of Severe Babesiosis/B. ElBeawby, A. Nawaz, P.X. Escalder, Cooperstown, NY, p.A5238


Facilitators:  D. Brodie, MD, New York, NY
              N.M. Kanodra, MBBS, Tacoma, WA

P701  Management of Massive Pulmonary Hemorrhage with Extracorporeal Membrane Oxygenation (ECMO) and Temporary Clamping of the Endotracheal Tube: A Case Report/C.-F. Lee, S.-Y. Ruan, H.-C. Wang, Taipei, Taiwan, p.A5240


P703  Status Asthmaticus in Pregnancy Requiring Sevoflurane and ECMO/B. Seth, M. Gonzalez, F. Schembri, Boston, MA, p.A5242

P704  A Rare Case of Diffuse Alveolar Hemorrhage Secondary to Dabigatran Successfully Treated with Extracorporeal Membrane Oxygenation/C.T. Hutchinson, H. Hirose, F.M. West, Philadelphia, PA, p.A5243

P705  Ivy Lungs: A Rare Case of Pulmonary Alveolar Microlithiasis Bridged to Transplant by AV ECMO/S. Kapadia, F. Alvarado, B. Lacey, R. Hooker, M. Pachinburav, K. Patel, Tampa, FL, p.A5244

P706  Successful Cannulation of Venovenous ECMO in a Patient with a Pre-Existing IVC Filter/D. Pau, J. Kasal, M.S. Plisco, St. Louis, MO, p.A5245


P708  An Unusual Case of Severe ARDS Incited by Extrapulmonary Coccidioidomycosis Requiring Extracorporeal Membrane Oxygenation in an Immunocompetent Host/N. Shamsid-Deen, A. Sinha, T. Whiting, Phoenix, AZ, p.A5247


Facilitators:  S. Sahetya, MD, Baltimore, MD
              M. Jabaudon, MD, MSc, Clermont-Ferrand, France


P714 Role of Cirrhosis Associated Immune Dysfunction in the Development of Coccidioidomycosis Induced ARDS Requiring Extracorporeal Membrane Oxygenation/A. Sinha, N. Shamsid-Deen, T. Ardiles, Phoenix, AZ, p.A5253

P715 Pulmonary Blastomycosis Induced Acute Respiratory Distress Syndrome Requiring Veno-Venous Extra Corporeal Membrane Oxygenation/D. Low, J.L. Denson, Aurora, CO, p.A5254

P716 Defeating the Legionella of Doom: A Case of Severe ARDS Requiring ECMO Support/M. Rahbe, M. Megally, E. Awerbuch, Queens, NY, p.A5255

P717 Near-Fatal Asthma Case Managed with Extracorporeal Membrane Oxygenation (ECMO) in a University Hospital in Latin America: Case Report/L. Fernandez, C.A. Calderon, D.F. Bautista, C.S. Leib, Cali, Colombia, p.A5256


P720 Diagnosis and Treatment of Severe ARDS from Legionella Pneumonia with Higher RESP Score Utilizing Venovenous ECMO/L. Riley, P. Tunsupon, Gainesville, FL, p.A5259

P721 Successful Treatment of a Ruptured Tracheoinnominate Fistula Following Long-Term Tracheotomy and Mycobacterium Chelonae Tracheobronchitis with Extracorporeal Membrane Oxygenation, Endovascular Stent Graft Implantation, and Surgical Bypass/Y.-S. Chien, K.-H. Hsu, Y.-C. Chao, M.-R. Chen, Taipei City, Taiwan, p.A5260


P723 Permissive Hypoxemia on ECMO in a Patient with Granulomatosis with Polyangiitis and MDR Pseudomonas Superinfection/T. Marston, K.J. Henry, R. Garcia-Orr, Phoenix, AZ, p.A5262

Facilitator: P.K. Park, MD, Ann Arbor, MI


P730 Treatment of Acute Asthma in the ICU with a Liquid Perfluorocarbon and CO2 Gas Combination/B.T. Wierstra, F.H.Y. Green, J. Dennis, J. Waechter, Calgary, Canada, p.A5269

P731 Is There a Role of Applied PEEP (PEEPe) in Controlled Mechanically Ventilated Severe Asthma Exacerbations?/A. Golchin, K. Hached, A. Khan, Springfield, MA, p.A5270


P733 Inhaled Epoprostenol as a Rescue Therapy for Acute Respiratory Distress Syndrome in a Patient with Acute Myeloid Leukemia, Leukostasis, and Tumor Lysis Syndrome/C. Tsai, B. Walsh, Danville, PA, p.A5272


P735 Independent Lung Ventilation in Asymmetric Acute Respiratory Distress Syndrome/W. Rodriguez, L. Gonzalez, A. Candelario, J. Torres-Palacios, A. Torres-Palacios, Y. Otero, O.J. Cantres Fonseca, San Juan, PR, p.A5274

Facilitator: A. Carlesse, DO, Bronx, NY

P736 Massive Pulmonary Arteriovenous Malformation Complicating Weaning from Mechanical Ventilation/D. Westerhausen, W.G. Carlos, Indianapolis, IN, p.A5275

P737 Endotracheal Intubation for 940 Days Without Tracheal Ulcers, Stenosis or Excavation/D. Damania, M. Nandigam, Z. Khan, M. Rodriguez, L. Gonzalez, A. Candelario, J. Torres-Palacios, A. Torres-Palacios, Y. Otero, O.J. Cantres Fonseca, San Juan, PR, p.A5274

Facilitator: A. Carlesse, DO, Bronx, NY


P739 Case Report: Pneumomediastinum, a Rare Complication of Noninvasive Ventilation Through a Descending Pathway/K. Mohamed Ahmed, F.G. Jamous, Sioux Falls, SD, p.A5278


P754 A Case of a Rare and Devastating Manifestation of Influenza/A. Andriotis, P.J. Rivera, New York, NY, p.A5292

P755 Severe Legionella Pneumonia Complicating Alemtuzumab Therapy for Relapsing Multiple Sclerosis/E. Villarreal, N. Jentzen, J. Zein, Cleveland, OH, p.A5293

Facilitators: B.J. Anderson, MD, MS, Philadelphia, PA
A. Niroula, MBBS, MD, Philadelphia, PA


P757 An Unusual Presentation of Chronic Disseminated Histoplasmosis/G.S. Thind, L. Yadav, Kalamazoo, MI, p.A5295

P758 A Case of Bacteroides Thetaiotaomicron Septic Shock Associated with Diffuse Bullous Pemphigoid/M.K. Loya, Omaha, NE, p.A5296

P759 Case of Recurrent Gram-Negative Bacteremia Secondary to Fistulization Between the SMA Coiled Aneurysm Sac and Small Bowel/V.V. Tambe, B. Sharma, M. Kosters, I. Amzuta, Syracuse, NY, p.A5297

P760 Citrobacter Braakii Bacteremia of Unclear Source: A Literature Review and Discussion/R. Mocerino, J. Jolly, E. Awerbuch, Queens, NY, p.A5298

P761 Refractory Hypoglycemia and Coma as Presentation of Fournier Gangrene/V. Mock, B. Li, J. Sunderram, New Brunswick, NJ, p.A5299

P762 A Patient with Anaplasmosis and Subsequent Spontaneous Splenic Rupture/A.S. Ray, H.C. Cain, New Haven, CT, p.A5300


P765 Acute Aortic Endocarditis Complicating ESBL E. Coli Spontaneous Bacterial Peritonitis/J. Ma, D. Xu, D.R. Crouch, San Diego, CA, p.A5303


Facilitators: E. Garpestad, MD, Boston, MA
S. Chawla, MD, New York, NY

P767 An Unusual Case Rejection/R. Akkari, E. Kyereme-Tuah, Cheverly, MD, p.A5305

P768 A Case of Disseminated Mucormycosis in a Patient with Graft Versus Host Disease/M. Yeager, R. Abdul Rahman, R.J. Schilz, Cleveland, OH, p.A5306


P770 Staphylococcus Epidermidis and Hemodialysis: A Deadly Duo Causing Native Valve Endocarditis/A. Sharma, D. Vadehra, P. Montesano, A. Singvi, Farmington, CT, p.A5308

P771 A Rare Cause of Sepsis in an Asplenic Female/M. Forte, D. Lee, J. Gordon, K. Cade, Pueblo, CO, p.A5309

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
Presentation with a Right Upper Lobe Mass Following a Trip to India/E. Nasr, Liverpool, United Kingdom, p.A5310

Pneumonia Due to Pan-Resistant Acinetobacter Baumannii?/M. Elahee, A. Talat, M.U. Khalid, M. Shah, R.S. Bailey, Youngstown, OH, p.A5311

An Unusual Presentation of CMV Pneumonitis/G. Mehta, Rochester, MN, p.A5312


Metastatic Angiosarcoma Presenting as Diffuse Alveolar Hemorrhage/K. Philip, A. Duncan, A. Cooper, Columbus, OH, p.A5324

Facilitator: J. Tonna, MD, Salt Lake City, UT

Adding Insult to Injury: Complicated Parapneumonic Effusion in a Patient with Lemierre’s Syndrome/A. Ajayi, D. Kirakossian, J. Murphy, H. Nasiri, Santa Clara, CA, p.A5325

Successful Treatment of Acute Interstitial Pneumonia in an Immunocompromised Lymphoma Patient with “Induced Inflammation”/X.-Y. Ni, J. She, C.-L. Gu, L. Zhu, Shanghai, China, p.A5326


Neurological Respiratory Failure Due to West Nile Virus Induced Phrenic Nerve Palsy/M. Rudrappa, L. Kokatnur, Shreveport, LA, p.A5328

Malaria with Acute Respiratory Distress Syndrome: Developing Country Complications Seen in America/R. Paranjvani, S. Davis, Fort Worth, TX, p.A5329


Coprothorax: A Faeulent Pleura/D. Shore, A. Malhotra, Hummelstown, PA, p.A5333

Unilateral Flash Pulmonary Edema in Refractory Heart Failure After Thoracentesis/N. Mesihaa, M. Alipour, L. Latypov, A. Mogla, F. Arjomand, L.N. Geroelemou, Brooklyn, NY, p.A5334


A Rare Case of Paradoxical Embolization During Thrombolysis for a Pulmonary Embolus/M. Onwochei-Ashei, W. McGee, M.A. Tidswell, P. Mailloux, Springfield, MA, p.A5336

P801  When the Phrenic Nerve Fails You/O. Chaudhary, M. Kosters, D.N. Manta, Syracuse, NY, p.A5338

P802  A Case of Delayed Diagnosis: Late Onset Tracheal Stenosis After Multiple Short Term Intubations/X. Gao, M. Bachan, Z. Khan, R.E. Siegel, Bronx, NY, p.A5339

P803  Spontaneous Pneumomediastinum in a Young Male- A Diagnostic Dilemma/S. Singh, M. Bargaje, A. Anokar, S. Shaikh, R. Deoskar, Pune, India, p.A5340


P805  A Rare Case of Pneumo-Pericardium and Pneumothorax After Left Nephrectomy/J. Margapuri, Bronx, NY, p.A5342

Facilitators: R. Kashyap, MBBS, Rochester, MN
A. Mehta, MD, Denver, CO


P807  Life Threatening Complication of Percutaneous Transthoracic Lung Biopsy/M.F. Khalid, E. Josan, K. Al Balbissi, Johnson City, TN, p.A5344


P809  Bilateral Phrenic Nerve Paralysis as a Complication of Decompressive Cervical Laminectomy/M. Hafiz, V. Maddipati, Greenville, NC, p.A5346


P814  Skin Sloughing and Hypoxic Respiratory Failure/R.D. Rogers, R. Young, B. Dembo, Hershey, PA, p.A5351

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.

P931  Familial Aggregation and Heritability of Sarcoidosis: A Swedish Nested Case-Control Study/M. Rossides, J. Grunewald, S. Kullberg, A. Eklund, D. Di Giuseppe, J. Askling, E.V. Arkema, Stockholm, Sweden, p.A5361

P932  Radiomic Features as a Biomarker for Pulmonary Sarcoidosis/N. Carlson, S. Ryan, N.Y. Hamzeh, T.E. Fingerlin, L.A. Maier, Aurora, CO, p.A5362


Facilitator: C.S. Glazer, MD, MSPH, Dallas, TX


P935  Comparison of Composite Physiologic Index and GAP Models in Patients with Idiopathic Pulmonary Fibrosis: A Nationwide Cohort Study/M. Sung, L. Sang Hoon, Y. Kang, C.M. Ahn, M.S. Park, Seoul, Korea, Republic of, p.A5365


THEMATIC POSTER SESSION

C57  TUBERCULOSIS EPIDEMIOLOGY

9:15 a.m. - 4:15 p.m.  SAN DIEGO CONVENTION CENTER

Area F (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion

12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: P.A. Lobue, MD, Atlanta, GA

P549  Prevalence of Multi and Extensively Drug-Resistant TB and Increasing Fluoroquinolone Resistance/M. Kohli, Delhi, India, p.A5370


Facilitator: M.C. Lipman, MD, London, United Kingdom


P557  Risk of Pulmonary Tuberculosis for Children and Adolescents with Various Factors/L. Gorbach, Minsk, Belarus, p.A5379


Facilitator: P.B. Shete, MD, San Francisco, CA


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.

P562 Comparing Canada and the USA TB Rates with Population Profile/S. Essien, T. Epp, V.H. Hoepnner, Saskatoon, Canada, p.A5384

P563 History of Tuberculosis, Associated Factors in Transvestites/Transsexual Women Residing in Sao Paulo, Brazil/P. A. Nogueira, S. Ferreira Junior, P.M.S.B. Francisco, Sao Paulo, Brazil, p.A5385

THEMATIC POSTER SESSION

C58 FUNGAL CASE REPORTS

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER

Area K (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: S.E. Evans, MD, Houston, TX

P1164 Ochroconis Gallopava Infection in a Patient with Bronchiectasis on Low Dose Steroids/C. Whitehurst, C. Patel, C. Beothel, Temple, TX, p.A5386

P1165 Candidal Thoracic Empyema Due to Esophageal Pleural Fistula/ M.F. Khalqi, P. Palabinde, H.E. Mohamed, Charleston, WV, p.A5387

P1166 A Case of Endobronchial Aspergilloma with Allergic Bronchopulmonary Aspergillosis/X. Wang, S. Ramakrishna, C.-W. Yang, H. Li, S. Saleem, B. Milekic, Y. Zhao, Scranton, PA, p.A5388


P1168 A Case of Pulmonary Blastomycosis Induced ARDS with Early Initiation of Steroids/D. MacDonald, N. Ingraham, G.A. Sarosi, Minneapolis, MN, p.A5390

P1169 The Infection Returns: A Case of Pulmonary Sporotrichosis Relapse After Chemotherapy/S. Farooqui, H. Youness, Oklahoma City, OK, p.A5391


P1171 Histoplasmosis: When the Diagnosis Can Be Deadly/D. Westerhausen, W.G. Carlos, Indianapolis, IN, p.A5393

P1172 Recognizing Fungal Pneumonia with Eosinophilia in Endemic Areas/V. Kumar, U. Chaddha, R. Mahdavi, Los Angeles, CA, p.A5394

Facilitator: C.A. Hage, MD, Indianapolis, IN

P1173 Gilchrist’s Disease: A Rare Endobronchial Tumor Mimic/S.T. Zaheer, R.Z. Abraham, Kankakee, IL, p.A5395


P1176 Pulmonary Mucormycosis Presenting as a Chronic Infection in a Poorly Controlled Diabetic Diagnosed by Fungal 18s rRNA Sequencing/M.B. McCarr, Stanford, CA, p.A5398


P1178 Chicago’s Disease, An Unusual Case of Pulmonary Blastomycosis with Large Cavitation/A. Mohammed, J. Dinino, A. Golchin, E. Khan, Springfield, MA, p.A5401

P1179 A Tale of Mold Not Often Told; Pulmonary Thromboembolism by Mucormycosis in a Well Controlled Diabetic/A. Khan, E.K. Rey-Mendoza, S. Sukhal, Chicago, IL, p.A5400

P1180 Hemoptysis Caused by an Enlarging Aspergilloma/S. Ershadi, P. Buddhadev, P. Jha, Milwaukee, WI, p.A5402

P1181 Aspergillus Empyema in a 70 Year Old Male Recently Started on Dexamethasone/D.L. See, Cleveland, OH, p.A5403

Facilitator: S.T. Qureshi, MD, Montreal, Canada

P1182 Wunderlich Syndrome: An Atypical Presentation of Disseminated Histoplasmosis in an Immunocompetent Adult/H. Karnib, K. El-Kersh, Louisville, KY, p.A5404


P1186 Blastomycosis in Patient Initially Diagnosed with Influenza A and Community-Acquired Pneumonia/D.F. Martin, Y.N. Kothari, Louisville, KY, p.A5408

P1187 Primary Pleural Coccidioidomycosis/H. Khudayar, Pawtucket, RI, p.A5409

P1188 Necrotizing Pneumonia and ARDS from Blastomyces Dermatitis in a Young Immunocompetent Patient/B. Hay, M.C. Exline, Columbus, OH, p.A5410

P1189 Pleural Effusion, an Uncommon Presentation of Histoplasmosis/M. Lannan, D. Westerhausen, A. Noor, Indianapolis, IN, p.A5411

P1190 A Case of Temozolomide Chemoradiotherapy Induced Pneumocystis Jirovecii Pneumonia in a Non-HIV Patient/J.Q. Yin, P. Patel, T. Thompson, Peoria, IL, p.A5412
THEMATIC POSTER SESSION

C59 UNUSUAL PULMONARY INFECTIONS

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER
Area K (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.
Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: R. Nusrat, MD, Princeton, NJ

P1207 The Black Bronchus Sign Radiological Diagnosis of Pneumocystis Jirovecii Pneumonia/N. Appusamy, Trichy, India, p.A5429
P1208 BetrAID Along the Path to Providing Just Patient Care/N.E. Ingraham, D. MacDonald, G.A. Sarosi, Minneapolis, MN, p.A5430
P1209 The Use of Endobronchial Ultrasound Guided Fine Needle Aspiration in the Diagnosis of Invasive Candida Tropicalis Infection/J. George, T. Plush, V. Ciocca, L.W. Greenspon, T.J. Meyer, Wynnewood, PA, p.A5431

P1200 Sarcoïdosis: A Risk Factor for Developing Chronic Pulmonary Aspergillosis/T. Khan, Neptun, NJ, p.A5422
P1201 A Case of Disseminated Pulmonary Mucormycosis Mimicking Malignancy Treated with Intrabronchial Antifungal/V. Sundararaszmy, M. Rafiq, Karaikal, India, p.A5423
P1203 Pulmonary Aspergillosis Disguised as Actinomyces Infection in a Healed Tuberculous Cavitary Lesion/U.A. Bhatti, M. Hayat, D. Rhoades, Oklahoma City, Ok, p.A5425
P1205 A Strange Case of Coccidioidomycosis: Utilization of Bronchoscopy to Diagnose a Chronic Cavitary Lesion/M. Nayeemuddin, M.D. Jankowich, A. Noska, E.J. Gartman, Providence, RI, p.A5427

Facilitator: E.M. Carmona Porquera, MD, PhD, Rochester, MN

P1207 The Black Bronchus Sign Radiological Diagnosis of Pneumocystis Jirovecii Pneumonia/N. Appusamy, Trichy, India, p.A5429
P1208 BetrAID Along the Path to Providing Just Patient Care/N.E. Ingraham, D. MacDonald, G.A. Sarosi, Minneapolis, MN, p.A5430
P1209 The Use of Endobronchial Ultrasound Guided Fine Needle Aspiration in the Diagnosis of Invasive Candida Tropicalis Infection/J. George, T. Plush, V. Ciocca, L.W. Greenspon, T.J. Meyer, Wynnewood, PA, p.A5431

Facilitator: E.M. Carmona Porquera, MD, PhD, Rochester, MN

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.


P1225 Strongyloides Hyperinfection After Glioblastoma Treatment Diagnosed with Bronchoalveolar Lavage/R. Baalachandran, E.J. Britt, Baltimore, MD, p.A5446

P1226 Atypical Pulmonary Strongyloidiasis in a Patient from a Non-Endemic Area for Strongyloides Stercoralis/M. Karagic, A. Schneider, A. Abraham, T. Madaline, D. Feraristaarou, Bronx, NY, p.A5447


P1229 Melioidosis - A Rare Case of Mediastinal Lymphadenopathy/S. Roche, R.J. Fahy, A. Mclaughlin, J.M. Keane, Dublin, Ireland, p.A5450

Facilitator: M.I. Restrepo, MD, MSc, San Antonio, TX

P1230 A Case Series Report: Three Cases of Streptococcus Anginosus Group Empyema During December 2016 in a Community Hospital, Nebraska/M.K. Loya, Omaha, NE, p.A5451

P1231 Hydro pneumothorax Secondary to Bronchoscopy: Known but Rare Complication/D. Makati, R.C. Stansbury, R.G. Sangani, Morgantown, WV, p.A5452


P1233 A Case of Necrotizing Pneumonia: Community Acquired Multi-Drug Resistant Pseudomonas Infection?/P. Sharma, I. Romero, Memphis, TN, p.A5454

P1234 Legionella Pneumonia Causing Rhabdomyolysis, Acute Renal Failure and Neurological Manifestations/L.E. Krowl, R. Subedi, A. Ghimire, Syracuse, NY, p.A5455


P1236 MRSA Necrotizing Pneumonia Mimicking Malignancy/A. Tandon, L. Orr, V. Tandon, Farmington, CT, p.A5458


Facilitator: S. Cherian, MBBS, MD, Houston, TX


P1243 A Case of Two Red Herrings/S. Beshay, M. Ahmad, T. Majumdar, Houston, TX, p.A5464


P1246 Moldy Hay and the Cirrhotic Farmer: The First Case of Pulmonary Nocardiosis - A Case of Two Rare Infections/P. Sharma, I. Romero, Memphis, TN, p.A5454


P1248 A Rare Case of Disseminated Chrysosporium Involving the Pancreas/C. Schuring, A. Yankovich, D. Lanade, A. Sodhi, Memphis, TN, p.A5471


P1250 A Rare Case of Disseminated Chrysosporium Involving the Pancreas/C. Schuring, A. Yankovich, D. Lanade, A. Sodhi, Memphis, TN, p.A5471


P1254 TB, or Not TB: That Is the Question/R. Baalachandran, E.J. Britt, Baltimore, MD, p.A5446


Facilitator: C. Dela Cruz, MD, PhD, New Haven, CT


P1257 MRSA Necrotizing Pneumonia Mimicking Malignancy/A. Tandon, L. Orr, V. Tandon, Farmington, CT, p.A5458


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
### TRANSLATIONAL AND BASIC INVESTIGATIONS IN PULMONARY INFECTION

**P1256** ARDS Due to Strongyloides Pneumonia/M.F. Khaliq, R.E. Ihle, J.D. Perry, H.E. Mohamed, Charleston, WV, p.A5477

**P1257** SIRVA: Uncommon Yet Debilitating Cause of Flu Vaccine Administration/V.R. Patel, T. Gronski, Milwaukee, WI, p.A5478

#### THEMATIC POSTER SESSION

**C60** TRANSLATIONAL AND BASIC INVESTIGATIONS IN PULMONARY INFECTION

**9:15 a.m. - 4:15 p.m.** SAN DIEGO CONVENTION CENTER

**Area K (Hall A-B2, Ground Level)**

**Viewing:** Posters will be on display for entire session.

**Discussion:**
- 11:15-12:00: authors will be present for individual discussion
- 12:00-1:00: authors will be present for discussion with assigned facilitators

**Facilitator:** A.E. Samarasinghe, PhD, Memphis, TN

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
<th>Institution/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1264</td>
<td>Long Noncoding RNA MEG3-4 Tissue Specifically Modulates IL-1b by Competing Its Binding to MicroRNA-138 in Pulmonary Bacterial Infection/M. Wu, Grand Forks, ND</td>
<td>M. Wu, Grand Forks</td>
<td>ND</td>
</tr>
</tbody>
</table>

**Facilitator:** H. Koziel, MD, Boston, MA

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
<th>Institution/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1268</td>
<td>Potential of the Phage Depolymerase from a Myoviridae Bacteriophage vB_AbaM_IME200 Against Pseudomonas-Resistant Acinetobacter Baumannii/C. Bai, Y. Liu, Z. Mi, Y. Tong, Beijing, China, p.A5488</td>
<td>C. Bai, Y. Liu, Z. Mi, Y. Tong</td>
<td>Beijing, China</td>
</tr>
</tbody>
</table>

**Facilitator:** C. Richards, MD, Boston, MA

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
<th>Institution/Location</th>
</tr>
</thead>
</table>

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.


P1279 Bacterial Contamination of Nebulizers After a Single In-Hospital Use/J. Dewald, Q. He, K. Wyckoff, J. Ferris, S. Elder, R. Dhand, Knoxville, TN, p.A5498

P1280 Inflammatory-Based Prognostic Score, C-Reactive Protein/Albumin Ratio Predicts Complications in Community-Acquired Pneumonia/F. Sanz, E. Fernandez Fabrellas, E. Chiner, M.L. Briones, A. Cervera, C. AguAr, R. Lera, J. Blanquer, Valencia, Spain, p.A5499

P1281 Twenty-Year Trends in Mortality Among Hospitalized Patients with Pneumococcal Community-Acquired Pneumonia/C. Cilloniz, A. Liapikou, C. Garcia-Vidal, J. Mensa, F. Marco, A. Ceccato, A. Torres, Barcelona, Spain, p.A5500


Facilitator: E.M. Mortensen, MD, MSc, Farmington, CT

P1287 Changes in the Etiology and Susceptibility of Bacteria Isolated from BAL in Patients with Ventilator-Associated Pneumonia (VAP) During the Last 25 Years/M.M. Perin, C.M. Luna, Buenos Aires, Argentina, p.A5506

P1288 Epidemiology and Complications of Respiratory Viral Infections in Patients Who Have Undergone Hematopoietic Stem Cell Transplantation/D. Reynolds, H. Yadav, Rochester, MN, p.A5507

P1289 Comparison of Early-Onset and Late Onset VAP in Terms of Microbiological Pathogens and Prognosis/B. Uysaler, P. Korkmaz Ekren, Z.N. Toreyin, H. Pidual, S. Aydemir, A. Sayiner, F. Bacakoglu, Izmir, Turkey, p.A5508

P1290 The Extent of Lung Involvement Was Associated with the Results of Serum Cryptococcal Antigen in Non-HIV Adult Patients with Pulmonary Cryptococcosis/T. Zhu, C. Li, H. Deng, W. Zhang, D. Wang, Chongqing, China, p.A5509


P1292 A Retrospective Audit on Pneumonia Mortality Rates in Elderly Patients and the Decision of Whether to Escalate to High Dependency Unit at University Hospital Southampton/E. Teng, B. McKe, B.G. Marshall, Southampton, United Kingdom, p.A5511


P1296 Aspergillus spp. in Patients with Chronic Lung Disease in Colombia: Prevalence of Increased Serum IgE, Aspergillus Sensitization and Colonization Chronic Obstructive Lung Disease COP/D.A. Canas, C. Alvarez-Moreno, P. Le Pape, B. Ariza, E. Robinson, J. Alvarado, A. Caballero, A. Montanez, Bogota, Colombia, p.A5515

Facilitator: K.A. Crothers, MD, Seattle, WA


P568 Peripheral Blood Circular RNAs as Novel Diagnostic Biomarker in Active Pulmonary Tuberculosis/T. Zhou, W. Gu, Z. Qian, Rens, NV, p.A5542


P577 Increase Diagnostic Yield of Tuberculous Serositis by Using Serous Fluid Drainage Flocky Precipitate (SFDFP) as a Testing Sample/X. Liu, L. Xia, Y. Song, S. Li, S. Lu, Y. Zhang, Y. Liu, Shanghai, China, p.A5551


P579 Prognostic Score to Predict Mortality During TB Treatment in TB/HIV Co-Infected Patients/D.T.M. Nguyen, H.E. Jenkins, E.A. Graviss, Houston, TX, p.A5553


P582 An Observational Study to Correlate Glycemic Control with Radiographic and Microbiologic Manifestation of Pulmonary Tuberculosis in Type 2 Diabetes Patients/T. Mahmood, Allahabad, India, p.A5556

P583 Predictive Score of Pulmonary Tuberculosis in Both Smear Negative and Culture Negative Bronchial Samples/C. Fraisse, G. Devouassoux, L. Kikouama, F. Ader, J. Giai, Lyon, France, p.A5557

Facilitator: R.D. Turner, MBCHB, PhD, London, United Kingdom


P586 Adverse Events During Drug Resistant Tuberculosis Treatment: The Experience of a Universitary Hospital in Rio de Janeiro, Brazil/A.P. Santos, J. Leung, M.A.M.D.S. Vieira, F.C.Q. Mello, Rio de Janeiro, Brazil, p.A5560


P588 Use of Immunosuppressants in Patients with Autoimmune Diseases and Latent Tuberculosis/M. Pombo, D. Burgos, E.S. Membriani, L. Limongi, A.M. Putruele, Buenos Aires, Argentina, p.A5562


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
P591 Adherence of Residents in Training of the University of Perpetual Help DALTA Medical Center to the 2009 International Standards for Tuberculosis Care and Their Correlation with Treatment Outcome/R.-J. Guarin, R.M. Salonga, J.E.V. Tamayo, I. Manuel, J. Benedicto, Las Pinas City, Philippines, p.A5565


TETHMIC POSTER SESSION

C63 PEDIATRIC FAMILY AND TRAINEE EDUCATION
9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER
Area J (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.
Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators
Facilitator: G.N. Bendiak, MD, MSc, Calgary, Canada


P1011 Publication Productivity Over 20-Year of Pediatric Pulmonary Fellowship Training from Thailand: Lesson from a Developing Country/W. Lilitwat, P. Somboon, Iowa City, IA, p.A5569

P1012 A Quality Improvement Project to Improve Attendance and Outcomes in a Pediatric Pulmonary Clinic/R.C. Cohn, L. Langdon, C. Driscoll, K. McClaskie, Dayton, OH, p.A5570

P1013 Intervening to Improve Family and Child Asthma Self-Management/S.D. Horner, Austin, TX, p.A5571


TETHMIC POSTER SESSION

C64 PEDIATRIC CASE REPORTS: AIRWAY DISEASES AND BRONCHOSCOPY
9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER
Area J (Hall A-B2, Ground Level)

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
P1032 Endobronchial Occlusion with One-Way Endobronchial Valve in the Treatment of a 13 Year Old Critically Ill Young Man with Bronchopleural Fistula on Mechanical Ventilation/A. Chadha, A. Wilson, M. Zgoda, Charlotte, NC, p.A5589

P1033 The Great Masquerade of Burkitt/A.L. Birdwell, P. Ong, O. Bode-Omoleye, A. Malave, San Antonio, TX, p.A5590

P1034 Isolated Unilateral Bronchomalacia in a Young Child with Recurrent Respiratory Illnesses/S. Das, K.F. Fakhoury, D. Mehta, Houston, TX, p.A5591

Facilitator: S.L. Peterson-Carmichael, MD, Indianapolis, IN


P1036 Gotta Catch 'Em All: Delayed Diagnosis of Cystic Fibrosis (CF) in an Infant with a Novel CF Transmembrane Conductance Regulator (CFTR) Mutation/N. Hong, S.D. Sagel, E.T. Zemanick, Y. Shi, J. Hoppe, Aurora, CO, p.A5593


P1038 New Sweat Chloride Ranges and Diagnosis of CFTR-Related Metabolic Syndrome with (TG)11-5T Homozygosity/M.H. Abul, L.P. Hayden, Boston, MA, p.A5596


P1041 Interesting Presentation of a Rare Endobronchial Lesion/K. Conway, A. Baig, S. Gupta, Syracuse, NY, p.A5598

P1042 Recurrent Pneumonia-When to Think Outside the Box/P.C. Cheng, J.C. Piccione, Philadelphia, PA, p.A5599


Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: A.I. Cristea, MD, Indianapolis, IN

P1046 A Novel Pathogenic Variant in FOXF1 Gene in an Infant with Severe Pulmonary Hypertension/R.H. Tillman, M.G. Parra, M.C. Gazzaneo, Houston, TX, p.A5602


P1048 A Congenital Cystic Lung Lesion with an Unusual Etiology/C. Kuklinski, J.S. Kemp, St. Louis, MO, p.A5604

P1049 A Rare Cause of Neonatal Respiratory Failure and Diffuse Pulmonary Infiltrates - Congenital Syphilis of the Lung Rises Again?!H. Hong, R. Kretzmer, M. Bansal, Los Angeles, CA, p.A5605


P1051 Tension Faecopneumothorax: A Rare Complication of Ruptured Morgagni Diaphragmatic Hernia: Case Report and Review of Literature/T.E.D. Abdelgalil, S. Yahia, A.E. Shabaan, M. Sabry, Mansoura, Egypt, p.A5607

P1052 Recurrent Life Threatening Pneumothorax Associated with Diffuse Subpleural Cystic Lung Disease in a Trisomy 21 Infant with Congenital Heart Disease: A Unique Case Report!/W. Lilitwat, H. Kothari, M. Luangrath, V. Allareddy, Iowa City, IA, p.A5608


P1054 Bilateral and Multilobar Congenital Pulmonary Airway Malformation Type 2: A Rare Case/C. Gorme, Quezon City, Philippines, p.A5610


P1056 Foregut Duplication Cyst: A Rare Cause of Cyanosis and Respiratory Distress in Neonate/F.J.L. Dago-oc, Quezon City, Philippines, p.A5612


P1058 A Rare Intralobar Pulmonary Sequestration of the Right Upper Lobe in an Infant: Case Report/C.L. Grizales, M.L. Perez, L. Fernandez, C.S. Leib, Cali, Colombia, p.A5614

P1059 Charlotte’s Web (of Bowels in the Chest)/M. Lyons, K. Krivchenia, R. Shell, Columbus, OH, p.A5615

Facilitator: L. Rhein, MD, Boston, MA


P1062 An Incidentally Discovered Congenital Pulmonary Airway Malformation/M. Koroscil, J.A. Hayes, Houston, TX, p.A5618


**THEMATIC POSTER SESSION**

**C66 PEDIATRIC CASE REPORTS: CARDIOVASCULAR AND CRITICAL CARE DISEASE**

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER

Area J (Hall A-B2, Ground Level)

**Viewing:** Posters will be on display for entire session.

**Discussion:**
- 11:15-12:00: authors will be present for individual discussion
- 12:00-1:00: authors will be present for discussion with assigned facilitators

**Facilitator:** J. Rettig, MD, Boston, MA


P1067 Right Ventricle to Pulmonary Artery (RV-PA) Conduit Conduct with Nuss Operation for Relieving the Compression of the Extracardiac Conduit and the Coronary Arteries/S. Kim, P.J. Choi, Busan, Korea, Republic of, p.A5622


P1069 When a Diagnosis Doesn't Stick: Pulmonary Embolism Disguised as High Altitude Pulmonary Edema in an Adolescent Male/E.K. Khan, A. Krack, P. Houin, Aurora, CO, p.A5624

P1070 Combination Therapy for Severe Portopulmonary Hypertension in a Child Allows for Successful Liver Transplantation/R. Serrano, G.S. Montgomery, M. Johansen, Indianapolis, IN, p.A5625

P1071 Multiple Mitochondrial Dysfunctions Syndrome Type 1: A Rare Cause of Pulmonary Hypertension in Infancy/N. Villafranco, A. Birjiniuk, N.P. Varghese, Houston, TX, p.A5626


**THEMATIC POSTER SESSION**

**C67 PEDIATRIC CASE REPORTS: INTERSTITIAL LUNG DISEASE**

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER

Area J (Hall A-B2, Ground Level)

**Viewing:** Posters will be on display for entire session.

**Discussion:**
- 11:15-12:00: authors will be present for individual discussion
- 12:00-1:00: authors will be present for discussion with assigned facilitators

**Facilitator:** E.K. Fiorino, MD, New Hyde Park, NY

P1073 Unilateral Pulmonary Artery Atresia in a Heterozygous Carrier for Alport Syndrome/D. Pratt, R. Shell, S. Bose-Brill, Columbus, OH, p.A5628

**Facilitator:** P.P. Moschovis, MPH, MD, Boston, MA

P1074 Neonatal Severe Refractory Persistent Pulmonary Hypertension of the Newborn (PPHN), Rare and Perplexing Diagnosis/A. Al-Turki, K. Krivchenia, S.J. Pinto, Columbus, OH, p.A5629


P1079 Treating Sleep Disordered Breathing Resolves Failure to Thrive in Child with Congenital Myasthenia/M. Hawkins, C.A. Canapari, New Haven, CT, p.A5634


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
C68  PEDIATRIC CASE REPORTS: IMMUNODEFICIENCY AND INFECTION

9:15 a.m. - 4:15 p.m.  SAN DIEGO CONVENTION CENTER

Area J (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator:  J.B. Taylor, MD, MSCR, Kansas City, MO

P1111  Hyperbaric Oxygen Therapy (HBOT) of an Adolescent Stem Cell Transplantation (SCT) Recipient with Hemorrhagic Cystitis, and BK Virus: A Rare Case Study in the United States/D. Lopez, L. Tan, A. Alismail, Loma Linda, CA, p.A5664

THEMATIC POSTER SESSION

C69 USE YOUR ILLUSION: NOVEL THERAPEUTIC APPROACHES IN PULMONARY HYPERTENSION

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER

Area C (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators: R.A. Dweik, MD, Cleveland, OH
A. Palomar, MD, Mexico, Mexico

P171 Rationale and Design of TRACE: A Double-Blind, Placebo-Controlled Phase 4 Study in Pulmonary Arterial Hypertension to Assess the Effect of Selexipag on Physical Activity, Patient-Reported Symptoms and Their Impact, in Daily Life/

P172 Transition from Parenteral to Oral Treprostinil: A Single Center Experience/

P173 Riociguat for the Treatment of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Safety Update from the EXPERT Registry/

P174 Triple Start Therapy for PAH in a Community Based Center/

P175 Transition to Oral from Intravenous Prostacyclins therapy in Pulmonary Arterial Hypertension/

P176 Partial Anomalous Pulmonary Venous Return: Different Management Approaches/

P177 Pulmonary Hypertension and Pregnancy: A Retrospective Cohort Study of 31 Patients/

P178 Safety of Ketogenic Diet in Group 2 Pulmonary Hypertension Patients/

P179 A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects with Pulmonary Hypertension Due to Parenchymal Lung Disease (Study RIN-PH-201)/

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.


P206 Right Heart Catheterisation: Is There a Role in Assessing Suitability for Complex Vascular Communication in Haemodialysis Patients?/C. Orton, E. Shaw, B. Madden, London, United Kingdom, p.A5714

P207 Risk Factors for Pulmonary Hypertension in Patients Undergoing Peritoneal Dialysis/V. Jayaschandran, M. Kwon, H. Ittkkhar, A. Michel, B.D. Dalal, Royal Oak, MI, p.A5715


P209 Pulmonary Vasoreactivity to Oxygen in Pulmonary Hypertension Due to Chronic Lung Disease/K. Kusaka, Y. Morio, S. Yamamoto, K. Takeda, M. Ohgiya, K. Masuda, K. Ohta, Kiyose City, Japan, p.A5717

P210 Central Sleep Apnea and Cheyne-Stokes Respiration Associated with Cardiac Function in Pulmonary Venous but Not Pulmonary Arterial Hypertension/B. Samhouri, H.L. Paz y Mar, M. Venkata Subramani, R. Mehra, N.F. Chaisson, Cleveland, OH, p.A5718


C71 CALIFORNIA DREAMING: NEW INSIGHTS INTO ENDOTHELIAL DYSFUNCTION IN ARDS

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER Area H (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion 12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: E.P. Schmidt, MD, Aurora, CO


P943 Pseudomonas Aeruginosa Induced Lung Endothelial Amyloid Proteinopathy: Characteristics and Inhibitors/M. Berrou, R. Stevens, S.B. Voth, C.D. Caesar Williams, R. Balczon, T. Stevens, Mobile, AL, p.A5724


P945 MRSA Induces Epigenetic Changes and Permeability in Lung Endothelium That Are Attenuated by FTY720 S-Phosphonate/L. Wang, L. Melton, E. Letsiou, H. Wang, S.M. Dudek, Chicago, IL, p.A5726


Facilitator: K.G. Birukov, PhD, MD, Baltimore, MD

P948 PP2A Dependent Differential Regulation of MAP Kinase Activation in CSE And LPS Induced Lung Injury/R. Wadgaonkar, A. Majumdar, A. Bhatt, A. Dabo, P. Geraghty, R. Foronyi, Brooklyn, NY, p.A5729


P950 Bosutinib Protects Against Endothelial Vascular Leakage by Preventing Focal Adhesion Disassembly/L. Botros, M. Pronk, J. Juschten, J. Liddle, F. Breijer, H.J. Bogaard, P. Hordijk, J. Aman, Cardiovascular Sciences Amsterdam, Netherlands, p.A5731


P952 Truncated Oxidized Phospholipids as a Factor Exacerbating ALL in the Aging Lung/S. Ke, A. Sitkov, S. Son, P. Karki, E. Berdyshev, A. Birukova, K.G. Birukov, Baltimore, MD, p.A5733
C72 PULMONARY FIBROSIS: MECHANISMS AND MODELS

9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER
Area D (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.
Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators
Facilitator: R. Guzy, MD, PhD, Chicago, IL


P266 Krüppel-Like Factor 4 (Klf4) Is a Novel Regulator of Neonatal Lung Fibroblast Homeostasis and Reduced in Hypoxia-Induced Lung Injury/D. Hirani, K. Dinger, J. Mohr, C. Vohlen, C. Klaudt, J. Dötsch, M.A. Alejandre Alcazar, Cologne, Germany, p.A5739


P268 Importin-5 Controls the Intracellular Degradation of IL-33 Precursor in Primary Pulmonary Fibroblasts/A. Cleman, N.G. Shah, N.W. Todd, S.P. Atamis, I.G. Luzina, Baltimore, MD, p.A5741


P270 A Precision-Cut Rat Lung Slice Model for Evaluation of Anti-Pulmonary Fibrosis Drugs/X. Huang, L. Li, R. Ammar, Y. Zhang, J. Thompson, G. Jarai, Pennington, NJ, p.A5743


Facilitator: R.S. Knipe, MD, Boston, MA


P276 Blood Monocyte Levels Correlate with Fibrotic Burden in IFP Patients and Show Pro-Fibrogenic Characteristics/E. Fraser, K. Bilardo, V. St noble, R. benamore, R. hoyles, L.-P. ho, oxford, United Kingdom, p.A5749


P281  Nintedanib Treatment Attenuates Histopathology of Interstitial Pneumonia in a New Humanized Mouse Model for IPF/A. Prasse, L. Plappert, B. Jäger, L. Wollin, Hannover, Germany, p.A5754


Facilitator:  J. Kropski, MD, Nashville, TN


P284  The Endocannabinoid/CB1R System Is Overactive in Disease-Specific Alterations in Glycosaminoglycans in IPF and COPD/S. Kanazawa, H. Ohkubo, A. Niimi, Nagoya, Japan, p.A5761


P286  CD36 Scavenger Receptor Promotes Pulmonary Fibrosis in Ontogeny of Osteopontin Expression in a Non-BRICHOS Mutant Surfactant Protein C Mouse Model of Idiopathic Pulmonary Fibrosis/B. Shea, MD, Providence, RI, p.A5754


P288  Tyrosine Phosphorylation of Tollip on C2 Domain Is Important for TGF-beta Pathway Inhibition Through Modulation of Smad7 Expression/ X. Li, H. Bahudhanapati, S. Yu, J. Zhao, D. Kass, Y. Zhang, Pittsburgh, PA, p.A5761

P289  Involvement of Adenosine A2a Receptor in the Lung Fibrosis Caused by Silica Particles in Mice/Y. Sá, L.E.B. Savio, R. Coutinho-Silva, V. Carregaro, J.C. Alves-Filho, C.M. Hogaboam, M.A. Martins, P.M. Silva, Rio de Janeiro, Brazil, p.A5762

P290  Nintedanib Attenuates Histopathology of Interstitial Pneumonia in a Transgenic Mouse Model of Arthritis/Y. Miura, S. Kanazawa, H. Ohkubo, A. Niimi, Nagoya, Japan, p.A5763


Facilitator:  B. Shea, MD, Providence, RI


P294  Does Cytochrome p450 3A4 Catalyzed Metabolism in Pulmonary Fibroblasts Contribute to Oxidative Stress in Idiopathic Pulmonary Fibrosis?/L. Rodriguez, R. Beuschel, E. Ellis, S. Bui, S.D. Nathan, G.M. Grant, Fairfax, VA, p.A5767


P300  Role of the Anti-Aging Hormone Klotho in Idiopathic Pulmonary Fibrosis/J. Ellis, S. Bui, S.D. Nathan, G.M. Grant, Fairfax, VA, p.A5772

P301  Increased Invadosome Formation by Fibroblasts in Experimental Lung Fibrosis/M. Lebel, M. Charbonneau, A. Cloutier, C.M. Dubois, A.M. Cantin, Sherbrooke, Canada, p.A5774

THEMATIC POSTER SESSION

C73  FIBROBLAST BIOLOGY

9:15 a.m. - 4:15 p.m.  SAN DIEGO CONVENTION CENTER
Area D (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: E.R. Neptune, MD, Baltimore, MD

P303 Calcium Silicate Pave a New Road to the Treatment of the Pulmonary Fibrosis/D. Weng, L. Lu, L. Huiping, Shanghai, China, p.A5766


P305 SM04646 Inhibited Wnt Pathway Gene Expression Stimulated in Response to Transforming Growth Factor-beta and was Effective in a Chronic Model of Bleomycin-induced Pulmonary Fibrosis/B. Tam, K. Chiu, E. Creger, L. Dellamary, S. KC, J. Stewart, Y. Yazici, San Diego, CA, p.A5778

P306 Unraveling the Role of MT1-mmp in Alveolar Epithelial Cells During Pulmonary Fibrosis/L. Placido, M. Maldonado, F. Toscano, Y. Romero, J. Cisneros, M. Selman, A. Pardo, Mexico City, Mexico, p.A5779


P308 Soluble Human Thy-1 Attenuates TGF-ß1-induced Lung Fibrosis in Mice/C. Tan, S.S. Wong, E. Connors, C. Espinoza, J.S. Hagood, Beijing, China, p.A7773


P314 Genes Encoding Redox Homeostasis Regulators Demonstrate Reduced Expression with Age in Normal Human Lung/D. Seward, E. Elko, V. Anathy, A.L.J. Van Der Velden, A. Van Der Vliet, Y. Janssen, Burlington, VT, p.A5783

P315 Primary Cilia Are Necessary for Fibroblast Migration and the Development of Pulmonary Fibrosis/C. Trepicus, S. Garantziotis, Research Triangle Park, NC, p.A5784


P322 Fibroblast Growth Factor 2 Decreases Bleomycin-Induced Production of TGF-ß1 in Human Lung Fibroblasts/R. Thannickal, P. Chen, Y. Zhou, Birmingham, AL, p.A5793

P323 IL-17A Induced Fibrogenic Responses in Normal Human Lung Fibroblast/S. Wang, D. Wang, J. Zhang, L. Wang, H. Zhao, D.J. Tschumperlin, R. Vassallo, Rochester, MN, p.A5792


P325 Direct Thrombin Inhibition with Dabigatran Alters the Matrix-Induced, Pro-Fibrotic Phenotype of Fibroblasts/T.B. Lumpkin, B.D. Southern, R.G. Scheraga, J.F. Crish, L. Grove, S. Abraham, M.A. Olman, Cleveland, OH, p.A5794


P329 miR-487b Expression Modifies BMI-1 and SUZ12 in Fibroblasts and Revealed a Dual Role in Proliferation and Migration in Hypersensitivity Pneumonitis/ J. Cisneros, M. Espina, B. Ortiz, F. Toscano, A. Garcia, I. Herrera, Mexico City, Mexico, p.A7775

P330 Relationship Between Allergen Challenge, Lung Inflammation and Revealed a Dual Role in Proliferation and Migration in Hypersensitivity Pneumonitis/ J. Cisneros, M. Espina, B. Ortiz, F. Toscano, A. Garcia, I. Herrera, Mexico City, Mexico, p.A7775

P331 The Role of Nociceptin/Orphanin FQ (N/OFQ) in Inflammation/ S.G. Chong, P. Nadarajan, L. Mthunzi, M. O’Callaghan, A. Fabre, P. McLoughlin, M.P. Keane, Dublin, Ireland, p.A5796


P333 Endotoxin Level in House Dust Mite Extract Impacts the Molecular Phenotype of Allergic Airways Inflammation in Mice/ C. Pascoe, A. Jha, J.E. Rowley, Birmingham, United Kingdom, p.A5798

P334 Endotoxin Level in House Dust Mite Extract Impacts the Molecular Phenotype of Allergic Airways Inflammation in Mice/ C. Pascoe, A. Jha, J.E. Rowley, Birmingham, United Kingdom, p.A5798

P335 Substrate Selective Targeting of ERK Signaling Mitigates Allergen-Induced Asthma Features in Mice/ A.P. Nayak, R. Yi, N. Wang, S.D. Shah, P. Shapiro, D.A. Deshpande, Philadelphia, PA, p.A5804


Facilitator: J.A. Hirota, PhD, Vancouver, Canada


P339 Expression of Th1 Cytokines Are Increased in Adolescent Mice with Steroid Resistant Allergic Airway Inflammation/ R.D. Britt, M. Thompson, C.M. Pabelick, Y.S. Prakash, Rochester, MN, p.A5808


P48 Lung-Resident Pericytes Acquire Increased Migratory Capacity in a House Dust Mite-Driven Model of Asthma/ J. Johnson, J.E. Rowley, Birmingham, United Kingdom, p.A5798


P50 Affects of Cigarette Smoke, Allergens, and IL-33 in a Murine Model of Asthma/ M. Minalt, M. Hanna, C. Kieffer, Y.T. Tu, P. Abel, R.G. Townley, Omaha, NE, p.A5800


P54 Substrate Selective Targeting of ERK Signaling Mitigates Allergen-Induced Asthma Features in Mice/ A.P. Nayak, R. Yi, N. Wang, S.D. Shah, P. Shapiro, D.A. Deshpande, Philadelphia, PA, p.A5804


Facilitator: J.A. Hirota, PhD, Vancouver, Canada


P58 Expression of Th1 Cytokines Are Increased in Adolescent Mice with Steroid Resistant Allergic Airway Inflammation/ R.D. Britt, M. Thompson, C.M. Pabelick, Y.S. Prakash, Rochester, MN, p.A5808


P60 MicroRNA-25 Modulates Proliferative Signaling Via the Mammalian Target of Rapamycin Pathway in Asthmatic Airways/ Y.S. Prakash, G.C. Sieck, Rochester, MN, p.A5811


P64 Heterogeneity of Human Sinonasal Epithelial Basal Cells/ S. Khalil, N. Gour, S. Lajoie, A.P. Lane, Baltimore, MD, p.A5814


Facilitator: T.S. Hallstrand, MD, MPH, Seattle, WA


P68 Sputum Eosinophils, Neutrophils, Bronchoconstriction Following Inhaled Allergen/C. Munoz, K.J. Killian, G.M. Gauvreau, P. O’Byrne, Hamilton, Canada, p.A5818

P69 Pulmonary Inflammation, but Not Bronchoconstriction, Increases Markers of Cardiovascular Risk in Asthma/L. Moore, A.R. Brotto, K. Kapoor, M. Bhutani, E.Y. Wong, M.K. Stickland, Edmonton, Canada, p.A5819


P71 Serological Markers of Intracellular Respiratory Pathogens (Mycoplasma Pneumoniae, Chlamydophila Pneumoniae) in Children with Different Asthma Control Levels/S. Tereshchenko, M. Shubina, I. Novickii, Krasnoyarsk, Russian Federation, p.A5821

P72 Inflammation and VEF1 Decline of Asthmatic Patients Followed for 10 Years/A.L.L. Godoy Fernandes, C.F. Farias, M. Amorim, M. Dracoulakis, L.B. Caetano, Sao Paulo, Brazil, p.A5822


P75 Cell Type Specific Activation of Heat Shock Proteins and Inhibition of Anti-Apoptotic Proteins May Explain the Beneficial Long Term Effect of Bronchial Thermoplasty/L. Fang, M. Tamm, M. Roth, D. Stolz, Basel, Switzerland, p.A5825

P76 Heparin-Binding EGF-Like Growth Factor Modulates the Bidirectional Activation of CD4+ T Cells and Dendritic Cells Independently of the Epidermal Growth Factor Receptor/M. Chen, S. Farahnak, J.G. Martin, Montreal, Canada, p.A5826

Facilitator: M. Ochs, MD, Hannover, Germany

P331 Estimation of Absolute Number of Alveolar Epithelial Type 2 Cells: A Comparison Between Flow Cytometry and Stereology/G. Dzhuaraev, J.A. Rodríguez-Castillo, J. Ruiz Camp, C. Mühlfeld, W. Seeger, R.E. Morty, Bad Nauheim, Germany, p.A5827

P332 The Role of Rapid On Site Cytology Evaluation in Diagnostic Interference Pulmonology/W. Jin, Hangzhou, China, p.A5828


P337 Alveolo-Capillary Membrane Thickness Estimate Based on Lung Surface and Carbon Monoxide Specific Conductance Measurements/J.-B. Martinot, B. Melki, B. Semin, B. Maury, H. Guenard, Namur, Belgium, p.A5833

Facilitator: D.M. Vasilescu, PhD, Vancouver, Canada

P338 Efficiency of Nebulized Delivery to Alveolus in Isolated Lungs/T. Nguyen, C.E. Perlman, Hoboken, NJ, p.A5834

P339 High-Resolution Time-Resolved Phase-Contrast Synchrotron CT for Mapping Cardiac-Induced Lung Motion/S. Bayat, L. Fardin, L. Broche, G. Lovric, A.S. Larsson, A. Bravin, Grenoble, France, p.A5835


P344 Pin-Point Spirometry (Local PFT): A Case Study/D. Wenger, S.E. Dubsly, A. Fournas, C.R. Samarage, Melbourne, Australia, p.A5840

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
P346  Peak Oxygen Consumption to Watt Relationship (J. Budde, MD, MPH, New York, NY)


P351  A New Noninvasive Method of Measuring Pulmonary Gas Exchange in Patients with Lung Disease/J.B. West, D.L. Wang, G.K. Prisk, La Jolla, CA, p.A5847

P352  Reference Values for Pulmonary Function Tests in Healthy Indian Adults/S. Sinha, S. Jain, S.K. Sharma, New Delhi, India, p.A5848

P353  Evaluate Respiratory Complications in Exhaled Fraction of FeNO from Patients Submitted to Cardiac Surgery, Abdominal Surgery and Healthy Volunteers/L. Amaral, D. Vento, C. Bottura, H. Chagas, B. Santos, A. Rodrigues, Ribeirao Preto, Brazil, p.A5849


P358  Comparison of Pulmonary CT Density Analysis Between Two Leading Software Programs/D. Crossley, S.M. Humphries, R.A. Stockley, A.M. Turner, Birmingham, United Kingdom, p.A5854


P361  Significance of Isolated Diffusing Capacity Abnormalities (DLCO) in Patients with Normal Pulmonary Function Tests (PFT)/J.A. Kileci, A. Miller, New York, NY, p.A5857

THEMATIC POSTER SESSION

C76  CHEST WALL, RESPIRATORY MUSCLES: NEURAL AND VENTILATORY CONTROL

9:15 a.m. - 4:15 p.m.  SAN DIEGO CONVENTION CENTER
Area D (Hall A-B2, Ground Level)

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator:  K.I. Berger, MD, New York, NY


P365  Excision of the Xiphoid Process for Chronic Pain: Patient Characteristics and Results/A. Swarup, J.D. Phillips, D.J. Finley, T.M. Millington, Lebanon, NH, p.A5860


P367  Respiratory Drive During Arm and Leg Cycling in Adults with Motor Incomplete Spinal Cord Injury/K.S. Alwadeai, G.S. Panza, J.E. Herrick, Fairfax, VA, p.A5862


Facilitator: M.G. Drake, MD, Portland, OR


Facilitator: D.C. Files, MD, Winston-Salem, NC


P384 Effect of Lung Volumes on Esophageal Pressure and Diaphragm EMG/H. Qin, S. Wu, Y. Wang, Y. Luo, Guangzhou, China, p.A5879

P385 A Single Centre 6 Year Audit of Diaphragm Dysfunction/M.T. Naughton, J. Taverner, L. Fuller, G.I. Smell, M. Hew, Melbourne, Australia, p.A5880


C77 PREDICTORS OF SLEEP DISORDERED BREATHING AND RESPONSE TO TREATMENT
9:15 a.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER

Area H (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: J.-L. Pepin, MD, PhD, Grenoble, France


P960 Different Relations Between Sleep Stage, Body Position and Respiratory Event in Positional and Non-Positional Obstructive Sleep Apnea/R. Zhang, M. Wang, Y. Wang, Z. Liang, Chengdu, China, p.A5884

P961 Influence of Obesity on Severity of Sleep Apnea and CPAP Pressure Requirement/A. Aiyer, S.R. Surani, A. Khan, Corpus Christi, TX, p.A5885

P962 Cerebrovascular Responsiveness in Older Adults with Sleep Disordered Breathing/S. Chowdhuri, R. Rastogi, B.J. Morgan, M.S. Badr, R. Williams, Detroit, MI, p.A5886

P963 Duration of Hypoxemia and Severity of OSA Are Not Substantially Impacted by Chronic Exposure to Traffic-Related Air Pollution in Patients with Obstructive Sleep Apnea/C. Laratta, C. Carlsten, M. Brauer, A.J. Hirsch Allen, N. Fox, B.U. Peres, N. Ayas, Edmonton, Canada, p.A5887

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.

Abdominal Muscle Fat Infiltration and OSA Pathogenesis/G. D'Angelo, P. Genta, A. Mello, Sao Paulo, Brazil, p.A5889

Facilitator: R. Bhattacharjee, MD, San Diego, CA

P966 Association of REM and Non REM AHI with OSA Severity and Sleep Stage Duration/O. Tahir, M. Ehtisham, P. Koo, New Haven, CT, p.A5890


P971 Pilot Study of a Newly Developed Expiratory Positive Airway Pressure Device in Obstructive Sleep Apnea/T. Dralyuk, M.A. Tanious, I. Randhawa, E. Nussbaum, Long Beach, CA, p.A5895


Facilitator: R.C. Stansbury, MD, Morgantown, WV

SERUM YKL-40 LEVEL IS CORRELATED WITH DISEASE SEVERITY IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA SYNDROME: A META-ANALYSIS/S. Liu, M. Bai, X. Tong, X. Yang, D. Wang, H. Fan, Chengdu, China, p.A5897

CONTRIBUTION OF NECK FAT TO OBSTRUCTIVE SLEEP APNEA IN OBSESE ADOLESCENTS/C.M. Cielo, R.J. Schwab, B. Keenan, C.L. Marcus, Philadelphia, PA, p.A5898


The Use of Automatic Continuous Positive Airway Pressure (APAP) Therapy in Severe Obstructive Sleep Apnoea (OSA)/H. Sivaramakrishnan, Y. Chung, G. Cossa, L. Laks, R. Brillante, Concord, Australia, p.A7779
WS5 CAREER DEVELOPMENT WORKSHOP: SWIMMING IN THE SEA OF BIG DATA FOR PULMONARY RESEARCH

Registration Fee: $75 (includes box lunch)
Attendance is limited. Pre-registration is required.

WS6 BRONCHOSCOPIC APPROACH TO THE PERIPHERAL LUNG NODULE

Registration Fee: $75 (includes box lunch)
Attendance is limited. Pre-registration is required.

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.

ATS 2018 • San Diego, CA
Objectives
At the conclusion of this session, the participant will be able to:

• apply new knowledge on how to combine r-EBUS and navigation bronchoscopy to achieve improved yield when sampling peripheral nodules;
• evaluate peripheral nodules with new navigational systems;
• improve use of r-EBUS in assessing peripheral pulmonary nodules.

Lung cancer screening in high risk population has been shown to effectively detect early lung cancer in the NLST trial. As such, United States Prevention Service Task Force has given a Grade B recommendation to annual low dose chest computed tomography scan for lung cancer screening. Since this development, there have been an increasing number of pulmonary nodules detected. The American College of Chest Physicians lung cancer guidelines recommended biopsies in patients who have moderate risk or patients who have high risk but desire tissue confirmation prior to resection. As a result, bronchoscopic approaches to reach peripheral lung nodule have become an integral part of the pulmonary practice. Development of navigational bronchoscopy and the use of radial EBUS probe has improved biopsy yield compared to conventional flexible bronchoscopy. Understanding the limitations and best applications of these tools will allow physicians to achieve better yield when diagnosing peripheral lung nodules.

Chairing:
M.M. Wahidi, MBA, MD, Durham, NC
G.Z. Cheng, MD, PhD, Durham, NC

11:45 Current Approaches in Electromagnetic Navigation Bronchoscopy 1
M.M. Wahidi, MBA, MD, Durham, NC

12:00 The Role of Radial Endobronchial Ultrasound in Peripheral Bronchoscopy 1
A.C. Chen, MD, St. Louis, MO

12:15 Interactive Session: Learning from the Experts
G.Z. Cheng, MD, PhD, Durham, NC
A.C. Chen, MD, St. Louis, MO
M.M. Wahidi, MBA, MD, Durham, NC

This session and the International Conference are supported by an educational grant from Boston Scientific Corporation. All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.
MEDICAL EDUCATION SEMINAR
CME Credits Available: 1

ME3  HOW DOCTORS THINK: DEFINING AND TEACHING CRITICAL THINKING IN CRITICAL CARE

Registration Fee: $70 (includes box lunch)
Attendance is limited. Pre-registration is required.
12:15 p.m. - 1:15 p.m. SAN DIEGO CONVENTION CENTER
Room 2 (Upper Level)

Target Audience
Residents, fellows, and other members in training, as well as anyone who has teaching responsibilities, including nurses and respiratory therapists

Objectives
At the conclusion of this session, the participant will be able to:
• To define the importance of critical thinking in the fast paced, high acuity critical care environment and describe its effect on patient outcomes
• Create questions to ask learners that stimulate critical thinking
• Utilize concept mapping to foster critical thinking in the intensive care unit

This 60 minute session will begin with a brief overview and definition of critical thinking and cognitive science. Then tangible strategies for teaching critical thinking will be discussed with an emphasis on asking appropriate questions and utilizing concept mapping.

Speakers:
M. Hayes, MD, Boston, MA
R. Schwartzstein, MD, Boston, MA
J. Richards, MD, MA, Boston, MA
W.G. Carlos, MD, MSCR, Indianapolis, IN

CLINICAL
THEMATIC SEMINAR SERIES
CME Credits Available: 1

TSS1  NEUROMUSCULAR RESPIRATORY FAILURE: PART 3

Registration Fee: $140 for full series (includes box lunch)
Attendance is limited. Pre-registration is required.
This is part 3 of a 3-part series. Those registering for this seminar series will be registered for all 3 parts. The program for the full series is included with the Sunday, May 20, 12:15 p.m. program.
12:15 p.m. - 1:15 p.m. MARRIOTT MARQUIS SAN DIEGO MARINA
Palomar (South Tower, Third Floor)

Management of Respiratory Failure in ALS: The VA as a Model in Team Based Approach to Care
K.A. Provost, DO, PhD, Buffalo, NY

Advance Disease Management and Transitioning to Hospice
J.O. Benditt, MD, Seattle, WA

CLINICAL
ADULT CLINICAL CORE CURRICULUM
CME Credits Available: 2
MOC Points Available: 2

CC4  CRITICAL CARE CLINICAL CORE CURRICULUM II
2:15 p.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER
Hall H (Ground Level)

Target Audience
Practicing internists, subspecialists, registered nurses and advanced practice nurses in pulmonary, critical care, and sleep medicine who work in a clinical setting and are currently engaged in maintenance of certification

Objectives
At the conclusion of this session, the participant will be able to:
• remain current with medical knowledge relevant to their practice in pulmonary, critical care, and sleep medicine;
• evaluate their understanding of key skills and content areas in pulmonary, critical care and sleep medicine, as well as receive feedback on their comprehension of a result of a pre-test/post-test comparison;
• support clinicians who are engaged in maintenance of certification activities by providing updates on subjects included in recertification requirements.

The ATS Clinical Core Curriculum Symposia focus on a 3-year content cycle of key medical content in the areas of Pulmonary, Critical Care, and Sleep Medicine. The topics are also aligned with corresponding MOC Medical Knowledge modules. This symposium is intended to assist clinicians with staying current with the growth of information relevant to their medical practice,
as well as provide an opportunity to evaluate individual knowledge and skills while earning MOC Medical Knowledge points.

Chairing: J.I. McSparron, MD, Ann Arbor, MI
M.M. Hayes, MD, Boston, MA
A. Lukas, MD, Seattle, WA

2:15 Infectious Diseases: CNS Infections
J. Town, MD, Seattle, WA

2:45 Infectious Diseases: Emerging Viral Infections
W.A. Fischer, MD, Chapel Hill, NC

3:15 Infectious Diseases: Empyema and Mediastinitis
L. Frye, MD, Chicago, IL

3:45 Infectious Diseases: Pneumonia CAP/HCAP/VAP
K. Hibbert, MD, Boston, MA

C82 SHIFTING FOCUS: HOW TO STUDY LUNG HEALTH INSTEAD OF DISEASE

Assemblies on Clinical Problems; Allergy, Immunology and Inflammation; Behavioral Science and Health Services Research; Environmental, Occupational and Population Health; Pulmonary Circulation; Pulmonary Rehabilitation

2:15 p.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER
Ballroom 20 B-C (Upper Level)

Target Audience
Clinicians and clinical and translational researchers focused on lung health and prevention of lung disease

Objectives
At the conclusion of this session, the participant will be able to:

• apply how the presence of respiratory symptoms, even in the absence of disease, has implications for both respiratory and overall health outcomes;

• learn new findings about how novel chest imaging findings relate to lung health and respiratory outcomes;

• integrate the current understanding of lung health and its manifestations and consequences to better inform testable hypotheses that can be incorporated into new research studies targeting the prevention of chronic lung disease.

Historically, respiratory research has been highly focused on risk factors and treatment of established lung disease rather than true disease prevention. A central component of disease prevention is health promotion. We will emphasize recent findings that inform how we, as a respiratory community, can shift away from exclusively studying disease and instead develop studies of lung health. Presentations will use current evidence from a variety of observational cohorts which have and continue to publish state of the art work around concepts of lung health. The session will serve as an update and inventory of current evidence and a preliminary understanding of what a true chronic lung disease prevention research agenda ought to include.

Chairing: R. Kalhan, MD, MS, Chicago, IL
N.N. Hansel, MD, MPH, Baltimore, MD
M.T. Dransfield, MD, Birmingham, AL

2:15 Introduction
R. Kalhan, MD, MS, Chicago, IL

2:18 Lung Health Across the Lifespan: What Birth Cohorts Teach Us
M.R. Sears, MD, Hamilton, Canada

2:38 The Implications of Impaired Lung Health From Young Adulthood to Middle Age
G.R. Washko, MD, Boston, MA

2:58 Impaired Lung Health: Interstitial Changes in Healthy Populations
D.J. Lederer, MD, MS, New York, NY

3:18 Lung Health Cannot Be Defined by Normal Spirometry
M.K. Han, MD, MS, Ann Arbor, MI

3:38 Setting the Research Agenda for Lung Health in the 21st Century
J.P. Kiley, PhD, Bethesda, MD

3:58 General Discussion
R. Kalhan, MD, MS, Chicago, IL
2:15  A 16 Month Old with Breathlessness  
M. Vielkind, MD, Aurora, CO  
Expert Discussant  
M. Dovey MD, Pittsburgh, PA

2:45  A 16 Year Old with Cough and Fatigue  
L. Feld, MD, Manhasset, NY  
Expert Discussant  
T. Vece MD, Chapel Hill, NC

3:15  An 8 Month Old with Blue Spells  
S. Shanthikumar, MBBS, Parkville, Australia  
Expert Discussant  
S. Ward MD, Los Angeles, CA

3:45  A 15 Year Old with Weight Loss  
E.A. Dominguez Silveyra, MD, Mineola, NY  
Expert Discussant  
P. Stillwell MD, Aurora, CO

ACUTE HYPOXIC RESPIRATORY FAILURE

Assemblies on Critical Care; Behavioral Science and Health Services Research

2:15 p.m. - 4:15 p.m.  SAN DIEGO CONVENTION CENTER  
Ballroom 20 A (Upper Level)

Target Audience  
Critical care clinicians, trainees, and researchers

Objectives  
At the conclusion of this session, the participant will be able to:

• become aware of evidence base for HFNC and NIPPV in early AHRF;
• understand pros/cons of early versus later intubation and invasive mechanical ventilation;
• learn about current knowledge gaps in treating AHRF and preventing progression to ARDS.

Acute hypoxic respiratory failure (AHRF) is a leading cause of ICU admission, morbidity, and mortality, yet most research focuses specifically on mechanically ventilated patients with ARDS. Are AHRF and ARDS really different clinical entities? Should our approach to treatment differ? In this session, experts will discuss and debate best practices for managing early AHRF. Speakers will address common management decisions faced by intensivists every day, such as when to use HFNC, when to consider NIPPV, and when to intubate patients with AHRF. They will also identify gaps in our knowledge and discuss future directions for research.

Chairing:  
H.C. Prescott, MD, MSci, Ann Arbor, MI  
V. Liu, MD, MS, Oakland, CA  
B.K. Patel, MD, Chicago, IL

2:15  Are AHRF and ARDS Different? What Is the Proof?  
T. Pham, MD, PhD, MPH, Toronto, Canada
Mitochondrial Oxidant and DNA Signaling in Lung Diseases
G. Shadel, PhD, New Haven, CT

Mitochondrial 8-Oxoguanine DNA Glycosylase (mtogg1) Mitigates Asbestos-Induced Aec Mitophagy Defects, Mitochondrial DNA Damage, Apoptosis And Lung Fibrosis
S. Kim, PhD, Chicago, IL

Caveolin1 Regulates Mitochondrial Homeostasis in the Alveolar Epithelium
H. Shaghaghi, PhD, Philadelphia, PA

Cyb5R3 an External Mitochondrial NADH-Dependent Reductase Confers Protection Against Lung Fibrosis
M. Bueno, PhD, Pittsburgh, PA

Systemic Immune-Metabolic Deficiency in Tobacco and Biomass Smoke Exposed COPD Subjects
A.R. Agarwal, MS, PhD, Pune, India

Pharmacologically Enhanced Mitochondrial DNA Repair Improves Performance of Ex Vivo Perfused Lungs from Brain-Dead Pigs
D. Hall, MD, Gainesville, FL

Indolamine-2, 3-Dioxygenase in Myeloid-Derived Suppressor Cells Alters Mitochondrial Dynamics and Mediates Metabolic Reprogramming in the Tumor Microenvironment of Lung Cancer
J. Deshane, PhD, Birmingham, AL

Mitochondria and Proteostasis
K. Zhou, PhD, Novato, CA

Mitochondrial 8-Oxoguanine DNA Glycosylase (mtogg1) Mitigates Asbestos-Induced Aec Mitophagy Defects, Mitochondrial DNA Damage, Apoptosis And Lung Fibrosis
S. Kim, PhD, Chicago, IL

Caveolin1 Regulates Mitochondrial Homeostasis in the Alveolar Epithelium
H. Shaghaghi, PhD, Philadelphia, PA

Cyb5R3 an External Mitochondrial NADH-Dependent Reductase Confers Protection Against Lung Fibrosis
M. Bueno, PhD, Pittsburgh, PA

Systemic Immune-Metabolic Deficiency in Tobacco and Biomass Smoke Exposed COPD Subjects
A.R. Agarwal, MS, PhD, Pune, India

Pharmacologically Enhanced Mitochondrial DNA Repair Improves Performance of Ex Vivo Perfused Lungs from Brain-Dead Pigs
D. Hall, MD, Gainesville, FL

Indolamine-2, 3-Dioxygenase in Myeloid-Derived Suppressor Cells Alters Mitochondrial Dynamics and Mediates Metabolic Reprogramming in the Tumor Microenvironment of Lung Cancer
J. Deshane, PhD, Birmingham, AL

Mitochondria and Proteostasis
K. Zhou, PhD, Novato, CA

The explosion of large data sets derived from high-throughput multi-omics technologies holds great promise for answering fundamental questions in lung health and disease. The integration of data sets generated by different technologies—such as combining epigenetic profiling with transcriptional profiling—poses significant challenges. This session aims to provide a vocabulary to aid in discussion of multi-omics integration; engender familiarity with literature on multi-omics technologies; and concretize conceptual and technical approaches to integration of multi-omics-derived data sets in lung health and disease.

Chearing: B.D. Singer, MD, Chicago, IL
N. Kaminski, MD, New Haven, CT
G. Ligresti, PhD, Rochester, MN

2:15 Integrating Epigenomics and Phenomics
H.M. Boezen, PhD, Groningen, Netherlands

2:30 Integrating Metabolomics and Epigenomics
N.S. Chandel, PhD, Chicago, IL

3:05 Integrating Proteomics and Interactomics
D.S. Phelps, PhD, Hershey, PA

3:25 Integrating Transcriptomics and Epigenomics
K. Lingappan, MBBS, Houston, TX

3:45 Integrating Transcriptomics and Proteomics
O. Eickelberg, MD, Denver, CO

C87 WHAT’S OLD IS NEW AGAIN: REPURPOSING APPROVED MEDICATIONS FOR NOVEL THERAPEUTICS IN PAH - EARLY CLINICAL STUDIES

Assemblies on Pulmonary Circulation; Clinical Problems
2:15 p.m. - 4:15 p.m. MARRIOTT MARQUIS SAN DIEGO MARINA
Pacific Ballroom 22 (North Tower, First Floor)

Target Audience
Those interested in pulmonary hypertension and basic/translational science professionals

Objectives
At the conclusion of this session, the participant will be able to:

- learn about novel pathways that are involved in the pathogenesis of pulmonary arterial hypertension and appreciate the limitations of the currently approved therapies for pulmonary arterial hypertension;
- familiarize novel therapeutic agents targeting the pulmonary vasculature and the right ventricle in pulmonary arterial hypertension that are in early phase 2 clinical trials;
- appreciate the potential for repurposing already FDA approved medications as novel treatment options for pulmonary arterial hypertension.

The goal of this session about be to discuss and highlight the early clinical study data for repurposing already approved medications for novel therapeutics targeting the pulmonary vasculature and right ventricle in PAH. As we continue to struggle with high costs of PAH-specific therapy and the significant lag in development of novel therapeutics, an attractive method moving forward would be to repurpose already approved medications as we could avoid the long delays for drug approval and proceed directly to clinical trials once there is...
strong preclinical evidence that they may be effective. This strategy may help us attack PAH pathophysiology through distinct mechanisms than the currently approved therapies do which increases the likelihood of identifying new agents to treat this devastating disease.

Chairing: I.M. Lang, MD PhD, Vienna, Austria
K. Prins, MD PhD, Minneapolis, MN

2:15 My Patient Is on Triple Therapy but Still Symptomatic, What’s Next?
Speaker To Be Announced

2:30 Metformin for End-Stage PAH (RV)
A. Hemnes, MD, Nashville, TN

2:45 Beta-Blockers for RV Dysfunction in PAH (RV)
T. Thenappan, MD, Minneapolis, MN

3:00 Anastrozole Reduces Estradiol Levels and Increases Walk Distance in PAH (Pulmonary Vasculature)
S.M. Kawut, MD, MS, Philadelphia, PA

3:15 Tacrolimus for End-Stage PAH
E.F. Spiekerkoetter, MD, Palo Alto, CA

3:30 Ubenimex in Patients With Pulmonary Arterial Hypertension
M.R. Nicolls, MD, Palo Alto, CA

This session and the International Conference are supported by educational grants from Actelion Pharmaceuticals US, Inc., Bayer US. All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

Target Audience
Clinicians from all professional backgrounds (MD, RN, APN, PA, SW, chaplain, pharmacist, respiratory therapist) who care for patients with serious illness

Objectives
At the conclusion of this session, the participant will be able to:

• list criteria for referral of outpatient pulmonary patients to palliative care;
• discuss evidence-based strategies for managing symptoms, disease-related distress, and improving quality of life for patients with chronic respiratory disease;
• describe challenges and solutions to managing an outpatient pulmonary-focused palliative care clinic.

Outpatient palliative care can provide welcome relief to patients who may live for many years with serious respiratory disease. The focus on relieving symptom burden, illness related distress, and improving quality of life complements disease directed treatment throughout the course of illness. Keynote presentations from two visionary thought leaders in pulmonary focused palliative care will showcase brief presentations of innovative implementation strategies from clinician scientists who are working in outpatient pulmonary palliative care.

Chairing:
D.M. Donesky, PhD, ANP-BC, San Francisco, CA
K.O. Lindell, PhD, RN, Pittsburgh, PA

2:15 A Patient’s Perspective
C. Camacho, MA, LSW, Ashland, MA

2:20 Developing and Funding a Breathlessness Service in Prehistoric Times
S. Booth, MD, Cambridge, United Kingdom

2:55 Nurse-Led Palliative Care Interventions
L.F. Reinke, PhD, APRN,BC, Seattle, WA

3:15 Transitions Across the Continuum of Care: Lessons From ILD
A. Russell, MScN, London, United Kingdom

3:35 10 Tips for Setting Up a Multidisciplinary Breathlessness Clinic
M.M. Roberts, RN, Westmead, Australia

3:55 Palliative Care as a Bridge Between Pulmonary Rehabilitation, Critical Care, and Hospice
A.R. Stephens, MD, Aurora, CO

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
respiratory infections. Current climate change initiatives will be futile if present population increases continue. This session will present the latest projections of relationships between climate change, environmental threats and increasing population how these will affect the future respiratory health of children. Advocacy strategies addressing these issues will be discussed.

Chairing: P.N. Le Souef, MD, MBBS, Perth, Australia

2:15 Current Projections of Climate Change and Respiratory Health in Children
Speaker To Be Announced

2:40 100 Year Projection of Child Health Outcomes By Population, Region and Age
C. Bradshaw, PhD, Adelaide, Australia

3:05 The Effects of Loss of Biodiversity on Children’s Respiratory Health
A. Annamalay, PhD, Perth, Australia

3:30 The Effect of Climate Change on Respiratory Disease in Developing Countries
R.T. Stein, MD, Porto Alegre, Brazil

3:50 100 Year Projections of Future Child Respiratory Health: Environment and World Population
P.N. Le Souef, MD, MBBS, Perth, Australia

The growing recognition of sleep apnea by clinicians and health systems, has led to the realization that sleep apnea is a chronic and complex disease with a wide range of phenotypic manifestations and morbidities. Furthermore, it has prompted observations that it may co-occur in the context of other respiratory diseases, and that such concurrent presence of sleep apnea and a lung disease may mutually alter their clinical presentation and course, as well as modify the response to treatment. This session will explore the current state of the art in the context of sleep apnea co-existing with other frequent lung diseases and identify potential clinical, research and educational opportunities in this relatively unexplored area.

Chairing: K. Connolly, BS, Danvers, MA
D. Gozal, MD, MBA, Chicago, IL

2:15 Annual PAR Awards Presentation
K. Connolly, BS, Danvers, MA

2:25 Obstructive Sleep Apnea and Asthma in Kids: Bedtime Stories
L. Kheirandish-Gozal, MD, MSc, Chicago, IL

2:45 Asthma and Obstructive Sleep Apnea in Adults
M. Teodorescu, MD, MS, Madison, WI

3:05 COPD and Obstructive Sleep Apnea: Overlapping What?
X. Soler, MD, PhD, San Diego, CA

3:25 Interstitial Lung Disease and Obstructive Sleep Apnea
D.J. Lederer, MD, MS, New York, NY

3:45 Insomnia, Sleep Quality and Lung Disease Burden
P.J. Strollo, MD, Pittsburgh, PA

4:05 Questions and Answers
K. Connolly, BS, Danvers, MA

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
2:15 p.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER
Room 33 A-C (Upper Level)

Target Audience
Health care professionals, patients and patient-support groups; clinicians and clinical investigators involved in translational and clinical research in both academic and industry settings

Objectives
At the conclusion of this session, the participant will be able to:
• understand parallels in disease progression in respiratory and other diseases;
• understand concepts of slowing disease progression and disease modification and the potential impact to patients with respiratory disease;
• learn the currently available science and the tools available to assess changes to respiratory physiology.

This session will provide a forward looking discussion around concepts of disease modification and future opportunities to change the course of chronic respiratory disease. It will bring forth new treatment paradigms that will ultimately impact the goals of therapy. There will be a review of the current landscape of disease progression and modification in respiratory medicine (e.g. IPF, ILDs, CF, A1T1-deficiency) and other therapeutic areas (e.g. RA, IBD), to identify potential parallels with chronic obstructive lung disease. Additionally, we will identify considerations required for conducting clinical research such as relevant clinical end-points (including technological approaches e.g. imaging) and molecules that may have the potential to modify the course of Respiratory disease.

Chairing: C. Reisner, MD, Morristown, NJ
F.C. Sciurba, MD, Pittsburgh, PA
M. Bafadhel, MD, Oxford, United Kingdom

2:15 What is Disease Modification in COPD? What Are the Potential Methods for Assessment?
M.K. Han, MD, MS, Ann Arbor, MI

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
MINI SYMPOSIUM

C94 HIGHLIGHTED HEALTH SERVICES RESEARCH IN CRITICAL CARE

2:15 p.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER
Room 14 A-B (Mezzanine Level)

Chairing: C.R. Cooke, MD, Ann Arbor, MI
M.P. Kerlin, MD, MS, Philadelphia, PA
A.J. Walkey, MD, MSc, Boston, MA

Oral Presentations


MINI SYMPOSIUM

C95 PROGRESS WITH BIOMARKER DEVELOPMENT IN COPD

2:15 p.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER
Room 29 A-D (Upper Level)

Chairing: J.M. Bon, MD, MS, Pittsburgh, PA

Featured Speaker
2:15 Biomarker Development in COPD: The Promise and Challenges/S.I. Rennard, MD, Melbourne, United Kingdom

Oral Presentations


3:45 Serum IgG Subclass Levels and Risk of Exacerbations and Monitoring COPD Disease Activity for Personalized, Preventative Treatment/R. Thomson, MBBS, PhD, Greenslopes, Australia

4:00 Alternative Trial Designs for Complex Infections/Featured Speaker

President

RS. Mallory, MD, MPH, Bethesda, MD

Oral Presentations


Featured Speaker

4:00 Alternative Trial Designs for Complex Infections/B. Saville, Austin, TX


### MINI SYMPOSIUM

#### C99 SLEEP PHENOTYPES, GENETICS, AND BIOMARKERS: NOVEL INSIGHTS

**2:15 p.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER**

**Room 7 A-B (Upper Level)**

**Chairs:** R. Mehra, MD, Cleveland, OH  
M. Sanchez De La Torre, PhD, Lleida, Spain  
R. Saxena, PhD, Boston, MA  

**Oral Presentations**


**3:15 Circulating Plasma Exosomes May Signal Circadian Clock Misalignment to Peripheral Tissues/A. Khalyfa, Chicago, IL, p.A5934**

**3:30 Quantifying the Severity of Pharyngeal Airflow Obstruction Using Polysomnography/D. Mann, A. Azarbarzin, S. Mariani, A. Franciosini, A. Camassa, L. Taranto-Montemurro, L. Messineo, S. Redline, D. White, A. Wellman, P. Terrill, S. Sands, Brisbane, Australia, p.A5935**


**4:00 Increases in Heart Sound Intensity Following Respiratory Events Are Positively Correlated with Drops in Oxygen Saturation During the Events/M.M. Kabir, B. Gavrilovic, S. Saha, K. Zhu, A. Yadollahi, Toronto, Canada, p.A5937**

---

**The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.**
C101 ASTHMA CLINICAL AND MECHANISTIC STUDIES
2:15 p.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER
Room 11 A-B (Upper Level)

Abstract Summaries
2:15-2:45
Viewing/Discussion
2:45-4:15

Chairing:
A. Haczku, MD, PhD, Davis, CA
A. Ray, PhD, Pittsburgh, PA
T.S. Hallstrand, MD, MPH, Seattle, WA

401 C3a is Required for ILC2 Function in Allergic Airway Inflammation
N. Gour, U. Smole, H.M. Yong, S. Lajoie, Baltimore, MD, p.A5945

402 Genetic Variation in Surfactant Protein-A2 Differentially Modulates Resolution of Eosinophilia During Allergic Airways Inflammation

403 Mitochondrial Reactive Oxygen Species (mROS) Signaling Contributes to Obese Allergic Airway Disease

404 Dupilumab Produces Rapid and Sustained Improvements in Asthma-Related Symptoms in Patients with Uncontrolled, Moderate-To-Severe Asthma from the LIBERTY ASTHMA QUEST Study

405 Type 2 Biomarkers Associated with Dupilumab Efficacy in Patients with Uncontrolled, Moderate-To-Severe Asthma Enrolled in the Phase 3 Study LIBERTY ASTHMA QUEST/S.E. Wenzel, I. Pavord, B. Zhang, J. Maroni, P. Rowe, J.D. Hamilton, B.N. Swanson, N. Amin, G. Pirozzi, N.M.H. Graham, A. Teper, Pittsburgh, PA, p.A5949

406 Secreted Phospholipase A2 Group X Regulates Type-2 Cytokine Expression in Mast Cells

407 Dehydroepiandrosterone Supplementation May Benefit Certain Women with Asthma: A Pilot Study
N. Marozkina, L. Logan, M. DeBoer, B. Gaston, Cleveland, OH, p.A5951

408 Interleukin-25 and Eosinophils Progenitor Cell Mobilization in Allergic Asthma
W. Tang, W. Du, S.G. Smith, R. Sehmi, P. O’Byrne, Shanghai, China, p.A5952

409 RNA-seq Transcriptomics and Time-Course Longitudinal Gene-Set Analyses Reveal Potential Pathways Altered During Bronchial Thermoplasty Treatment in Severe Asthmatics


411 House Dust Mite-Derived Protease Allergen Sensing by Lung Endothelial and Proangiogenic Cells Induces Asthma
K. Asosingh, K. Queisser, N. Wanner, M.A. Aronica, S.C. Erzurum, Cleveland, OH, p.A5955

412 An ‘Omics’ Study to Investigate the Mechanisms Underlying Circadian Rhythm in Asthma

413 Longitudinal Follow-Up of Sputum Transcriptomic-Associated Clusters in Asthma from the U-BIOPRED Cohort

414 Time Series Fluctuation of Clinical and Molecular Markers in Healthy and Asthmatic Subjects Before and After Rhinovirus Inoculation

415 Fevipiprant, a Selective Prostaglandin D2 Receptor 2 Antagonist, Potently Inhibits Chemotaxis and Cytokine Production by Group 2 Innate Lymphoid Cells

416 Long-Term Efficacy and Safety of Bronchial Thermoplasty (BT): 3 Year Follow-Up Results from a Large Scale Prospective Study

417 The Effect of rs750064 on SPLUNC1 Expression and Function in Asthmatic Airway Epithelial Cells

418 Improvements in Asthma-Related Quality of Life Observed Within 4 Weeks of Treatment with Tezepelumab

419 IgE Stimulates Airway Mesenchymal Cells by Two Independent Signaling Pathways: STAT3 and MicroRNA21-5p and PI3K-akt-mTOR Signaling Pathway
L. Fang, M. Tamm, D. Stolz, M. Roth, Basel, Switzerland, p.A5963

Gut Microbiome Patterns in Adults Differentiate Asthma and Asthma-Related Clinical Features/Y.J. Huang, L.A. Begley, O. Ndum, A. Baptist, J. Erb-Downward, Ann Arbor, MI, p.A5965


Lowered Expression of Soluble Adenylate Cyclase (sAC) and Cellular Redox Enzymes in Human Airway Smooth Muscle Cells Derived from Asthma/A. Ghosh, R.A. Panettieri, D.J. Stuehr, Cleveland, OH, p.A5968

Age-Specific Associations Between Circulation of Viral Pathogens and Asthma Health Services Utilization/L. Feldman, J. Zhu, T.M. To, Toronto, Canada, p.A5969


Success Factors and Barriers in Lung Cancer Screening Program Implementation in the VA: Results of a Qualitative Study/A.E. Fabbrini, S.E. Lillie, S.S. Fu, C.H. Wendt, A.C. Melzer, Minneapolis, MN, p.A5977


“I Just Want to Know”: A Qualitative Study of Patients Offered Lung Cancer Screening/ S. Golden, S. Ono, S. Thakurta, R.S. Wiener, A.C. Melzer, S. Datta, C.G. Slatore, Portland, OR, p.A5979


Patient and Clinician Perspectives on Smoking Cessation in Three Lung Cancer Screening Programs/ S. Golden, S. Ono, R.S. Wiener, A.C. Melzer, J. Davis, C.G. Slatore, Portland, OR, p.A5981

Identifying Eligibility for Lung Cancer Screening in Hospitalized Smokers: An Opportunity to Improve Screening Rates/D. Kim, R.S. Wiener, E. Helm, H. Kathuria, Boston, MA, p.A5982


The Product of Pulse Pressure and Heart Rate, an Early Indicator of Nearly 20% of ED Patients with Clinical Sepsis Are Not Lung Cancer in the Palm of Our Hands- A Critical Appraisal of Classification and Regression Tree Analysis to Predict E-Consult Management of Lung Nodules: Do Primary Care Chairing:

RAPID: RAPID ABSTRACT POSTER DISCUSSION SESSION

C103 CRITICAL CARE: SEPSIS AND SHOCK - WHAT WE ARE SUPPOSED TO DO, WHAT IS ACTUALLY DONE, AND WHAT CAN WE DO BETTER

2:15 p.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER
Room 31 A-C (Upper Level)

Abstract Summaries
2:15-2:45

Viewing/Discussion
2:45-4:15

Chairing: J.-T.T. Chen, MD, Bronx, NY
C.W. Seymour, MS, MSc, Pittsburg, PA
I.S. Douglas, MD, Denver, CO


702 Nearly 20% of ED Patients with Clinical Sepsis Are Not Admitted to the Hospital/ Pelitan, N.C. Dean, J.R. Bledsoe, T.L. Allen, E.L. Wilson, M.M. Samore, S.M. Brown, Murray, UT, p.A5994

703 The Product of Pulse Pressure and Heart Rate, an Early Indicator of the Presence of Sepsis/D. Lynch, T.J. Rice, Chapel Hill, NC, p.A5995


710 Frequency of Surviving Sepsis Campaign Bundle Compliance for Hospital-Acquired Sepsis/S. Goodman, S. Shah, B. Varghese, J.A. Greenberg, Chicago, IL, p.A6002

711 Disparities in the Care of Patients with Sepsis/C. Rabascalay Ayoub, J. Rey-Mendoza, W. Kowacz, S.J. Quinn, A. Kaye, V. Esmero, A. Tulaimat, J.A. Greenberg, R. Gueret, Chicago, IL, p.A6003


718 A Phase 2a Randomized Controlled Trial of Echocardiogram-Guided Resuscitation in Early Septic Shock/R. Burk, S.M. Brown, E. Wilson, C.K. Grissom, E.L. Hirshberg, M.J. Lanspa, Salt Lake City, UT, p.A6010

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
C105 CRITICAL CARE: MULTI-ORGAN FAILURE AND NON-PULMONARY CRITICAL CARE - FROM RESEARCH TO PRACTICE

2:15 p.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER
Room 28 C-E (Upper Level)

Abstract Summaries
2:15-2:45

Viewing/Discussion
2:45-4:15

Chairing: D.C. Files, MD, Winston-Salem, NC
M. Hua, MD, MSci, New York, NY


503 Simplified 2Ts Score for Heparin-Induced Thrombocytopenia Risk/T. Gallo, A. Padilla-Jones, H. Bal, S. Curry, K. Ramos, R. Raschke, Phoenix, AZ, p.A6042


507 Impact of Dexametomidine for the Treatment of Alcohol Withdrawal Syndrome Upon Intensive Care Unit Length of Stay/E. Yavaronovich, M. Bintvihok, J. McCarty, J. Breeze, P. LaCamera, Burlington, MA, p.A6046


509 Critically Ill Caucasian Patients Admitted for Alcohol Withdrawal Have a Longer Hospital Length of Stay and Receive Higher Doses of Benzodiazepines/N. Ghionni, A.M. Abdul Hameed, B.E. Iriarte, A. Malik, A. Maheshwari, D.J. Valenti, Ill, Darby, PA, p.A6048

510 Treatment of Alcohol Withdrawal Syndrome with Benzodiazepines or Phenobarbital in the Medical Intensive Care Unit, a Retrospective Comparison/J.J. Saukkonen, T. Mekuria, M. Ronan, G. Connell, West Roxbury, MA, p.A6049

511 Trends Over Time in Drug Administration During Adult In-Hospital Cardiac Arrest/A. Moskowitz, C. Ross, L.W. Andersen, A.V. Grosestreuer, K.M. Berg, M.W. Donnino, Boston, MA, p.A6050


513 Role of Admission Glycated Hemoglobin in Critically Ill Patients with Pneumonia/C.-Y. Kuo, W.-A. Chang, C.-M. Chen, Y.-C. Tsai, S.-F. Huang, M.-J. Tsai, J.-R. Tsai, C.-C. Sheu, Kaohsiung, Taiwan, p.A6052

514 Challenging the Obesity Paradox in the Medical Intensive Care Unit/A. Chowdhury, X. Han, X. Wang, A. Duggal, Cleveland, OH, p.A6053

515 Challenging Dogma - Early Endoscopic Intervention Is an Option for Necrotizing Pancreatitis Resulting in Significant Improvement in Organ Failure/P. Tawfik, G.V. Trikudanathan, Minneapolis, MN, p.A6054


The Relationship between Disease Severity and Sleep Quality in the Context of Intensive Care Unit Sleep-Promoting Interventions: A Randomized Controlled Trial/N. Murali, M.A. Pisani, M.P. Knaeuert, New Haven, CT, p.A6058


Association Between Temperature Variability and Mortality in Hospitalized Patients with Infection/S. Bhavani, K. Carey, D. Edelson, M.M. Churpek, Chicago, IL, p.A6060


New Mexico Female Miners Have Lower Odds for COPD than Their Male Counterparts/P. Sen, O.B. Myers, X. Wang, M. Moreno, R. Karr, T. Sanchez, L. Cook, A. Sood, N.A. Assad, Albuquerque, NM, p.A6067


Lung Function Declines in Former Coal Mine Workers Absent Further Exposure/S. Gandhi, K. Almberg, L. Go, R.A. Cohen, Chicago, IL, p.A6069

Discordance in Prevalence of Abnormal Spirometry Based on Different Reference Equations in a Depleted Uranium-Exposed Surveillance Cohort/B. Weiler, M. McDermid, M. Cloeren, J. Gaitens, S.E. Hines, Baltimore, MD, p.A6070


Strategic Research Objectives for Occupational Respiratory Health from the National Occupational Research Agenda/P.K. Henneberger, A. Sood, D.N. Weissman, Morgantown, WV, p.A6074


C107 HIV: BENCH TO BEDSIDE
2:15 p.m. - 4:15 p.m. MARRIOTT MARQUIS SAN DIEGO MARINA
Grand Ballroom 11-13 (North Tower, Lobby Level)

Poster Viewing 2:15-3:00
Discussion 3:00-4:15

Chairing:
- L. Huang, MD, San Francisco, CA
- E. Attia, MD, MPH, Seattle, WA
- B.S. Staitieh, MD, Atlanta, GA


808 Doxycline Is Safe and Well-Tolerated in HIV-Positive Individuals with COPD and/or Early Emphysema/R.J. Kaner, S.L. O’Beirne, T.J. Walsh, R.G. Crystal, M.A. Glesby, New York, NY, p.A6094


811 Marijuana Smoking and Pneumonia Risk: Findings from the Multi-Center AIDS Cohort Study/D.P. Tashkin, J. Quint, R. Detels, Los Angeles, CA, p.A6097


POSTER DISCUSSION SESSION

C109  SURF CITY: EXERCISE AND RV FUNCTION IN PH

2:15 p.m. - 4:15 p.m.  MARRIOTT MARQUIS SAN DIEGO MARINA

Pacific Ballroom 24-26 (North Tower, First Floor)

Poster Viewing  2:15-3:00
Discussion  3:00-4:15

Chairing:  T. Lahm, MD, Indianapolis, IN  E. Brittain, MD, Nashville, TN  C.E. Ventetuolo, MD, MSCR, Providence, RI


1002  Comparison of Electrophysiological Remodeling in the Right Ventricles of Rats with Pulmonary Hypertension and Pulmonary Fibrosis-Associated Pulmonary Hypertension/N. Cao, M. Vaillancourt, G. Ruffenach, T. Le, S. Moazeni, M. Eghbali, S. Umar, Los Angeles, CA, p.A6128

1003  Direct Association Between Mitochondria Alterations and Impaired Contractile Function in Right Ventricular Failure Due to Pressure Overload in Rats/J.L. Philip, T.-C. Cheng, D.M. Tabima, T.A. Hacker, N.C. Chesler, Madison, WI, p.A6129


1005  Alpha 7 Nicotinic Acetylcholine Receptor (a7 nAChR) Signaling Modulates Right Ventricular Fibrosis in Pulmonary Hypertension/A. Vang, R.T. Clements, A. Allawzi, N.R. Kue, T.J. Mancini, G. Choudhary, Providence, RI, p.A6131


1007  Long Noncoding RNA H19 in the Development of Pulmonary Arterial Hypertension and Right Ventricular Failure/J. Omura, T. Peterlini, S. Provencher, S. Bonnet, Quebec City, Canada, p.A6133


C110 INTERVENTIONAL PULMONOLOGY: THE SWISS ARMY KNIFE FOR THORACIC ONCOLOGY

2:15 p.m. - 4:15 p.m. SAN DIEGO CONVENTION CENTER
Room 5 A-B (Upper Level)

Abstract Summaries
2:15-2:45

Viewing/Discussion
2:45-4:15

Chairing:
R. Semaan, MD, Pittsburgh, PA
B. Furukawa, MD, Loma Linda, CA
L. Mudambi, MD, Portland, OR
A.D. Lerner, MD, Baltimore, MD

Outcome of PD-L1 Testing in Endobronchial Ultrasound Guided Transbronchial Needle Aspiration (EBUS-TBNA)/
N. Al Nasrallah, K.J. Diab, Indianapolis, IN, p.A6147


Standardized Sample Handling During Endobronchial Ultrasound Guided Transbronchial Needle Aspiration Enhances Yield in the Diagnosis and Staging of Lung Cancer/S. Newhouse, S. Klebe, A. Williams, D. Moffat, R. Woodman, J. D’Costa, A. Rose, Bedford Park, Australia, p.A6150

Radiation Dose to Patients and Clinicians During Biopsy of Peripheral Pulmonary Lesions Guided by Augmented Fluoroscopy/K. Bhadra, Chattanooga, TN, p.A6151


Augmented Endobronchial Fluoroscopic Navigation and Localization System: Comparison with Cone Beam CT/M. Pritchett, Pinehurst, NC, p.A6156


PD-L1 Testing of EBUS-TBNA Samples Acquired for the Diagnosis and Staging of Non-Small Cell Lung Cancer: Feasibility and Results/A. Smith, H. Wang, A. Zerbo, S. Beaudoin, L.M. Oliara, A. Benedetti, A.V. Gonzalez, Montreal, Canada, p.A6158


4:30 p.m.-6:30 p.m.
SECTION MEMBERSHIP MEETINGS
The Section meetings are open to all ATS members and other interested individuals. Items to be discussed include the Sections’ current projects and future directions.

MEDICAL EDUCATION
MANCHESTER GRAND HYATT SAN DIEGO
Seaport Ballroom A (Second Level, Seaport Tower)
Chairing: Jennifer W. McCallister, MD, Columbus, OH
Henry Fessler, MD, Baltimore, MD

TERRORISM AND INHALATION DISASTERS
MANCHESTER GRAND HYATT SAN DIEGO
Seaport Ballroom B (Second Level, Seaport Tower)
Chairing: Carl W. White, MD, Denver, CO
Sven Jordt, PhD, Chapel Hill, NC
PCC4  PEDIATRIC CLINICAL CORE CURRICULUM

7:00 a.m. - 8:00 a.m.  SAN DIEGO CONVENTION CENTER  
Room 6 A (Upper Level)

Target Audience
Pediatric pulmonary and critical care physicians who work in a clinical setting and are currently engaged in maintenance of certification

Objectives
At the conclusion of this session, the participant will be able to:
- remain current with medical knowledge relevant to their practice in pediatric pulmonology;
- evaluate their understanding of key skills and content areas in pediatric pulmonology as well as receive feedback on their comprehension of a result of a pre-test/post-test comparison;
- support clinicians who are engaged in maintenance of certification activities by providing updates on subjects included in recertification requirements.

The Pediatric Core Curriculum symposia promote lifelong learning and the enhancement of the clinical judgment and skills essential for practicing pediatrician. The symposia will address topics that have been identified by an ATS pediatric working group, which is comprised of members of the ATS Education Committee and the International Conference Committee, who have identified important areas within pediatric medicine (including severe asthma, ILD, BPD, pulmonary hypertension and pulmonary manifestations of pulmonary disease). Attendees will increase their medical knowledge as a result of attending this symposium, and this will be measured by a comparison of pre-test vs. post-test results on the corresponding maintenance of certification module. The ATS Pediatric Core Curriculum will focus on a 3-year content cycle of key medical content in the area of pediatric medicine.

Chairing:  J. Retting, MD, Boston, MA

7:00  New Concepts in Pediatric Pulmonary Physiology
C.L. Ren, MD, Indianapolis, IN

7:30  How Pulmonary Physiology Guides Intensive Care Management
P.A. Verhoeft, PhD, MD, Chicago, IL

SUNRISE SEMINARS

CME Credits Available: 1

Registration Fee: $50.00 (includes continental breakfast.)
Attendance is limited. Pre-registration is required.

7:00 a.m. - 8:00 a.m.  MARRIOTT MARQUIS SAN DIEGO MARINA

SS301  LOOKING FOR PATTERNS AND BEYOND IN RESPIRATORY DISEASES
B. Suki, PhD, Boston, MA  
T. Winkler, PhD, Boston, MA  
Grand Ballroom 1 (North Tower, Lobby Level)

SS302  WHAT’S IN A NAME? ENDOTYPES AND PERSONALIZED MEDICINE IN LUNG DISEASE: 2018 AND BEYOND
D. Russell, MD, Birmingham, AL  
Grand Ballroom 2 (North Tower, Lobby Level)

SS303  ILD AND THE ANTISYNTHETASE SYNDROME: DIAGNOSTIC AND TREATMENT CHALLENGES
R. Hallowell, MD, Boston, MA  
Grand Ballroom 3 (North Tower, Lobby Level)

SS304  OPTIMIZING MY PATIENT FOR LUNG TRANSPLANTATION: A STEP BY STEP GUIDE TO REFERRAL, EVALUATION AND SELECTION
A. Venado, MD, San Francisco, CA  
Grand Ballroom 4 (North Tower, Lobby Level)

SS305  DIAGNOSTIC APPROACH TO THE ADULT PATIENT WITH CYSTIC LUNG DISEASE
A. Kumar, MD, Grand Rapids, MI  
Presidio 1 (North Tower, Lobby Level)

SS306  CONTROVERSIES IN THE DIAGNOSIS AND MANAGEMENT OF MALIGNANT PLEURAL EFFUSIONS
O. Epelbaum, MD, Valhalla, NY  
Presidio 2 (North Tower, Lobby Level)

SS307  “SARCOIDOLOGIST”: THE SHIP NEEDS A CAPTAIN
K. Provost, DO, PhD, Buffalo, NY  
Temecula 1-2 (North Tower, First Floor)

SS308  COMPLICATIONS OF BRONCHOSCOPY: MANAGEMENT STRATEGIES AND PREVENTION
C. Argento, MD, Chicago, IL  
Temecula 3-4 (North Tower, First Floor)

SS309  CLINICAL FRAILTY: A FUNCTIONAL OUTCOME IN IPF
J.S. Sheth, MD, Ann Arbor, MI  
Leucadia (South Tower, First Floor)

SS310  A GLOBAL PERSPECTIVE ON SEPSIS: IDENTIFICATION AND MANAGEMENT IN LOW, MIDDLE AND HIGH INCOME COUNTRIES
S.T. Jacob, MD, MPH, Liverpool, United Kingdom  
S. Murthy, MD, Vancouver, Canada  
Point Loma (South Tower, First Floor)
SS311 UP IN SMOKE: THE EFFECT OF ALTITUDE AND SMOKE EXPOSURE ON LUNG GENE EXPRESSION
J.P. Metcalf, MD, Oklahoma City, OK
Solana (South Tower, First Floor)

SS312 TAKE A DEEP BREATH: AEROSOLIZED ANTIBIOTICS FOR LUNG DISEASE
G. Hong, MD, MHS, Philadelphia, PA
Balboa (South Tower, Third Floor)

SS313 WHEN IT’S NOT THE HEART: THE PULMONOLOGIST IN THE CARDIOLOGY CLINIC
D. Liptzin, MD, MS, Aurora, CO
Mission Hills (South Tower, Third Floor)

SS314 CREATING A PULMONARY EMBOLISM RESPONSE TEAM
P. Rali, MD, Philadelphia, PA
Cardiff (South Tower, Third Floor)

SS315 ORGANS-ON-CHIPS FOR THE LUNGS: ADVANCED MICROPHYSILOGICAL SYSTEMS FOR BIOMARKER DISCOVERY AND DRUG DEVELOPMENT
K. Hajipouran Benam, PhD, Aurora, CO
Del Mar (South Tower, Third Floor)

SS316 INVESTIGATING THE 3D PATHOLOGY OF THE HUMAN LUNG USING MULTI-RESOLUTION COMPUTED TOMOGRAPHY AND STEREOLOGY
D.M. Vasilescu, PhD, Vancouver, Canada
Miramar (South Tower, Third Floor)

SS317 POSITIONAL THERAPY FOR THE TREATMENT OF OSA: EPIDEMIOLOGY, PATHOPHYSIOLOGY AND TREATMENT OPTIONS
G. Hamilton, MBBS, PhD, Clayton, Australia
Palomar (South Tower, Third Floor)

BASIC • CLINICAL • TRANSLATIONAL
ATS KEYNOTE SERIES

The Keynote Series provides state of the art lectures on selected topics in an unopposed format showcasing timely and diverse topics which relate to pulmonary, critical care and sleep medicine.

Two sessions are presented each morning during the conference.

Below are the topics for Wednesday, May 23rd

K7 ON PHARMA: THE COMPLEXITY OF INNOVATION
8:15 a.m. - 9:00 a.m. SAN DIEGO CONVENTION CENTER
Room 6 B (Upper Level)
Speaker: Theodore F. Reiss, MD, MBE, New Hope, PA

K8 THE PULMONOLOGIST AS MEDICAL EDUCATOR: A PERSONAL PERSPECTIVE
8:15 a.m. - 9:00 a.m. SAN DIEGO CONVENTION CENTER
Room 6 C/F (Upper Level)
Speaker: Steven E. Weinberger, MD, Philadelphia, PA

FACULTY DEVELOPMENT SEMINAR

FD3 THE MENTOR/MENTEE RELATIONSHIP: HOW TO FORM AN EFFECTIVE PARTNERSHIP AND RESOLVE CONFLICTS

Conference badges are required for admission.
Space is limited and admittance is on a first-come, first-served basis.
There is no additional fee.

7:00 a.m. - 8:00 a.m. SAN DIEGO CONVENTION CENTER
Room 2 (Upper Level)

Target Audience
Early and mid-career clinical and/or research faculty, clinical and postdoctoral fellows, medical and graduate students, residents, nurses, and allied health professionals involved in or seeking careers in academic pulmonary, critical care and/or sleep medicine

Objectives
At the conclusion of this session, the participant will be able to:

• describe the importance of the mentor-mentee relationship and how this relationship will mature and change over time as the early career professional develops their independent career;

• describe a plan for achieving independence from their mentor, and delineate a plan to openly discuss and negotiate this transition;

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
Supportive relationships between mentor and mentee are critical for early career professionals’ success. Mentors can provide advice, infrastructure, monetary, and other support critical to mentees’ success. Successful mentors must recognize that each mentee has different qualities, capabilities, and challenges. As part of career development, however, it is necessary for early career professionals to establish an independent career path that is distinguished from their mentors. This is a process and should be handled thoughtfully and openly by both the mentor and mentee. This session will focus on how to foster a supportive partnership and anticipate and resolve any conflicts in the mentor/mentee relationship.

Chairing: G.P. Downey, MD, Denver, CO

Speakers: T. Blackwell, MD, Nashville, TN
          B. Moore, PhD, Ann Arbor, MI
          Z. Borok, MD, Los Angeles, CA
          I. Petrache, MD, Denver, CO

Target Audience
Providers including physicians, nurses, respiratory therapists, nurse practitioners, physician assistants; trainees including residents and fellows; clinical researchers

Objectives
At the conclusion of this session, the participant will be able to:
• apply new clinical research knowledge to clinical practice;
• learn new findings about key conditions in pulmonary, critical care, and sleep;
• have new strategies to manage the care of common conditions in pulmonary, critical care, and sleep.

Recent discoveries in the clinical and basic science arena have changed the clinical and scientific approach to chronic graft failure after lung transplantation. This session will be of interest to clinicians and researchers alike. New clinical tools to phenotype patients, to improve prognostication, and to tailor therapeutic interventions in chronic lung allograft dysfunction (CLAD) will be discussed. Novel clinical, translational, and basic science methods being employed to further our understanding of CLAD will be reviewed.

Chairing: A.R. Glanville, MD, MBBS, Sydney, Australia
          E. Belloli, MD, Ann Arbor, MI
          V.N. Lama, MD, MS, Ann Arbor, MI

D2 UNDERSTANDING CHRONIC LUNG ALLOGRAFT DYSFUNCTION: UPDATE FROM THE BEDSIDE AND BENCH

Assemblies on Clinical Problems; Allergy, Immunology and Inflammation; Respiratory Cell and Molecular Biology

9:15 a.m. - 11:15 a.m. SAN DIEGO CONVENTION CENTER
        Ballroom 20 B-C (Upper Level)

Target Audience
Clinicians, researchers and patient care providers in the field of lung transplantation

Objectives
At the conclusion of this session, the participant will be able to:
• learn novel methodologies for monitoring graft function in lung transplant recipients and evaluating chronic graft failure;
• better define prognosis and select suitable treatment options for patients with CLAD;
• become aware of the ongoing research in the field and potential new therapeutic options on the horizon.
D3  WOMEN AND LUNG DISEASE

Assemblies on Clinical Problems; Behavioral Science and Health Services Research; Environmental, Occupational and Population Health

9:15 a.m. - 11:15 a.m.  SAN DIEGO CONVENTION CENTER
Ballroom 20 D (Upper Level)

Target Audience
Providers of lung health

Objectives
At the conclusion of this session, the participant will be able to:
• advance clinicians and researchers knowledge about gender differences in specific pulmonary diseases (COPD, Lung Cancer, PAH, ILD, and Asthma);
• facilitate the integration of newly acquired knowledge into clinical practice by personalizing and improving management of women with specific lung diseases;
• improve patient related outcomes by delivering personalized medicine and identifying new areas for research leading to novel approaches.

Sex differences exist in pulmonary medicine. Certain diseases present differently in females, have a greater severity compared to males, or affect women almost exclusively. Some disorders have been traditionally viewed as male-specific (COPD) or are rare diseases and diagnostic delays are common. Potential theories include detrimental effects of sex hormones, gender susceptibility and differences in lifestyle. Data also suggests that outcomes differ in females in specific pulmonary diseases. Current guidelines lack tailored approach to diagnose and manage women with pulmonary disorders. Nevertheless, experts in the field believe that more research leading to personalized management is needed to improve outcomes.

Chairing:  T.Y. Beiko, MD, Charleston, SC
K.K. Guntupalli, MD, Houston, TX

9:15  A Patient’s Perspective
P. Ortiz, Escondido, CA

9:20  Asthma in Women
K.K. Guntupalli, MD, Houston, TX

9:43  COPD inWomen
T.Y. Beiko, MD, Charleston, SC

10:06  ILD inWomen
T.P. Whelan, MD, Charleston, SC

10:29  Lung Cancer in Women
B. Bade, MD, New Haven, CT

10:52  PAH inWomen
R.G. Argula, MBBS, MPH, Charleston, SC

This session and the International Conference are supported by educational grants from Actelion Pharmaceuticals US, Inc., AstraZeneca LP, Bayer US, GlaxoSmithKline, Sanofi Genzyme and Regeneron Pharmaceuticals, Sunovion Pharmaceuticals Inc. All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
### D5 MANIPULATING INFLAMMATORY AND EPITHELIAL NETWORKS FOR PREVENTION AND TREATMENT OF LUNG CANCER

**Assemblies on Thoracic Oncology; Allergy, Immunology and Inflammation; Respiratory Cell and Molecular Biology**

**9:15 a.m. - 11:15 a.m.**

**SAN DIEGO CONVENTION CENTER**

Room 16 A-B (Mezzanine Level)

**Target Audience**
Basic and translational researchers with an interest in the interaction between the airway epithelium and inflammatory cells, especially in premalignancy and early cancer

**Objectives**
At the conclusion of this session, the participant will be able to:

- learn about new findings in interactions between the immune system and cancer cells;
- improve knowledge about immunotherapy and novel therapies aiming to manipulate immune evasion;
- understand the role of the immune system in cancer prevention.

Major recent advances in cancer biology have brought interactions between inflammatory and epithelial cells into sharp focus. Epithelial oncogenic alteration can predate tumor formation and may activate or inhibit inflammatory surveillance networks. The dynamics of this interaction dictate how a tumor may form, regress, or progress. This session will explore these dynamics, with a focus on strategies to manipulate the interaction of premalignant and malignant epithelial cells with infiltrating inflammatory cells to prevent or treat lung cancer.

**Chairing:**
- E. Ostrin, MD, PhD, Houston, TX
- S.J. Moghaddam, MD, Houston, TX
- R. Savai, PhD, Bad Nauheim, Germany

**9:15** A Patient's Perspective
B. Johnson-Filipiak, Ottawa Hills, OH

**9:20** The Role of the Immunoproteasome in Lung Carcinogenesis
E. Ostrin, MD, PhD, Houston, TX

**9:40** Immune Checkpoint Inhibition in Lung Cancer Chemoprevention
R.L. Keith, MD, Denver, CO

**10:00** Interplay Between STAT3/NF-kB Mediated Cytokine Network and Estrogen Signaling in K-Ras Mutant Lung Tumorigenesis
S.J. Moghaddam, MD, Houston, TX

**10:20** Immunometabolism in Early and Advanced Lung Cancer
F. Kheradmand, MD, Houston, TX

**10:40** Cancer Cell and Macrophage Cross-Talk in the Lung Tumor Microenvironment
R. Savai, PhD, Bad Nauheim, Germany

---

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
**D7 FROM CANCER BIOLOGY TO NEW THERAPEUTICS: TARGETING CELL PROLIFERATION SIGNALING HUBS IN PULMONARY HYPERTENSION AND FIBROSIS**

**Assemblies on Pulmonary Circulation; Respiratory Cell and Molecular Biology; Respiratory Structure and Function; Thoracic Oncology**

9:15 a.m. - 11:15 a.m.  
SAN DIEGO CONVENTION CENTER

**Room 15 A-B (Mezzanine Level)**

**Target Audience**
Clinicians and scientists who are interested in understanding the mechanisms driving disease pathogenesis and novel therapeutic developments in pulmonary hypertension, pulmonary fibrosis and lung cancer

**Objectives**
At the conclusion of this session, the participant will be able to:

- understand the mechanistic roles of major pro-proliferative signaling pathways that act as “central signaling hubs” in PH, IPF and cancer;
- learn new findings about cellular, pre-clinical and clinical studies focused on cancer-shared PH and IPF abnormalities;
- learn about novel and emerging anti-proliferative therapies for PH and IPF.

Pulmonary hypertension (PH) and idiopathic pulmonary fibrosis (IPF) are progressive diseases with high mortality rates and poor treatment options, both of which share incredible number of pathological molecular mechanisms with human cancers. This offers exciting opportunity to employ cancer-specific strategies and/or re-purpose anti-cancer agents for treatment of those diseases. This session will provide overview of major pro-proliferative signaling pathways that act as “central signaling hubs” in PH, IPF and cancer, summarize recent progress in cellular, pre-clinical and clinical studies focused on cancer-shared abnormalities, and discuss the opportunities for re-purposing or cross-development of anti-cancer agents that can be used in improving PH and IPF treatment.

**Chairing:** M. Rabinovitch, MD, Stanford, CA  
W. Seeger, MD, Giessen, Germany

9:15  
**PH: Analogous Features with Carcinogenesis**  
R. Savai, PhD, Bad Nauheim, Germany

9:35  
**HIPPO-mTOR Signaling Hubs: Cancer-Like Alterations in Pulmonary Hypertension**  
E.A. Goncharova, PhD, Pittsburgh, PA

9:55  
**IPF: Analogous Features of Carcinogenesis - TGFβ-ALK5 Signaling Hub as an Example**  
R.C. Chambers, PhD, London, United Kingdom

10:15  
**FoxO: Critical Integrator of Growth Factor and Inflammatory Signaling Hubs - FoxO Activation as a Strategy to Treat PH and IPF**  
S.S. Pullamsetti, PhD, Bad Nauheim, Germany

10:35  
**New Molecular Targets in Pulmonary Fibrosis: Experiences and Perspective From the Clinic**  
P.W. Noble, MD, Los Angeles, CA

10:55  
**PH: From Cancer Biology to New Therapeutics: Are We Ready to Translate?**  
M.T. Gladwin, MD, Pittsburgh, PA

---

**D8 UNRAVELING THE MYSTERIES OF THE MITOCHONDRIA IN PULMONARY INFLAMMATION/INJURY**

**Assemblies on Allergy, Immunology and Inflammation; Respiratory Cell and Molecular Biology**

9:15 a.m. - 11:15 a.m.  
SAN DIEGO CONVENTION CENTER

**Room 14 A-B (Mezzanine Level)**

**Target Audience**
Clinical and basic science researchers

**Objectives**
At the conclusion of this session, the participant will be able to:

- learn new findings about the significance of mitochondrial biogenesis signals in pulmonary inflammation;
- apply the mechanisms of mitochondrial dysfunction to infection or inflammation;
- discuss potential therapeutic targets to treat pulmonary inflammation.

Recent high impact papers show the critical role of the mitochondria in lung inflammation and associated tissue injury. Apart from the cellular energy powerhouse of the mitochondria, recent studies suggest critical inflammatory signaling pathways drive cell behavior and death. The goal of this symposium is to highlight recent exciting data that points to possible mitochondrial mechanisms (e.g. heme biosynthesis, oxygen sensing, mitochondria biogenesis, mitophagy, and mitochondrial repair) that drive pulmonary inflammation and injury. Targeting these pathways have the potential to lead to a novel therapeutic approach to treat acute lung tissue injury induced by inflammation.

**Chairing:** R.G. Scheraga, MD, Cleveland, OH  
A. Rogers, MPH, MD, Stanford, CA  
P.T. Schumacker, PhD, Chicago, IL

9:15  
**Mitochondrial Integrity in the Setting of Pulmonary Infection**  
C.A. Piantadosi, MD, Durham, NC

9:35  
**Mitochondrial Damage and Inflammasome Activation**  
M. Karin, PhD, La Jolla, CA

9:55  
**Mitochondrial Regulation of Lung Inflammation**  
J. Bhattacharya, MD, New York, NY

10:15  
**Mitochondria Damage Associated Molecular Patterns (DAMPs) in Bacterial Pneumonia**  
P. Ray, PhD, Pittsburgh, PA

10:35  
**Mitophagy and Mesenchymal Stem Cell Survival**  
L.A. Ortiz, MD, Pittsburgh, PA

10:55  
**Autophagy and Mitochondrial Dysfunction**  
S.M. Cloonan, PhD, New York, NY
D9 CONTROVERSIES IN CLINICAL PEDIATRIC PULMONOLOGY

Assemblies on Pediatrics; Allergy, Immunology and Inflammation; Clinical Problems; Respiratory Structure and Function

9:15 a.m. - 11:15 a.m. • SAN DIEGO CONVENTION CENTER
  Room 6 A (Upper Level)

Target Audience
Pediatric pulmonologists; adult pulmonologists; respiratory therapists; nurses

Objectives
At the conclusion of this session, the participant will be able to:

- learn about potential modes of transmission of pathogens in Cystic Fibrosis that are not prevented by the current methods of infection control;
- integrate the evaluation and management of the pulmonary complications of Sickle Cell Disease into the overall management of the disease;
- apply or modify the current guidelines for the management of viral bronchiolitis in clinical practice.

Despite the number of publications and the development of guidelines for the evaluation and management of various diseases, there are still many issues pertaining to their diagnosis and management that remain controversial. This session will present 3 such controversial topics in a “Pro/Con” format. The first topic refers to the clinical significance of the FEF25-75 in the evaluation of lung diseases. The second topic, discuss the clinical appropriateness of the most recent guidelines on bronchiolitis. The third topic is discussing the significance of the pulmonary evaluation of patients with Sickle Cell Disease.

Chairing:
A.C. Koumbourlis, MD, MPH, Washington, DC
M. Gappa, MD, Hanover, Germany

9:15 Introduction
A.C. Koumbourlis, MD, MPH, Washington, DC

9:20 PRO: Bronchodilators, Steroids and Oxygen Should Not Be Given in Viral Bronchiolitis
M.A. Brown, MD, Aurora, CO

9:37 CON: Bronchodilators, Steroids and Oxygen Should Not Be Given in Viral Bronchiolitis
M.A. Wall, MD, Portland, OR

9:54 PRO: Pulmonary Function Testing and Evaluation Are Not Necessary for the Standard Management of Patients with Sickle Cell Disease
K. Smith-Whitley, MD, Philadelphia, PA

10:11 CON: Pulmonary Function Testing and Evaluation Are Not Necessary for the Standard Management of Patients with Sickle Cell Disease
A.C. Koumbourlis, MD, MPH, Washington, DC

10:28 PRO: Routine Visits to the CF Clinics Should Be Reduced Due to the Increased Risk of Infection
C. Wainwright, MBBS, MD, Brisbane, Australia

10:45 CON: Routine Visits to the CF Clinics Should Be Reduced Due to the Increased Risk of Infection
G.S. Sawicki, MPH, MD, Boston, MA

This session and the International Conference are supported by an educational grant from Vertex Pharmaceuticals Inc. All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

D10 GROWING UP WITH CHRONIC PULMONARY DISEASE: CHALLENGES IN THE TRANSITION FROM PEDIATRIC TO ADULT FOCUSED HEALTH CARE

Assemblies on Pediatrics; Behavioral Science and Health Services Research; Clinical Problems; Nursing; Education Committee; Training Committee: Members in Transition and Training Committee

9:15 a.m. - 11:15 a.m. • SAN DIEGO CONVENTION CENTER
  Room 33 A-C (Upper Level)

Target Audience
Physicians, registered nurses, advanced practice nurses and other allied health professionals providing care to those with chronic respiratory conditions of childhood in which successful transition to adult focused health care is of importance

Objectives
At the conclusion of this session, the participant will be able to:

- develop new strategies to manage barriers and developmental challenges in the transition from pediatric to adult care for patients with chronic childhood-onset pulmonary disease;
- discuss successful evidence based transition models in pulmonary disease populations, focusing on key process and outcome measures for success;
- describe current needs in transitional care education and be able to integrate such topics in formal curricula for pediatric and adult pulmonary trainees.

Over the past several decades survival has increased dramatically amongst children with many chronic respiratory conditions including cystic fibrosis, chronic respiratory insufficiency, and neuromuscular disease. As a result, health systems need to develop and support programs to improve the transition from pediatric to adult focused health care. Adolescents and young adults are often ill equipped to complete this transition successfully, formalized transition programs are uncommon, and resources for certain populations are lacking within adult-focused health care systems. This symposium will address the challenges patients, their caregivers and clinicians have in transitioning care, and will review evidence-based tools used to foster this transition.

Chairing:
E. Crowley, MD, Indianapolis, IN
D. Li, MD, Los Angeles, CA
G.S. Sawicki, MPH, MD, Boston, MA
9:15 Health Care Transition in the United States: Current State of Affairs  
G.S. Sawicki, MPH, MD, Boston, MA

9:35 Lost in Transition: Growing Older with Cystic Fibrosis  
C. Kvam, JD, MPP, Rochester, NY

9:50 Providing Care for a Changing Cystic Fibrosis Population: A Model for Health Care Transition  
E. Crowley, MD, Indianapolis, IN

10:10 Challenges in Pediatric to Adult Transition in Neuromuscular Disease  
J.P. Brown, MD, PhD, Salt Lake City, UT

10:30 The Adolescent with Chronic Pulmonary Disease: Developmental and Psychosocial Challenges for Self-Management and Transition  
J. Butcher, PhD, Ann Arbor, MI

10:50 A Better Workforce for Transitional Care: Training Issues  
S.E. Kirkby, MD, Columbus, OH

This session and the International Conference are supported by an educational grant from Vertex Pharmaceuticals Inc.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

**BEHAVIORAL • CLINICAL**

**SCIENTIFIC SYMPOSIUM**

CME Credits Available: 2
Nursing Contact Hours Available: 2.4

**D11 BATTLING BURNOUT: OVERCOMING THE BIGGEST THREAT TO HEALTH CARE QUALITY AND SAFETY**

Assemblies on Behavioral Science and Health Services Research; Clinical Problems; Critical Care; Nursing; Pediatrics; Thoracic Oncology; Membership Committee

9:15 a.m. - 11:15 a.m.  
SAN DIEGO CONVENTION CENTER  
Room 1 A-B (Upper Level)

**Target Audience**

Practicing health care workers, researchers, registered nurses, advanced practice nurses, trainees, educators, health care administrators, and policy-makers

**Objectives**

At the conclusion of this session, the participant will be able to:

- define burnout syndrome and describe the scope of the problem, including prevalence and adverse effects of burnout among health care workers with different clinical roles;
- identify major determinants of burnout among health care workers practicing in different clinical settings;
- describe specific interventions that can help reduce the burden of burnout.

The purpose of this session is to engage researchers, clinicians, educators, trainees and administrators in an effort to address the crisis of burnout syndrome among practicing health care workers. This is pertinent to clinicians who care for patients with critical illness, cancer, advanced lung diseases, or children with chronic respiratory illnesses. We will discuss the scope of the problem, including the prevalence, risk factors, and outcomes related to burnout among nurses, advanced practitioners, physicians, and trainees. We will discuss evidence-based solutions and develop a platform to discuss future directions for research, policy, and clinical practice to overcome the burden of burnout.

**Chairing:**  
S. Rinne, MD, PhD, Bedford, MA  
S.M. Kassutto, MD, Philadelphia, PA  
R. Adamson, MBBS, Seattle, WA

**D12 IMMUNOTHERAPY IN LUNG DISEASE**

9:15 a.m. - 11:15 a.m.  
MARRIOTT MARQUIS SAN DIEGO MARINA  
Grand Ballroom 5-6 (North Tower, Lobby Level)

**Chairing:**  
G.M. Gauvreau, PhD, Hamilton, Canada  
P. Akuthota, MD, La Jolla, CA

**Oral Presentations**


9:30 Dupilumab Treatment Produces Rapid and Sustained Improvements in FEV1 in Patients with Uncontrolled, Moderate-To-Severe Asthma from the LIBERTY ASTHMA QUEST Study/M. Castro, W.W. Busse, B. Zhang, J. Maroni, P. Rowe, N. Amin, G. Pirozzi, N.M.H. Graham, A. Teper, St. Louis, MO, p.A6163


10:00 On-Demand Inhaled Interferon-Beta 1a for the Prevention of Severe Asthma Exacerbations: Results of the INEXAS Phase 2a Study/C. McCrae, M. Olsson, M. Aurell, C. Lundin, J. Paraskos, A. Cavallin, M. Kjerrulf, K. Karlsson, R. Marsden, A. Malmgren, P. Gustafson, T. Harrison, Molndal, Sweden, p.A6165


11:00 Social Determinants of Adherence to Pulmonary Rehabilitation in Hospitalized Patients?/V. G. Press, C. Kelly, L. Venable, K. Carey, S. R. White, V. Arora, Chicago, IL, p.A6174

MINI SYMPOSIUM
D13 IMPROVING DIAGNOSIS, CARE QUALITY, AND ADHERENCE IN COPD

9:15 a.m. - 11:15 a.m. SAN DIEGO CONVENTION CENTER

Room 32 A-B (Upper Level)

Chairing: V.S. Fan, MD, MPH, Seattle, WA
A. Lambert, MD, MHS, Spokane, WA
M.S. Stefan, MD, PhD, Springfield, MA

Oral Presentations


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.


A New Sarcoidosis Diagnostic Score/A. Bickett, E.E. Lower, R.P. Baughman, Cincinnati, OH, p.A6184


10:45  Co-Exposure to Diesel Exhaust and Allergen Impairs Lung Function and Induces Local and Systemic Inflammation/D. Wooding, M. Syberg-Olsen, A. Yuen, C. Carlsten, Vancouver, Canada, p.A6198

11:00  Spatial Analysis of Air Pollutants that Impact the Respiratory Health of North Central Texas by the Application of Principal Component Analysis and Hierarchical Clustering/N. Cao, A. Hunt, Arlington, TX, p.A6199

MINI SYMPOSIUM

D17  THE BEASTS WITHIN US: TARGETING THE MICROBIOME

9:15 a.m. - 11:15 a.m.  MARRIOTT MARQUIS SAN DIEGO MARINA

Chairing:
A. Pragman, MD, PhD, Minneapolis, MN
A.M. Morris, MD, MS, Pittsburgh, PA
J.D. Chalmers, MD, PhD, Dundee, United Kingdom

Oral Presentations

9:15  Integrated Microbiome and Metabolome Analysis of Lung Sputum as a Novel Approach to Precision Medicine/R. Quinn, L. Deright-Goldasich, G. Humphrey, R. Knight, D.J. Conrad, P.C. Dorrestein, La Jolla, CA, p.A6200


9:45  Microbiome Communities in Pseudomonas Aeruginosa Pneumonia/C. Pickens, P. Hountras, J.M. Walter, J.M. Kruser, C. Qi, B.D. Singer, S. Green, P. Seed, R.G. Wunderink, Chicago, IL, p.A6202

Featured Speaker

10:00  The Evolving Landscape of Lung Microbiota and Its Interactions with the Host/L.N. Segal, MD, New York, NY

Oral Presentations


MINI SYMPOSIUM

D18  THE EPI (THELIAL) CENTER IN LUNG DISEASE

9:15 a.m. - 11:15 a.m.  MARRIOTT MARQUIS SAN DIEGO MARINA

Pacific Ballroom 22 (North Tower, First Floor)

Chairing:
J. Verheyden, PhD, La Jolla, CA
R. Zemens, MD, Ann Arbor, MI

Featured Speaker

9:15  Mind the Gap: Linking Alveolar Epithelial Cell Dysfunction to Pulmonary Fibrosis/L.R. Young, MD, Nashville, TN

Oral Presentations


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
**D19 SLEEP DISORDERED BREATHING AND CARDIOMETABOLIC OUTCOMES: BENCH TO BEDSIDE**

9:15 a.m. - 11:15 a.m.  
SAN DIEGO CONVENTION CENTER

**Chairing:** N.A. Shah, MD, MPH, MSci, New York, NY  
J. Sunderam, MD, New Brunswick, NJ  
M.S. Badr, MD, Detroit, MI

**Abstract Summaries 9:15-9:45**

801 Rhinovirus Infection Induces Inflammasome Activation In Vivo  

802 Differential Effects of IL-33 on Anti-Viral Immune Responses in Asthmatic and Healthy Individuals  
J.W. Upham, L. Jurak, Y. Xi, Woolloomooloo, Australia, p.A6222

803 Club Cell Secretory Protein-16 Protects Against Mycoplasma Pneumoniae-Induced Airway Remodeling  

804 Poor Baseline Asthma Control Is Associated with Greater Virus Load Following Rhinovirus Infection  
J. Dhariwal, E. Wong, B. Trujillo-torralbo, D.J. Jackson, S.L. Johnston, London, United Kingdom, p.A6224

805 IL-33 Drives Influenza-Induced Exacerbations of Asthma and Halts Innate and Adaptive Anti-Viral Responses by Instruction of Epithelial and Dendritic Cells  

806 The Histone Deacetylase Inhibitor Trichostatin a Modulates Rhinovirus-Induced Airway Responses in Immature Mice Through IL-1 Receptor Antagonist  
J.K. Bentley, J.L. Hinde, J. Lei, T. Ishikawa, C. Rajput, M. Han, M.B. Hershenson, Ann Arbor, MI, p.A6226

807 Deficient IFIH1 Expression and Type-I Interferon Response to Rhinovirus by Nasal Epithelial Cells from Asthmatic Children Homozygous for the IFIH1 Minor Alleles of SNPs rs3747517 and rs1990760 Is Associated with Increased Viral Replication Ex Vivo  
K.A. Barrow, M.P. White, S.R. Reeves, J.A. Gorman, R. James, J.S. Debley, Seattle, WA, p.A6227

808 Multiplex Molecular Detection of Respiratory Pathogens of Adult Patients Admitted to Hospital for Asthma Exacerbation and Their Clinical Outcomes  

809 Transcriptomic Profiles of Conditional Reprogrammed Cells from Human Infant Airway Epithelial Cells Demonstrate Stability of Antiviral Immunity  

**Rapid: Rapid Abstract Poster Discussion Session**

**D21 INFECTIONS AND IMMUNITY**

9:15 a.m. - 11:15 a.m.  
MARRIOTT MARQUIS SAN DIEGO MARINA

**Grand Ballroom 11-13 (North Tower, Lobby Level)**

**Abstract Summaries 9:15-9:45**

**Viewing/Discussion 9:45-11:15**

**Chairing:** C. Dela Cruz, MD, PhD, New Haven, CT  
J.C. Deng, MS, MD, Ann Arbor, MI  
B. Mehrad, MD, Gainesville, FL

801 AEC2 Expansion After Lung Injury in Mice  


813  TBK1 Controls Inflammatory Cytokine Expression in S. Pneumoniae Pneumonia/R.S. Hagan, J.C. Gomez, J.L. Torres-Castillo, J.R. Martin, C.M. Doerschuk, Chapel Hill, NC, p.A6233

814  Priming of Innate Immune Cells by Type I and II Interferons During Infections of Influenza Virus and Streptococcus Pneumoniae/S. Hanada, K. Carver, Z. Tsai, J.C. Deng, Ann Arbor, MI, p.A6234


817  Mechanical Forces Suppress Innate Anti-Viral Immunity in Primary Human Airway Epithelial Cells Obtained from Asthma Donors/P.C. Veerati, N.W. Bartlett, K. Nichol, P.A. Wark, D.A. Knight, C.L. Grainge, New Lambton Heights, Australia, p.A6237


822  Cell-based Comprehensive and Systematic Binding Analysis Between HLA-DR or -DQ Regions and T Cell Epitopes of TB Antigens/Y. Hoshino, H. Miyadera, H. Nagai, T. Yoshiyama, K. Tokunaga, Tokyo, Japan, p.A6242


D22  CUTTING EDGE RESEARCH IN SMOKING CESSATION AND E-CIGARETTES

9:15 a.m. - 11:15 a.m.  SAN DIEGO CONVENTION CENTER

Room 11 A-B (Upper Level)

Abstract Summaries 9:15-9:45

Viewing/Discussion 9:45-11:15

Chairing: S. Pakhalke, MD, MSCE, Ottawa, Canada

H.J. Farber, MD, MSPH, Houston, TX

D.J. Upson, MD, MA, Albuquerque, NM


403  'To Vape or Not to Vape': Young Peoples Beliefs About Emerging Tobacco Products/I. Foster, B. Oliver, J. Bozier, Sydney, Australia, p.A6246

404  Electronic Cigarette, Conventional Cigarette and Marijuana Use Patterns in San Diego County/C. Bojanowski, C. Dagni, Farmington, CT, p.A6245

405  Validity of VHA Administrative Data to Determine Accurate Smoking Status/S. Golden, M. Howard, S. Shull, C. Forsberg, E. Hooker, K.A. Crothers, C.G. Slatore, Portland, OR, p.A6248


408  Social, Economic, and Behavioral Determinants of Successful Smoking Cessation - Findings from the REGARDS Cohort/T. Parekh, C. Wu, L. McClure, V. Howard, M. Cushman, A. Malek, K. Harrington, A. Cherrington, M.T. Dransfield, S. Bhatia, Birmingham, AL, p.A6251

409  Related Factors to Smoking Cessation Rate in Individuals with and Without COPD After 3 and 12 Months in a Smoking Cessation Primary Care Attention Center (prevfumo)/O.A. Nascimento, J. O. Barros, N.R. Santos, N.C. Oliveira, R. Vicente, J.R. Jardim, Sao Paulo, Brazil, p.A6252

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
ADULT CF AND NON-CF BRONCHIECTASIS

9:15 a.m. - 11:15 a.m. SAN DIEGO CONVENTION CENTER
Room 30 C-E (Upper Level)

Abstract Summaries
9:15-9:45

Viewing/Discussion
9:45-11:15

Chairing:
A.E. O'Donnell, MD, Washington, DC
D. Polineni, MD, MPH, Kansas City, KS


Non-Cystic Fibrosis Bronchiectasis Associated with Chronic Obstructive Pulmonary Disease: Who is at Risk for More Severe Disease?/A.S. Sadigov, R. Baylarov, K. Abasalievya, Baku, Azerbaijan, p.A6272

Etiologies of Bronchiectasis in an Active Duty Military Population/I. McInnis, E.T. Mccann, B. Barber, M.J. Morris, JBSA - Fort Sam Houston, TX, p.A6273


Identification of Aspergillus in Patients with Cystic Fibrosis/M.A. Azevedo, C. Nemastil, S.E. Kirkby, Columbus, OH, p.A6264

A Specialised Processing Method Enables Correlation of Inflammatory Mediators in Spontaneously Expectorated and Induced Sputum with Bronchoalveolar Lavage Fluid in Cystic Fibrosis for Clinical Trial Purposes/O.J. McElvaney, D. Horan, C. Gunaratnam, E.P. Reeves, N.G. McElvaney, Dublin, Ireland, p.A6265


The Impacts of Particulate Pollution on Acute Pulmonary Exacerbations, FEV1, and FVC in Cystic Fibrosis Patients/D.L. Mendoza, C.S. Pirozzi, T.G. Liou, N.P. Harlan, R. Paine, Salt Lake City, UT, p.A6268


Demographics of Cystic Fibrosis Liver Disease: A Single Center Review/R. Helton, J. Lascano, J. Immergluck, Oklahoma City, OK, p.A6270

Adherence to Therapy and Patient Reported Satisfaction Using a Novel Airway Clearance and Lung Expansion Treatment in Motor Neuron Disease (MND) and Cystic Fibrosis (CF) Patients in the Home Setting/R. Sharma, M. Prickett, J.M. Coleman, J.L. Hixon, L.F. Wolfe, Chicago, IL, p.A6271


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
Sleep Quality in Relation to Pulmonary Function in Patients with Cystic Fibrosis/S.A. Tahir, J.R. Woytanowski, M.J. Stephen, Philadelphia, PA, p.A6277


Effect of Inhaled Liposomal Ciprofloxacin on Severe Pulmonary Exacerbations in Patients with Bronchiectasis and Chronic Pseudomonas Aeruginosa Lung Infections/I. Chalmers, C. Haworth, A.M. Davis, I. Gonda, J.K. Froehlich, A.E. O'Donnell, Dundee, United Kingdom, p.A6279


Longitudinal Analysis of Pulmonary Exacerbations: Results from ORBIT-3 and ORBIT-4 Trials of ARD-3150 in Patients with Non Cystic Fibrosis Bronchiectasis and Chronic Infection with Pseudomonas Aeruginosa/J. Froehlich, D. Cipolla, A.M. Davis, I. Gonda, B. Thompson, Hayward, CA, p.A6281


The Impact of Partial Adherence to Lung Protective Ventilation on Outcomes in Acute Respiratory Distress Syndrome
G.S. Schneider, N.N. Goel, S. Ranginwala, G.T. Loo, K.S. Mathews, New York, NY, p.A6297

After the FACTT: Volume Overload, Implementation of Fluid Management Strategies, and Outcomes in Moderate-Severe ARDS

Simulation-Based Mastery Learning Improves Resident Skill Managing Mechanical Ventilators

Quality Improvement in Ventilation Times in Patients Excluded from a Protocol as Evidence of Culture Change

Role of STAT Chest X-Ray in Uncomplicated Intubations in ICU
R. Ratnani, A. Akber, G. Cheewala, S.R. Surani, D. Bawa, Houston, TX, p.A6301

Ventilator Associated Complications: Development and Validation of an Automated Detection Algorithm and Application in a Population-Based Cohort of Adult Critical Care Patients in Alberta
D.C. Vis, A. Soo, D.J. Zuege, Calgary, Canada, p.A6302

Does an Antimicrobial Time Out Impact the Duration of Usage of Antimicrobials in the ICU?

Reduction of Central Line Associated Bloodstream Infections and Catheter Associated Urinary Tract Infections by Utilizing a Morning Report Format in the ICU
Arshed, O.A. Abe, P. Trivedi, J. Gasperino, Flushing, NY, p.A6304

Delayed Dose of Pharmacological VTE Prophylaxis and VTE Incidence in Hospitalized Patients
S. Patil, S. Karanth, M. Ayad, P. Vijnani, S. Kaushal, A. Sen, K. Gopal, B. Patel, Houston, TX, p.A6305

Impact of Weekly Tele-Education Sessions Based on CERTAIN Platform in a Medical Intensive Care Unit with Limited Resources

Predictors of Post-Discharge Outcomes and Care-Seeking Behaviors among Children with Acute Infectious Illness in Southwestern Uganda

The Feasibility and Acceptability of a Written Exposure Therapy (WET) Resilience Intervention in Critical Care Nurses
M. Mealer, K. Cochran, J. Evans, M. Moss, Aurora, CO, p.A6308

Impact of Physician Workload on Risk of ICU Readmission and Accuracy for Predicting Bouncebacks

Hurricane Harvey: Impact on ICU Admission
A. Sen, M. Ayad, S. Karanth, S. Patil, K. Luther, B. Patel, Houston, TX, p.A6310

Intensivist Service Impact on ICU Length of Stay Over a Two-Year Period in a Community Hospital


218  Abnormal Surfactant Protein Expression and Activation of Anti-Apotptic Pathways in Severe Intestinal Lung Disease (ILD) in Rubinstein-Taybi Syndrome (RTS)/X. Li, S.S. Wong, J. Zhao, A. Jegga, K. Shayan, J.S. Hagood, Tianjin, China, p.A7787

D26  WITH FRIENDS LIKE THESE: INSIDE THE SPECTRUM OF PE AND CTEPH

9:15-10:00
Discussion
10:00-11:15

Chairing: N.H. Kim, MD, La Jolla, CA
W.R. Auger, MD, La Jolla, CA
P.A. Thistlethwaite, MD, PhD, La Jolla, CA

Impact of Discontinuation of Pulmonary Hypertension-Targeted Drugs in Chronic Thromboembolic Pulmonary Hypertension Patients After Balloon Pulmonary Angioplasty/Y. Shintani, J. Ueda, T. Ogo, Osaka, Japan, p.A6341
RASPOA: RAPID ABSTRACT POSTER DISCUSSION SESSION

D27 REDOX AND BEYOND: MITOCHONDRIA, ER STRESS, AND PROTEASOMES

9:15 a.m. - 11:15 a.m. MARRIOTT MARQUIS SAN DIEGO MARINA
Pacific Ballroom 15-17 (North Tower, First Floor)

Abstract Summaries 9:15-9:45
Viewing/Discussion 9:45-11:15

Chairing: M.-J. Kang, MD, PhD, New Haven, CT
C.J. Gottardi, PhD, Chicago, IL
S. Meiners, PhD, Munich, Germany


905 MUC5B Expression in IPF Is Associated with ER Stress/E. Dobrinskikh, A.D. Walts, D.A. Schwartz, Aurora, CO, p.A6354


907 Integreated Stress Response and Mitochondrial Function During Adaptation to Smoke Exposure in Alveolar Epithelial Type 2 Cells/A. Blumental-Perry, I. Bederman, N.A. Perry, J. Wu, D. Krokovski, D.M. Townsend, Y. Perry, M. Hatzoglou, Cleveland, OH, p.A6356


909 Defining PiMZ AATD Liver Disease Susceptibility with CRISPR Targeted Syngeneic iPSCs/W. Kaserman, M. Higgins, D.N. Kotton, A.A. Wilson, Boston, MA, p.A6358

911 Stanniocalcin-1 (STC1) Maintains Mitochondrial Bioenergetics and Prevents Oxidant-Induced Lung Injury Via TLR4/Y. Zhang, P.J. Lee, New Haven, CT, p.A6360

912 The Key Interplay of Fatty Acid Oxidation and Apoptosis Resistance of Macrophages in Pulmonary Fibrosis/L. Gu, J.L. Casey, D. Davis, A.B.B. Carter, Birmingham, AL, p.A6361


914 NOX4 Modulates Lung Macrophage Polarization in Pulmonary Fibrosis Via Regulation of Mitochondrial Biogenesis/C. He, J. Larson-Casey, L. Gu, V.J. Thannickal, A.B.B. Carter, Birmingham, AL, p.A6363


1012 Intrapulmonary Deposition and Uptake Kinetics of Electronic Cigarette Vapor Imaged with PET/J.G. Venegas, J. Zhao, G.C. Motta Ribeiro, P. Demokritou, M. Papisov, Boston, MA, p.A6385


1016 CT DPM FSAD Measurements Compared at RV Vs. FRC in a Normal and COPD Population: COPDGene/A.P. Comellas, J.D. Newell Jr, M. Kirby, J.P. Sieren, S. Peterson, E.A. Hoffman, Iowa City, IA, p.A6389


1021 Interpretation and Variation of DLCO with Obesity: Conclusions from 14 Years of Pulmonary Function Data/P.H. Patil, S. Patolia, A. Krvavac, H. Wilson, G.L. Ruppel, R. Nayak, St. Louis, MO, p.A6394


1025 Cross-Sectional Associations of High Fraction of Exhaled Nitric Oxide (FENO) in the National Health and Nutrition Examination Surveys (NHANES)/F. Kukhon, M. Ehtisham, M. Roberts, C. Eaton, Pawtucket, RI, p.A6398
D31 INTERVENTIONAL PULMONARY: CASE REPORTS II
9:15 a.m. - 3:30 p.m. SAN DIEGO CONVENTION CENTER
Area G (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: L.A. Seaburg, MD, Seattle, WA

P624 Spypite Forceps Biopsy Using Spyglass Direct Visualization System Vs Transbronchial Lung Biopsy to Diagnose Non-Small Cell Lung Cancer/S. Pilli, T. Kirtane, N. Thosani, P. Jani, Houston, TX, p.A6426
P625 Sequential Treatment for Persistent Air Leak: Persistence Pays Off/M.U. Khawar, S. Benzaquen, A. Aragaki, Cincinnati, OH, p.A6427
P626 Diagnostic and Therapeutic Challenges in Managing a Persistent Air Leak: Intrabronchial Valve Placement/S. Keshishyan, O. Epelbaum, L.P. Paul, K.N. Harris, Valhalla, NY, p.A6428
P628 A Case of Adapting to Antiplatelets: Successful Diagnosis of Nocardia Via Endobronchial Ultrasound Using a 25 Gauge Needle/J. Prete, S.A. Waheed, A. Goyal, Maywood, IL, p.A6430
P629 Narrow Road Ahead - Diagnosing a Mediastinal Lymphadenopathy in the Patient with a Tracheostomy Tube by Conventional Transbronchial Needle Aspiration/Y.L. Shen, Y.H. Hsiao, Taipei, Taiwan, p.A6431
P630 Extranodal NK/T-Cell Lymphoma of the Trachea Causing Airway Compromise/S. Raju, S. Sethi, Cleveland, OH, p.A6432
P631 Inflammatory Myofibroblastic Tumor of the Bronchus: Bronchoscopic Treatment and Molecular Analysis/A.N. Iyer, T. Radonic, L. Heukamp, E. Thunnissen, H. Daniels, Amsterdam, Netherlands, p.A6433
P633 The Expanding Applications of EUS/EBUS/E. Ho, S. Tonthat, P. Hegde, Fresno, CA, p.A6435
P634 Long-Term Management of HHT-Related PAVM: Lessons Learned on the Need for More HHT Centres of Excellence/F. Chowdhury, R.J. Owen, O. Halliwell, D.P. Vethanayagam, Edmonton, Canada, p.A6436

Facilitator: A.D. Lerner, MD, Baltimore, MD

P635 Severe Mediastinal Abscess After Endobronchial Ultrasound with Transbronchial Needle Aspiration/J. Dai, Naijing, China, p.A6437
P638 Not All Wheezes Are the Same: A Rare Presentation of Pulmonary Benign Metastasizing Leiomyma/M. Darnell, E. Jiang, L.M. Catalano, Philadelphia, PA, p.A6440
P640 Use of Endotracheal Stent for Hemostasis of a Bleeding Glomus Tumor/G. Samuel, A. Chrissian, J. Diaz-Mendoza, Detroit, MI, p.A6442
P642 Minimally Invasive Precision Lung Biopsies: Cryobiopsy Coupled with Electromagnetic Navigational Bronchoscopy/J.M. Wilson, K.N. Cao, Tampa, FL, p.A6444
P646 Unrelenting Tracheobronchial Stenosis in Relapsing Polychondritis/S. Murney, C. Radchenko, R.W. Shepherd, Richmond, VA, p.A6448

Facilitator: K. Klooster, RN, Groningen, Netherlands

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
Not Your Ordinary Sore Throat: A Rare Case of Extraneal Lymphoma/J. Lyu, T.T. Cheng, N. Wahid, J. Longoria, M. Davoudi, Orange, CA, p.A6450


Acute Bacterial Pericarditis: A Rare Complication of Transbronchial Biopsy/J. Rathod, V.R. Patel, Milwaukee, WI, p.A6452


Carcinoma Ex Pleomorphic Adenoma of the Airway and Parenchyma/J. Reisenauer, N. Azadeh, R. Pillappa, E.S. Edell, Rochester, MN, p.A6455

A Novel Method for Diagnosis of Mesothelioma/A. Ramaswamy, J. Puchalski, New Haven, CT, p.A6456


Endobronchial Ultrasound Guided Transbronchial Needle Aspiration in Histoplasmosis Diagnosis/T. Vandemoortele, G. Courteau Godmaire, Montreal, Canada, p.A6458


A Surprising Cause of Pulmonary Nodules/M. Oron, B. Husta, New York, NY, p.A6460

Cerebral Air Embolism as a Cause of Acute Stroke Following Argon Plasma Coagulation as Treatment for Bronchial Webs/D.K. Mathew, C. Srinaroo, Tampa, FL, p.A6461


Treated Bronchoscopy with Cryotherapy in Patient with Broncholithiasis - Case Report/L.V. dos Reis, L.P. Bruno, P. Azevedo, E. de Souza, Brazil, p.A6463


A Stent in the Vein for a Man’s Pain - a Case of Pulmonary Venous Stenosis Cured by a 4mm Stent/N. Jayakumar, M. Patel, J. Thomas, Rancho Mirage, CA, p.A6466


“That Was Amazing!” - Use of Virtual Reality Distraction as Adjunct for Bronchoscopy/D. Golovyan, B.A. Khan, M.O. Farber, Indianapolis, IN, p.A6469

EBUS Identification of Vasculitis Masquerading as a Pet-Positive Mediastinal Mass/C. Volk, R.J. Miller, San Diego, CA, p.A6478

Incomplete Heerfordt’s Syndrome as an Initial Presentation of Sarcoidosis/M. Halifz, A. El-Bakush, O.N. Obi, Greenville, NC, p.A6479


Pulmonologist Insight on Renal Sarcoidosis: Report of Two Cases/M.I. Shafii, S.D. Williams, I. Waseem, Cleveland, OH, p.A6481

Hypersensitivity Pneumonitis with Elevated IgE: A Novel Subtype?/V. Patel, W. Khan, New Brunswick, NJ, p.A6482


Synthesising the Correct Diagnosis in the Work-Up of Interstitial Lung Disease: Myositis Panel May Be Key/S. Walsh, A.W. O’Regan, Galway, Ireland, p.A6484


Rare Case of Severe Cryptogenic Organizing Pneumonia Resistant to Steroids Plus Azathioprine/H.S. Bukamur, H. Mezughii, Y. Shweihat, Huntington, WV, p.A6486


HIV False Positivity Due to Sarcoidosis/J. Lio, G. Barmaimon, P.S. Patrawalla, New York, NY, p.A6489

Cavitary Sarcoidosis Complicated by Invasive Pulmonary Aspergillosis/M. Bilkak, A. Noor, Indianapolis, IN, p.A6490

Light-Chain Deposition Disease: A Rare Cause of Cystic Lung Disease/S. Cullivan, K.F. Deasy, N. Mayer, M.R. Cahill, M.P. Kennedy, Cork, Ireland, p.A6491

Heerfordts Syndrome and Hypercalcemia as the Presenting Features of Sarcoidosis/D. Lane, I. Wong, L. Gross, Brooklyn, NY, p.A6492


A Case of Pancreatic and Splenic Involvement as the Main Presentation of Sarcoidosis/H.S. Pinto Souza, F. Marques da Costa, L. Paez Vargas, L. Kawano Dourado, B.G. Baldi, R.A. Kairalla, Sao Paulo, Brazil, p.A6494

Facilitator: E.D. Ferrand, MD, San Francisco, CA


An Atypical Case of Eosinophilic Radiation Pneumonitis/A. Bommakanti, R. Masrouje, E. El Ghoul, Cleveland, OH, p.A6497

Paradoxical Development of Panuveitis and Granulomatous Interstitial Lung Disease Associated with Adalimumab Therapy for Psoriasis/H. Saijad, I. Han, J.S. Wilson, Iowa City, IA, p.A6498


A Pulmonary Puzzle: Granulomatous Lung Disease and Organizing Pneumonia In a Patient with HIV/A. Poor, S. Dua, New York, NY, p.A6501


Relapsing Remitting Isolated Pulmonary Anti Glomerular Basement Membrane Disease/M. Rudrappa, L. Kokatur, Shreveport, LA, p.A6503

Focal Organizing Pneumonia in a Severe Hemophiliac: A Diagnostic Dilemma/J. Lau, Rochester, MN, p.A6504


Intestinal Lung Disease as an Extrahepatic Manifestation of Autoimmune Hepatitis/A.D. Hyslop, N. Gupta, K.A. Wikenheiser-Brokamp, Cincinnati, OH, p.A6506

Lymphangioliomyomatosis (LAM) of the Uterus: Risk of Pulmonary LAM?/K.B. Ascher, M.K. Glassberg, Csete, Miami, FL, p.A6507

Obliterative Bronchiolitis: A Rare Complication of Aspiration Pneumonitis/C. Choong, K.M. Eu, A. Lim, J.A. Abisheganaden, G.T. Chai, Singapore, Singapore, p.A6508


Cryptococcus Neoformans Found in the Lymph Node of a Patient with Sarcoidosis Not on Immunosuppressive Therapy: A Unique Case/M. Reddy, R. Nayak, St. Louis, MO, p.A6511
P907  Pulmonary Alveolar Proteinosis: A Rare Disease, First-Line Treatment Resulting in a Near-Fatal Complication/T. Onger, S. Velani, J. Kazakov, Cleveland, OH, p.A6526


P910  Presentation of MPO-ANCA Positive Microscopic Polyangiitis with Usual Interstitial Pneumonia/A. Bryan, A.K. Udumian, S. Gezahegne, K. Thavarajah, Detroit, MI, p.A6529

P911  Fibrosing Mediastinitis Due to Histoplasma: A Rare but Potentially Treatable Entity/A. Yankovich, C. Schuring, A. Sodhi, Memphis, TN, p.A6530


P914  Association Between Sjogren Syndrome, Primary Biliary Cirrhosis and Interstitial Lung Disease/A. Das, A. Faisal, A. Kumar, Grand Rapids, MI, p.A6533

P915  Lymphangiomatosis/M. Abdulkader, M. Jamal, L.G. Jean, York, PA, p.A6534


P917  Sarcoidosis Presenting as Dacryoadenitis/V. Pathak, J. Wininger, Raleigh, NC, p.A6536

P918  Approach to Progressive Mixed Obstructive and Restrictive Lung Disease with Persistent Mosaicism on Computed Tomography in an Asymptomatic Young Female/V. Kaul, R. Mocerino, T.M. McGary, Elmhurst, NY, p.A6537

P919  Cystic Lung Disease Due to Primary Light Chain Deposition/A.T. Fabro, L.F. Biazim, F.M. Lima, V. Carvalho, J. Castelli, P.D.S. Leao, S.S. Batah, M.K. Santos, J. Baddini-Martinez, Ribeirao Preto, Brazil, p.A6538

P920  A Case of Sarcoidosis Imitating Lymphoma/G. Dellinger, E. Crowley, A. Noor, Indianapolis, IN, p.A6539

P921  Symptomatic Sarcoidosis, Asthma or Both? A Diagnostic and Management Dilemma/A. Khwaja, R.M. Kotloff, Cleveland, OH, p.A6540

Facilitator: A. O. Adegunsoye, MD, Chicago, IL


P923  Interstitial Lung Disease in a Patient with Quiescent Ulcerative Colitis/K.P. Chen, D. Kahn, Danbury, CT, p.A6542
P1018 Acute Respiratory Failure: A Rare Presentation of a Well-Known Chronic Disease in Lung Transplantation/T. Thaniyavarn, D.C. Neujahr, Durham, NC, p.A6573

P1019 Regrets Over a Missed Opportunity to Have a Biological Child - One Couple’s Journey After Lung Transplantation for Cystic Fibrosis/S. Ladores, L.A. Bray, J. Brown, Birmingham, AL, p.A6574

P1020 Case Studies on HPV Post Lung Transplant and Implication on Management/L. Khorsheed, Dublin, Ireland, p.A6575

P1021 A Rare Case of Cocaine-Induced Organizing Pneumonia/C. Halasan, E. Nadler, P. Uy, C. Monterroso, Farmington, CT, p.A6576

P1022 Pulmonary Toxicity Due to 5-Fluorouracil (5-FU) Manifested as Diffuse Alveolar Hemorrhage: Case Report/L. Fernandez, A. Dominguez, W. Martinez, F. Sanabria, C.S. Leib, Cali, Colombia, p.A6577

P1023 Alveolar Hemorrhage and Respiratory Failure Secondary to Apixaban/J.E. Morales, B.P. Emerick, P.L. Griffin, J. Grill, Sun City, AZ, p.A6578

P1024 Leflunomide Worsening or Improving Rheumatoid Nodules?/A. Fadda, D. Singh, Phoenix, AZ, p.A6579


P1029 Rituximab and Bendamustine Induced Diffuse Alveolar Damage/Z. Esper, W. Mansour, B. Karam, M. Chalhoub, Staten Island, NY, p.A6584

P1030 Diffuse Alveolar Hemorrhage Mimicking Pneumonia Secondary to Apixaban Administration/S.T. Katta, L. Aljundi, W.A. Ventimiglia, Grosse Pointe Farms, MI, p.A6585

P1031 Cocaine Induced Severe Resistant Pulmonary Hypertension/K. Srour, M.S. Khan, Z. Khan, M. Banifadel, F. Khateeb, J. Hammersley, Toledo, OH, p.A6586

P1032 Benzocaine Spray-Induced Methemoglobinemia/N. Jiwa, U. Ibe, R. Beri, Waterbury, CT, p.A6587

P1033 Every Dog Has Its Day: FIBOS Caused by Diacetyl Exposure from an Unusual Source/K. Warrior, A.J. Gamino, Chicago, IL, p.A6588


P1036 Acute Interstitial Pneumonitis with Crazy Paving Pattern After Chemotherapy for Colorectal Cancer/J.E. Morales, B.P. Emerick, Sun City, AZ, p.A6591


P1038 Rare Presentation of Thyroid Storm with Diffuse Alveolar Hemorrhage/G. Malhotra, A. Khurana, L. Srinivasan, North Chicago, IL, p.A6593


P1042 Use of Venovenous Extracorporeal Membrane Oxygenation for Diffuse Alveolar Hemorrhage Due to Inhaled Synthetic Cannabinoids or “Spice”/M. Patel, L.M. Tormoeullen, D. Gutteridge, Indianapolis, IN, p.A6597


P1045 An Unusual Case of Unilateral Pulmonary Fibrosis Induced by Amiodarone Toxicity/A. Madanieh, A. Rajasekaran, C. Orabi, F. Afridi, Orlando, FL, p.A6600

P1046 TNF Alpha Antagonist Induced Sarcoidosis/J. Katsis, L. Frye, R.S. Bermea, B. Kaumeyer, A. Husain, Chicago, IL, p.A6601


P1048 A Case of Exogenous Lipoid Pneumonia Caused by Sesame Oil Pulling Successfully Treated with Whole Lung Lavage/K. Akasaka, Y. Tsukahara, T. Nishizawa, T. Oba, M. Amano, H. Matsushima, Saitama, Japan, p.A6603
D36 PLEURAL DISEASE: CASE REPORTS II
9:15 a.m. - 3:30 p.m. SAN DIEGO CONVENTION CENTER
Area G (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.
Discussion: 11:15-12:00: authors will be present for individual discussion. 12:00-1:00: authors will be present for discussion with assigned facilitators.

Facilitator: N. Arger, MD, San Francisco, CA


P673 Pancreaticopleural Fistulae; a Rare Pulmonary Complication of an Intra-Abdominal Disease/M. Antoine, B. Sharma, D. Markabawi, P. Kopparthly, Syracuse, NY, p.A6655


P677 Re-Expansion Pulmonary Edema After Large Volume Thoracentesis: A Teachable Moment/Z. Khan, A. Wahab, A. Abdullah, Toledo, OH, p.A6659


P679 Pychocholethorax: A Rare Complication of Percutaneous Transhepatic Biliary Drainage/Z. Khan, M.S. Khan, K. Srour, J. Hammersley, Toledo, OH, p.A6661

P680 Bilateral Chylothorax and Chylous Ascites: A Rare Presentation of an Uncommon Disorder/A. Mahajan, P. Sankhyan, B. Boonpheng, E. Josan, K. Bajaj, Johnson City, TN, p.A6662
P681 Benign Nodular Adenomatous Hyperplasia of the Thyroid: An Unusual Cause of Pleural Effusion?/S. Pilli, B.J. McKelvy
Facilitator: G.A. Fernandez Romero, MD, Philadelphia, PA
Houston, TX, p.A6663

P682 Getting it off Your Chest: A Case of Actinomyces Israelii Causing Empyema Necessitatis/A. Bello, D. Sese, H. Kakarala
Akor, OH, p.A6664

P683 Tainted Milk: Dasatinib-Induced Bilateral Chylothorax with Associated Streptococcal Infection/W. Brasher, P. Patel
Houston, TX, p.A6665

P684 A Rare Cause of Empyema in a Patient with Germ Cell Tumor/R. Mangat, A. Eranki, Syracuse, NY, p.A6666

P685 Talcoma: The Confounding of a Differential Diagnosis in a Patient with a Pleural-Based Mass/P. Ramirez, B. Giri, Temple, TX, p.A6667


P688 Extramedullary Hematopoiesis of the Pleura: A Rare Cause of Massive Hemothorax/K. Linder, O. Epelbaum, A. Agarwal, Valhalla, NY, p.A6670


P690 Exudative Pleural Effusion as an Initial Presentation of Rheumatoid Arthritis/N. George, Houston, TX, p.A6672


P692 Isolated Chylothorax After Intra-Abdominal Surgery/N. Seif, A. Noor, Indianapolis, IN, p.A6674


P694 Resection of Solitary Fibrous Tumor of the Pleura with Single Port VATS/K. Zakharov, J. Gumer, G. Brevetti, Brooklyn, NY, p.A6676

P695 Asymptomatic Reexpansion Pulmonary Edema Following Thoracoscopy/N. Appusamy, Trichy, India, p.A6677

P696 Spontaneous Pneumomediastinum (Hamman’s Syndrome): A Case Report/Y. Elsalaamizaad, M. Berrou, P. Almalouf, Mobile, AL, p.A6678

P697 Deadly Imposter: A Rare Pleural Tumor Masquerading as Pulmonary Abscess/E.E. O’Shea Paudel, S.E. Kopec, Worcester, MA, p.A6679


P700 Spontaneous Pneumothorax Caused by Excessive Positive Airway Pressure Therapy for Obstructive Sleep Apnea/J.T. Mao, A. Bernabei, N. Cutrufoello, J.D. Kern, Albuquerque, NM, p.A6682


Facilitator: A.M. Goyanes, MD, Baltimore, MD


P704 Malignant Pleural Effusion as the First Presentation of Thyroid Cancer/T. Phupitakphol, R. Alejandro, S.-L.C. Kwa, Framingham, MA, p.A6686


P706 Spontaneous Chylothorax in an Adult with Noonan Syndrome/R. Baalachandran, M. Paparo, A. Sachdeva, E. Pickering, Baltimore, MD, p.A6688

P707 Pleural Effusion as Initial Manifestation of Ovarian Malignancy/E. Kandoth, R. Mocerino, V. Kaul, T.M. McGarry, Queens, NY, p.A6689


P709 Smells Like Anaerobes: Cooperative Immune Evasion and a Foul-Smelling Intensive Care Unit/R. Belecanech, K.M. DeMerle, B.J. McVerry, Pittsburgh, PA, p.A6691

P710 Another Case of Pleural Based Malignancy or Perhaps Not: An Unusual Presentation of Gunshot Injury/J. Duke, P. Vijhani, S.V. Cherian, R.M. Estrada-Y-Martin, Houston, TX, p.A6692

P711 When Normal Flora Goes Wild! A Rare Cause of a Complicated Pneumonia/O. Epelbaum, A. Agarwal, A. Shallal, M. Reaume, L. Yadav, M. Olken, Kalamazoo, MI, p.A6693

Facilitator: A. Sergew, MD, Denver, CO


P713 A Complex Parapneumonic Pleural Effusion Presenting with Back Spasms/A. Shallal, M. Reaume, L. Yadav, M. Olken, Kalamazoo, MI, p.A6695


P716  A Case of Cryptogenic Bilateral Fibrosing Pleuritis, an Extremely Rare Form of Interstitial Lung Disease/G. Ivashchuk, M. Sanchez Sierra Marino, R. Arauco Brown, McAllen, TX, p.A6698

P717  A Pleural Effusion May Be Your Only Clue: A Rare Presentation of Advanced Ovarian Carcinoma/A. Labus, M.B. Abdelfattah, R.G. Sangani, Morgantown, WV, p.A6699


P719  Lung Entrapment Due to Pleural Involvement of Lipophosphomuc Lympoma in Waldenstrom Macroglobulinemia/N. Ntamah, R. Hakim, D. Singh, S.B. Smith, Chicago, IL, p.A6701


THEMATIC POSTER SESSION

D37  CF AND NON-CF BRONCHIECTASIS AND IMMUNE DEFICIENCIES: CASE REPORTS

9:15 a.m. - 3:30 p.m.  SAN DIEGO CONVENTION CENTER
Area G (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion 12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator:  K.M. Robinson, DrMed, Pittsburgh, PA

P725  Williams-Campbell Syndrome: An Elusive Cause of Bronchiectasis/M. Naddour, M. Kalani, A. Singh, Pittsburgh, PA, p.A6704

P726  Tracheobronomegaly “Mounier-Kuhn Syndrome”/H. Asad, Kansas City, MO, p.A6705

P727  A Large Airway Problem: A Case of an Elderly Female with Mounier-Kuhn Syndrome/A. Vu, J.P. Utz, Rochester, MN, p.A6706

P728  Reversible Adult Bronchiectasis/D. Hou, Y. Song, Shanghai, China, p.A6707


P731  Obliterative Bronchitis and Bronchiolitis After Toxic Epidermal Necrolysis/J. O’Connor, J. Barney, Birmingham, AL, p.A6710

P732  Long Term Sequel of Refrigerator Exposure, All Obstruction Is Not COPD/O. Chuikhary, G. Trikha, Syracuse, NY, p.A6711


Facilitator:  S.A. Sellers, MD, Chapel Hill, NC

P736  An Extremely Rare Case of c.418C>T Cystic Fibrosis Transmembrane Regulator Gene Mutation Causing Recurrent Sinopulmonary Infections and Bronchiectasis/T. Ashby, A. Babbar, P. Staiano, J. Cury, Jacksonville, FL, p.A6715


P738  Comorbid Pulmonary Disease May Mask Adult Cystic Fibrosis with Clinical Benefit from Initiation of CF-Specific Therapies - An Illustrative Case/Y. Matusov, N. Achamallah, R.A. Belkin, Santa Barbara, CA, p.A6717


P743  CFTR Mutation Carriers State Presenting with CFTR Related Diseases/P. Ramirez, A.J. Hayek, V.E. Brito, Temple, TX, p.A6722

P744  A Rare Cause of Overwhelming Sepsis in an Asplenic Patient/H. Ahmad, H. Erickson, Minneapolis, MN, p.A6723

P745  Endemic Kaposi Disease (KD) with Pulmonary Localization: A Case Report/L. Delasos, C. Mosebach, Farmington, CT, p.A6724

P746  Not so “Cryptogenic”: A Case of Organizing Pneumonia (OP) Associated with Common Variable Immunodeficiency (CVID)/G. Manek, L. Delasos, C. Mosebach, Farmington, CT, p.A6725
### D38 COUGH: CASE REPORTS

**SAN DIEGO CONVENTION CENTER**  
Area G (Hall A-B2, Ground Level)

**Viewing:** Posters will be on display for entire session.

**Discussion:**
- 11:15-12:00: authors will be present for individual discussion
- 12:00-1:00: authors will be present for discussion with assigned facilitators

**Facilitator:**  
D. Price, MD, New York, NY

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P752</td>
<td>Tracheobronchopatia Osteochondroplastica; a Rare Cause of Persistent Cough/R. Rico, Y. Perez, Y. Buryk, D.J. De La Zerda, R.A. Calderon-Candelario, Miami, FL, p.A6728</td>
<td></td>
</tr>
<tr>
<td>P753</td>
<td>Tracheobronchopathia Osteochondroplastica Newly Diagnosed in a Nonagenarian with Chronic Cough/F. Zahiruddin, A. Colomer, J. Zimmerman, Houston, TX, p.A6729</td>
<td></td>
</tr>
<tr>
<td>P756</td>
<td>Chronic Cough in a Woman from Cameroon: A Case of Tropical Pulmonary Eosinophilia/A. Chada, S. Ayub, L.G. Johnson, Little Rock, p.A6732</td>
<td></td>
</tr>
<tr>
<td>P758</td>
<td>Pulmonary Botryomycosis/J.M. Yachachin, O. Gayoso, W. Ruoss, Stanford, CA, p.A6734</td>
<td></td>
</tr>
<tr>
<td>P759</td>
<td>Late Presentation of Retained Intrathoracic Foreign Body/P. Kaur, G. Elshmy, B. Singh, Paterson, NJ, p.A6735</td>
<td></td>
</tr>
<tr>
<td>P761</td>
<td>Tracheobronchopathia Osteochondroplastica: Rare Cause of Dyspnea, Cough, and Bronchitis/B.A. Hirsh, L.W. Greenspon, Wynnwood, PA, p.A6737</td>
<td></td>
</tr>
</tbody>
</table>


### D39 DYSPNEA: CASE REPORTS II

**SAN DIEGO CONVENTION CENTER**  
Area G (Hall A-B2, Ground Level)

**Viewing:** Posters will be on display for entire session.

**Discussion:**
- 11:15-12:00: authors will be present for individual discussion
- 12:00-1:00: authors will be present for discussion with assigned facilitators

**Facilitator:**  
J.Y. So, MD, Philadelphia, PA

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P769</td>
<td>Myhre Syndrome in Montana, a Case Report/K. Mitchell, F. Caceres, Billings, MT, p.A6742</td>
<td></td>
</tr>
<tr>
<td>P770</td>
<td>Unexplained Cough, Dyspnea, and Eosinophilia: Don’t Forget the Zebras/R. Guthrie, L.C. Moses, Richmond, VA, p.A6743</td>
<td></td>
</tr>
<tr>
<td>P771</td>
<td>The Liver’s Caprice: Porto-Pulmonary Hypertension and Hepato-Pulmonary Syndrome Together/P.J. Thacker, A. Abichandani, H. Grover, A. Singh, Abington, PA, p.A6744</td>
<td></td>
</tr>
</tbody>
</table>

**Facilitator:**  
J. Evankovich, MD Pittsburgh, PA

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P774</td>
<td>A Curious Case of Hypoxia: Hepatopulmonary Syndrome in Dyskeratosis Congenital/A. Rose, R. Hsiao, D. Koura, D.R. Crouch, La Jolla, CA, p.A6747</td>
<td></td>
</tr>
<tr>
<td>P775</td>
<td>Croup in Adults: All Bite and No Bark?/P.P. Patel, C. Jacob, G.S. Thind, M. Loehrke, Kalamazoo, MI, p.A6748</td>
<td></td>
</tr>
<tr>
<td>P778</td>
<td>An Uncommon Cause for a Common Complaint: Dyspnea on Exertion Caused by a Double Aortic Arch/C.M. Bojanowski, V. Pretorius, T.M. Fernandes, La Jolla, CA, p.A6751</td>
<td></td>
</tr>
<tr>
<td>P779</td>
<td>Pentoxifylline Reduces Intrapulmonary Shunt in a Patient with Hepatopulmonary Syndrome/N. Alipanah, N. Juul, V. Mohindra, A.A. Gohil, San Jose, CA, p.A6752</td>
<td></td>
</tr>
</tbody>
</table>

**Facilitator:**  
B.C. Tran, MD, Baltimore, MD

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P780</td>
<td>Acute Respiratory Failure: A Rare Manifestation of Sweet Hydrothorax/M.A. Mohammad Alahmad, A. Gundabolu, R. Kasmani, Toledo, OH, p.A6753</td>
<td></td>
</tr>
</tbody>
</table>
P781 Vanishing Bone Disease/A. Tamura, S.J. Evans, Honolulu, HI, p.A6754
P782 An Unusual Presentation of Multiple Myeloma as Diffuse Alveolar Hemorrhage/M. Khattab, Z. Smith, J. West, H.A. Hussein, Oklahoma City, OK, p.A6755
P783 A Rare Disease Associated with Acute Respiratory Failure in an ICU Patient/R. Westman, Columbus, OH, p.A6756
Facilitator: D.W. Chang, MD, Torrance, CA
P786 Bilateral Vocal Cord Paralysis from Type 1 Chiari Malformation Masquerading as Chronic Obstructive Pulmonary Disease/A. Kalansky, A.M. Khan, D.E. Murphy, A.G. Peerless, Cincinnati, OH, p.A6759
P788 High Flow Nasal Cannula (HFNC) Oxygen Therapy as a Palliative Measure in End Stage Lung Disease (ESLD)/D. Khateeb, J.A. Marigilo, Philadelphia, PA, p.A6761
P790 A Toothache to Kill. A Case of Dental Abscess Complicated with Descending Necrotizing Mediastinitis/M. Dogra, M. Abdelghany, H. Dharia, J. Lamichhane, Syracuse, NY, p.A6763
P793 “Casting” for a Diagnosis: A Case of Plastic Bronchitis in an Adult Patient Following Cardiopulmonary Bypass/K. Lam, Stanford, CA, p.A6766
P794 An Unusual Case of Gastrointestinal-Induced Lung Compression with Hypoxia/L. Delasos, G. Maneck, P. Troy, Farmington, CT, p.A6767
P795 Isolated Congenital Sternal Defect/Absence in a Patient of 58 Year Old/Y. Abdel-Aziz, A. Kubbara, Y. Yoon, Toledo, OH, p.A6768
P796 Breathless with Dapsone/A. Munir, A. Thandra, A.K. Rakhra, D. Huang, A.D. Wells, Omaha, NE, p.A6769
P797 Mitochondrial Myopathy Presenting in Late Adulthood: A Rare Occurrence/H. Hadid, Detroit, MI, p.A6770

THEMATIC POSTER SESSION

D40 COPD: CASE REPORTS
9:15 a.m. - 3:30 p.m. SAN DIEGO CONVENTION CENTER
Area L (Hall A-B2, Ground Level)
Viewing: Posters will be on display for entire session.
Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators
Facilitator: C. Riley, MD, Pittsburgh, PA
P1327 Quantitative Computed Tomography in Diagnosing Emphysema/L.G. Vargas Buonfiglio, S.J. Kraus, A.P. Comellas, Iowa City, IA, p.A6773
P1329 Mycobacterium Avium Masquerading as a Possible Lung Carcinoma in a Patient with Advanced COPD/M. Shahzadi, A.Z. Rasheed, R. Chand, L. Iatypov, L.N. Gerolemou, Brooklyn, NY, p.A6775
P1331 A Twisted Pulmonary Complication Following Surgery/T.H.-Y. Pan, R. Choudhury, T. Alias, D. Feiter, A. Mora, Dallas, TX, p.A6777
Facilitator: A. Lambert, MD, MHS, Seattle, WA
P1334 The Cocktail Effect of Cigarettes and Marijuana in Giant Bullous Emphysema/J.N. Blixt, D.K. Narendra, Houston, TX, p.A6780
P1335 A Rare Case of Spontaneous Pulmonary Bleeding into an Emphysematous Bulla/A.A. Innabi, A. Chada, T. Bartter, Little Rock, AR, p.A6781
P1336 Recurrent Acute Pancreatitis Secondary to Alpha-1-Antitrypsin Deficiency/Z. Awan, A. Turner, Birmingham, United Kingdom, p.A6782

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.


P1340 A Case of Fluid Filled Emphysematous Bullae: A Cause for Concern?/J. Wong, Minneapolis, MN, p.A6786

THEMATIC POSTER SESSION

D41 CRITICAL CARE: LEARNING TO FLY - INNOVATIONS IN EDUCATION

9:15 a.m. - 3:30 p.m. SAN DIEGO CONVENTION CENTER

Area K (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators: M.J. Lanspa, MD, MSCR, Salt Lake City, UT
A.A. Hope, MD, Bronx, NY


P1132 Impact of A One Day Introductory Course to Pulmonary and Pleural Procedures/A. de Lima, A. Majid, A.C. Chee, M.S. Parikh, Boston, MA, p.A6788


P1136 High Fidelity Simulation-Based Education to Improve Medical Resident Competence and Comfort in Ventilator Management in the Intensive Care Unit/M. Champion, E. Pohoata, J.A. Gold, S.A. Nonas, Portland, OR, p.A6792


P1138 Implementation of a Formal Medical Intensive Care Unit Curriculum for Housestaff/J. Willoughby, A. Trivedi, Chicago, IL, p.A6794

D42 CRITICAL CARE: BLINDED BY THE LIGHT - IMAGING IN CRITICAL CARE

9:15 a.m. - 3:30 p.m. SAN DIEGO CONVENTION CENTER

Area K (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators: S.B. Fain, PhD, Madison, WI
G.F. Curley, MB, PhD, Toronto, Canada

P1146 BMI Does Not Influence Cardiac View in Critically Ill Patients/V. Sharma, R. Gueret, J. Bailitz, Chicago, IL, p.A6801

P1147 Formalized Ultrasound Education/C. Rappaport, J. Smock, A. Vose, Iowa City, IA, p.A6802

P1148 Effectiveness of a Self-Directed Critical Care Ultrasound Course/Z. Fulkerson, K.J. Diab, W.G.G. Carlos, Indianapolis, IN, p.A6803


P1150 A Startling Conclusion: The Presence of B Lung Ultrasonography Performed by Medical Residents Did Not Lead to Less Fluid Administration/C. Iskandir, V. Viswanathan, H. Bhatt, R.C. Rajmane, Brooklyn, NY, p.A6805

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.


P1153 A Survey of the Use of Ultrasound Based Parameters to Assess Fluid Responsiveness/V. Sharma, N. Hammond, H. Li, J. Rodriguez, R. Gueret, J. Bailitz, Chicago, IL, p.A6808


P1155 Evaluating the Practice of Repositioning Endotracheal Tubes in Neonates and Children Based on Radiographic Location/D.D. Im, P.A. Ross, J. Hotz, C.J. Newth, Los Angeles, CA, p.A6810


Facilitators: A. Amaral, MD, Toronto, Canada
I.K. Louh, MD, PhD, New York, NY


P1166 Improving Documentation of Endotracheal Intubations in the Medical Intensive Care Unit at a Tertiary Care Hospital/B. Lindgren, P. Azizad-Pinto, O. Rojanapairat, U. Hoang, Los Angeles, CA, p.A6820

P1167 Institution of a Pre-Intubation Checklist in the Medical Intensive Care Unit/E. Beck, J.P. Boltax, Salt Lake City, UT, p.A6821


P1169 A Clinical Decision Support System to Enable Precision Delivery of Evidence-Based Care to Mechanically-Ventilated Patients/S. Assar, S. Fountain, B. Stoffer, K.S. Ramos, S. Curry, R.A. Raschke, Phoenix, AZ, p.A6823

P1170 Wake Up and Exubate: A Case Control Study Investigating the Association Between the Daily Spontaneous Awakening Trial and Unplanned Extubations/M. Ferrera, R. Hyzy, J. Du, Ann Arbor, MI, p.A6824


Facilitator: K. Kashani, MD, MSc, Rochester, MN

P1172 The Design of an Electronic Medical Record Based Clinical Decision Support System in a Large Healthcare System to Improve Antibiotic Safety Using a Validated Risk Score/C. Heise, T. Gallo, S. Curry, R. Woosley, Phoenix, AZ, p.A6826


P1180 Changing Practice of Stress Ulcer Prophylaxis in Medical Intensive Care Unit at Tertiary Care Center/K. Patel, V. Pronesti, M.A. Kalani, P. Kim, K. Ma, A. Singh, Pittsburgh, PA, p.A6834

P1181 Reduction in the Use of Gastric Acid Suppression in a Regional Medical Center ICU After Implementation of an Evidence-Based Algorithm for Stress Ulcer Prophylaxis/S. Pasnick, S. Beane, J. Demirovic, S. Lyon, D. Otero-Bell, M. Montoya, T. Dammad, L. Goitein, Santa Fe, NM, p.A6835

P1182 Resident Physician’s Perspective on Transitions of Care in a Medical Intensive Care Unit: A Quality Improvement Pre-Intervention Descriptive Study/M. Dongol, E.O. Ortiz-Diaz, A. Kunadu, A. Otokiti, P. Cruz, R. Ayinla, New York, NY, p.A6836

Facilitators: R.D. Hite, MD, Cleveland, OH
J. Maguire, MD, Chapel Hill, NC


P1186 Arrival to the ICU During Night Shift Is More Frequent in Infected Patients Directly Admitted to the ICU Compared to Transfers from the Floor/S.P. Taylor, C. Karvetski, C. Lewis, A. Heffner, B.T. Taylor, Charlotte, NC, p.A6839


P1190 Internal Medicine Resident Education and Experience - Difference Between a “Closed” and “Open” Critical Care Unit Model/G. Gupta, S.S. Alagusundaramoorthy, A. Jacob, V. Kramer, C. Patton, Long Branch, NJ, p.A6843

P1191 Outcomes of Patients Admitted to a Medical Intermediate Care Unit/C. Ohri, J. Kunal, M.D. Hashmi, C.M. Chan, Washington, DC, p.A6844


P1194 Effect of Conversion from Open to Closed Medical Intensive Care Unit in a Large Teaching Hospital/D. J. De La Zerda, I. Gutierrez, E.C. Santillana, R.A. Calderon Candelario, S. Farasat, Miami, FL, p.A6847

Facilitators: J.E. Sevriansky, MD, Atlanta, GA
S. Ahmed, MBBS, Albuquerque, NM


Facilitators: R.D. Hite, MD, Cleveland, OH
J. Maguire, MD, Chapel Hill, NC
P1199  Impact of Peripheral Pressors and Midodrine in the ICU/K. Chapla, W. Brinigershgold, Madison, WI, p.A6852


P1202  PICC use in Sepsis and Septic Shock Patients Admitted to the Intensive Care Unit/B. Alvarez Concejo, H.A. Raza, B. Nokes, R. Cartin-Ceba, Dallas, TX, p.A6855


P1205  “ICU HIT” Me with Your Best Shot”: A Single-Centered Experience for Improving Quality Intensive Care Unit Handoffs from Inter-Hospital Transfers (ICU-HIT Project)/W. Karkowsky, V.K. Holden, K. S. Robinett, Baltimore, MD, p.A6858

D45  CRITICAL CARE CASE REPORTS: I (DON’T) WANT TO BE SEDATED - NEUROCUTLICAL CARE, SEDATION, AND DELIRIUM

9:15 a.m. - 3:30 p.m.  SAN DIEGO CONVENTION CENTER
Area K (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators:  M. R. Baldwin, MD, MS, New York, NY
S. Nalamalapu, MD, Baltimore, MD


P1208  Propofol Induced Dystonia: A Rare Drug Reaction/M. Reddy, A. Miller, A. Scalzo, S. Osmond, C. Krausz, St. Louis, MO, p.A6860


P1211  Dysphagia to Respiratory Failure in 5 Hours: Presentation of a Rare Variant of Guillain-Barré Syndrome/E. Matayeva, T. Henson, A. Alaverdian, J. Iqbal, J. Akella, East Meadow, NY, p.A6863


P1213  A Case of Anti-NMDA Encephalitis in the ICU/K. Tsui, B. Ramgopal, K. Pollard, P. Aguilar, St. Louis, MO, p.A6865


P1215  Cefepime-Induced Non-Convulsive Status Epilepticus: A Rare and Treatable Delirium/M. Naddour, M. Kalani, M. Balaan, Pittsburgh, PA, p.A6867


Facilitators:  A. C. Arroliga, MD, Temple, TX
C. M. Goodson, MD, Baltimore, MD

P1218  Colon Adenocarcinoma with Leptomeningeal Carcinomatosis Mimicking Subdural Empyema/B. J. Akhavan, G. Sanchez Petitto, M. J. Kwak, T. Sison, J. Goodman, M. Bhattarcharjee, Houston, TX, p.A6870

P1219  Life Threatening Case of Brain Swelling: Pachymeningitis/J. Rathod, V.R. Patel, Milwaukee, WI, p.A6871

P1220  Irreversible Cranial Nerve Palsies After Resolution of Pneumonia: Clue to Missed Meningitis/L. Yadv, K. Kailasam, W. Nichols, Kalamazoo, MI, p.A6872


P1225  A Rare Case of Guillain-Barré Syndrome Without Identifiable Trigger in Polycythemia Vera Patient/P. Taweesedt, A. Gupta, M. Bachan, Z. Khan, Bronx, NY, p.A6877

D46  CRITICAL CARE CASE REPORTS: TOXICOLOGY AND POISONINGS

9:15 a.m. - 3:30 p.m.  SAN DIEGO CONVENTION CENTER
Area K (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.
Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators: M. de Wit, MD, Richmond, VA
F. Moazed, MD, San Francisco, CA

P1243  Intravenous Lipid Emulsion for Cardiac Arrest and Refractory Shock Caused by Intentional Propranolol Overdose: A Human Case Report
J. Amayo, K. Horton, J.D. Butler, Atlanta, GA, p.A6894

P1244  Opium Poppy Seed Tea: A Lesser Known but Deadly Cocktail/N. Poponea, M.T. Kashlan, J. Vollstaedt, Pontiac, MI, p.A6895

P1245  Breaking Ricin/Y. Wakwaya, B. Graney, Aurora, CO, p.A6896

P1246  Finding the Silver Lining: A Puzzling Case of Shock Caused by Intentional Propranolol Overdose: A Human Case Report
J. Amayo, K. Horton, J.D. Butler, Atlanta, GA, p.A6894

P1247  A Rare Case of Theophylline Toxicity Due to Influenza A Infection in an Adult with Asthma/Z. Khan, U. Darr, M.S. Khan, K. Srour, T. Javaid, Toledo, OH, p.A6898

P1248  Hyperosmolarity and Lactic Acidosis Due to Propylene Glycol Toxicity Induced by Intravenous Trimethoprim/Sulfamethoxazole Therapy/H. Shah, D. Datta, Farmington, CT, p.A6899


P1250  An Unusual Constellation of Copper Deficiency: Myelopathy and Leukopenia/D. Vera-Vazquez, Grand Rapids, MI, p.A6901


P1252  Methotrexate Toxicity: Skin in the Game/S. Noronha, N. Achamallah, Y. Matusov, J.C. Fried, Santa Barbara, CA, p.A6900

P1253  Down but Not Out: Severe Amitriptyline Overdose for Extended Duration Due to Genetic Polymorphism/D. Gekhman, G. Marmolejos, N. Agarwal, Philadelphia, PA, p.A6904

P1255  Life Threatening Neurologic and Cardiac Toxicity due to Cesium Chloride Used for the Holistic Treatment/V.R. Patel, J. Rathod, Milwaukee, WI, p.A6906
P1256  Venlafaxine-Induced Hypertensive Emergency/Y. Mogilevskaya, S. Patel, B.A. Mina, New York, NY, p.A6907
P1257  Loperamide Induced Cardiotoxicity/B. McNeely, A. Kasniunas, P. Jagtap, D. Sanghavi, Springfield, IL, p.A6908
P1259  Non Cardiogenic Pulmonary Edema Due to Chronic BC Powder Use/T. Warmoth, H. Edriss, Lubbock, TX, p.A6910
P1261  Amantadine Toxicity: Uncovering a Rare Cause of Severe Encephalopathy/K. Albretson, A. Mandviwala, C. Donatelli, D. Soliman, J. Lackamp, C.V. Teba, Cleveland, OH, p.A6912
Facilitators: J.M. Shapiro, MD, New York, NY, R. Mehta, MD, Maywood, IL
P1263  Metabolic Encephalopathy in a Sickle Cell Patient Taking Deferasirox/A. Bommakanth, J. McKell, Cleveland, OH, p.A6914
P1266  Demonstration of Colchicine Clearance by Continuous Venovenous Hemofiltration (CVVH) in Severe Toxicity/O. Rahman, J. Jacobi, H. Peters, J. Mowry, M. Sohail, Indianapolis, IN, p.A6917
P1267  Daptomycin Induced Rhabdomyolysis: A Rare Complication in Critical Care Patients/X. Gao, M. Bachan, Z. Khan, R.E. Siegel, Bronx, NY, p.A6918
P1268  Lipid Emulsion Therapy and High Dose Insulin in Management of Calcium Channel Blocker Toxicity/N. Mesha, M. Gugnani, S. Tieku, Trenton, NJ, p.A6919
P1269  Development of the Serotonin Syndrome in a Dialysis Patient: A Case Report and Literature Review/S. Congrete, B. Jaber, P. LaCamera, Boston, MA, p.A6920
P1270  Not the Typical Pneumonia: an Unusual Case of Rasburicase Induced Methotrexobinemia/M. Younis, S.S. Gupta, H. Desoky, Y. Kupfer, Brooklyn, NY, p.A6921
P1271  A Case of Massive Acetaminophen Toxicity Needing Emergent Hemodialysis/I. Melgarejo, G. Devendra, Honolulu, HI, p.A6922
P1272  High Dose Insulin for Severe Heart Failure Due to Beta-Blocker Overdose/A. S. Calzadilla, M. Mirseaidei, Miami, FL, p.A6923
Facilitators: L. Burry, PhD, Toronto, Canada S.W. Robison, MD, Birmingham, AL
P1273  Cardiomyopathy Associated to Anabolic-Androgenic Steroid (AAS) Abuse/O. Garner, M. Yakoby, A. Ramirez-Berlio, A. Iardino, C.W. Spellman, Odessa, TX, p.A6924
P1275  Methanol Induced ST Elevation and Brain Death/E. Chow, A. Khosla, L. Berman, Norwalk, CT, p.A6926
P1276  Trimethoprim-Sulfamethoxazole Induced Non-Anaphylactic Circulatory Shock/P. Liu, G.P. Ranches, J.A. Gold, Portland, OR, p.A6927
P1277  Rapid Near-Fatal Piperacillin/Tazobactam-Induced Thrombocytopenia/R. Marsoujeh, B. Bonder, A. Mandviwala, A. Haj Abdulkader, Cleveland, OH, p.A6928
P1278  Agitated Delirium in an Intravenous Drug User: Don’t Jump to Conclusions/A. Abdelrahman, M. Borden, M.A. Ghamloush, Boston, MA, p.A6929
P1280  An Steven Johnson Patient with Pulmonary and Cardiac Involvement/W. Rodriguez, A. Candelario, L. Gonzalez, O.J. Cantres, San Juan, PR, p.A6931
P1281  Metformin-Induced Lactic Acidosis in a Patient with End-Stage Renal Disease/M. Allipur, A. Mogla, N. Mesiha, L.N. Geroloum, Brooklyn, NY, p.A6932
Facilitators: D. Krutsinger, MD, Philadelphia, PA A. Martinez, MD, Baltimore, MD
P1285  ST Elevation Myocardial Infarction Due to Carbon Monoxide Toxicity/G. Eisinger, C. Kaide, J.E. Stasek, Columbus, OH, p.A6936
P1286  The Perplexing Case of Desquamative Skin Lesions in a Patient Initially Presenting with Volume Overload/K. Poosti, C. Do, M. Boudreaux, V. Dietz, J. Shweihat, Huntington, WV, p.A6937

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
D47  TUBERCULOSIS: CASE REPORTS

9:15 a.m. - 3:30 p.m.  SAN DIEGO CONVENTION CENTER
Area A (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.
Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators
Facilitator:  C. Yoon, MD, MPH, MSCR, San Francisco, CA


P2  Hemothysis 52 Years Following Plombage Thoracoplasty for Mycobacterium Tuberculosis/V. Esmero, J. Mehrotra, P. Shah, A.J. Gamino, Chicago, IL, p.A6943

P3  Tuberculous Tracheobronchial Stricture Treated Successfully with Balloon Dilatation/A. Wee, A. Verma, J. Venkatachalam, Singapore, Singapore, p.A6944


P5  Pseudotumoral Bronchopulmonary Tuberculosis in an Immunocompetent Young Adult/C.F.E.F. Koudessi, F.B.R. Mbaye, N.O. Toure Badiane, Dakar, Senegal, p.A6946


P8  A Unilateral Pleural Effusion in a Pregnant Woman from Ethiopia/J. Kim, P. Jackson, Portland, OR, p.A6949

Facilitator:  G.W. Eather, MD, Brisbane, Australia


P14  Slowly but Surely: A Case of Positive Cerebrospinal Fluid Culture in Tuberculous Meningitis/A. Mohammed, D. Saul, R. Gueret, Chicago, IL, p.A6955


Facilitator:  K.P. Fennelly, MD, MPH, Bethesda, MD


P17  Transmission of Acquired Rifampin Resistant Tuberculosis Among Three Sisters in Texas/N. Keaton, A. Vasquez, San Antonio, TX, p.A6958


P19  Isoniazid Induced Fever/C.-C. Hsu, Y.-T. Huang, S.-E. Tseng, Y.-N. Shih, X. Zhu, Taipei, Taiwan, p.A6960

P20  Anti-Tuberculosis Treatment Induced Hyperacute Hepatic Encephalopathy in a Young Boy with Tuberculous Pleural Effusion/M. Mishra, S. Kumar, Rishikesh, India, p.A6961


P22  Endobronchial Mass,1 Year After Successful Bilateral Lung Transplant/M. Azar, C. Zhang, D. Roe, C. Hage, Indianapolis, IN, p.A6963

Facilitator:  L.C. Eldredge, MD, PhD, Seattle, WA

P801  Role of Rac1 in Alveolar Epithelial Cells in Apoptotic Cell Removal During Lung Development/A. Kadil, A. Desmet, P. Jayaguru, S. Tundup, Charlottesville, VA, p.A6965


P804 Increased Adherence of Immature Type I Alveolar Epithelial Cells to Extracellular Matrix Proteins Is Partially Inhibited by sRAGE/E. Noh, H.J. Rozycki, Richmond, VA, p.A6968

P805 Reduction In MiR-133a/b Expression in Lungs During Neonatal Hyperoxia Leads to the Development of Pulmonary Hypertension in Neonatal Mice/T. Chen, Chicago, IL, p.A6969

P806 Role of Alternative Splicing in a Murine Model of Neonatal Hyperoxic Lung Injury and Sex-Biased Differences: Implications for Bronchopulmonary Dysplasia/K. Lingappan, J. Dong, C. Coarfa, Houston, TX, p.A6970

P807 Loss of IL-6 Preserves Surfactant Protein Expression and Enables Lung Growth in Newborn Mice Exposed to Prolonged Hyperoxia/D. Hirani, K. Dinger, B. Darvishan, J. Mohr, C. Vohlen, F. Klein, M. Odenthal, J. Dötsch, M.A. Alejandro Alcazar, Cologne, Germany, p.A6971


P811 Extracellular Vesicles from Bone Marrow Derived Mesenchymal Stromal Cells Induces Angiogenesis in HuvEc Through Akt Dependent Enos Signaling/C. Chetty, G. Swanson, G. Nelson, R.K. Braun, V. Balasubramaniam, Madison, WI, p.A6975


P813 Gestational Intermittent Hypoxia (GIH) Impairs Uterine Artery Function in Pregnant Mice/M. Badran, S. Golbidi, N. Ayas, I. Laher, Vancouver, Canada, p.A6977


Facilitator: J. Sucre, MD, Nashville, TN


P822 Characterization of Patients with Bronchopulmonary Dysplasia (BPD) in a University Hospital in Latin America between July 2015 and July 2017/C.L. Grizales, I.E. Padilla, L. Fernandez, J.M. Sanchez, M. Jaramillo, C.S. Leib, Cali, Colombia, p.A6986


P824 Mice Deficient in Mesenchymal Gaq/11 Signalling Have Airways Enlargement and Increased Alveolar Wall Thickness Consistent with Defective Alveolarisation/A. Goodwin, A. Hlabgood, A.L. Tatler, N.C. Henderson, S. Offermanns, A.E. John, R.G. Jenkins, Nottingham, United Kingdom, p.A7791


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
P432 Extracorporeal Membrane Oxygenation, an Effective Therapy for Pulmonary Veno-Occlusive Disease and Pulmonary Capillary Hemangiomatosis/S.D. Bali, Orlando, FL, p.A6991
P433 An Unusual Manifestation of Hyperthyroidism/P. Sharma, N. Chandrasekaran, Pittsburgh, PA, p.A6992
P436 Right Side Aortic Arch with Aberrant Left Subclavian Artery/M. Rudrappa, L. Kokatnur, Shreveport, LA, p.A6995
P437 Congenital Dyserythropoietic Anemia Type II and Chronic Thromboembolic Pulmonary Hypertension/S. Miyashita, K. Bhatia, T. Maeda, J.A. Kileci, N. Li, H.D. Poor, D. Steiger, New York, NY, p.A6996
P438 Giant Pulmonary Artery Aneurysms in a Patient with Pulmonary Arterial Hypertension/J.P. Sy-Go, N. Ariyoshi, J.R. Go, C. Fiack, Honolulu, HI, p.A6997
P439 Which Shunt Is the Culprit? A Case of Hepatopulmonary Syndrome/C. Prohaska, A. Shah, C.J. King, Aurora, CO, p.A6998
P441 Cardiac Tamponade: As a Manifestation of Pulmonary Veno-Occlusive Disease (PVO)/M. Rives-Sanchez, N. AlQsous, A. Quintos, A. Niroula, A. Salehbeiki, S. Sharma, Philadelphia, PA, p.A7000
P442 A Rare Cause of Severe Pulmonary Hypertension: Unilateral Pulmonary Artery Agenesis Presenting in an Elderly Female/B. Graney, K.A. McPherson, T.M. Bull, Aurora, CO, p.A7001
P443 A Fatal Case of Pulmonary Artery Dissection as a Result of Longstanding Pulmonary Hypertension/L. DiChiachio, A. Weichold, K. Rajagopal, K.M. Jones, Baltimore, MD, p.A7002
P444 A Case of Idiopathic Pulmonary Vein Thrombosis and Peripheral Embolization/C. Morton, I. Haimi, New Haven, CT, p.A7003
P445 A CTEPH Mimic: In Situ Clot in Severe Pulmonary Hypertension/A. Rose, N.H. Kim, La Jolla, CA, p.A7004
P447 High-Altitude Pulmonary Hypertension: A Case of Reversal with Descent/B.A. Jalil, K. El-Kersh, Louisville, KY, p.A7006
P448 Hemoptysis from Complex Systemic to Pulmonary Arteriovenous Malformation After Previous Mycobacterium Tuberculosis Infection/B. Hay, N. Sood, Columbus, OH, p.A7007
P450 Is Venous Thromboembolism a Risk Factor for Pulmonary Hypertension in Fibrosing Mediastinitis?/M. Teixeira, A.S. Niven, Rochester, MN, p.A7009
P451 Pulmonary Capillary Hemangiomatosis with Clinical Improvement on Antiangiogenic Treatment with Doxycycline/H. Li, S. Kooragayalu, M. Sekosan, R. Lenhardt, Chicago, IL, p.A7010
P452 A Partial Eclipse of the Heart: A Tale of an Unnecessary Computed Tomography Angiogram (CTA)/N. Cassell, B.J. McKelvy, Houston, TX, p.A7011
P453 So It’s Not a Pulmonary Embolism? A Rare Case of Cardiac Rosai-Dorfman Disease/M. Darnell, C. Vahdatpour, L.M. Catalano, Philadelphia, PA, p.A7012
P455 Pulmonary Arterial Hypertension Presenting as an AIDS Defining Illness/M.D. Bernens, G. Brayman, M. Hooper, Norfolk, VA, p.A7014
P456 High Output Heart Failure Associated with Pulmonary AVM-Induced Massive Hemoptysis/B. Li, J.M. Radbel, New Brunswick, NJ, p.A7015
P457 A High Pressure Situation: Pulmonary Arterial Hypertension and a Large Pericardial Effusion/M. Zhang, M. Petersile, N. Ruopp, H.W. Farber, Boston, MA, p.A7016
P458  Silicosis-Associated Fibrosing Mediastinitis a Rare Cause of Pulmonary Hypertension/Y. T. Debeba, M. Mira-Avendano, C. Rojas, A. Khoor, M. Kwon, Jacksonville, FL, p.A7017
P459  Successful Outpatient Transition from Intravenous Treprostinil to Oral Selexipag/ L. L. Kimming, R. Bag, Chicago, IL, p.A7018
P461  Significance of Pericardial Effusion in Pulmonary Arterial Hypertension/A. Vaughn, Y. Segon, A. Rusk, Milwaukee, WI, p.A7020

**THEMATIC POSTER SESSION**

**D50  CLOT ON THE ROCKS: CASE REPORTS OF PE AND CTEPH**

9:15 a.m. - 3:30 p.m.  SAN DIEGO CONVENTION CENTER  
Area E (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion  
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator:  P. Forfia, MD, Philadelphia, PA

P464  Non Thrombotic Pulmonary Embolism Due to Polidocanol Sclerotherapy/B. Akkok, E. Yarar, Kahramanmaras, Turkey, p.A7022
P465  Large Pulmonary Arteriovenous Malformation: Reversible Cause of Hypoxemia/M. Naddour, M. Hewston, M. Balaan, Pittsburgh, PA, p.A7023
P466  Tacrolimus and Mycophenolate Mofetil Induced Pulmonary Hypertension in a Kidney Transplant Patient/S. Rygielski, M. Rojas, K. Khoor, M. Kwon, Jacksonville, FL, p.A7024
P467  Pulmonary Embolism and Diverticular Bleeding: A Missed Diagnosis and Clinical Dilemma/A. Chowdhury, F. Berenyi, B. Akkok, E. Yarar, Kahramanmaras, Turkey, p.A7025
P468  Between a Clot and a Hard Place: Half-Dose TPA in a Post-Operative Patient with a Massive PE/J. Keen, N. Al Nasrallah, W.G. Carlos, Indianapolis, IN, p.A7026
P469  Severe Pulmonary Artery Hypertension in the Setting of Isolated Unilaterally Absent Pulmonary Artery/IP. Sharedalal, N. Shah, N. Parikh, Philadelphia, PA, p.A7027
P471  Broken Bones and Pulmonary Stones- A Rare Case of Pulmonary Embolism/S. Prueksartanong, G. Ogunbayo, J. Gurley, Lexington, KY, p.A7029

Facilitator:  Y.K. Sung, MD, Palo Alto, CA

P472  Successful Management of Hemodynamically Compromised Acute Pulmonary Embolism with Percutaneous Mechanical Thrombectomy/S. Prueksartanong, G. Ogunbayo, J. Gurley, Lexington, KY, p.A7030
P473  Unusual Presentation of Rare Cervical Mass (Angiolipoma)/S. Mariappan, S. Subramaniam, Tirunelveli, India, p.A7031
P474  A Case of a Massive Pulmonary Artery Aneurysm/A. Al-Aghil, W.J. Chang, R.J. Schilz, Cleveland, OH, p.A7032

Facilitator:  V.J. Test, MD, Durham, NC

P481  Repair with Caution: Diffuse Alveolar Hemorrhage Associated with Mitral Valve Repair/N. Victor, J. Hettenbaugh, J.D. Dickinson, Omaha, NE, p.A7039
P482  Successful Treatment of Refractory Massive Pulmonary Embolism with Repeated Administration of Systemic Thrombolysis: A Case Series/A. Poor, H. Poor, New York, NY, p.A7040
P484  Obstructive Pulmonary Hypertension Caused by Fibrosing Mediastinitis Successfully Treated with Riociguat/V. Martinez, D.R. Fraidenburg, Chicago, IL, p.A7042
P485  Chronic Thromboembolic Pulmonary Hypertension: The Difficulty in Definitive Diagnosis/A. Gibbs, L. Lin, Portland, OR, p.A7043
P488  A Case Report of Surviving Pulmonary Arterial Hypertension in Pregnancy/M. Botros, C. Daniels, Columbus, OH, p.A7046
P489  Unexpected Cause of Acute Severe Headache in a Patient on Chronic Rivaroxaban for Chronic Thromboembolic Pulmonary Hypertension/M.M. Khan, J.M. Elwing, Cincinnati, OH, p.A7047

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
Facilitator: T.M. Bull, MD, Aurora, CO

P490 Hemoptysis 38 Years After Radiation Therapy for Hodgkin’s Lymphoma: A Rare but Serious Complication/A. Minami, M. Mowafy, S. Al-Adwan, T. Minami, Pawtucket, RI, p.A7048

P491 Long-Term Treatment of Pulmonary Arterial Hypertension with Treprostinil in Patient with Eisenmenger and Down Syndromes/Z. Gasior, A. Sikora-Puz, K. Banska-Kisiel, Katowice, Poland, p.A7049

P492 A Rare Case of Extremely Large Pulmonary Artery Aneurysm/A. Al Akshar, E. Costanzo, Neptune, NJ, p.A7050

P493 PEA Arrest Due to Massive Pulmonary Embolism (PE) with Ensuing Consumptive Coagulopathy: Human Physiology Gone Wrong/I.R. Mocerino, T.M. McGarry, V. Kaul, Queens, NY, p.A7051


P495 Management of Thrombus-in-Transit in a Young Man with Sickle Cell Disease/M. Zhang, N. Bosch, E.S. Kling, Boston, MA, p.A7053


P497 Systemic Artery to Pulmonary Artery Fistula Misdiagnosed as Pulmonary Embolism/A. Siddiqui, S. Sahay, J. Gibbs, Houston, TX, p.A7055

THEMATIC POSTER SESSION

D51 PHYSIOLOGY AND PHYSICAL ACTIVITY IN PULMONARY REHABILITATION

9:15 a.m. - 3:30 p.m. SAN DIEGO CONVENTION CENTER

Area F (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion 12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: X. Soler, MD, PhD, San Diego, CA

P539 Ventilatory and Circulatory Power: Characterization in Patients with Chronic Obstructive Pulmonary Disease (COPD)/X.P. Bocca Ruiz, C. Xavier, Buenos Aires, Argentina, p.A7056

P540 Criterion Validity of Hand-Held Dynamometry to Assess Quadriceps Strength in Patients with Lung Disease/C. Burtin, J. De Brandt, M.A. Spruit, Diepenbeek, Belgium, p.A7057

P541 Comparison of Calculated and Measured Peak Oxygen Uptake in COPD/M. Tomatore, R.J. Perez, D. Datta, R. Wu, Farmington, CT, p.A7058

P542 Age Related Changes in Cardiopulmonary Exercise Test and Exercise Echocardiography of the Pulmonary Circulation in Adolescents/F. Kevin, Y. Motoji, V. Faoro, R. Naeije, Brussels, Belgium, p.A7059


P545 Reentry High Altitude Pulmonary Edema After Chest Trauma/C. Ebert-Santos, Frisco, CO, p.A7062

Facilitator: L. Vanfleteren, MD, PhD, Horn, Netherlands


P551 ‘Let’s Start the Conversation?’ - The Perspectives of Health Care Professionals on Physical Activity Prescription for People with COPD/A. Lahham, C. McDonald, A. Burge, A.E. Holland, Melbourne, Australia, p.A7068

P552 Interventions for Promoting Physical Activity in People with Chronic Obstructive Pulmonary Disease (COPD): A Cochrane Systematic Review/A. Burge, N. Cox, M. Abramson, Holland, A.E. Melbourne, Australia, p.A7069

Facilitator: H. Demeyer, PT, MSc, Leuven, Belgium


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.

ATS 2018 • San Diego, CA
### THEMATIC POSTER SESSION

**D52 DECONSTRUCTING TUMORS AND MALIGNANCIES**

<table>
<thead>
<tr>
<th>Session Time</th>
<th>Location</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:15 a.m. - 3:30 p.m.</td>
<td>Area D (Hall A-B2, Ground Level)</td>
<td>Out-Clinic Pulmonary Rehabilitation on the Basis of Pedometer Intervention to Ameliorate Daily Physical Activity and QOL in Patients with Stable COPD</td>
<td>Y. Sano, R. Matsuoka, Y. Sato, S. Kimura, S. Mihara, H. Kurosawa, Tokyo, Japan</td>
</tr>
<tr>
<td>9:15 a.m. - 3:30 p.m.</td>
<td>Area D (Hall A-B2, Ground Level)</td>
<td>The Trajectory of Physical Activity Following Outpatient Pulmonary Rehabilitation</td>
<td>P. Chandrika, C.L. Rochester, L. Nici, L. Trow, E. Swart, T. Tucker, R.L. ZuWallack, Hartford, CT</td>
</tr>
<tr>
<td>9:15 a.m. - 3:30 p.m.</td>
<td>Area D (Hall A-B2, Ground Level)</td>
<td>Do Plasma Levels of Biomarkers Reflect Muscle Injury in Patients Admitted to the Floors in Acute Care Hospitals?</td>
<td>B.H. Reynolds, E. Martin, A. Williams, B. Akpa, J. Ferris, R.E. Heidel, S. Baveja, R. Dhand, Knoxville, TN</td>
</tr>
</tbody>
</table>

**THEMATIC POSTER SESSION**

**D52 DECONSTRUCTING TUMORS AND MALIGNANCIES**

<table>
<thead>
<tr>
<th>Session Time</th>
<th>Location</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:15 a.m. - 3:30 p.m.</td>
<td>Area D (Hall A-B2, Ground Level)</td>
<td>Out-Clinic Pulmonary Rehabilitation on the Basis of Pedometer Intervention to Ameliorate Daily Physical Activity and QOL in Patients with Stable COPD</td>
<td>Y. Sano, R. Matsuoka, Y. Sato, S. Kimura, S. Mihara, H. Kurosawa, Tokyo, Japan</td>
</tr>
<tr>
<td>9:15 a.m. - 3:30 p.m.</td>
<td>Area D (Hall A-B2, Ground Level)</td>
<td>The Trajectory of Physical Activity Following Outpatient Pulmonary Rehabilitation</td>
<td>P. Chandrika, C.L. Rochester, L. Nici, L. Trow, E. Swart, T. Tucker, R.L. ZuWallack, Hartford, CT</td>
</tr>
<tr>
<td>9:15 a.m. - 3:30 p.m.</td>
<td>Area D (Hall A-B2, Ground Level)</td>
<td>Do Plasma Levels of Biomarkers Reflect Muscle Injury in Patients Admitted to the Floors in Acute Care Hospitals?</td>
<td>B.H. Reynolds, E. Martin, A. Williams, B. Akpa, J. Ferris, R.E. Heidel, S. Baveja, R. Dhand, Knoxville, TN</td>
</tr>
</tbody>
</table>

**THEMATIC POSTER SESSION**

**D52 DECONSTRUCTING TUMORS AND MALIGNANCIES**

<table>
<thead>
<tr>
<th>Session Time</th>
<th>Location</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:15 a.m. - 3:30 p.m.</td>
<td>Area D (Hall A-B2, Ground Level)</td>
<td>Out-Clinic Pulmonary Rehabilitation on the Basis of Pedometer Intervention to Ameliorate Daily Physical Activity and QOL in Patients with Stable COPD</td>
<td>Y. Sano, R. Matsuoka, Y. Sato, S. Kimura, S. Mihara, H. Kurosawa, Tokyo, Japan</td>
</tr>
<tr>
<td>9:15 a.m. - 3:30 p.m.</td>
<td>Area D (Hall A-B2, Ground Level)</td>
<td>The Trajectory of Physical Activity Following Outpatient Pulmonary Rehabilitation</td>
<td>P. Chandrika, C.L. Rochester, L. Nici, L. Trow, E. Swart, T. Tucker, R.L. ZuWallack, Hartford, CT</td>
</tr>
<tr>
<td>9:15 a.m. - 3:30 p.m.</td>
<td>Area D (Hall A-B2, Ground Level)</td>
<td>Do Plasma Levels of Biomarkers Reflect Muscle Injury in Patients Admitted to the Floors in Acute Care Hospitals?</td>
<td>B.H. Reynolds, E. Martin, A. Williams, B. Akpa, J. Ferris, R.E. Heidel, S. Baveja, R. Dhand, Knoxville, TN</td>
</tr>
</tbody>
</table>


P276 MiRNA-3670 and miR-8078 Induce the Apoptosis Mediated by SERPINB5 in Lung Cancers/T. Lee, J. Rye, E.J. Im, J. Park, S.I. Yoon, H.-O. Park, Daejeon, Korea, Republic of, p.A7097


P279 Frequency of the Promoter Polymorphism MMP2 -1306 CT in Misteto Ecuadorian Population: Implications in Lung Cancer Development/A. Aguirre, Quito, Ecuador, p.A7100

P280 The Receptor for Advanced Glycation End Products Enhances Tumor Metastasis to the Lungs/E. Beck, T. Huecksteadt, L. Hubbard, T. Wuren, K.A. Sanders, J.R. Hoidal, Salt Lake City, UT, p.A7101

Facilitator: A.A. Balekian, MD, MS, Los Angeles, CA


P283 PD-L1 as a Potential Therapeutic Target for Patients with Advanced or Radio-therapy-Pamargi Pulmonary Lymphangioleiomyomatosis (LAM)/V.P. Krymskaya, Philadelphia, PA, p.A7104


P287 Src Activation is Critical for KRAS-Dependent Regulation of Human Airway Basal Cell Differentiation into Secretory and Ciliated Cells/F. Ogawa, M.S. Walters, R.G. Crystal, New York, NY, p.A7108

P288 Translationally Controlled Tumour Protein: A Novel Therapeutic Target for Lymphangioleiomyomatosis?!/M. Ho, M.S.H. Ho, D.J. Stewart, Ottawa, Canada, p.A7109

P289 Genetic Features of Metastatic Tsc2-Null Cells: Relevance to Pulmonary LAM/K. Obraztsova, R. Rue, E.N. Atochina-Vasserman, C.J. Guo, A. Gow, V.P. Krymskaya, Philadelphia, PA, p.A7110


P291 Primary Lung Cancer Cell Culture from Samples of Transtracheal Needle Biopsy/M.J. Fernández-Sánchez, A.P. Rojas, A. Cañas, A. Herreño, A.M. Mejía, O.M. Moreno, L. Rey, F.J. Busto, M. Montecino, Bogotá, Colombia, p.A7793


P293 PP2A Functions as a Tumor Suppressor in Lung Adenocarcinoma/J. Zhang, L. Zhang, J. Li, Z. Su, Y. Xu, X. Lv, Changchun District, China, p.A7795


P1350  Decreased SIRT-1 Impairs HIF-1a Nuclear Translocation in Response to Hypoxia: A Potential Mechanism of Emphysema/M. To, N. Honda, A. Hitani, I. Kano, K. Ito, K. Haruki, Saitama, Japan, p.A7118

P1351  FPRs Inhibition Halts Chronic Lung Inflammation and Disease Progression that Follow Smoking Cessation in a Preclinical Model of COPD/D. DeCunto, B. Bartalesi, E. Cavarra, E. Balzano, G. Lungarella, M. Lucattelli, Siena, Italy, p.A7119

P1352  Chronic Obstructive Pulmonary Disease Biomarker Research Using the Word Embedding/D.H. Moon, J. Park, S.S. Han, J. Heo, Y. Hong, Chuncheon-si, Korea, Republic of, p.A7120

Facilitator: S.V. Raju, BPharm, PhD, Birmingham, AL


P1357  Proteasomal Degradation of Histone Protein Arginine Methyltransferases (PRMT6) Mediated by F-Box Protein FBW17 Promote Cigarette Smoke Extract Induced Epithelial Cell Death/X. He, T. Li, L. Chen, H. Zeng, Y. Chen, Changsha, China, p.A7125


P1359  A Comprehensive Repository of AATD Patient-Specific Induced Pluripotent Stem Cells with Detailed Clinical Phenotyping for Translational Research/A.A. Wilson, J.E. Kaserman, K.J. Hurley, M. Dodge, M. Higgins, E. Meninno, J.C. Jean, M.F. James, G. Mostoslavsky, D.N. Kotton, Boston, MA, p.A7127


P1361  Recombinant Alpha-1-Antitrypsin (AAT) ZZ Mutant Among Other Mutants Activity Against Different Serine Proteinase/S. Kim, Seoul, Korea, Republic of, p.A7129

Facilitator: D.L. DeMeo, MD, Boston, MA


P1364  Inhibition of Calpain Attenuates Airway and Pulmonary Vascular Remodeling in COPD/I. Zhu, W. Han, Y. Su, Yichang, China, p.A7132


P1367  Potential Platelet Phospholipid Fatty Acid Biomarkers in Chronic Obstructive Pulmonary Disease and Asthma. A Comparison with Lung Cancer Patients/M. C. Rodriguez, P. Sanchez, J. Sanchez, Salamanca, Spain, p.A7135


P1370 Exogenous Shh Protein Protects Bone Marrow-Derived Endothelial Progenitor Cells from Decreased Proliferation Induced by Cigarette Smoke Extract/Y. Zhao, A. Zhou, P. Chen, Changsha, Hunan Province, China, p.A7138


P1372 Cigarette Smoking Induced Elevated CXCL5/ENA-78 Levels in Bronchoalveolar Lavage Fluid and Plasma of Patients with Chronic Obstructive Pulmonary Disease/J. Chen, T. Wang, L. Dai, F. Wen, Chengdu, China, p.A7140


P1374 Azithromycin Restores Cigarette Smoke-Induced HDAC2 Decrease in THP-1 Cells/C. Tan, Y. Wu, L. Xuan, R. Zhao, Q. Hou, H. Wang, Beijing, China, p.A7142


P1376 Cigarette Smoke Condensate Induces the Glycolysis and Pentose Phosphate Pathways in Normal Airway Epithelial Cells/X. Ji, Atlanta, GA, p.A7144


P1379 The Changes in Proliferation and Differentiation Potentials of Alveolar Type 2 Cells in Cigarette-Smoke Induced Emphysema in Mice/A. Tsutsumi, M. Ozaki, K. Sakurai, H. Irie, N. Kameyama, S. Chubachi, A.E. Hegab, T. Betsuyaku, Tokyo, Japan, p.A7147


P1383 Pharmacological Inhibition of Poly ADP-Ribose Polymerase Ameliorates Elastase Induced Inflammation and Emphysema in Mice/A.S. Naura, V. Dharwal, Chandigarh, India, p.A7151


P1385 The 1392 A>G Polymorphism in the Gene of the Nicotinic Receptor Subunit Alpha 5 (CHRNA5) and Susceptibility to Developing Chronic Obstructive Pulmonary Disease/S. Jodra, V. Guevara-Velázquez, M.A. Hernández, J. Ramos, R. Cordovilla, J. Vallejo, E. Bueno, R. González, M. Barrueco, Salamanca, Spain, p.A7153


P1387 Increased Free Desmosine May Be an Early Indicator of Pulmonary Emphysema/J. Cantor, A. Ochoa, S. Ma, X. Liu, Y.Y. Lin, G. Turino, Queens, NY, p.A7155


---

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.


P1395  Role of MiR-126 on Lung Endothelial Signaling During CS Exposure/D. Cao, K. Schweitzer, M.J. Justice, I. Petrache, Denver, CO, p.A7798

THEMATIC POSTER SESSION

D54  INTERPLAY OF DIVERSE CELLULAR AND MOLECULAR PATHWAYS IN ASTHMA AND AIRWAY DISEASE

9:15 a.m. - 3:30 p.m.  SAN DIEGO CONVENTION CENTER

Area L (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion. 12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator:  N.M. Weathington, MD, PhD, Pittsburgh, PA


P1399  Targeting Sphingosine Kinase 2 to Reverse Airway Smooth Muscle Thickening in Asthma/D. Marsolais, P. Blais Lecours, Quebec, Canada, p.A7163

P1400  The Receptor for Advanced Glycation Endproducts Is a Critical Mediator of Type 2 Cytokine Signaling in Mice and Primary Human Cultures/T.N. Perkins, R.E. Dutz, T.D. Oury, Pittsburgh, PA, p.A7164


P1403  The Role of Asthma Risk Genotypes on Bronchial Epithelial Expression of IL33 and ST2 Following Asthma Relevant Stimulation/M.A. Portelli, S. Johnson, D. Shaw, C. Brightling, I. Sayers, Nottingham, United Kingdom, p.A7167


Facilitator:  X. Sun, PhD, San Diego, CA


Establishing a Primary Epithelial Cell Model to Investigate the Genomic Response To Corticosteroids In Airway Smooth Variants of NFE2L2 Associated with Susceptibility to Intrinsic Inflammatory and Innate Immune Gene Profiling in NLRC4 Gene Variants Are Associated with mRNA Expressino Efficacy of Mucolytic Treatment in Decreasing Airway Defect in Translational Control Leads to Hyperresponsive Facilitator: S.V. Raju, BPharm, PhD, Birmingham, AL

The Role of Beta-Catenin/CREB Binding Protein (CBP) - Dependent Signalling in Airway Epithelial Barrier Function and CCL20 Release/V. N.S. Kuchibhotla, D.A. Knight, M.C. Nawijn, I.H. Heijink, Groningen, Netherlands, p.A7178


Variants of NFE2L2 Associated with Susceptibility to Asthma/M. Zhang, J.-Q. He, Chengdu, China, p.A7183


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
Facilitator: B.J. Smith, PhD, Aurora, CO

P1311 Mitochondrial DNA Variation Regulates Susceptibility to Hyperoxic Lung Injury/J. Kandasamy, G. Rezoniew, S. Ballinger, N. Ambalavanaran, Birmingham, AL, p.A7801


P1316 Revisiting Atelectasis on 100% O2 in Lung Units with Low Ventilation/Perfusion Ratios/J.P. Butler, A. Malhotra, S.H. Loring, Boston, MA, p.A7231

P1317 Respiratory Mechanics and Exubation Outcomes in Mechanically Ventilated Patients: A Descriptive Analysis/F. Kukhon, A. Chahin, F.D. McCool, Pawtucket, RI, p.A7232


THEMATIC POSTER SESSION

D56 WHAT'S NEW IN LUNG INFECTION: BACTERIAL, VIRAL, AND FUNGAL

9:15 a.m. - 3:30 p.m. SAN DIEGO CONVENTION CENTER

Area A (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: E.T. Osei, PhD, Vancouver, Canada


P26 Key Role for TLR2 in Bacterial Activation of Airway Sensory Nerves/M.A. Wotton, J.J. Adcock, E.D. Dubuis, S.J. Bonvini, M.A. Birrell, M.G. Belvisi, London, United Kingdom, p.A7239


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
P28  HIV infection and Smoking: Functional PET Imaging to Determine Early Pulmonary Perfusion Changes in Individuals Susceptible to COPD/I. Kohli, T. Winkler, M. Kone, V.J. Kelly, K. Hibbert, C. Bjorn, J.L. Cho, D. Kwon, B.D. Medoff, R.S. Harris, Boston, MA, p.A7241

Facilitator: K. Yatera, MD, Kitakyushu, Japan

P29  IRF-7 Modulates RIG-I and Antiviral Responses Through Direct Facilitator: K. Huey, MD, Oklahoma City, OK, p.A7242

P30  Empyema Necessitans in the Modern Era: Systematic Review/T. Hackett, PhD, Vancouver, Canada, p.A7243


THEMATIC POSTER SESSION

D57  LUNG TRANSPLANT: CELLULAR AND PHYSIOLOGICAL INVESTIGATIONS

9:15 a.m. - 3:30 p.m. SAN DIEGO CONVENTION CENTER Area B (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for discussion with assigned facilitators

Facilitator: T.-L. Hackett, PhD, Vancouver, Canada


P79  Neural Respiratory Drive in Lung Transplant Recipients with or without Chronic Lung Allograft Dysfunction/M. Patou, G. Kaltakas, A. Arbane, N.M. Shoh, S. Soresi, N. Hart, P. Marino, A. Simon, M. Carbin, A. Reed, E. Hluillier, P.B. Murphy, London, United Kingdom, p.A7249


P83  Effect of Bilateral Lung Transplantation on Excessive Dynamic Airway Collapse/J. Singh, D. Sese, C.J. Lehr, B.M. Pichurko, A.C. Mehta, Cleveland, OH, p.A7253


THEMATIC POSTER SESSION

D58  AIRWAYS HYPERRESPONSIVENESS: NOVEL MECHANISMS AND TARGETS

9:15 a.m. - 3:30 p.m. SAN DIEGO CONVENTION CENTER Area B (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for discussion 12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitator: W. Zhang, MD, PhD, Indianapolis, IN

P87  Contribution of Calcium-Sensing Receptor to Intracellular Calcium Regulation in Human Fetal Airway Smooth Muscle Cells/A. Mores, K. Cummings, L.J. Manlove, J. Ravix, M.A. Thompson, C.M. Pabelick, R.J. Martin, P. MacFarlane, Y.S. Prakash, Rochester, MN, p.A7256

P88  Calcium Regulation in Pediatric Airway Smooth Muscle Cells/A. Glanvino, M. Thompson, Y.S. Prakash, P. MacFarlane, C.M. Pabelick, Hradec Kralove, Czech Republic, p.A7257
<table>
<thead>
<tr>
<th>Session Code</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P89</td>
<td>Androgen Receptor Signaling and Intracellular Calcium Regulation in Human Airway Smooth Muscle Cells</td>
<td>R. Katragadda, N.A. Borkar, M.A. Thompson, C.M. Pabelick, Y.S. Prakash, S. Venkatachalam</td>
</tr>
<tr>
<td>P90</td>
<td>Differential Estrogen Receptor Signaling Regulates Store Operated Calcium Entry in Human Airway Smooth Muscle</td>
<td>R.S.R. Kalidhindi, N.S. Ambhore, M. Thompson, C.M. Pabelick, Y.S. Prakash, S. Venkatachalam</td>
</tr>
<tr>
<td>P91</td>
<td>Alpha- and Beta-Parvin Isoforms Regulate Phenotype Switching in Canine Airway Smooth Muscle</td>
<td>Y. Huang, S.J. Gunst, Indianapolis, IN</td>
</tr>
<tr>
<td>P92</td>
<td>Arrestins Differentially Regulate OGR1 Signaling in Airway Smooth Muscle Cells</td>
<td>T. Pera, E. Tompkins, D.A. Dshpande, A.P. Nayak, R.B. Penn, Philadelphia, PA</td>
</tr>
<tr>
<td>P93</td>
<td>Unraveling the Signaling Pathways Involved with the Pro-Inflammatory Features of Oxidized Phosphatidylcholine in Airway Smooth Muscle</td>
<td>C. Pascoe, M. Ragheb, G.L. Stelmack, A. Jha, J. Kindrachuk, A.J. Halayko, Winnipeg, Canada</td>
</tr>
<tr>
<td>P95</td>
<td>The Role of Protein Arginine N-Methyltransferase 1 (PRMT1) in Inflammatory Gene Expression of Airway Smooth Muscle Cells in Asthma</td>
<td>K.A. Kaczmarek, R.L. Clifford, J. Patel, D. Shaw, J. Dowden, A.J. Knox, Nottingham, United Kingdom</td>
</tr>
<tr>
<td>P96</td>
<td>Targeted Gene Therapy to Deplete Airway Smooth Muscle</td>
<td>S. Ram-Mohan, C. Da Silva, S. Yao, Y. Bai, B. Wojcik, X. Ai, C. Ferran, R. Krishnan, Boston, MA</td>
</tr>
<tr>
<td>P97</td>
<td>Role of KISS1/GPR54 Signaling in PDGF Induced Human Airway Smooth Muscle Remodeling</td>
<td>S.J. MacAlinden, B. Oliver, M. Hagg, P. Sharma, Sydney, Australia</td>
</tr>
<tr>
<td>P98</td>
<td>Autophagy Is Selectively Activated and Correlated with Airway Remodeling in Asthma</td>
<td>K. Kaczmarek, R.L. Clifford, J. Patel, D. Shaw, J. Dowden, A.J. Knox, Nottingham, United Kingdom</td>
</tr>
<tr>
<td>P100</td>
<td>Modulation of Airway Smooth Muscle Phenotype Through Physical Contact with CD4+ T-Cells</td>
<td>J.H. Jang, S. Farahnak, R. Sharan, A. Wang, J.G. Martin, Montreal, Canada</td>
</tr>
<tr>
<td>P101</td>
<td>Free Fatty Acid Receptors 1 and 4 Mediate Desensitisation-Resistant Bronchodiilation and Are Expressed in Asthmatic Airways</td>
<td>J.E. Bourke, R. Angeles, C. Donovan, S. Royce, M. Lam, Clayton, Australia</td>
</tr>
<tr>
<td>P102</td>
<td>Inhibition of Viral Infection-Induced Inflammatory Responses by Targeting the CLOCK Regulator Casein Kinase 1</td>
<td>M. Li, S.Y. Langenbach, C. Keenan, Y.C. Xia, T. Harris, A. Stewart, Melbourne, Australia</td>
</tr>
</tbody>
</table>

**THEMATIC POSTER SESSION**

**D59 CASE REPORTS IN SLEEP DISORDERS**

**9:15 a.m. - 3:30 p.m.**

**SAN DIEGO CONVENTION CENTER**

**Area F (Hall A-B2, Ground Level)**

**Viewing**: Posters will be on display for entire session.

**Discussion**: 11:15-12:00: authors will be present for individual discussion 12:00-1:00: authors will be present for discussion with assigned facilitators

**Facilitator**: H.-L. Tan, MBBS, London, United Kingdom


Facilitator: M.A. Tamee Kakazu, MD, Grand Rapids, MI

P564 Hypoglossal Nerve Stimulator Dysfunction Following Cardioversion/D.S. Imanirad, K. Calero, Tampa, FL, p.A7283


Facilitator: P.E. Brockmann, MD, Santiago, Chile

P567 Delayed Sleep-Wake Phase Disorder and a New College Roommate/H. Baig, B. Colaco, Jacksonville, FL, p.A7286

P568 Blue Rubber Bleb Nevus Syndrome: A Rare Cause of Obstructive Sleep Apnea/F.-A. Vézina, Sherbrooke, Canada, p.A7287

P569 Abrupt Onset of Early Morning Parasomnias in an Adult with Untreated Obstructive Sleep Apnea: Sometimes It is a Zebra/O. Sever, D. Maehara, E. Valladares, T.C. Hammond, Los Angeles, CA, p.A7288


P574 Hypersomnia in Cancer Patients Based on Multiple Sleep Latency Testing/N. Cassell, D.D. Balachandran, L. Bashoura, S.A. Faiz, Houston, TX, p.A7292


P310 The eXcelon Transbronchial Aspiration Needle: Assessing Safety and Diagnostic Yield for Use with Radial Ultrasound-Guided Peripheral Lung Lesion Sampling/P.H. Hanneman, K.J. Diab, Indianapolis, IN, p.A7311

P311 Bronchoscopic Interventions for Malignant Central Airway Obstruction: A Prospective Clinical Profile and Outcome Assessment in a Tertiary Centre of North India/A. Mohan, P. Shreshta, K. Madan, V. Hadda, R. Guleria, G. Khilnani, R.M. Pandey, New Delhi, India, p.A7312


Facilitator: C. Argento, MD, Chicago, IL


Facilitator: Y.B. Gesthalter, MD, Boston, MA

P322 Endobronchial Ultrasound-Guided Transvascular Needle Aspiration (EBUS-TVNA), Ten Years of Experience and Success/M.M. Rachid, E. Mekhaiel, Oak Lawn, IL, p.A7323


P325 Negative Predictive Value of Endobronchial Ultrasound Guided Needle Aspiration of Mediastinal and Hilar Lymph Nodes/M. Frohlich, H. Wang, C. Robitaille, L. Sakr, Montreal, Canada, p.A7326


P331 Prognostic Value of Systemic Immune Inflammation Index in Advanced Non Small Cell Lung Cancer/L. Dan, Y. Xia, Y. He, L. Weimin, Chengdu, China, p.A7331


P333 C-Reactive Protein to Albumin Ratio as a Prognostic Factor in Lung Cancer/J. Jin, D. Liu, Y. Zhou, Chengdu, China, p.A7333

P334 Correlations of Tumor Stage and Serum Tumor Markers with Age in Nonsmoking Females with Lung Adenocarcinoma/Y. Gan, P. Zhou, W. Li, Chengdu, China, p.A7334


P336 The Role of Serum and Tissue YKL-40 in Lung Cancer/D. Wang, X. Tong, H. Fan, Chengdu, China, p.A7336


Facilitator: L.M. Kamman, MD, St. Paul, MN


P342 The Higher Prevalence of Epidermal Growth Factor Receptor Mutation in the Male Patients of Lung Adenocarcinoma in Makassar, Indonesia/A. Santoso, S. Munwarrah, Makassar, Indonesia, p.A7342


P345 Analysis of the Pathological Distribution of Lung Cancer and Survival Trends in Lincolnshire Over a 2 Year Period/M.N. Okoye, Boston, United Kingdom, p.A7345


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
P351 Evaluation of 8th TNM Staging System in a Retrospective Cohort of Patients with Early Stage Non-Small Cell Lung Cancer Who Received Adjuvant Chemotherapy/A. Ozcan, D. Koksal, O.S. Kosan, S. Sarinc Ulusli, H. Bayiz, Y. Agackiran, G. Findik, Ankara, Turkey, p.A7351


P353 Molecular Testing of Lung Cancer/A. Trabolsi, E. Rodriguez, Miami Beach, FL, p.A7353

P354 Is Advanced Age a Prognostic Factor for Adjuvant Chemotherapy in Completely Resected Non-Small-Cell Lung Cancer (NSCLC)?/O. Batum, C. Anar, Y. Ozdogan, S. Ermin, U. Yilmaz, Izmir, Turkey, p.A7354

THEMATIC POSTER SESSION

D63 DETECTION AND DIAGNOSIS: THE TWO “D’s” OF THORACIC ONCOLOGY

9:15 a.m. - 3:30 p.m. SAN DIEGO CONVENTION CENTER Area D (Hall A-B2, Ground Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:15-12:00: authors will be present for individual discussion
12:00-1:00: authors will be present for discussion with assigned facilitators

Facilitators: P.R. Montgrain, MD, San Diego, CA


P357 Imaging Characteristics of Thymic Hyperplasia as Compared to Benign Thymic Tissue in Patients with Myasthenia Gravis/A. Mitchell, A. Yen, E. Weihe, P. Thistlethwaite, S. Brouha, La Jolla, CA, p.A7356


BEHAVIORAL • CLINICAL WORKSHOP

WS7 DELIVERING PULMONARY REHABILITATION ACROSS THE SPECTRUM OF CARE FROM HOSPITAL TO COMMUNITY

Registration Fee: $75 (includes box lunch)
Attendance is limited. Pre-registration is required.

Assemblies on Pulmonary Rehabilitation; Clinical Problems; Nursing
11:45 a.m. - 1:15 p.m. SAN DIEGO CONVENTION CENTER Room 9 (Upper Level)

Target Audience
Clinicians involved with mobilization, discharge planning, and rehabilitation of patients of patients with respiratory conditions in locations ranging from the ICU to home

Objectives
At the conclusion of this session, the participant will be able to:
• describe examples of delivery of rehabilitation in different locations and in different systems;
• offer examples of system strategies and resources to offer to your patient;
• increase awareness of rehabilitative services available to pulmonary patients among health care providers throughout the continuum of care.

There is an increasing body of literature identifying improvements in outcomes such as length of stay, functional status and reduction in re admissions with the use of rehabilitation programs when they are carefully and appropriately implemented in a variety of settings ranging from the ICU to outpatient rehabilitation programs. This session provides a view of how to apply these studies in a range of health care systems and locations.

Chairing: E.P. Riesenfeld, MD, Cooperstown, NY
R.H. Crouch, DPT, MS, PT, Buies Creek, NC

11:45 Pulmonary Rehabilitation
R.H. Crouch, DPT, MS, PT, Buies Creek, NC
12:00 Pittsburgh Readmission Efforts
B.W. Carlin, MD, Sewickley, PA

12:10 Multiple Resources in a Rural Health Care Network
E.P. Riesenfeld, MD, Cooperstown, NY

12:20 Outpatient Resources Including VNA and PT and Finances
K. Hyden, MSN, MEd, APN-BC, ACHPN, Denver, CO

12:35 Inpatient Rehabilitation
R.S. Novitch, MD, White Plains, NY

12:45 Early Rehabilitation in the ICU
C.T. Hough, MD, MSc, Seattle, WA

WS8 SHOULD THIS STUDY CHANGE MY PRACTICE? SKILLS FOR ADEPT APPRAISAL OF CRITICAL CARE LITERATURE

Registration Fee: $75 (includes box lunch)
Attendance is limited. Pre-registration is required.

Assemblies on Critical Care; Behavioral Science and Health Services Research
11:45 a.m. - 1:15 p.m. SAN DIEGO CONVENTION CENTER
Room 10 (Upper Level)

Target Audience
Critical care practitioners and trainees who wish to improve their ability to assess and apply clinical studies and non-intensivist clinicians as the principles are broadly applicable

Objectives
At the conclusion of this session, the participant will be able to:
• understand features of observational studies, clinical trials, and meta-analyses that impact the quality of evidence;
• systematically evaluate clinical studies using validated tools;
• navigate challenges in applying clinical to an individual patient.

The goal of the session is to enhance the ability of critical care practitioners to systematically examine and apply clinical studies. Lectures will address core concepts in critical appraisal of observational studies, clinical trials, and meta-analyses. Guided by an expert panel, participants will use validated and publicly available frameworks to analyze two pre-read critical care publications. The session will conclude with a synopsis of the learning objectives and discussion of challenges encountered when applying research findings to individual patients.

Chairing: E.A. Vail, MD, San Antonio, TX
L.K. Vande Vusse, MD, MSc, Seattle, WA
R.S. Wiener, MD, MPH, Boston, MA

11:45 Principles of Appraising Clinical Research
E.A. Vail, MD, MSc, San Antonio, TX

11:55 Common Challenges with Clinical Trials and Meta-Analyses
D.C. Scales, MD, PhD, Toronto, Canada

12:15 Common Challenges in Interpreting Observational Studies
A.J. Walkey, MD, MSc, Boston, MA

12:35 Practice with Literature Appraisal Tools
M.J. Lanspa, MD, MSCR, Salt Lake City, UT
A.J. Walkey, MD, MSc, Boston, MA
R.S. Wiener, MD, MPH, Boston, MA
H.B. Gershengorn, MD, Miami, FL
C. R. Cooke, MD, Univ of Michigan, Ann Arbor, MI

1:05 To the Bedside: Pitfalls in Applying Clinical Research to Our Patients
C.Summers, BSc(Hons), BM, PhD, MRCP, Cambridge, United Kingdom

CC5 PULMONARY CLINICAL CORE CURRICULUM I
11:45 a.m. - 1:15 p.m. SAN DIEGO CONVENTION CENTER
Room 15 A-B (Mezzanine Level)

Target Audience
Practicing internists and subspecialists in Pulmonary, Critical Care, and Sleep medicine who work in a clinical setting and are currently engaged in maintenance of certification

Objectives
At the conclusion of this session, the participant will be able to:
• remain current with medical knowledge relevant to their practice in pulmonary, critical care, and sleep medicine;
• evaluate their understanding of key skills and content areas in pulmonary, critical care and sleep medicine, as well as receive feedback on their comprehension of a result of a pre-test/post-test comparison;
• support clinicians who are engaged in maintenance of certification activities by providing updates on subjects included in recertification requirements.

The ATS Clinical Core Curriculum Symposia focus on a 3-year content cycle of key medical content in the areas of Pulmonary, Critical Care, and Sleep Medicine. The topics are also aligned with corresponding MOC Medical Knowledge modules. This symposium is intended to assist clinicians with staying current with the growth of information relevant to their medical practice, as well as provide an opportunity to evaluate individual knowledge and skills while earning MOC Medical Knowledge points.

Chairing: J.L. Cho, MD, Denver, CO

11:45 Manifestations and Diagnosis of Connective Tissue Disease-Associated Interstitial Lung Disease
J. Solomon, MD, Denver, CO

12:15 Diagnosis and Management of Interstitial Lung Disease-Associated Pulmonary Hypertension
K.A. Smith, MD, Philadelphia, PA

12:45 Inherited Diffuse Parenchymal Lung Diseases
J.J. Swigris, DO, MS, Denver, CO
**CENTERS FOR DISEASE CONTROL AND PREVENTION**

**L21** PREVENTING HALF A MILLION ASTHMA-RELATED EMERGENCY DEPARTMENT VISITS AND HOSPITALIZATION IN CHILDREN  
12:15 p.m. - 1:15 p.m.  
Room 14 A-B (Mezzanine Level)  
SAN DIEGO CONVENTION CENTER

**Target Audience**  
Those serving pediatric populations; those who work across multiple sectors, such as health care, schools or public health; those who work with multidisciplinary asthma programs

**Objectives**  
At the conclusion of this session, the participant will be able to:  
- learn more about evidence based interventions in children with asthma;  
- understand the relationship between public health and health care to help reduce the burden of asthma;  
- learn about a major initiative at the CDC.

CDC’s National Asthma Control Program started a new initiative focused on reducing the number of hospitalizations and emergency room visits among children with asthma called CCARE (Controlling Childhood Asthma Reducing Emergencies). Our goal is to reduce emergency department and hospitalization visits for children by half a million in five years. We plan to do this by promoting public health and health care collaboration and asthma self-management education (AS-ME), extinguishing second hand smoke, home visits with AS-ME, guidelines-based medical management and asthma-friendly policies. We plan to promote interventions across sectors, and linkages between programs and clinicians.

**Chairing:**  
P.L. Garbe, DVM, Atlanta, GA  
12:15 CCARE 101  
K. Sircar, PhD, MPH, Chamblee, GA

12:30 Perspective on State Public Health Asthma Program  
C. Bailey, PhD, Atlanta, GA

12:45 Linkages: An Opportunity to Improve Asthma Care  
S.F. Beavers, MD, Chamblee, GA

**DEPARTMENT OF VETERANS AFFAIRS**

**L22** VETERANS HEALTH STUDIES AND PROGRAMS IN PULMONARY DEPLOYMENT HEALTH  
12:15 p.m. - 1:15 p.m.  
SAN DIEGO CONVENTION CENTER  
Room 7 A-B (Upper Level)

**Target Audience**  
Pulmonary providers; those needing instruction in areas of medicine outside of their primary specialty; new and established investigators

**Objectives**  
At the conclusion of this session, the participant will be able to:  
- learn new findings about military deployment-related exposures that is the focus of VA and DoD research programs;  
- learn about VA and DoD research program and projects and research opportunities regarding Veterans pulmonary health;  
- apply new knowledge regarding deployment health to the practice of pulmonary medicine.

There are over 2.5 million US Veterans with deployments to Iraq, Afghanistan, Kuwait, and other Southwest Asian countries. Those with land-based deployments were exposed to high levels of particulate matter from dust storms, burn pit smoke (i.e., smoke from solid waste combustion at US bases), and unregulated industrial and vehicular sources. This session will outline the pulmonary health conditions and exposures that are being assessed by Department of Defense (DoD) and VA funded investigators. The session will provide insight into resources and programs available to stimulate additional research in respiratory hazards and deployment health.

**Chairing:**  
E. Garshick, MD, West Roxbury, MA  
J.K. Brown, MD, San Francisco, CA

12:15 Overview of Deployment Health Research  
E. Garshick, MD, West Roxbury, MA

12:20 Assessment of Respiratory Hazards in Deployed Military Personnel  
C. Baird, MD, MPH, Gunpowder, MD

12:31 Clinical findings in Veterans and the VA Airborne Hazards and Open Burn Pit Registry  
M.J. Falvo, PhD, East Orange, NJ

12:42 Deployment-Related Lung Diseases and Noninvasive Markers of Effects on Small Airways  
S.D. Krefft, MD, MPH, Denver, CO

12:53 Va and DoD-Based Veteran and Military Epidemiology Programs  
R. Rull, PhD, San Diego, CA

1:04 VA Merit Review, Cooperative Studies, Million Veteran Program, and Deployment Health  
K. Myrie, PhD, Washington, DC

**NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH**

**L23** UPDATE ON WORK-RELATED AIRWAYS DISEASE  
12:15 p.m. - 1:15 p.m.  
SAN DIEGO CONVENTION CENTER  
Room 1 A-B (Upper Level)

**Target Audience**  
those with an interest in preventing, caring for, or doing research to address work-related airways disease

**Objectives**  
At the conclusion of this session, the participant will be able to:  
- recognize relationships between work exposures and asthma and the implications of work-related asthma for severity of disease;  
- recognize and follow up on histories of occupational exposures potentially associated with work-related small airways disease.

**ATS 2018 • San Diego, CA**

*The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.*
This session will provide an update on a range of current topics in work-related airways disease. These will include an update on the national burden of work-related asthma as indicated by NIOSH surveillance, emerging issues in work-related small airways diseases such as obliterative bronchiolitis, and the role of forced oscillation testing in providing diagnostic information about small airways disease beyond that provided by standard assessment using spirometry.

Chairing: D.N. Weissman, MD, Morgantown, WV

12:15 Burden of Work-Related Airways Disease: Findings From National Surveillance
J. Mazurek, MD, PhD, Morgantown, WV

12:35 Emerging Issues in Small Airways Disease
K.J. Cummings, MD, MPH, Morgantown, WV

12:55 Use of Forced Oscillation Testing (FOT) for Investigating Small Airways Disease
K.I. Berger, MD, New York, NY

12:15 NHIR Consortium
S.S. Nadadur, PhD, Durham, NC

12:22 Multiple pathways of exposure to Nanoparticles
K.E. Pinkerton, PhD, Davis, CA

12:38 Biological Response Profiles of Engineered Nanomaterials after Perinatal Inhalation Exposure
Speaker To Be Announced

12:54 Optical Methods for Studying Label Free Nanomaterial Uptake and Toxicology
Speaker To Be Announced

1:10 General Discussion
12:35 Emerging Concepts and New Technologies for Bioequivalence of Orally Inhaled and Nasal Drug Products
K.A. Witzmann, MD, Silver Spring, MD

12:52 Update for Generic Orally Inhaled and Nasal Drug Products
B. Newman, PhD, Silver Spring, MD

1:09 Questions and Answers
K.A. Witzmann, MD, Silver Spring, MD

DIVISION OF LUNG DISEASES/NHLBI, NIH

L26 ASTHMANET: CURRENT CLINICAL TRIAL RESULTS
12:15 p.m. - 1:15 p.m. SAN DIEGO CONVENTION CENTER
Room 33 A-C (Upper Level)

Target Audience
Clinicians managing asthma

Objectives
At the conclusion of this session, the participant will be able to:
• understand approaches to manage African American patients with asthma;
• learn and understand the relevance of sputum eosinophilia;
• understand the differences in outcomes in African American children and adults with asthma.

Investigators from NHLBI’s multi-site clinical trial network to address asthma management in children and adults will present the results of their recently completed clinical trials. The clinical trials to be presented will include alternative approaches to asthma treatment in specific populations of both children and adults. One of the clinical trials to be discussed will address the approach to asthma management in individuals who self-identify as African American: Best African American Response to Asthma Drugs (BARD). The other clinical trial presented will address asthma management based on one phenotype, Steroids in Eosinophil Negative Asthma (SIENA).

Chairing:
W.W. Busse, MD, Madison, WI
M.M. Freemer, MD, MPH, Bethesda, MD

12:15 Best African American Response to Asthma Drugs (BARD)
M. Wechsler, MD, Denver, CO

12:45 Steroids in Eosinophil Negative Asthma (SIENA)
S.C. Lazarus, MD, San Francisco, CA

1:05 Questions and Answers/Discussion

DIVISION OF LUNG DISEASES/NHLBI, NIH

L27 LESSONS LEARNED FROM NHLBI SPONSORED INHALED PROGRAM: HIV AND AGING
12:15 p.m. - 1:15 p.m. SAN DIEGO CONVENTION CENTER
Room 30 A-B (Upper Level)

Target Audience
Providers of lung health, medical fellows in training, graduate, post-doctoral fellows and established scientists in basic research on lung biology, HIV pathogenesis, and infection disease

Objectives
At the conclusion of this session, the participant will be able to:
• better understand the mechanisms of HIV related lung diseases in the HAART era;
• improve the understanding of the accelerated aging process in the HIV lung;
• learn new findings about the role of the virome, immunosenescence and oxidative stress in the aging lung in the context of HIV infection.

Effective antiretroviral therapy has significantly reduced infectious complications in HIV infection by limiting the loss of immune function and promoting immune reconstitution. However, the decline in infectious complications have been offset by an increased frequency of pulmonary and vascular diseases associated with chronic inflammation. Interestingly, the types of complications seen in HIV infected subjects today mirror those seen in an older non-HIV infected population, leading to the suggestion that HIV infection is a model for premature aging. This session will explore similarities and differences in lung disease found in HIV infected subjects and non-HIV infected aging populations. Potential similar pathogenic mechanisms leading to chronic inflammation will be discussed, including alterations in host immunity resulting in T cell immunosenescence, changes in the lung microbial composition (with a focus on viral changes), and excess oxidative stress. This work suggests a role for studying HIV infection as a potential model for chronic lung diseases found in the normal aging population.

Chairing:
J.F. McDyer, MD, Pittsburgh, PA
E. Caler, PhD, Bethesda, MD

12:15 The Lung Virome, Inflammation, and Lung Complications in HIV Infection
H.L. Twigg, MD, Indianapolis, IN

12:27 Immunosenescence in the HIV Lung and the Aging Lung
A.P. Fontenot, MD, Aurora, CO

12:39 Oxidative Stress in the HIV Lung and Aging Lung
J. Roman, MD, Louisville, KY

12:51 Does the Lung in HIV Infection Structurally or at the Cellular Level Look and Behave Like An “Old” Lung?
R.G. Crystal, MD, New York, NY

1:03 Comparison of Epidemiology of Lung Disease in HIV Infection and Aging Population
J. Atkinson, MD, St. Louis, MO

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
Objectives
At the conclusion of this session, the participant will be able to:

- learn new findings about clinical and molecular phenotypes of severe asthma;
- more appropriately refer to approaches being taken by NHLBI to improve understanding of severe asthma and accelerate progress toward new treatments;
- improve understanding of how the clinical features of severe asthma varies in children and adults.

In this session, on work in progress in the NHLBI sponsored severe asthma research program, there are four presentations planned to provide the learner with a cutting edge, data driven understanding of the clinical features of pediatric and adult severe asthma. Each presentation will cover the context, rationale and recent progress in addressing clinically relevant questions in severe asthma pathobiology, diagnosis and management, including baseline cross-sectional data on recruited healthy and asthmatic subjects, risk factors for asthma exacerbations, and, importantly, the change in pathophysiologic features of disease and phenotypes over time and their association with clinical outcome.

Chairing: S.E. Wenzel, MD, Pittsburgh, PA
T. Croxton, MD, PhD, Bethesda, MD

12:15 Adult 3 Year Longitudinal Follow-up
Nizar N. Jarjour, MD, Univ of Wisconsin Hosps, Madison, WI

12:30 Pediatric 3 Year Longitudinal Follow-up
B.M. Gaston, MD, Cleveland, OH

12:45 SARP Through the Years
S.E. Wenzel, MD, Pittsburgh, PA

1:00 Group Discussion

L29 NEW RESULTS FROM THE COPDGENE STUDY

12:15 p.m. - 1:15 p.m. SAN DIEGO CONVENTION CENTER
Room 32 A-B (Upper Level)

Target Audience
Researchers, medical trainees, those with an interest in COPD pathogenesis

Objectives
At the conclusion of this session, the participant will be able to:

- learn about imaging in the COPDGene study;
- understand and learn about subtypes identified by the COPDGene study;
- learn about longitudinal follow-up in the COPDGene study.

Chronic obstructive pulmonary disease (COPD), the third leading cause of death in the United States, is a heterologous syndrome. The COPDGene study has created the largest cohort of well-characterized current and former smokers for respiratory disease research. The primary goals of COPDGene are: 1) to identify new genetic loci that influence the development of COPD and COPD-related phenotypes and 2) to reclassify COPD into subtypes that can ultimately be used to develop effective therapies. In this session, presenters will discuss new results from the COPDGene study, including protein biomarkers, genetics, and transcriptomics. In addition, presenters will discuss new insights that have developed from the COPDGene study into the diagnosis of prognosis of COPD patients.

Chairing: L. Postow, PhD, Bethesda, MD
J.D. Crapo, MD, Denver, CO
E.K. Silverman, MD, PhD, Boston, MA

12:15 Introduction: Translating COPDGene Results to Clinical Practice
J.D. Crapo, MD, Denver, CO

12:23 Imaging Updates from COPDGene
S.P. Bhatt, Birmingham, AL

12:36 Developing Biomarkers for COPD
C.P. Hersh, MD, MPH, Boston, MA

12:49 Insights into COPD Diagnosis from COPDGene
M.H. Cho, MPH, MD, Boston, MA

1:02 Insights into COPD Prognosis from COPDGene
G. Kinney, MPH, PhD, Aurora, CO

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
**Target Audience**
Practicing internists, subspecialists, registered nurses and advanced practice nurses in pulmonary, critical care, and sleep medicine who work in a clinical setting and are currently engaged in maintenance of certification.

**Objectives**
At the conclusion of this session, the participant will be able to:

- remain current with medical knowledge relevant to their practice in pulmonary, critical care, and sleep medicine;
- evaluate their understanding of key skills and content areas in pulmonary, critical care and sleep medicine, as well as receive feedback on their comprehension of a result of a pre-test/post-test comparison;
- support clinicians who are engaged in maintenance of certification activities by providing updates on subjects included in recertification requirements.

The ATS Clinical Core Curriculum Symposia focus on a 3-year content cycle of key medical content in the areas of Pulmonary, Critical Care, and Sleep Medicine. The topics are also aligned with corresponding MOC Medical Knowledge modules. This symposium is intended to assist clinicians with staying current with the growth of information relevant to their medical practice, as well as provide an opportunity to evaluate individual knowledge and skills while earning MOC Medical Knowledge points.

**Chairing:**
G.W. Garrison, MD, Burlington, VT

1:30 Pulmonary Complications of Neuromuscular Disease
G.T. Bosslet, MD, MA, Indianapolis, IN

2:00 Lung Transplant for Interstitial Lung Disease: Allocation, Preparation, and Outcomes
D. Sayah, MD, PhD, Los Angeles, CA

---

**BEHAVIORAL • CLINICAL • TRANSLATIONAL**

**D82 INTERVENTIONAL APPROACHES TO THE TREATMENT OF OBSTRUCTIVE LUNG DISEASES**

**Assemblies on Clinical Problems; Critical Care; Nursing; Pulmonary Rehabilitation; Respiratory Structure and Function; Thoracic Oncology**

1:30 p.m. - 3:30 p.m.  
**SAN DIEGO CONVENTION CENTER**

**Ballroom 20 B-C (Upper Level)**

**Target Audience**
All clinicians, physicians, registered nurses, advanced practice nurses, residents, fellows, therapists and researchers caring for patients with COPD.

**Objectives**
At the conclusion of this session, the participant will be able to:

- recognize the types of bronchoscopic interventions now available to treat irreversible airways obstruction;
- discuss the need for a multidisciplinary approach to treat a patient with irreversible airways obstruction;
- describe the different levels of lung obstructive disorders- airways obstruction due to asthma vs chronic bronchitis or advanced emphysema and the role of the different techniques to alleviate the separate entities causing airways obstruction.

There have been major advances in diagnostic and therapeutic bronchoscopy over the past decade. New bronchoscopic techniques for the diagnosis and therapy of a range of lung disorders is now possible. One major evolving area of investigation is the treatment of patients with obstructive lung disorders. From asthma to emphysema, chronic bronchitis, central airways obstruction and dynamic large airway collapse selective bronchoscopic therapies to alleviate irreversible airflow obstruction is now possible. This session will review the new bronchoscopic approaches for these different entities.

**Chairing:**
G.J. Criner, MD, Philadelphia, PA
F.J. Herth, MD, Heidelberg, Germany
D. Slebos, PhD, MD, Groningen, Netherlands
P. Shah, MD, London, United Kingdom

1:30 Introduction to Obstructive Lung Diseases Amenable to Bronchoscopic Intervention
G.J. Criner, MD, Philadelphia, PA

1:45 Technical Aspects of Bronchoscopic Interventions to Treat Obstructive Lung Diseases
F.J. Herth, MD, Heidelberg, Germany

2:00 Bronchial Thermoplasty for Treatment of Severe Asthma
D. Gompelmann, MD, Heidelberg, Germany
2:15 Use of Cryotherapy in Chronic Bronchitis
P. Shah, MD, London, United Kingdom

2:30 Targeted Lung Denervation in Irreversible Airways Obstruction
D. Siebos, PhD, MD, Groningen, Netherlands

2:45 Lung Reduction in Advanced Emphysema
F.C. Sciurba, MD, Pittsburgh, PA

3:00 Dynamic Tracheobronchial Collapse
K. Klooster, RN, Groningen, Netherlands

3:15 Central Airways Obstruction
M. Weir, MBChB, Philadelphia, PA

**CLINICAL • TRANSLATIONAL**

**D83 CLINICAL TRIAL DESIGN IN IPF**

Assembly on Clinical Problems

1:30 p.m. - 3:30 p.m. SAN DIEGO CONVENTION CENTER
Ballroom 20 D (Upper Level)

**Target Audience**
Clinicians, researchers, regulatory board members, industry

**Objectives**
At the conclusion of this session, the participant will be able to:

- gain an understanding and appreciation for the basics and design of clinical trial design. They will be expected to learn what constitutes a valid endpoint and surrogate endpoint for clinical trials of IPF and how other endpoints may be validated;
- understand the potential ethical and logistical impact on performing clinical trials in IPF;
- incorporate the lessons learned into the design of innovative randomized controlled trials in the future to study IPF.

While the approval of pirfenidone and nintedanib represents an exciting advancement in the treatment of IPF, many questions remain including whether to initiate therapy, which therapy to choose, how to define drug efficacy given side effect profiles, and how these drugs should be incorporated into trials evaluating new therapies. To answer these questions, careful attention to trial design will be crucial. We will discuss the utility of clinical meaningful and surrogate endpoints in clinical IPF trials, including patient reported outcomes, serum biomarkers, and imaging characteristics. The ethics and logistics of recruiting subjects for trials in the era of antifibrotic drugs will be addressed.

**Chairing:**
M. Porteous, MD, MSCE, Philadelphia, PA
H.R. Collard, MD, San Francisco, CA
K. Anstrom, PhD, Durham, NC

1:30 Feels, Function, Survives: Are Clinically Meaningful Endpoints Feasible in IPF Clinical Trials?
L. Richeldi, MD, PhD, Rome, Italy

1:55 Surrogate Endpoints in IPF: Are They Ready for Prime Time?
Speaker To Be Announced

**2:20 Future of Imaging in IPF for Inclusion and Outcome Assessment**
M. Porteous, MD, MSCE, Philadelphia, PA

**2:45 Novel IPF Trial Design in the Era of Anti-Fibrotic Therapy**
K. Anstrom, PhD, Durham, NC

**3:10 Improving Efficiencies in Clinical Trial Conduct**
P.J. Smith, PhD, MD, Durham, NC

**D84 CRITICAL ILLNESS AND THE AGING BRAIN: DEMENTIA AND DELIRIUM IN THE ICU**

Assembly on Critical Care; Nursing

1:30 p.m. - 3:30 p.m. SAN DIEGO CONVENTION CENTER
Ballroom 20 A (Upper Level)

**Target Audience**
Nurses, physicians, pharmacists, therapists, and social workers who provide care in the intensive care unit (ICU), inpatient providers caring for patients transferred from the ICU; clinical and translational scientists

**Objectives**
At the conclusion of this session, the participant will be able to:

- identify tools to screen for cognitive impairment/ dementia in patients with critical illness and to review common clinical problems among those with cognitive impairment/dementia who are admitted to the ICU and discuss their management;
- understand best practices to facilitate communication, screen for delirium, and mobilize those with cognitive impairment/dementia with critical illness;
- understand important interrelated epidemiological trends related to aging, cognitive impairment/dementia, and critical illness and implications for critical care providers, health systems, and society.

The number of persons with cognitive impairment/dementia will triple in the next 30 years. The bidirectional relationship between cognitive impairment and critical illness means a growing number of persons with cognitive impairment/dementia will be admitted to the ICU. Moreover, among the growing number of survivors, up to 75% will develop new or worsened cognitive impairment as the result of their critical illness. This session will use a diverse and interdisciplinary panel of speakers to explore the associations between cognitive impairment and critical illness and discuss the unique issues that patients with cognitive impairment/dementia who become critically ill face in the ICU.

**Chairing:**
N.E. Brummel, MD, MSci, Nashville, TN
C.A. Austin, MD, Chapel Hill, NC
M. Kho, PT, PhD, Hamilton, Canada

1:30 How Critical Illness Changed My Brain: A Patient's Perspective
H. Felt, Northport, AL

1:50 Dementia on the (ICU) Doorstep
R.L. Owens, MD, La Jolla, CA

2:10 Clarifying the Confusion: Detecting Delirium During Dementia
A. Slooter, MD, PhD, Utrecht, Netherlands
2:30 Silence is Not Golden: Communicating with Cognitively Impaired Patients in the ICU
J. Tate, PhD, RN, Columbus, OH

2:50 This Is Your Brain on Exercise
S. Berney, PhD, PT, Heidelberg, Australia

3:10 Critical Illness Brain Injury: Pathways from Delirium to Dementia
N.E. Brummel, MD, MSCI, Nashville, TN

D85 HYPOGLOSSAL MOTONEURONS IN OSA: HOW TO FIX THE BROKEN ENGINE
Assembly on Sleep and Respiratory Neurobiology; Drug Device Discovery and Development Committee

Target Audience
Health providers for sleep apnea patients those interested in developing novel therapies for sleep apnea

Objectives
At the conclusion of this session, the participant will be able to:
• describe the role of hypoglossal neurons in obstructive sleep apnea pathogenesis.
• identify novel pathways that can be targeted in sleep apnea.
• recognize the scientific and regulatory process of developing pharmacotherapies for OSA.

Obstructive sleep apnea (OSA) is recurrent obstruction of upper airway during sleep caused by a combination of anatomical and functional factors. Among these, lack of airway neuromuscular tone during sleep is a major factor. Continuous positive airway pressure (CPAP) is the first-line therapy for OSA, but is often poorly tolerated. Recently, we improved our understanding of upper airway muscle control during sleep, opening new horizons for sleep apnea therapeutics. This Major Symposium will review the state of the art knowledge about control of hypoglossal neurons in health and disease, as well as novel approaches to pharmacotherapy of OSA.

Chairing:
L.F. Drager, MD, Sao Paulo, Brazil
G.S. Gilmartin, MD, Boston, MA
A. Jordan, PhD, Parkville, Australia

1:30 Hypoglossal Neurons and Control of Breathing
J. Feldman, PhD, Los Angeles, CA

1:55 Hypoglossal Motoneurons as a Drug Target in OSA
R.L. Homer, PhD, Toronto, Canada

2:20 Chemogenetic Modulation of Hypoglossal Motoneurons: Can DREADDs Treat OSA?
V.Y. Polotsky, MD, PhD, Baltimore, MD

2:45 Deep Phenotyping of the Upper Airway: What Is Wrong with the Motor?
D.A. Wellman, MD, PhD, Boston, MA

3:10 What Is the Next Step for Pharmacotherapy of OSA: Round Table
G.S. Gilmartin, MD, Boston, MA

BEHAVIORAL • CLINICAL • TRANSLATIONAL

D86 INTERDISCIPLINARY TEAMS: OPTIMIZING CARE IN ADULT AND PEDIATRIC PULMONARY AND CRITICAL CARE
Assemblies on Behavioral Science and Health Services Research; Nursing; Pediatrics

Target Audience
Applicable to a broad span of attendees, including clinicians, registered nurses, advanced practice nurses, administrators, and researchers who utilize or are considering team-based care models for clinical care and research.

Objectives
At the conclusion of this session, the participant will be able to:
• discuss the evidence for team based care, including patient and provider outcomes;
• describe several team based care models which include medical professionals and non-professionals and their outcomes;
• compare and contrast structure, feasibility, and financing of team-based care models in order to be able to replicate and adapt these models for their institutions.

Interdisciplinary health care teams are increasingly used to deliver high-quality, high value care. This symposium will examine the evidence for team based care, including patient and provider outcomes. We will feature various care models of teams that incorporate professionals, non-professionals, patients or families to optimize care in adult and pediatric pulmonary and critical care across clinical and community settings. Examples include communication facilitators in critical care, integrated teams in pulmonary clinic, lay health workers in asthma care, and care coordinators outside the health care system. Each care model will share granular program components, including structure, feasibility, and financing, to allow attendees to replicate these models in their settings.

Chairing:
A. Volerman, MD, Chicago, IL
N. Thakur, MD, MPH, San Francisco, CA
M.B. Happ, PhD, Columbus, OH

1:30 Introduction
A. Volerman, MD, Chicago, IL

1:33 The Evidence For Team-Based Care in Pulmonary And Critical Care Medicine
D.M. Donesky, PhD, ANP-BC, San Francisco, CA

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
1:45 Incorporating Communication Facilitators in Critical Care
J.R. Curtis, MD, MPH, Seattle, WA

2:00 Integrating Former Patients on the Team to Improve Outcomes for ICU Survivors
K.J. Haines, PhD, PT, St Albans, Australia

2:15 Maximizing the Role of Respiratory Therapists to Deliver COPD Care in Clinic
G. Atkins, BSc(Hons), MBChB, MRCP, Lebanon, NH
H. Pelchat, RT, Lebanon, NH

2:30 Utilizing Patient Advocates to Facilitate Adult Asthma Care in Real World Practice
A.J. Apter, MA, MD, MSc, Philadelphia, PA

2:45 Expanding Care Coordination to Outside the Health Care System
N. Thakur, MD, MPH, San Francisco, CA

3:00 Integrating Lay Health Workers for Pediatric Asthma in Community Settings
A. Volerman, MD, Chicago, IL

3:15 Summary and Panel Discussion
M.B. Happ, PhD, Columbus, OH

BASIC • TRANSLATIONAL
SCIENTIFIC SYMPOSIUM
CME Credits Available: 2

D87 TO EACH ITS OWN: SINGLE CELL MRNA SEQUENCING IN LUNG DEVELOPMENT AND DISEASE
Assemblies on Respiratory Cell and Molecular Biology; Pediatrics; Thoracic Oncology
1:30 p.m. - 3:30 p.m. MARRIOTT MARQUIS SAN DIEGO MARINA Pacific Ballroom 21 (North Tower, First Floor)

Target Audience
Providers of lung health; those with clinical and research responsibilities; and those needing instruction in novel approaches to studying disease biomarkers

Objectives
At the conclusion of this session, the participant will be able to:
- learn new findings about the use of single-cell RNA-Seq to evaluate cellular heterogeneity in lung development and disease;
- understand the complexity of lung disease states such as cancer and fibrosis and how a diversity of affected cell types contribute to disease pathogenesis;
- develop an understanding of novel approaches that apply analysis of cellular complexity to the development of new treatments.

Speakers will represent a broad range of pulmonary investigation from development to cancer to fibrosis who are using the novel technique of single cell mRNA sequencing for discovery of cellular heterogeneity and novel pathways in lung biology. Major themes will include the use of advanced bioinformatic and big data approaches for understanding clusters and trends within single cell transcriptomic datasets; illustration of the unique advantages of single cell seq as a discovery tool; and application of the technology to clinical samples with attention to diagnostic and therapeutic implications.

Chairing: M. Bhattacharya, MD, San Francisco, CA
L. Ikonomou, PhD, Boston, MA

1:30 Epithelial Cell Heterogeneity in IPF
Y. Xu, PhD, Cincinnati, OH

1:50 Specification of the Proximal-Distal Axis in Lung Epithelial Development
D.B. Frank, MD, PhD, Philadelphia, PA

2:10 Single Cell Genomic and Transcriptomic Analysis of Lung Cancer
A. Ramachandran, PhD, Boston, MA

2:30 Identifying Macrophages in Fibrotic Lung: Annotation of Single Cell mRNA Seq
D. Aran, PhD, San Francisco, CA

2:50 Multiplexed Single Cell mRNA Detection in Lung by Proximity Ligation
T. Desai, MD, MPH, Stanford, CA

3:10 Quantification of Somatic Mutations in Individual Cell Division Events by "Lineage Sequencing"
Y. Brody, PhD, Cambridge, MA
allows for personalized health, a more preventive orientation. For example, a better understanding of the relationship between environmental exposure and the lung epigenome might lead to more efficient preventive measures. This symposium brings together experts who present data supporting a personalized approach to preventing lung disease.

Chairing:

C. Carlsten, MD, MPH, Vancouver, Canada  
E. Brigham, MD, MHS, Baltimore, MD  
T.D. LeVan, PhD, Omaha, NE

1:30: Patient's Perspective  
D. Matlach, DMin, Fountain Hills, AZ

1:35: What Does Personalized Prevention of Lung Disease Really Mean?  
C. Carlsten, MD, MPH, Vancouver, Canada

1:50: Targeting Early Origins of Chronic Lung Disease: A Personalized Approach  
E. Melen, PhD, MD, Stockholm, Sweden

2:10: Personalizing Prevention of COPD  
R.G. Barr, MD, DrPH, New York, NY

2:30: Biomarkers to Guide Personalized Prevention of Lung Disease  
S. Guerra, MD, PhD, Tucson, AZ

2:50: Modifiable Factors That May Affect Susceptibility to Exposures: A Look at Diet and Obesity  
N.N. Hansel, MD, MPH, Baltimore, MD

3:10: Epigenetic Plasticity and Primary Prevention of Lung Disease  
D.L. DeMeo, MD, Boston, MA

BEHAVIORAL • CLINICAL  
SCIENTIFIC SYMPOSIUM  
CME Credits Available: 2

D90  DIVERSITY ACROSS THE CRITICAL CARE SPECTRUM FROM PATIENTS TO CLINICIANS TO LEADERS: WHY IT MATTERS

Assemblies on Critical Care; Behavioral Science and Health Services Research; Pediatrics  
1:30 p.m. - 3:30 p.m.  
SAN DIEGO CONVENTION CENTER  
Room 33 A-C (Upper Level)

Target Audience  
Physicians who care for patients hospitalized with pneumonia (e.g., intensivists, pulmonologists, hospitalists, emergency medicine, infectious diseases), and those with research interests in respiratory infections.

Objectives  
At the conclusion of this session, the participant will be able to:

• describe the impact of respiratory infections on long-term mortality and morbidity;
• explain the relationship of respiratory infections and cardiovascular events;
• describe the potential biomarkers associated with increased long-term mortality and morbidity in patients with respiratory infections.

This session will have internationally recognized experts review and synthesize the current literature on long-term (1 year) outcomes, including mortality, cardiac events, and lung function, for patients with respiratory infections including pneumonia and bronchiectasis, as well as sepsis. The lectures will focus on identifying those at risk for increased long term complications as well as potential treatments to avoid these complications.

Chairing:

E.M. Mortensen, MD, MSc, Farmington, CT  
N.C. Dean, MD, Murray, UT

1:30: Long-Term Outcomes After Pneumonia and Sepsis: It’s Not Over Until It’s Over!  
E.M. Mortensen, MD, MSc, Farmington, CT

1:55: Cardiac Complications After Respiratory Infections  
J.D. Chalmers, MD, PhD, Dundee, United Kingdom

2:15: Chronic Lung Disease After Respiratory Infections  
C. Dela Cruz, MD, PhD, New Haven, CT

2:40: Complications of Bronchiectasis  
M.L. Metersky, MD, Farmington, CT

3:00: Predictors of Long-Term Outcomes for Patients with Pneumonia and Sepsis  
S. Yende, MD, Pittsburgh, PA

This session and the International Conference are supported by an educational grant from Insmed Incorporated.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
outcomes through real world case studies. The session will then focus on pragmatic strategies to diversify the critical care workforce, research, and leadership committees, concluding with a panel discussion between the audience, speakers, and prominent leaders in critical care.

Chairing: T.S. Valley, MD, MSc, Ann Arbor, MI  
H.B. Gershengorn, MD, Miami, FL  
M. Hua, MD, MSci, New York, NY

1:30 Cross-Cultural Comparisons: Using International Critical Care Practices to Understand Differences in Patient Care  
S. Murthy, MD, Vancouver, Canada

1:46 Interventions to Reduce Disparities in Critical Care: Lessons from Payment and Delivery System Reform  
M. Chin, MD, MPH, Chicago, IL

2:04 Breaking the Mold: Diversifying the Emerging Critical Care Workforce  
M.B. Lane-Fall, MD, MSHP, Philadelphia, PA

2:20 Why It Matters: Strategies to Maintain a Pipeline of Diverse Intensivists  
B. Cryer, MD, Dallas, TX

2:38 An Evolving Workforce for the Evolving Needs of Critically Ill Children  
C.L. Riley, MD, MPP, MHS, Cincinnati, OH

2:54 Learning From the Past and Moving Towards the Future: Gender Parity in Academic Medicine  
S. Mehta, MD, Toronto, Canada

3:10 Panel Discussion  
H.B. Gershengorn, MD, Miami, FL

---

**MINI SYMPOSIUM**

**D92 GENETICS AND GENOMICS OF OBSTRUCTIVE LUNG DISEASE**

1:30 p.m. - 3:30 p.m.  
SAN DIEGO CONVENTION CENTER  
Room 6 A (Upper Level)

**Chairing:** C.P. Hersh, MD, MPH, Boston, MA  
M.H. Cho, MPH, MD, Boston, MA

**Oral Presentations**


---

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.


3:00 Stable Lung Transplant Survival Benefit at High Values of the Lung Allocation Score/S. Li, D. Tumin, W. Stewart, J.D. Tobias, D. Hayes, Columbus, OH, p.A7374


3:00 Effects of Changes in the ICU Beds Supply on ICU Utilization in the United States/I. Barbash, D. Wallace, J. Kahn, Pittsburgh, PA, p.A7382


**MINI SYMPOSIUM**

**D95 MECHANISMS OF BRONCHOPULMONARY DYSPLASIA**

1:30 p.m. - 3:30 p.m. SAN DIEGO CONVENTION CENTER Room 6 B (Upper Level)

Chairing: R.M. Ryan, MD, Charleston, SC
J. Benjamien, MD, MPH, Nashville, TN

Oral Presentations


1:45 Monocyte/Macrophage Populations Evolve in Tracheal Samples from Patients at Risk for Bronchopulmonary Dysplasia/L.C. Eldredge, R.S. Creasy, S.E. Juul, D.E. Mayock, S.F. Ziegler, Seattle, WA, p.A7385

2:00 Endothelial Specific Deletion of IKKb in the Early Alveolar Lung Impairs Alveolarization and VEGF-Mediated Angiogenesis/S. Rao, M. Liu, C.M. Alvira, Palo Alto, CA, p.A7386

2:15 Maternal High Fat Diet Causes Decreased Alveolarization and Persistent Pulmonary Inflammation in the Offspring/L.K. Rogers, K. Heyob, S. Mieth, T.E. Tippie, Columbus, OH, p.A7387

2:30 Neonatal CCR2 Knockout Mice Are Protected from Chronic LPS-Induced Pulmonary Inflammation and Hypoalveolarization/C. Fulton, T.X. Cui, A.P. Popova, Ann Arbor, MI, p.A7388

2:45 Early Lipopolysaccharide Exposure Disrupts Alveolarization in Neonatal Mice: Implications for Postnatal Sepsis-Mediated Bronchopulmonary Dysplasia in Preterm Infants/B. Shivanna, R. Menon, A. Shrestha, Houston, TX, p.A7389


3:15 Signature of Top Omic Profile in Bronchopulmonary Dysplasia (STOP BPD)/C.V. Lal, N. Olave, N. Ambalavanar, Birmingham, AL, p.A7391

**MINI SYMPOSIUM**

**D96 CRACKING THE CELLULAR CODE IN PULMONARY HYPERTENSION**

1:30 p.m. - 3:30 p.m. SAN DIEGO CONVENTION CENTER Room 30 A-B (Upper Level)

Chairing: S.S. Pullamsetti, PhD, Bad Nauheim, Germany
G. Kwapiszewska, PhD, Graz, Austria
C. Guignabert, PhD, Le Kremlin Bicetre, France

Oral Presentations


1:45 Pathogenic Variants in CRIPAK Are Associated with Endothelial Dysfunction and Small Vessel Loss in Pulmonary Arterial Hypertension/J. Tenorio, M. Orcholski, E. Shamskhou, K. Yuan, E. Granda, P. Larumena, V. De Jesus Perez, Madrid and Stanford, CA, p.A7393


2:15 Upregulation of CHK1 in PAH-PASMCs Is Essential for Proliferation and Survival by Promoting DNA Repair Mechanisms/T. Peterlini, M.-C.C. Lampron, N. Samson, A. Bourgeois, S. Breuls-Bonnet, T. Bertero, S.Y. Chan, S. Provencer, O. Bacherat, S. Bonnet, Quebec, Canada, p.A7395


3:15 ACTRIIA-Fc Rebalances BMP and Activin/TGF-ß Signaling to Attenuate Experimental Pulmonary Hypertension/L.-M. Yung, P. Yang, G. Bocobo, T. Dinter, S. Pearsall, D. Sako, R. Kumar, P.B. Yu, Boston, MA, p.A7399

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
MINI SYMPOSIUM

D97 IF YOU LOVE IT, LET IT GO: EXOSOMES AND SECRETOMES

1:30 p.m. - 3:30 p.m. MARRIOTT MARQUIS SAN DIEGO MARINA
Pacific Ballroom 22 (North Tower, First Floor)

Chairs: M. Sauler, MD, New Haven, CT
A. Sarkar, PhD, Columbus, OH
R.L. Damico, MD, PhD, Baltimore, MD

Oral Presentations

1:30 miR-24-3p: A Regulator of Cell Fate Following Cigarette Smoke Mediated DNA Damage in COPD/M. Sauler, E. Finnemore, J.L. Gomez, N. Kaminski, P. Lee, New Haven, CT, p.A7400


2:00 Mesenchymal Stem Cell Exosomes Ameliorate Experimental Idiopathic Pulmonary Fibrosis by Modulating Alveolar Macrophage Phenotype and Monocyte Recruitment/N. Mansouri, G.R. Willis, A. Fernandez-Gonzalez, M. Reis, A. Mitsialis, S. Kourembanas, Boston, MA, p.A7402


2:45 Therapeutic Effects of Extracellular Vesicles Released from Bone Marrow, Adipose and Lung Tissue-Derived Mesenchymal Stem Cells in Experimental Sepsis/N. Blanco, N. Machado, L. Castro, F.F. Cruz, J.D. Silva, P.L. Silva, P.R.M. Rocco, Rio de Janeiro, Brazil, p.A7405


Featured Speaker

3:15 Precision Medicine at the MIF Locus/R. Bucala, MD, PhD, New Haven, CT

MINI SYMPOSIUM

D98 ASTHMA AND COPD: THE BEST OF RESPIRATORY STRUCTURE AND FUNCTION

1:30 p.m. - 3:30 p.m. MARRIOTT MARQUIS SAN DIEGO MARINA
Pacific Ballroom 18-19 (North Tower, First Floor)

Chairs: B. Camoretti-Mercado, PhD, Tampa, FL
E.K. Silverman, MD, PhD, Boston, MA
M.G. Belvisi, PhD, London, United Kingdom

Oral Presentations


1:45 The Novel Notch Ligand DNER Modulates IFNγ Levels in Recruited Macrophages by Enhancing Non-Canonical Notch During COPD Progression/C. Ballester Lopez, T.M. Conlon, Z. Erütüz, O. Eickelberg, A.O. Yildirim, Munich, Germany, p.A7408

2:00 Profiling the Regulatory Landscape of Emphysema and Small Airways Disease in COPD: Combining microCT Imaged Tissue Pathology with Transcriptomics./S. Booth, J.C. Hogg, Vancouver, Canada, p.A7409


2:45 Heterogeneity in the Rate and Severity of Exacerbations in Severe Eosinophilic Asthma: Insight from a Pooled Analysis of Two Large Clinical Trials/M. Sadatsafavi, J.M. Fitzgerald, A. Safari, Vancouver, Canada, p.A7412


3:15 Novel Oligonucleotide Therapy Alters the Lung Transcriptome in a House Dust Mite (HDM), Cyclic DiGMP Mouse Model of Severe, Corticosteroid-Resistant Asthma/W.T. Gerthoffer, S.C. Ramelli, J. Bell, R. Barrington, J. Sparks, M. Matar, Reno, NV, p.A7414

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
MINI SYMPOSIUM

D99 CLINICALLY INFORMATIVE BIOMARKERS IN LUNG CANCER: A NEEDLE IN A HAYSTACK
1:30 p.m. - 3:30 p.m. SAN DIEGO CONVENTION CENTER
Room 1 A-B (Upper Level)

Chairing: R.L. Keith, MD, Denver, CO  T. Peikert, MD, Rochester, MN  P. Nana-Sinkam, MD, Richmond, VA

Oral Presentations
1:30 Validation of Plasma TIMP-1 to Identify Lung Cancer in Smokers/V.S. Nair, M. Beggs, H. Yu, L. Carbonell, S.X. Wang, A. Vachani, Stanford, CA, p.A7415

Featured Speaker
3:15 Biomarkers and Cancer Care: Moving from Development to Application/ P.J. Mazzone, MPH, MD, Cleveland, OH

RAPID: RAPID ABSTRACT POSTER DISCUSSION SESSION

D101 MECHANISTIC AND TRANSLATIONAL STUDIES IN COPD
1:30 p.m. - 3:30 p.m. SAN DIEGO CONVENTION CENTER
Room 30 C-E (Upper Level)

Chairing: R.M. Tighe, MD, Durham, NC  C.M. Freeman, PhD, Ann Arbor, MI  P. Kohli, MD, Boston, MA

Abstract Summaries 1:30-2:00
Viewing/Discussion 2:00-3:30

6. Neutrophil Elastase and Proteinase 3 Activity in PiSZ Alpha-1 Antitrypsin Deficiency/P.R. Newby, R.A. Stockley, Birmingham, United Kingdom, p.A7427

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
Use of STOP-Bang Questionnaire to Identify Patients at High Risk for Obstructive Sleep Apnea in the Context of Limited Resources/K.D. Duong, K.D. Bui, V.T. Le, Ho Chi Minh City, Viet Nam, p.A7447


An Analysis of Compliance with Positive Pressure Breathing Device in Patients with Obstructive Sleep Apnea Diagnosed in-Lab Vs at Home in an Inner City Hospital/B. Bajani, K. Habbal, D. Lvovsky, Bronx, NY, p.A7452

Effects of Adaptive Servo Ventilation Therapy on Paroxysmal Atrial Fibrillation and Ventricular Tachycardia in Heart Failure Patients Due to Ischemic Heart Disease/T. Nagasaka, T. Nagasaka, N. Takama, Maebashi, Japan, p.A7453


Change in Sleep Microarchitecture, Homeostasis and Vigilance with CPAP in Obstructive Sleep Apnea/A. Parekh, A.W. Varga, D.M. Rapoport, I.A. Ayappa, New York, NY, p.A7455


Nightly Hypoxemia in the Elderly Inpatient Population and Its Link to Dementia - Further Study Group Results/S. WImmer, S. Profant, S. Gibson, C. Milesi, Palo Alto, CA, p.A7457

CPAP Treatment Can Improved Cognition and Memory Dysfunction in Obstructive Sleep Apnea Syndrome/E.-T. Chang, Hualien, Taiwan, p.A7458

The Effect of Obstructive Sleep Apnea on Decision Making/K. Wong, S. Guo, A. Jain, W. Liu, R. Owens, La Jolla, CA, p.A7459

Continuous Positive Airway Pressure (CPAP) Therapy for Obstructive Sleep Apnea and Psychotropic Drug Use/A. Delbarre, F. Gagnadoux, B. Kohier, N. Pelletier-Fleury, Villejuif, France, p.A7460


Effective and Economic Evaluation of Screen for Obstructive Sleep Apnea Syndrome by Using Overnight Oximetry/W.-S. Chung, Y.-F. Chen, L.-W. Hung, Taichung City, Taiwan, p.A7466

RAPID: RAPID ABSTRACT POSTER DISCUSSION SESSION

D103 TRANSPLANT AND ILD POTPOURRI

1:30 p.m. - 3:30 p.m. SAN DIEGO CONVENTION CENTER

Room 6 D (Upper Level)

Abstract Summaries 1:30-2:00

Viewing/Discussion 2:00-3:30

Chairing: T.J. Doyle, MD, MPH, Boston, MA
S. Nathan, MD, Falls Church, VA


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
203 Pulmonary Involvement in Scleroderma Varies Based on ANA Titer/K. Warrior, E. Marrow, A.A. Ansari, K. Dennis-Aren, C. Mary, M.E. Hinchliff, J.E. Dematte, S.M. Bhorade, Chicago, IL, p.A7469


211 Capturing Systemic Sclerosis-Associated Interstitial Lung Disease Onset: A Comparison of Common Definitions and an Advanced Statistical Model/M. Caron, K.J. Schwartzman, M. Hudson, M. Baron, R.J. Steele, Montreal, Canada, p.A7477


214 Primary Sjögren’s Syndrome-Associated Interstitial Lung Disease-A Descriptive Study/J. Marco, N. Gupta, Cincinnati, OH, p.A7480


224 Heparin-Induced Thrombocytopenia (HIT) in Lung Transplant Recipients: A Retrospective Review/B.L. Small, M.P. Gomes, X. Han, X. Wang, K. McCurry, A. Ataya, M.M. Budev, Cleveland, OH, p.A7490

The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
D104 PHENOTYPES AND THE MULTIPLE DIMENSIONS OF COPD

1:30 p.m. - 3:30 p.m. SAN DIEGO CONVENTION CENTER
Room 28 C-E (Upper Level)

Abstract Summaries 1:30-2:00
Viewing/Discussion 2:00-3:30

Chairing:

G.R. Washko, MD, Boston, MA
S.P. Bhatt, MD, Birmingham, AL
X. Soler, MD, PhD, San Diego, CA


507 Frailty in Patients with Chronic Obstructive Pulmonary Disease and Risk of Acute Exacerbations/N. Yee, E.R. Locke, H.Q. Nguyen, V.S. Fan, Seattle, WA, p.A7497


517 Non-Traumatic Vertebral Fractures Among Chronic Obstructive Pulmonary Disease (COPD) Patients/G. Epstein Shochet, M. Koslow, D.A. King, D. Shiriti, Kfar Saba, Israel, p.A7507


Ventilator Dyssynchrony Is Associated with a Temporally Delayed Increase in Driving Pressure/P.D. Sottile, D. Albers, M. Moss, Aurora, CO, p.A7521


Spatial Distribution of Ventilator Induced Lung Injury at the µm-Scale. An In-Vivo Synchrotron Phase-Contrast Microscopy Study in BALB/c Mice/G. Lovric, L. Broche, C.M. Schleputz, L. Fardin, J.C. Schittny, A.S. Larsson, S. Bayat, Villingen, Switzerland, p.A7526


720 Transcriptional Regulation of NAMPT by Mechanical Stress and Inflammatory Factors in Human Lung Endothelium/X. Sun, P. Awuah, M. Khawam, G. Reyad, A. Sun, J.G.N. Garcia, Tucson, AZ, p.A7535


723 Knockdown of TFPI-Anchored Endothelial Cells Exacerbates LPS-Induced Acute Lung Injury Via NF-κB Signaling Pathway/M. Shi, ShangHai, China, p.A7538

724 PD-1 Inhibition Promotes Th1 Inflammation and Alters Lymphocyte Activation in Mice After LPS-Lung Injury/K. Gibbs, L.D. Purcell, C. Liu, D.C. Files, Winston-Salem, NC, p.A7539

111 Participation of FIZZ1 in Mouse Model of Silicosis/W. Martins, A.L. da Silva, P.R.M. Rocco, V. Capelozzi, Sao Paulo, Brazil, p.A7552


114 Ozone Exposure Induces IL-17A Production in Group 2 Innate Lymphoid Cells in the Absence of Surfactant Protein-D/C.H. Flayer, M.Q. Ge, E. Larson, S. Killingbeck, A. Haczku, Davis, CA, p.A7555

115 CD163 Protects Against Ozone Increased Susceptibility to Bacterial Pneumonia/K.M. Gowdy, S.W. Reece, K.L. Cuddapah, P.A7555


117 Ozone-Induced Airway Hyperresponsiveness Involves an ATP-P2X7-Mast Cell Pathway/S.L. Tilley, Z.A. German, C.M. Jania, S.D. Budney, K.D. Chason, Chapel Hill, NC, p.A7559

118 Ozone-Induced Airway Hyperresponsiveness Involves an ATP-P2X7-Mast Cell Pathway/S.L. Tilley, Z.A. German, C.M. Jania, S.D. Budney, K.D. Chason, Chapel Hill, NC, p.A7559


123 ST2-Dependent Responses to Ozone Are Regulated by the Gut Microbiota/D.I. Kasahara, Y. Cho, S.A. Shore, Boston, MA, p.A7564

1:30 p.m. - 3:30 p.m. SAN DIEGO CONVENTION CENTER
Room 11 A-B (Upper Level)

Abstract Summaries
1:30-2:00

Viewing/Discussion
2:00-3:30

Chairing: R.T. Zamanian, MD, Stanford, CA
F.P. Rischar, MD, Tucson, AZ
D. Kiely, MD, Sheffield, United Kingdom


Early Initiation of Intra-venous Prostanoid Therapy is Associated with Improved Outcomes in Patients with PAH/S. Bartolone, N. Sood, T.G. Shah, K. Stryvoky, F. Torres, K.M. Chin, Dallas, TX, p.A7587

Combination Therapy Reduces Hospitalizations in Patients with Pulmonary Arterial Hypertension/C.M. Blanchette, J.M. Noone, E. Zacherlie, K. Gordon, P. Pozella, R. Howden, A. Nelsen, Charlotte, NC, p.A7588


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
415  Exploring the Delivery of Palliative and End of Life Care in Patients with Pulmonary Arterial Hypertension; A U.K Based Qualitative Interview Study/S. Woolcock, D.W. Hamilton, P.A. Corris, C. Exley, Newcastle upon Tyne, United Kingdom, p.A7594


D109  NEW PLAYERS IN LUNG INJURY AND REPAIR

1:30 p.m. - 3:30 p.m.  MARRIOTT MARQUIS SAN DIEGO MARINA

Abstract Summaries  1:30:00 - 2:00:00

Pacific Ballroom 15-17 (North Tower, First Floor)

Viewing/Discussion  2:00:00 - 3:30:00

Chairing:  W.J. Janssen, MD, Denver, CO
S. Herold, MD, PhD, Giessen, Germany
Y. Zhang, PhD, New Haven, CT

901  Platelet and Airway Epithelial Bioenergetics Are Different in Obese Versus Lean Asthmatics/D.E. Winnica, C. Corey, L.G. Que, F. Holguin, S. Shiva, Aurora, CO, p.A7595

902  Dissecting the Role of Pulmonary Neuroendocrine Cells in Lung Immune Responses/X. Sun, P. Sui, San Diego, CA, p.A7596


907  The Limit of Lung Ischemia in Mouse Lung Transplantation: 72 Hours at 0°C or 3 Hours at 37°C/X. Wang, Pittsburgh, PA, p.A7601

908  Adult Monocytes Protect Juvenile Mice from Influenza A Virus-Induced Lung Injury/B. Coates, M. Turner, Q. Satava, M. Ciesielski, Y. Chengyuan, K.M. Ridge, Chicago, IL, p.A7602


911  TACC2 Protein Mediates Epithelial Cell Survival and Alveolar Integrity Against Cigarette Smoke Exposure/T. Nyunoya, X. Li, J. Jang, C. Zou, R. Mallampalli, Pittsburgh, PA, p.A7605


913  Cigarette Smoke Increases Severity of Influenza A Viral Infection and Impairs Epithelial Antiviral Responses in a Mouse Model/P. Duffney, A. Nogales, T.H. Thacher, L. Martinez-Sobrido, R.P. Phipps, P.J. Sime, Rochester, NY, p.A7607


918  Cystic Fibrosis Transmembrane Conductance Regulator Potentiation as a Therapeutic Strategy for Pulmonary Edema: A Proof-of-Concept Study in Pigs/X. Li, L.G. Vargas Buonfiglio, R. Adam, D.A. Stoltz, J. Zabner, A.P. Cornelias, Iowa City, IA, p.A7612


920  Human Alveolar-Like Macrophages Derived from Embryonic Stem Cells for the Treatment and Prevention of Lung Disease/S. Bouch, M.L. Litvack, M. Post, Toronto, Canada, p.A7614

921  Nosocomial Lung Infection Induces a Pulmonary Monogenic Prionopathy that Disrupts the Endothelial Barrier of the Brain/S.B. Voth, M. Lin, R. Balczon, C.M. Francis, T. Stevens, Mobile, AL, p.A7615


Rapid: Rapid Abstract Poster Discussion Session

D110  Epithelial Function in Health and Disease
1:30 p.m. - 3:30 p.m.  Marriott Marquis San Diego Marina
Pacific Ballroom 24-26 (North Tower, First Floor)

Abstract Summaries 1:30-2:00
Viewing/Discussion 2:00-3:30

Chairing: I.H. Heijink, PhD, Groningen, Netherlands
D.A. Knight, PhD, Callaghan, Australia
J.S. Debley, MD, Seattle, WA


1009  Isolation, Reactivation and Stimulation of Axonemes Extracted from Cultured Primary Human Airway Epithelial Cells/M. Price, J.A. Pavlik, D.M. Kafatasich, K.L. Bailey, J.H. Sisson, Omaha, NE, p.A7628

1010  Study on the Role and Mechanism of Aquaporin 3 in Pulmonary Infection Caused by Pseudomonas Aeruginosa/M. Chang, Shanghai, China, p.A7629

1011  Antisense Oligonucleotide Mediated Reduction of SPDEF Regulates Goblet Cell Formation in Multiple Murine Pulmonary Disease Models/J.R. Crosby, C. Zhao, D. Bai, M. Zhang, B.P. Monia, S. Guo, Carlsbad, CA, p.A7630


1014  Targeting Cellular Senescence Prevents Cigarette Smoke-Induced Pulmonary Emphysema/T. Cottage, J. Kearley, A. Berlin, N. Peterson, J. Connor, R. Lemaire, Gaithersburg, MD, p.A7633


1017  Regional Expression of Secretory Mucins MUC5AC and MUC5B in Normal Human Airways/N. Marchetti, G.J. Criner, M.R. Wolfson, Philadelphia, PA, p.A7635


1020  Surfactant Protein-D (SP-D) Modulates O3-Induced Inflammatory Response in the Airway Via TNFalpha and Ceramide Signaling/A. Haczku, M.Q. Ge, S.L. Vu, S. Chung, C.H. Flayer, T. Goldkorn, Davis, CA, p.A7639


The information contained in this program is up to date as of April 16, 2018. For the most current session information, please visit the online program itinerary.
1022  Conditional Deletion of Nedd4-2 in Lung Epithelial Cells Causes Diffuse Parenchymal Lung Disease in Adult Mice/D.

1023  Oxidized Phosphatidylcholine Induces Mitochondrial and Endoplasmic Reticulum Stress in Airway Epithelial Cells/C.

1024  Senescent Lung Fibroblasts Reduce Alveolar Epithelial Cell Regeneration: Implications for Pulmonary Fibrosis/K.E.C.

Final Program